assay_id,assay_test_type,tissue_id,tid,assay_tax_id,curated_by,src_id,assay_tissue,assay_type,cell_id,description,assay_subcellular_fraction,assay_category,bao_format,relationship_type,assay_strain,doc_id,assay_organism,assay_cell_type
1,,,12052,,Autocuration,1,,B,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,,BAO_0000019,H,,11087,,
2,,,22226,,Autocuration,1,,F,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,,BAO_0000219,U,,684,,
3,,,22226,,Autocuration,1,,B,,,,,BAO_0000019,U,,15453,,
4,,,104729,9913.0,Autocuration,1,,B,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,,BAO_0000249,H,,17841,Bos taurus,
5,,,80001,9606.0,Intermediate,1,,F,163.0,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,,BAO_0000219,N,,17430,Homo sapiens,143B
6,,,80001,9606.0,Intermediate,1,,F,163.0,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,,BAO_0000219,N,,17430,Homo sapiens,143B
7,,,80001,10090.0,Intermediate,1,,F,163.0,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,,BAO_0000219,N,,13799,Mus musculus,143B
8,,,80001,9606.0,Expert,1,,F,163.0,In vitro cell cytotoxicity was determined against 143B cell line,,,BAO_0000219,N,,17774,Homo sapiens,143B
9,,,80001,9606.0,Intermediate,1,,F,163.0,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,,BAO_0000219,N,,3801,Homo sapiens,143B
10,,,80001,9606.0,Intermediate,1,,F,163.0,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,,BAO_0000219,N,,17430,Homo sapiens,143B
11,,,80001,9606.0,Intermediate,1,,F,163.0,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,,BAO_0000219,N,,17430,Homo sapiens,143B
12,,,80001,9606.0,Expert,1,,F,163.0,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,,BAO_0000219,N,,17774,Homo sapiens,143B
13,,,50185,1280.0,Intermediate,1,,F,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,BAO_0000218,N,,11324,Staphylococcus aureus,
14,,,50185,1280.0,Intermediate,1,,F,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,BAO_0000218,N,,11324,Staphylococcus aureus,
15,,,50185,1280.0,Intermediate,1,,F,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,BAO_0000218,N,,11324,Staphylococcus aureus,
16,,,50185,1280.0,Intermediate,1,,F,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,BAO_0000218,N,,11324,Staphylococcus aureus,
17,,,100122,10116.0,Expert,1,,A,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,,BAO_0000357,D,,11347,Rattus norvegicus,
18,,,12054,,Autocuration,1,,B,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,,BAO_0000357,H,,16474,,
19,,,12054,,Autocuration,1,,B,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,,BAO_0000019,H,,10091,,
20,,,12054,,Autocuration,1,,B,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,BAO_0000357,H,,16474,,
21,,,12054,,Autocuration,1,,B,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,,BAO_0000357,H,,16474,,
22,,,12054,,Autocuration,1,,B,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,BAO_0000357,H,,16474,,
23,,,12054,,Autocuration,1,,B,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,BAO_0000357,H,,16474,,
24,,,12054,,Autocuration,1,,B,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,BAO_0000357,H,,16474,,
25,,,22226,,Autocuration,1,,B,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,,BAO_0000219,U,,14352,,
26,,,12054,9986.0,Autocuration,1,,B,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,,BAO_0000357,H,,5646,Oryctolagus cuniculus,
27,,,12054,9986.0,Autocuration,1,,B,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,,BAO_0000357,H,,5646,Oryctolagus cuniculus,
28,,,12426,,Autocuration,1,,B,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,,BAO_0000219,H,,10997,,
29,,,12054,3847.0,Autocuration,1,,B,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,,BAO_0000357,H,,6309,soya bean,
30,,,12054,3847.0,Autocuration,1,,B,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,,BAO_0000357,H,,167,Glycine max,
31,,,12054,3847.0,Autocuration,1,,B,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,,BAO_0000357,H,,167,Glycine max,
32,,,12054,3847.0,Autocuration,1,,B,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,,BAO_0000357,H,,11087,Glycine max,
33,,,12054,3847.0,Autocuration,1,,B,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,,BAO_0000357,H,,11087,Glycine max,
34,,,12054,3847.0,Autocuration,1,,B,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,,BAO_0000357,H,,13622,Glycine max,
35,,,12054,3847.0,Autocuration,1,,B,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,,BAO_0000357,H,,13622,Glycine max,
36,,,22226,10116.0,Autocuration,1,,A,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,,BAO_0000019,U,,11347,Rattus norvegicus,
37,,,22226,562.0,Autocuration,1,,B,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,,BAO_0000019,U,,5926,Escherichia coli,
38,,,22226,,Autocuration,1,,B,,Dissociation constant with dimeric 16S rRNA RNA construct B,,,BAO_0000019,U,,4567,,
39,,,22222,,Intermediate,1,,B,,Dissociation constant towards 16S rRNA construct A,,,BAO_0000225,M,,3782,,
40,,,22222,,Intermediate,1,,B,,Dissociation constant towards 16S rRNA construct B,,,BAO_0000225,M,,3782,,
41,,,100263,562.0,Expert,1,,B,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,,BAO_0000225,M,,4466,Escherichia coli,
42,,,100263,562.0,Expert,1,,B,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,,BAO_0000225,M,,6592,Escherichia coli,
43,,,13053,,Autocuration,1,,B,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,BAO_0000019,H,,898,,
44,,,13053,,Autocuration,1,,B,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,BAO_0000019,H,,898,,
45,,,20001,9606.0,Autocuration,1,,B,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,,BAO_0000019,H,,13163,Homo sapiens,
46,,,20001,9606.0,Autocuration,1,,B,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,,BAO_0000019,H,,13163,Homo sapiens,
47,,,12971,10116.0,Expert,1,,B,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,,BAO_0000019,D,,10691,Rattus norvegicus,
48,,,12971,10116.0,Expert,1,,B,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,,BAO_0000019,D,,10691,Rattus norvegicus,
49,,,12971,10116.0,Expert,1,,B,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,,BAO_0000019,D,,10691,Rattus norvegicus,
50,,,12971,10116.0,Expert,1,,B,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,,BAO_0000019,D,,10691,Rattus norvegicus,
51,,,13053,,Autocuration,1,,B,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,BAO_0000019,H,,898,,
52,,,11512,,Autocuration,1,,B,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,,BAO_0000357,H,,912,,
53,,,11512,,Autocuration,1,,B,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,,BAO_0000357,H,,912,,
54,,,11512,,Autocuration,1,,B,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,,BAO_0000357,H,,912,,
55,,,104740,10116.0,Autocuration,1,,B,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,Membranes,,BAO_0000249,D,,15103,Rattus norvegicus,
56,,,80002,9606.0,Intermediate,1,,F,506.0,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,,BAO_0000219,N,,5116,Homo sapiens,1A9
57,,,104835,10116.0,Autocuration,1,,F,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,,BAO_0000219,D,,14578,Rattus norvegicus,Oocytes
58,,,104821,10116.0,Autocuration,1,,F,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,,BAO_0000219,D,,14578,Rattus norvegicus,Oocytes
59,,,104848,10116.0,Autocuration,1,,F,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,,BAO_0000219,D,,14578,Rattus norvegicus,Oocytes
60,,,80002,9606.0,Expert,1,,F,506.0,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,,BAO_0000219,N,,4787,Homo sapiens,1A9
61,,,80002,9606.0,Intermediate,1,,F,506.0,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,,BAO_0000219,N,,4787,Homo sapiens,1A9
62,,,80002,9606.0,Intermediate,1,,F,506.0,Cytotoxic activity against human ovarian cancer (1A9) cell line,,,BAO_0000219,N,,3547,Homo sapiens,1A9
63,,,80002,9606.0,Intermediate,1,,F,506.0,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,,BAO_0000219,N,,3547,Homo sapiens,1A9
64,,,80002,9606.0,Intermediate,1,,F,506.0,Effective dose of compound against replication of 1A9 cell line was evaluated,,,BAO_0000219,N,,6726,Homo sapiens,1A9
65,,,80002,9606.0,Expert,1,,F,506.0,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,,BAO_0000219,N,,3455,Homo sapiens,1A9
66,,,80002,9606.0,Intermediate,1,,F,506.0,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,,BAO_0000219,N,,5726,Homo sapiens,1A9
67,,,80002,9606.0,Intermediate,1,,F,506.0,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,,BAO_0000219,N,,5726,Homo sapiens,1A9
68,,,80002,9606.0,Intermediate,1,,F,506.0,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,,BAO_0000219,N,,5726,Homo sapiens,1A9
69,,,80002,9606.0,Intermediate,1,,F,506.0,Inhibitory activity against Taxol resistant 1A9 cell lines,,,BAO_0000219,N,,3395,Homo sapiens,1A9
70,,,80002,9606.0,Expert,1,,F,506.0,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,,BAO_0000219,N,,3415,Homo sapiens,1A9
71,,,80002,9606.0,Expert,1,,F,506.0,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,,BAO_0000219,N,,3415,Homo sapiens,1A9
72,,,80002,9606.0,Expert,1,,F,506.0,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,,BAO_0000219,N,,17099,Homo sapiens,1A9
73,,,80002,9606.0,Intermediate,1,,F,506.0,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,,BAO_0000219,N,,17099,Homo sapiens,1A9
74,,,80002,9606.0,Intermediate,1,,F,506.0,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,,BAO_0000219,N,,17099,Homo sapiens,1A9
75,,,80002,9606.0,Intermediate,1,,F,506.0,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,,BAO_0000219,N,,17099,Homo sapiens,1A9
76,,,81072,9606.0,Intermediate,1,,F,503.0,Inhibitory concentration against Jurkat cells,,,BAO_0000219,N,,17721,Homo sapiens,Jurkat
77,,,22226,,Intermediate,1,,F,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,,BAO_0000019,U,,1229,,
78,,,100121,10116.0,Expert,1,,A,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,,BAO_0000357,D,,11347,Rattus norvegicus,
79,,,11231,,Expert,1,,B,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,BAO_0000357,H,,17117,,
80,,,11231,,Expert,1,,B,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,BAO_0000357,H,,17117,,
81,,,11231,,Expert,1,,B,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,,BAO_0000357,H,,17117,,
82,,,11231,5476.0,Autocuration,1,,B,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",Microsomes,,BAO_0000251,H,,11375,Candida albicans,
83,,,11231,5476.0,Autocuration,1,,B,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",Microsomes,,BAO_0000251,H,,11375,Candida albicans,
84,,,11231,4932.0,Autocuration,1,,B,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",Microsomes,,BAO_0000251,H,,11375,Saccharomyces cerevisiae,
85,,,11231,4932.0,Autocuration,1,,B,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",Microsomes,,BAO_0000251,H,,11375,Saccharomyces cerevisiae,
86,,2107.0,12083,9823.0,Autocuration,1,Liver,B,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",Microsomes,,BAO_0000251,H,,11375,Sus scrofa,
87,,,11231,10116.0,Autocuration,1,,B,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,,BAO_0000019,H,,791,Rattus norvegicus,
88,,,11231,10116.0,Autocuration,1,,B,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,,BAO_0000019,H,,791,Rattus norvegicus,
89,,,11231,10116.0,Autocuration,1,,B,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,,BAO_0000019,H,,791,Rattus norvegicus,
90,,2107.0,12083,10116.0,Autocuration,1,Liver,B,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",Microsomes,,BAO_0000251,D,,11375,Rattus norvegicus,
91,,2107.0,12083,10116.0,Autocuration,1,Liver,B,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Microsomes,,BAO_0000251,D,,11375,Rattus norvegicus,
92,,2107.0,12083,10116.0,Autocuration,1,Liver,B,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Microsomes,,BAO_0000251,D,,153,Rattus norvegicus,
93,,,11377,,Expert,1,,B,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,,BAO_0000357,H,,8269,,
94,,,11377,,Expert,1,,B,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,,BAO_0000357,H,,8269,,
95,,,81020,9606.0,Expert,1,,F,726.0,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,,BAO_0000219,N,,17653,Homo sapiens,HepG2
96,,,81020,9606.0,Intermediate,1,,F,726.0,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,,BAO_0000219,N,,14277,Homo sapiens,HepG2
97,,,81020,9606.0,Intermediate,1,,F,726.0,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,,BAO_0000219,N,,1717,Homo sapiens,HepG2
98,,,81020,9606.0,Intermediate,1,,F,726.0,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,,BAO_0000219,N,,14091,Homo sapiens,HepG2
99,,,81020,9606.0,Intermediate,1,,F,726.0,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,,BAO_0000219,N,,14091,Homo sapiens,HepG2
100,,,50606,10407.0,Expert,1,,F,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,,BAO_0000218,N,,17653,Hepatitis B virus,
101,,,81020,9606.0,Intermediate,1,,F,726.0,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,,BAO_0000219,N,,13105,Homo sapiens,HepG2
102,,,81020,9606.0,Intermediate,1,,F,726.0,Concentration required to inhibit 50% of 2.2.15 cell line,,,BAO_0000219,N,,1717,Homo sapiens,HepG2
103,,,81020,9606.0,Intermediate,1,,A,726.0,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,,BAO_0000219,N,,13105,Homo sapiens,HepG2
104,,,50587,9606.0,Intermediate,1,,F,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,,BAO_0000218,N,,13600,Homo sapiens,2.2.15
105,,,50587,9606.0,Intermediate,1,,F,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,,BAO_0000218,N,,13467,Homo sapiens,2.2.15
106,,,50606,10407.0,Expert,1,,F,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,,BAO_0000218,N,,17477,Hepatitis B virus,2.2.15
107,,,50587,9606.0,Intermediate,1,,F,,In vitro anti-HBV activity in 2.2.15 cells,,,BAO_0000218,N,,1593,Homo sapiens,2.2.15
108,,,50587,9606.0,Intermediate,1,,F,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,,BAO_0000218,N,,1593,Homo sapiens,2.2.15
109,,,50587,9606.0,Intermediate,1,,F,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,,BAO_0000218,N,,15089,Homo sapiens,2.2.15
110,,,50587,9606.0,Intermediate,1,,F,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,,BAO_0000218,N,,15089,Homo sapiens,2.2.15
111,,,50587,9606.0,Intermediate,1,,F,,Cytotoxicity in 2.2.15 cells,,,BAO_0000218,N,,1593,Homo sapiens,2.2.15
112,,,50587,9606.0,Intermediate,1,,F,,Cytotoxicity in 2.2.15 cells; Not determined,,,BAO_0000218,N,,1593,Homo sapiens,2.2.15
113,,,50587,9606.0,Intermediate,1,,F,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,,BAO_0000218,N,,13600,Homo sapiens,2.2.15
114,,,50587,9606.0,Intermediate,1,,F,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,,BAO_0000218,N,,13467,Homo sapiens,2.2.15
115,,,50587,9606.0,Intermediate,1,,F,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,,BAO_0000218,N,,13467,Homo sapiens,2.2.15
116,,,81020,9606.0,Intermediate,1,,F,726.0,Antiviral activity against HBV was determined in 2.215 cell line,,,BAO_0000219,N,,14764,Homo sapiens,HepG2
117,,,22226,9606.0,Autocuration,1,,B,,Inhibition of 20-HETE synthesis in human renal microsomes,Microsomes,,BAO_0000251,U,,6531,Homo sapiens,
118,,,22226,,Autocuration,1,,B,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,,BAO_0000019,U,,17322,,
119,,,80612,9606.0,Intermediate,1,,F,388.0,Inhibitory concentration against 2008 (ovarian) cells,,,BAO_0000219,N,,17072,Homo sapiens,2008
120,,,80612,9606.0,Intermediate,1,,F,388.0,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,,BAO_0000219,N,,16936,Homo sapiens,2008
121,,,80612,9606.0,Intermediate,1,,F,388.0,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,,BAO_0000219,N,,16936,Homo sapiens,2008
122,,,80612,9606.0,Intermediate,1,,F,388.0,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,,BAO_0000219,N,,17146,Homo sapiens,2008
123,,,80612,9606.0,Intermediate,1,,F,388.0,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,,BAO_0000219,N,,17146,Homo sapiens,2008
124,,,80613,9606.0,Intermediate,1,,F,561.0,In vitro inhibition of 2008/R ovarian cancer cell line,,,BAO_0000219,N,,10797,Homo sapiens,2008/R
125,,,80613,9606.0,Intermediate,1,,F,561.0,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,,BAO_0000219,N,,10797,Homo sapiens,2008/R
126,,,80614,9606.0,Intermediate,1,,F,389.0,In vitro inhibition of 2008/S ovarian cancer cell line,,,BAO_0000219,N,,10797,Homo sapiens,2008/S
127,,,80614,9606.0,Intermediate,1,,F,389.0,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,,BAO_0000219,N,,10797,Homo sapiens,2008/S
128,,,100256,9606.0,Expert,1,,B,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,,BAO_0000220,S,,4823,Homo sapiens,
129,,,100256,9606.0,Intermediate,1,,B,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,,BAO_0000220,S,,12912,Homo sapiens,
130,,,100256,,Expert,1,,B,,Inhibition of chymotrypsin-like activity of 20S proteasome,,,BAO_0000220,S,,2957,,
131,,,100256,,Expert,1,,B,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,,BAO_0000220,S,,2957,,
132,,,100256,,Intermediate,1,,B,,Inhibitory activity against 20S proteosome,,,BAO_0000220,S,,3260,,
133,,,22226,9606.0,Autocuration,1,,B,,Compound was tested for inhibitory activity against tryptase,,,BAO_0000019,U,,3451,Homo sapiens,
134,,,81020,9606.0,Intermediate,1,,F,726.0,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,,BAO_0000219,N,,13885,Homo sapiens,HepG2
135,,,81020,9606.0,Intermediate,1,,F,726.0,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,,BAO_0000219,N,,13885,Homo sapiens,HepG2
136,,,22226,,Autocuration,1,,B,,Compound was tested for the inhibition of Alpha-glucosidase,,,BAO_0000019,U,,3676,,
137,,,235,,Autocuration,1,,B,,Inhibitory concentration against human neutrophil elastase (HNE),,,BAO_0000357,H,,6043,,
138,,948.0,22226,10116.0,Autocuration,1,Heart,F,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,,BAO_0000218,U,,11140,Rattus norvegicus,
139,,,19640,,Autocuration,1,,F,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,BAO_0000019,H,,10543,,
140,,,19640,,Expert,1,,F,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,BAO_0000019,H,,10543,,
141,,,19640,,Autocuration,1,,B,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,BAO_0000357,H,,10543,,
142,,,19640,,Expert,1,,F,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,BAO_0000019,H,,10543,,
143,,,80360,10090.0,Intermediate,1,,F,524.0,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,,BAO_0000219,N,,11365,Mus musculus,P338
144,,,80360,10090.0,Intermediate,1,,F,524.0,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,,BAO_0000219,N,,11365,Mus musculus,P338
145,,,80384,9606.0,Intermediate,1,,F,554.0,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,,BAO_0000219,N,,11803,Homo sapiens,PBL
146,,,22226,9940.0,Autocuration,1,,F,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,,BAO_0000019,U,,11803,Ovis aries,
147,,,22226,9940.0,Autocuration,1,,F,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,,BAO_0000019,U,,11803,Ovis aries,
148,,,191,,Autocuration,1,,B,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,,BAO_0000357,H,,12278,,
149,,,22226,9606.0,Autocuration,1,,F,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,,BAO_0000019,U,,8249,Homo sapiens,
150,,,22226,9606.0,Autocuration,1,,F,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,,BAO_0000019,U,,8249,Homo sapiens,
151,,,22226,9606.0,Autocuration,1,,F,635.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,,BAO_0000219,U,,8249,Homo sapiens,CCRF-CEM
152,,,22226,9606.0,Autocuration,1,,F,635.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,,BAO_0000219,U,,8249,Homo sapiens,CCRF-CEM
153,,,22226,9606.0,Autocuration,1,,F,635.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,,BAO_0000219,U,,8249,Homo sapiens,CCRF-CEM
154,,,22226,9606.0,Autocuration,1,,F,635.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,,BAO_0000219,U,,8249,Homo sapiens,CCRF-CEM
155,,,22226,9606.0,Autocuration,1,,F,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,,BAO_0000019,U,,8249,Homo sapiens,
156,,,22226,9606.0,Autocuration,1,,F,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,,BAO_0000019,U,,8249,Homo sapiens,
157,,,104290,,Autocuration,1,,B,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,,BAO_0000249,H,,16992,,
158,,,50264,1314.0,Intermediate,1,,F,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,,BAO_0000218,N,,10543,Streptococcus pyogenes,
159,,,50527,10335.0,Intermediate,1,,F,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,,BAO_0000218,N,,17833,Human herpesvirus 3,
160,,,50527,10335.0,Expert,1,,F,468.0,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,,BAO_0000218,N,,17290,vericilla zoster virus,HEL
161,,,50527,10335.0,Intermediate,1,,F,,Antiviral activity against 07/1 strain of VZV; ND: No data,,,BAO_0000218,N,,17290,vericilla zoster virus,
162,,,50527,10335.0,Intermediate,1,,F,,Antiviral activity against 07/1 strain of VZV; ND=No data,,,BAO_0000218,N,,17290,vericilla zoster virus,
163,,,50145,561.0,Intermediate,1,,F,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,,BAO_0000218,N,,10932,escherichia cloac,
164,,,22226,,Autocuration,1,,B,,Ratio of Ki at A2 to Ki at A1 receptors,,,BAO_0000019,U,,9707,,
165,,,11143,5476.0,Expert,1,,B,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,,BAO_0000249,H,,2346,Candida albicans,
166,,,18077,284593.0,Expert,1,,B,,"Inhibition of 1,3-beta-glucan synthase",,,BAO_0000357,H,,2205,Candida glabrata CBS 138,
167,,,80609,9606.0,Intermediate,1,,F,832.0,Inhibition of growth of 1-87 human tumor cell line,,,BAO_0000219,N,,11900,Homo sapiens,1-87 tumor cell line
168,,,12166,10116.0,Expert,1,,B,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,,BAO_0000219,D,,14864,Rattus norvegicus,
169,,,100171,3847.0,Autocuration,1,,B,,Inhibitory activity against soybean 1-lipoxygenase (SLO),,,BAO_0000357,D,,16474,Glycine max,
170,,,100171,3847.0,Autocuration,1,,B,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,,BAO_0000357,D,,16474,Glycine max,
171,,,100171,3847.0,Autocuration,1,,B,,% inhibition against soybean 1-lipoxygenase (SLO),,,BAO_0000357,D,,16474,Glycine max,
172,,,100171,3847.0,Autocuration,1,,B,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,,BAO_0000357,D,,16474,Glycine max,
173,,,100171,3847.0,Autocuration,1,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,,BAO_0000357,D,,3094,Glycine max,
174,,,100171,3847.0,Autocuration,1,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,,BAO_0000357,D,,3094,Glycine max,
175,,,100171,3847.0,Autocuration,1,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,,BAO_0000357,D,,3094,Glycine max,
176,,,100171,3847.0,Autocuration,1,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,,BAO_0000357,D,,3094,Glycine max,
177,,,100171,3847.0,Autocuration,1,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,,BAO_0000357,D,,3094,Glycine max,
178,,,100171,3847.0,Autocuration,1,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,,BAO_0000357,D,,3094,Glycine max,
179,,,100171,3847.0,Autocuration,1,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,,BAO_0000357,D,,3094,Glycine max,
180,,,100171,3847.0,Autocuration,1,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,,BAO_0000357,D,,3094,Glycine max,
181,,,100171,3847.0,Autocuration,1,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,,BAO_0000357,D,,3094,Glycine max,
182,,,100171,3847.0,Autocuration,1,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,,BAO_0000357,D,,3094,Glycine max,
183,,,100171,3847.0,Autocuration,1,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,,BAO_0000357,D,,3094,Glycine max,
184,,,22226,10090.0,Autocuration,1,,B,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,,BAO_0000019,U,,10413,Mus musculus,
185,,,80049,10090.0,Intermediate,1,,F,294.0,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,,BAO_0000219,N,,16929,Mus musculus,C3H 10T1/2
186,,,22226,,Intermediate,1,,F,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,,BAO_0000019,U,,1229,,
187,,,11489,,Autocuration,1,,B,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,BAO_0000357,H,,16587,,
188,,,11862,,Autocuration,1,,B,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,BAO_0000357,H,,16587,,
189,,,11862,,Autocuration,1,,B,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,,BAO_0000357,H,,16587,,
190,,,11489,,Autocuration,1,,B,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,,BAO_0000357,H,,16587,,
191,,,11862,,Autocuration,1,,B,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,,BAO_0000357,H,,16587,,
192,,,12347,9913.0,Expert,1,,F,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,,BAO_0000019,D,,8058,Bos taurus,
193,,,100120,10116.0,Expert,1,,B,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,,BAO_0000357,D,,9065,Rattus norvegicus,
194,,2369.0,100120,10116.0,Expert,1,Adrenal gland,B,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,,BAO_0000357,D,,8865,Rattus norvegicus,
195,,,100120,10116.0,Expert,1,,B,,Inhibition of rat adrenal 11-beta-hydroxylase,,,BAO_0000357,D,,9066,Rattus norvegicus,
196,,,100120,10116.0,Expert,1,,B,,Inhibition of rat adrenal 11-beta-hydroxylase,,,BAO_0000357,D,,8394,Rattus norvegicus,
197,,,100120,10116.0,Expert,1,,B,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,,BAO_0000357,D,,8394,Rattus norvegicus,
198,,,10328,,Autocuration,1,,B,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,,BAO_0000019,H,,6431,,
199,,,11490,,Autocuration,1,,B,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,BAO_0000357,H,,6431,,
200,,,11490,,Autocuration,1,,B,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,BAO_0000357,H,,6431,,
201,,,11134,,Autocuration,1,,F,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,,BAO_0000019,H,,9295,,
202,,,12052,,Autocuration,1,,B,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,BAO_0000019,H,,10193,,
203,,,11134,,Autocuration,1,,B,,Compound was tested in vitro for inhibition of 12-LO human platelet,,,BAO_0000019,H,,13622,,
204,,,11134,,Autocuration,1,,F,,Inhibitory concentration against human platelet 12-lipoxygenase,,,BAO_0000019,H,,12079,,
205,,,11134,,Autocuration,1,,B,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,,BAO_0000019,H,,13622,,
206,,,11134,9606.0,Autocuration,1,,F,,Inhibitory concentration against human platelet 12-lipoxygenase,,,BAO_0000019,D,,12079,Homo sapiens,
207,,,11835,,Expert,1,,B,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,,BAO_0000019,H,,13500,,
208,,,11601,,Expert,1,,B,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,,BAO_0000357,H,,13723,,
209,,,11134,,Autocuration,1,,B,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,,BAO_0000019,H,,16474,,
210,,,11134,,Autocuration,1,,B,,Inhibitory activity against human platelet 12-lipoxygenase,,,BAO_0000019,H,,1630,,
211,,,11134,,Autocuration,1,,B,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,,BAO_0000019,H,,167,,
212,,,11134,,Autocuration,1,,B,,% inhibition against human platelet 12-lipoxygenase (12-HLO),,,BAO_0000019,H,,16474,,
213,,,11134,,Autocuration,1,,B,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,,BAO_0000019,H,,167,,
214,,,11134,,Autocuration,1,,B,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,,BAO_0000019,H,,16474,,
215,,,11601,,Autocuration,1,,B,,Inhibitory activity towards porcine 12-lipoxygenase,,,BAO_0000357,H,,10091,,
216,,,11601,,Autocuration,1,,B,,Tested for inhibition against porcine 12-LO,,,BAO_0000357,H,,11966,,
217,,,12052,,Autocuration,1,,B,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,,BAO_0000019,H,,951,,
218,,,12052,,Autocuration,1,,B,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,,BAO_0000019,H,,10997,,
219,,,12052,,Expert,1,,B,,In vitro inhibition of rat platelet 12-lipoxygenase,,,BAO_0000019,H,,10193,,
220,,,12052,,Autocuration,1,,B,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,BAO_0000019,H,,10193,,
221,,,12052,,Autocuration,1,,B,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,,BAO_0000019,H,,10193,,
222,,,12052,,Autocuration,1,,B,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,,BAO_0000019,H,,10193,,
223,,,12052,,Autocuration,1,,B,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,BAO_0000019,H,,10193,,
224,,,12052,,Autocuration,1,,B,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,,BAO_0000019,H,,10193,,
225,,,12052,,Autocuration,1,,B,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,,BAO_0000019,H,,11087,,
226,,,80007,9606.0,Intermediate,1,,F,621.0,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,,BAO_0000219,N,,15569,Homo sapiens,41M
227,,,80007,9606.0,Expert,1,,F,621.0,In vitro antitumor activity against 41M cell line.,,,BAO_0000219,N,,12989,Homo sapiens,41M
228,,,80007,9606.0,Intermediate,1,,F,621.0,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,,BAO_0000219,N,,16745,Homo sapiens,41M
229,,,80007,9606.0,Intermediate,1,,F,621.0,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,,BAO_0000219,N,,15569,Homo sapiens,41M
230,,,80007,9606.0,Expert,1,,F,621.0,In vitro antitumor activity against 41McisR cell line.,,,BAO_0000219,N,,12989,Homo sapiens,41M
231,,,80007,9606.0,Expert,1,,F,621.0,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,,BAO_0000219,N,,12989,Homo sapiens,41M
232,,,80007,9606.0,Intermediate,1,,F,621.0,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,,BAO_0000219,N,,16745,Homo sapiens,41M
233,,,84,9606.0,Expert,1,,B,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,,BAO_0000357,D,,6210,Homo sapiens,
234,,,68,9606.0,Expert,1,,B,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,BAO_0000357,D,,6210,Homo sapiens,
235,,,68,,Expert,1,,B,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,BAO_0000357,H,,6226,,
236,,,10201,,Expert,1,,B,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,BAO_0000357,H,,17855,,
237,,,10201,,Expert,1,,B,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,,BAO_0000357,H,,17855,,
238,,,10201,,Expert,1,,B,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,BAO_0000357,H,,17855,,
239,,,12220,,Autocuration,1,,B,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,BAO_0000357,H,,10413,,
240,,,11303,562.0,Autocuration,1,,B,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,,BAO_0000357,H,,10413,Escherichia coli,
241,,,11303,562.0,Autocuration,1,,B,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,,BAO_0000357,H,,10413,Escherichia coli,
242,,,11303,562.0,Autocuration,1,,B,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,,BAO_0000357,H,,10413,Escherichia coli,
243,,,12220,,Autocuration,1,,B,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,BAO_0000357,H,,10413,,
244,,,12220,,Autocuration,1,,B,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,,BAO_0000357,H,,10413,,
245,,,11303,9823.0,Autocuration,1,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,BAO_0000357,H,,7587,Sus scrofa,
246,,,11303,9823.0,Autocuration,1,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,,BAO_0000019,H,,7587,Sus scrofa,
247,,,11303,9823.0,Autocuration,1,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,,BAO_0000357,H,,7587,Sus scrofa,
248,,,11303,9823.0,Autocuration,1,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,,BAO_0000357,H,,7587,Sus scrofa,
249,,,11303,9823.0,Autocuration,1,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,BAO_0000357,H,,7587,Sus scrofa,
250,,,11303,9823.0,Autocuration,1,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,,BAO_0000019,H,,7587,Sus scrofa,
251,,,11303,9823.0,Autocuration,1,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,,BAO_0000019,H,,7587,Sus scrofa,
252,,,11303,9823.0,Autocuration,1,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,,BAO_0000019,H,,7587,Sus scrofa,
253,,,11303,9823.0,Autocuration,1,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,,BAO_0000019,H,,7587,Sus scrofa,
254,,,11303,9823.0,Autocuration,1,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,,BAO_0000019,H,,7587,Sus scrofa,
255,,,11303,9823.0,Autocuration,1,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,BAO_0000357,H,,7587,Sus scrofa,
256,,,11303,9823.0,Autocuration,1,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,,BAO_0000019,H,,7587,Sus scrofa,
257,,,11303,,Autocuration,1,,B,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,,BAO_0000357,H,,7323,,
258,,,22226,9823.0,Autocuration,1,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,,BAO_0000019,U,,7587,Sus scrofa,
259,,,22226,9823.0,Autocuration,1,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,,BAO_0000019,U,,7587,Sus scrofa,
260,,,100249,4932.0,Expert,1,,B,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,,BAO_0000357,H,,13750,Saccharomyces cerevisiae,
261,,,22226,10116.0,Autocuration,1,,B,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,,BAO_0000019,U,,7662,Rattus norvegicus,
262,,,22226,10116.0,Autocuration,1,,B,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,,BAO_0000019,U,,7662,Rattus norvegicus,
263,,,22226,10116.0,Autocuration,1,,B,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,,BAO_0000019,U,,7662,Rattus norvegicus,
264,,,104698,,Autocuration,1,,F,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,BAO_0000019,H,,12211,,
265,,,104698,,Autocuration,1,,F,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,BAO_0000019,H,,12211,,
266,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,,BAO_0000221,D,,12211,Cavia porcellus,
267,,,10623,,Expert,1,,F,,Stimulatory activity of intragastric pressure was tested in the rat,,,BAO_0000019,H,,12211,,
268,,,121,,Autocuration,1,,B,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,,BAO_0000357,H,,15453,,
269,,,22226,10116.0,Autocuration,1,,F,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,,BAO_0000218,U,,11884,Rattus norvegicus,
270,,,12688,,Autocuration,1,,F,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,BAO_0000019,H,,7185,,
271,,,121,9606.0,Expert,1,,B,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,,BAO_0000357,D,,6876,Homo sapiens,
272,,,121,9606.0,Expert,1,,B,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,,BAO_0000357,D,,6876,Homo sapiens,
273,,,12198,,Autocuration,1,,F,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,,BAO_0000019,H,,11863,,
274,,,12198,,Autocuration,1,,B,,Inhibition constant of high-affinity 5-HT uptake,,,BAO_0000357,H,,11863,,
275,,,12198,,Autocuration,1,,F,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,,BAO_0000019,H,,11863,,
276,,,12198,,Autocuration,1,,F,,Maximum rate was determined for high affinity transport of 5-HT,,,BAO_0000019,H,,11863,,
277,,,104714,,Autocuration,1,,F,,Compound was tested for agonistic activity against 5-HT uptake,,,BAO_0000019,H,,4639,,
278,,,10577,,Expert,1,,B,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,,BAO_0000019,H,,15796,,
279,,,105,9913.0,Expert,1,,B,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,,BAO_0000357,H,,15796,Bos taurus,
280,,,104744,10116.0,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,BAO_0000224,D,,12801,Rattus norvegicus,
281,,,104744,,Autocuration,1,,B,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,,BAO_0000224,H,,12801,,
282,,,104744,,Autocuration,1,,B,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,Membranes,,BAO_0000249,H,,12120,,
283,,,104744,,Autocuration,1,,B,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,Membranes,,BAO_0000249,H,,12120,,
284,,,104744,,Autocuration,1,,B,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,BAO_0000019,H,,11963,,
285,,,51,,Autocuration,1,,F,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,,BAO_0000019,H,,11701,,
286,,10000000.0,51,,Autocuration,1,Hippocampus,B,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,BAO_0000221,H,,9995,,
287,,10000000.0,51,,Autocuration,1,Hippocampus,B,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,BAO_0000221,H,,9995,,
288,,10000000.0,51,,Autocuration,1,Hippocampus,B,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,BAO_0000221,H,,9995,,
289,In vivo,,10576,,Autocuration,1,,F,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,,BAO_0000218,H,,16394,,
290,,,105570,10141.0,Intermediate,1,,F,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,,BAO_0000019,D,,11574,Cavia porcellus,
291,,,279,,Autocuration,1,,B,449.0,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,BAO_0000219,H,,15779,,CHO
292,,,107,,Autocuration,1,,B,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,15363,,
293,,,12687,10116.0,Expert,1,,F,,Efficacy against 5-hydroxytryptamine 2A receptor,,,BAO_0000019,D,,15363,Rattus norvegicus,
294,,,12687,,Expert,1,,F,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,,BAO_0000019,H,,15329,,
295,,,12687,,Expert,1,,F,,Relative potency towards 5-HT2A receptor of rat tail artery,,,BAO_0000019,H,,15329,,
296,,,12687,,Expert,1,,F,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,BAO_0000019,H,,15329,,
297,,,12687,,Expert,1,,F,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,,BAO_0000019,H,,15329,,
298,,,12687,,Autocuration,1,,F,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,,BAO_0000019,H,,15329,,
299,,,12687,,Expert,1,,F,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,BAO_0000019,H,,15329,,
300,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,,BAO_0000221,D,,273,Cavia porcellus,
301,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,,BAO_0000221,D,,273,Cavia porcellus,
302,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,,BAO_0000221,D,,273,Cavia porcellus,
303,,,10623,,Autocuration,1,,B,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,,BAO_0000357,H,,12092,,
304,,,10623,10116.0,Expert,1,,F,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,BAO_0000019,D,,1317,Rattus norvegicus,
305,,,168,,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 4 receptor,,,BAO_0000357,H,,12409,,
306,,,22226,9031.0,Autocuration,1,,B,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,,BAO_0000019,U,,11126,Gallus gallus,
307,,,22226,9606.0,Autocuration,1,,F,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,,BAO_0000019,U,,11126,Homo sapiens,
308,,,22226,9606.0,Autocuration,1,,F,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,,BAO_0000019,U,,11126,Homo sapiens,
309,,,80156,9606.0,Autocuration,1,,B,649.0,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,,BAO_0000219,N,,11126,Homo sapiens,HL-60
310,,,22226,9606.0,Autocuration,1,,B,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,,BAO_0000019,U,,11126,Homo sapiens,
311,,,22226,9606.0,Autocuration,1,,B,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,,BAO_0000019,U,,11126,Homo sapiens,
312,,,104703,9606.0,Autocuration,1,,B,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,,BAO_0000219,D,,17807,Homo sapiens,Oocytes
313,,,100256,,Intermediate,1,,F,,Chymotryptic inhibitory activity against 26S proteasome,,,BAO_0000220,S,,16575,,
314,,,100256,,Intermediate,1,,B,,Inhibitory activity against 26S proteasome degradation of IkB,,,BAO_0000220,S,,15407,,
315,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro inhibition of 2780/DOX ovarian cancer cell line,,,BAO_0000219,N,,10797,Homo sapiens,A2780
316,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro inhibition of 2780/S ovarian cancer cell line,,,BAO_0000219,N,,10797,Homo sapiens,A2780
317,,,22226,9606.0,Autocuration,1,,F,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,,BAO_0000019,U,,3469,Homo sapiens,
318,,,22222,,Intermediate,1,,B,,Association constant for binding to AATT 28-mer AATT hairpin,,,BAO_0000225,M,,16037,,
319,,,22222,,Intermediate,1,,B,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,,BAO_0000225,M,,16037,,
320,,,22222,,Intermediate,1,,B,,Reaction Rate Parameter for 28-mer AATT hairpin,,,BAO_0000225,M,,16037,,
321,,,22222,,Intermediate,1,,B,,Reaction Rate Parameter for 28-mer AATT hairpin,,,BAO_0000225,M,,16037,,
322,,,22226,9606.0,Autocuration,1,,F,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,,BAO_0000019,U,,16524,Homo sapiens,
323,,,22226,9606.0,Autocuration,1,,F,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,,BAO_0000019,U,,16524,Homo sapiens,
324,,,22226,9606.0,Autocuration,1,,F,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,,BAO_0000019,U,,16524,Homo sapiens,
325,,,22226,10029.0,Autocuration,1,,F,,Cytotoxicity against cell line 2SC/20 determined by MTT test,,,BAO_0000019,U,,16758,Cricetulus griseus,
326,,,22226,10029.0,Autocuration,1,,F,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,,BAO_0000019,U,,16758,Cricetulus griseus,
327,,,22226,10029.0,Autocuration,1,,F,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,,BAO_0000019,U,,16758,Cricetulus griseus,
328,,,241,,Autocuration,1,,B,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,,BAO_0000357,H,,14360,,
329,,,241,9606.0,Expert,1,,B,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,,BAO_0000357,D,,14360,Homo sapiens,
330,,,22226,10116.0,Autocuration,1,,B,,Selectivity ratio of ID50 in liver and heart,,,BAO_0000019,U,,9964,Rattus norvegicus,
331,,,12132,,Autocuration,1,,B,,"Selectivity, ratio of relative ID50 in liver and heart",,,BAO_0000019,H,,9964,,
332,,,12132,,Autocuration,1,,B,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,,BAO_0000019,H,,9964,,
333,,,12132,,Autocuration,1,,B,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,BAO_0000218,H,,9964,,
334,,,12132,,Autocuration,1,,B,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,BAO_0000218,H,,9964,,
335,In vivo,,12132,,Autocuration,1,,B,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,BAO_0000218,H,,9964,,
336,In vivo,,12132,,Autocuration,1,,F,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,BAO_0000218,H,,9964,,
337,,,22226,,Autocuration,1,,B,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,,BAO_0000019,U,,9964,,
338,,,12132,,Autocuration,1,,B,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,,BAO_0000019,H,,9964,,
339,,,22226,9606.0,Autocuration,1,,B,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,,BAO_0000019,U,,9964,Homo sapiens,
340,,,12132,,Autocuration,1,,B,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,BAO_0000019,H,,9964,,
341,,,12132,,Autocuration,1,,F,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,BAO_0000019,H,,9964,,
342,,,12132,,Autocuration,1,,B,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,,BAO_0000019,H,,9964,,
343,,,22226,10116.0,Autocuration,1,,B,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,,BAO_0000218,U,,9964,Rattus norvegicus,
344,In vivo,,12132,,Autocuration,1,,B,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,,BAO_0000218,H,,9964,,
345,,,12132,,Autocuration,1,,B,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,BAO_0000218,H,,9964,,
346,,,22226,10116.0,Autocuration,1,,B,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,,BAO_0000218,U,,9964,Rattus norvegicus,
347,,,12132,,Autocuration,1,,B,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,BAO_0000019,H,,9964,,
348,,,12132,,Autocuration,1,,F,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,BAO_0000019,H,,9964,,
349,,,22226,10116.0,Autocuration,1,,B,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,,BAO_0000019,U,,3796,Rattus norvegicus,
350,,,19690,562.0,Autocuration,1,,B,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,,BAO_0000357,H,,4251,Escherichia coli,
351,,,19690,562.0,Autocuration,1,,B,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,,BAO_0000357,H,,4251,Escherichia coli,
352,,,19690,562.0,Autocuration,1,,B,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,,BAO_0000357,H,,4251,Escherichia coli,
353,,,19690,562.0,Autocuration,1,,B,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,,BAO_0000357,H,,4251,Escherichia coli,
354,,,19690,,Autocuration,1,,B,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,,BAO_0000357,H,,166,,
355,,,19690,,Autocuration,1,,B,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,,BAO_0000357,H,,17861,,
356,,,19690,,Autocuration,1,,B,,Inhibition constant against 3-dehydroquinate synthase,,,BAO_0000357,H,,166,,
357,,,19690,,Autocuration,1,,B,,Association rate constant against 3-dehydroquinate synthase,,,BAO_0000357,H,,166,,
358,,,19690,,Autocuration,1,,B,,Rate constant against 3-dehydroquinate synthase,,,BAO_0000357,H,,166,,
359,,,22226,,Autocuration,1,,B,,Inhibitory activity against fuc-TVII,,,BAO_0000019,U,,3548,,
360,,2107.0,12236,10116.0,Autocuration,1,Liver,B,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,,BAO_0000251,D,,9877,Rattus norvegicus,
361,,2107.0,12236,10116.0,Autocuration,1,Liver,B,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,,BAO_0000251,D,,9877,Rattus norvegicus,
362,,2107.0,12236,10116.0,Autocuration,1,Liver,B,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,,BAO_0000251,D,,9877,Rattus norvegicus,
363,,2107.0,12236,10116.0,Autocuration,1,Liver,B,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,,BAO_0000251,D,,9877,Rattus norvegicus,
364,,2107.0,12236,10116.0,Autocuration,1,Liver,B,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,,BAO_0000251,D,,9877,Rattus norvegicus,
365,,2107.0,12236,10116.0,Autocuration,1,Liver,B,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,Microsomes,,BAO_0000251,D,,9877,Rattus norvegicus,
366,,2107.0,12236,10116.0,Autocuration,1,Liver,B,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,Microsomes,,BAO_0000251,D,,9877,Rattus norvegicus,
367,,2107.0,12236,10116.0,Autocuration,1,Liver,B,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,Microsomes,,BAO_0000251,D,,9877,Rattus norvegicus,
368,,2107.0,12236,10116.0,Autocuration,1,Liver,B,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,Microsomes,,BAO_0000251,D,,9877,Rattus norvegicus,
369,,2107.0,12236,10116.0,Autocuration,1,Liver,B,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,Microsomes,,BAO_0000251,D,,9877,Rattus norvegicus,
370,,2107.0,12236,10116.0,Autocuration,1,Liver,B,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,Microsomes,,BAO_0000251,D,,9877,Rattus norvegicus,
371,,,104832,,Autocuration,1,,B,,Inhibitory activity against 3-phosphoglycerate kinase.,,,BAO_0000224,H,,3003,,
372,,,104832,,Autocuration,1,,B,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,,BAO_0000224,H,,3003,,
373,,,104832,,Autocuration,1,,B,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,,BAO_0000224,H,,3003,,
374,,,10612,9606.0,Expert,1,,B,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,,BAO_0000357,D,,17185,Homo sapiens,
375,,,80616,9606.0,Intermediate,1,,F,844.0,Cytotoxicity on 3677 melanoma cells,,,BAO_0000219,N,,6072,Homo sapiens,3677 melanoma cell line
376,,,80616,9606.0,Intermediate,1,,F,844.0,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,,BAO_0000219,N,,6072,Homo sapiens,3677 melanoma cell line
377,,,80617,10090.0,Intermediate,1,,F,700.0,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,,BAO_0000219,N,,5018,Mus musculus,MC-38
378,,,22226,9606.0,Intermediate,1,,F,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,,BAO_0000019,U,,2852,Homo sapiens,
379,,,22226,,Autocuration,1,,F,798.0,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,,BAO_0000218,U,,8663,,B16
380,,,22226,,Autocuration,1,,F,798.0,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,,BAO_0000218,U,,8663,,B16
381,,,12464,12131.0,Expert,1,,F,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,,BAO_0000019,D,,3245,Human rhinovirus 14,
382,,,50085,169066.0,Intermediate,1,,F,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,,BAO_0000218,N,,3245,Human rhinovirus sp.,
383,,,50679,169066.0,Intermediate,1,,F,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,,BAO_0000218,N,,3877,human rhinovirus type 14,
384,,,50679,169066.0,Intermediate,1,,F,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,,BAO_0000218,N,,3877,human rhinovirus type 14,
385,,,12464,12131.0,Expert,1,,F,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,BAO_0000019,D,,5861,Human rhinovirus 14,
386,,,12464,12131.0,Expert,1,,F,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,BAO_0000019,D,,5861,Human rhinovirus 14,
387,,,12464,12131.0,Expert,1,,F,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,BAO_0000019,D,,5861,Human rhinovirus 14,
388,,,12464,12131.0,Expert,1,,F,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,,BAO_0000019,D,,5861,Human rhinovirus 14,
389,,,50665,12059.0,Intermediate,1,,F,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,,BAO_0000218,N,,13748,Enterovirus,
390,,,50665,12059.0,Intermediate,1,,F,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,,BAO_0000218,N,,13748,Enterovirus,
391,,,50665,12059.0,Intermediate,1,,F,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,,BAO_0000218,N,,13748,Enterovirus,
392,,,50665,12059.0,Intermediate,1,,F,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,,BAO_0000218,N,,13748,Enterovirus,
393,,,12464,147712.0,Expert,1,,B,,Inhibition of human rhinovirus 3C protease,,,BAO_0000357,H,,13748,Human rhinovirus B,
394,,,22226,9606.0,Autocuration,1,,B,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,,BAO_0000019,U,,17699,Homo sapiens,
395,,,80619,10090.0,Intermediate,1,,F,833.0,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,,BAO_0000218,N,,7145,Mus musculus,3EM 37
396,,,80619,10090.0,Intermediate,1,,F,833.0,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,,BAO_0000218,N,,7145,Mus musculus,3EM 37
397,,,80619,10090.0,Intermediate,1,,F,833.0,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,,BAO_0000218,N,,7145,Mus musculus,3EM 37
398,,,80619,10090.0,Intermediate,1,,F,833.0,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,,BAO_0000218,N,,7145,Mus musculus,3EM 37
399,,,80619,10090.0,Intermediate,1,,F,833.0,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,,BAO_0000218,N,,7145,Mus musculus,3EM 37
400,,,80619,10090.0,Intermediate,1,,F,833.0,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,,BAO_0000218,N,,7145,Mus musculus,3EM 37
401,,,80620,10090.0,Intermediate,1,,F,847.0,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,,BAO_0000218,N,,5325,Mus musculus,3LL cell line
402,,,80620,10090.0,Intermediate,1,,F,847.0,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,,BAO_0000218,N,,5325,Mus musculus,3LL cell line
403,,,80620,10090.0,Expert,1,,F,847.0,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,,BAO_0000218,N,,5325,Mus musculus,3LL cell line
404,,,80620,10090.0,Intermediate,1,,F,847.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
405,,,80620,10090.0,Intermediate,1,,F,847.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
406,,,80620,10090.0,Intermediate,1,,F,847.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
407,,,80620,10090.0,Intermediate,1,,F,847.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
408,,,80620,10090.0,Intermediate,1,,F,847.0,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
409,,,80620,10090.0,Intermediate,1,,F,847.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
410,,,80620,10090.0,Intermediate,1,,F,847.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
411,,,80620,10090.0,Intermediate,1,,F,847.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
412,,,80620,10090.0,Intermediate,1,,F,847.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
413,,,80620,10090.0,Intermediate,1,,F,847.0,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
414,,,80620,10090.0,Intermediate,1,,F,847.0,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
415,,,80620,10090.0,Intermediate,1,,F,847.0,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
416,,,80620,10090.0,Intermediate,1,,F,847.0,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
417,,,80620,10090.0,Intermediate,1,,F,847.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
418,,,80620,10090.0,Intermediate,1,,F,847.0,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
419,,,80620,10090.0,Intermediate,1,,F,847.0,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
420,,,80620,10090.0,Intermediate,1,,F,847.0,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
421,,,80620,10090.0,Intermediate,1,,F,847.0,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
422,,,80620,10090.0,Intermediate,1,,F,847.0,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
423,,,80620,10090.0,Intermediate,1,,F,847.0,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
424,,,80620,10090.0,Intermediate,1,,F,847.0,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
425,,,80620,10090.0,Intermediate,1,,F,847.0,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
426,,,80620,10090.0,Intermediate,1,,F,847.0,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
427,,,80620,10090.0,Intermediate,1,,F,847.0,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
428,,,80620,10090.0,Intermediate,1,,F,847.0,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
429,,,80620,10090.0,Intermediate,1,,F,847.0,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,,BAO_0000219,N,,16169,Mus musculus,3LL cell line
430,,,80621,9606.0,Intermediate,1,,F,971.0,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,,BAO_0000219,N,,15547,Homo sapiens,3LLD122
431,,,22226,,Autocuration,1,,F,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,,BAO_0000218,U,,8663,,
432,,,22226,,Autocuration,1,,F,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,,BAO_0000218,U,,8663,,
433,,,22226,,Autocuration,1,,F,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,,BAO_0000218,U,,8663,,
434,,,22226,,Autocuration,1,,F,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,,BAO_0000218,U,,8663,,
435,,,80951,10090.0,Intermediate,1,,F,723.0,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,,BAO_0000219,N,,4504,Mus musculus,NIH3T3
436,,,80951,10090.0,Intermediate,1,,F,723.0,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,,BAO_0000219,N,,4504,Mus musculus,NIH3T3
437,,,11169,,Expert,1,,F,723.0,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,,BAO_0000219,H,,12695,,NIH3T3
438,,,80951,10090.0,Intermediate,1,,F,723.0,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,,BAO_0000219,N,,12695,Mus musculus,NIH3T3
439,,,80951,10090.0,Intermediate,1,,F,723.0,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,,BAO_0000219,N,,12695,Mus musculus,NIH3T3
440,,,80951,10090.0,Expert,1,,F,723.0,Effective dose against murine 3T3 fibroblasts cells,,,BAO_0000219,N,,17642,Mus musculus,NIH3T3
441,,,80951,10090.0,Expert,1,,F,723.0,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,,BAO_0000219,N,,17642,Mus musculus,NIH3T3
442,,,80951,10090.0,Expert,1,,F,723.0,Cytotoxic effect on 3T3 cells,,,BAO_0000219,N,,12340,Mus musculus,NIH3T3
443,,,80951,10090.0,Expert,1,,F,723.0,Cytotoxic effect on 3T3 cells,,,BAO_0000219,N,,12340,Mus musculus,NIH3T3
444,,,80951,10090.0,Intermediate,1,,F,723.0,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,,BAO_0000219,N,,12716,Mus musculus,NIH3T3
445,,,80951,10090.0,Intermediate,1,,F,723.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,,BAO_0000219,N,,6277,Mus musculus,NIH3T3
446,,,80951,10090.0,Intermediate,1,,F,723.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,,BAO_0000219,N,,6277,Mus musculus,NIH3T3
447,,,80951,10090.0,Expert,1,,F,723.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,,BAO_0000219,N,,6277,Mus musculus,NIH3T3
448,,,80951,10090.0,Expert,1,,F,723.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,,BAO_0000219,N,,6277,Mus musculus,NIH3T3
449,,,80951,10090.0,Intermediate,1,,F,723.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,,BAO_0000219,N,,6277,Mus musculus,NIH3T3
450,,,80951,10090.0,Expert,1,,F,723.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,,BAO_0000219,N,,6277,Mus musculus,NIH3T3
451,,,80951,10090.0,Expert,1,,F,723.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,,BAO_0000219,N,,6277,Mus musculus,NIH3T3
452,,,80951,10090.0,Intermediate,1,,F,723.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,,BAO_0000219,N,,6277,Mus musculus,NIH3T3
453,,,80951,10090.0,Expert,1,,F,723.0,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,,BAO_0000218,N,,17780,Mus musculus,NIH3T3
454,,,104860,10090.0,Autocuration,1,,F,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,,BAO_0000219,D,,12751,Mus musculus,
455,,,80951,10090.0,Expert,1,,F,723.0,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,,BAO_0000219,N,,12380,Mus musculus,NIH3T3
456,,,80951,10090.0,Intermediate,1,,F,723.0,Inhibitory activity against 3T3 cell line,,,BAO_0000219,N,,14892,Mus musculus,NIH3T3
457,,,80951,10090.0,Intermediate,1,,F,723.0,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,,BAO_0000219,N,,12695,Mus musculus,NIH3T3
458,,,11169,,Expert,1,,F,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,,BAO_0000019,H,,12695,,
459,,,80951,10090.0,Intermediate,1,,F,723.0,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,,BAO_0000219,N,,12695,Mus musculus,NIH3T3
460,,,80951,10090.0,Intermediate,1,,F,723.0,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,,BAO_0000219,N,,12695,Mus musculus,NIH3T3
461,,,11169,,Expert,1,,F,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,,BAO_0000019,H,,12695,,
462,,,11169,,Expert,1,,F,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,,BAO_0000019,H,,12695,,
463,,,80951,10090.0,Intermediate,1,,F,723.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,,BAO_0000219,N,,6277,Mus musculus,NIH3T3
464,,,80951,10090.0,Expert,1,,F,723.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,,BAO_0000219,N,,6277,Mus musculus,NIH3T3
465,,,9,9606.0,Expert,1,,F,723.0,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,,BAO_0000219,D,,4959,Homo sapiens,NIH3T3
466,,,9,9606.0,Expert,1,,F,723.0,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,,BAO_0000219,D,,4959,Homo sapiens,NIH3T3
467,,,188,9606.0,Expert,1,,F,723.0,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,,BAO_0000219,D,,4959,Homo sapiens,NIH3T3
468,,,188,9606.0,Expert,1,,F,723.0,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,,BAO_0000219,D,,4959,Homo sapiens,NIH3T3
469,,,80951,10090.0,Intermediate,1,,F,723.0,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,,BAO_0000219,N,,12082,Mus musculus,NIH3T3
470,,,80951,10090.0,Intermediate,1,,F,723.0,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,,BAO_0000219,N,,12082,Mus musculus,NIH3T3
471,,,80951,10090.0,Intermediate,1,,F,723.0,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,,BAO_0000219,N,,12082,Mus musculus,NIH3T3
472,,,80951,10090.0,Intermediate,1,,F,723.0,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,,BAO_0000219,N,,12082,Mus musculus,NIH3T3
473,,,80951,10090.0,Intermediate,1,,F,723.0,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,,BAO_0000219,N,,2643,Mus musculus,NIH3T3
474,,,80951,10090.0,Expert,1,,F,723.0,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,,BAO_0000219,N,,11926,Mus musculus,NIH3T3
475,,,80951,10090.0,Intermediate,1,,A,723.0,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,,BAO_0000219,N,,15204,Mus musculus,NIH3T3
476,,,80951,10090.0,Expert,1,,F,723.0,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,,BAO_0000219,N,,15992,Mus musculus,NIH3T3
477,,,80951,10090.0,Intermediate,1,,F,723.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,,BAO_0000219,N,,16279,Mus musculus,NIH3T3
478,,,80951,10090.0,Intermediate,1,,F,723.0,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,BAO_0000219,N,,16279,Mus musculus,NIH3T3
479,,,80951,10090.0,Intermediate,1,,F,723.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,BAO_0000219,N,,16279,Mus musculus,NIH3T3
480,,,80951,10090.0,Intermediate,1,,F,723.0,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,BAO_0000219,N,,16279,Mus musculus,NIH3T3
481,,,80951,10090.0,Intermediate,1,,F,723.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,BAO_0000219,N,,16279,Mus musculus,NIH3T3
482,,,80951,10090.0,Intermediate,1,,F,723.0,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,BAO_0000219,N,,16279,Mus musculus,NIH3T3
483,,,80951,10090.0,Expert,1,,F,723.0,Inhibition of swiss 3T3 mouse fibroblast proliferation,,,BAO_0000219,N,,12831,Mus musculus,NIH3T3
484,,,80951,10090.0,Intermediate,1,,F,723.0,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,,BAO_0000219,N,,13497,Mus musculus,NIH3T3
485,,,80006,,Intermediate,1,,F,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,BAO_0000218,N,,13715,,3T3-L1
486,,,80006,10090.0,Intermediate,1,,F,620.0,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,,BAO_0000219,N,,13618,Mus musculus,3T3-L1
487,,,80006,10090.0,Intermediate,1,,F,620.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,,BAO_0000219,N,,11902,Mus musculus,3T3-L1
488,,,80006,10090.0,Intermediate,1,,F,620.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,,BAO_0000219,N,,11902,Mus musculus,3T3-L1
489,,,80006,10090.0,Intermediate,1,,F,620.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,,BAO_0000219,N,,11902,Mus musculus,3T3-L1
490,,,80006,10090.0,Intermediate,1,,F,620.0,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,,BAO_0000218,N,,14840,Mus musculus,3T3-L1
491,,,80006,10090.0,Intermediate,1,,F,620.0,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,,BAO_0000218,N,,14840,Mus musculus,3T3-L1
492,,,80006,,Intermediate,1,,F,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,,BAO_0000219,N,,13715,,3T3-L1
493,,,80006,,Intermediate,1,,F,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,,BAO_0000219,N,,13715,,3T3-L1
494,,,80006,,Intermediate,1,,F,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,BAO_0000219,N,,13715,,3T3-L1
495,,,80006,,Intermediate,1,,F,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,,BAO_0000219,N,,13715,,3T3-L1
496,,,80006,,Intermediate,1,,F,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,BAO_0000219,N,,13715,,3T3-L1
497,,,80006,,Intermediate,1,,F,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,,BAO_0000218,N,,13715,,3T3-L1
498,,,80006,,Intermediate,1,,F,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,,BAO_0000218,N,,13715,,3T3-L1
499,,,80006,,Intermediate,1,,F,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,,BAO_0000218,N,,13715,,3T3-L1
500,,,80006,,Intermediate,1,,F,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,BAO_0000218,N,,13715,,3T3-L1
501,,,80006,,Expert,1,,F,620.0,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,,BAO_0000218,N,,13715,,3T3-L1
502,,,80006,,Expert,1,,F,620.0,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,BAO_0000218,N,,13715,,3T3-L1
503,,,80006,,Intermediate,1,,F,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,,BAO_0000218,N,,13715,,3T3-L1
504,,,80006,,Intermediate,1,,F,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,BAO_0000218,N,,13715,,3T3-L1
505,,,80006,,Intermediate,1,,F,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,,BAO_0000218,N,,13715,,3T3-L1
506,,,80006,,Expert,1,,F,620.0,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,BAO_0000218,N,,13715,,3T3-L1
507,,,80006,,Expert,1,,F,620.0,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,BAO_0000218,N,,13715,,3T3-L1
508,,,80006,,Expert,1,,F,620.0,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,,BAO_0000218,N,,13715,,3T3-L1
509,,,80006,,Intermediate,1,,F,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,,BAO_0000219,N,,13715,,3T3-L1
510,,,80006,,Intermediate,1,,F,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,BAO_0000219,N,,13715,,3T3-L1
511,,,80006,,Intermediate,1,,F,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,,BAO_0000219,N,,13715,,3T3-L1
512,,,80006,,Intermediate,1,,F,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,,BAO_0000218,N,,13715,,3T3-L1
513,,,80006,,Intermediate,1,,F,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,BAO_0000218,N,,13715,,3T3-L1
514,,,80006,,Intermediate,1,,F,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,BAO_0000218,N,,13715,,3T3-L1
515,,,80006,,Intermediate,1,,F,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,BAO_0000218,N,,13715,,3T3-L1
516,,,80006,,Intermediate,1,,F,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,,BAO_0000218,N,,13715,,3T3-L1
517,,,11214,,Expert,1,,F,620.0,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,,BAO_0000219,H,,6411,,3T3-L1
518,,,80006,10090.0,Intermediate,1,,F,620.0,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,,BAO_0000219,N,,6411,Mus musculus,3T3-L1
519,,,11214,,Expert,1,,F,620.0,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,,BAO_0000219,H,,6411,,3T3-L1
520,,,80006,10090.0,Expert,1,,F,620.0,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,,BAO_0000219,N,,3966,Mus musculus,3T3-L1
521,,,80006,10090.0,Intermediate,1,,F,620.0,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,,BAO_0000219,N,,3966,Mus musculus,3T3-L1
522,,,80006,10090.0,Expert,1,,F,620.0,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,,BAO_0000219,N,,15556,Mus musculus,3T3-L1
523,,,80006,10090.0,Expert,1,,F,620.0,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,,BAO_0000219,N,,5845,Mus musculus,3T3-L1
524,,,80006,10090.0,Expert,1,,F,620.0,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,,BAO_0000219,N,,14422,Mus musculus,3T3-L1
525,,,80006,10090.0,Expert,1,,F,620.0,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,,BAO_0000219,N,,5845,Mus musculus,3T3-L1
526,,,80006,10090.0,Expert,1,,F,620.0,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,,BAO_0000219,N,,14508,Mus musculus,3T3-L1
527,,,80006,10090.0,Expert,1,,F,620.0,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,,BAO_0000219,N,,14508,Mus musculus,3T3-L1
528,,,80006,10090.0,Expert,1,,F,620.0,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,,BAO_0000219,N,,14508,Mus musculus,3T3-L1
529,,,80622,10116.0,Intermediate,1,,F,1118.0,Inhibitory activity against rat fibroblast (3Y1) cell line,,,BAO_0000219,N,,6349,Rattus norvegicus,3Y1 cell line
530,,,80622,10116.0,Expert,1,,F,1118.0,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,,BAO_0000219,N,,15899,Rattus norvegicus,3Y1 cell line
531,,,80622,10116.0,Expert,1,,F,1118.0,Cytotoxicity in 3Y1 cells.,,,BAO_0000219,N,,15899,Rattus norvegicus,3Y1 cell line
532,,,80622,10116.0,Expert,1,,F,1118.0,Cytostatic effect in 3Y1 cells.,,,BAO_0000219,N,,15899,Rattus norvegicus,3Y1 cell line
533,,,80622,10116.0,Intermediate,1,,F,1118.0,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,,BAO_0000219,N,,15899,Rattus norvegicus,3Y1 cell line
534,,,80622,10116.0,Expert,1,,F,1118.0,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,,BAO_0000219,N,,17038,Rattus norvegicus,3Y1 cell line
535,,,22226,,Autocuration,1,,B,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,,BAO_0000019,U,,12421,,
536,,,22226,,Autocuration,1,,B,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,BAO_0000019,U,,12947,,
537,,,22226,,Autocuration,1,,B,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,BAO_0000019,U,,12947,,
538,,,11607,9823.0,Expert,1,,B,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,,BAO_0000019,D,,4896,Sus scrofa,
539,,,11607,,Autocuration,1,,B,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,,BAO_0000019,H,,6148,,
540,,,11607,,Autocuration,1,,B,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,,BAO_0000019,H,,16432,,
541,,,11607,,Expert,1,,B,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,,BAO_0000019,H,,4978,,
542,,,11607,,Expert,1,,B,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,,BAO_0000019,H,,4978,,
543,,,11607,,Autocuration,1,,B,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,,BAO_0000019,H,,3723,,
544,,,11607,,Autocuration,1,,B,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,,BAO_0000357,H,,3518,,
545,,,11607,,Autocuration,1,,B,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,,BAO_0000019,H,,4164,,
546,,,11607,,Autocuration,1,,B,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,,BAO_0000019,H,,3518,,
547,,,11607,9823.0,Expert,1,,B,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,,BAO_0000019,D,,4164,Sus scrofa,
548,,,11607,,Autocuration,1,,B,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,,BAO_0000019,H,,3518,,
549,,,11607,,Autocuration,1,,B,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,,BAO_0000357,H,,3518,,
550,,,11607,,Autocuration,1,,B,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,,BAO_0000019,H,,4978,,
551,,,11607,,Autocuration,1,,B,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,,BAO_0000019,H,,4978,,
552,,,104733,,Autocuration,1,,B,,Binding affinity against melatonin (MT1) receptor (pC1),,,BAO_0000224,H,,6455,,
553,,,22226,,Autocuration,1,,B,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,,BAO_0000019,U,,2222,,
554,,,22226,,Autocuration,1,,B,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,,BAO_0000019,U,,13020,,
555,,,22226,,Autocuration,1,,B,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,,BAO_0000019,U,,13021,,
556,,,10619,,Autocuration,1,,B,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,,BAO_0000357,H,,14532,,
557,,,10619,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,BAO_0000357,H,,14118,,
558,,10000000.0,51,,Autocuration,1,Hippocampus,B,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,,BAO_0000221,H,,11884,,
559,,,51,,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,13969,,
560,,,51,,Expert,1,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,13392,,
561,,,51,,Expert,1,,B,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,,BAO_0000019,H,,14430,,
562,,10000000.0,51,,Autocuration,1,Hippocampus,B,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,BAO_0000221,H,,12248,,
563,,10000000.0,51,,Autocuration,1,Hippocampus,B,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,BAO_0000221,H,,12249,,
564,,10000000.0,51,,Autocuration,1,Hippocampus,B,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,BAO_0000221,H,,9995,,
565,,10000000.0,51,,Autocuration,1,Hippocampus,B,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,BAO_0000221,H,,9995,,
566,,10000000.0,51,,Autocuration,1,Hippocampus,B,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,BAO_0000221,H,,9995,,
567,,10000000.0,51,,Autocuration,1,Hippocampus,B,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,BAO_0000221,H,,9995,,
568,,10000000.0,51,,Autocuration,1,Hippocampus,B,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,BAO_0000221,H,,9995,,
569,,10000000.0,51,,Autocuration,1,Hippocampus,B,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,BAO_0000221,H,,12249,,
570,,10000000.0,51,,Autocuration,1,Hippocampus,B,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,BAO_0000221,H,,11799,,
571,,,10576,10116.0,Expert,1,,B,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,Membranes,,BAO_0000249,D,,14331,Rattus norvegicus,
572,,10000000.0,51,9913.0,Expert,1,Hippocampus,B,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,,BAO_0000221,H,,11884,Bos taurus,
573,,10000000.0,51,,Autocuration,1,Hippocampus,B,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,,BAO_0000221,H,,14331,,
574,,10000000.0,51,,Autocuration,1,Hippocampus,B,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,,BAO_0000221,H,,11701,,
575,,10000000.0,51,,Expert,1,Hippocampus,B,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,,BAO_0000221,H,,11701,,
576,,10000000.0,51,,Autocuration,1,Hippocampus,B,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,,BAO_0000221,H,,12248,,
577,,,51,,Autocuration,1,,B,449.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,,BAO_0000219,H,,12248,,CHO
578,,10000000.0,51,,Expert,1,Hippocampus,B,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,BAO_0000221,H,,12248,,
579,,10000000.0,51,,Expert,1,Hippocampus,B,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,BAO_0000221,H,,12249,,
580,,,51,,Autocuration,1,,B,449.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,BAO_0000219,H,,12248,,CHO
581,,10000000.0,51,,Expert,1,Hippocampus,B,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,BAO_0000221,H,,11799,,
582,,,51,,Autocuration,1,,B,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,BAO_0000357,H,,634,,
583,,10000000.0,51,,Autocuration,1,Hippocampus,B,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,BAO_0000221,H,,9995,,
584,,10000000.0,51,,Autocuration,1,Hippocampus,B,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,BAO_0000221,H,,9995,,
585,,10000000.0,51,,Autocuration,1,Hippocampus,B,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,BAO_0000221,H,,9995,,
586,,10000000.0,51,,Autocuration,1,Hippocampus,B,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,BAO_0000221,H,,9995,,
587,,10000000.0,51,,Autocuration,1,Hippocampus,B,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,BAO_0000221,H,,9995,,
588,,10000000.0,51,,Expert,1,Hippocampus,B,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,,BAO_0000218,H,,12210,,
589,,10000000.0,51,,Expert,1,Hippocampus,B,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,BAO_0000221,H,,13311,,
590,,,51,9606.0,Expert,1,,B,449.0,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,,BAO_0000219,D,,2331,Homo sapiens,CHO
591,,,51,10141.0,Autocuration,1,,F,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,,BAO_0000019,H,,1375,Cavia porcellus,
592,,,51,10141.0,Autocuration,1,,F,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,,BAO_0000019,H,,1375,Cavia porcellus,
593,,10000000.0,51,10141.0,Autocuration,1,Hippocampus,F,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,,BAO_0000221,H,,11574,Cavia porcellus,
594,,2116.0,51,10141.0,Autocuration,1,Ileum,B,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,,BAO_0000221,H,,12867,Cavia porcellus,
595,,2116.0,51,10141.0,Autocuration,1,Ileum,B,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,BAO_0000221,H,,12867,Cavia porcellus,
596,,2116.0,51,10141.0,Autocuration,1,Ileum,B,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,,BAO_0000221,H,,12867,Cavia porcellus,
597,,2116.0,51,10141.0,Autocuration,1,Ileum,B,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,BAO_0000221,H,,12867,Cavia porcellus,
598,,2116.0,51,10141.0,Autocuration,1,Ileum,B,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,BAO_0000221,H,,12867,Cavia porcellus,
599,,2116.0,51,10141.0,Autocuration,1,Ileum,B,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,,BAO_0000221,H,,12867,Cavia porcellus,
600,,,51,10141.0,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,11574,Cavia porcellus,
601,,,51,10141.0,Autocuration,1,,B,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,13114,Cavia porcellus,
602,,,51,10141.0,Autocuration,1,,B,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,13181,Cavia porcellus,
603,,10000000.0,106,10141.0,Autocuration,1,Hippocampus,B,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,,BAO_0000221,H,,10639,Cavia porcellus,
604,,10000000.0,106,10141.0,Autocuration,1,Hippocampus,F,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,,BAO_0000221,H,,10639,Cavia porcellus,
605,,,11863,10029.0,Autocuration,1,,B,449.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,,BAO_0000218,H,,11883,Cricetulus griseus,CHO
606,,,51,,Autocuration,1,,B,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,17785,,
607,,,51,,Autocuration,1,,F,308.0,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,,BAO_0000219,H,,1558,,HeLa
608,,,51,,Autocuration,1,,F,308.0,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,,BAO_0000219,H,,1558,,HeLa
609,,,51,,Autocuration,1,,F,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,BAO_0000019,H,,15740,,
610,,,51,,Autocuration,1,,F,449.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,,BAO_0000219,H,,17624,,CHO
611,,,51,,Expert,1,,F,449.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,,BAO_0000219,H,,17624,,CHO
612,,,51,,Autocuration,1,,F,449.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,,BAO_0000219,H,,17624,,CHO
613,,,51,,Autocuration,1,,F,449.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,,BAO_0000219,H,,17624,,CHO
614,,,51,,Expert,1,,B,449.0,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,BAO_0000219,H,,17624,,CHO
615,,,51,,Expert,1,,B,449.0,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,BAO_0000219,H,,17624,,CHO
616,,,51,,Autocuration,1,,B,449.0,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,,BAO_0000219,H,,17624,,CHO
617,,,51,,Autocuration,1,,F,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,,BAO_0000219,H,,14256,,
618,,,51,9606.0,Expert,1,,B,308.0,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,,BAO_0000219,D,,3445,Homo sapiens,HeLa
619,,,51,9606.0,Expert,1,,B,308.0,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,,BAO_0000219,D,,3445,Homo sapiens,HeLa
620,,,51,9606.0,Expert,1,,B,449.0,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,,BAO_0000219,D,,17200,Homo sapiens,CHO
621,,,51,9606.0,Expert,1,,B,449.0,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,,BAO_0000219,D,,17200,Homo sapiens,CHO
622,,,51,,Autocuration,1,,F,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,BAO_0000019,H,,15180,,
623,,,51,,Autocuration,1,,F,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,BAO_0000019,H,,15180,,
624,,,51,,Autocuration,1,,F,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,BAO_0000019,H,,16026,,
625,,,51,,Autocuration,1,,F,449.0,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,BAO_0000219,H,,2759,,CHO
626,,,51,9606.0,Expert,1,,F,449.0,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,,BAO_0000219,D,,2759,Homo sapiens,CHO
627,,,51,,Autocuration,1,,F,449.0,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,,BAO_0000219,H,,2759,,CHO
628,,,51,9606.0,Expert,1,,F,449.0,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,,BAO_0000219,D,,2759,Homo sapiens,CHO
629,,,51,,Autocuration,1,,F,449.0,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,BAO_0000219,H,,2759,,CHO
630,,,51,,Autocuration,1,,F,449.0,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,,BAO_0000219,H,,2759,,CHO
631,,,51,9606.0,Expert,1,,F,449.0,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,,BAO_0000219,D,,2759,Homo sapiens,CHO
632,,,51,,Autocuration,1,,F,449.0,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,,BAO_0000219,H,,2759,,CHO
633,,,51,9606.0,Expert,1,,F,449.0,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,,BAO_0000219,D,,2759,Homo sapiens,CHO
634,,,51,9606.0,Expert,1,,F,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,,BAO_0000019,D,,3445,Homo sapiens,
635,,,51,9606.0,Expert,1,,F,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,BAO_0000019,D,,5272,Homo sapiens,
636,,,51,9606.0,Expert,1,,F,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,,BAO_0000019,D,,5272,Homo sapiens,
637,,,51,9606.0,Expert,1,,F,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,,BAO_0000019,D,,5272,Homo sapiens,
638,,,51,,Autocuration,1,,F,449.0,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,BAO_0000219,H,,17624,,CHO
639,,,51,,Autocuration,1,,F,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,BAO_0000219,H,,17624,,CHO
640,,,51,,Autocuration,1,,F,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,,BAO_0000219,H,,17624,,CHO
641,,,51,,Expert,1,,F,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,BAO_0000219,H,,17624,,CHO
642,,,51,,Autocuration,1,,F,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,,BAO_0000219,H,,17624,,CHO
643,,,51,,Autocuration,1,,F,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,,BAO_0000219,H,,17624,,CHO
644,,,51,,Autocuration,1,,F,449.0,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,BAO_0000219,H,,17624,,CHO
645,,,51,,Autocuration,1,,F,449.0,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,,BAO_0000219,H,,17624,,CHO
646,,,51,,Expert,1,,F,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,BAO_0000219,H,,17624,,CHO
647,,,51,,Autocuration,1,,F,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,,BAO_0000219,H,,17624,,CHO
648,,,51,,Autocuration,1,,F,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,BAO_0000219,H,,17624,,CHO
649,,,51,,Autocuration,1,,F,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,,BAO_0000219,H,,17624,,CHO
650,,,51,,Autocuration,1,,F,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,BAO_0000019,H,,6563,,
651,,,51,,Autocuration,1,,F,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,BAO_0000019,H,,6563,,
652,,,51,,Autocuration,1,,F,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,BAO_0000019,H,,6563,,
653,,,51,,Autocuration,1,,F,722.0,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,BAO_0000219,H,,17296,,HEK293
654,,,51,9606.0,Expert,1,,F,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,,BAO_0000019,D,,6876,Homo sapiens,
655,,,51,,Expert,1,,F,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,,BAO_0000019,H,,6876,,
656,,,51,9606.0,Expert,1,,F,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,,BAO_0000019,D,,5272,Homo sapiens,
657,,,51,9606.0,Expert,1,,F,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,,BAO_0000019,D,,5272,Homo sapiens,
658,,,51,,Autocuration,1,,F,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,BAO_0000019,H,,5548,,
659,,,51,,Expert,1,,F,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,,BAO_0000019,H,,5548,,
660,,,51,,Autocuration,1,,F,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,BAO_0000019,H,,5548,,
661,,,51,,Autocuration,1,,F,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,BAO_0000019,H,,5548,,
662,,,51,,Expert,1,,F,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,,BAO_0000019,H,,5929,,
663,,,51,9606.0,Expert,1,,F,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,,BAO_0000019,D,,5929,Homo sapiens,
664,,,51,9606.0,Expert,1,,F,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,,BAO_0000019,D,,5929,Homo sapiens,
665,,,51,,Autocuration,1,,F,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,,BAO_0000019,H,,16245,,
666,,,51,,Expert,1,,F,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,BAO_0000019,H,,5640,,
667,,,51,,Autocuration,1,,F,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,,BAO_0000019,H,,5640,,
668,,,51,,Autocuration,1,,F,449.0,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,,BAO_0000219,H,,14509,,CHO
669,,,51,,Expert,1,,F,449.0,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,,BAO_0000219,H,,14509,,CHO
670,,,51,,Autocuration,1,,B,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,BAO_0000357,H,,15331,,
671,,,51,,Autocuration,1,,B,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,BAO_0000357,H,,15331,,
672,,,51,,Autocuration,1,,F,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,BAO_0000019,H,,6563,,
673,,,51,,Autocuration,1,,F,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,,BAO_0000019,H,,6563,,
674,,,51,,Autocuration,1,,F,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,BAO_0000019,H,,6563,,
675,,,51,9606.0,Expert,1,,F,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,,BAO_0000019,D,,6563,Homo sapiens,
676,,,51,,Autocuration,1,,F,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,BAO_0000019,H,,6563,,
677,,,51,9606.0,Expert,1,,F,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,,BAO_0000019,D,,5272,Homo sapiens,
678,,,51,9606.0,Expert,1,,F,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,BAO_0000019,D,,5272,Homo sapiens,
679,,,51,9606.0,Expert,1,,F,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,,BAO_0000019,D,,5272,Homo sapiens,
680,,,51,9606.0,Expert,1,,F,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,,BAO_0000019,D,,5272,Homo sapiens,
681,,,51,9606.0,Expert,1,,F,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,,BAO_0000019,D,,5272,Homo sapiens,
682,,,51,9606.0,Expert,1,,F,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,BAO_0000019,D,,5272,Homo sapiens,
683,,,51,9606.0,Expert,1,,F,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,,BAO_0000019,D,,5272,Homo sapiens,
684,,,51,9606.0,Expert,1,,F,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,,BAO_0000019,D,,5272,Homo sapiens,
685,,,51,9606.0,Expert,1,,B,,Inhibition of human 5-hydroxytryptamine 1A receptor,,,BAO_0000357,D,,16146,Homo sapiens,
686,,,51,,Autocuration,1,,B,449.0,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,BAO_0000219,H,,17624,,CHO
687,,,105,,Expert,1,,B,722.0,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,,BAO_0000219,D,,13706,,HEK293
688,,,51,,Autocuration,1,,B,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,,BAO_0000219,H,,15250,,CHO
689,,,51,,Autocuration,1,,F,449.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,BAO_0000219,H,,17624,,CHO
690,,,51,,Expert,1,,B,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,,BAO_0000357,H,,6861,,
691,,,51,9606.0,Expert,1,,B,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,BAO_0000357,D,,17200,Homo sapiens,
692,,,51,,Autocuration,1,,B,449.0,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,,BAO_0000219,H,,17624,,CHO
693,,,51,,Autocuration,1,,B,449.0,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,BAO_0000219,H,,17624,,CHO
694,In vivo,,22226,10116.0,Autocuration,1,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,,BAO_0000218,U,,12058,Rattus norvegicus,
695,In vivo,,22226,10116.0,Autocuration,1,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,,BAO_0000218,U,,12058,Rattus norvegicus,
696,In vivo,,22226,10116.0,Autocuration,1,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,,BAO_0000218,U,,12058,Rattus norvegicus,
697,In vivo,,22226,10116.0,Autocuration,1,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,,BAO_0000218,U,,12058,Rattus norvegicus,
698,In vivo,,22226,10116.0,Autocuration,1,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,,BAO_0000218,U,,12058,Rattus norvegicus,
699,In vivo,,22226,10116.0,Autocuration,1,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,,BAO_0000218,U,,12058,Rattus norvegicus,
700,In vivo,,22226,10116.0,Autocuration,1,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,,BAO_0000218,U,,12058,Rattus norvegicus,
701,In vivo,,22226,10116.0,Autocuration,1,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,,BAO_0000218,U,,12058,Rattus norvegicus,
702,In vivo,,22226,10116.0,Autocuration,1,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,,BAO_0000218,U,,12058,Rattus norvegicus,
703,In vivo,,22226,10116.0,Autocuration,1,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,,BAO_0000218,U,,12058,Rattus norvegicus,
704,In vivo,,22226,10116.0,Autocuration,1,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,,BAO_0000218,U,,12058,Rattus norvegicus,
705,In vivo,,22226,10116.0,Autocuration,1,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,,BAO_0000218,U,,12058,Rattus norvegicus,
706,In vivo,,22226,10116.0,Autocuration,1,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,,BAO_0000218,U,,12058,Rattus norvegicus,
707,In vivo,,22226,10116.0,Autocuration,1,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,,BAO_0000218,U,,12058,Rattus norvegicus,
708,In vivo,,22226,10116.0,Autocuration,1,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,,BAO_0000218,U,,12058,Rattus norvegicus,
709,In vivo,,22226,10116.0,Autocuration,1,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,,BAO_0000218,U,,12058,Rattus norvegicus,
710,In vivo,,22226,10116.0,Autocuration,1,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,,BAO_0000218,U,,12058,Rattus norvegicus,
711,In vivo,,22226,10116.0,Autocuration,1,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,,BAO_0000218,U,,12058,Rattus norvegicus,
712,In vivo,,22226,10116.0,Autocuration,1,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,,BAO_0000218,U,,12058,Rattus norvegicus,
713,,,105093,,Autocuration,1,,B,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,,BAO_0000019,H,,11440,,
714,,1898.0,11923,,Autocuration,1,Hypothalamus,B,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,,BAO_0000249,H,,6238,,
715,,,10577,,Autocuration,1,,B,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,,BAO_0000019,H,,10046,,
716,,,10577,,Autocuration,1,,B,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,,BAO_0000019,H,,10046,,
717,,,10577,,Expert,1,,B,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,BAO_0000019,H,,10046,,
718,,,55,,Autocuration,1,,B,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,,BAO_0000357,H,,167,,
719,,,55,,Autocuration,1,,B,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,,BAO_0000357,H,,167,,
720,,,12166,,Autocuration,1,,F,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,,BAO_0000019,H,,11520,,
721,,,12166,,Autocuration,1,,F,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,BAO_0000019,H,,11520,,
722,,,12166,,Autocuration,1,,F,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,BAO_0000019,H,,11520,,
723,,,12166,,Autocuration,1,,F,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,BAO_0000019,H,,11520,,
724,,,55,10141.0,Autocuration,1,,F,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,,BAO_0000019,H,,135,Cavia porcellus,
725,,,55,10141.0,Autocuration,1,,F,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,,BAO_0000019,H,,135,Cavia porcellus,
726,,,55,10141.0,Autocuration,1,,B,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,,BAO_0000019,H,,11311,Cavia porcellus,
727,,,55,10141.0,Autocuration,1,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,,BAO_0000357,H,,10193,Cavia porcellus,
728,,,55,9606.0,Expert,1,,B,,Inhibitory concentration against 5-lipoxygenase from human whole blood,,,BAO_0000357,D,,12281,Homo sapiens,
729,,,55,,Autocuration,1,,B,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,BAO_0000219,H,,11311,,
730,,,17087,,Autocuration,1,,F,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,BAO_0000218,H,,12576,,
731,,,17087,,Autocuration,1,,B,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,,BAO_0000357,H,,12281,,
732,,,17087,,Autocuration,1,,F,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,BAO_0000218,H,,12576,,
733,,,55,9823.0,Expert,1,,B,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,,BAO_0000019,H,,11089,Sus scrofa,
734,,,12166,,Expert,1,,B,,In vitro inhibition of rat 5-Lipoxygenase,,,BAO_0000357,H,,11006,,
735,,,12166,10116.0,Expert,1,,B,,Inhibitory activity against 5-Lipoxygenase,,,BAO_0000357,D,,11481,Rattus norvegicus,
736,,,12166,,Expert,1,,B,702.0,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,,BAO_0000219,H,,10864,,RBL-1
737,,,12166,,Autocuration,1,,B,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,BAO_0000219,H,,3595,,RBL-1
738,,,12166,,Autocuration,1,,B,702.0,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,,BAO_0000219,H,,11311,,RBL-1
739,,,12166,,Autocuration,1,,B,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,,BAO_0000019,H,,11311,,
740,,,12166,,Autocuration,1,,B,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,,BAO_0000219,H,,11311,,
741,,,12166,,Autocuration,1,,B,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,BAO_0000357,H,,11006,,
742,,,12166,,Autocuration,1,,B,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,,BAO_0000219,H,,3595,,RBL-1
743,,,12166,,Autocuration,1,,B,,The compound was tested for inhibition of isolated 5-Lipoxygenase,,,BAO_0000357,H,,11311,,
744,,,22226,10116.0,Autocuration,1,,B,,Ratio of IC50 against 5-LO and COX,,,BAO_0000019,U,,11481,Rattus norvegicus,
745,,,12166,,Autocuration,1,,B,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,BAO_0000357,H,,11006,,
746,,,12166,,Autocuration,1,,B,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,,BAO_0000357,H,,11006,,
747,,,12166,,Autocuration,1,,B,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,,BAO_0000219,H,,11311,,
748,,,12166,,Autocuration,1,,F,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,,BAO_0000019,H,,11006,,
749,,2367.0,120,,Autocuration,1,Prostate gland,B,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,,BAO_0000357,H,,4288,,
750,,,22226,8932.0,Autocuration,1,,B,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,,BAO_0000019,U,,7587,Columba livia,
751,,,22226,8932.0,Autocuration,1,,B,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,,BAO_0000019,U,,7587,Columba livia,
752,,,22226,8932.0,Autocuration,1,,B,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,,BAO_0000019,U,,7587,Columba livia,
753,,,10732,,Autocuration,1,,B,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,,BAO_0000357,H,,11249,,
754,,,12198,10116.0,Expert,1,,F,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,,BAO_0000019,D,,8003,Rattus norvegicus,
755,,,12198,10116.0,Expert,1,,F,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,,BAO_0000019,D,,8003,Rattus norvegicus,
756,,,12198,10116.0,Expert,1,,F,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,,BAO_0000019,D,,8003,Rattus norvegicus,
757,,10000000.0,10576,,Expert,1,Hippocampus,B,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,BAO_0000221,H,,12416,,
758,,,51,,Autocuration,1,,B,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,,BAO_0000357,H,,16293,,
759,,,22226,9986.0,Autocuration,1,,B,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,BAO_0000019,U,,13047,Oryctolagus cuniculus,
760,,,22226,9986.0,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,BAO_0000019,U,,13047,Oryctolagus cuniculus,
761,,,22226,9986.0,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,,BAO_0000019,U,,13047,Oryctolagus cuniculus,
762,,,22226,9986.0,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,,BAO_0000019,U,,13047,Oryctolagus cuniculus,
763,,10000000.0,104744,,Autocuration,1,Hippocampus,B,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,BAO_0000221,H,,10085,,
764,,10000000.0,104744,,Autocuration,1,Hippocampus,B,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,BAO_0000221,H,,10085,,
765,,10000000.0,104744,,Autocuration,1,Hippocampus,B,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,BAO_0000221,H,,10085,,
766,,,104744,,Autocuration,1,,B,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,Membranes,,BAO_0000249,H,,9841,,
767,,,104744,10116.0,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,,BAO_0000249,D,,8822,Rattus norvegicus,
768,,,104744,10116.0,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,,BAO_0000019,D,,9806,Rattus norvegicus,
769,,,104744,10116.0,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,,BAO_0000019,D,,9806,Rattus norvegicus,
770,,,104744,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,,BAO_0000224,H,,8868,,
771,,10000000.0,104744,,Autocuration,1,Hippocampus,B,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,,BAO_0000221,H,,9036,,
772,,10000000.0,104744,,Autocuration,1,Hippocampus,B,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,,BAO_0000221,H,,11374,,
773,,,104744,,Autocuration,1,,B,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,,BAO_0000224,H,,10881,,
774,,,104744,,Autocuration,1,,B,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,,BAO_0000019,H,,8822,,
775,,,104744,10116.0,Autocuration,1,,B,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,,BAO_0000249,D,,9806,Rattus norvegicus,
776,,,104744,,Autocuration,1,,B,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,BAO_0000019,H,,15463,,
777,,,104744,,Autocuration,1,,B,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,BAO_0000019,H,,15463,,
778,,955.0,104744,,Autocuration,1,Brain,B,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,BAO_0000221,H,,14542,,
779,,955.0,104744,,Autocuration,1,Brain,B,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,BAO_0000221,H,,14542,,
780,,,104744,,Autocuration,1,,B,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,,BAO_0000019,H,,8569,,
781,,,104744,10116.0,Autocuration,1,,B,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,,BAO_0000224,D,,10062,Rattus norvegicus,
782,,,104744,,Autocuration,1,,B,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,,BAO_0000224,H,,4771,,
783,,,104744,,Autocuration,1,,B,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,BAO_0000224,H,,10062,,
784,,,104744,,Autocuration,1,,B,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,BAO_0000224,H,,10062,,
785,,,104744,,Autocuration,1,,B,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,BAO_0000224,H,,10062,,
786,,,104744,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,BAO_0000019,H,,15463,,
787,,,104744,,Autocuration,1,,B,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,BAO_0000019,H,,15463,,
788,,,104744,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,,BAO_0000224,H,,9098,,
789,,,22226,10116.0,Autocuration,1,,B,,Affinity for 5-hydroxytryptamine 1 receptor,,,BAO_0000019,U,,3070,Rattus norvegicus,
790,,955.0,104744,,Autocuration,1,Brain,B,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,,BAO_0000221,H,,14542,,
791,,955.0,104744,,Autocuration,1,Brain,B,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,BAO_0000221,H,,14542,,
792,,,104744,,Autocuration,1,,B,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,,BAO_0000224,H,,6398,,
793,,955.0,104744,,Autocuration,1,Brain,B,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,,BAO_0000221,H,,1344,,
794,,,104744,,Autocuration,1,,B,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,BAO_0000019,H,,11963,,
795,,,22226,10116.0,Autocuration,1,,B,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,,BAO_0000019,U,,8908,Rattus norvegicus,
796,,,104744,,Autocuration,1,,B,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,,BAO_0000019,H,,9098,,
797,,,104744,10116.0,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,,BAO_0000019,D,,8841,Rattus norvegicus,
798,,,22226,10116.0,Autocuration,1,,B,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,,BAO_0000019,U,,8814,Rattus norvegicus,
799,,,104744,,Autocuration,1,,B,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,,BAO_0000019,H,,11752,,
800,,955.0,104744,,Autocuration,1,Brain,B,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,,BAO_0000221,H,,11642,,
801,,,104744,,Autocuration,1,,B,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,,BAO_0000019,H,,11642,,
802,,955.0,104744,,Autocuration,1,Brain,B,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,,BAO_0000220,H,,9231,,
803,,955.0,104744,,Autocuration,1,Brain,B,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,,BAO_0000221,H,,11351,,
804,,,22226,,Autocuration,1,,B,,Compound was tested for binding affinity against 5-HT1 receptor,,,BAO_0000019,U,,4639,,
805,,,22226,,Autocuration,1,,B,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,,BAO_0000019,U,,1205,,
806,,,10576,,Expert,1,,B,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,BAO_0000357,H,,10025,,
807,,,10576,,Autocuration,1,,F,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,BAO_0000249,H,,13241,,
808,In vivo,,10576,,Autocuration,1,,F,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,,BAO_0000218,H,,16245,,
809,In vivo,,10576,,Autocuration,1,,F,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,,BAO_0000218,H,,16245,,
810,,,10576,,Autocuration,1,,F,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,,BAO_0000019,H,,12438,,
811,In vivo,,10576,,Autocuration,1,,F,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,,BAO_0000218,H,,16245,,
812,In vivo,,10576,,Autocuration,1,,F,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,,BAO_0000218,H,,16245,,
813,,,10576,,Autocuration,1,,F,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,,BAO_0000019,H,,15740,,
814,,,10576,,Autocuration,1,,F,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,,BAO_0000219,H,,15535,,
815,,,51,,Expert,1,,F,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,,BAO_0000219,H,,15535,,
816,,,10576,,Autocuration,1,,F,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,,BAO_0000219,H,,15535,,
817,,,10576,,Expert,1,,B,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,,BAO_0000249,H,,9888,,
818,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,,BAO_0000221,H,,10085,,
819,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,,BAO_0000221,H,,10085,,
820,,,10576,,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,Membranes,,BAO_0000249,H,,17331,,
821,,10000000.0,10576,10116.0,Expert,1,Hippocampus,B,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,,BAO_0000221,D,,10845,Rattus norvegicus,
822,,10000000.0,10576,10116.0,Expert,1,Hippocampus,B,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,,BAO_0000221,D,,10845,Rattus norvegicus,
823,,10000000.0,10576,,Expert,1,Hippocampus,B,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,,BAO_0000221,H,,10845,,
824,,10000000.0,10576,10116.0,Expert,1,Hippocampus,B,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,,BAO_0000221,D,,10845,Rattus norvegicus,
825,,10000000.0,10576,10116.0,Expert,1,Hippocampus,B,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,,BAO_0000221,D,,10845,Rattus norvegicus,
826,,,10576,,Expert,1,,B,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,13730,,
827,,,10576,,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,,BAO_0000249,H,,13508,,
828,,10000000.0,10576,,Expert,1,Hippocampus,B,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,,BAO_0000249,H,,13508,,
829,,10000000.0,10576,,Expert,1,Hippocampus,B,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,BAO_0000221,H,,12073,,
830,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,,BAO_0000221,H,,4671,,
831,,10000000.0,10576,,Expert,1,Hippocampus,B,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,,BAO_0000221,H,,13631,,
832,,,10576,,Autocuration,1,,B,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,12438,,
833,,,10576,,Autocuration,1,,B,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,,BAO_0000019,H,,10483,,
834,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,,BAO_0000221,H,,10483,,
835,,,10576,,Intermediate,1,,B,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,,BAO_0000249,H,,12352,,
836,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,,BAO_0000249,H,,14732,,
837,,,10576,10116.0,Expert,1,,B,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,,BAO_0000019,D,,11049,Rattus norvegicus,
838,,,10576,10116.0,Expert,1,,B,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,,BAO_0000019,D,,11049,Rattus norvegicus,
839,,,10576,,Expert,1,,B,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,,BAO_0000249,H,,13657,,
840,,,10576,,Autocuration,1,,B,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,,BAO_0000019,H,,11473,,
841,,,10576,,Autocuration,1,,B,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,BAO_0000249,H,,2014,,
842,,10000000.0,10576,,Expert,1,Hippocampus,B,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,BAO_0000221,H,,3086,,
843,,,10576,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,BAO_0000019,H,,15854,,
844,,10000000.0,10576,,Expert,1,Hippocampus,B,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,BAO_0000221,H,,10922,,
845,,10000000.0,10576,,Expert,1,Hippocampus,B,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,,BAO_0000221,H,,13346,,
846,,,10576,,Expert,1,,B,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,,BAO_0000357,H,,15311,,
847,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,BAO_0000221,H,,10922,,
848,,,10576,,Autocuration,1,,B,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,,BAO_0000357,H,,10025,,
849,,,10576,,Expert,1,,B,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,BAO_0000357,H,,10025,,
850,,,10576,,Autocuration,1,,B,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,BAO_0000019,H,,9742,,
851,,,10576,,Autocuration,1,,F,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,BAO_0000019,H,,9742,,
852,,,10576,,Expert,1,,B,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,BAO_0000019,H,,12304,,
853,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,,BAO_0000221,H,,15789,,
854,,,10576,,Autocuration,1,,B,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,,BAO_0000019,H,,9912,,
855,,,10576,,Autocuration,1,,B,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,,BAO_0000019,H,,9912,,
856,,,10576,,Autocuration,1,,B,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,,BAO_0000019,H,,9912,,
857,,,10576,,Expert,1,,B,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,BAO_0000019,H,,16693,,
858,,,10576,,Expert,1,,B,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,BAO_0000357,H,,13276,,
859,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,BAO_0000221,H,,12678,,
860,,,10576,,Autocuration,1,,B,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,,BAO_0000357,H,,11825,,
861,,,10576,,Expert,1,,B,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,,BAO_0000357,H,,12443,,
862,,,10576,,Expert,1,,B,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,13830,,
863,,10000000.0,10576,,Expert,1,Hippocampus,B,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,,BAO_0000249,H,,14286,,
864,,10000000.0,10576,10116.0,Expert,1,Hippocampus,B,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,BAO_0000221,D,,14356,Rattus norvegicus,
865,,,10576,,Autocuration,1,,B,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,15306,,
866,,,10576,,Expert,1,,B,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,,BAO_0000357,H,,15306,,
867,,,10576,10116.0,Expert,1,,F,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,,BAO_0000249,D,,16616,Rattus norvegicus,
868,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,,BAO_0000221,H,,3651,,
869,,10000000.0,10576,,Autocuration,1,Hippocampus,F,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,BAO_0000221,H,,14331,,
870,,10000000.0,10576,,Autocuration,1,Hippocampus,F,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,BAO_0000221,H,,14331,,
871,,,10576,10116.0,Expert,1,,B,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,,BAO_0000357,D,,14178,Rattus norvegicus,
872,,,10576,10116.0,Expert,1,,B,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,,BAO_0000019,D,,10639,Rattus norvegicus,
873,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,BAO_0000221,H,,12306,,
874,,,10576,10116.0,Expert,1,,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,,BAO_0000357,D,,1348,Rattus norvegicus,
875,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,,BAO_0000221,H,,13605,,
876,,,51,,Autocuration,1,,B,449.0,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,BAO_0000219,H,,17624,,CHO
877,,,51,,Autocuration,1,,F,449.0,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,BAO_0000219,H,,17624,,CHO
878,,,51,,Autocuration,1,,F,449.0,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,BAO_0000219,H,,17624,,CHO
879,,,51,,Autocuration,1,,B,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,15267,,
880,,,51,,Autocuration,1,,B,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,,BAO_0000357,H,,16532,,
881,,,51,,Autocuration,1,,F,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,BAO_0000019,H,,6563,,
882,,,51,,Autocuration,1,,B,449.0,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,,BAO_0000219,H,,4751,,CHO
883,,,51,,Autocuration,1,,B,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,15463,,
884,,,51,,Autocuration,1,,B,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,,BAO_0000357,H,,3805,,
885,,,51,,Autocuration,1,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,5640,,
886,,,51,,Autocuration,1,,B,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,,BAO_0000357,H,,6563,,
887,,,51,,Autocuration,1,,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,,BAO_0000357,H,,5548,,
888,,,51,,Autocuration,1,,B,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,6347,,
889,,,51,,Autocuration,1,,F,722.0,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,BAO_0000219,H,,17296,,HEK293
890,,,51,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,,BAO_0000019,H,,13047,,
891,,,51,,Autocuration,1,,B,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,,BAO_0000357,H,,15740,,
892,,,51,,Expert,1,,F,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,BAO_0000019,H,,5640,,
893,,,51,,Autocuration,1,,F,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,,BAO_0000019,H,,5640,,
894,,,51,,Expert,1,,B,308.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,,BAO_0000219,H,,17211,,HeLa
895,,,51,,Autocuration,1,,B,449.0,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,,BAO_0000219,H,,4751,,CHO
896,,,51,9606.0,Expert,1,,B,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,,BAO_0000357,D,,6491,Homo sapiens,
897,,,51,,Autocuration,1,,B,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,,BAO_0000357,H,,4707,,
898,,,51,9606.0,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,BAO_0000357,D,,13910,Homo sapiens,
899,,,51,,Autocuration,1,,B,308.0,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,,BAO_0000219,H,,16190,,HeLa
900,,,51,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,16633,,
901,,,51,,Autocuration,1,,B,449.0,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,,BAO_0000219,H,,11898,,CHO
902,,,51,,Autocuration,1,,B,449.0,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,BAO_0000219,H,,11898,,CHO
903,,,51,,Autocuration,1,,B,,Binding affinity against human 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,14331,,
904,,,51,,Expert,1,,B,449.0,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,,BAO_0000219,H,,17624,,CHO
905,,,51,,Autocuration,1,,B,449.0,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,,BAO_0000219,H,,17624,,CHO
906,,,51,,Autocuration,1,,B,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,3307,,
907,,,51,9606.0,Expert,1,,B,449.0,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,BAO_0000219,D,,6563,Homo sapiens,CHO
908,,,51,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,,BAO_0000019,H,,14165,,
909,,,51,,Autocuration,1,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,BAO_0000357,H,,5732,,
910,,,51,,Expert,1,,B,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,BAO_0000357,H,,13366,,
911,,,51,,Autocuration,1,,B,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,17626,,
912,,,51,,Expert,1,,B,308.0,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,,BAO_0000219,H,,6588,,HeLa
913,,,51,,Autocuration,1,,B,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,,BAO_0000357,H,,16209,,
914,,,51,,Autocuration,1,,B,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,15463,,
915,,,51,,Autocuration,1,,B,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,15463,,
916,,,51,,Autocuration,1,,B,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,,BAO_0000357,H,,14770,,
917,,,51,,Autocuration,1,,B,1167.0,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,,BAO_0000219,H,,16245,,Cell line
918,,,51,,Autocuration,1,,B,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,,BAO_0000019,H,,16245,,
919,,,51,,Autocuration,1,,B,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,5548,,
920,,,51,,Expert,1,,B,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,5548,,
921,,,51,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,5548,,
922,,,51,,Expert,1,,B,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,,BAO_0000357,H,,6876,,
923,,,51,,Autocuration,1,,B,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,2598,,
924,,,51,,Expert,1,,B,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,,BAO_0000357,H,,17785,,
925,,,51,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,6013,,
926,,,51,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,5929,,
927,,,51,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,16633,,
928,,,51,,Autocuration,1,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,BAO_0000357,H,,1558,,
929,,,51,,Expert,1,,B,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,16026,,
930,,,51,,Autocuration,1,,B,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,,BAO_0000219,H,,12469,,
931,,,51,9606.0,Expert,1,,B,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,BAO_0000357,D,,15874,Homo sapiens,
932,,,51,,Autocuration,1,,B,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,BAO_0000357,H,,15874,,
933,,,51,,Autocuration,1,,B,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,3935,,
934,,,51,,Autocuration,1,,B,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,15818,,
935,,,51,,Autocuration,1,,B,485.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,,BAO_0000219,H,,13706,,CHO-K1
936,,,51,,Expert,1,,F,485.0,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,,BAO_0000219,H,,13729,,CHO-K1
937,,,51,,Autocuration,1,,B,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,,BAO_0000019,H,,15413,,
938,,,51,,Autocuration,1,,B,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,,BAO_0000019,H,,15413,,
939,,,51,,Autocuration,1,,B,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,,BAO_0000019,H,,15413,,
940,,,51,,Autocuration,1,,B,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,,BAO_0000019,H,,15413,,
941,,,51,9606.0,Expert,1,,B,308.0,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,,BAO_0000219,D,,3445,Homo sapiens,HeLa
942,,,51,,Autocuration,1,,B,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,15740,,
943,,,51,,Autocuration,1,,B,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,,BAO_0000357,H,,15740,,
944,,,51,,Autocuration,1,,B,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,17626,,
945,,,51,9606.0,Expert,1,,B,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,,BAO_0000357,D,,4234,Homo sapiens,
946,,,51,,Expert,1,,B,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,BAO_0000357,H,,5640,,
947,,,51,10116.0,Expert,1,,B,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,,BAO_0000357,H,,5272,Rattus norvegicus,
948,,,51,,Autocuration,1,,B,449.0,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,,BAO_0000219,H,,4622,,CHO
949,,,51,,Expert,1,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,,BAO_0000019,H,,17085,,
950,,,51,,Autocuration,1,,B,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,BAO_0000357,H,,3025,,
951,,,51,,Expert,1,,B,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,15315,,
952,,,51,,Autocuration,1,,B,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,,BAO_0000357,H,,15267,,
953,,,51,,Autocuration,1,,B,308.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,,BAO_0000219,H,,17158,,HeLa
954,,,51,9606.0,Expert,1,,B,308.0,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,,BAO_0000219,D,,14214,Homo sapiens,HeLa
955,,,51,,Autocuration,1,,B,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,17133,,
956,,,51,,Autocuration,1,,B,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,,BAO_0000357,H,,16532,,
957,,,51,9606.0,Expert,1,,B,,Affinity for 5-hydroxytryptamine 1A receptor subtype,,,BAO_0000357,D,,2391,Homo sapiens,
958,,,51,,Autocuration,1,,B,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,,BAO_0000019,H,,14447,,
959,,,51,,Autocuration,1,,B,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,,BAO_0000019,H,,14447,,
960,,,51,,Autocuration,1,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,,BAO_0000357,H,,15086,,
961,,,51,9606.0,Expert,1,,B,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,BAO_0000357,D,,13051,Homo sapiens,
962,,,51,,Autocuration,1,,F,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,,BAO_0000019,H,,16026,,
963,,,51,,Expert,1,,B,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,,BAO_0000019,H,,17085,,
964,,,51,,Autocuration,1,,B,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,17133,,
965,,,51,,Autocuration,1,,B,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,,BAO_0000357,H,,17133,,
966,,,51,,Autocuration,1,,B,308.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,BAO_0000219,H,,17211,,HeLa
967,,,51,,Autocuration,1,,B,308.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,,BAO_0000219,H,,17211,,HeLa
968,,,51,,Autocuration,1,,B,308.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,BAO_0000219,H,,17211,,HeLa
969,,,51,,Autocuration,1,,B,308.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,BAO_0000219,H,,17211,,HeLa
970,,,51,,Autocuration,1,,F,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,BAO_0000019,H,,16394,,
971,,,51,,Autocuration,1,,F,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,BAO_0000019,H,,16394,,
972,,,51,,Autocuration,1,,F,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,BAO_0000019,H,,16394,,
973,In vivo,,51,,Autocuration,1,,F,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,,BAO_0000218,H,,16394,,
974,,,51,,Autocuration,1,,B,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,,BAO_0000019,H,,16394,,
975,,,51,,Autocuration,1,,F,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,,BAO_0000019,H,,15740,,
976,,,51,,Autocuration,1,,F,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,,BAO_0000019,H,,15740,,
977,,,51,,Autocuration,1,,B,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,15740,,
978,,,51,,Autocuration,1,,F,722.0,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,BAO_0000219,H,,17296,,HEK293
979,,,51,,Expert,1,,F,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,,BAO_0000019,H,,5640,,
980,,,51,,Autocuration,1,,F,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,,BAO_0000019,H,,5640,,
981,,,51,,Autocuration,1,,F,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,,BAO_0000019,H,,5640,,
982,,,51,,Autocuration,1,,F,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,,BAO_0000019,H,,5640,,
983,,,51,,Autocuration,1,,F,449.0,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,BAO_0000219,H,,2759,,CHO
984,,,51,,Autocuration,1,,F,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,,BAO_0000019,H,,16394,,
985,,,51,9606.0,Expert,1,,F,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,,BAO_0000019,D,,16394,Homo sapiens,
986,,,51,9606.0,Expert,1,,F,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,,BAO_0000019,D,,3445,Homo sapiens,
987,,,51,,Expert,1,,B,449.0,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,,BAO_0000219,H,,4316,,CHO
988,,,51,,Expert,1,,B,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,,BAO_0000019,H,,4316,,
989,,,51,9606.0,Expert,1,,F,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,,BAO_0000019,D,,15180,Homo sapiens,
990,,,51,9606.0,Expert,1,,F,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,,BAO_0000019,D,,15180,Homo sapiens,
991,,,51,,Autocuration,1,,F,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,BAO_0000019,H,,15042,,
992,,,51,,Autocuration,1,,F,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,BAO_0000019,H,,15042,,
993,,,51,,Autocuration,1,,F,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,BAO_0000019,H,,15042,,
994,,,51,,Autocuration,1,,F,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,BAO_0000019,H,,15042,,
995,,,51,,Autocuration,1,,F,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,BAO_0000019,H,,15042,,
996,,,51,,Autocuration,1,,F,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,BAO_0000019,H,,15042,,
997,,,51,,Autocuration,1,,F,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,BAO_0000019,H,,15042,,
998,,,51,9606.0,Expert,1,,F,308.0,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,,BAO_0000219,D,,15180,Homo sapiens,HeLa
999,,,51,9606.0,Expert,1,,F,308.0,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,,BAO_0000219,D,,15180,Homo sapiens,HeLa
1000,,,51,9606.0,Expert,1,,F,308.0,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,,BAO_0000219,D,,15180,Homo sapiens,HeLa
1001,,,51,,Autocuration,1,,F,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,,BAO_0000019,H,,16245,,
1002,,,51,,Autocuration,1,,F,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,BAO_0000019,H,,16026,,
1003,,,51,,Autocuration,1,,F,722.0,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,BAO_0000219,H,,17296,,HEK293
1004,,,51,,Autocuration,1,,F,449.0,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,,BAO_0000219,H,,2759,,CHO
1005,,,51,,Autocuration,1,,F,449.0,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,BAO_0000219,H,,2759,,CHO
1006,,,51,9606.0,Expert,1,,F,449.0,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,,BAO_0000219,D,,2759,Homo sapiens,CHO
1007,,,51,,Autocuration,1,,F,449.0,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,,BAO_0000219,H,,2759,,CHO
1008,,,51,,Expert,1,,F,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,,BAO_0000219,H,,15419,,
1009,,,51,,Autocuration,1,,F,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,,BAO_0000219,H,,15419,,
1010,,,51,,Autocuration,1,,F,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,BAO_0000019,H,,16026,,
1011,In vitro,,51,,Expert,1,,B,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,,BAO_0000219,H,,1414,,
1012,In vitro,,51,,Expert,1,,B,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,,BAO_0000219,H,,1414,,
1013,,,51,,Autocuration,1,,B,,Binding activity radioligand.,,,BAO_0000357,H,,12861,,
1014,,,51,,Autocuration,1,,B,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,BAO_0000019,H,,12861,,
1015,,,51,,Autocuration,1,,B,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,5104,,
1016,,,51,,Autocuration,1,,B,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,5105,,
1017,,,51,,Autocuration,1,,B,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,16312,,
1018,,,51,9606.0,Expert,1,,B,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,,BAO_0000357,D,,15180,Homo sapiens,
1019,,,51,,Autocuration,1,,B,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,5033,,
1020,,,51,9606.0,Expert,1,,B,449.0,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,,BAO_0000219,D,,16909,Homo sapiens,CHO
1021,,,51,,Autocuration,1,,F,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,,BAO_0000019,H,,2590,,
1022,,,51,,Autocuration,1,,F,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,,BAO_0000019,H,,2590,,
1023,,,51,,Expert,1,,B,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,,BAO_0000019,H,,16394,,
1024,,,51,9606.0,Expert,1,,B,722.0,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,,BAO_0000219,D,,4540,Homo sapiens,HEK293
1025,,,51,,Autocuration,1,,B,722.0,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,,BAO_0000219,H,,17296,,HEK293
1026,,,51,,Autocuration,1,,B,722.0,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,,BAO_0000219,H,,17296,,HEK293
1027,,,51,,Autocuration,1,,B,722.0,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,,BAO_0000219,H,,15779,,HEK293
1028,,,51,,Autocuration,1,,B,722.0,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,,BAO_0000219,H,,15779,,HEK293
1029,,,51,,Autocuration,1,,B,722.0,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,,BAO_0000219,H,,15779,,HEK293
1030,,,51,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,6166,,
1031,,,51,,Autocuration,1,,B,722.0,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,,BAO_0000219,H,,15779,,HEK293
1032,,,51,,Autocuration,1,,B,722.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,,BAO_0000219,H,,4199,,HEK293
1033,,,51,,Autocuration,1,,B,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,,BAO_0000219,H,,15316,,
1034,,,51,,Autocuration,1,,B,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,14875,,
1035,,,51,,Expert,1,,B,308.0,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,BAO_0000219,H,,14727,,HeLa
1036,,,51,,Expert,1,,B,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,BAO_0000019,H,,14727,,
1037,,,51,,Autocuration,1,,B,722.0,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,,BAO_0000219,H,,15146,,HEK293
1038,,,51,,Autocuration,1,,B,722.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,,BAO_0000219,H,,5213,,HEK293
1039,,,51,,Autocuration,1,,B,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,,BAO_0000219,H,,16429,,
1040,,,51,9606.0,Expert,1,,B,308.0,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,,BAO_0000219,D,,15042,Homo sapiens,HeLa
1041,,,51,,Autocuration,1,,B,722.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,,BAO_0000219,H,,14818,,HEK293
1042,,,51,,Autocuration,1,,B,722.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,,BAO_0000219,H,,4829,,HEK293
1043,,,51,,Expert,1,,B,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,BAO_0000357,D,,17200,,
1044,,,51,9606.0,Autocuration,1,,B,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,,BAO_0000357,D,,13051,Homo sapiens,
1045,,,106,,Autocuration,1,,B,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,BAO_0000357,H,,5486,,
1046,,,105,,Autocuration,1,,B,,Binding affinity against 5-HT1D receptor,,,BAO_0000357,H,,5254,,
1047,,,105,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,5254,,
1048,,,107,,Autocuration,1,,B,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,BAO_0000357,H,,15331,,
1049,,,10576,9606.0,Autocuration,1,,B,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,BAO_0000357,H,,13506,Homo sapiens,
1050,,,51,,Autocuration,1,,B,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,15267,,
1051,In vivo,,11863,,Autocuration,1,,F,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,,BAO_0000218,H,,16616,,
1052,In vivo,,11863,,Autocuration,1,,F,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,,BAO_0000218,H,,16616,,
1053,In vivo,,11863,,Autocuration,1,,F,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,,BAO_0000218,H,,16616,,
1054,,,11863,10090.0,Expert,1,,F,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,,BAO_0000218,D,,16616,Mus musculus,
1055,,,11863,10090.0,Expert,1,,F,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,,BAO_0000218,D,,16616,Mus musculus,
1056,,,11863,10090.0,Expert,1,,F,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,,BAO_0000218,D,,16616,Mus musculus,
1057,,,11863,10090.0,Expert,1,,F,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,,BAO_0000218,D,,16616,Mus musculus,
1058,,,11863,10090.0,Expert,1,,F,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,,BAO_0000218,D,,16616,Mus musculus,
1059,,,11863,10090.0,Expert,1,,F,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,,BAO_0000218,D,,16616,Mus musculus,
1060,,10000000.0,11863,,Autocuration,1,Hippocampus,B,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,,BAO_0000221,H,,10297,,
1061,,,11863,,Expert,1,,B,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,,BAO_0000357,H,,13704,,
1062,,10000000.0,11863,10090.0,Expert,1,Hippocampus,B,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,,BAO_0000221,D,,10297,Mus musculus,
1063,,10000000.0,11863,,Autocuration,1,Hippocampus,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,BAO_0000221,H,,10297,,
1064,,10000000.0,11863,10090.0,Expert,1,Hippocampus,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,,BAO_0000221,D,,10297,Mus musculus,
1065,,10000000.0,11863,,Autocuration,1,Hippocampus,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,BAO_0000221,H,,10297,,
1066,,,11863,,Autocuration,1,,B,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,,BAO_0000357,H,,217,,
1067,,10000000.0,11863,10090.0,Expert,1,Hippocampus,B,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,,BAO_0000221,D,,10297,Mus musculus,
1068,,,51,9823.0,Autocuration,1,,B,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,4921,Sus scrofa,
1069,,,51,9823.0,Autocuration,1,,B,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,,BAO_0000357,H,,4921,Sus scrofa,
1070,,,51,9823.0,Autocuration,1,,B,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,,BAO_0000019,H,,4996,Sus scrofa,
1071,,,51,9823.0,Autocuration,1,,B,,Compound was evaluated for the binding affinity at 5- HT1A receptor,,,BAO_0000357,H,,12918,Sus scrofa,
1072,,,51,9823.0,Autocuration,1,,B,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,,BAO_0000019,H,,5333,Sus scrofa,
1073,,,51,9823.0,Autocuration,1,,B,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,,BAO_0000019,H,,4437,Sus scrofa,
1074,,,51,9823.0,Autocuration,1,,B,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,,BAO_0000019,H,,1742,Sus scrofa,
1075,,,51,9823.0,Expert,1,,B,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,16688,Sus scrofa,
1076,,,51,9823.0,Autocuration,1,,B,,Binding activity radioligand.,,,BAO_0000357,H,,12861,Sus scrofa,
1077,,,51,9823.0,Expert,1,,B,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,,BAO_0000019,H,,12861,Sus scrofa,
1078,,,51,9823.0,Autocuration,1,,B,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,,BAO_0000019,H,,12861,Sus scrofa,
1079,,,10624,,Expert,1,,B,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,,BAO_0000019,H,,12490,,
1080,,,51,9823.0,Expert,1,,B,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,,BAO_0000019,H,,11828,Sus scrofa,
1081,,10000000.0,51,9823.0,Autocuration,1,Hippocampus,B,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,,BAO_0000221,H,,11866,Sus scrofa,
1082,,,51,9823.0,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,,BAO_0000249,H,,12827,Sus scrofa,
1083,,,51,9823.0,Autocuration,1,,B,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,,BAO_0000019,H,,12918,Sus scrofa,
1084,,,51,9823.0,Expert,1,,F,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,,BAO_0000019,H,,12919,Sus scrofa,
1085,,,51,9986.0,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,,BAO_0000019,H,,13047,Oryctolagus cuniculus,
1086,,,10576,10116.0,Expert,1,,B,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,,BAO_0000249,D,,15796,Rattus norvegicus,
1087,,10000000.0,10576,10116.0,Expert,1,Hippocampus,B,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,,BAO_0000221,D,,3651,Rattus norvegicus,
1088,,,10576,,Autocuration,1,,B,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,,BAO_0000357,H,,188,,
1089,,,10576,10116.0,Expert,1,,F,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Membranes,,BAO_0000249,D,,16616,Rattus norvegicus,
1090,,10000000.0,10576,10116.0,Expert,1,Hippocampus,F,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Membranes,,BAO_0000249,D,,16616,Rattus norvegicus,
1091,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,BAO_0000221,H,,12306,,
1092,,10000000.0,10576,10116.0,Expert,1,Hippocampus,B,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,,BAO_0000221,D,,17167,Rattus norvegicus,
1093,,,10576,,Autocuration,1,,B,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,,BAO_0000019,H,,14776,,
1094,,,10576,,Expert,1,,B,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,,BAO_0000357,H,,12158,,
1095,,,10576,,Autocuration,1,,B,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,BAO_0000357,H,,13481,,
1096,In vitro,,10576,,Autocuration,1,,B,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,BAO_0000219,H,,13427,,
1097,,,10576,,Autocuration,1,,B,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,,BAO_0000357,H,,10210,,
1098,,,10576,,Autocuration,1,,B,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,Membranes,,BAO_0000249,H,,10205,,
1099,,,10576,,Autocuration,1,,B,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,Membranes,,BAO_0000249,H,,10205,,
1100,,,10576,,Expert,1,,B,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,Membranes,,BAO_0000249,H,,10205,,
1101,,,10576,10116.0,Expert,1,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,,BAO_0000357,D,,12280,Rattus norvegicus,
1102,,,10576,,Expert,1,,B,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,17386,,
1103,,,10576,,Expert,1,,B,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,,BAO_0000357,H,,13654,,
1104,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,,BAO_0000221,H,,14423,,
1105,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,,BAO_0000221,H,,15412,,
1106,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,BAO_0000221,H,,12073,,
1107,,,10576,10116.0,Expert,1,,B,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,,BAO_0000357,D,,4101,Rattus norvegicus,
1108,,,10576,,Autocuration,1,,B,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,10062,,
1109,,,10576,,Autocuration,1,,B,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,,BAO_0000249,H,,6238,,
1110,,,10576,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,16273,,
1111,,,10576,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,,BAO_0000357,H,,11139,,
1112,,,10576,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,BAO_0000019,H,,16796,,
1113,,955.0,10576,10116.0,Expert,1,Brain,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,BAO_0000221,D,,9548,Rattus norvegicus,
1114,,955.0,10576,,Autocuration,1,Brain,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,BAO_0000221,H,,10381,,
1115,,,10576,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,,BAO_0000249,H,,13408,,
1116,,10000000.0,10576,10116.0,Expert,1,Hippocampus,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,,BAO_0000221,D,,13825,Rattus norvegicus,
1117,,10000000.0,10576,,Expert,1,Hippocampus,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,,BAO_0000221,H,,11147,,
1118,,,10576,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,,BAO_0000249,H,,10552,,
1119,,2435.0,10576,,Autocuration,1,Striatum,B,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,BAO_0000249,H,,10552,,
1120,,,10576,10116.0,Expert,1,,B,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,Membranes,,BAO_0000249,D,,17136,Rattus norvegicus,
1121,,,10576,10116.0,Expert,1,,B,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,Membranes,,BAO_0000249,D,,5778,Rattus norvegicus,
1122,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,BAO_0000221,H,,13481,,
1123,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,,BAO_0000221,H,,13481,,
1124,,10000000.0,10576,,Intermediate,1,Hippocampus,B,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,,BAO_0000221,H,,13630,,
1125,,,10576,,Expert,1,,B,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,BAO_0000249,H,,16245,,
1126,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,,BAO_0000221,H,,14509,,
1127,,10000000.0,10576,,Expert,1,Hippocampus,B,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,BAO_0000221,H,,14509,,
1128,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,,BAO_0000221,H,,14509,,
1129,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,,BAO_0000221,H,,14509,,
1130,,,10576,,Expert,1,,B,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,,BAO_0000019,H,,14256,,
1131,,,10576,,Autocuration,1,,B,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,11139,,
1132,,,10576,10116.0,Expert,1,,B,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,,BAO_0000019,D,,11047,Rattus norvegicus,
1133,,,10576,10116.0,Expert,1,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,,BAO_0000019,D,,11047,Rattus norvegicus,
1134,,,10576,10116.0,Expert,1,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,,BAO_0000019,D,,11047,Rattus norvegicus,
1135,,,10576,10116.0,Expert,1,,B,485.0,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,,BAO_0000219,D,,2395,Rattus norvegicus,CHO-K1
1136,,,10576,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,9699,,
1137,,10000000.0,10576,10116.0,Expert,1,Hippocampus,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,,BAO_0000221,D,,12028,Rattus norvegicus,
1138,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,,BAO_0000221,H,,12028,,
1139,,,10576,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,BAO_0000019,H,,5815,,
1140,,,10576,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,,BAO_0000019,H,,16616,,
1141,,,10576,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,,BAO_0000019,H,,5815,,
1142,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,,BAO_0000221,H,,2761,,
1143,,,10576,,Expert,1,,B,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,,BAO_0000357,H,,13133,,
1144,,,10576,,Autocuration,1,,B,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,,BAO_0000019,H,,10444,,
1145,,,10576,10116.0,Expert,1,,B,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,,BAO_0000357,D,,13278,Rattus norvegicus,
1146,,,10576,,Autocuration,1,,B,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,BAO_0000357,H,,15874,,
1147,,2435.0,10576,,Autocuration,1,Striatum,B,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Membranes,,BAO_0000249,H,,10552,,
1148,,,10576,,Autocuration,1,,B,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,,BAO_0000357,H,,11130,,
1149,In vivo,,10576,,Autocuration,1,,B,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,,BAO_0000218,H,,11130,,
1150,,955.0,10576,,Autocuration,1,Brain,B,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,,BAO_0000221,H,,14542,,
1151,,,10576,10116.0,Expert,1,,B,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,BAO_0000357,D,,13670,Rattus norvegicus,
1152,,,10576,,Expert,1,,B,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,,BAO_0000249,H,,9888,,
1153,,,10576,10116.0,Expert,1,,B,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,Membranes,,BAO_0000249,D,,3678,Rattus norvegicus,
1154,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,BAO_0000221,H,,11332,,
1155,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,BAO_0000221,H,,11332,,
1156,,,10576,,Expert,1,,B,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,1185,,
1157,,,10576,,Expert,1,,B,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,,BAO_0000249,H,,2014,,
1158,,,10576,,Autocuration,1,,B,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,1185,,
1159,,,10576,,Expert,1,,B,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,,BAO_0000019,H,,14429,,
1160,,,10576,,Expert,1,,B,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,,BAO_0000019,H,,16288,,
1161,,,10576,10116.0,Expert,1,,B,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,,BAO_0000019,D,,5432,Rattus norvegicus,
1162,,,10576,,Autocuration,1,,B,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,,BAO_0000019,H,,14429,,
1163,,,10576,,Expert,1,,B,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,,BAO_0000357,H,,13672,,
1164,,10000000.0,10576,,Expert,1,Hippocampus,B,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,BAO_0000221,H,,11296,,
1165,,,10576,,Autocuration,1,,B,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,,BAO_0000357,H,,11296,,
1166,,,10576,,Expert,1,,B,449.0,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,,BAO_0000219,H,,14749,,CHO
1167,,,10576,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,,BAO_0000019,H,,15086,,
1168,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,,BAO_0000221,H,,13462,,
1169,,,10576,,Autocuration,1,,B,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,BAO_0000019,H,,15363,,
1170,,,10576,,Autocuration,1,,B,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,BAO_0000019,H,,15363,,
1171,,,10576,,Autocuration,1,,B,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,10796,,
1172,,955.0,10576,,Expert,1,Brain,B,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,,BAO_0000221,H,,12816,,
1173,,10000000.0,10576,,Expert,1,Hippocampus,B,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,BAO_0000221,H,,13542,,
1174,,,10576,,Expert,1,,B,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,,BAO_0000019,H,,13308,,
1175,,10000000.0,10576,,Expert,1,Hippocampus,B,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,,BAO_0000221,H,,13541,,
1176,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,,BAO_0000221,H,,10058,,
1177,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,,BAO_0000221,H,,10058,,
1178,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,,BAO_0000221,H,,10058,,
1179,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,,BAO_0000221,H,,10058,,
1180,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,,BAO_0000221,H,,10058,,
1181,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,,BAO_0000221,H,,10058,,
1182,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,,BAO_0000221,H,,10058,,
1183,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,,BAO_0000221,H,,10058,,
1184,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,,BAO_0000221,H,,10058,,
1185,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,,BAO_0000221,H,,10058,,
1186,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,,BAO_0000221,H,,10058,,
1187,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,,BAO_0000221,H,,10058,,
1188,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,,BAO_0000221,H,,10058,,
1189,,10000000.0,10576,10116.0,Expert,1,Hippocampus,B,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,,BAO_0000221,D,,10058,Rattus norvegicus,
1190,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,,BAO_0000221,H,,10058,,
1191,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,,BAO_0000221,H,,10058,,
1192,,,10576,,Expert,1,,B,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,,BAO_0000019,H,,12879,,
1193,,,10576,,Expert,1,,B,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,,BAO_0000019,H,,11964,,
1194,,,10576,,Autocuration,1,,B,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,,BAO_0000019,H,,11964,,
1195,,,10576,,Autocuration,1,,B,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,,BAO_0000019,H,,11964,,
1196,,955.0,10576,,Expert,1,Brain,B,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,BAO_0000221,H,,9548,,
1197,,,10576,,Expert,1,,B,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,,BAO_0000019,H,,9098,,
1198,,,10576,,Autocuration,1,,B,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,,BAO_0000019,H,,9098,,
1199,,,10576,,Autocuration,1,,B,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,,BAO_0000019,H,,9098,,
1200,,,10576,,Expert,1,,B,449.0,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,,BAO_0000219,H,,13248,,CHO
1201,,,10576,,Expert,1,,B,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,,BAO_0000249,H,,3147,,
1202,,,10576,,Expert,1,,B,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,BAO_0000019,H,,13949,,
1203,,,10576,,Autocuration,1,,B,449.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,,BAO_0000218,H,,11883,,CHO
1204,,,10576,,Autocuration,1,,B,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,,BAO_0000218,H,,11883,,
1205,,,10576,10116.0,Expert,1,,B,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,,BAO_0000357,D,,11883,Rattus norvegicus,
1206,,,10576,,Expert,1,,B,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Membranes,,BAO_0000249,H,,15535,,
1207,,,10576,,Autocuration,1,,B,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,,BAO_0000249,H,,15535,,
1208,,,10576,,Autocuration,1,,B,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,,BAO_0000249,H,,15535,,
1209,,,51,9606.0,Expert,1,,B,449.0,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,BAO_0000219,D,,16372,Homo sapiens,CHO
1210,,,10576,,Expert,1,,B,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,,BAO_0000249,H,,14608,,
1211,,10000000.0,10576,10116.0,Expert,1,Hippocampus,B,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,,BAO_0000221,D,,4795,Rattus norvegicus,
1212,,,10576,,Autocuration,1,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,13863,,
1213,,,10576,,Autocuration,1,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,,BAO_0000357,H,,13863,,
1214,,,10576,,Autocuration,1,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,,BAO_0000357,H,,13863,,
1215,,,10576,,Autocuration,1,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,,BAO_0000357,H,,13863,,
1216,,,10576,,Autocuration,1,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,,BAO_0000357,H,,13863,,
1217,,,10576,,Autocuration,1,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,,BAO_0000357,H,,13863,,
1218,,,10576,,Autocuration,1,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,,BAO_0000357,H,,13863,,
1219,,,10576,,Autocuration,1,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,,BAO_0000357,H,,13863,,
1220,,,10576,,Autocuration,1,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,,BAO_0000357,H,,13863,,
1221,,,10576,,Autocuration,1,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,,BAO_0000357,H,,13863,,
1222,,,10576,,Autocuration,1,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,,BAO_0000357,H,,13863,,
1223,,,10576,,Autocuration,1,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,,BAO_0000357,H,,13863,,
1224,,,10576,,Autocuration,1,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,,BAO_0000357,H,,13863,,
1225,,,10576,,Autocuration,1,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,,BAO_0000357,H,,13863,,
1226,,,10576,,Autocuration,1,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,,BAO_0000357,H,,13863,,
1227,,,10576,,Autocuration,1,,B,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,,BAO_0000019,H,,9742,,
1228,,,10576,,Autocuration,1,,B,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,12073,,
1229,,,10576,,Autocuration,1,,B,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,,BAO_0000357,H,,4101,,
1230,,,10576,,Autocuration,1,,B,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,,BAO_0000019,H,,15360,,
1231,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,BAO_0000221,H,,11576,,
1232,,,10576,,Expert,1,,B,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,,BAO_0000019,H,,5834,,
1233,,,10576,10116.0,Expert,1,,B,485.0,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,,BAO_0000219,D,,2395,Rattus norvegicus,CHO-K1
1234,,,10576,,Autocuration,1,,B,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,,BAO_0000019,H,,1375,,
1235,,,10576,,Autocuration,1,,B,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,,BAO_0000019,H,,1375,,
1236,,,10576,,Autocuration,1,,B,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,,BAO_0000357,H,,3967,,
1237,,,10576,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,,BAO_0000357,H,,12884,,
1238,,,10576,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,,BAO_0000357,H,,2343,,
1239,,,10576,,Autocuration,1,,B,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,BAO_0000019,H,,11511,,
1240,,,10576,10116.0,Expert,1,,B,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,BAO_0000019,D,,11511,Rattus norvegicus,
1241,In vivo,,10576,,Autocuration,1,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,,BAO_0000218,H,,16394,,
1242,In vivo,,10576,,Autocuration,1,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,,BAO_0000218,H,,16394,,
1243,In vivo,,10576,,Autocuration,1,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,,BAO_0000218,H,,16394,,
1244,In vivo,,10576,,Autocuration,1,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,,BAO_0000218,H,,16394,,
1245,In vivo,,10576,,Autocuration,1,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,,BAO_0000218,H,,16394,,
1246,In vivo,,10576,,Autocuration,1,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,,BAO_0000218,H,,16394,,
1247,In vivo,,10576,,Autocuration,1,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,,BAO_0000218,H,,16394,,
1248,In vivo,,10576,,Autocuration,1,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,,BAO_0000218,H,,16394,,
1249,In vivo,,10576,,Autocuration,1,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,,BAO_0000218,H,,16394,,
1250,In vivo,,10576,,Autocuration,1,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,,BAO_0000218,H,,16394,,
1251,In vivo,,10576,,Autocuration,1,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,,BAO_0000218,H,,16394,,
1252,In vivo,,10576,,Autocuration,1,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,,BAO_0000218,H,,16394,,
1253,In vivo,,10576,,Autocuration,1,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,,BAO_0000218,H,,16394,,
1254,In vivo,,10576,,Autocuration,1,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,,BAO_0000218,H,,16394,,
1255,In vivo,,10576,,Autocuration,1,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,,BAO_0000218,H,,16394,,
1256,,,10576,10116.0,Expert,1,,F,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Membranes,,BAO_0000249,D,,16616,Rattus norvegicus,
1257,,,10576,,Autocuration,1,,B,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,,BAO_0000019,H,,16796,,
1258,,,10576,,Autocuration,1,,B,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,BAO_0000019,H,,16796,,
1259,,,10576,,Autocuration,1,,B,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,,BAO_0000357,H,,15629,,
1260,,,10576,,Autocuration,1,,F,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,BAO_0000249,H,,13241,,
1261,,10000000.0,10576,,Expert,1,Hippocampus,B,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,BAO_0000221,H,,12073,,
1262,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,,BAO_0000249,H,,14286,,
1263,,955.0,10576,,Autocuration,1,Brain,B,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,,BAO_0000221,H,,14542,,
1264,,,10576,,Autocuration,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,BAO_0000019,H,,13630,,
1265,,,10576,,Autocuration,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,,BAO_0000019,H,,13630,,
1266,,,10576,,Autocuration,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,,BAO_0000019,H,,13630,,
1267,,,10576,,Autocuration,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,BAO_0000019,H,,13630,,
1268,,,10576,,Expert,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,BAO_0000019,H,,13630,,
1269,,,10576,,Autocuration,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,,BAO_0000019,H,,13630,,
1270,,,10576,10116.0,Expert,1,,F,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,,BAO_0000019,D,,13630,Rattus norvegicus,
1271,,,10576,,Autocuration,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,BAO_0000019,H,,13630,,
1272,,,10576,,Expert,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,,BAO_0000019,H,,13630,,
1273,,,10576,,Autocuration,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,,BAO_0000019,H,,13630,,
1274,,,10576,,Expert,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,,BAO_0000019,H,,13630,,
1275,,,10576,,Autocuration,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,,BAO_0000019,H,,13630,,
1276,,,10576,,Expert,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,BAO_0000019,H,,13630,,
1277,,,10576,,Autocuration,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,,BAO_0000019,H,,13630,,
1278,,,10576,,Autocuration,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,BAO_0000019,H,,13630,,
1279,,,10576,,Autocuration,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,,BAO_0000019,H,,13630,,
1280,,,10576,,Expert,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,,BAO_0000019,H,,13630,,
1281,,,10576,,Expert,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,BAO_0000019,H,,13630,,
1282,,,10576,,Autocuration,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,,BAO_0000019,H,,13630,,
1283,,,10576,,Expert,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,,BAO_0000019,H,,13630,,
1284,,,10576,,Autocuration,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,,BAO_0000019,H,,13630,,
1285,,,10576,,Autocuration,1,,F,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,,BAO_0000019,H,,13630,,
1286,,,10576,,Autocuration,1,,F,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,BAO_0000019,H,,13630,,
1287,,,10576,,Autocuration,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,BAO_0000019,H,,13630,,
1288,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,,BAO_0000221,H,,9783,,
1289,,10000000.0,10576,,Expert,1,Hippocampus,B,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,,BAO_0000221,H,,9783,,
1290,,,10576,10116.0,Expert,1,,B,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,Membranes,,BAO_0000249,D,,14331,Rattus norvegicus,
1291,,10000000.0,10576,,Expert,1,Hippocampus,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,,BAO_0000221,H,,15260,,
1292,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,,BAO_0000221,H,,15260,,
1293,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,,BAO_0000221,H,,15260,,
1294,,,10576,10116.0,Expert,1,,F,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,,BAO_0000249,D,,16616,Rattus norvegicus,
1295,,,10576,,Autocuration,1,,B,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,,BAO_0000357,H,,15629,,
1296,,,10576,,Autocuration,1,,B,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,BAO_0000019,H,,15086,,
1297,,,10576,,Expert,1,,F,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,BAO_0000019,H,,5717,,
1298,,,10576,,Autocuration,1,,B,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,BAO_0000357,H,,12652,,
1299,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,,BAO_0000221,H,,14608,,
1300,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,BAO_0000221,H,,12306,,
1301,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,BAO_0000221,H,,12306,,
1302,,,10576,10116.0,Expert,1,,B,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,BAO_0000357,D,,15247,Rattus norvegicus,
1303,,10000000.0,10576,,Expert,1,Hippocampus,B,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,,BAO_0000221,H,,17529,,
1304,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,BAO_0000221,H,,14826,,
1305,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,BAO_0000221,H,,14826,,
1306,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,BAO_0000221,H,,13241,,
1307,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,,BAO_0000221,H,,14093,,
1308,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,,BAO_0000221,H,,14093,,
1309,,955.0,10576,,Autocuration,1,Brain,B,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,,BAO_0000221,H,,14442,,
1310,,,10576,,Autocuration,1,,B,,Affinity for 5-hydroxytryptamine 1A receptor site,,,BAO_0000357,H,,9919,,
1311,,,10576,,Autocuration,1,,B,,Affinity for 5-hydroxytryptamine 1A receptor site,,,BAO_0000357,H,,9919,,
1312,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,,BAO_0000221,H,,11440,,
1313,,,10576,,Autocuration,1,,B,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,,BAO_0000357,H,,11257,,
1314,,,10576,,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,,BAO_0000357,H,,10330,,
1315,,10000000.0,10576,10116.0,Expert,1,Hippocampus,B,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,,BAO_0000221,D,,17331,Rattus norvegicus,
1316,,,10576,,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,,BAO_0000249,H,,16567,,
1317,,,10576,10116.0,Expert,1,,B,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,BAO_0000019,D,,12058,Rattus norvegicus,
1318,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,,BAO_0000221,H,,9699,,
1319,,,10576,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,,BAO_0000357,H,,9547,,
1320,,,10576,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,,BAO_0000357,H,,10330,,
1321,,,10576,,Autocuration,1,,B,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,14331,,
1322,,,10576,10116.0,Expert,1,,B,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,,BAO_0000019,D,,14060,Rattus norvegicus,
1323,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,,BAO_0000221,H,,14744,,
1324,,,10576,,Autocuration,1,,B,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,BAO_0000357,H,,13506,,
1325,,955.0,10576,,Expert,1,Brain,B,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,BAO_0000221,H,,10862,,
1326,,955.0,10576,,Expert,1,Brain,B,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,BAO_0000221,H,,10862,,
1327,,,10576,,Expert,1,,B,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,,BAO_0000357,H,,10062,,
1328,,,10576,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,,BAO_0000357,H,,12073,,
1329,,,106,,Autocuration,1,,B,,GTPgammaS radioligand binding assay,,,BAO_0000357,H,,14875,,
1330,,,106,,Autocuration,1,,B,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,BAO_0000357,H,,2391,,
1331,,,106,,Autocuration,1,,F,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,,BAO_0000019,H,,2391,,
1332,,,106,,Autocuration,1,,F,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,,BAO_0000019,H,,2391,,
1333,,,106,,Autocuration,1,,B,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,BAO_0000357,H,,2391,,
1334,,,106,,Autocuration,1,,B,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,BAO_0000357,H,,2391,,
1335,,,106,,Autocuration,1,,F,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,,BAO_0000019,H,,2391,,
1336,,,106,,Expert,1,,B,308.0,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,,BAO_0000219,H,,17211,,HeLa
1337,,,106,,Autocuration,1,,B,308.0,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,,BAO_0000219,H,,17211,,HeLa
1338,,,106,9606.0,Expert,1,,B,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,,BAO_0000357,D,,6491,Homo sapiens,
1339,,,106,,Autocuration,1,,B,449.0,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,,BAO_0000219,H,,16190,,CHO
1340,,,106,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,,BAO_0000019,H,,14165,,
1341,,,106,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,,BAO_0000019,H,,14165,,
1342,,,106,9606.0,Expert,1,,B,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,,BAO_0000357,D,,4234,Homo sapiens,
1343,,,106,,Expert,1,,B,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,BAO_0000219,H,,6328,,
1344,,,106,,Autocuration,1,,B,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,BAO_0000357,H,,14770,,
1345,,,106,,Autocuration,1,,B,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,,BAO_0000357,H,,2598,,
1346,,,106,,Expert,1,,B,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,BAO_0000357,H,,6897,,
1347,,,106,,Autocuration,1,,B,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,BAO_0000357,H,,6897,,
1348,,,106,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,BAO_0000357,H,,6013,,
1349,,,106,,Expert,1,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,BAO_0000357,H,,5843,,
1350,,,106,,Expert,1,,B,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,,BAO_0000357,H,,14454,,
1351,,,106,,Autocuration,1,,B,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,,BAO_0000357,H,,16209,,
1352,,,106,,Autocuration,1,,B,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,,BAO_0000357,H,,3935,,
1353,,,106,,Expert,1,,F,485.0,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,,BAO_0000219,H,,13729,,CHO-K1
1354,,,106,,Expert,1,,F,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,,BAO_0000019,H,,14251,,
1355,,,106,,Expert,1,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,,BAO_0000019,H,,17085,,
1356,,,106,,Autocuration,1,,B,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,BAO_0000357,H,,3025,,
1357,,,106,,Expert,1,,B,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,,BAO_0000357,H,,15315,,
1358,,,106,9606.0,Expert,1,,B,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,,BAO_0000219,D,,14214,Homo sapiens,
1359,,,106,9606.0,Expert,1,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,BAO_0000357,D,,3804,Homo sapiens,
1360,,,106,9606.0,Expert,1,,B,,Affinity for 5-hydroxytryptamine 1B receptor subtype,,,BAO_0000357,D,,2391,Homo sapiens,
1361,,,106,9606.0,Expert,1,,B,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,,BAO_0000357,D,,4175,Homo sapiens,
1362,,,106,,Autocuration,1,,B,449.0,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,,BAO_0000219,H,,17296,,CHO
1363,,,106,,Expert,1,,B,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,,BAO_0000019,H,,17085,,
1364,,,106,,Autocuration,1,,B,308.0,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,,BAO_0000219,H,,17211,,HeLa
1365,,,106,,Autocuration,1,,B,308.0,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,,BAO_0000219,H,,17211,,HeLa
1366,,,106,,Autocuration,1,,B,308.0,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,,BAO_0000219,H,,17211,,HeLa
1367,,,106,9606.0,Expert,1,,B,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,,BAO_0000357,D,,15926,Homo sapiens,
1368,,,106,,Autocuration,1,,B,485.0,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,,BAO_0000219,H,,16312,,CHO-K1
1369,,,106,,Expert,1,,B,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,,BAO_0000357,H,,5843,,
1370,,,106,,Autocuration,1,,B,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,,BAO_0000357,H,,5843,,
1371,,,106,,Expert,1,,B,485.0,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,,BAO_0000219,H,,16312,,CHO-K1
1372,,,106,9606.0,Expert,1,,B,,Binding activity against human 5-hydroxytryptamine 1B receptor,,,BAO_0000357,D,,15926,Homo sapiens,
1373,,,106,9606.0,Expert,1,,B,,Binding activity against human 5-hydroxytryptamine 1B receptor,,,BAO_0000357,D,,15926,Homo sapiens,
1374,,,106,9606.0,Expert,1,,B,449.0,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,,BAO_0000219,D,,4540,Homo sapiens,CHO
1375,,,106,,Autocuration,1,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,,BAO_0000357,H,,6166,,
1376,,,106,,Autocuration,1,,B,449.0,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,,BAO_0000219,H,,17296,,CHO
1377,,,106,,Autocuration,1,,B,449.0,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,,BAO_0000219,H,,17296,,CHO
1378,,,106,,Autocuration,1,,B,449.0,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,,BAO_0000219,H,,17296,,CHO
1379,,,106,,Autocuration,1,,B,449.0,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,BAO_0000219,H,,15779,,CHO
1380,,,106,,Autocuration,1,,B,449.0,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,BAO_0000219,H,,15779,,CHO
1381,,,106,,Autocuration,1,,B,449.0,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,,BAO_0000219,H,,15779,,CHO
1382,,,106,,Autocuration,1,,B,449.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,,BAO_0000219,H,,4199,,CHO
1383,,,106,9606.0,Expert,1,,B,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,,BAO_0000357,D,,14875,Homo sapiens,
1384,,,106,,Autocuration,1,,B,449.0,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,,BAO_0000219,H,,15146,,CHO
1385,,,106,,Autocuration,1,,B,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,,BAO_0000357,H,,5213,,
1386,,,106,,Autocuration,1,,B,449.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,,BAO_0000219,H,,14818,,CHO
1387,,,106,,Autocuration,1,,B,449.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,,BAO_0000219,H,,4829,,CHO
1388,,,106,,Expert,1,,F,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,,BAO_0000019,H,,14454,,
1389,,,106,,Expert,1,,F,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,,BAO_0000019,H,,14454,,
1390,,,106,,Autocuration,1,,F,449.0,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,,BAO_0000219,H,,14875,,CHO
1391,,,106,,Autocuration,1,,F,449.0,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,,BAO_0000219,H,,14875,,CHO
1392,,,105,,Autocuration,1,,F,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,,BAO_0000019,H,,15250,,
1393,,,105,,Autocuration,1,,B,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,,BAO_0000219,H,,15250,,CHO
1394,,,17105,,Autocuration,1,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,BAO_0000357,H,,15086,,
1395,,,106,9986.0,Autocuration,1,,F,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,,BAO_0000019,H,,3025,Oryctolagus cuniculus,
1396,,,106,9986.0,Autocuration,1,,B,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,,BAO_0000019,H,,14998,Oryctolagus cuniculus,
1397,,,106,9986.0,Intermediate,1,,B,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,,BAO_0000019,H,,14998,Oryctolagus cuniculus,
1398,,,106,9986.0,Autocuration,1,,B,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,,BAO_0000019,H,,14998,Oryctolagus cuniculus,
1399,,,10577,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,,BAO_0000357,H,,13969,,
1400,,,10577,,Intermediate,1,,B,,Binding affinity for 5-hydroxytryptamine 1B receptor,,,BAO_0000357,D,,13392,,
1401,,2435.0,10577,10116.0,Expert,1,Striatum,B,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,,BAO_0000019,D,,3651,Rattus norvegicus,
1402,,,10577,,Expert,1,,B,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,BAO_0000357,H,,10025,,
1403,,,10576,,Autocuration,1,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,,BAO_0000357,H,,13863,,
1404,,,10576,,Autocuration,1,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,,BAO_0000357,H,,13863,,
1405,,,10576,,Autocuration,1,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,,BAO_0000357,H,,13863,,
1406,,,10576,,Autocuration,1,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,,BAO_0000357,H,,13863,,
1407,,,10576,,Autocuration,1,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,,BAO_0000357,H,,13863,,
1408,,,10576,,Autocuration,1,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,,BAO_0000357,H,,13863,,
1409,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,,BAO_0000249,H,,4622,,
1410,,,10576,,Intermediate,1,,B,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,BAO_0000019,H,,14911,,
1411,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,BAO_0000221,H,,12678,,
1412,,10000000.0,10576,,Expert,1,Hippocampus,B,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,,BAO_0000221,H,,12678,,
1413,,10000000.0,10576,,Expert,1,Hippocampus,B,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,BAO_0000221,H,,14235,,
1414,,10000000.0,10576,,Expert,1,Hippocampus,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,BAO_0000221,H,,14949,,
1415,,10000000.0,10576,,Expert,1,Hippocampus,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,BAO_0000221,H,,14949,,
1416,,10000000.0,10576,,Expert,1,Hippocampus,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,,BAO_0000221,H,,14949,,
1417,,10000000.0,10576,,Expert,1,Hippocampus,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,,BAO_0000221,H,,14949,,
1418,,10000000.0,10576,,Expert,1,Hippocampus,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,,BAO_0000221,H,,14949,,
1419,,,10576,,Expert,1,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,BAO_0000249,H,,16118,,
1420,,,10576,,Autocuration,1,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,,BAO_0000249,H,,3268,,
1421,,,10576,,Autocuration,1,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,,BAO_0000249,H,,3268,,
1422,,,10576,,Expert,1,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,,BAO_0000357,H,,16117,,
1423,,10000000.0,10576,,Expert,1,Hippocampus,B,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,,BAO_0000221,H,,9783,,
1424,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,,BAO_0000221,H,,9783,,
1425,,10000000.0,10576,10116.0,Expert,1,Hippocampus,B,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,,BAO_0000221,D,,14356,Rattus norvegicus,
1426,,,10576,,Autocuration,1,,F,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,BAO_0000019,H,,15740,,
1427,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,BAO_0000221,H,,12306,,
1428,,10000000.0,10576,10116.0,Expert,1,Hippocampus,B,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,,BAO_0000221,D,,13348,Rattus norvegicus,
1429,,,10576,,Autocuration,1,,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,,BAO_0000249,H,,10394,,
1430,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,,BAO_0000221,H,,15260,,
1431,,10000000.0,10576,,Expert,1,Hippocampus,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,BAO_0000221,H,,10046,,
1432,,10000000.0,10576,,Intermediate,1,Hippocampus,F,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,,BAO_0000221,H,,15260,,
1433,,,10576,,Autocuration,1,,B,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,12851,,
1434,,10000000.0,10576,10116.0,Expert,1,Hippocampus,B,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,,BAO_0000221,D,,2148,Rattus norvegicus,
1435,,,10576,,Expert,1,,B,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,,BAO_0000357,H,,13134,,
1436,,,10576,,Autocuration,1,,B,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,,BAO_0000019,H,,12462,,
1437,,,10576,,Expert,1,,B,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,,BAO_0000019,H,,12462,,
1438,,,10576,,Autocuration,1,,B,449.0,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,,BAO_0000219,H,,12462,,CHO
1439,,,10576,,Expert,1,,B,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,11933,,
1440,,,10576,,Autocuration,1,,B,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,,BAO_0000357,H,,11933,,
1441,,10000000.0,10576,10116.0,Expert,1,Hippocampus,B,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,,BAO_0000221,D,,403,Rattus norvegicus,
1442,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,,BAO_0000221,H,,15538,,
1443,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,,BAO_0000221,H,,15538,,
1444,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,,BAO_0000221,H,,15538,,
1445,,,10576,,Intermediate,1,,B,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,,BAO_0000019,H,,12464,,
1446,,,10576,,Expert,1,,B,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,,BAO_0000357,H,,1455,,
1447,,,10576,,Autocuration,1,,B,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,BAO_0000357,H,,12652,,
1448,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,,BAO_0000221,H,,12639,,
1449,,,10576,,Expert,1,,B,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,,BAO_0000249,H,,13949,,
1450,,,10576,10116.0,Expert,1,,B,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,,BAO_0000357,D,,12463,Rattus norvegicus,
1451,,10000000.0,10576,,Expert,1,Hippocampus,B,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,,BAO_0000221,H,,14829,,
1452,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,,BAO_0000221,H,,14829,,
1453,,,10576,,Autocuration,1,,B,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,,BAO_0000357,H,,12092,,
1454,,,10576,,Autocuration,1,,B,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,,BAO_0000249,H,,403,,
1455,,,10576,,Autocuration,1,,B,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,,BAO_0000249,H,,403,,
1456,,,10576,,Expert,1,,B,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,,BAO_0000357,H,,3967,,
1457,,,10576,10116.0,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,,BAO_0000019,D,,12771,Rattus norvegicus,
1458,,,10576,,Autocuration,1,,B,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,BAO_0000019,H,,15086,,
1459,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,BAO_0000221,H,,14909,,
1460,,10000000.0,10576,,Expert,1,Hippocampus,B,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,BAO_0000221,H,,14949,,
1461,,10000000.0,10576,10116.0,Expert,1,Hippocampus,B,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,,BAO_0000221,D,,2309,Rattus norvegicus,
1462,,,10576,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,4170,,
1463,,10000000.0,10576,10116.0,Expert,1,Hippocampus,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,,BAO_0000221,D,,11642,Rattus norvegicus,
1464,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,,BAO_0000221,H,,11642,,
1465,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,,BAO_0000221,H,,12953,,
1466,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,BAO_0000221,H,,12953,,
1467,,10000000.0,10576,,Expert,1,Hippocampus,B,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,,BAO_0000221,H,,12953,,
1468,,,10576,,Expert,1,,B,449.0,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,,BAO_0000219,H,,12903,,CHO
1469,,,10576,,Expert,1,,B,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,12536,,
1470,,,10576,,Autocuration,1,,B,,The inhibition activity of 5-HT1A at 1 uM,,,BAO_0000357,H,,10058,,
1471,,,10576,,Expert,1,,B,485.0,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,,BAO_0000219,H,,12902,,CHO-K1
1472,,,10576,,Expert,1,,B,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,,BAO_0000249,H,,14057,,
1473,,,10576,,Autocuration,1,,B,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,,BAO_0000357,H,,11296,,
1474,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,BAO_0000221,H,,11296,,
1475,,10000000.0,10576,,Expert,1,Hippocampus,B,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,BAO_0000221,H,,11296,,
1476,,,10576,10116.0,Expert,1,,F,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,Membranes,,BAO_0000249,D,,16616,Rattus norvegicus,
1477,,10000000.0,10576,10116.0,Expert,1,Hippocampus,F,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Membranes,,BAO_0000249,D,,16616,Rattus norvegicus,
1478,,,10576,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,,BAO_0000019,H,,16567,,
1479,,,10576,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,,BAO_0000019,H,,16567,,
1480,,,10576,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,,BAO_0000019,H,,16567,,
1481,,,10576,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,,BAO_0000019,H,,16567,,
1482,,,10576,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,,BAO_0000249,H,,17136,,
1483,,,10576,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,,BAO_0000249,H,,17136,,
1484,,,10576,10116.0,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,,BAO_0000019,D,,16616,Rattus norvegicus,
1485,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,,BAO_0000221,H,,17331,,
1486,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,,BAO_0000221,H,,17331,,
1487,,10000000.0,10576,10116.0,Expert,1,Hippocampus,B,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,,BAO_0000221,D,,17167,Rattus norvegicus,
1488,,,10576,,Autocuration,1,,F,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,BAO_0000019,H,,15740,,
1489,,,10576,,Autocuration,1,,F,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,,BAO_0000019,H,,15740,,
1490,,,10576,,Autocuration,1,,B,,Ratio of binding affinity to 5-HT 1A and D2 receptor,,,BAO_0000357,H,,4671,,
1491,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,BAO_0000221,H,,10058,,
1492,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,BAO_0000221,H,,10058,,
1493,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,,BAO_0000221,H,,10058,,
1494,,,10576,,Autocuration,1,,B,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,12073,,
1495,,,10576,,Autocuration,1,,B,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,BAO_0000249,H,,2759,,
1496,,,10576,,Autocuration,1,,F,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,BAO_0000249,H,,2759,,
1497,,,10576,,Autocuration,1,,B,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,BAO_0000249,H,,2759,,
1498,,,10576,,Autocuration,1,,F,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,BAO_0000249,H,,2759,,
1499,,,10576,,Autocuration,1,,F,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,BAO_0000249,H,,2759,,
1500,,955.0,10576,,Autocuration,1,Brain,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,BAO_0000249,H,,9737,,
1501,,,10576,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,,BAO_0000019,H,,9737,,
1502,,,10576,,Expert,1,,F,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,,BAO_0000019,H,,5717,,
1503,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,BAO_0000221,H,,12253,,
1504,,,10576,,Autocuration,1,,B,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,,BAO_0000019,H,,14025,,
1505,,,10576,,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,,BAO_0000249,H,,10425,,
1506,,,10576,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,,BAO_0000019,H,,14998,,
1507,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,,BAO_0000221,H,,13694,,
1508,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,,BAO_0000221,H,,13694,,
1509,,,10576,,Autocuration,1,,B,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,,BAO_0000357,H,,4342,,
1510,,,10576,10116.0,Expert,1,,B,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,BAO_0000357,D,,12936,Rattus norvegicus,
1511,,,10576,10116.0,Expert,1,,B,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,,BAO_0000019,D,,13144,Rattus norvegicus,
1512,,,10576,,Expert,1,,B,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,,BAO_0000019,H,,13343,,
1513,,,10576,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,BAO_0000357,H,,12132,,
1514,,,10576,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,,BAO_0000019,H,,15419,,
1515,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,BAO_0000221,H,,1479,,
1516,,,10576,,Expert,1,,B,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,,BAO_0000019,H,,14287,,
1517,,,10576,,Expert,1,,B,,Binding affinity at 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,13116,,
1518,,,10576,10116.0,Expert,1,,B,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,Membranes,,BAO_0000249,D,,2759,Rattus norvegicus,
1519,,,10576,,Autocuration,1,,B,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,BAO_0000249,H,,2759,,
1520,,,10576,,Expert,1,,B,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,,BAO_0000019,H,,14748,,
1521,,,10576,,Autocuration,1,,B,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,BAO_0000019,H,,12304,,
1522,,10000000.0,10576,10116.0,Expert,1,Hippocampus,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,,BAO_0000221,D,,12409,Rattus norvegicus,
1523,,10000000.0,10576,10116.0,Expert,1,Hippocampus,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,,BAO_0000221,D,,12409,Rattus norvegicus,
1524,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,,BAO_0000221,H,,13267,,
1525,,,10576,,Autocuration,1,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,BAO_0000357,H,,15194,,
1526,,,10576,,Expert,1,,B,,pKi value against rat 5-hydroxytryptamine 1A receptor.,,,BAO_0000357,H,,14256,,
1527,,,10576,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,,BAO_0000019,H,,16567,,
1528,,,10576,,Autocuration,1,,F,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,BAO_0000019,H,,15740,,
1529,,,12687,10116.0,Expert,1,,B,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,,BAO_0000357,D,,13278,Rattus norvegicus,
1530,,,10626,,Expert,1,,B,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Membranes,,BAO_0000249,H,,1970,,
1531,,955.0,10576,,Autocuration,1,Brain,B,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,,BAO_0000221,H,,10034,,
1532,,,51,10116.0,Autocuration,1,,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,,BAO_0000019,H,,13348,Rattus norvegicus,
1533,,,10576,,Autocuration,1,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,BAO_0000019,H,,13630,,
1534,,955.0,10576,,Autocuration,1,Brain,B,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,BAO_0000221,H,,10862,,
1535,,,10576,,Autocuration,1,,B,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,BAO_0000019,H,,12058,,
1536,,,51,,Autocuration,1,,B,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,4639,,
1537,,,51,,Expert,1,,B,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,,BAO_0000357,H,,15453,,
1538,,,51,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,4820,,
1539,,,51,,Autocuration,1,,B,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,1089,,
1540,,,51,,Autocuration,1,,B,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,Brain membranes,,BAO_0000249,H,,386,,
1541,,,51,,Autocuration,1,,B,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,,BAO_0000357,H,,6011,,
1542,,,51,,Autocuration,1,,B,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,5014,,
1543,,,51,,Expert,1,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,4402,,
1544,,,51,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,17066,,
1545,,,51,,Autocuration,1,,B,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,,BAO_0000357,H,,17515,,
1546,,,51,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,2474,,
1547,,,51,,Autocuration,1,,B,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,,BAO_0000357,H,,4775,,
1548,,,51,9606.0,Expert,1,,B,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,,BAO_0000357,D,,14294,Homo sapiens,
1549,,,51,9606.0,Expert,1,,B,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,,BAO_0000357,D,,14294,Homo sapiens,
1550,,,51,,Autocuration,1,,B,449.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,BAO_0000219,H,,12249,,CHO
1551,,,51,,Expert,1,,B,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,,BAO_0000219,H,,11376,,
1552,In vivo,,51,,Autocuration,1,,B,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,BAO_0000218,H,,2474,,
1553,,10000000.0,51,,Autocuration,1,Hippocampus,B,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,BAO_0000221,H,,13311,,
1554,,,51,,Autocuration,1,,B,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,,BAO_0000357,H,,4373,,
1555,,,51,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,,BAO_0000357,H,,1633,,
1556,,,51,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,BAO_0000357,H,,11866,,
1557,,,51,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,BAO_0000357,H,,4373,,
1558,,,51,,Autocuration,1,,B,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,4687,,
1559,,,11863,,Autocuration,1,,B,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,16946,,
1560,,,11863,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,,BAO_0000357,H,,13291,,
1561,,,11863,,Autocuration,1,,B,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,14159,,
1562,,,11863,,Autocuration,1,,B,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,,BAO_0000357,H,,10812,,
1563,,,11863,10090.0,Expert,1,,B,449.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,,BAO_0000219,D,,3032,Mus musculus,CHO
1564,,,11863,,Autocuration,1,,B,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,16655,,
1565,,,11863,,Autocuration,1,,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,,BAO_0000357,H,,14532,,
1566,,,11863,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,13944,,
1567,,,11863,,Autocuration,1,,B,,Binding affinity against serotonergic 5-HT1a receptor,,,BAO_0000357,H,,13033,,
1568,,,11863,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,10321,,
1569,,,11863,10090.0,Expert,1,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor,,,BAO_0000357,D,,2968,Mus musculus,
1570,,,11863,,Autocuration,1,,B,,Binding affinity at 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,13964,,
1571,,,11863,,Autocuration,1,,B,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,,BAO_0000357,H,,15527,,
1572,,,11863,,Autocuration,1,,B,449.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,BAO_0000219,H,,12248,,CHO
1573,,,11863,,Autocuration,1,,B,449.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,BAO_0000219,H,,12249,,CHO
1574,,,11863,,Autocuration,1,,B,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,15120,,
1575,,,11863,,Autocuration,1,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,,BAO_0000357,H,,13313,,
1576,,,11863,,Autocuration,1,,B,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,,BAO_0000218,H,,2613,,
1577,,,11863,,Autocuration,1,,B,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,,BAO_0000357,H,,16700,,
1578,,,11863,,Autocuration,1,,B,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,2201,,
1579,,,11863,10090.0,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,BAO_0000357,D,,1274,Mus musculus,
1580,,,11863,,Autocuration,1,,B,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,BAO_0000357,H,,1317,,
1581,,,11863,,Autocuration,1,,B,,Tested against 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,12146,,
1582,,,11863,,Autocuration,1,,B,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,14059,,
1583,,,106,9986.0,Expert,1,,B,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,,BAO_0000019,H,,14025,Oryctolagus cuniculus,
1584,,,106,9986.0,Autocuration,1,,B,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,,BAO_0000019,H,,14025,Oryctolagus cuniculus,
1585,,,105571,9593.0,Intermediate,1,,B,722.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,,BAO_0000219,D,,14447,Gorilla gorilla,HEK293
1586,In vivo,,106,10141.0,Autocuration,1,,F,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,,BAO_0000218,H,,3025,Cavia porcellus,
1587,In vivo,,106,10141.0,Autocuration,1,,F,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,,BAO_0000218,H,,3025,Cavia porcellus,
1588,,,106,10141.0,Autocuration,1,,F,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,,BAO_0000019,H,,15329,Cavia porcellus,
1589,,,106,10141.0,Autocuration,1,,F,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,,BAO_0000019,H,,15329,Cavia porcellus,
1590,,,106,10141.0,Autocuration,1,,F,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,,BAO_0000019,H,,15847,Cavia porcellus,
1591,,,106,10141.0,Autocuration,1,,F,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,,BAO_0000019,H,,15847,Cavia porcellus,
1592,,,106,,Autocuration,1,,F,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,,BAO_0000019,H,,14165,,
1593,,,106,,Autocuration,1,,F,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,,BAO_0000019,H,,14214,,
1594,,,106,,Autocuration,1,,F,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,,BAO_0000019,H,,14214,,
1595,,,106,9606.0,Expert,1,,F,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,,BAO_0000019,D,,14214,Homo sapiens,
1596,,,106,9606.0,Expert,1,,F,485.0,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,,BAO_0000219,D,,13729,Homo sapiens,CHO-K1
1597,,,106,,Autocuration,1,,F,449.0,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,,BAO_0000219,H,,3025,,CHO
1598,,,106,,Autocuration,1,,B,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,BAO_0000357,H,,2391,,
1599,,,106,,Autocuration,1,,F,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,,BAO_0000019,H,,2391,,
1600,,,106,,Expert,1,,F,449.0,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,,BAO_0000219,H,,14956,,CHO
1601,,,106,,Autocuration,1,,F,449.0,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,,BAO_0000219,H,,2598,,CHO
1602,,,106,,Autocuration,1,,F,449.0,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,,BAO_0000219,H,,2598,,CHO
1603,,,106,,Autocuration,1,,F,449.0,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,,BAO_0000219,H,,2598,,CHO
1604,,,106,,Autocuration,1,,F,449.0,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,,BAO_0000219,H,,2598,,CHO
1605,,,106,,Expert,1,,F,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,,BAO_0000019,H,,14956,,
1606,,,106,,Autocuration,1,,F,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,,BAO_0000019,H,,14956,,
1607,,,106,9606.0,Expert,1,,B,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,,BAO_0000357,D,,14214,Homo sapiens,
1608,,,106,,Expert,1,,B,449.0,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,,BAO_0000219,H,,3463,,CHO
1609,,,106,,Autocuration,1,,B,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,,BAO_0000357,H,,15331,,
1610,,,106,9606.0,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 1B receptor,,,BAO_0000357,D,,16146,Homo sapiens,
1611,,,106,9606.0,Expert,1,,B,449.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,,BAO_0000219,D,,14159,Homo sapiens,CHO
1612,,,106,,Expert,1,,B,449.0,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,,BAO_0000219,H,,14158,,CHO
1613,,,106,,Autocuration,1,,B,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,,BAO_0000357,H,,14159,,
1614,,,106,,Expert,1,,B,449.0,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,,BAO_0000219,H,,15250,,CHO
1615,,,106,,Expert,1,,B,449.0,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,,BAO_0000219,H,,15250,,CHO
1616,,,106,,Expert,1,,B,449.0,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,,BAO_0000219,H,,15331,,CHO
1617,,,106,,Expert,1,,B,449.0,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,,BAO_0000219,H,,15332,,CHO
1618,,,106,,Expert,1,,B,449.0,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,,BAO_0000219,H,,14956,,CHO
1619,,,106,,Autocuration,1,,B,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,,BAO_0000357,H,,3805,,
1620,,,106,,Autocuration,1,,B,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,,BAO_0000357,H,,14875,,
1621,,,105,9986.0,Autocuration,1,,F,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,BAO_0000019,H,,14454,Oryctolagus cuniculus,
1622,,,105,9986.0,Expert,1,,F,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,BAO_0000019,H,,14454,Oryctolagus cuniculus,
1623,,,105,,Autocuration,1,,B,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,,BAO_0000357,H,,16288,,
1624,,,105,,Autocuration,1,,B,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,,BAO_0000357,H,,16288,,
1625,,,105,,Autocuration,1,,B,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,,BAO_0000357,H,,16312,,
1626,,,105,9913.0,Expert,1,,B,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,,BAO_0000357,H,,1348,Bos taurus,
1627,,,105,9913.0,Autocuration,1,,B,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,,BAO_0000357,H,,5834,Bos taurus,
1628,,2435.0,105,9913.0,Autocuration,1,Striatum,B,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,,BAO_0000019,H,,13366,Bos taurus,
1629,,,105,9913.0,Expert,1,,B,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,,BAO_0000357,H,,1414,Bos taurus,
1630,,,105,9913.0,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,,BAO_0000019,H,,14998,Bos taurus,
1631,,,105,9913.0,Autocuration,1,,B,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,,BAO_0000357,H,,11473,Bos taurus,
1632,,,105,9913.0,Autocuration,1,,B,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,,BAO_0000357,H,,11473,Bos taurus,
1633,,,105,9913.0,Autocuration,1,,B,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,,BAO_0000357,H,,10639,Bos taurus,
1634,,,105,9913.0,Autocuration,1,,B,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,,BAO_0000357,H,,10639,Bos taurus,
1635,,,105,9913.0,Autocuration,1,,B,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,,BAO_0000357,H,,1375,Bos taurus,
1636,,,105,9913.0,Autocuration,1,,B,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,,BAO_0000357,H,,1375,Bos taurus,
1637,,,105,9913.0,Autocuration,1,,B,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,,BAO_0000357,H,,16532,Bos taurus,
1638,,,105,9913.0,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,,BAO_0000357,H,,11147,Bos taurus,
1639,,2435.0,105,9913.0,Autocuration,1,Striatum,B,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,,BAO_0000019,H,,13366,Bos taurus,
1640,,,105,9913.0,Autocuration,1,,B,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,,BAO_0000019,H,,10444,Bos taurus,
1641,,,105,9913.0,Autocuration,1,,B,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,,BAO_0000357,H,,16532,Bos taurus,
1642,,,105,9913.0,Autocuration,1,,B,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,,BAO_0000357,H,,16532,Bos taurus,
1643,,,105,9913.0,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,,BAO_0000249,H,,12827,Bos taurus,
1644,,,105,9913.0,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,,BAO_0000249,H,,12827,Bos taurus,
1645,,,105,9913.0,Expert,1,,F,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,BAO_0000019,H,,12919,Bos taurus,
1646,,,105,9913.0,Autocuration,1,,B,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,,BAO_0000019,H,,14025,Bos taurus,
1647,,,105,9913.0,Expert,1,,F,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,BAO_0000019,H,,12919,Bos taurus,
1648,,,105,9913.0,Expert,1,,F,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,BAO_0000019,H,,12919,Bos taurus,
1649,,,105,9913.0,Expert,1,,F,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,BAO_0000019,H,,12919,Bos taurus,
1650,,,105,9593.0,Autocuration,1,,B,722.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,,BAO_0000219,H,,14447,Gorilla gorilla,HEK293
1651,,,105570,10141.0,Intermediate,1,,B,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,,BAO_0000019,D,,1375,Cavia porcellus,
1652,,,105570,10141.0,Intermediate,1,,B,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,,BAO_0000019,D,,1375,Cavia porcellus,
1653,,,105570,10141.0,Intermediate,1,,F,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,,BAO_0000019,D,,12409,Cavia porcellus,
1654,,,105570,10141.0,Intermediate,1,,F,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,BAO_0000019,D,,12409,Cavia porcellus,
1655,,,105570,10141.0,Intermediate,1,,F,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,,BAO_0000019,D,,12409,Cavia porcellus,
1656,,,105570,10141.0,Intermediate,1,,F,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,,BAO_0000019,D,,12409,Cavia porcellus,
1657,,,105570,10141.0,Intermediate,1,,F,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,,BAO_0000019,D,,12409,Cavia porcellus,
1658,,,105570,10141.0,Intermediate,1,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor,,,BAO_0000357,D,,11574,Cavia porcellus,
1659,,,105570,10141.0,Intermediate,1,,B,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,,BAO_0000357,D,,1558,Cavia porcellus,
1660,,,105570,10141.0,Intermediate,1,,F,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,BAO_0000218,D,,12409,Cavia porcellus,
1661,,,105570,10141.0,Intermediate,1,,F,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,BAO_0000218,D,,12409,Cavia porcellus,
1662,,,105570,10141.0,Intermediate,1,,F,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,BAO_0000218,D,,12409,Cavia porcellus,
1663,,,105570,10141.0,Intermediate,1,,F,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,,BAO_0000218,D,,12409,Cavia porcellus,
1664,,,105570,10141.0,Intermediate,1,,B,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,,BAO_0000019,D,,12253,Cavia porcellus,
1665,,,105570,10141.0,Intermediate,1,,B,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,,BAO_0000357,D,,12936,Cavia porcellus,
1666,,,105,10141.0,Autocuration,1,,B,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,,BAO_0000019,H,,13181,Cavia porcellus,
1667,,2435.0,105570,10141.0,Intermediate,1,Striatum,B,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,,BAO_0000357,D,,12409,Cavia porcellus,
1668,,,105570,10141.0,Intermediate,1,,B,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,,BAO_0000357,D,,10639,Cavia porcellus,
1669,,,51,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor,,,BAO_0000357,H,,5254,,
1670,,,106,,Autocuration,1,,B,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,,BAO_0000357,H,,13051,,
1671,,,105,,Expert,1,,F,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,,BAO_0000019,H,,3463,,
1672,,,105,,Autocuration,1,,F,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,,BAO_0000019,H,,15315,,
1673,,,105,,Autocuration,1,,F,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,,BAO_0000019,H,,6011,,
1674,,,105,9606.0,Expert,1,,F,449.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,,BAO_0000219,D,,14159,Homo sapiens,CHO
1675,,,105,,Autocuration,1,,F,449.0,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,,BAO_0000219,H,,14159,,CHO
1676,,,105,,Expert,1,,B,449.0,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,,BAO_0000219,H,,15250,,CHO
1677,,,105,,Autocuration,1,,B,449.0,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,,BAO_0000219,H,,15250,,CHO
1678,,,105,,Expert,1,,F,449.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,,BAO_0000219,H,,15331,,CHO
1679,,,105,9606.0,Expert,1,,F,449.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,,BAO_0000219,D,,15332,Homo sapiens,CHO
1680,,,105,,Expert,1,,F,449.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,,BAO_0000219,H,,15332,,CHO
1681,,,105,,Autocuration,1,,F,449.0,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,,BAO_0000219,H,,3294,,CHO
1682,,,105,,Expert,1,,F,449.0,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,,BAO_0000219,H,,14158,,CHO
1683,,,105,,Expert,1,,F,449.0,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,,BAO_0000219,H,,14956,,CHO
1684,,,105,,Autocuration,1,,F,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,,BAO_0000019,H,,12469,,
1685,,,105,,Expert,1,,F,449.0,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,,BAO_0000219,H,,3463,,CHO
1686,,,105,9606.0,Expert,1,,F,449.0,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,,BAO_0000219,D,,15250,Homo sapiens,CHO
1687,,,105,9606.0,Expert,1,,F,449.0,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,,BAO_0000219,D,,15250,Homo sapiens,CHO
1688,,,105,,Expert,1,,F,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,,BAO_0000019,H,,14956,,
1689,,,105,,Autocuration,1,,F,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,,BAO_0000019,H,,14159,,
1690,,,105,9606.0,Expert,1,,F,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,,BAO_0000019,D,,14159,Homo sapiens,
1691,,,105,9606.0,Expert,1,,F,449.0,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,,BAO_0000219,D,,14499,Homo sapiens,CHO
1692,,,105,,Autocuration,1,,F,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,,BAO_0000019,H,,15315,,
1693,In vitro,,105,,Autocuration,1,,B,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,,BAO_0000219,H,,3294,,
1694,,,105,,Expert,1,,B,449.0,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,,BAO_0000219,H,,3463,,CHO
1695,,,105,,Autocuration,1,,B,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,,BAO_0000357,H,,15331,,
1696,,,105,9606.0,Expert,1,,B,449.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,BAO_0000219,D,,14159,Homo sapiens,CHO
1697,,,105,,Expert,1,,B,449.0,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,,BAO_0000219,H,,14158,,CHO
1698,,,105,,Autocuration,1,,B,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,,BAO_0000357,H,,14159,,
1699,,,105,,Expert,1,,B,449.0,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,,BAO_0000219,H,,15250,,CHO
1700,,,105,,Expert,1,,B,449.0,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,BAO_0000219,H,,15250,,CHO
1701,,,105,,Expert,1,,B,449.0,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,BAO_0000219,H,,15331,,CHO
1702,,,105,9606.0,Expert,1,,B,449.0,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,BAO_0000219,D,,15332,Homo sapiens,CHO
1703,,,105,9606.0,Expert,1,,B,449.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,BAO_0000219,D,,14499,Homo sapiens,CHO
1704,,,105,,Expert,1,,B,449.0,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,BAO_0000219,H,,15332,,CHO
1705,,,105,,Expert,1,,B,449.0,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,BAO_0000219,H,,14956,,CHO
1706,,,105,,Autocuration,1,,B,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,,BAO_0000357,H,,3805,,
1707,,,105,9606.0,Expert,1,,B,449.0,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,,BAO_0000219,D,,6011,Homo sapiens,CHO
1708,,,105,,Autocuration,1,,B,449.0,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,,BAO_0000219,H,,16190,,CHO
1709,,,105,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,,BAO_0000019,H,,14165,,
1710,,,105,9606.0,Expert,1,,B,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,,BAO_0000357,D,,4234,Homo sapiens,
1711,,,105,,Autocuration,1,,B,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,,BAO_0000357,H,,15527,,
1712,,,105,,Expert,1,,B,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,BAO_0000219,H,,6328,,
1713,,,105,,Autocuration,1,,B,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,,BAO_0000357,H,,16209,,
1714,,,105,,Autocuration,1,,B,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,,BAO_0000357,H,,14770,,
1715,,,105,,Autocuration,1,,B,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,,BAO_0000357,H,,2598,,
1716,,,105,,Expert,1,,B,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,,BAO_0000357,H,,6897,,
1717,,,105,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1D receptor,,,BAO_0000357,H,,6013,,
1718,,,105,,Expert,1,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,BAO_0000357,H,,5843,,
1719,,,105,,Expert,1,,B,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,,BAO_0000357,H,,14454,,
1720,,,105,,Autocuration,1,,B,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,,BAO_0000357,H,,14454,,
1721,,,105,,Autocuration,1,,B,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,,BAO_0000357,H,,14454,,
1722,,,105,,Autocuration,1,,B,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,,BAO_0000357,H,,15818,,
1723,,,105,,Expert,1,,F,485.0,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,,BAO_0000219,H,,13729,,CHO-K1
1724,In vitro,,105,9606.0,Expert,1,,B,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,,BAO_0000219,D,,6011,Homo sapiens,
1725,,,105,9606.0,Expert,1,,B,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,,BAO_0000357,D,,4234,Homo sapiens,
1726,,,105,,Expert,1,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,BAO_0000019,H,,17085,,
1727,,,105,,Autocuration,1,,B,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,BAO_0000357,H,,3025,,
1728,,,105,,Expert,1,,B,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,,BAO_0000357,H,,15315,,
1729,,,105,9606.0,Expert,1,,B,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,,BAO_0000219,D,,14214,Homo sapiens,
1730,,,105,9606.0,Expert,1,,B,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,BAO_0000357,D,,3804,Homo sapiens,
1731,,,105,,Autocuration,1,,B,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,,BAO_0000357,H,,16700,,
1732,,,105,9606.0,Expert,1,,B,,Affinity for 5-hydroxytryptamine 1D receptor subtype,,,BAO_0000357,D,,2391,Homo sapiens,
1733,,,105,9606.0,Expert,1,,B,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,BAO_0000357,D,,4175,Homo sapiens,
1734,,,105,,Autocuration,1,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,BAO_0000019,H,,17085,,
1735,,,105,,Expert,1,,B,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,,BAO_0000019,H,,17085,,
1736,,,105,9606.0,Expert,1,,B,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,,BAO_0000357,D,,15926,Homo sapiens,
1737,,,105,,Autocuration,1,,B,485.0,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,,BAO_0000219,H,,16312,,CHO-K1
1738,,,105,,Autocuration,1,,B,485.0,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,,BAO_0000219,H,,16312,,CHO-K1
1739,,,104802,,Autocuration,1,,B,449.0,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,,BAO_0000219,H,,14956,,CHO
1740,,,105,,Autocuration,1,,F,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,,BAO_0000019,H,,3294,,
1741,,,105,,Autocuration,1,,B,,Binding activity radioligand.,,,BAO_0000357,H,,12861,,
1742,,,105,,Autocuration,1,,B,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,BAO_0000019,H,,12861,,
1743,,,105,,Expert,1,,B,485.0,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,,BAO_0000219,H,,16312,,CHO-K1
1744,,,105,,Autocuration,1,,B,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,BAO_0000357,H,,5104,,
1745,,,105,,Autocuration,1,,B,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,BAO_0000357,H,,5105,,
1746,,,105,,Autocuration,1,,B,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,,BAO_0000357,H,,14499,,
1747,,,105,9606.0,Expert,1,,B,,Binding activity against human 5-hydroxytryptamine 1D receptor,,,BAO_0000357,D,,15926,Homo sapiens,
1748,,,105,9606.0,Expert,1,,B,449.0,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,,BAO_0000219,D,,4540,Homo sapiens,CHO
1749,,,105,,Autocuration,1,,B,449.0,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,,BAO_0000219,H,,15779,,CHO
1750,,,105,,Autocuration,1,,B,449.0,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,BAO_0000219,H,,15779,,CHO
1751,,,105,,Autocuration,1,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,BAO_0000357,H,,6166,,
1752,,,105,,Autocuration,1,,B,449.0,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,,BAO_0000219,H,,15779,,CHO
1753,,,105,,Autocuration,1,,B,449.0,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,,BAO_0000219,H,,15779,,CHO
1754,,,105,,Autocuration,1,,B,722.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,,BAO_0000219,H,,17451,,HEK293
1755,,,105,,Autocuration,1,,B,722.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,,BAO_0000219,H,,17451,,HEK293
1756,,,105,,Autocuration,1,,B,722.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,,BAO_0000219,H,,17451,,HEK293
1757,,,105,,Autocuration,1,,B,449.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,,BAO_0000219,H,,4199,,CHO
1758,,,105,9606.0,Expert,1,,B,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,BAO_0000357,D,,14875,Homo sapiens,
1759,,,105,,Autocuration,1,,B,449.0,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,,BAO_0000219,H,,15146,,CHO
1760,,,105,,Autocuration,1,,B,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,,BAO_0000357,H,,5213,,
1761,,,105,,Autocuration,1,,B,449.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,,BAO_0000219,H,,14818,,CHO
1762,,,105,,Autocuration,1,,B,449.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,,BAO_0000219,H,,4829,,CHO
1763,,,105,,Expert,1,,F,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,,BAO_0000019,H,,14454,,
1764,,,105,,Expert,1,,F,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,,BAO_0000019,H,,14454,,
1765,,,108,,Autocuration,1,,B,,Binding affinity against 5-HT2C receptor,,,BAO_0000357,H,,5254,,
1766,,,108,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor,,,BAO_0000357,H,,5254,,
1767,,,10577,,Autocuration,1,,B,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,BAO_0000357,H,,10639,,
1768,,,10577,,Autocuration,1,,F,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,BAO_0000019,H,,10639,,
1769,,,10577,,Expert,1,,B,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,,BAO_0000019,H,,12352,,
1770,,,10577,,Autocuration,1,,B,,Binding affinity towards 5-HT1B was determined,,,BAO_0000357,H,,9098,,
1771,,,10577,,Expert,1,,B,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,,BAO_0000019,H,,14430,,
1772,,,10577,,Expert,1,,B,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,,BAO_0000019,H,,13657,,
1773,,,10577,,Autocuration,1,,B,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,,BAO_0000019,H,,13657,,
1774,,,10577,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,BAO_0000019,H,,15854,,
1775,,,10577,10116.0,Expert,1,,B,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,,BAO_0000019,D,,10639,Rattus norvegicus,
1776,,,10577,,Autocuration,1,,B,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,BAO_0000357,H,,10025,,
1777,,,10577,,Autocuration,1,,B,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,,BAO_0000357,H,,10025,,
1778,,,10577,,Autocuration,1,,B,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,BAO_0000249,H,,14286,,
1779,,2435.0,10577,,Autocuration,1,Striatum,B,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,,BAO_0000019,H,,3651,,
1780,,,10577,10116.0,Expert,1,,B,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,,BAO_0000357,D,,14178,Rattus norvegicus,
1781,,,10577,,Autocuration,1,,B,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,,BAO_0000019,H,,10639,,
1782,,2435.0,10577,,Autocuration,1,Striatum,B,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,,BAO_0000019,H,,13605,,
1783,,2435.0,10577,,Autocuration,1,Striatum,B,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,,BAO_0000019,H,,5834,,
1784,,2435.0,10577,,Autocuration,1,Striatum,B,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,,BAO_0000357,H,,10922,,
1785,,,10577,,Autocuration,1,,B,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,BAO_0000249,H,,14286,,
1786,,,10577,,Autocuration,1,,B,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,,BAO_0000357,H,,11825,,
1787,,2435.0,10577,,Autocuration,1,Striatum,B,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,,BAO_0000019,H,,14826,,
1788,,2435.0,10577,,Autocuration,1,Striatum,B,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,,BAO_0000019,H,,9699,,
1789,,,10577,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,,BAO_0000019,H,,14423,,
1790,,,10577,,Expert,1,,B,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,,BAO_0000357,H,,10062,,
1791,,,10577,,Autocuration,1,,B,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,BAO_0000357,H,,10062,,
1792,,,10577,10116.0,Expert,1,,B,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,,BAO_0000357,D,,12280,Rattus norvegicus,
1793,,2435.0,10577,,Autocuration,1,Striatum,B,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,,BAO_0000357,H,,15412,,
1794,,2435.0,10577,,Autocuration,1,Striatum,B,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,,BAO_0000357,H,,15412,,
1795,,,10577,,Autocuration,1,,B,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,BAO_0000357,H,,10062,,
1796,,,10577,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,BAO_0000357,H,,11147,,
1797,,,10577,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,,BAO_0000019,H,,9547,,
1798,,,10577,,Autocuration,1,,B,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,,BAO_0000019,H,,10444,,
1799,,2435.0,10577,,Autocuration,1,Striatum,B,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,,BAO_0000019,H,,12469,,
1800,,,10577,,Expert,1,,B,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,,BAO_0000019,H,,9098,,
1801,,,10577,,Autocuration,1,,B,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,,BAO_0000019,H,,9098,,
1802,,,10577,,Autocuration,1,,B,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,,BAO_0000357,H,,9699,,
1803,,,10577,,Autocuration,1,,B,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,BAO_0000249,H,,10394,,
1804,,,10577,,Autocuration,1,,B,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,,BAO_0000357,H,,12092,,
1805,,,10577,,Autocuration,1,,B,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,,BAO_0000357,H,,16700,,
1806,,,10577,10116.0,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,,BAO_0000249,D,,403,Rattus norvegicus,
1807,,,10577,10116.0,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,BAO_0000357,D,,12771,Rattus norvegicus,
1808,,,10577,,Autocuration,1,,B,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,,BAO_0000019,H,,11642,,
1809,,,10577,,Autocuration,1,,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,,BAO_0000357,H,,12953,,
1810,,,10577,,Autocuration,1,,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,,BAO_0000357,H,,12953,,
1811,,2435.0,10577,,Expert,1,Striatum,B,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,,BAO_0000019,H,,12953,,
1812,,,10577,,Autocuration,1,,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,,BAO_0000357,H,,12953,,
1813,,955.0,10577,,Autocuration,1,Brain,B,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,BAO_0000249,H,,9737,,
1814,,,10577,,Autocuration,1,,B,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,,BAO_0000019,H,,9737,,
1815,,955.0,10577,,Autocuration,1,Brain,B,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,BAO_0000249,H,,9737,,
1816,,,10577,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,,BAO_0000357,H,,12827,,
1817,,,10577,,Autocuration,1,,B,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,,BAO_0000357,H,,5033,,
1818,,,10577,10116.0,Expert,1,,B,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,,BAO_0000019,D,,9786,Rattus norvegicus,
1819,,,10577,,Expert,1,,B,,Binding affinity at 5-hydroxytryptamine 1B receptor,,,BAO_0000357,H,,13116,,
1820,,,10577,,Autocuration,1,,B,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,,BAO_0000019,H,,16429,,
1821,,,10577,10116.0,Expert,1,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,,BAO_0000249,D,,12409,Rattus norvegicus,
1822,,,10577,,Autocuration,1,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,BAO_0000357,H,,15194,,
1823,,,10577,,Autocuration,1,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,BAO_0000357,H,,15194,,
1824,,,104686,,Autocuration,1,,B,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,,BAO_0000019,H,,5486,,
1825,,,106,,Autocuration,1,,B,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,BAO_0000357,H,,4639,,
1826,,,106,,Autocuration,1,,B,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,Brain membranes,,BAO_0000249,H,,386,,
1827,,,106,,Autocuration,1,,B,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,,BAO_0000357,H,,2474,,
1828,,,106,,Autocuration,1,,B,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,,BAO_0000357,H,,6011,,
1829,,,106,,Autocuration,1,,B,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,,BAO_0000357,H,,5014,,
1830,,,106,,Autocuration,1,,B,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,,BAO_0000357,H,,17515,,
1831,,,106,,Autocuration,1,,B,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,,BAO_0000357,H,,4373,,
1832,,,106,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,,BAO_0000357,H,,1633,,
1833,,,106,,Autocuration,1,,B,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,,BAO_0000357,H,,1633,,
1834,,,106,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,,BAO_0000357,H,,4373,,
1835,,,106,,Autocuration,1,,B,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,,BAO_0000357,H,,4687,,
1836,,,106,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1B receptor,,,BAO_0000357,H,,11574,,
1837,,,106,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,,BAO_0000357,H,,10321,,
1838,,,106,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,BAO_0000357,H,,15527,,
1839,,,106,,Autocuration,1,,B,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,,BAO_0000357,H,,17200,,
1840,,,104802,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,,BAO_0000224,H,,14423,,
1841,,,108,9913.0,Autocuration,1,,B,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,,BAO_0000357,H,,5834,Bos taurus,
1842,,,108,9823.0,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,,BAO_0000357,H,,11473,Sus scrofa,
1843,,,108,9823.0,Autocuration,1,,B,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,,BAO_0000357,H,,11473,Sus scrofa,
1844,,,108,9823.0,Autocuration,1,,B,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,,BAO_0000357,H,,10639,Sus scrofa,
1845,,,108,9823.0,Autocuration,1,,B,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,,BAO_0000357,H,,10639,Sus scrofa,
1846,,,108,9823.0,Autocuration,1,,B,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,,BAO_0000357,H,,14331,Sus scrofa,
1847,,,108,9823.0,Autocuration,1,,B,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,,BAO_0000357,H,,10796,Sus scrofa,
1848,,,108,9823.0,Expert,1,,B,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,,BAO_0000357,H,,9098,Sus scrofa,
1849,,,108,9823.0,Expert,1,,B,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,,BAO_0000357,H,,14331,Sus scrofa,
1850,,,108,9823.0,Expert,1,,B,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,,BAO_0000019,H,,11828,Sus scrofa,
1851,,,108,9823.0,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,,BAO_0000357,H,,11866,Sus scrofa,
1852,,,108,9986.0,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,,BAO_0000019,H,,13047,Oryctolagus cuniculus,
1853,,,12689,10116.0,Autocuration,1,,B,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,,BAO_0000357,D,,188,Rattus norvegicus,
1854,,,12689,10116.0,Autocuration,1,,B,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,,BAO_0000357,D,,11825,Rattus norvegicus,
1855,,,12689,10116.0,Autocuration,1,,B,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,,BAO_0000357,D,,11825,Rattus norvegicus,
1856,,,12689,10116.0,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,,BAO_0000019,D,,11624,Rattus norvegicus,
1857,,,12689,10116.0,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,,BAO_0000357,D,,11139,Rattus norvegicus,
1858,,,12689,10116.0,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,,BAO_0000357,D,,11147,Rattus norvegicus,
1859,,,12689,10116.0,Autocuration,1,,B,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,,BAO_0000019,D,,10444,Rattus norvegicus,
1860,,,12689,10116.0,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 1C receptor,,,BAO_0000357,D,,11624,Rattus norvegicus,
1861,,,12689,10116.0,Autocuration,1,,B,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,BAO_0000019,D,,11662,Rattus norvegicus,
1862,,,12689,10116.0,Autocuration,1,,B,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,BAO_0000019,D,,11662,Rattus norvegicus,
1863,,,12689,10116.0,Expert,1,,B,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,BAO_0000019,D,,11662,Rattus norvegicus,
1864,,,12689,10116.0,Autocuration,1,,B,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,BAO_0000019,D,,11662,Rattus norvegicus,
1865,,,12689,10116.0,Autocuration,1,,B,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,,BAO_0000357,D,,9098,Rattus norvegicus,
1866,,,12689,10116.0,Autocuration,1,,B,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,,BAO_0000249,D,,10394,Rattus norvegicus,
1867,,,12689,,Expert,1,,B,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,,BAO_0000357,H,,11933,,
1868,,,12689,10116.0,Autocuration,1,,B,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,,BAO_0000357,D,,12092,Rattus norvegicus,
1869,,,12689,10116.0,Autocuration,1,,B,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,,BAO_0000019,D,,12253,Rattus norvegicus,
1870,,,12689,10116.0,Autocuration,1,,B,722.0,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,,BAO_0000219,D,,12253,Rattus norvegicus,HEK293
1871,,,108,,Autocuration,1,,B,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,BAO_0000357,H,,1558,,
1872,,,108,,Autocuration,1,,B,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,BAO_0000357,H,,2474,,
1873,,,108,,Autocuration,1,,B,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,BAO_0000357,H,,2474,,
1874,,,12689,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1C receptor,,,BAO_0000357,H,,11574,,
1875,,,12689,,Autocuration,1,,B,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,BAO_0000357,H,,1558,,
1876,,,12689,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1C receptor,,,BAO_0000357,H,,13944,,
1877,,,12689,,Autocuration,1,,B,,Binding affinity against serotonergic 5-HT1c receptor,,,BAO_0000357,H,,13033,,
1878,,,12689,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,,BAO_0000357,H,,10321,,
1879,,,12689,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,,BAO_0000357,H,,11866,,
1880,,,105,9986.0,Autocuration,1,,B,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,BAO_0000019,H,,14454,Oryctolagus cuniculus,
1881,,,104686,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,,BAO_0000224,H,,11574,,
1882,,,104686,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,,BAO_0000224,H,,11574,,
1883,,,104686,,Autocuration,1,,B,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,,BAO_0000019,H,,13631,,
1884,,,104686,10116.0,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,,BAO_0000019,D,,9630,Rattus norvegicus,
1885,,,104686,10116.0,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,,BAO_0000249,D,,8822,Rattus norvegicus,
1886,,955.0,104686,10116.0,Autocuration,1,Brain,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,,BAO_0000221,D,,9064,Rattus norvegicus,
1887,,,104686,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,,BAO_0000224,H,,8868,,
1888,,,104686,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,,BAO_0000224,H,,9064,,
1889,,,104686,,Autocuration,1,,B,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,,BAO_0000019,H,,9806,,
1890,,,104686,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,BAO_0000224,H,,9098,,
1891,,,104686,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,,BAO_0000224,H,,8868,,
1892,,,104686,,Autocuration,1,,B,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,BAO_0000224,H,,12765,,
1893,,,104686,,Autocuration,1,,B,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,BAO_0000019,H,,11049,,
1894,,,104686,,Autocuration,1,,B,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,BAO_0000019,H,,11049,,
1895,,,104686,,Autocuration,1,,B,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,,BAO_0000019,H,,11049,,
1896,,,104686,,Autocuration,1,,B,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,,BAO_0000019,H,,11049,,
1897,,,104686,,Autocuration,1,,B,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,BAO_0000019,H,,11049,,
1898,,,104686,,Autocuration,1,,B,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,,BAO_0000019,H,,11473,,
1899,,,104686,,Autocuration,1,,B,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,,BAO_0000019,H,,11473,,
1900,,,104686,,Autocuration,1,,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,,BAO_0000019,H,,3086,,
1901,,,104686,,Autocuration,1,,B,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,BAO_0000019,H,,11049,,
1902,,,104686,,Autocuration,1,,B,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,BAO_0000019,H,,11049,,
1903,,,104686,,Autocuration,1,,B,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,,BAO_0000019,H,,10639,,
1904,,,104686,,Autocuration,1,,B,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,,BAO_0000019,H,,10922,,
1905,,955.0,104686,10116.0,Autocuration,1,Brain,B,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,,BAO_0000221,D,,9064,Rattus norvegicus,
1906,,955.0,104686,,Autocuration,1,Brain,B,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,,BAO_0000221,H,,10748,,
1907,,,104686,,Autocuration,1,,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,Membranes,,BAO_0000249,H,,11614,,
1908,,,104686,,Autocuration,1,,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,Membranes,,BAO_0000249,H,,11615,,
1909,,,104686,,Autocuration,1,,B,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,11615,,
1910,,,104686,,Autocuration,1,,B,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,Membranes,,BAO_0000249,H,,11614,,
1911,,,104686,,Autocuration,1,,B,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,,BAO_0000224,H,,11702,,
1912,,,104686,,Autocuration,1,,B,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,,BAO_0000224,H,,11702,,
1913,,,104686,10116.0,Autocuration,1,,B,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,,BAO_0000224,D,,11702,Rattus norvegicus,
1914,,,104686,,Autocuration,1,,B,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,,BAO_0000224,H,,11702,,
1915,,,104686,,Autocuration,1,,B,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,,BAO_0000019,H,,13346,,
1916,,,104686,,Autocuration,1,,B,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,10025,,
1917,,,104686,,Autocuration,1,,B,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,BAO_0000224,H,,10025,,
1918,,,104686,,Autocuration,1,,B,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,BAO_0000224,H,,10025,,
1919,,,104686,,Autocuration,1,,B,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,,BAO_0000224,H,,9036,,
1920,,,104686,,Autocuration,1,,B,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,,BAO_0000224,H,,9036,,
1921,,,104686,,Autocuration,1,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,,BAO_0000019,H,,9161,,
1922,,,104686,,Autocuration,1,,B,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,,BAO_0000019,H,,12304,,
1923,,,104686,,Autocuration,1,,B,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,,BAO_0000224,H,,13276,,
1924,,,104686,,Autocuration,1,,B,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,BAO_0000224,H,,11825,,
1925,,,104686,,Autocuration,1,,B,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,,BAO_0000224,H,,12443,,
1926,,,104686,,Autocuration,1,,B,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,13830,,
1927,,,104686,,Autocuration,1,,B,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,Membranes,,BAO_0000249,H,,9592,,
1928,,,104686,,Autocuration,1,,B,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,Membranes,,BAO_0000249,H,,9592,,
1929,,,104686,,Autocuration,1,,B,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,,BAO_0000224,H,,10881,,
1930,,,104686,,Autocuration,1,,B,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,,BAO_0000019,H,,13605,,
1931,,,104686,10116.0,Autocuration,1,,B,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,,BAO_0000224,D,,11624,Rattus norvegicus,
1932,,,104686,,Autocuration,1,,B,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,BAO_0000224,H,,4101,,
1933,,,104686,,Autocuration,1,,B,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,BAO_0000224,H,,4101,,
1934,,,104686,,Autocuration,1,,B,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,,BAO_0000019,H,,15360,,
1935,,,104686,,Autocuration,1,,B,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,,BAO_0000019,H,,11576,,
1936,,,104686,,Autocuration,1,,B,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,,BAO_0000019,H,,5834,,
1937,,,104686,10116.0,Autocuration,1,,B,485.0,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,,BAO_0000219,D,,2395,Rattus norvegicus,CHO-K1
1938,,,104686,,Autocuration,1,,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,Membranes,,BAO_0000249,H,,11965,,
1939,,,104686,,Autocuration,1,,B,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,,BAO_0000224,H,,3967,,
1940,,,104686,,Autocuration,1,,B,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),Brain membranes,,BAO_0000249,H,,11130,,
1941,In vitro,,104686,,Autocuration,1,,B,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,BAO_0000219,H,,13427,,
1942,,,104686,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,9443,,
1943,,,104686,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,BAO_0000224,H,,9443,,
1944,,,104686,,Autocuration,1,,B,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,BAO_0000224,H,,11825,,
1945,,,104686,,Autocuration,1,,B,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,Membranes,,BAO_0000249,H,,12120,,
1946,,,104686,,Autocuration,1,,B,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,Membranes,,BAO_0000249,H,,12120,,
1947,,1515.0,104686,,Autocuration,1,Thoracic aorta,F,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,,BAO_0000019,H,,11963,,
1948,,,104686,,Autocuration,1,,B,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,,BAO_0000019,H,,9069,,
1949,,,104686,,Autocuration,1,,B,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,BAO_0000224,H,,8868,,
1950,,,10624,,Autocuration,1,,B,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,BAO_0000357,H,,17200,,
1951,,,10624,,Autocuration,1,,B,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,BAO_0000357,H,,17200,,
1952,,,17106,,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,,BAO_0000357,H,,13969,,
1953,,,17106,,Expert,1,,B,,Binding affinity for 5-hydroxytryptamine 1D receptor,,,BAO_0000357,D,,13392,,
1954,,,17106,,Autocuration,1,,B,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,BAO_0000249,H,,1742,,
1955,,,17106,,Autocuration,1,,B,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,BAO_0000249,H,,1742,,
1956,,2435.0,17106,,Autocuration,1,Striatum,B,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,,BAO_0000357,H,,14331,,
1957,,,17106,,Autocuration,1,,F,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,,BAO_0000019,H,,12861,,
1958,,,17106,,Expert,1,,B,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,,BAO_0000019,H,,12861,,
1959,,,17106,,Autocuration,1,,B,,Binding activity radioligand.,,,BAO_0000357,H,,12861,,
1960,,,17106,,Autocuration,1,,B,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,BAO_0000019,H,,12861,,
1961,,,17106,,Expert,1,,B,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,BAO_0000019,H,,12861,,
1962,,,17106,,Autocuration,1,,B,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,BAO_0000019,H,,12861,,
1963,,,17106,,Autocuration,1,,B,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,BAO_0000249,H,,675,,
1964,,,17106,,Expert,1,,B,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,,BAO_0000019,H,,12490,,
1965,,,17106,,Expert,1,,B,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,,BAO_0000249,H,,11828,,
1966,,,17106,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,,BAO_0000357,H,,11866,,
1967,,,105,9823.0,Autocuration,1,,B,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,,BAO_0000357,H,,773,Sus scrofa,
1968,,,105,9986.0,Expert,1,,B,,The compound was tested for intrinsic activity against 5-HT1D receptor,,,BAO_0000357,H,,13047,Oryctolagus cuniculus,
1969,,,105,9986.0,Autocuration,1,,B,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,BAO_0000019,H,,13047,Oryctolagus cuniculus,
1970,,,105,9986.0,Expert,1,,B,,The compound was tested for binding affinity against 5-HT1D receptor,,,BAO_0000357,H,,13047,Oryctolagus cuniculus,
1971,,,10578,,Autocuration,1,,B,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,,BAO_0000357,H,,188,,
1972,,,10578,,Autocuration,1,,F,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,,BAO_0000019,H,,10639,,
1973,,,10578,,Autocuration,1,,F,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,,BAO_0000019,H,,12438,,
1974,,,10578,,Autocuration,1,,B,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,,BAO_0000357,H,,12438,,
1975,,,10578,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,BAO_0000019,H,,15854,,
1976,,,10578,,Autocuration,1,,B,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,BAO_0000249,H,,10394,,
1977,,,10578,,Autocuration,1,,B,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,,BAO_0000357,H,,12092,,
1978,,,10578,,Expert,1,,B,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,,BAO_0000019,H,,3389,,
1979,,,105,,Autocuration,1,,B,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,,BAO_0000357,H,,6011,,
1980,,,105,,Autocuration,1,,B,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,,BAO_0000357,H,,4639,,
1981,,,105,,Autocuration,1,,B,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,,BAO_0000357,H,,2474,,
1982,,,105,,Autocuration,1,,B,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,,BAO_0000357,H,,5014,,
1983,,,105,,Autocuration,1,,B,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,,BAO_0000357,H,,17515,,
1984,,,105,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,,BAO_0000357,H,,11866,,
1985,,,105,,Autocuration,1,,B,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,,BAO_0000357,H,,4687,,
1986,,,105,,Autocuration,1,,B,,Tested against 5-hydroxytryptamine 1D receptor,,,BAO_0000357,H,,12146,,
1987,,,105,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,,BAO_0000357,H,,10321,,
1988,,,105,,Autocuration,1,,B,722.0,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,,BAO_0000219,H,,13267,,HEK293
1989,,,105,9606.0,Expert,1,,B,,Binding affinity against 5-Hydroxytryptamine 1D receptor,,,BAO_0000357,D,,1274,Homo sapiens,
1990,,,105,,Autocuration,1,,B,,,,,BAO_0000357,H,,15250,,
1991,,,106,,Autocuration,1,,B,485.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,BAO_0000219,H,,13706,,CHO-K1
1992,,,105,,Autocuration,1,,B,485.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,BAO_0000219,H,,13706,,CHO-K1
1993,,,105,,Autocuration,1,,B,722.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,,BAO_0000219,H,,13706,,HEK293
1994,,,105,,Autocuration,1,,B,722.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,,BAO_0000219,H,,13706,,HEK293
1995,,,105,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,BAO_0000019,H,,13047,,
1996,,,105,,Autocuration,1,,B,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,,BAO_0000357,H,,13366,,
1997,,,105,,Expert,1,,B,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,,BAO_0000357,H,,13366,,
1998,,,105,,Autocuration,1,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,,BAO_0000357,H,,1558,,
1999,,,105,,Expert,1,,B,485.0,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,,BAO_0000219,H,,12902,,CHO-K1
2000,,,105,,Autocuration,1,,B,485.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,BAO_0000219,H,,13706,,CHO-K1
2001,,,105,,Autocuration,1,,F,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,,BAO_0000019,H,,13706,,
2002,,,105,,Autocuration,1,,F,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,BAO_0000019,H,,13706,,
2003,,,105,,Autocuration,1,,F,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,BAO_0000019,H,,14251,,
2004,,,105,,Autocuration,1,,F,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,BAO_0000019,H,,14251,,
2005,,,105,,Autocuration,1,,F,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,BAO_0000019,H,,14251,,
2006,,,105,,Autocuration,1,,B,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,,BAO_0000357,H,,13313,,
2007,,,105,,Autocuration,1,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,,BAO_0000357,H,,13313,,
2008,,,105,,Autocuration,1,,B,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,,BAO_0000357,H,,13366,,
2009,,,105,,Expert,1,,B,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,,BAO_0000357,H,,13051,,
2010,,,105,,Expert,1,,B,449.0,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,,BAO_0000219,H,,12903,,CHO
2011,,,105,9606.0,Autocuration,1,,B,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,,BAO_0000219,D,,12469,Homo sapiens,
2012,,,17106,,Autocuration,1,,B,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,,BAO_0000357,H,,5619,,
2013,,,105,9986.0,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,,BAO_0000019,H,,13047,Oryctolagus cuniculus,
2014,,,105,,Autocuration,1,,B,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,,BAO_0000357,H,,16633,,
2015,,,105,,Autocuration,1,,B,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,BAO_0000357,H,,16633,,
2016,,,105,,Autocuration,1,,B,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,BAO_0000357,H,,16633,,
2017,,,105,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,16633,,
2018,,,105,,Autocuration,1,,B,,Affinity against 5-hydroxytryptamine 1D receptor alpha,,,BAO_0000357,H,,3269,,
2019,,,105,,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,,BAO_0000357,H,,12409,,
2020,,,106,,Autocuration,1,,F,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,BAO_0000019,H,,13706,,
2021,,,106,,Autocuration,1,,B,722.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,,BAO_0000219,H,,13706,,HEK293
2022,,,106,,Autocuration,1,,B,722.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,,BAO_0000219,H,,13706,,HEK293
2023,,,106,,Autocuration,1,,B,449.0,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,,BAO_0000219,H,,12903,,CHO
2024,,,106,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,BAO_0000019,H,,13047,,
2025,,,106,,Expert,1,,B,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,BAO_0000357,D,,13366,,
2026,,,106,,Expert,1,,B,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,BAO_0000357,D,,13366,,
2027,,,106,,Expert,1,,B,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,BAO_0000357,D,,13366,,
2028,,,106,,Autocuration,1,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,13366,,
2029,,,106,,Autocuration,1,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,,BAO_0000357,H,,13366,,
2030,,,106,,Autocuration,1,,B,449.0,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,,BAO_0000219,H,,12469,,CHO
2031,,,106,,Autocuration,1,,B,485.0,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,,BAO_0000219,H,,13706,,CHO-K1
2032,,,106,,Autocuration,1,,B,485.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,,BAO_0000219,H,,13706,,CHO-K1
2033,,,106,,Autocuration,1,,F,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,BAO_0000019,H,,13706,,
2034,,,106,,Expert,1,,B,485.0,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,,BAO_0000219,H,,12902,,CHO-K1
2035,,,105,,Expert,1,,B,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,,BAO_0000357,H,,13051,,
2036,,,106,,Expert,1,,B,449.0,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,,BAO_0000219,H,,12903,,CHO
2037,,,105,,Autocuration,1,,F,485.0,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,,BAO_0000219,H,,1558,,CHO-K1
2038,,,105,,Autocuration,1,,F,485.0,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,,BAO_0000219,H,,1558,,CHO-K1
2039,,,105,,Autocuration,1,,F,485.0,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,,BAO_0000219,H,,1558,,CHO-K1
2040,,,105,,Autocuration,1,,F,485.0,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,,BAO_0000219,H,,1558,,CHO-K1
2041,,,105,,Autocuration,1,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,,BAO_0000357,H,,1558,,
2042,,,106,9986.0,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,,BAO_0000019,H,,13047,Oryctolagus cuniculus,
2043,,,105,,Autocuration,1,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,,BAO_0000357,H,,13313,,
2044,,,105,,Autocuration,1,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,,BAO_0000357,H,,13313,,
2045,,,105,,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,,BAO_0000357,H,,12409,,
2046,,,10618,,Autocuration,1,,B,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,,BAO_0000219,H,,15250,,CHO
2047,,,10618,9606.0,Expert,1,,B,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,,BAO_0000357,D,,1348,Homo sapiens,
2048,,,10618,,Autocuration,1,,B,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,,BAO_0000357,H,,1348,,
2049,,,10618,9606.0,Expert,1,,B,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,,BAO_0000357,D,,4234,Homo sapiens,
2050,,,10618,,Autocuration,1,,B,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,,BAO_0000357,H,,16209,,
2051,,,10618,,Autocuration,1,,B,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,,BAO_0000019,H,,10444,,
2052,,,10618,,Autocuration,1,,B,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,,BAO_0000357,H,,3935,,
2053,,,10618,,Autocuration,1,,B,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,,BAO_0000357,H,,15818,,
2054,,,10618,,Autocuration,1,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,,BAO_0000019,H,,17085,,
2055,,,10618,9606.0,Expert,1,,B,449.0,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,,BAO_0000219,D,,12936,Homo sapiens,CHO
2056,,,10618,,Autocuration,1,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,,BAO_0000357,H,,6166,,
2057,,,10618,,Autocuration,1,,B,449.0,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,BAO_0000219,H,,15779,,CHO
2058,,,10618,,Autocuration,1,,B,449.0,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,,BAO_0000219,H,,15779,,CHO
2059,,,10618,,Autocuration,1,,B,449.0,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,,BAO_0000219,H,,15779,,CHO
2060,,,10618,,Autocuration,1,,B,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,,BAO_0000357,H,,13181,,
2061,,,10618,,Autocuration,1,,B,449.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,,BAO_0000219,H,,4199,,CHO
2062,,,10618,,Autocuration,1,,B,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,,BAO_0000357,H,,14875,,
2063,,,10618,,Autocuration,1,,B,449.0,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,,BAO_0000219,H,,15146,,CHO
2064,,,10618,,Autocuration,1,,B,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,,BAO_0000357,H,,5213,,
2065,,,10618,,Autocuration,1,,B,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,,BAO_0000357,H,,12146,,
2066,,,10618,,Autocuration,1,,B,449.0,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,,BAO_0000219,H,,13267,,CHO
2067,,,10618,,Autocuration,1,,B,449.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,,BAO_0000219,H,,14818,,CHO
2068,,,10618,,Autocuration,1,,B,449.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,,BAO_0000219,H,,4829,,CHO
2069,,,10618,,Autocuration,1,,B,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,,BAO_0000357,H,,4373,,
2070,,,10618,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,,BAO_0000357,H,,4373,,
2071,,,10618,,Autocuration,1,,B,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,,BAO_0000357,H,,14159,,
2072,,,10618,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1E receptor,,,BAO_0000357,H,,16633,,
2073,,,279,,Autocuration,1,,F,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,,BAO_0000019,H,,17085,,
2074,,,279,,Expert,1,,F,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,,BAO_0000019,H,,17085,,
2075,,,279,,Autocuration,1,,F,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,,BAO_0000019,H,,16209,,
2076,,,279,,Autocuration,1,,F,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,,BAO_0000019,H,,16209,,
2077,,,279,,Expert,1,,F,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,,BAO_0000019,H,,17085,,
2078,,,279,,Autocuration,1,,B,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,,BAO_0000357,H,,14159,,
2079,,,279,,Autocuration,1,,B,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,,BAO_0000219,H,,15250,,CHO
2080,,,279,,Autocuration,1,,B,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,,BAO_0000357,H,,3805,,
2081,,,279,,Autocuration,1,,B,449.0,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,,BAO_0000219,H,,16190,,CHO
2082,,,279,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,,BAO_0000357,H,,16190,,
2083,,,279,,Autocuration,1,,B,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,,BAO_0000357,H,,16209,,
2084,,,279,,Autocuration,1,,B,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,,BAO_0000357,H,,16209,,
2085,,,279,,Autocuration,1,,B,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,,BAO_0000357,H,,16209,,
2086,,,279,,Autocuration,1,,B,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,,BAO_0000357,H,,6866,,
2087,,,279,,Expert,1,,B,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,,BAO_0000019,H,,17085,,
2088,,,279,,Autocuration,1,,B,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,,BAO_0000357,H,,16312,,
2089,,,279,,Autocuration,1,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,,BAO_0000357,H,,6166,,
2090,,,279,,Autocuration,1,,B,449.0,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,BAO_0000219,H,,15779,,CHO
2091,,,279,,Autocuration,1,,B,449.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,,BAO_0000219,H,,4199,,CHO
2092,,,279,,Autocuration,1,,B,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,,BAO_0000357,H,,14875,,
2093,,,279,,Autocuration,1,,B,449.0,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,,BAO_0000219,H,,15146,,CHO
2094,,,279,,Autocuration,1,,B,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,,BAO_0000357,H,,5213,,
2095,,,279,,Autocuration,1,,B,449.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,,BAO_0000219,H,,14818,,CHO
2096,,,279,,Autocuration,1,,B,449.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,,BAO_0000219,H,,4829,,CHO
2097,,,279,,Autocuration,1,,B,449.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,,BAO_0000219,H,,4829,,CHO
2098,,,279,,Autocuration,1,,B,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,,BAO_0000357,H,,4373,,
2099,,,279,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,,BAO_0000357,H,,4373,,
2100,,,279,,Autocuration,1,,B,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,,BAO_0000357,H,,5014,,
2101,,,104686,,Autocuration,1,,B,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,,BAO_0000019,H,,11662,,
2102,,,104686,,Autocuration,1,,B,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,BAO_0000019,H,,11662,,
2103,,,104686,,Autocuration,1,,B,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,BAO_0000019,H,,11662,,
2104,,,12687,,Autocuration,1,,B,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,BAO_0000019,H,,14093,,
2105,In vivo,,104686,,Autocuration,1,,F,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,,BAO_0000218,H,,11200,,
2106,,,104686,,Autocuration,1,,F,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,BAO_0000019,H,,11200,,
2107,,,17005,,Intermediate,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,,BAO_0000019,H,,12352,,
2108,,,22226,9913.0,Autocuration,1,,B,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,,BAO_0000019,U,,13657,Bos taurus,
2109,,,22226,9913.0,Autocuration,1,,B,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,,BAO_0000019,U,,14331,Bos taurus,
2110,,,22226,9913.0,Autocuration,1,,B,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,,BAO_0000019,U,,14331,Bos taurus,
2111,,,22226,,Autocuration,1,,B,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,,BAO_0000019,U,,14331,,
2112,,,104784,10141.0,Autocuration,1,,B,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,,BAO_0000019,H,,12685,Cavia porcellus,
2113,,,104784,10141.0,Autocuration,1,,B,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,,BAO_0000019,H,,14389,Cavia porcellus,
2114,,,104784,10141.0,Autocuration,1,,B,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,,BAO_0000019,H,,14386,Cavia porcellus,
2115,,,104784,,Autocuration,1,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,,BAO_0000224,H,,5732,,
2116,,,104784,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,BAO_0000224,H,,16293,,
2117,,,104784,,Autocuration,1,,B,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,2078,,
2118,,,10209,,Autocuration,1,,B,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,BAO_0000357,H,,5486,,
2119,In vivo,,104826,,Autocuration,1,,B,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,,BAO_0000218,H,,11820,,
2120,,,104826,,Autocuration,1,,B,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,BAO_0000019,H,,10297,,
2121,,,104826,,Autocuration,1,,B,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,,BAO_0000224,H,,13704,,
2122,,,104826,10090.0,Autocuration,1,,B,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,,BAO_0000019,D,,10297,Mus musculus,
2123,In vivo,,104826,,Autocuration,1,,B,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,,BAO_0000218,H,,11820,,
2124,,,104826,10090.0,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,,BAO_0000019,D,,10297,Mus musculus,
2125,,,104826,,Autocuration,1,,B,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,11555,,
2126,,,104826,,Autocuration,1,,B,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,,BAO_0000224,H,,11555,,
2127,,,104826,,Autocuration,1,,B,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,,BAO_0000224,H,,11555,,
2128,,,104826,10090.0,Autocuration,1,,B,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,BAO_0000019,D,,10297,Mus musculus,
2129,,,104784,9823.0,Autocuration,1,,B,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,,BAO_0000224,H,,16688,Sus scrofa,
2130,,,104784,9823.0,Autocuration,1,,B,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,,BAO_0000224,H,,16688,Sus scrofa,
2131,,,22226,,Autocuration,1,,B,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,BAO_0000221,U,,5333,,
2132,,,22226,,Autocuration,1,,B,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,BAO_0000221,U,,4437,,
2133,,,17005,9823.0,Autocuration,1,,B,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,,BAO_0000357,H,,5033,Sus scrofa,
2134,,,104686,,Autocuration,1,,B,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,BAO_0000019,H,,15267,,
2135,,,104686,,Autocuration,1,,B,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,BAO_0000019,H,,15267,,
2136,,,104826,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,,BAO_0000019,H,,11820,,
2137,,,104686,,Autocuration,1,,B,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,9069,,
2138,,,104686,10116.0,Autocuration,1,,B,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,,BAO_0000019,D,,9162,Rattus norvegicus,
2139,,,104686,,Autocuration,1,,B,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,,BAO_0000019,H,,9162,,
2140,,,104686,,Autocuration,1,,B,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,,BAO_0000019,H,,9162,,
2141,,,104686,,Autocuration,1,,F,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,,BAO_0000019,H,,10428,,
2142,,,104686,,Autocuration,1,,B,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,,BAO_0000019,H,,9628,,
2143,,,104686,,Autocuration,1,,B,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,12704,,
2144,,,104686,10116.0,Autocuration,1,,B,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,BAO_0000224,D,,15453,Rattus norvegicus,
2145,,,104686,,Autocuration,1,,B,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,,BAO_0000224,H,,188,,
2146,,,104686,,Autocuration,1,,B,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,,BAO_0000224,H,,10349,,
2147,,,104686,,Autocuration,1,,B,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,,BAO_0000224,H,,10349,,
2148,,,104686,,Autocuration,1,,B,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,BAO_0000224,H,,8868,,
2149,,,104686,,Autocuration,1,,B,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,BAO_0000224,H,,10025,,
2150,,,104686,,Autocuration,1,,B,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,BAO_0000224,H,,10025,,
2151,,,104686,,Autocuration,1,,B,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,,BAO_0000224,H,,11702,,
2152,,,104686,,Autocuration,1,,B,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,11702,,
2153,,,104686,,Autocuration,1,,B,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,,BAO_0000224,H,,11702,,
2154,,,104686,,Autocuration,1,,F,,Compound was tested for the inhibition of quipazine induced head twitches in rats,,,BAO_0000019,H,,11702,,
2155,,,104686,,Autocuration,1,,F,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,,BAO_0000019,H,,11702,,
2156,,10000000.0,104686,,Autocuration,1,Hippocampus,B,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,,BAO_0000221,H,,10085,,
2157,,10000000.0,104686,,Autocuration,1,Hippocampus,B,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,,BAO_0000221,H,,10085,,
2158,,955.0,104686,10116.0,Autocuration,1,Brain,B,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,,BAO_0000221,D,,9630,Rattus norvegicus,
2159,,,104686,,Autocuration,1,,B,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,,BAO_0000019,H,,11070,,
2160,,,104686,,Autocuration,1,,B,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,Membranes,,BAO_0000249,H,,9841,,
2161,,,104686,,Autocuration,1,,B,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,Membranes,,BAO_0000249,H,,9841,,
2162,,,104686,,Autocuration,1,,B,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,,BAO_0000019,H,,13291,,
2163,,,104686,,Autocuration,1,,F,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,,BAO_0000019,H,,10590,,
2164,,955.0,104686,10116.0,Autocuration,1,Brain,B,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,,BAO_0000221,D,,9064,Rattus norvegicus,
2165,,,104686,10116.0,Autocuration,1,,B,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,Membranes,,BAO_0000249,D,,12268,Rattus norvegicus,
2166,,955.0,104686,,Autocuration,1,Brain,B,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,,BAO_0000221,H,,13508,,
2167,,,104686,,Autocuration,1,,F,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,BAO_0000019,H,,11279,,
2168,,,104686,,Autocuration,1,,F,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,,BAO_0000019,H,,11200,,
2169,,,104686,,Autocuration,1,,F,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,BAO_0000019,H,,11200,,
2170,,,104686,,Autocuration,1,,F,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,BAO_0000019,H,,11200,,
2171,,,104686,,Autocuration,1,,F,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,BAO_0000019,H,,11200,,
2172,,,104686,,Autocuration,1,,F,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,BAO_0000019,H,,11200,,
2173,,955.0,104686,,Autocuration,1,Brain,B,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,,BAO_0000220,H,,9231,,
2174,,,104686,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,BAO_0000019,H,,9737,,
2175,,955.0,104686,,Autocuration,1,Brain,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,BAO_0000249,H,,9737,,
2176,,,104686,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,,BAO_0000019,H,,9737,,
2177,,,104686,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,BAO_0000019,H,,9737,,
2178,,,104686,10116.0,Autocuration,1,,B,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,,BAO_0000019,D,,11828,Rattus norvegicus,
2179,,,104686,,Autocuration,1,,B,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,,BAO_0000019,H,,12253,,
2180,,,104686,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,,BAO_0000019,H,,12253,,
2181,,,104686,,Autocuration,1,,F,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,,BAO_0000019,H,,11279,,
2182,,,104686,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,,BAO_0000019,H,,11866,,
2183,,,104686,10116.0,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,,BAO_0000224,D,,14424,Rattus norvegicus,
2184,,,104686,10116.0,Autocuration,1,,B,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,,BAO_0000019,D,,15180,Rattus norvegicus,
2185,,,104686,10116.0,Autocuration,1,,B,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,,BAO_0000019,D,,15180,Rattus norvegicus,
2186,,,104686,10116.0,Autocuration,1,,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,,BAO_0000019,D,,9786,Rattus norvegicus,
2187,,,104686,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,,BAO_0000224,H,,12132,,
2188,,,104686,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,,BAO_0000249,H,,5486,,
2189,,,104686,,Autocuration,1,,B,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,,BAO_0000019,H,,15316,,
2190,,,104686,,Autocuration,1,,B,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,,BAO_0000019,H,,16429,,
2191,,,104686,,Autocuration,1,,B,,pKi value for 5-hydroxytryptamine 2 receptor binding site,,,BAO_0000224,H,,14617,,
2192,,955.0,104686,,Autocuration,1,Brain,B,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,,BAO_0000221,H,,11351,,
2193,,,104686,,Autocuration,1,,F,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,BAO_0000019,H,,11279,,
2194,,,105075,,Autocuration,1,,B,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,BAO_0000019,H,,9523,,
2195,,,105075,,Autocuration,1,,B,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,BAO_0000019,H,,9523,,
2196,,,105075,,Autocuration,1,,B,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,BAO_0000019,H,,9523,,
2197,,,105075,,Autocuration,1,,B,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,BAO_0000019,H,,9523,,
2198,,,105075,,Autocuration,1,,B,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,BAO_0000019,H,,9523,,
2199,,,105075,,Autocuration,1,,B,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,BAO_0000019,H,,9523,,
2200,,,105075,,Autocuration,1,,B,,Hill coefficient of compound was determined,,,BAO_0000224,H,,9523,,
2201,,,22226,,Autocuration,1,,B,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,,BAO_0000019,U,,4771,,
2202,,,104686,10116.0,Autocuration,1,,B,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,,BAO_0000019,D,,5033,Rattus norvegicus,
2203,,,12687,,Expert,1,,B,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,,BAO_0000019,H,,10845,,
2204,,,12687,,Expert,1,,B,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,,BAO_0000019,H,,10845,,
2205,,,12687,,Autocuration,1,,B,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,,BAO_0000357,H,,16288,,
2206,,,12687,,Autocuration,1,,B,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,,BAO_0000019,H,,16288,,
2207,,,12687,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,,BAO_0000019,H,,16190,,
2208,,,104686,10116.0,Autocuration,1,,B,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,,BAO_0000224,D,,12463,Rattus norvegicus,
2209,,,104686,,Autocuration,1,,B,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,,BAO_0000224,H,,9699,,
2210,,,104686,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,,BAO_0000224,H,,9699,,
2211,,,104686,,Autocuration,1,,B,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,BAO_0000019,H,,11662,,
2212,,,104784,,Autocuration,1,,B,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,1205,,
2213,,,22226,,Autocuration,1,,B,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,,BAO_0000219,U,,11376,,
2214,,,104784,,Autocuration,1,,B,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,,BAO_0000219,H,,11376,,
2215,,,104784,,Autocuration,1,,B,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,4639,,
2216,,,104784,,Autocuration,1,,B,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,2222,,
2217,,,104784,,Autocuration,1,,B,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,1558,,
2218,,,104784,,Autocuration,1,,B,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,1089,,
2219,,,104784,,Autocuration,1,,B,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,Brain membranes,,BAO_0000249,H,,386,,
2220,,,104784,,Autocuration,1,,B,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,,BAO_0000224,H,,2474,,
2221,,,104784,,Autocuration,1,,B,,Binding affinity towards 5-HT2 receptor,,,BAO_0000224,H,,17066,,
2222,,,104784,,Autocuration,1,,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,959,,
2223,,,104784,,Autocuration,1,,B,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,,BAO_0000224,H,,6398,,
2224,,,104686,,Autocuration,1,,B,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,,BAO_0000224,H,,11889,,
2225,,,104784,,Autocuration,1,,B,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,4221,,
2226,,,104784,,Autocuration,1,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,,BAO_0000224,H,,11026,,
2227,,,104784,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,,BAO_0000224,H,,11866,,
2228,,,104784,,Autocuration,1,,B,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,4221,,
2229,,,22226,,Autocuration,1,,B,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,BAO_0000019,U,,13950,,
2230,,,104784,,Autocuration,1,,B,,5-hydroxytryptamine 2 receptor binding affinity,,,BAO_0000224,H,,1263,,
2231,,,17005,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,,BAO_0000357,H,,13291,,
2232,,,17005,,Autocuration,1,,B,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,,BAO_0000357,H,,10812,,
2233,,,104784,,Autocuration,1,,B,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,BAO_0000224,H,,13020,,
2234,,,104784,,Autocuration,1,,B,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,,BAO_0000224,H,,13021,,
2235,,,104784,,Autocuration,1,,B,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,BAO_0000224,H,,13020,,
2236,,,17005,,Autocuration,1,,B,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,,BAO_0000357,H,,14532,,
2237,,,17005,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor,,,BAO_0000357,H,,13944,,
2238,,,17005,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor,,,BAO_0000357,H,,14331,,
2239,,,17005,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,BAO_0000357,H,,14118,,
2240,,,17005,,Autocuration,1,,B,,Binding affinity against serotonergic 5-HT2 receptor,,,BAO_0000357,H,,13033,,
2241,,,17005,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,,BAO_0000357,H,,10321,,
2242,,,17005,,Autocuration,1,,B,,Compound was evaluated for the binding affinity at 5- HT2 receptor,,,BAO_0000357,H,,12918,,
2243,,,17005,,Autocuration,1,,B,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,,BAO_0000357,H,,15120,,
2244,,,17005,,Autocuration,1,,B,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,,BAO_0000218,H,,2613,,
2245,,,104784,9606.0,Autocuration,1,,B,,Inhibitory activity against cloned human 5-HT2 receptor,,,BAO_0000224,D,,13378,Homo sapiens,
2246,,,104784,9606.0,Autocuration,1,,B,449.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,,BAO_0000219,D,,2331,Homo sapiens,CHO
2247,,,104784,9606.0,Autocuration,1,,B,449.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,,BAO_0000219,D,,2331,Homo sapiens,CHO
2248,,,104784,9606.0,Autocuration,1,,B,449.0,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,,BAO_0000219,D,,2331,Homo sapiens,CHO
2249,,,104784,9606.0,Autocuration,1,,B,449.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,,BAO_0000219,D,,2331,Homo sapiens,CHO
2250,,,104784,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,4170,,
2251,,,104784,,Autocuration,1,,B,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,BAO_0000224,H,,15453,,
2252,,,17005,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,BAO_0000357,H,,1479,,
2253,,,104686,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,,BAO_0000224,H,,11139,,
2254,,,17005,,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,,BAO_0000357,H,,13969,,
2255,,,17005,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,13392,,
2256,,,17005,,Expert,1,,B,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,,BAO_0000019,H,,14430,,
2257,,,107,10141.0,Autocuration,1,,B,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,13181,Cavia porcellus,
2258,,,51,,Autocuration,1,,B,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,BAO_0000357,H,,17200,,
2259,,,107,,Autocuration,1,,B,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,BAO_0000357,H,,17200,,
2260,,,51,,Autocuration,1,,B,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,BAO_0000357,H,,17200,,
2261,,,107,,Autocuration,1,,B,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,,BAO_0000357,H,,13463,,
2262,,,107,,Autocuration,1,,B,449.0,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,,BAO_0000219,H,,6347,,CHO
2263,,,107,9606.0,Expert,1,,F,449.0,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,,BAO_0000219,D,,6857,Homo sapiens,CHO
2264,,,107,,Autocuration,1,,F,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,BAO_0000219,H,,4176,,
2265,,,107,,Autocuration,1,,F,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,,BAO_0000219,H,,4176,,
2266,,,107,,Autocuration,1,,F,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,BAO_0000219,H,,4176,,
2267,,,107,,Autocuration,1,,B,449.0,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,,BAO_0000219,H,,6347,,CHO
2268,,,107,,Autocuration,1,,B,449.0,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,,BAO_0000219,H,,6347,,CHO
2269,,,107,,Autocuration,1,,B,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,,BAO_0000357,H,,15331,,
2270,,,107,9606.0,Expert,1,,B,,Inhibition of human 5-hydroxytryptamine 2A receptor,,,BAO_0000357,D,,16146,Homo sapiens,
2271,,,107,,Autocuration,1,,B,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,BAO_0000219,H,,15250,,CHO
2272,,,107,,Expert,1,,B,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,,BAO_0000219,H,,13631,,
2273,,,107,,Autocuration,1,,B,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,,BAO_0000357,H,,3805,,
2274,,,107,,Autocuration,1,,B,449.0,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,,BAO_0000219,H,,4011,,CHO
2275,,,107,,Expert,1,,B,449.0,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,,BAO_0000219,H,,4012,,CHO
2276,,,107,,Expert,1,,B,307.0,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,,BAO_0000219,H,,6366,,L929
2277,,,107,,Expert,1,,B,449.0,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,BAO_0000219,H,,15949,,CHO
2278,,,107,,Autocuration,1,,F,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,,BAO_0000019,H,,14093,,
2279,,,107,,Autocuration,1,,F,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,BAO_0000019,H,,13481,,
2280,,,107,,Autocuration,1,,B,449.0,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,,BAO_0000219,H,,6347,,CHO
2281,,,107,,Autocuration,1,,B,449.0,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,,BAO_0000219,H,,6347,,CHO
2282,,,107,,Autocuration,1,,F,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,,BAO_0000019,H,,14093,,
2283,,,107,,Autocuration,1,,F,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,,BAO_0000019,H,,14093,,
2284,,,107,,Autocuration,1,,F,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,BAO_0000019,H,,13481,,
2285,,,107,,Autocuration,1,,B,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,,BAO_0000357,H,,14442,,
2286,,,107,,Autocuration,1,,B,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,BAO_0000357,H,,14442,,
2287,,,107,,Autocuration,1,,B,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,,BAO_0000357,H,,14755,,
2288,,,107,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,,BAO_0000357,H,,16441,,
2289,,,107,,Autocuration,1,,B,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,,BAO_0000357,H,,14744,,
2290,,,107,,Expert,1,,B,449.0,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,BAO_0000219,H,,16659,,CHO
2291,,,107,,Autocuration,1,,B,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,3307,,
2292,,,107,9606.0,Expert,1,,B,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,,BAO_0000019,D,,6857,Homo sapiens,
2293,,,107,,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,,BAO_0000357,H,,5635,,
2294,,,107,9606.0,Expert,1,,B,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,,BAO_0000357,D,,4234,Homo sapiens,
2295,,,107,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,BAO_0000357,H,,15527,,
2296,,,107,,Expert,1,,B,449.0,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,,BAO_0000219,H,,6588,,CHO
2297,,,107,,Expert,1,,B,,Binding affinity towards human 5-HT2A receptor in BEK cells,,,BAO_0000219,H,,13631,,
2298,,,107,,Autocuration,1,,B,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,17723,,
2299,,,107,,Autocuration,1,,B,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,BAO_0000357,H,,14770,,
2300,,,107,9606.0,Expert,1,,B,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,,BAO_0000357,D,,16293,Homo sapiens,
2301,,,107,,Autocuration,1,,B,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,BAO_0000357,H,,16209,,
2302,,,107,,Autocuration,1,,B,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,,BAO_0000219,H,,12469,,
2303,,,107,,Autocuration,1,,B,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,15363,,
2304,,,107,,Autocuration,1,,B,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,15363,,
2305,,,107,,Expert,1,,B,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,,BAO_0000019,H,,16441,,
2306,,,107,,Autocuration,1,,B,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,,BAO_0000357,H,,8,,
2307,,,107,,Autocuration,1,,B,722.0,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,,BAO_0000219,H,,4176,,HEK293
2308,,,107,,Autocuration,1,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,,BAO_0000019,H,,17085,,
2309,,,107,,Autocuration,1,,B,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,BAO_0000357,H,,17200,,
2310,,,107,9606.0,Expert,1,,B,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,BAO_0000357,D,,17200,Homo sapiens,
2311,,,107,9606.0,Expert,1,,B,449.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,,BAO_0000219,D,,4013,Homo sapiens,CHO
2312,,,107,,Autocuration,1,,B,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,5088,,
2313,,,107,9606.0,Expert,1,,B,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,,BAO_0000357,D,,5088,Homo sapiens,
2314,,,107,,Autocuration,1,,B,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,,BAO_0000357,H,,5088,,
2315,,,107,9606.0,Expert,1,,B,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,,BAO_0000357,D,,5088,Homo sapiens,
2316,,,107,,Autocuration,1,,B,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,,BAO_0000357,H,,5088,,
2317,,,107,,Autocuration,1,,B,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,BAO_0000357,H,,5088,,
2318,,,104686,,Autocuration,1,,B,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,,BAO_0000019,H,,9786,,
2319,,,104686,10116.0,Autocuration,1,,B,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,,BAO_0000019,D,,9205,Rattus norvegicus,
2320,,,104686,,Autocuration,1,,B,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,,BAO_0000224,H,,11257,,
2321,,,104686,,Autocuration,1,,B,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,BAO_0000019,H,,9362,,
2322,,,104686,,Autocuration,1,,B,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,BAO_0000019,H,,9362,,
2323,,,104686,,Autocuration,1,,B,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,,BAO_0000224,H,,10590,,
2324,,,104686,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,BAO_0000019,H,,10468,,
2325,,,104686,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,,BAO_0000019,H,,13050,,
2326,,,104686,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,,BAO_0000019,H,,11624,,
2327,,,104686,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,BAO_0000019,H,,10468,,
2328,,,104686,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,BAO_0000224,H,,10330,,
2329,,,104686,,Autocuration,1,,B,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,BAO_0000224,H,,10062,,
2330,,,104686,,Autocuration,1,,B,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,11642,,
2331,,,104686,,Autocuration,1,,B,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,10062,,
2332,In vitro,,104686,,Autocuration,1,,B,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,BAO_0000219,H,,13427,,
2333,,,104686,10116.0,Autocuration,1,,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,BAO_0000224,D,,12280,Rattus norvegicus,
2334,,,104686,10116.0,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,,BAO_0000224,D,,4101,Rattus norvegicus,
2335,,,104686,,Autocuration,1,,B,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,10062,,
2336,,,104686,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,,BAO_0000224,H,,11147,,
2337,,,104686,10116.0,Autocuration,1,,B,485.0,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,,BAO_0000219,D,,2395,Rattus norvegicus,CHO-K1
2338,,,104686,10116.0,Autocuration,1,,B,485.0,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,,BAO_0000219,D,,2395,Rattus norvegicus,CHO-K1
2339,,,104686,10116.0,Autocuration,1,,B,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,,BAO_0000019,D,,9098,Rattus norvegicus,
2340,,,104686,,Autocuration,1,,B,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,,BAO_0000019,H,,9098,,
2341,,,104686,10116.0,Autocuration,1,,B,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,,BAO_0000019,D,,9098,Rattus norvegicus,
2342,,,104686,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,9443,,
2343,,,104686,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,BAO_0000224,H,,9443,,
2344,,,104686,,Autocuration,1,,B,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,,BAO_0000019,H,,9699,,
2345,,,104686,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,,BAO_0000019,H,,9699,,
2346,,,104686,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,BAO_0000224,H,,9098,,
2347,,,104686,10116.0,Autocuration,1,,B,,Affinity for 5-hydroxytryptamine 2 receptor,,,BAO_0000224,D,,3070,Rattus norvegicus,
2348,,,104686,,Autocuration,1,,B,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,,BAO_0000224,H,,9547,,
2349,,,104686,,Autocuration,1,,B,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,,BAO_0000019,H,,10444,,
2350,,,104686,,Autocuration,1,,B,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,,BAO_0000019,H,,14617,,
2351,,,104686,,Autocuration,1,,B,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,,BAO_0000019,H,,14617,,
2352,,,104686,,Autocuration,1,,B,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,,BAO_0000224,H,,11130,,
2353,In vivo,,104686,,Autocuration,1,,B,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,,BAO_0000218,H,,11130,,
2354,,955.0,104686,,Autocuration,1,Brain,B,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,,BAO_0000221,H,,14542,,
2355,,,104686,,Autocuration,1,,B,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,,BAO_0000224,H,,2797,,
2356,,,104686,,Autocuration,1,,B,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,BAO_0000019,H,,11332,,
2357,,,104686,,Autocuration,1,,B,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,BAO_0000019,H,,11332,,
2358,,1870.0,104686,,Autocuration,1,Frontal cortex,B,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,,BAO_0000019,H,,10752,,
2359,,,104686,,Autocuration,1,,B,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,1185,,
2360,,,104686,,Autocuration,1,,B,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,1185,,
2361,,,104686,10116.0,Autocuration,1,,B,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,,BAO_0000224,D,,11624,Rattus norvegicus,
2362,,,104686,,Autocuration,1,,B,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,,BAO_0000019,H,,1344,,
2363,,2435.0,104686,10116.0,Autocuration,1,Striatum,B,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,,BAO_0000019,D,,15453,Rattus norvegicus,
2364,,,104686,,Autocuration,1,,B,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,BAO_0000019,H,,11662,,
2365,,,104686,,Autocuration,1,,B,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,BAO_0000019,H,,11662,,
2366,,,104686,,Autocuration,1,,B,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,10796,,
2367,,,104686,,Autocuration,1,,B,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,9069,,
2368,,,104686,10116.0,Autocuration,1,,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,,BAO_0000019,D,,8814,Rattus norvegicus,
2369,,,104686,10116.0,Autocuration,1,,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,,BAO_0000019,D,,8908,Rattus norvegicus,
2370,,,104686,,Autocuration,1,,B,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,BAO_0000019,H,,9098,,
2371,,,104686,,Autocuration,1,,B,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,,BAO_0000019,H,,9098,,
2372,,,104686,,Autocuration,1,,B,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,BAO_0000019,H,,9098,,
2373,,,104686,,Autocuration,1,,B,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,,BAO_0000019,H,,9098,,
2374,,,104686,,Autocuration,1,,B,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,,BAO_0000249,H,,9098,,
2375,,,104686,,Autocuration,1,,B,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,,BAO_0000019,H,,9098,,
2376,,,104686,,Autocuration,1,,B,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,,BAO_0000019,H,,9098,,
2377,,,104686,,Autocuration,1,,B,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,,BAO_0000019,H,,9161,,
2378,,,104686,,Autocuration,1,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,,BAO_0000019,H,,9161,,
2379,,,104686,,Autocuration,1,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,,BAO_0000019,H,,9161,,
2380,,,104686,,Autocuration,1,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,,BAO_0000019,H,,9161,,
2381,,,104686,,Autocuration,1,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,,BAO_0000019,H,,9161,,
2382,,,104686,,Autocuration,1,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,,BAO_0000019,H,,9161,,
2383,,,104686,,Autocuration,1,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,,BAO_0000019,H,,9161,,
2384,,,104686,,Autocuration,1,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,,BAO_0000019,H,,9161,,
2385,,,104686,,Autocuration,1,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,,BAO_0000019,H,,9161,,
2386,,,104686,,Autocuration,1,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,,BAO_0000019,H,,9161,,
2387,,,104686,,Autocuration,1,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,,BAO_0000019,H,,9161,,
2388,,,104686,,Autocuration,1,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,,BAO_0000019,H,,9161,,
2389,,,104686,,Autocuration,1,,B,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,,BAO_0000019,H,,12094,,
2390,,,104686,,Autocuration,1,,B,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,,BAO_0000249,H,,12018,,
2391,,,104686,,Autocuration,1,,B,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,,BAO_0000249,H,,10394,,
2392,,,104686,,Autocuration,1,,B,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,15260,,
2393,,,104686,10116.0,Autocuration,1,,B,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,,BAO_0000224,D,,11624,Rattus norvegicus,
2394,,,104686,,Autocuration,1,,B,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,13654,,
2395,,,104686,,Autocuration,1,,B,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,,BAO_0000019,H,,9541,,
2396,,,104686,,Autocuration,1,,B,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,,BAO_0000224,H,,11933,,
2397,,,104686,,Autocuration,1,,B,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,,BAO_0000019,H,,15538,,
2398,,,104686,,Autocuration,1,,B,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,,BAO_0000019,H,,15538,,
2399,,,104686,,Autocuration,1,,B,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,,BAO_0000019,H,,15538,,
2400,,,104686,,Autocuration,1,,B,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,,BAO_0000019,D,,8841,,
2401,,,104686,,Autocuration,1,,B,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,,BAO_0000224,H,,1455,,
2402,,,104686,,Autocuration,1,,B,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,,BAO_0000224,H,,1455,,
2403,,,104686,,Autocuration,1,,B,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,,BAO_0000019,H,,11752,,
2404,,955.0,104686,,Autocuration,1,Brain,B,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,,BAO_0000221,H,,11642,,
2405,,,104686,,Autocuration,1,,B,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,,BAO_0000224,H,,12092,,
2406,,,104686,,Autocuration,1,,B,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,,BAO_0000224,H,,3967,,
2407,,,104686,10116.0,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,BAO_0000224,D,,12771,Rattus norvegicus,
2408,,,104686,,Autocuration,1,,B,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,,BAO_0000019,H,,11642,,
2409,,,104686,,Autocuration,1,,B,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,,BAO_0000224,H,,11628,,
2410,,,104686,,Autocuration,1,,B,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,BAO_0000224,H,,13654,,
2411,,,104686,,Autocuration,1,,F,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,BAO_0000019,H,,11200,,
2412,,,104686,,Autocuration,1,,F,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,BAO_0000019,H,,11200,,
2413,In vivo,,104686,,Autocuration,1,,F,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,,BAO_0000218,H,,11200,,
2414,In vivo,,104686,,Autocuration,1,,F,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,,BAO_0000218,H,,11200,,
2415,In vivo,,104686,,Autocuration,1,,F,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,,BAO_0000218,H,,11200,,
2416,In vivo,,104686,,Autocuration,1,,F,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,,BAO_0000218,H,,11200,,
2417,,955.0,12687,,Expert,1,Brain,B,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,,BAO_0000221,H,,15436,,
2418,,,12687,10116.0,Expert,1,,B,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,BAO_0000019,D,,15436,Rattus norvegicus,
2419,,,12687,,Autocuration,1,,B,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,,BAO_0000019,H,,14025,,
2420,,,12687,,Autocuration,1,,B,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,,BAO_0000357,H,,4342,,
2421,,,12687,10116.0,Expert,1,,B,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,,BAO_0000019,D,,13735,Rattus norvegicus,
2422,,,12687,10116.0,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,BAO_0000357,D,,5816,Rattus norvegicus,
2423,,,12687,,Expert,1,,B,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,,BAO_0000019,H,,14287,,
2424,,,12687,,Autocuration,1,,B,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,,BAO_0000357,H,,15738,,
2425,,,12687,10116.0,Expert,1,,B,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,,BAO_0000357,D,,15738,Rattus norvegicus,
2426,,,12687,,Autocuration,1,,B,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,,BAO_0000019,H,,15026,,
2427,,,12687,,Expert,1,,B,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,BAO_0000019,H,,16647,,
2428,,,12687,,Autocuration,1,,B,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,,BAO_0000019,H,,16647,,
2429,,,12687,10116.0,Expert,1,,B,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,,BAO_0000019,D,,13345,Rattus norvegicus,
2430,,,12687,,Autocuration,1,,B,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,Membranes,,BAO_0000249,H,,1543,,
2431,,,12687,,Autocuration,1,,B,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,,BAO_0000019,H,,12444,,
2432,,,12687,,Expert,1,,B,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,,BAO_0000019,H,,16404,,
2433,,,12687,,Autocuration,1,,B,449.0,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,,BAO_0000219,H,,16404,,CHO
2434,,,12687,,Expert,1,,B,,Kinetic inhibition constant evaluated by measuring serotonergic activity,,,BAO_0000357,H,,15577,,
2435,,,12687,,Autocuration,1,,B,,Serotonergic activity of the compound.,,,BAO_0000357,H,,15577,,
2436,,,12687,,Autocuration,1,,B,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,,BAO_0000249,H,,2495,,
2437,,,12687,10116.0,Expert,1,,B,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,,BAO_0000019,D,,15042,Rattus norvegicus,
2438,,,12687,,Expert,1,,B,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,,BAO_0000249,H,,15026,,
2439,,,12687,10116.0,Expert,1,,F,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,BAO_0000019,D,,12919,Rattus norvegicus,
2440,,,12687,10116.0,Expert,1,,F,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,BAO_0000019,D,,12919,Rattus norvegicus,
2441,,,12687,10116.0,Expert,1,,F,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,BAO_0000019,D,,12919,Rattus norvegicus,
2442,,,12687,,Autocuration,1,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,BAO_0000357,H,,15194,,
2443,,,12687,,Autocuration,1,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,,BAO_0000357,H,,15194,,
2444,,,107,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,4820,,
2445,,,107,,Autocuration,1,,B,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,,BAO_0000357,H,,6736,,
2446,,,107,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,,BAO_0000357,H,,5163,,
2447,,,107,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,,BAO_0000357,H,,5163,,
2448,,,107,,Autocuration,1,,B,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,,BAO_0000357,H,,6011,,
2449,,,107,9606.0,Expert,1,,B,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,,BAO_0000357,D,,14294,Homo sapiens,
2450,,,107,,Autocuration,1,,B,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,5014,,
2451,,,107,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,17066,,
2452,,,107,,Autocuration,1,,B,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,,BAO_0000357,H,,17515,,
2453,,,107,,Expert,1,,B,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,6736,,
2454,,,107,,Expert,1,,B,,Affinity for 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,5163,,
2455,,,107,,Expert,1,,B,723.0,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,,BAO_0000219,H,,16911,,NIH3T3
2456,,,107,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,BAO_0000357,H,,6841,,
2457,,,107,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,,BAO_0000357,H,,6119,,
2458,,,107,,Autocuration,1,,B,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,3962,,
2459,,,107,,Autocuration,1,,B,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,,BAO_0000357,H,,4373,,
2460,,,107,,Autocuration,1,,B,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,,BAO_0000357,H,,4373,,
2461,,,107,,Autocuration,1,,F,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,,BAO_0000019,H,,3962,,
2462,,,107,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,BAO_0000357,H,,1633,,
2463,,,107,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,,BAO_0000357,H,,4373,,
2464,,,107,,Expert,1,,B,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,6576,,
2465,,,107,,Autocuration,1,,B,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,4687,,
2466,,,107,,Autocuration,1,,B,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,16946,,
2467,,,107,,Autocuration,1,,B,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,14159,,
2468,,,107,10090.0,Expert,1,,B,449.0,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,,BAO_0000219,H,,3032,Mus musculus,CHO
2469,,,107,,Autocuration,1,,B,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,16655,,
2470,,,107,,Autocuration,1,,B,,Binding affinity at 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,13964,,
2471,,,107,,Expert,1,,B,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,16989,,
2472,,,107,,Autocuration,1,,B,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,,BAO_0000357,H,,16117,,
2473,,,107,,Autocuration,1,,B,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,,BAO_0000357,H,,16700,,
2474,,,107,,Autocuration,1,,B,,Affinity against 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,3269,,
2475,,,107,9606.0,Expert,1,,B,,Binding affinity against 5-Hydroxytryptamine 2A receptor,,,BAO_0000357,D,,1274,Homo sapiens,
2476,,,107,,Autocuration,1,,B,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,BAO_0000357,H,,1317,,
2477,,,107,,Autocuration,1,,B,,Tested against 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,12146,,
2478,,,105075,,Autocuration,1,,B,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,BAO_0000224,H,,12652,,
2479,,,105075,,Autocuration,1,,B,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,,BAO_0000224,H,,12652,,
2480,,,105075,,Autocuration,1,,B,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,,BAO_0000224,H,,12652,,
2481,,,105075,,Autocuration,1,,B,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,BAO_0000224,H,,12652,,
2482,,,107,,Autocuration,1,,B,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,,BAO_0000357,H,,16647,,
2483,,,227,9606.0,Expert,1,,B,722.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,,BAO_0000219,D,,15851,Homo sapiens,HEK293
2484,,,227,9606.0,Expert,1,,F,449.0,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,,BAO_0000219,D,,6857,Homo sapiens,CHO
2485,,,227,,Autocuration,1,,B,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,,BAO_0000357,H,,3805,,
2486,,,227,9606.0,Expert,1,,B,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,,BAO_0000357,D,,6491,Homo sapiens,
2487,,,227,,Autocuration,1,,F,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,,BAO_0000019,H,,14093,,
2488,,,227,,Autocuration,1,,F,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,,BAO_0000019,H,,13481,,
2489,,,227,,Autocuration,1,,F,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,,BAO_0000019,H,,14093,,
2490,,,227,,Autocuration,1,,F,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,,BAO_0000019,H,,14093,,
2491,,,227,,Autocuration,1,,F,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,,BAO_0000019,H,,14093,,
2492,,,227,,Autocuration,1,,F,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,BAO_0000019,H,,13481,,
2493,,,227,,Autocuration,1,,B,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,,BAO_0000357,H,,14442,,
2494,,,227,,Autocuration,1,,B,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,,BAO_0000357,H,,14442,,
2495,,,227,,Autocuration,1,,B,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,BAO_0000357,H,,14442,,
2496,,,107,,Autocuration,1,,B,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,12369,,
2497,,,107,,Expert,1,,B,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,,BAO_0000357,H,,12369,,
2498,,,107,,Expert,1,,B,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,,BAO_0000357,H,,12369,,
2499,,,107,,Autocuration,1,,B,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,,BAO_0000019,H,,14447,,
2500,,,107,,Autocuration,1,,B,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,,BAO_0000019,H,,14447,,
2501,,,107,,Autocuration,1,,B,723.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,BAO_0000219,H,,17451,,NIH3T3
2502,,,107,,Autocuration,1,,F,449.0,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,BAO_0000219,H,,6857,,CHO
2503,,,107,9606.0,Expert,1,,F,449.0,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,BAO_0000219,D,,6857,Homo sapiens,CHO
2504,,,104817,,Autocuration,1,,B,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,,BAO_0000224,H,,5635,,
2505,,,107,,Autocuration,1,,B,,Binding activity radioligand.,,,BAO_0000357,H,,12861,,
2506,,,107,,Autocuration,1,,B,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,BAO_0000019,H,,12861,,
2507,,,107,,Autocuration,1,,B,307.0,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,,BAO_0000219,H,,5105,,L929
2508,,,107,,Expert,1,,B,307.0,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,,BAO_0000219,H,,5104,,L929
2509,,,107,,Expert,1,,B,307.0,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,,BAO_0000219,H,,5105,,L929
2510,,,107,,Autocuration,1,,B,307.0,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,,BAO_0000219,H,,5105,,L929
2511,,,107,,Autocuration,1,,B,,Binding affinity against 5-HT2A receptor,,,BAO_0000357,H,,5254,,
2512,,,107,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,5254,,
2513,,,107,,Autocuration,1,,B,722.0,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,,BAO_0000219,H,,13267,,HEK293
2514,,,107,,Autocuration,1,,B,722.0,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,,BAO_0000219,H,,13267,,HEK293
2515,,,107,9606.0,Expert,1,,B,722.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,,BAO_0000219,D,,14157,Homo sapiens,HEK293
2516,,,107,9606.0,Expert,1,,B,722.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,BAO_0000219,D,,12936,Homo sapiens,HEK293
2517,,,107,,Expert,1,,B,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,,BAO_0000357,H,,14068,,
2518,,,107,9606.0,Expert,1,,B,722.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,BAO_0000219,D,,12936,Homo sapiens,HEK293
2519,,,107,9606.0,Expert,1,,B,722.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,BAO_0000219,D,,12936,Homo sapiens,HEK293
2520,,,107,9606.0,Expert,1,,B,722.0,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,,BAO_0000219,D,,4540,Homo sapiens,HEK293
2521,,,107,,Expert,1,,B,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,,BAO_0000357,H,,6166,,
2522,,,107,,Autocuration,1,,B,722.0,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,,BAO_0000219,H,,17296,,HEK293
2523,,,107,,Autocuration,1,,B,722.0,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,,BAO_0000219,H,,17296,,HEK293
2524,,,107,,Autocuration,1,,B,722.0,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,,BAO_0000219,H,,17296,,HEK293
2525,,,107,9606.0,Expert,1,,B,722.0,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,,BAO_0000219,D,,15779,Homo sapiens,HEK293
2526,,,107,,Expert,1,,B,722.0,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,,BAO_0000219,H,,14391,,HEK293
2527,,,107,,Expert,1,,B,722.0,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,,BAO_0000219,H,,15851,,HEK293
2528,,,107,9606.0,Expert,1,,B,722.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,,BAO_0000219,D,,15851,Homo sapiens,HEK293
2529,,,107,,Expert,1,,B,722.0,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,,BAO_0000219,H,,3832,,HEK293
2530,,,107,,Expert,1,,B,722.0,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,,BAO_0000219,H,,3833,,HEK293
2531,,,107,9606.0,Expert,1,,B,722.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,BAO_0000219,D,,12936,Homo sapiens,HEK293
2532,,,107,,Autocuration,1,,B,723.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,,BAO_0000219,H,,17451,,NIH3T3
2533,,,107,,Autocuration,1,,B,723.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,BAO_0000219,H,,17451,,NIH3T3
2534,,,107,,Autocuration,1,,B,723.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,BAO_0000219,H,,17451,,NIH3T3
2535,,,107,,Autocuration,1,,B,722.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,,BAO_0000219,H,,4199,,HEK293
2536,,,107,,Autocuration,1,,B,485.0,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,,BAO_0000219,H,,1883,,CHO-K1
2537,,,107,,Expert,1,,B,485.0,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,,BAO_0000219,H,,1883,,CHO-K1
2538,,,107,9606.0,Expert,1,,B,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,,BAO_0000357,D,,14875,Homo sapiens,
2539,,,107,,Autocuration,1,,B,722.0,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,,BAO_0000219,H,,15146,,HEK293
2540,,,107,,Autocuration,1,,B,722.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,,BAO_0000219,H,,5213,,HEK293
2541,,,107,9606.0,Expert,1,,B,449.0,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,,BAO_0000219,D,,16404,Homo sapiens,CHO
2542,,,107,,Autocuration,1,,B,722.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,,BAO_0000219,H,,14818,,HEK293
2543,,,107,,Autocuration,1,,B,722.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,,BAO_0000219,H,,4829,,HEK293
2544,,,10620,,Autocuration,1,,F,723.0,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,,BAO_0000219,H,,12652,,NIH3T3
2545,,,107,,Expert,1,,B,723.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,,BAO_0000219,H,,4682,,NIH3T3
2546,,,10620,,Autocuration,1,,F,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,,BAO_0000019,H,,12652,,
2547,,,10621,,Autocuration,1,,B,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,4921,,
2548,,,10621,,Autocuration,1,,B,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,,BAO_0000357,H,,4921,,
2549,,,107,9986.0,Autocuration,1,,B,,Binding affinity against rabbit aorta 5-HT2A receptor,,,BAO_0000357,H,,16312,Oryctolagus cuniculus,
2550,,,107,9986.0,Expert,1,,B,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,,BAO_0000357,H,,14998,Oryctolagus cuniculus,
2551,,,107,9986.0,Expert,1,,B,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,,BAO_0000357,H,,14025,Oryctolagus cuniculus,
2552,,,107,9986.0,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,,BAO_0000019,H,,13047,Oryctolagus cuniculus,
2553,,,107,9986.0,Expert,1,,B,,The compound was tested for binding affinity against 5-HT2A receptor,,,BAO_0000357,H,,13047,Oryctolagus cuniculus,
2554,,,10576,,Autocuration,1,,B,485.0,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,,BAO_0000219,H,,1883,,CHO-K1
2555,,,12687,,Autocuration,1,,B,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,,BAO_0000019,H,,13463,,
2556,,,12687,,Autocuration,1,,B,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,BAO_0000019,H,,13463,,
2557,,945.0,12687,,Autocuration,1,Stomach,B,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,,BAO_0000019,H,,13463,,
2558,,945.0,12687,10116.0,Expert,1,Stomach,B,,Binding affinity for 5-HT 2A in rat stomach fundus,,,BAO_0000019,D,,13463,Rattus norvegicus,
2559,,,12687,,Autocuration,1,,B,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,BAO_0000019,H,,13463,,
2560,,,12687,,Expert,1,,B,723.0,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,,BAO_0000219,H,,16326,,NIH3T3
2561,,,12687,,Autocuration,1,,F,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,,BAO_0000019,H,,14093,,
2562,,,12687,,Autocuration,1,,F,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,,BAO_0000019,H,,14093,,
2563,,,12687,,Autocuration,1,,B,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,15740,,
2564,,,12687,,Autocuration,1,,B,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,,BAO_0000357,H,,16633,,
2565,,,12687,10116.0,Expert,1,,F,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,,BAO_0000019,D,,17200,Rattus norvegicus,
2566,,,12687,,Autocuration,1,,B,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,17133,,
2567,,,12687,,Autocuration,1,,B,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,17133,,
2568,,,12687,,Autocuration,1,,B,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,17133,,
2569,,,12687,,Autocuration,1,,F,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,BAO_0000219,H,,17200,,
2570,,,12687,,Autocuration,1,,F,,Efficacy at 5-hydroxytryptamine 2A receptor,,,BAO_0000019,H,,15363,,
2571,,,12687,,Autocuration,1,,B,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,BAO_0000357,H,,17200,,
2572,,,12687,10116.0,Expert,1,,B,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,BAO_0000357,D,,17200,Rattus norvegicus,
2573,,,12687,10116.0,Expert,1,,B,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,,BAO_0000357,D,,17200,Rattus norvegicus,
2574,,,12687,10116.0,Expert,1,,F,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,BAO_0000219,D,,17200,Rattus norvegicus,
2575,,,12687,,Autocuration,1,,F,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,BAO_0000219,H,,17200,,
2576,,,12687,,Autocuration,1,,B,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,,BAO_0000019,H,,17211,,
2577,,,12687,,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,,BAO_0000019,H,,17331,,
2578,,,12687,,Expert,1,,B,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,,BAO_0000249,H,,13565,,
2579,,,12687,,Expert,1,,B,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,,BAO_0000357,H,,13730,,
2580,,,12687,,Expert,1,,B,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,,BAO_0000019,H,,12416,,
2581,,,12687,,Autocuration,1,,B,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,15295,,
2582,,,12687,,Autocuration,1,,B,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,,BAO_0000019,H,,1742,,
2583,,,12687,,Autocuration,1,,B,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,15295,,
2584,,,12687,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,,BAO_0000019,H,,14970,,
2585,,,12687,,Expert,1,,B,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,,BAO_0000019,H,,16693,,
2586,,,12687,10116.0,Expert,1,,B,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,,BAO_0000019,D,,14776,Rattus norvegicus,
2587,,,12687,,Autocuration,1,,B,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,BAO_0000249,H,,14286,,
2588,,,12687,10116.0,Expert,1,,B,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,,BAO_0000019,D,,17200,Rattus norvegicus,
2589,,,12687,,Expert,1,,B,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,,BAO_0000357,H,,15306,,
2590,,,12687,10116.0,Expert,1,,B,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,,BAO_0000357,D,,14178,Rattus norvegicus,
2591,,,12687,10116.0,Expert,1,,B,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,,BAO_0000019,D,,14229,Rattus norvegicus,
2592,,,12687,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,,BAO_0000357,H,,12884,,
2593,,,12687,,Expert,1,,B,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,,BAO_0000357,H,,13149,,
2594,,,12687,10116.0,Expert,1,,B,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,,BAO_0000019,D,,15295,Rattus norvegicus,
2595,,,12687,,Autocuration,1,,B,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,,BAO_0000357,H,,15740,,
2596,,,12687,,Autocuration,1,,B,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,,BAO_0000019,H,,15185,,
2597,,,12687,,Autocuration,1,,B,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,,BAO_0000019,H,,15185,,
2598,,,12687,,Expert,1,,B,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,,BAO_0000019,H,,17529,,
2599,,,12687,,Autocuration,1,,B,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,BAO_0000019,H,,14826,,
2600,,,12687,,Expert,1,,B,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,,BAO_0000019,H,,17211,,
2601,,,12687,,Autocuration,1,,B,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,BAO_0000019,H,,14826,,
2602,,,12687,,Autocuration,1,,B,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,BAO_0000019,H,,14093,,
2603,,,12687,,Autocuration,1,,B,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,,BAO_0000019,H,,14093,,
2604,,,12687,,Expert,1,,B,723.0,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,,BAO_0000219,H,,13246,,NIH3T3
2605,,,12687,,Expert,1,,B,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,,BAO_0000357,H,,13246,,
2606,,,12687,10116.0,Expert,1,,B,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,BAO_0000019,D,,15436,Rattus norvegicus,
2607,,,12687,10116.0,Expert,1,,B,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,BAO_0000019,D,,15436,Rattus norvegicus,
2608,,955.0,12687,,Autocuration,1,Brain,B,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,,BAO_0000221,H,,14442,,
2609,,,12687,,Expert,1,,B,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,12457,,
2610,,,12687,,Expert,1,,B,723.0,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,,BAO_0000219,H,,12457,,NIH3T3
2611,,,12687,,Autocuration,1,,F,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,,BAO_0000221,H,,14755,,
2612,,,12687,,Autocuration,1,,B,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,,BAO_0000357,H,,4707,,
2613,,,12687,,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,13297,,
2614,,,12687,,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,,BAO_0000019,H,,17331,,
2615,,,12687,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,,BAO_0000019,H,,4664,,
2616,,,12687,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,BAO_0000357,H,,16633,,
2617,,,12687,10116.0,Expert,1,,B,723.0,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,,BAO_0000219,D,,4664,Rattus norvegicus,NIH3T3
2618,,,12687,,Expert,1,,B,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,BAO_0000357,H,,16133,,
2619,,,12687,,Expert,1,,B,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,BAO_0000357,H,,16133,,
2620,,,12687,10116.0,Expert,1,,B,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,,BAO_0000019,D,,14060,Rattus norvegicus,
2621,,,12687,,Expert,1,,B,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,BAO_0000357,H,,16326,,
2622,,,12687,,Expert,1,,B,449.0,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,BAO_0000219,H,,16659,,CHO
2623,,,12687,,Autocuration,1,,B,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,,BAO_0000019,H,,14776,,
2624,,,12687,,Autocuration,1,,B,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,BAO_0000357,H,,13481,,
2625,,,12687,,Autocuration,1,,B,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,17386,,
2626,,,12687,10116.0,Expert,1,,B,,Binding affinity for 5-hydroxytryptamine 2A receptor,,,BAO_0000357,D,,6611,Rattus norvegicus,
2627,,,12687,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,,BAO_0000019,H,,14423,,
2628,,,12687,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,,BAO_0000019,H,,15412,,
2629,,,12687,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,,BAO_0000019,H,,15412,,
2630,,,12687,,Autocuration,1,,B,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,,BAO_0000019,H,,6238,,
2631,,,12687,,Expert,1,,B,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,,BAO_0000357,H,,6648,,
2632,,,12687,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,,BAO_0000357,H,,5667,,
2633,,,12687,10116.0,Expert,1,,B,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,,BAO_0000357,D,,6611,Rattus norvegicus,
2634,,,12687,,Autocuration,1,,B,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,BAO_0000357,H,,13481,,
2635,,,12687,,Autocuration,1,,B,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,,BAO_0000357,H,,13481,,
2636,,,12687,,Expert,1,,B,723.0,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,,BAO_0000219,H,,15558,,NIH3T3
2637,,,12687,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,6013,,
2638,,,12687,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,BAO_0000357,H,,16633,,
2639,,,12687,,Autocuration,1,,B,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,,BAO_0000357,H,,6013,,
2640,,,12687,10116.0,Expert,1,,B,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,,BAO_0000357,D,,6013,Rattus norvegicus,
2641,,,12687,,Autocuration,1,,B,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,,BAO_0000357,H,,6013,,
2642,,,12687,,Expert,1,,B,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,,BAO_0000357,H,,6013,,
2643,,,12687,,Autocuration,1,,B,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,,BAO_0000357,H,,6013,,
2644,,,12687,,Autocuration,1,,B,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,,BAO_0000357,H,,6013,,
2645,,,12687,,Autocuration,1,,B,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,16293,,
2646,,,12687,,Expert,1,,B,723.0,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,,BAO_0000219,H,,17175,,NIH3T3
2647,,,12687,10116.0,Expert,1,,B,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,,BAO_0000357,D,,13278,Rattus norvegicus,
2648,,5383.0,12687,,Autocuration,1,Caudate-putamen,B,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,,BAO_0000019,H,,3682,,
2649,,,12687,,Autocuration,1,,B,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,,BAO_0000357,H,,2014,,
2650,,,12687,,Autocuration,1,,B,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,,BAO_0000357,H,,2014,,
2651,,,12687,,Autocuration,1,,B,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,,BAO_0000357,H,,4932,,
2652,,,12687,,Autocuration,1,,B,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,,BAO_0000019,H,,4932,,
2653,,,12687,,Autocuration,1,,B,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,3935,,
2654,,10000000.0,12687,10116.0,Expert,1,Hippocampus,B,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,,BAO_0000221,D,,5432,Rattus norvegicus,
2655,,,12687,,Autocuration,1,,B,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,15818,,
2656,,,12687,,Autocuration,1,,B,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,,BAO_0000357,H,,13672,,
2657,,,12687,,Autocuration,1,,B,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,,BAO_0000357,H,,13672,,
2658,,,12687,,Expert,1,,B,723.0,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,,BAO_0000219,H,,14749,,NIH3T3
2659,,,12687,,Autocuration,1,,B,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,,BAO_0000019,H,,13462,,
2660,,,12687,,Autocuration,1,,B,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,15740,,
2661,,,12687,,Expert,1,,B,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,BAO_0000019,H,,16647,,
2662,,955.0,12687,,Autocuration,1,Brain,B,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,,BAO_0000221,H,,13345,,
2663,,,12687,,Autocuration,1,,B,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,BAO_0000249,H,,16740,,
2664,,,12687,,Autocuration,1,,B,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,BAO_0000249,H,,16740,,
2665,,,12687,10116.0,Expert,1,,B,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,,BAO_0000019,D,,15535,Rattus norvegicus,
2666,,,12687,,Expert,1,,B,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,BAO_0000249,H,,16740,,
2667,,,12687,,Autocuration,1,,B,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,BAO_0000249,H,,16740,,
2668,,,12687,,Autocuration,1,,B,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,BAO_0000249,H,,16740,,
2669,,,12687,10116.0,Expert,1,,B,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,,BAO_0000019,D,,4795,Rattus norvegicus,
2670,,,12687,,Expert,1,,B,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,,BAO_0000019,H,,8,,
2671,,,12687,,Autocuration,1,,B,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,,BAO_0000019,H,,8,,
2672,,,12687,10116.0,Expert,1,,B,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,,BAO_0000019,D,,17200,Rattus norvegicus,
2673,,,12687,10116.0,Expert,1,,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,,BAO_0000019,D,,2148,Rattus norvegicus,
2674,,,105102,10116.0,Expert,1,,B,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,,BAO_0000224,D,,13345,Rattus norvegicus,
2675,,,12687,,Autocuration,1,,B,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,BAO_0000357,H,,5088,,
2676,,,12687,,Autocuration,1,,B,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,BAO_0000357,H,,5088,,
2677,,,12687,,Autocuration,1,,B,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,,BAO_0000357,H,,17133,,
2678,,,12687,10116.0,Expert,1,,B,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,,BAO_0000357,D,,17133,Rattus norvegicus,
2679,,,12687,,Autocuration,1,,B,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,,BAO_0000357,H,,16532,,
2680,,,12687,,Autocuration,1,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,,BAO_0000357,H,,15086,,
2681,,,12687,10116.0,Expert,1,,B,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,BAO_0000019,D,,2309,Rattus norvegicus,
2682,,,12687,,Expert,1,,B,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,,BAO_0000019,H,,12953,,
2683,,,12687,,Autocuration,1,,B,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,,BAO_0000019,H,,12953,,
2684,,,12687,,Autocuration,1,,B,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,,BAO_0000019,H,,12953,,
2685,,,12687,,Autocuration,1,,B,449.0,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,,BAO_0000219,H,,16659,,CHO
2686,,,12687,,Autocuration,1,,B,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,BAO_0000019,H,,16740,,
2687,,,12687,,Autocuration,1,,B,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,BAO_0000019,H,,16740,,
2688,,,12687,,Autocuration,1,,B,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,,BAO_0000357,H,,17133,,
2689,,,12687,,Autocuration,1,,B,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,,BAO_0000019,H,,17211,,
2690,,,12687,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,,BAO_0000019,H,,17331,,
2691,,,12687,,Autocuration,1,,B,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,,BAO_0000218,H,,16633,,
2692,,,12687,,Autocuration,1,,B,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,,BAO_0000218,H,,16633,,
2693,,,12687,,Autocuration,1,,B,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,,BAO_0000218,H,,16633,,
2694,,,12687,,Expert,1,,B,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,,BAO_0000357,H,,15026,,
2695,,,12687,,Expert,1,,B,,Ratio of pKi of 5-HT2A to that of D2 receptor,,,BAO_0000357,H,,15026,,
2696,,,105093,,Expert,1,,B,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,BAO_0000224,H,,16404,,
2697,,,105093,,Expert,1,,B,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,BAO_0000224,H,,16404,,
2698,,,105075,,Expert,1,,B,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,,BAO_0000224,H,,16404,,
2699,,,12687,,Autocuration,1,,B,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,,BAO_0000357,H,,16404,,
2700,,,12687,,Expert,1,,B,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,,BAO_0000357,H,,16326,,
2701,,,12687,,Autocuration,1,,F,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,,BAO_0000019,H,,15847,,
2702,,,12687,,Autocuration,1,,F,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,,BAO_0000019,H,,15847,,
2703,,,12687,,Autocuration,1,,F,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,,BAO_0000019,H,,15329,,
2704,,1515.0,12687,,Expert,1,Thoracic aorta,F,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,,BAO_0000019,H,,16404,,
2705,,1515.0,12687,,Expert,1,Thoracic aorta,F,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,,BAO_0000019,H,,16404,,
2706,,1515.0,12687,,Autocuration,1,Thoracic aorta,F,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,,BAO_0000019,H,,16404,,
2707,,,12687,,Autocuration,1,,B,,Binding activity radioligand.,,,BAO_0000357,H,,12861,,
2708,,,12687,,Expert,1,,B,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,BAO_0000019,H,,12861,,
2709,,,12687,,Autocuration,1,,B,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,BAO_0000019,H,,12861,,
2710,,,12687,,Expert,1,,B,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,,BAO_0000019,H,,12490,,
2711,,,12687,,Autocuration,1,,B,339.0,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,,BAO_0000219,H,,12827,,N1E-115
2712,,,12687,,Autocuration,1,,B,339.0,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,,BAO_0000219,H,,12827,,N1E-115
2713,,,12687,,Autocuration,1,,B,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,,BAO_0000019,H,,12918,,
2714,,,12687,10116.0,Expert,1,,F,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,,BAO_0000019,D,,12919,Rattus norvegicus,
2715,,,108,,Autocuration,1,,B,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,17723,,
2716,,,108,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,6013,,
2717,,,108,,Autocuration,1,,B,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,16293,,
2718,,,108,,Expert,1,,B,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,BAO_0000019,H,,3857,,
2719,,,108,,Expert,1,,B,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,,BAO_0000019,H,,3857,,
2720,,,108,,Expert,1,,B,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,BAO_0000019,H,,3857,,
2721,,,108,,Autocuration,1,,B,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,15363,,
2722,,,108,,Autocuration,1,,B,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,15363,,
2723,,,108,,Expert,1,,B,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,,BAO_0000019,H,,16441,,
2724,,,108,,Expert,1,,B,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,,BAO_0000019,H,,16441,,
2725,,,108,,Autocuration,1,,B,722.0,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,,BAO_0000219,H,,4176,,HEK293
2726,,,108,,Autocuration,1,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,,BAO_0000019,H,,17085,,
2727,,,108,9606.0,Expert,1,,B,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,,BAO_0000357,D,,17200,Homo sapiens,
2728,,,108,,Expert,1,,B,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,,BAO_0000357,H,,5088,,
2729,,,108,,Autocuration,1,,B,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,,BAO_0000357,H,,5088,,
2730,,,108,,Autocuration,1,,B,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,BAO_0000357,H,,5088,,
2731,,,108,,Autocuration,1,,B,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,BAO_0000357,H,,5088,,
2732,,,108,,Autocuration,1,,B,449.0,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,BAO_0000219,H,,16659,,CHO
2733,,,108,,Autocuration,1,,B,449.0,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,,BAO_0000219,H,,16659,,CHO
2734,,,108,,Autocuration,1,,B,723.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,BAO_0000219,H,,17451,,NIH3T3
2735,,,108,9606.0,Expert,1,,F,449.0,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,BAO_0000219,D,,6857,Homo sapiens,CHO
2736,,,108,,Expert,1,,B,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,BAO_0000019,H,,3857,,
2737,,,108,,Autocuration,1,,B,,Binding activity radioligand.,,,BAO_0000357,H,,12861,,
2738,,,108,,Autocuration,1,,B,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,BAO_0000019,H,,12861,,
2739,,,108,,Expert,1,,B,449.0,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,,BAO_0000219,H,,5104,,CHO
2740,,,108,,Expert,1,,B,449.0,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,,BAO_0000219,H,,5105,,CHO
2741,,,108,,Autocuration,1,,B,449.0,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,,BAO_0000219,H,,5105,,CHO
2742,,,108,,Autocuration,1,,B,,Binding affinity against 5-HT2C receptor,,,BAO_0000357,H,,5254,,
2743,,,108,,Autocuration,1,,B,722.0,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,,BAO_0000219,H,,13267,,HEK293
2744,,,108,9606.0,Expert,1,,B,722.0,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,,BAO_0000219,D,,14157,Homo sapiens,HEK293
2745,,,108,9606.0,Expert,1,,B,722.0,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,,BAO_0000219,D,,12936,Homo sapiens,HEK293
2746,,,108,,Expert,1,,B,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,,BAO_0000357,H,,14068,,
2747,,,108,9606.0,Expert,1,,B,722.0,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,,BAO_0000219,D,,12936,Homo sapiens,HEK293
2748,,,108,9606.0,Expert,1,,B,722.0,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,,BAO_0000219,D,,4540,Homo sapiens,HEK293
2749,,,108,9606.0,Expert,1,,B,722.0,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,,BAO_0000219,D,,4540,Homo sapiens,HEK293
2750,,,108,,Autocuration,1,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,,BAO_0000357,H,,6166,,
2751,,,108,,Autocuration,1,,B,722.0,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,,BAO_0000219,H,,17296,,HEK293
2752,,,108,,Autocuration,1,,B,722.0,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,,BAO_0000219,H,,17296,,HEK293
2753,,,108,,Autocuration,1,,B,722.0,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,BAO_0000219,H,,15779,,HEK293
2754,,,108,,Autocuration,1,,B,722.0,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,BAO_0000219,H,,15779,,HEK293
2755,,,108,,Expert,1,,B,722.0,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,,BAO_0000219,H,,14391,,HEK293
2756,,,108,,Autocuration,1,,B,722.0,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,,BAO_0000219,H,,15779,,HEK293
2757,,,108,,Expert,1,,B,722.0,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,,BAO_0000219,H,,15851,,HEK293
2758,,,108,9606.0,Expert,1,,B,722.0,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,,BAO_0000219,D,,15851,Homo sapiens,HEK293
2759,,,108,,Autocuration,1,,B,722.0,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,,BAO_0000219,H,,15779,,HEK293
2760,,,108,,Expert,1,,B,722.0,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,,BAO_0000219,H,,3832,,HEK293
2761,,,108,,Expert,1,,B,722.0,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,,BAO_0000219,H,,3833,,HEK293
2762,,,108,,Autocuration,1,,B,723.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,,BAO_0000219,H,,17451,,NIH3T3
2763,,,108,,Autocuration,1,,B,722.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,,BAO_0000219,H,,4199,,HEK293
2764,,,108,,Expert,1,,B,485.0,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,,BAO_0000219,H,,1883,,CHO-K1
2765,,,108,9606.0,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 2C receptor,,,BAO_0000357,D,,4321,Homo sapiens,
2766,,,108,,Autocuration,1,,B,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,14875,,
2767,,,108,,Autocuration,1,,B,722.0,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,,BAO_0000219,H,,15146,,HEK293
2768,,,108,,Autocuration,1,,B,722.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,,BAO_0000219,H,,5213,,HEK293
2769,,,108,,Autocuration,1,,B,308.0,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,,BAO_0000219,H,,16404,,HeLa
2770,,,108,,Autocuration,1,,F,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,,BAO_0000019,H,,13267,,
2771,,10000000.0,108,,Autocuration,1,Hippocampus,F,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,,BAO_0000221,H,,13267,,
2772,,,108,,Autocuration,1,,B,722.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,,BAO_0000219,H,,14818,,HEK293
2773,,,108,,Autocuration,1,,B,722.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,,BAO_0000219,H,,4829,,HEK293
2774,,,11864,,Autocuration,1,,B,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,,BAO_0000357,H,,13463,,
2775,,945.0,11864,,Autocuration,1,Stomach,B,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,,BAO_0000019,H,,13463,,
2776,,945.0,11864,,Autocuration,1,Stomach,B,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,,BAO_0000019,H,,13463,,
2777,,,11864,,Autocuration,1,,F,625.0,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,,BAO_0000219,H,,12652,,A9
2778,,,11864,,Autocuration,1,,B,723.0,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,,BAO_0000219,H,,4682,,NIH3T3
2779,,,11864,,Autocuration,1,,B,723.0,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,,BAO_0000219,H,,4682,,NIH3T3
2780,,,11864,,Autocuration,1,,B,723.0,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,,BAO_0000219,H,,4682,,NIH3T3
2781,,,11864,,Autocuration,1,,F,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,,BAO_0000019,H,,12652,,
2782,,945.0,12689,10090.0,Autocuration,1,Stomach,B,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,,BAO_0000019,H,,13463,Mus musculus,
2783,,945.0,12689,10116.0,Expert,1,Stomach,B,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,,BAO_0000019,D,,13463,Rattus norvegicus,
2784,,,108,,Expert,1,,B,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,,BAO_0000357,H,,13969,,
2785,,,108,9823.0,Expert,1,,B,,Binding affinity for 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,13392,Sus scrofa,
2786,,,108,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,13392,,
2787,,,108,,Expert,1,,B,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,,BAO_0000019,H,,14430,,
2788,,,108,,Autocuration,1,,B,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,,BAO_0000019,H,,1742,,
2789,,,108,,Autocuration,1,,B,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,,BAO_0000249,H,,14286,,
2790,,,108,,Autocuration,1,,B,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,5619,,
2791,,,108,,Autocuration,1,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,15086,,
2792,,,108,,Autocuration,1,,B,,Binding activity radioligand.,,,BAO_0000357,H,,12861,,
2793,,,108,,Expert,1,,B,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,BAO_0000019,H,,12861,,
2794,,,108,,Autocuration,1,,B,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,BAO_0000019,H,,12861,,
2795,,,108,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,,BAO_0000249,H,,12827,,
2796,,,108,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,,BAO_0000249,H,,12827,,
2797,,,108,9823.0,Expert,1,,F,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,,BAO_0000019,H,,12919,Sus scrofa,
2798,,,108,9823.0,Expert,1,,F,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,,BAO_0000019,H,,12919,Sus scrofa,
2799,,,108,9823.0,Autocuration,1,,B,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,,BAO_0000357,H,,16429,Sus scrofa,
2800,,,108,9823.0,Autocuration,1,,B,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,,BAO_0000019,H,,773,Sus scrofa,
2801,,,108,9823.0,Autocuration,1,,B,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,5033,Sus scrofa,
2802,,,12687,,Autocuration,1,,B,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,BAO_0000019,H,,12861,,
2803,,,12689,,Autocuration,1,,F,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,,BAO_0000019,H,,14093,,
2804,,,12689,,Expert,1,,B,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,,BAO_0000357,H,,14970,,
2805,,,12689,,Autocuration,1,,B,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,,BAO_0000357,H,,14970,,
2806,,,12689,,Autocuration,1,,B,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,,BAO_0000357,H,,14970,,
2807,,,12689,10116.0,Expert,1,,B,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,,BAO_0000357,D,,14178,Rattus norvegicus,
2808,,,12689,10116.0,Expert,1,,B,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,,BAO_0000357,D,,14178,Rattus norvegicus,
2809,,,12689,10116.0,Expert,1,,B,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,Brain membranes,,BAO_0000249,D,,14229,Rattus norvegicus,
2810,,,12689,,Autocuration,1,,B,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,,BAO_0000357,H,,16532,,
2811,,,12689,,Autocuration,1,,B,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,,BAO_0000019,H,,14826,,
2812,,,12689,,Autocuration,1,,B,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,,BAO_0000019,H,,17211,,
2813,In vitro,,12689,,Expert,1,,B,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,,BAO_0000219,H,,17211,,
2814,,,12689,,Expert,1,,B,723.0,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,,BAO_0000219,H,,13246,,NIH3T3
2815,,,12689,,Expert,1,,B,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,,BAO_0000357,H,,13246,,
2816,,,12689,,Expert,1,,B,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,12457,,
2817,,,12689,,Expert,1,,B,723.0,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,,BAO_0000219,H,,12457,,NIH3T3
2818,,,12689,,Autocuration,1,,B,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,,BAO_0000357,H,,4707,,
2819,,,12689,,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,13297,,
2820,,,12689,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,BAO_0000357,H,,16633,,
2821,,,12689,,Expert,1,,B,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,BAO_0000357,H,,16133,,
2822,,,12689,,Expert,1,,B,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,,BAO_0000357,H,,16326,,
2823,,,12689,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,,BAO_0000019,H,,14423,,
2824,,,12689,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,,BAO_0000019,H,,15412,,
2825,,,12689,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,,BAO_0000019,H,,15412,,
2826,,,12689,,Expert,1,,B,625.0,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,,BAO_0000219,H,,15558,,A9
2827,,,12689,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,BAO_0000357,H,,16633,,
2828,,,12689,,Expert,1,,B,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,,BAO_0000357,H,,6013,,
2829,In vitro,,12689,,Expert,1,,B,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,,BAO_0000219,H,,17175,,
2830,,,12689,,Autocuration,1,,B,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,,BAO_0000219,H,,12469,,
2831,,5383.0,12689,,Autocuration,1,Caudate-putamen,B,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,,BAO_0000019,H,,3682,,
2832,,,12689,,Autocuration,1,,B,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,,BAO_0000357,H,,4932,,
2833,,,12689,,Autocuration,1,,B,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,,BAO_0000019,H,,4932,,
2834,,,12689,,Autocuration,1,,B,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,3935,,
2835,,,12689,,Autocuration,1,,B,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,15818,,
2836,,,12689,,Autocuration,1,,B,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,15818,,
2837,,,12689,,Expert,1,,B,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,,BAO_0000219,H,,14749,,
2838,,,12689,,Autocuration,1,,B,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,15740,,
2839,,,12689,10116.0,Expert,1,,B,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,,BAO_0000357,D,,17133,Rattus norvegicus,
2840,,,12689,,Autocuration,1,,B,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,,BAO_0000357,H,,16532,,
2841,,,12689,,Autocuration,1,,B,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,12369,,
2842,,,12689,,Expert,1,,B,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,,BAO_0000219,H,,12369,,
2843,,,12689,10116.0,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,,BAO_0000019,D,,2309,Rattus norvegicus,
2844,,,12689,,Autocuration,1,,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,12953,,
2845,,,12689,,Autocuration,1,,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,,BAO_0000019,H,,12953,,
2846,,,12689,,Autocuration,1,,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,,BAO_0000357,H,,12953,,
2847,,,12689,,Expert,1,,B,,Binding affinity for 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,12953,,
2848,,,12689,,Autocuration,1,,B,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,,BAO_0000357,H,,17133,,
2849,,,12689,,Autocuration,1,,B,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,,BAO_0000019,H,,17211,,
2850,,,12689,,Autocuration,1,,B,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,,BAO_0000019,H,,17211,,
2851,,,12689,,Autocuration,1,,B,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,,BAO_0000019,H,,14025,,
2852,,,12689,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,,BAO_0000019,H,,14998,,
2853,,,12689,,Autocuration,1,,B,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,,BAO_0000357,H,,4342,,
2854,,,12689,10116.0,Expert,1,,B,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,,BAO_0000019,D,,13735,Rattus norvegicus,
2855,,,12689,,Autocuration,1,,B,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,BAO_0000357,H,,13181,,
2856,,,12689,,Autocuration,1,,B,485.0,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,,BAO_0000219,H,,1883,,CHO-K1
2857,,,12689,,Autocuration,1,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,BAO_0000357,H,,15194,,
2858,,,12689,,Autocuration,1,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,,BAO_0000357,H,,15194,,
2859,,,12689,,Autocuration,1,,F,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,,BAO_0000019,H,,14579,,
2860,,,108,,Autocuration,1,,B,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,4639,,
2861,,,108,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,4820,,
2862,,,227,,Autocuration,1,,B,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,,BAO_0000357,H,,14442,,
2863,,,227,,Autocuration,1,,B,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,,BAO_0000357,H,,14755,,
2864,,,227,,Autocuration,1,,B,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,,BAO_0000357,H,,14744,,
2865,,,227,9606.0,Expert,1,,B,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,,BAO_0000019,D,,6857,Homo sapiens,
2866,,,227,,Autocuration,1,,B,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,,BAO_0000357,H,,16209,,
2867,,,227,,Autocuration,1,,B,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,BAO_0000357,H,,15363,,
2868,,,227,,Autocuration,1,,B,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,BAO_0000357,H,,15363,,
2869,,,227,,Autocuration,1,,B,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,,BAO_0000357,H,,15363,,
2870,,,227,,Autocuration,1,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,,BAO_0000019,H,,17085,,
2871,,,227,9606.0,Expert,1,,B,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,,BAO_0000357,D,,17200,Homo sapiens,
2872,,,227,9606.0,Expert,1,,B,722.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,,BAO_0000219,D,,15851,Homo sapiens,HEK293
2873,,,227,9606.0,Expert,1,,B,722.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,,BAO_0000219,D,,15851,Homo sapiens,HEK293
2874,,,227,9606.0,Expert,1,,F,449.0,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,BAO_0000219,D,,6857,Homo sapiens,CHO
2875,,,227,9606.0,Expert,1,,F,449.0,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,BAO_0000219,D,,6857,Homo sapiens,CHO
2876,,,227,,Autocuration,1,,B,722.0,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,BAO_0000219,H,,15779,,HEK293
2877,,,227,,Expert,1,,B,722.0,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,,BAO_0000219,H,,15851,,HEK293
2878,,,227,,Autocuration,1,,B,722.0,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,,BAO_0000219,H,,15779,,HEK293
2879,,,227,9606.0,Expert,1,,B,722.0,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,,BAO_0000219,D,,14157,Homo sapiens,HEK293
2880,,,227,9606.0,Expert,1,,B,722.0,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,,BAO_0000219,D,,4540,Homo sapiens,HEK293
2881,,,227,,Autocuration,1,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,,BAO_0000357,H,,6166,,
2882,,,227,,Autocuration,1,,B,722.0,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,,BAO_0000219,H,,15779,,HEK293
2883,,,227,,Expert,1,,B,722.0,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,,BAO_0000219,H,,14391,,HEK293
2884,,,227,,Expert,1,,B,722.0,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,,BAO_0000219,H,,3832,,HEK293
2885,,,227,,Expert,1,,B,722.0,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,,BAO_0000219,H,,3833,,HEK293
2886,,,227,9606.0,Expert,1,,B,722.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,,BAO_0000219,D,,15851,Homo sapiens,HEK293
2887,,,227,9606.0,Expert,1,,B,722.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,,BAO_0000219,D,,15851,Homo sapiens,HEK293
2888,,,227,,Autocuration,1,,B,722.0,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,,BAO_0000219,H,,4199,,HEK293
2889,,,227,,Expert,1,,B,485.0,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,,BAO_0000219,H,,1883,,CHO-K1
2890,,,227,,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 2B receptor,,,BAO_0000357,H,,4321,,
2891,,,227,,Autocuration,1,,B,722.0,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,,BAO_0000219,H,,15146,,HEK293
2892,,,227,,Autocuration,1,,B,722.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,,BAO_0000219,H,,5213,,HEK293
2893,,,227,,Autocuration,1,,B,722.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,,BAO_0000219,H,,14818,,HEK293
2894,,,227,,Autocuration,1,,B,722.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,BAO_0000219,H,,4829,,HEK293
2895,,,227,,Autocuration,1,,B,722.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,BAO_0000219,H,,4829,,HEK293
2896,,,227,9986.0,Autocuration,1,,B,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,,BAO_0000019,H,,14025,Oryctolagus cuniculus,
2897,,945.0,12688,,Expert,1,Stomach,B,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,,BAO_0000019,H,,13463,,
2898,,945.0,12688,,Expert,1,Stomach,B,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,,BAO_0000357,H,,7259,,
2899,,945.0,12688,,Autocuration,1,Stomach,B,,Affinity against serotonergic receptor in the isolated rat stomach fundus,,,BAO_0000357,H,,7259,,
2900,,945.0,12688,10116.0,Expert,1,Stomach,F,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,,BAO_0000019,D,,7185,Rattus norvegicus,
2901,,,12688,10116.0,Expert,1,,F,,Antagonistic against 5-hydroxytryptamine 2B receptor,,,BAO_0000019,D,,7185,Rattus norvegicus,
2902,,945.0,12688,,Autocuration,1,Stomach,F,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,,BAO_0000019,H,,13267,,
2903,,945.0,12688,10116.0,Expert,1,Stomach,B,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,,BAO_0000357,D,,13735,Rattus norvegicus,
2904,,,12688,,Autocuration,1,,F,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,,BAO_0000019,H,,15738,,
2905,,,12688,,Autocuration,1,,F,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,,BAO_0000019,H,,15738,,
2906,,,12688,,Autocuration,1,,F,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,,BAO_0000019,H,,15738,,
2907,,945.0,12688,10116.0,Expert,1,Stomach,B,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,BAO_0000357,D,,12936,Rattus norvegicus,
2908,,945.0,12688,10116.0,Expert,1,Stomach,B,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,BAO_0000357,D,,12936,Rattus norvegicus,
2909,,945.0,12688,10116.0,Expert,1,Stomach,B,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,BAO_0000357,D,,12936,Rattus norvegicus,
2910,,945.0,12688,10116.0,Expert,1,Stomach,B,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,BAO_0000357,D,,12936,Rattus norvegicus,
2911,,945.0,12688,,Autocuration,1,Stomach,F,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,BAO_0000019,H,,16404,,
2912,,945.0,12688,,Expert,1,Stomach,F,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,BAO_0000019,H,,16404,,
2913,,945.0,12688,,Autocuration,1,Stomach,F,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,,BAO_0000019,H,,16404,,
2914,,945.0,12688,,Autocuration,1,Stomach,F,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,,BAO_0000019,H,,16404,,
2915,,945.0,12688,10116.0,Expert,1,Stomach,F,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,,BAO_0000019,D,,16404,Rattus norvegicus,
2916,,1515.0,12688,,Autocuration,1,Thoracic aorta,F,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,,BAO_0000019,H,,16404,,
2917,,,12688,,Autocuration,1,,B,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,BAO_0000357,H,,7483,,
2918,,,12688,,Expert,1,,B,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,,BAO_0000357,H,,7483,,
2919,,,12688,,Autocuration,1,,B,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,BAO_0000357,H,,7483,,
2920,,,12688,,Autocuration,1,,B,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,,BAO_0000357,H,,7483,,
2922,,945.0,12688,10116.0,Autocuration,1,Stomach,F,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,BAO_0000019,D,,16404,Rattus norvegicus,
2923,,,227,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,BAO_0000357,H,,6347,,
2924,,,227,,Autocuration,1,,B,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,,BAO_0000357,H,,4373,,
2925,,,227,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,,BAO_0000357,H,,4373,,
2926,,,227,,Autocuration,1,,B,,Evaluated for the binding affinity to 5-HT 2B receptor,,,BAO_0000357,H,,4687,,
2927,,,227,,Autocuration,1,,B,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,,BAO_0000357,H,,16946,,
2928,,,227,,Autocuration,1,,B,,Binding affinities against 5-hydroxytryptamine 2B receptor,,,BAO_0000357,H,,16633,,
2929,,,227,,Autocuration,1,,B,,Binding affinities towards 5-hydroxytryptamine 2B receptor,,,BAO_0000357,H,,16633,,
2930,,,227,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,,BAO_0000357,H,,16633,,
2931,,,108,,Expert,1,,B,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,BAO_0000357,H,,15026,,
2932,,,108,9913.0,Autocuration,1,,B,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,,BAO_0000357,H,,15738,Bos taurus,
2933,,,108,9913.0,Autocuration,1,,B,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,,BAO_0000357,H,,15738,Bos taurus,
2934,,,108,9913.0,Autocuration,1,,B,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,,BAO_0000357,H,,15738,Bos taurus,
2935,,,108,9913.0,Autocuration,1,,B,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,,BAO_0000357,H,,15738,Bos taurus,
2936,,,108,9913.0,Expert,1,,B,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,,BAO_0000357,H,,16404,Bos taurus,
2937,,,108,9913.0,Expert,1,,B,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,BAO_0000357,H,,15026,Bos taurus,
2938,,,108,9913.0,Autocuration,1,,B,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,,BAO_0000357,H,,15738,Bos taurus,
2939,,,108,10141.0,Autocuration,1,,B,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,,BAO_0000019,H,,16312,Cavia porcellus,
2940,,2435.0,20033,10141.0,Intermediate,1,Striatum,B,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,,BAO_0000357,D,,5486,Cavia porcellus,
2941,,,51,,Autocuration,1,,B,,Binding affinity against 5-HT1A receptor,,,BAO_0000357,H,,5254,,
2942,,,108,,Expert,1,,F,449.0,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,,BAO_0000219,H,,3857,,CHO
2943,,,108,9606.0,Expert,1,,F,449.0,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,,BAO_0000219,D,,6857,Homo sapiens,CHO
2944,,,108,,Autocuration,1,,F,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,,BAO_0000219,H,,4176,,
2945,,,108,,Autocuration,1,,B,449.0,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,,BAO_0000219,H,,6347,,CHO
2946,,,108,,Autocuration,1,,B,449.0,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,,BAO_0000219,H,,6347,,CHO
2947,,,108,9606.0,Expert,1,,B,,Inhibition of human 5-hydroxytryptamine 2C receptor,,,BAO_0000357,D,,16146,Homo sapiens,
2948,,,108,,Autocuration,1,,B,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,,BAO_0000357,H,,3805,,
2949,,,108,,Autocuration,1,,B,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,BAO_0000019,H,,3857,,
2950,,,108,,Autocuration,1,,B,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,5635,,
2951,,,108,,Autocuration,1,,B,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,BAO_0000357,H,,5635,,
2952,,,108,,Autocuration,1,,B,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,BAO_0000357,H,,5635,,
2953,,,108,,Expert,1,,B,449.0,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,,BAO_0000219,H,,4012,,CHO
2954,,,108,,Expert,1,,B,449.0,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,,BAO_0000219,H,,6366,,CHO
2955,,,108,,Expert,1,,B,449.0,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,BAO_0000219,H,,15949,,CHO
2956,,,108,,Autocuration,1,,B,449.0,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,,BAO_0000219,H,,17211,,CHO
2957,,,108,9606.0,Expert,1,,B,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,,BAO_0000357,D,,6491,Homo sapiens,
2958,,,108,,Autocuration,1,,F,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,,BAO_0000019,H,,14093,,
2959,,,108,,Autocuration,1,,F,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,BAO_0000019,H,,13481,,
2960,,,108,10116.0,Expert,1,,B,449.0,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,,BAO_0000219,H,,6347,Rattus norvegicus,CHO
2961,,,108,,Autocuration,1,,F,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,,BAO_0000019,H,,14093,,
2962,,,108,,Autocuration,1,,F,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,,BAO_0000019,H,,14093,,
2963,,,108,,Autocuration,1,,F,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,BAO_0000019,H,,13481,,
2964,,,108,,Autocuration,1,,B,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,,BAO_0000357,H,,14442,,
2965,,,108,,Autocuration,1,,B,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,,BAO_0000357,H,,14442,,
2966,,,108,,Autocuration,1,,B,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,,BAO_0000357,H,,14442,,
2967,,,108,,Autocuration,1,,B,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,,BAO_0000357,H,,14755,,
2968,,,108,,Autocuration,1,,B,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,,BAO_0000357,H,,14744,,
2969,,,108,,Expert,1,,B,449.0,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,BAO_0000219,H,,16659,,CHO
2970,,,108,9606.0,Expert,1,,B,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,,BAO_0000019,D,,6857,Homo sapiens,
2971,,,108,,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,,BAO_0000357,H,,5635,,
2972,,,108,9606.0,Expert,1,,B,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,,BAO_0000357,D,,4234,Homo sapiens,
2973,,,108,,Autocuration,1,,B,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,,BAO_0000357,H,,16209,,
2974,,,104698,10116.0,Autocuration,1,,B,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,Membranes,,BAO_0000249,D,,5778,Rattus norvegicus,
2975,,,104698,,Autocuration,1,,B,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,,BAO_0000223,H,,5094,,
2976,,,104698,10116.0,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,,BAO_0000019,D,,809,Rattus norvegicus,
2977,,,104698,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,,BAO_0000019,H,,1578,,
2978,,,104698,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,,BAO_0000019,H,,809,,
2979,,,104698,,Autocuration,1,,B,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,,BAO_0000219,H,,12469,,
2980,,,104698,,Autocuration,1,,B,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,,BAO_0000019,H,,14290,,
2981,,,104698,,Autocuration,1,,B,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,,BAO_0000019,H,,14290,,
2982,,,104698,,Autocuration,1,,B,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,,BAO_0000223,H,,10609,,
2983,,,104698,,Autocuration,1,,B,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,,BAO_0000223,H,,10609,,
2984,,,104698,,Autocuration,1,,B,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,,BAO_0000223,H,,10609,,
2985,,,104698,,Autocuration,1,,B,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,BAO_0000249,H,,15253,,
2986,,,104698,,Autocuration,1,,B,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,BAO_0000249,H,,15253,,
2987,,,104698,,Autocuration,1,,B,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,Membranes,,BAO_0000249,H,,11683,,
2988,,,104698,,Autocuration,1,,B,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,,BAO_0000223,H,,12092,,
2989,,,104698,,Autocuration,1,,B,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,BAO_0000019,H,,1946,,
2990,,,104698,,Autocuration,1,,B,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,,BAO_0000223,H,,11623,,
2991,,,104698,,Autocuration,1,,B,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,,BAO_0000223,H,,11623,,
2992,,,104698,,Autocuration,1,,B,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,,BAO_0000019,H,,14788,,
2993,,,104698,10116.0,Autocuration,1,,B,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,,BAO_0000019,D,,5432,Rattus norvegicus,
2994,,,104698,,Autocuration,1,,B,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,BAO_0000249,H,,14826,,
2995,,,104698,,Autocuration,1,,B,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,BAO_0000223,H,,2222,,
2996,,,104698,,Autocuration,1,,B,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,,BAO_0000019,H,,11963,,
2997,,,104698,,Autocuration,1,,B,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,,BAO_0000019,H,,14145,,
2998,,,104698,,Autocuration,1,,B,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,,BAO_0000019,H,,17819,,
2999,,,104698,,Autocuration,1,,B,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,BAO_0000249,H,,10394,,
3000,,,104698,,Autocuration,1,,B,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,BAO_0000249,H,,10394,,
3001,,,104698,,Autocuration,1,,B,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,BAO_0000019,H,,15034,,
3002,,,104698,,Autocuration,1,,B,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,BAO_0000019,H,,691,,
3003,,,104698,,Autocuration,1,,B,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,Membranes,,BAO_0000249,H,,12092,,
3004,,,104698,10116.0,Autocuration,1,,B,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,BAO_0000223,D,,11752,Rattus norvegicus,
3005,,955.0,104698,,Autocuration,1,Brain,B,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,,BAO_0000221,H,,11752,,
3006,,,104698,,Autocuration,1,,B,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,,BAO_0000019,H,,301,,
3007,,,104698,,Autocuration,1,,B,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,,BAO_0000223,H,,16532,,
3008,,,104698,,Autocuration,1,,B,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,BAO_0000223,H,,16532,,
3009,,,104698,,Autocuration,1,,B,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,,BAO_0000223,H,,12092,,
3010,,,104698,,Autocuration,1,,B,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,,BAO_0000223,H,,11684,,
3011,,,104698,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,,BAO_0000223,H,,11684,,
3012,,,104698,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,,BAO_0000019,H,,12953,,
3013,,,104698,,Autocuration,1,,B,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,,BAO_0000019,H,,12953,,
3014,,,104698,,Autocuration,1,,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,,BAO_0000223,H,,12953,,
3015,,,104698,,Autocuration,1,,B,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,BAO_0000019,H,,12861,,
3016,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3017,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3018,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3019,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3020,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3021,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3022,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3023,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3024,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3025,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3026,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3027,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3028,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3029,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3030,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3031,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3032,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3033,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3034,,,104698,,Autocuration,1,,F,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,,BAO_0000019,H,,10609,,
3035,,,104698,,Autocuration,1,,B,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,,BAO_0000019,H,,12861,,
3036,,,104698,10116.0,Autocuration,1,,B,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,,BAO_0000019,D,,12861,Rattus norvegicus,
3037,,,104698,,Autocuration,1,,B,,Binding activity radioligand.,,,BAO_0000223,H,,12861,,
3038,,,104698,,Autocuration,1,,B,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,Brain membranes,,BAO_0000249,H,,10728,,
3039,,,104698,,Autocuration,1,,B,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,Brain membranes,,BAO_0000249,H,,10728,,
3040,,,108,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,,BAO_0000357,H,,5163,,
3041,,,108,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,,BAO_0000357,H,,5163,,
3042,,,108,,Autocuration,1,,B,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,,BAO_0000357,H,,6011,,
3043,,,108,,Autocuration,1,,B,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,5014,,
3044,,,108,,Autocuration,1,,B,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,5635,,
3045,,,108,,Expert,1,,B,,Affinity for 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,5163,,
3046,,,108,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,BAO_0000357,H,,6841,,
3047,,,108,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,,BAO_0000357,H,,6119,,
3048,,,108,,Autocuration,1,,B,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,,BAO_0000357,H,,4373,,
3049,,,108,,Autocuration,1,,B,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,,BAO_0000357,H,,1633,,
3050,,,108,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,,BAO_0000357,H,,1633,,
3051,,,108,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,,BAO_0000357,H,,4373,,
3052,,,108,,Expert,1,,B,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,6576,,
3053,,,108,,Autocuration,1,,B,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,4687,,
3054,,,108,,Autocuration,1,,B,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,,BAO_0000357,H,,12146,,
3055,,,108,,Autocuration,1,,B,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,,BAO_0000357,H,,12146,,
3056,,,108,,Autocuration,1,,B,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,16946,,
3057,,,108,,Autocuration,1,,B,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,14159,,
3058,,,108,,Autocuration,1,,B,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,,BAO_0000357,H,,16700,,
3059,,,108,,Autocuration,1,,B,,Affinity against 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,3269,,
3060,,,108,9606.0,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 2C receptor,,,BAO_0000357,D,,1274,Homo sapiens,
3061,,,108,,Autocuration,1,,B,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,,BAO_0000357,H,,1317,,
3062,,,144,9913.0,Autocuration,1,,B,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,,BAO_0000357,H,,5834,Bos taurus,
3063,,,144,9913.0,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,,BAO_0000357,H,,11147,Bos taurus,
3064,,,104714,10141.0,Expert,1,,F,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,,BAO_0000019,H,,14145,Cavia porcellus,
3065,,2116.0,104714,10141.0,Autocuration,1,Ileum,B,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,,BAO_0000221,H,,10561,Cavia porcellus,
3066,,,104714,10141.0,Autocuration,1,,F,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,,BAO_0000019,H,,15847,Cavia porcellus,
3067,,,104714,10141.0,Autocuration,1,,F,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,,BAO_0000019,H,,15847,Cavia porcellus,
3068,,2116.0,104714,10141.0,Autocuration,1,Ileum,B,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,,BAO_0000221,H,,10561,Cavia porcellus,
3069,,2116.0,104714,10141.0,Autocuration,1,Ileum,B,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,,BAO_0000221,H,,11454,Cavia porcellus,
3070,,,104714,10141.0,Autocuration,1,,F,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,,BAO_0000019,H,,4639,Cavia porcellus,
3071,,,104714,10141.0,Autocuration,1,,F,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,,BAO_0000019,H,,4639,Cavia porcellus,
3072,,,104714,10141.0,Autocuration,1,,F,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,,BAO_0000019,H,,4639,Cavia porcellus,
3073,,,104714,10141.0,Autocuration,1,,F,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,,BAO_0000019,H,,4639,Cavia porcellus,
3074,,,104714,10141.0,Autocuration,1,,F,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,,BAO_0000019,H,,4639,Cavia porcellus,
3075,,,104714,10141.0,Autocuration,1,,F,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,,BAO_0000019,H,,4639,Cavia porcellus,
3076,,2116.0,104714,10141.0,Autocuration,1,Ileum,F,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,,BAO_0000221,H,,15253,Cavia porcellus,
3077,,2116.0,104714,10141.0,Autocuration,1,Ileum,F,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,,BAO_0000221,H,,15253,Cavia porcellus,
3078,,2116.0,104714,10141.0,Autocuration,1,Ileum,F,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,,BAO_0000221,H,,11963,Cavia porcellus,
3079,,2116.0,104714,10141.0,Autocuration,1,Ileum,B,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,,BAO_0000221,H,,1946,Cavia porcellus,
3080,,2116.0,104714,10141.0,Autocuration,1,Ileum,B,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,,BAO_0000221,H,,1946,Cavia porcellus,
3081,,,104714,10141.0,Autocuration,1,,B,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,,BAO_0000223,H,,12045,Cavia porcellus,
3082,,2116.0,104714,10141.0,Autocuration,1,Ileum,B,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,BAO_0000221,H,,1559,Cavia porcellus,
3083,,2116.0,104714,10141.0,Autocuration,1,Ileum,F,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,BAO_0000221,H,,273,Cavia porcellus,
3084,,2116.0,104714,10141.0,Autocuration,1,Ileum,F,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,,BAO_0000221,H,,273,Cavia porcellus,
3085,,2116.0,104714,10141.0,Autocuration,1,Ileum,F,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,,BAO_0000221,H,,188,Cavia porcellus,
3086,,2116.0,104714,10141.0,Autocuration,1,Ileum,F,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,,BAO_0000221,H,,12919,Cavia porcellus,
3087,,2116.0,104714,10141.0,Autocuration,1,Ileum,F,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,,BAO_0000221,H,,12918,Cavia porcellus,
3088,,2116.0,104714,10141.0,Autocuration,1,Ileum,B,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,BAO_0000221,H,,1559,Cavia porcellus,
3089,,2116.0,104714,10141.0,Autocuration,1,Ileum,F,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,BAO_0000221,H,,273,Cavia porcellus,
3090,,2116.0,104714,10141.0,Autocuration,1,Ileum,B,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,BAO_0000221,H,,1559,Cavia porcellus,
3091,,2116.0,104714,10141.0,Autocuration,1,Ileum,B,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,,BAO_0000221,H,,1559,Cavia porcellus,
3092,,2116.0,104714,10141.0,Autocuration,1,Ileum,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,,BAO_0000221,H,,1559,Cavia porcellus,
3093,,2116.0,104714,10141.0,Autocuration,1,Ileum,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,,BAO_0000221,H,,14424,Cavia porcellus,
3094,,,22226,10141.0,Autocuration,1,,B,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,,BAO_0000019,U,,13181,Cavia porcellus,
3095,,,51,,Autocuration,1,,B,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,,BAO_0000357,H,,5486,,
3096,,,104714,9606.0,Expert,1,,B,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,,BAO_0000223,D,,6491,Homo sapiens,
3097,,,104714,,Autocuration,1,,B,,Binding affinity towards 5-HT3 receptor,,,BAO_0000223,H,,6013,,
3098,,,104714,,Autocuration,1,,B,,Binding activity radioligand.,,,BAO_0000223,H,,12861,,
3099,,,104714,,Autocuration,1,,B,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,,BAO_0000019,H,,12861,,
3100,,,104714,,Autocuration,1,,B,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,BAO_0000223,H,,5104,,
3101,,,104714,,Autocuration,1,,B,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,BAO_0000223,H,,5105,,
3102,,,104714,,Autocuration,1,,B,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,,BAO_0000223,H,,5104,,
3103,,,22226,,Autocuration,1,,B,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,,BAO_0000019,U,,3935,,
3104,,,105030,,Expert,1,,B,433.0,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,,BAO_0000219,H,,13657,,NG108-15
3105,In vivo,,105030,,Autocuration,1,,B,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,,BAO_0000218,H,,10369,,
3106,,,105030,,Autocuration,1,,B,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,BAO_0000019,H,,10369,,
3107,,,105030,,Autocuration,1,,B,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,,BAO_0000224,H,,12918,,
3108,,,105030,,Autocuration,1,,B,,Compound was evaluated for the binding affinity at 5- HT3 receptor,,,BAO_0000224,H,,12918,,
3109,,,105030,,Autocuration,1,,B,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,BAO_0000019,H,,10369,,
3110,,,105030,,Autocuration,1,,B,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,BAO_0000019,H,,773,,
3111,,,105030,,Autocuration,1,,F,,5-hydroxytryptamine 3 receptor agonism in mouse,,,BAO_0000218,H,,12918,,
3112,,,105030,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,,BAO_0000219,H,,10561,,
3113,,,105030,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,BAO_0000019,H,,12827,,
3114,,,105030,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,BAO_0000019,H,,12827,,
3115,,,105030,,Autocuration,1,,B,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,,BAO_0000224,H,,12918,,
3116,,,105030,,Autocuration,1,,B,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,BAO_0000219,H,,273,,
3117,,,105030,,Autocuration,1,,B,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,BAO_0000219,H,,273,,
3118,,,105030,,Autocuration,1,,B,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,BAO_0000224,H,,10561,,
3119,In vitro,,105030,,Autocuration,1,,B,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,,BAO_0000219,H,,5033,,
3120,,,105030,,Autocuration,1,,B,339.0,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,,BAO_0000219,H,,16429,,N1E-115
3121,,,11765,,Autocuration,1,,B,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,BAO_0000019,H,,10322,,
3122,,,11765,,Autocuration,1,,B,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,,BAO_0000219,H,,14331,,
3123,,,10630,10090.0,Autocuration,1,,B,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,,BAO_0000357,D,,13462,Mus musculus,
3124,,,17106,,Autocuration,1,,B,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,BAO_0000019,H,,12861,,
3125,,,144,9823.0,Autocuration,1,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,,BAO_0000357,H,,15086,Sus scrofa,
3126,,,144,9823.0,Autocuration,1,,B,,Binding activity radioligand.,,,BAO_0000357,H,,12861,Sus scrofa,
3127,,,104714,9986.0,Autocuration,1,,B,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,,BAO_0000223,H,,10561,Oryctolagus cuniculus,
3128,,,104714,9986.0,Autocuration,1,,B,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,BAO_0000223,H,,10561,Oryctolagus cuniculus,
3129,,,104714,9986.0,Autocuration,1,,B,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,,BAO_0000223,H,,10561,Oryctolagus cuniculus,
3130,,,104714,9986.0,Autocuration,1,,B,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,BAO_0000019,H,,10561,Oryctolagus cuniculus,
3131,,,104714,9986.0,Autocuration,1,,F,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,BAO_0000019,H,,273,Oryctolagus cuniculus,
3132,,,104714,9986.0,Autocuration,1,,F,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,BAO_0000019,H,,273,Oryctolagus cuniculus,
3133,,2116.0,104714,9986.0,Autocuration,1,Ileum,F,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,BAO_0000221,H,,273,Oryctolagus cuniculus,
3134,,,104714,9986.0,Autocuration,1,,F,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,BAO_0000019,H,,273,Oryctolagus cuniculus,
3135,,,104714,9986.0,Autocuration,1,,F,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,BAO_0000019,H,,273,Oryctolagus cuniculus,
3136,,,104714,9986.0,Autocuration,1,,F,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,BAO_0000019,H,,273,Oryctolagus cuniculus,
3137,,,104714,9986.0,Autocuration,1,,F,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,BAO_0000019,H,,273,Oryctolagus cuniculus,
3138,,,104714,9986.0,Autocuration,1,,B,449.0,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,,BAO_0000219,H,,13047,Oryctolagus cuniculus,CHO
3139,,,104698,10116.0,Autocuration,1,,B,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,,BAO_0000019,D,,1650,Rattus norvegicus,
3140,,,12020,,Autocuration,1,,B,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,,BAO_0000019,H,,16288,,
3141,,,12020,,Autocuration,1,,B,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,,BAO_0000357,H,,16288,,
3142,,,104698,10116.0,Autocuration,1,,B,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,,BAO_0000019,D,,10254,Rattus norvegicus,
3143,,,104698,,Autocuration,1,,B,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,,BAO_0000019,H,,14532,,
3144,In vivo,948.0,104698,,Autocuration,1,Heart,F,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,,BAO_0000218,H,,13392,,
3145,,948.0,104698,,Autocuration,1,Heart,F,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,BAO_0000019,H,,13392,,
3146,,948.0,104698,,Autocuration,1,Heart,F,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,,BAO_0000019,H,,13392,,
3147,,948.0,104698,,Autocuration,1,Heart,F,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,,BAO_0000019,H,,13392,,
3148,,948.0,104698,,Autocuration,1,Heart,F,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,BAO_0000019,H,,13392,,
3149,,,104698,,Autocuration,1,,F,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,,BAO_0000019,H,,13392,,
3150,,,104698,,Autocuration,1,,F,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,BAO_0000019,H,,13392,,
3151,,,104698,,Autocuration,1,,F,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,BAO_0000019,H,,13392,,
3152,,,104698,,Autocuration,1,,F,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,,BAO_0000019,H,,13392,,
3153,In vivo,,104698,10116.0,Autocuration,1,,F,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,,BAO_0000218,D,,1089,Rattus norvegicus,
3154,In vivo,,104698,,Autocuration,1,,F,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,,BAO_0000218,H,,1089,,
3155,In vivo,,104698,10116.0,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,D,,11454,Rattus norvegicus,
3156,,,104698,10116.0,Autocuration,1,,F,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,,BAO_0000019,D,,11454,Rattus norvegicus,
3157,In vivo,,104698,10116.0,Autocuration,1,,F,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,,BAO_0000218,D,,12205,Rattus norvegicus,
3158,,,104698,10116.0,Autocuration,1,,F,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,,BAO_0000019,D,,1089,Rattus norvegicus,
3159,,,104698,,Autocuration,1,,B,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,BAO_0000019,H,,5094,,
3160,,,104698,10116.0,Autocuration,1,,B,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,,BAO_0000019,D,,2622,Rattus norvegicus,
3161,,,104698,,Autocuration,1,,B,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,,BAO_0000223,H,,245,,
3162,,,104698,,Autocuration,1,,B,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,,BAO_0000019,H,,14788,,
3163,,,104698,,Autocuration,1,,B,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,,BAO_0000019,H,,14788,,
3164,,,104698,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,,BAO_0000249,H,,3020,,
3165,,,104698,,Autocuration,1,,B,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,,BAO_0000019,H,,1742,,
3166,,955.0,104698,,Autocuration,1,Brain,B,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,,BAO_0000249,H,,17394,,
3167,,955.0,104698,,Autocuration,1,Brain,B,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,,BAO_0000221,H,,17394,,
3168,,,104698,,Autocuration,1,,B,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,BAO_0000249,H,,17394,,
3169,,,104698,,Autocuration,1,,B,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,BAO_0000249,H,,14286,,
3170,,,104698,,Autocuration,1,,B,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,,BAO_0000019,H,,14178,,
3171,,,104698,10116.0,Autocuration,1,,B,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,,BAO_0000019,D,,14178,Rattus norvegicus,
3172,,,104698,10116.0,Autocuration,1,,B,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,,BAO_0000019,D,,14178,Rattus norvegicus,
3173,,,104698,10116.0,Autocuration,1,,B,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,,BAO_0000223,D,,14178,Rattus norvegicus,
3174,,,104698,,Autocuration,1,,B,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,BAO_0000019,H,,15034,,
3175,,,104698,,Autocuration,1,,B,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",Membranes,,BAO_0000249,H,,1089,,
3176,,,104698,10116.0,Autocuration,1,,B,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,,BAO_0000019,D,,1089,Rattus norvegicus,
3177,,,104698,,Autocuration,1,,B,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,BAO_0000223,H,,16532,,
3178,,,104698,10116.0,Autocuration,1,,B,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,,BAO_0000223,D,,12801,Rattus norvegicus,
3179,,,104698,,Autocuration,1,,B,433.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,,BAO_0000219,H,,15194,,NG108-15
3180,,,104698,,Autocuration,1,,B,433.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,,BAO_0000219,H,,15194,,NG108-15
3181,,,104698,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,,BAO_0000019,H,,15194,,
3182,,,104698,,Autocuration,1,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,,BAO_0000019,H,,15194,,
3183,,,104698,,Autocuration,1,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,,BAO_0000019,H,,15194,,
3184,,,104698,,Autocuration,1,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,,BAO_0000019,H,,15194,,
3185,,,104698,,Autocuration,1,,F,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,,BAO_0000019,H,,10610,,
3186,,,104698,10116.0,Autocuration,1,,F,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,,BAO_0000019,D,,10355,Rattus norvegicus,
3187,,,104698,,Autocuration,1,,F,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,,BAO_0000019,H,,691,,
3188,,,104698,,Autocuration,1,,F,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,,BAO_0000218,H,,10611,,
3189,In vivo,,104698,,Autocuration,1,,F,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,,BAO_0000218,H,,12801,,
3190,,,104698,,Autocuration,1,,F,,Inhibition of 5-HT evoked reflex bradycardia in rat.,,,BAO_0000218,H,,10609,,
3191,In vivo,,104698,,Autocuration,1,,F,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3192,In vivo,,104698,,Autocuration,1,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3193,In vivo,,104698,,Autocuration,1,,F,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,,BAO_0000218,H,,11454,,
3194,In vivo,,104698,10116.0,Autocuration,1,,F,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,D,,11454,Rattus norvegicus,
3195,In vivo,,104698,,Autocuration,1,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3196,In vivo,,104698,,Autocuration,1,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,,BAO_0000218,H,,11454,,
3197,In vivo,,104698,,Autocuration,1,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3198,In vivo,,104698,,Autocuration,1,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3199,In vivo,,104698,,Autocuration,1,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3200,In vivo,,104698,,Autocuration,1,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3201,In vivo,,104698,,Autocuration,1,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3202,In vivo,,104698,,Autocuration,1,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3203,In vivo,,104698,,Autocuration,1,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3204,In vivo,,104698,,Autocuration,1,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3205,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3206,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3207,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3208,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,,BAO_0000218,H,,11454,,
3209,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,,BAO_0000218,H,,11454,,
3210,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,,BAO_0000218,H,,11454,,
3211,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,,BAO_0000218,H,,11454,,
3212,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,,BAO_0000218,H,,11454,,
3213,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3214,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3215,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3216,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3217,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3218,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3219,In vivo,,104698,,Autocuration,1,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,,BAO_0000218,H,,11454,,
3220,,,104698,,Autocuration,1,,F,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,,BAO_0000218,H,,670,,
3221,,,104698,,Autocuration,1,,F,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,,BAO_0000218,H,,670,,
3222,In vivo,,104698,,Autocuration,1,,F,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,,BAO_0000218,H,,10321,,
3223,In vivo,,104698,,Autocuration,1,,F,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,,BAO_0000218,H,,10321,,
3224,In vivo,,104698,,Autocuration,1,,F,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,,BAO_0000218,H,,10321,,
3225,In vivo,,104698,,Autocuration,1,,F,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,,BAO_0000218,H,,10321,,
3226,In vivo,,104698,,Autocuration,1,,F,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,,BAO_0000218,H,,10321,,
3227,In vivo,,104698,,Autocuration,1,,F,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,,BAO_0000218,H,,10322,,
3228,,,104698,,Autocuration,1,,F,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,BAO_0000019,H,,15412,,
3229,,,104698,,Autocuration,1,,F,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,BAO_0000019,H,,15412,,
3230,,,104698,10116.0,Autocuration,1,,B,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,,BAO_0000223,D,,15412,Rattus norvegicus,
3231,,,104698,,Autocuration,1,,F,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,,BAO_0000019,H,,15412,,
3232,,10000000.0,104698,,Intermediate,1,Hippocampus,B,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,,BAO_0000221,D,,15412,,
3233,,,104698,10116.0,Autocuration,1,,B,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,,BAO_0000019,D,,15412,Rattus norvegicus,
3234,,,104698,10116.0,Autocuration,1,,B,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,,BAO_0000019,D,,17394,Rattus norvegicus,
3235,,,104698,,Autocuration,1,,B,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,,BAO_0000223,H,,12457,,
3236,,,104698,,Autocuration,1,,B,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,,BAO_0000019,H,,12457,,
3237,,,104698,,Autocuration,1,,B,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,,BAO_0000019,H,,12205,,
3238,,,104698,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,,BAO_0000019,H,,14532,,
3239,,,104698,,Autocuration,1,,B,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,,BAO_0000019,H,,1122,,
3240,,,104698,,Autocuration,1,,B,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,BAO_0000019,H,,5094,,
3241,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,,BAO_0000221,D,,809,Cavia porcellus,
3242,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,,BAO_0000221,D,,809,Cavia porcellus,
3243,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,,BAO_0000221,D,,14290,Cavia porcellus,
3244,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,,BAO_0000221,D,,14290,Cavia porcellus,
3245,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,,BAO_0000221,D,,14290,Cavia porcellus,
3246,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,,BAO_0000221,D,,14290,Cavia porcellus,
3247,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,,BAO_0000221,D,,14290,Cavia porcellus,
3248,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,,BAO_0000221,D,,13961,Cavia porcellus,
3249,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,,BAO_0000221,D,,13961,Cavia porcellus,
3250,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,,BAO_0000221,D,,809,Cavia porcellus,
3251,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,,BAO_0000221,D,,809,Cavia porcellus,
3252,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,,BAO_0000221,D,,809,Cavia porcellus,
3253,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,,BAO_0000221,D,,14290,Cavia porcellus,
3254,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,,BAO_0000221,D,,14290,Cavia porcellus,
3255,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,,BAO_0000221,D,,14290,Cavia porcellus,
3256,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,,BAO_0000221,D,,14290,Cavia porcellus,
3257,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,,BAO_0000221,D,,14290,Cavia porcellus,
3258,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,,BAO_0000221,D,,14290,Cavia porcellus,
3259,,,20033,10141.0,Intermediate,1,,B,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,,BAO_0000357,D,,15034,Cavia porcellus,
3260,,2435.0,20033,10141.0,Intermediate,1,Striatum,B,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,,BAO_0000249,D,,5094,Cavia porcellus,
3261,,2435.0,20033,10141.0,Intermediate,1,Striatum,B,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,,BAO_0000249,D,,5094,Cavia porcellus,
3262,,2435.0,20033,10141.0,Intermediate,1,Striatum,B,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,,BAO_0000357,D,,5399,Cavia porcellus,
3263,,2435.0,20033,10141.0,Intermediate,1,Striatum,B,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,,BAO_0000357,D,,17394,Cavia porcellus,
3264,,2435.0,20033,10141.0,Intermediate,1,Striatum,B,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,,BAO_0000357,D,,17394,Cavia porcellus,
3265,,2435.0,20033,10141.0,Intermediate,1,Striatum,B,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,,BAO_0000357,D,,17394,Cavia porcellus,
3266,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,,BAO_0000221,D,,13961,Cavia porcellus,
3267,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,,BAO_0000221,D,,13961,Cavia porcellus,
3268,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,,BAO_0000221,D,,13961,Cavia porcellus,
3269,,,20033,10141.0,Intermediate,1,,B,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,,BAO_0000357,D,,16946,Cavia porcellus,
3270,,,20033,10141.0,Intermediate,1,,B,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,,BAO_0000357,D,,16946,Cavia porcellus,
3271,,,20033,10141.0,Intermediate,1,,F,,Agonistic activity against 5-hydroxytryptamine 4 receptor,,,BAO_0000019,D,,15034,Cavia porcellus,
3272,,,20033,10141.0,Intermediate,1,,F,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,,BAO_0000019,D,,15034,Cavia porcellus,
3273,,,20033,10141.0,Intermediate,1,,F,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,,BAO_0000019,D,,12918,Cavia porcellus,
3274,,,20033,10141.0,Intermediate,1,,B,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,,BAO_0000357,D,,16946,Cavia porcellus,
3275,,2435.0,20033,10141.0,Intermediate,1,Striatum,B,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,,BAO_0000357,D,,17394,Cavia porcellus,
3276,,2435.0,20033,10141.0,Intermediate,1,Striatum,B,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,,BAO_0000357,D,,15034,Cavia porcellus,
3277,,2435.0,20033,10141.0,Intermediate,1,Striatum,B,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,,BAO_0000249,D,,5094,Cavia porcellus,
3278,,2435.0,20033,10141.0,Intermediate,1,Striatum,B,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,,BAO_0000249,D,,5094,Cavia porcellus,
3279,,2116.0,20033,10141.0,Intermediate,1,Ileum,B,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,,BAO_0000221,D,,17358,Cavia porcellus,
3280,,,20033,10141.0,Expert,1,,B,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,,BAO_0000357,D,,12953,Cavia porcellus,
3281,,,20033,10141.0,Intermediate,1,,B,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,,BAO_0000357,D,,12953,Cavia porcellus,
3282,,,20033,10141.0,Intermediate,1,,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,,BAO_0000357,D,,12953,Cavia porcellus,
3283,,,20033,10141.0,Intermediate,1,,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,,BAO_0000357,D,,12953,Cavia porcellus,
3284,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,,BAO_0000221,D,,273,Cavia porcellus,
3285,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,,BAO_0000221,D,,12918,Cavia porcellus,
3286,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,,BAO_0000221,D,,12919,Cavia porcellus,
3287,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,,BAO_0000221,D,,273,Cavia porcellus,
3288,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,,BAO_0000221,D,,273,Cavia porcellus,
3289,,,20033,10141.0,Intermediate,1,,B,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,,BAO_0000357,D,,13181,Cavia porcellus,
3290,,,168,10141.0,Autocuration,1,,B,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,,BAO_0000357,H,,13181,Cavia porcellus,
3291,,,20033,10141.0,Intermediate,1,,F,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,,BAO_0000019,D,,15034,Cavia porcellus,
3292,,,20033,10141.0,Intermediate,1,,B,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,,BAO_0000357,D,,5033,Cavia porcellus,
3293,,,20033,10141.0,Intermediate,1,,B,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,,BAO_0000019,D,,1980,Cavia porcellus,
3294,,,168,10141.0,Autocuration,1,,B,722.0,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,,BAO_0000219,H,,13181,Cavia porcellus,HEK293
3295,,,20033,10141.0,Intermediate,1,,B,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,,BAO_0000019,D,,14287,Cavia porcellus,
3296,,,20033,10141.0,Intermediate,1,,B,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,,BAO_0000357,D,,1317,Cavia porcellus,
3297,,,20033,10141.0,Intermediate,1,,B,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,,BAO_0000357,D,,15316,Cavia porcellus,
3298,,2435.0,20033,10141.0,Intermediate,1,Striatum,B,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,,BAO_0000357,D,,16429,Cavia porcellus,
3299,,10000000.0,20033,10141.0,Intermediate,1,Hippocampus,B,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,,BAO_0000221,D,,14818,Cavia porcellus,
3300,,,20033,10141.0,Intermediate,1,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,,BAO_0000357,D,,15194,Cavia porcellus,
3301,,,20033,10141.0,Intermediate,1,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,,BAO_0000357,D,,15194,Cavia porcellus,
3302,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,,BAO_0000221,D,,13961,Cavia porcellus,
3303,,,108,,Autocuration,1,,B,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,,BAO_0000357,H,,5486,,
3304,,,168,,Autocuration,1,,B,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,,BAO_0000357,H,,16209,,
3305,,,168,,Autocuration,1,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,,BAO_0000019,H,,17085,,
3306,,,168,,Autocuration,1,,B,308.0,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,,BAO_0000219,H,,4199,,HeLa
3307,,,168,,Autocuration,1,,B,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,,BAO_0000357,H,,15146,,
3308,,,168,,Autocuration,1,,B,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,,BAO_0000357,H,,5213,,
3309,,,168,,Autocuration,1,,B,308.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,,BAO_0000219,H,,4829,,HeLa
3310,,,10622,,Autocuration,1,,B,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,,BAO_0000357,H,,17358,,
3311,,,10622,,Autocuration,1,,B,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,,BAO_0000357,H,,17358,,
3312,,,10622,,Autocuration,1,,B,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,,BAO_0000219,H,,16946,,
3313,,,10622,,Autocuration,1,,B,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,,BAO_0000357,H,,17358,,
3314,,2081.0,11249,,Autocuration,1,Cardiac atrium,F,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,,BAO_0000019,H,,268,,
3315,,2081.0,11249,,Autocuration,1,Cardiac atrium,F,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,,BAO_0000019,H,,268,,
3316,,,11249,,Autocuration,1,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,,BAO_0000357,H,,15086,,
3317,,10000000.0,11249,,Autocuration,1,Hippocampus,B,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,,BAO_0000221,H,,14875,,
3318,,10000000.0,168,9823.0,Autocuration,1,Hippocampus,B,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,,BAO_0000221,H,,13267,Sus scrofa,
3319,,,168,9986.0,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,,BAO_0000019,H,,13047,Oryctolagus cuniculus,
3320,,,10623,10116.0,Expert,1,,B,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,,BAO_0000357,D,,1650,Rattus norvegicus,
3321,,,10623,,Autocuration,1,,F,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,BAO_0000019,H,,567,,
3322,,,10623,,Autocuration,1,,B,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,,BAO_0000357,H,,17358,,
3323,,,10623,,Autocuration,1,,B,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,,BAO_0000357,H,,188,,
3324,,,10623,,Autocuration,1,,F,,lntrinsic activity relative to 5-HT receptor,,,BAO_0000019,H,,670,,
3325,,,10623,,Autocuration,1,,F,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,,BAO_0000019,H,,204,,
3326,,,10623,,Expert,1,,F,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,,BAO_0000019,H,,1946,,
3327,,,10623,,Autocuration,1,,F,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,,BAO_0000019,H,,6398,,
3328,,,10623,,Autocuration,1,,F,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,,BAO_0000019,H,,6398,,
3329,,,10623,,Autocuration,1,,F,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,,BAO_0000019,H,,17358,,
3330,,,10623,,Autocuration,1,,F,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,,BAO_0000019,H,,6398,,
3331,,,10623,,Expert,1,,B,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,,BAO_0000357,H,,11752,,
3332,,,10623,,Autocuration,1,,F,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,,BAO_0000019,H,,809,,
3333,,,10623,10116.0,Expert,1,,B,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,,BAO_0000357,D,,14178,Rattus norvegicus,
3334,,,10623,,Autocuration,1,,B,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,BAO_0000357,H,,567,,
3335,,,10623,,Autocuration,1,,B,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,,BAO_0000357,H,,1946,,
3336,,,10623,,Autocuration,1,,B,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,,BAO_0000357,H,,1946,,
3337,,,10623,10116.0,Expert,1,,B,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,,BAO_0000019,D,,13961,Rattus norvegicus,
3338,,2435.0,10623,,Autocuration,1,Striatum,B,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,,BAO_0000249,H,,6238,,
3339,,,10623,,Autocuration,1,,B,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,,BAO_0000249,H,,14290,,
3340,,,10623,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,,BAO_0000249,H,,14290,,
3341,,2435.0,10623,10116.0,Expert,1,Striatum,B,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,,BAO_0000019,D,,809,Rattus norvegicus,
3342,,2435.0,10623,,Autocuration,1,Striatum,B,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,,BAO_0000019,H,,1578,,
3343,,2435.0,10623,,Expert,1,Striatum,B,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,,BAO_0000249,H,,16709,,
3344,,2435.0,10623,,Expert,1,Striatum,B,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,,BAO_0000019,H,,1946,,
3345,,2435.0,10623,,Expert,1,Striatum,B,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,,BAO_0000249,H,,15253,,
3346,,2435.0,10623,,Expert,1,Striatum,B,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,BAO_0000249,H,,4535,,
3347,,,10623,,Expert,1,,B,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,,BAO_0000249,H,,13961,,
3348,,955.0,10623,,Autocuration,1,Brain,F,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,,BAO_0000221,H,,17358,,
3349,,,10623,,Autocuration,1,,F,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,,BAO_0000019,H,,15847,,
3350,,,10623,,Autocuration,1,,F,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,,BAO_0000019,H,,15847,,
3351,,,10623,,Autocuration,1,,F,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,,BAO_0000019,H,,670,,
3352,,,10623,,Autocuration,1,,F,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,,BAO_0000019,H,,670,,
3353,,,10623,,Autocuration,1,,F,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,BAO_0000019,H,,1317,,
3354,,,10623,10116.0,Expert,1,,B,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,,BAO_0000357,D,,12936,Rattus norvegicus,
3355,,2435.0,10623,,Expert,1,Striatum,B,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,BAO_0000249,H,,4535,,
3356,,,10623,10116.0,Expert,1,,F,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,,BAO_0000019,D,,14424,Rattus norvegicus,
3357,,,10623,,Expert,1,,F,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,,BAO_0000019,H,,14424,,
3358,,,10623,,Expert,1,,F,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,BAO_0000019,H,,14424,,
3359,,,10623,10116.0,Expert,1,,F,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,,BAO_0000019,D,,14424,Rattus norvegicus,
3360,,,10623,,Autocuration,1,,F,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,,BAO_0000019,H,,14424,,
3361,,,10623,,Expert,1,,F,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,,BAO_0000019,H,,14424,,
3362,,,10623,,Expert,1,,F,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,,BAO_0000218,H,,14424,,
3363,,,10623,,Autocuration,1,,F,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,BAO_0000019,H,,14424,,
3364,,,168,10116.0,Autocuration,1,,F,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,,BAO_0000019,H,,1980,Rattus norvegicus,
3365,,,168,,Autocuration,1,,F,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,,BAO_0000019,H,,4639,,
3366,,,168,,Autocuration,1,,B,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,,BAO_0000357,H,,17358,,
3367,,,168,,Autocuration,1,,B,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,,BAO_0000357,H,,17358,,
3368,,,168,,Autocuration,1,,B,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,,BAO_0000357,H,,17358,,
3369,,,168,,Autocuration,1,,B,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,,BAO_0000357,H,,1558,,
3370,,,168,,Autocuration,1,,F,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,BAO_0000019,H,,17358,,
3371,,,168,,Autocuration,1,,B,,In vitro binding affinity towards 5-HT4 receptor was determined,,,BAO_0000357,H,,16117,,
3372,,,168,,Autocuration,1,,F,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,BAO_0000019,H,,17358,,
3373,,,168,,Autocuration,1,,F,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,,BAO_0000019,H,,17358,,
3374,,,168,,Autocuration,1,,B,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,,BAO_0000357,H,,17358,,
3375,,,168,,Autocuration,1,,B,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,,BAO_0000357,H,,17358,,
3376,,,168,,Autocuration,1,,B,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,,BAO_0000357,H,,17358,,
3377,,,168,,Autocuration,1,,B,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,,BAO_0000357,H,,17358,,
3378,,,168,,Expert,1,,B,,Binding affinity against 5-Hydroxytryptamine 4 receptor,,,BAO_0000357,H,,1274,,
3379,,,104698,,Autocuration,1,,B,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,Brain membranes,,BAO_0000249,H,,10728,,
3380,,,104698,,Autocuration,1,,B,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,Brain membranes,,BAO_0000249,H,,11695,,
3381,,,104698,,Autocuration,1,,B,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,Brain membranes,,BAO_0000249,H,,11695,,
3382,,,104698,,Autocuration,1,,B,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,,BAO_0000019,H,,12490,,
3383,,,104698,10116.0,Autocuration,1,,B,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,,BAO_0000019,D,,11828,Rattus norvegicus,
3384,,10000000.0,104698,,Autocuration,1,Hippocampus,B,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,,BAO_0000221,H,,12253,,
3385,,,104698,,Autocuration,1,,B,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,BAO_0000019,H,,10561,,
3386,,,104698,,Autocuration,1,,B,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,,BAO_0000019,H,,10561,,
3387,,,104698,,Autocuration,1,,F,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,,BAO_0000019,H,,14432,,
3388,,,104698,10116.0,Autocuration,1,,B,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,,BAO_0000223,D,,12936,Rattus norvegicus,
3389,,,104698,10116.0,Autocuration,1,,B,,Binding affinity against 5-Hydroxytryptamine 3 receptor,,,BAO_0000223,D,,1274,Rattus norvegicus,
3390,,,104698,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,,BAO_0000019,H,,1980,,
3391,,,104698,,Autocuration,1,,B,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,,BAO_0000249,H,,670,,
3392,,,104698,10116.0,Autocuration,1,,B,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,,BAO_0000019,D,,968,Rattus norvegicus,
3393,,,104698,,Autocuration,1,,B,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,,BAO_0000019,H,,14287,,
3394,,,104698,,Autocuration,1,,B,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,,BAO_0000019,H,,567,,
3395,,,104698,,Autocuration,1,,B,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,,BAO_0000019,H,,13267,,
3396,,,104698,,Autocuration,1,,B,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,,BAO_0000249,H,,14826,,
3397,,,104698,,Autocuration,1,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,,BAO_0000223,H,,15194,,
3398,,,104698,,Autocuration,1,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,,BAO_0000223,H,,15194,,
3399,,,104698,10116.0,Autocuration,1,,B,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,,BAO_0000223,D,,10394,Rattus norvegicus,
3400,,,10576,,Expert,1,,B,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,,BAO_0000249,D,,13657,,
3401,,955.0,12020,,Autocuration,1,Brain,F,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,,BAO_0000221,H,,1879,,
3402,,,12020,,Autocuration,1,,F,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,,BAO_0000019,H,,1879,,
3403,,,12020,,Autocuration,1,,F,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,,BAO_0000019,H,,1879,,
3404,In vivo,,12020,,Autocuration,1,,F,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,,BAO_0000218,H,,204,,
3405,,,12020,,Autocuration,1,,B,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,BAO_0000019,H,,1879,,
3406,,,12020,,Autocuration,1,,B,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,BAO_0000357,H,,1879,,
3407,,,12020,,Autocuration,1,,B,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,BAO_0000019,H,,1879,,
3408,,,12020,,Autocuration,1,,B,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,,BAO_0000019,H,,1879,,
3409,,,104698,,Autocuration,1,,B,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,,BAO_0000019,H,,10641,,
3410,,,12020,,Autocuration,1,,B,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,BAO_0000019,H,,773,,
3411,,,104698,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,,BAO_0000249,H,,11952,,
3412,,,12020,10116.0,Autocuration,1,,F,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,,BAO_0000019,D,,14145,Rattus norvegicus,
3413,,,144,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,BAO_0000357,H,,17066,,
3414,,,104714,,Autocuration,1,,B,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,,BAO_0000223,H,,6398,,
3415,,,22226,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,BAO_0000019,U,,10321,,
3416,,,104714,,Autocuration,1,,F,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,,BAO_0000019,H,,511,,
3417,,,104714,,Autocuration,1,,B,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,,BAO_0000223,H,,4639,,
3418,,,104714,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,BAO_0000223,H,,4639,,
3419,,,104714,10141.0,Autocuration,1,,F,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,,BAO_0000019,H,,4639,Cavia porcellus,
3420,,,104714,10141.0,Autocuration,1,,F,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,,BAO_0000019,H,,4639,Cavia porcellus,
3421,,,104714,10141.0,Autocuration,1,,F,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,,BAO_0000019,H,,4639,Cavia porcellus,
3422,,,104714,,Autocuration,1,,B,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,BAO_0000223,H,,1558,,
3423,,,104714,,Autocuration,1,,F,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,,BAO_0000019,H,,268,,
3424,,,104714,,Autocuration,1,,B,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,,BAO_0000223,H,,2474,,
3425,,,104714,,Autocuration,1,,F,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,,BAO_0000019,H,,5067,,
3426,,,104714,,Autocuration,1,,F,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,,BAO_0000019,H,,5067,,
3427,,,104714,,Autocuration,1,,F,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,,BAO_0000019,H,,5067,,
3428,,,104714,,Autocuration,1,,B,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,,BAO_0000223,H,,5067,,
3429,,,104714,,Autocuration,1,,F,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,,BAO_0000019,H,,5067,,
3430,,,104714,,Autocuration,1,,F,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,,BAO_0000019,H,,5067,,
3431,,,104714,,Autocuration,1,,F,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,,BAO_0000019,H,,5067,,
3432,,,104714,,Autocuration,1,,B,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,,BAO_0000223,H,,5067,,
3433,,,104714,,Autocuration,1,,B,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,,BAO_0000223,H,,5067,,
3434,,,104714,,Autocuration,1,,F,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,,BAO_0000019,H,,5067,,
3435,,,104714,,Autocuration,1,,B,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,,BAO_0000223,H,,5067,,
3436,,,104714,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,BAO_0000223,H,,5067,,
3437,,,104714,,Autocuration,1,,B,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,,BAO_0000219,H,,14331,,
3438,,,104714,,Autocuration,1,,B,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,,BAO_0000223,H,,5067,,
3439,,,104714,,Autocuration,1,,B,433.0,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,,BAO_0000219,H,,6179,,NG108-15
3440,,,104714,,Autocuration,1,,B,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,,BAO_0000019,H,,4265,,
3441,,,104714,,Autocuration,1,,B,433.0,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,,BAO_0000219,H,,4265,,NG108-15
3442,,,104714,,Autocuration,1,,B,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,BAO_0000223,H,,17358,,
3443,,,104714,,Autocuration,1,,B,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,,BAO_0000223,H,,17358,,
3444,In vitro,,104714,,Autocuration,1,,B,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,,BAO_0000219,H,,13628,,
3445,,,104714,,Autocuration,1,,B,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,BAO_0000223,H,,4612,,
3446,,,104714,,Autocuration,1,,F,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,,BAO_0000019,H,,17358,,
3447,,,104714,10141.0,Autocuration,1,,F,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,,BAO_0000019,H,,4639,Cavia porcellus,
3448,,,104714,10141.0,Autocuration,1,,F,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,,BAO_0000019,H,,4639,Cavia porcellus,
3449,,,104714,10141.0,Autocuration,1,,F,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,,BAO_0000019,H,,4639,Cavia porcellus,
3450,,,104714,10141.0,Autocuration,1,,F,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,,BAO_0000019,H,,4639,Cavia porcellus,
3451,,,104714,,Autocuration,1,,B,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,,BAO_0000223,H,,511,,
3452,,,104714,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,BAO_0000223,H,,1479,,
3453,,,104714,,Autocuration,1,,B,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,,BAO_0000223,H,,1317,,
3454,,,104714,,Autocuration,1,,B,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,,BAO_0000223,H,,12146,,
3455,,,104714,,Autocuration,1,,B,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,,BAO_0000223,H,,12146,,
3456,,,104714,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,,BAO_0000223,H,,13969,,
3457,,,108,,Expert,1,,B,,Binding affinity for 5-hydroxytryptamine 2C receptor,,,BAO_0000357,H,,13392,,
3458,,,104698,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,BAO_0000223,H,,13392,,
3459,,,144,,Autocuration,1,,B,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,,BAO_0000357,H,,14159,,
3460,,,144,,Autocuration,1,,B,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,BAO_0000357,H,,1558,,
3461,,,144,,Autocuration,1,,B,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,BAO_0000357,H,,16655,,
3462,,,104714,,Autocuration,1,,B,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,BAO_0000223,H,,13020,,
3463,,,104714,,Autocuration,1,,B,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,,BAO_0000223,H,,13021,,
3464,,,104714,,Autocuration,1,,B,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,BAO_0000223,H,,13020,,
3465,,,144,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,BAO_0000019,H,,10321,,
3466,,,144,,Autocuration,1,,B,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,BAO_0000357,H,,15818,,
3467,,,144,,Autocuration,1,,B,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,BAO_0000357,H,,15818,,
3468,,,144,,Autocuration,1,,B,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,BAO_0000357,H,,17358,,
3469,,,144,,Autocuration,1,,B,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,BAO_0000357,H,,2222,,
3470,,,144,,Autocuration,1,,B,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,BAO_0000019,H,,10322,,
3471,,,144,,Autocuration,1,,B,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,BAO_0000357,H,,16117,,
3472,,,144,,Autocuration,1,,B,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,,BAO_0000357,H,,17200,,
3473,,,144,,Autocuration,1,,F,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,,BAO_0000019,H,,17358,,
3474,,,144,,Autocuration,1,,B,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,,BAO_0000357,H,,16700,,
3475,,,144,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,,BAO_0000019,H,,1980,,
3476,,,144,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,,BAO_0000019,H,,1980,,
3477,,,104714,,Autocuration,1,,B,,Binding affinity against the 5-hydroxytryptamine 3 receptor,,,BAO_0000223,H,,12409,,
3478,,,144,,Autocuration,1,,B,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,BAO_0000357,H,,4365,,
3479,,,144,,Autocuration,1,,F,,Percent efficacy against 5-hydroxytryptamine 3A receptor,,,BAO_0000019,H,,4365,,
3480,,,144,,Autocuration,1,,B,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,BAO_0000357,H,,4365,,
3481,,,12020,10116.0,Expert,1,,F,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,,BAO_0000219,D,,6769,Rattus norvegicus,Oocytes
3482,,,12020,10116.0,Expert,1,,F,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,,BAO_0000219,D,,6769,Rattus norvegicus,Oocytes
3483,,,12020,10116.0,Expert,1,,F,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,,BAO_0000219,D,,6769,Rattus norvegicus,Oocytes
3484,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,,BAO_0000221,D,,809,Cavia porcellus,
3485,,2116.0,20033,10141.0,Intermediate,1,Ileum,F,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,,BAO_0000221,D,,809,Cavia porcellus,
3486,,,20033,10141.0,Intermediate,1,,F,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,,BAO_0000019,D,,14290,Cavia porcellus,
3487,,2116.0,20033,10141.0,Intermediate,1,Ileum,B,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,,BAO_0000221,D,,17358,Cavia porcellus,
3488,,,20033,10141.0,Intermediate,1,,B,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,,BAO_0000357,D,,17358,Cavia porcellus,
3489,,2116.0,20033,10141.0,Intermediate,1,Ileum,B,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,,BAO_0000221,D,,17358,Cavia porcellus,
3490,,2116.0,10209,,Autocuration,1,Ileum,B,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,BAO_0000221,H,,17386,,
3491,,,10209,,Autocuration,1,,B,,Affinity against 5-hydroxytryptamine 7 receptor,,,BAO_0000357,H,,3269,,
3492,,,104841,10141.0,Autocuration,1,,B,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,,BAO_0000224,H,,7721,Cavia porcellus,
3493,,,104841,10141.0,Autocuration,1,,B,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,,BAO_0000224,H,,7721,Cavia porcellus,
3494,,2116.0,104841,10141.0,Autocuration,1,Ileum,B,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,,BAO_0000221,H,,9117,Cavia porcellus,
3495,,,104841,10141.0,Autocuration,1,,B,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,,BAO_0000224,H,,7721,Cavia porcellus,
3496,,,104841,10141.0,Autocuration,1,,B,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,,BAO_0000224,H,,7721,Cavia porcellus,
3497,,,104841,10141.0,Autocuration,1,,F,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,,BAO_0000019,H,,15796,Cavia porcellus,
3498,,,104841,10141.0,Autocuration,1,,F,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,,BAO_0000019,H,,15796,Cavia porcellus,
3499,,2081.0,168,9606.0,Expert,1,Cardiac atrium,B,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,,BAO_0000219,D,,15650,Homo sapiens,
3500,,2081.0,168,9606.0,Expert,1,Cardiac atrium,B,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,,BAO_0000219,D,,15650,Homo sapiens,
3501,,,104841,9606.0,Autocuration,1,,F,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,,BAO_0000019,D,,6866,Homo sapiens,
3502,,2081.0,168,9606.0,Expert,1,Cardiac atrium,F,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,,BAO_0000219,D,,15650,Homo sapiens,
3503,,,22226,10090.0,Autocuration,1,,B,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,,BAO_0000019,U,,10063,Mus musculus,
3504,,,22226,10090.0,Autocuration,1,,B,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,,BAO_0000019,U,,12665,Mus musculus,
3505,,,104705,,Autocuration,1,,B,,5-hydroxytryptamine receptor binding affinity was determined in rats,,,BAO_0000019,H,,7504,,
3506,,,104705,,Autocuration,1,,B,,Binding affinity at rat 5-hydroxytryptamine receptor.,,,BAO_0000224,H,,7504,,
3507,,,104705,,Autocuration,1,,B,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,,BAO_0000019,H,,7038,,
3508,,,104705,,Autocuration,1,,B,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,,BAO_0000224,H,,7626,,
3509,,,104705,,Autocuration,1,,B,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,,BAO_0000224,H,,7626,,
3510,,945.0,104705,,Autocuration,1,Stomach,F,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,,BAO_0000019,H,,7185,,
3511,,945.0,104705,,Autocuration,1,Stomach,F,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,,BAO_0000019,H,,7185,,
3512,,,104705,,Autocuration,1,,F,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,BAO_0000019,H,,7185,,
3513,,,104705,,Autocuration,1,,B,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,,BAO_0000224,H,,6960,,
3514,,,104705,,Autocuration,1,,B,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,,BAO_0000224,H,,6960,,
3515,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,BAO_0000221,H,,12416,,
3516,,,12198,,Expert,1,,B,,Binding affinity for rat 5-hydroxytryptamine transporter.,,,BAO_0000357,H,,15753,,
3517,,,104705,,Autocuration,1,,B,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,,BAO_0000019,H,,8062,,
3518,,,104705,10116.0,Autocuration,1,,B,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,,BAO_0000019,D,,9036,Rattus norvegicus,
3519,,,104705,10116.0,Autocuration,1,,B,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,,BAO_0000224,D,,15067,Rattus norvegicus,
3520,,955.0,12198,10116.0,Expert,1,Brain,F,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,,BAO_0000019,D,,15753,Rattus norvegicus,
3521,,2037.0,12198,10116.0,Expert,1,Cerebellum,F,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,,BAO_0000221,D,,15753,Rattus norvegicus,
3522,,,104705,10116.0,Autocuration,1,,B,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,,BAO_0000019,D,,15295,Rattus norvegicus,
3523,,,104705,10116.0,Autocuration,1,,B,,Percent binding affinity against 5-hydroxytryptamine receptor,,,BAO_0000224,D,,6347,Rattus norvegicus,
3524,,,22226,,Autocuration,1,,B,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,,BAO_0000019,U,,6763,,
3525,,,104705,10116.0,Autocuration,1,,B,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,,BAO_0000224,D,,12092,Rattus norvegicus,
3526,,,104705,10116.0,Autocuration,1,,B,,Affinity against 5-hydroxytryptamine receptor was determined,,,BAO_0000224,D,,1579,Rattus norvegicus,
3527,,945.0,104705,10116.0,Autocuration,1,Stomach,B,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,,BAO_0000019,D,,1579,Rattus norvegicus,
3528,In vitro,,121,9606.0,Expert,1,,B,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,,BAO_0000219,D,,5963,Homo sapiens,
3529,In vitro,,121,9606.0,Expert,1,,B,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,,BAO_0000219,D,,5963,Homo sapiens,
3530,,,18065,,Autocuration,1,,B,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,,BAO_0000357,H,,5030,,
3531,,,121,,Expert,1,,B,,Inhibition of 5-hydroxytryptamine reuptake,,,BAO_0000357,H,,15796,,
3532,,,18065,,Autocuration,1,,F,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,,BAO_0000019,H,,15413,,
3533,,,18065,,Autocuration,1,,F,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,,BAO_0000019,H,,15413,,
3534,,,18065,,Autocuration,1,,F,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,,BAO_0000019,H,,15413,,
3535,,,18065,,Autocuration,1,,F,,Tested for 5-hydroxytryptamine receptor uptake,,,BAO_0000019,H,,12409,,
3536,,,51,9606.0,Expert,1,,B,449.0,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,,BAO_0000219,D,,16909,Homo sapiens,CHO
3537,,,51,9606.0,Expert,1,,F,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,,BAO_0000019,D,,16909,Homo sapiens,
3538,,,10576,9606.0,Autocuration,1,,B,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,,BAO_0000249,H,,15629,Homo sapiens,
3539,,,10576,,Autocuration,1,,B,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,,BAO_0000357,H,,15629,,
3540,,,10576,,Expert,1,,B,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,,BAO_0000249,H,,15629,,
3541,,2435.0,10825,,Autocuration,1,Striatum,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,,BAO_0000019,H,,10034,,
3542,,2435.0,10825,,Autocuration,1,Striatum,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,,BAO_0000019,H,,10034,,
3543,,2435.0,10825,,Autocuration,1,Striatum,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,,BAO_0000019,H,,10034,,
3544,,2435.0,10825,,Autocuration,1,Striatum,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,,BAO_0000019,H,,10034,,
3545,,2435.0,10825,,Autocuration,1,Striatum,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,,BAO_0000019,H,,10034,,
3546,,2435.0,10825,,Autocuration,1,Striatum,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,,BAO_0000019,H,,10034,,
3547,,2435.0,10825,,Autocuration,1,Striatum,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,,BAO_0000019,H,,10034,,
3548,,2435.0,10825,,Autocuration,1,Striatum,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,,BAO_0000019,H,,10034,,
3549,,2435.0,10825,,Autocuration,1,Striatum,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,,BAO_0000019,H,,10034,,
3550,,2435.0,10825,,Autocuration,1,Striatum,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,,BAO_0000019,H,,10034,,
3551,,2435.0,10825,,Autocuration,1,Striatum,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,,BAO_0000019,H,,10034,,
3552,,349.0,10825,,Autocuration,1,Limbic system,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,,BAO_0000019,H,,10034,,
3553,,349.0,10825,,Autocuration,1,Limbic system,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,BAO_0000019,H,,10034,,
3554,,349.0,10825,,Autocuration,1,Limbic system,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,,BAO_0000019,H,,10034,,
3555,,349.0,10825,,Autocuration,1,Limbic system,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,,BAO_0000019,H,,10034,,
3556,,349.0,10825,,Autocuration,1,Limbic system,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,,BAO_0000019,H,,10034,,
3557,,349.0,10825,,Autocuration,1,Limbic system,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,,BAO_0000019,H,,10034,,
3558,,349.0,10825,,Autocuration,1,Limbic system,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,,BAO_0000019,H,,10034,,
3559,,,168,,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 4 receptor,,,BAO_0000357,H,,1274,,
3560,,,168,,Autocuration,1,,F,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,BAO_0000019,H,,17358,,
3561,,,168,,Autocuration,1,,B,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,,BAO_0000357,H,,14532,,
3562,,,168,,Expert,1,,B,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,,BAO_0000357,H,,16989,,
3563,,,168,,Autocuration,1,,B,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,,BAO_0000357,H,,17200,,
3564,,,168,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 4 receptor,,,BAO_0000357,H,,15779,,
3565,,,168,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,BAO_0000357,H,,15779,,
3566,,,168,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,BAO_0000357,H,,15779,,
3567,,,168,,Autocuration,1,,B,643.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,,BAO_0000219,H,,15650,,COS-7
3568,,,168,,Autocuration,1,,B,643.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,,BAO_0000219,H,,15650,,COS-7
3569,,,168,,Autocuration,1,,B,643.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,,BAO_0000219,H,,15650,,COS-7
3570,,,168,,Autocuration,1,,B,643.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,,BAO_0000219,H,,15650,,COS-7
3571,,,168,,Autocuration,1,,B,673.0,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,,BAO_0000219,H,,17046,,C6
3572,,,168,,Expert,1,,B,673.0,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,,BAO_0000219,H,,17046,,C6
3573,,,168,,Expert,1,,B,673.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,,BAO_0000219,H,,15650,,C6
3574,,,168,,Expert,1,,B,673.0,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,,BAO_0000219,H,,17046,,C6
3575,,,10624,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 5 receptor,,,BAO_0000357,H,,17066,,
3576,,,105,,Autocuration,1,,B,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,,BAO_0000357,H,,17200,,
3577,,,10624,9606.0,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 5A receptor,,,BAO_0000357,D,,16146,Homo sapiens,
3578,,,10624,,Autocuration,1,,B,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,,BAO_0000219,H,,15250,,CHO
3579,,,10624,9606.0,Expert,1,,B,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,,BAO_0000357,D,,6491,Homo sapiens,
3580,,,10624,9606.0,Expert,1,,B,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,,BAO_0000357,D,,17066,Homo sapiens,
3581,,,10624,9606.0,Expert,1,,B,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,,BAO_0000357,D,,17066,Homo sapiens,
3582,,,10624,9606.0,Expert,1,,B,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,,BAO_0000357,D,,4234,Homo sapiens,
3583,,,10624,,Autocuration,1,,B,,Binding affinity towards 5-HT5A receptor,,,BAO_0000357,H,,6013,,
3584,,,10624,,Expert,1,,B,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,BAO_0000357,H,,17175,,
3585,,,10624,,Autocuration,1,,B,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,,BAO_0000357,H,,15818,,
3586,,,10624,,Autocuration,1,,B,,Binding affinity towards cloned human 5-HT5A receptor was determined,,,BAO_0000357,H,,6166,,
3587,,,10624,,Autocuration,1,,B,722.0,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,BAO_0000219,H,,15779,,HEK293
3588,,,10624,,Autocuration,1,,B,722.0,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,,BAO_0000219,H,,15779,,HEK293
3589,,,10624,,Autocuration,1,,B,722.0,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,,BAO_0000219,H,,5213,,HEK293
3590,,,10625,10090.0,Expert,1,,B,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,,BAO_0000357,D,,17066,Mus musculus,
3591,,,10625,10090.0,Expert,1,,B,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,,BAO_0000357,D,,17066,Mus musculus,
3592,,,10625,10090.0,Expert,1,,B,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,,BAO_0000357,D,,17066,Mus musculus,
3593,,,10625,10090.0,Expert,1,,B,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,,BAO_0000357,D,,17066,Mus musculus,
3594,,,10625,10090.0,Expert,1,,B,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,,BAO_0000357,D,,17066,Mus musculus,
3595,,,10625,,Expert,1,,B,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,BAO_0000357,H,,17175,,
3596,,,10576,,Autocuration,1,,B,722.0,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,,BAO_0000219,H,,16190,,HEK293
3597,,,10626,,Autocuration,1,,B,722.0,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,,BAO_0000219,H,,16190,,HEK293
3598,,,10624,,Expert,1,,B,,Binding affinity towards 5-HT5a receptor,,,BAO_0000357,H,,4820,,
3599,,,10624,9606.0,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 5A receptor,,,BAO_0000357,D,,17066,Homo sapiens,
3600,,,10624,,Expert,1,,B,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,,BAO_0000357,H,,17066,,
3601,,,10624,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,,BAO_0000357,H,,17175,,
3602,,,10624,,Autocuration,1,,B,,Binding affinities against 5-hydroxytryptamine 5A receptor,,,BAO_0000357,H,,16633,,
3603,,,10624,,Autocuration,1,,B,,Binding affinities towards 5-hydroxytryptamine 5A receptor,,,BAO_0000357,H,,16633,,
3604,,,10624,,Autocuration,1,,B,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,,BAO_0000357,H,,16700,,
3605,,,104714,10141.0,Autocuration,1,,F,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,,BAO_0000019,H,,4639,Cavia porcellus,
3606,,,104714,,Autocuration,1,,B,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,,BAO_0000223,H,,5486,,
3607,,,10627,9606.0,Expert,1,,B,,Inhibition of human 5-hydroxytryptamine 6 receptor,,,BAO_0000357,D,,16146,Homo sapiens,
3608,,,10627,9606.0,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,,BAO_0000357,D,,17273,Homo sapiens,
3609,,,10627,,Autocuration,1,,B,,Inhibition against human 5-hydroxytryptamine 6 receptor,,,BAO_0000357,H,,17687,,
3610,,,10627,9606.0,Expert,1,,B,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,,BAO_0000357,D,,6491,Homo sapiens,
3611,,,10627,,Expert,1,,B,308.0,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,,BAO_0000219,H,,16190,,HeLa
3612,,,10627,9606.0,Expert,1,,B,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,,BAO_0000357,D,,17066,Homo sapiens,
3613,,,10627,9606.0,Expert,1,,B,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,BAO_0000357,D,,17066,Homo sapiens,
3614,,,10627,9606.0,Expert,1,,B,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,,BAO_0000357,D,,17066,Homo sapiens,
3615,,,10627,9606.0,Expert,1,,B,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,,BAO_0000357,D,,17066,Homo sapiens,
3616,,,10627,9606.0,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 6 receptor,,,BAO_0000357,D,,3555,Homo sapiens,
3617,,,10627,,Expert,1,,B,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,BAO_0000357,H,,5808,,
3618,,,10627,,Autocuration,1,,B,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,BAO_0000357,H,,6013,,
3619,,,10627,,Expert,1,,B,722.0,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,,BAO_0000219,H,,15818,,HEK293
3620,,,10627,,Autocuration,1,,B,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,,BAO_0000357,H,,16209,,
3621,,,10627,,Expert,1,,B,722.0,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,,BAO_0000219,H,,3935,,HEK293
3622,,,10627,,Autocuration,1,,B,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,,BAO_0000357,H,,15818,,
3623,,,10627,9606.0,Expert,1,,B,722.0,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,,BAO_0000219,D,,3805,Homo sapiens,HEK293
3624,,,10627,,Expert,1,,B,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,,BAO_0000019,H,,16441,,
3625,,,10627,,Expert,1,,B,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,BAO_0000019,H,,16441,,
3626,,,10627,,Expert,1,,B,643.0,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,,BAO_0000219,H,,6786,,COS-7
3627,,,10627,9606.0,Expert,1,,B,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,,BAO_0000357,D,,4234,Homo sapiens,
3628,,,10627,,Autocuration,1,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,,BAO_0000019,H,,17085,,
3629,,,10627,,Autocuration,1,,B,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,,BAO_0000357,H,,17200,,
3630,,,10627,,Autocuration,1,,B,722.0,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,,BAO_0000219,H,,17451,,HEK293
3631,,,10627,,Autocuration,1,,F,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,,BAO_0000019,H,,3935,,
3632,,,10627,,Autocuration,1,,B,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,,BAO_0000357,H,,5033,,
3633,,,10627,,Expert,1,,B,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,BAO_0000357,H,,4540,,
3634,,,10627,9606.0,Expert,1,,B,308.0,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,,BAO_0000219,D,,4540,Homo sapiens,HeLa
3635,,,10627,9606.0,Expert,1,,B,308.0,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,,BAO_0000219,D,,4540,Homo sapiens,HeLa
3636,,,10627,,Autocuration,1,,B,308.0,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,,BAO_0000219,H,,17296,,HeLa
3637,,,10627,,Autocuration,1,,B,308.0,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,,BAO_0000219,H,,17296,,HeLa
3638,,,10627,,Autocuration,1,,B,308.0,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,,BAO_0000219,H,,17296,,HeLa
3639,,,10627,,Autocuration,1,,B,449.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,BAO_0000219,H,,15779,,CHO
3640,,,10627,,Autocuration,1,,B,722.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,BAO_0000219,H,,15779,,HEK293
3641,,,10627,,Autocuration,1,,B,722.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,,BAO_0000219,H,,15779,,HEK293
3642,,,10627,,Autocuration,1,,B,722.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,,BAO_0000219,H,,15779,,HEK293
3643,,,10627,,Autocuration,1,,B,308.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,,BAO_0000219,H,,15779,,HeLa
3644,,,10627,,Autocuration,1,,B,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,BAO_0000357,H,,6166,,
3645,,,10627,,Autocuration,1,,B,308.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,,BAO_0000219,H,,17451,,HeLa
3646,,,10627,,Autocuration,1,,B,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,,BAO_0000357,H,,15316,,
3647,,,10627,,Expert,1,,B,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,BAO_0000357,H,,4199,,
3648,,,10627,,Expert,1,,B,308.0,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,,BAO_0000219,H,,15146,,HeLa
3649,,,10627,,Autocuration,1,,B,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,,BAO_0000357,H,,5213,,
3650,,,10627,,Autocuration,1,,B,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,,BAO_0000219,H,,16429,,
3651,,,10627,,Autocuration,1,,B,308.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,,BAO_0000219,H,,14818,,HeLa
3652,,,10627,,Autocuration,1,,B,308.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,,BAO_0000219,H,,4829,,HeLa
3653,,,10627,,Autocuration,1,,B,308.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,,BAO_0000219,H,,4829,,HeLa
3654,,,10627,,Autocuration,1,,B,308.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,,BAO_0000219,H,,4829,,HeLa
3655,,,10628,,Autocuration,1,,B,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,,BAO_0000219,H,,15250,,CHO
3656,,,10628,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,,BAO_0000019,H,,14423,,
3657,,,10628,,Autocuration,1,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,,BAO_0000357,H,,15086,,
3658,,,10628,,Autocuration,1,,B,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,,BAO_0000357,H,,4342,,
3659,,,10627,9606.0,Autocuration,1,,B,308.0,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,,BAO_0000219,D,,16190,Homo sapiens,HeLa
3660,,,10627,,Expert,1,,B,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,BAO_0000357,H,,4820,,
3661,,,10627,,Autocuration,1,,B,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,,BAO_0000357,H,,4639,,
3662,,,10627,9606.0,Expert,1,,F,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,BAO_0000019,D,,17066,Homo sapiens,
3663,,,10627,,Autocuration,1,,B,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,,BAO_0000357,H,,6011,,
3664,,,10627,,Expert,1,,B,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,BAO_0000357,H,,17066,,
3665,,,10627,,Autocuration,1,,B,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,,BAO_0000357,H,,17515,,
3666,,,10627,,Autocuration,1,,B,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,,BAO_0000357,H,,5014,,
3667,,,10627,,Autocuration,1,,B,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,,BAO_0000357,H,,4373,,
3668,,,10627,,Expert,1,,F,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,,BAO_0000019,H,,17066,,
3669,,,10627,,Expert,1,,F,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,BAO_0000019,H,,17066,,
3670,,,10627,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,,BAO_0000357,H,,4373,,
3671,,,10627,,Autocuration,1,,B,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,,BAO_0000357,H,,4687,,
3672,,,10627,,Autocuration,1,,B,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,,BAO_0000357,H,,16946,,
3673,,,10627,,Autocuration,1,,B,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,,BAO_0000357,H,,16946,,
3674,,,10627,,Autocuration,1,,B,,Binding affinities against 5-hydroxytryptamine 6 receptor,,,BAO_0000357,H,,16633,,
3675,,,10627,,Autocuration,1,,B,,Binding affinities towards 5-hydroxytryptamine 6 receptor,,,BAO_0000357,H,,16633,,
3676,,,10627,9606.0,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 6 receptor,,,BAO_0000357,D,,17066,Homo sapiens,
3677,,,10627,,Autocuration,1,,B,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,,BAO_0000357,H,,16700,,
3678,,,10627,,Autocuration,1,,B,,Affinity against 5-hydroxytryptamine 6 receptor,,,BAO_0000357,H,,3269,,
3679,,,10627,,Autocuration,1,,B,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,,BAO_0000357,H,,5486,,
3680,,,10209,9606.0,Expert,1,,B,,Inhibition of human 5-hydroxytryptamine 7 receptor,,,BAO_0000357,D,,16146,Homo sapiens,
3681,,,10209,,Autocuration,1,,B,722.0,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,,BAO_0000219,H,,5014,,HEK293
3682,,,10209,,Autocuration,1,,B,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,,BAO_0000357,H,,15463,,
3683,,,10209,,Autocuration,1,,B,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,,BAO_0000357,H,,3805,,
3684,,,10209,,Expert,1,,B,722.0,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,,BAO_0000219,H,,5014,,HEK293
3685,,,10209,9606.0,Expert,1,,B,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,,BAO_0000357,D,,6491,Homo sapiens,
3686,,,10209,,Autocuration,1,,B,449.0,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,,BAO_0000219,H,,16190,,CHO
3687,,,10209,9606.0,Expert,1,,B,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,,BAO_0000357,D,,17066,Homo sapiens,
3688,,,10209,9606.0,Expert,1,,B,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,,BAO_0000357,D,,17066,Homo sapiens,
3689,,,10209,9606.0,Expert,1,,B,,Binding affinity against 5-hydroxytryptamine 7 receptor,,,BAO_0000357,D,,3555,Homo sapiens,
3690,,,10209,,Expert,1,,B,449.0,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,,BAO_0000219,H,,6588,,CHO
3691,,,10209,,Autocuration,1,,B,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,,BAO_0000357,H,,15463,,
3692,,,10209,,Autocuration,1,,B,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,BAO_0000357,H,,6013,,
3693,,,10209,,Autocuration,1,,B,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,BAO_0000357,H,,16209,,
3694,,,10209,,Autocuration,1,,B,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,,BAO_0000357,H,,3935,,
3695,,,10209,,Autocuration,1,,B,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,,BAO_0000357,H,,15818,,
3696,,,10209,,Expert,1,,B,722.0,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,,BAO_0000219,H,,5014,,HEK293
3697,,,10209,,Expert,1,,B,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,,BAO_0000019,H,,16441,,
3698,,,10209,,Expert,1,,B,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,BAO_0000019,H,,16441,,
3699,,,10209,9606.0,Expert,1,,B,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,,BAO_0000357,D,,4234,Homo sapiens,
3700,,,10209,,Autocuration,1,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,,BAO_0000019,H,,17085,,
3701,,,10209,,Autocuration,1,,B,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,,BAO_0000357,H,,17200,,
3702,,,10209,,Autocuration,1,,B,449.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,,BAO_0000219,H,,17451,,CHO
3703,,,10209,,Autocuration,1,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,,BAO_0000019,H,,17085,,
3704,,,10209,,Autocuration,1,,B,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,,BAO_0000357,H,,5104,,
3705,,,10209,,Autocuration,1,,B,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,,BAO_0000357,H,,5104,,
3706,,,10209,9606.0,Expert,1,,B,643.0,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,,BAO_0000219,D,,5033,Homo sapiens,COS-7
3707,,,10209,,Autocuration,1,,B,643.0,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,,BAO_0000219,H,,5486,,COS-7
3708,,,10209,9606.0,Expert,1,,B,722.0,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,,BAO_0000219,D,,4540,Homo sapiens,HEK293
3709,,,10209,,Expert,1,,B,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,,BAO_0000357,H,,6166,,
3710,,,10209,,Expert,1,,B,722.0,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,,BAO_0000219,H,,17342,,HEK293
3711,,,10209,,Expert,1,,B,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,,BAO_0000357,H,,17342,,
3712,,,10209,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 7 human receptors,,,BAO_0000357,H,,17296,,
3713,,,10209,,Expert,1,,B,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,,BAO_0000219,H,,16429,,
3714,,,10209,,Autocuration,1,,B,722.0,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,,BAO_0000219,H,,15779,,HEK293
3715,,,10209,,Autocuration,1,,B,722.0,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,BAO_0000219,H,,15779,,HEK293
3716,,,10209,,Autocuration,1,,B,722.0,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,BAO_0000219,H,,15779,,HEK293
3717,,,10209,,Autocuration,1,,B,722.0,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,BAO_0000219,H,,15779,,HEK293
3718,,,10209,,Autocuration,1,,B,722.0,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,,BAO_0000219,H,,15779,,HEK293
3719,,,10209,,Autocuration,1,,B,449.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,,BAO_0000219,H,,17451,,CHO
3720,,,10209,,Autocuration,1,,B,722.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,,BAO_0000219,H,,4199,,HEK293
3721,,,10209,,Expert,1,,B,722.0,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,,BAO_0000219,D,,4199,,HEK293
3722,,,10209,,Autocuration,1,,B,722.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,,BAO_0000219,H,,4199,,HEK293
3723,,,10209,,Intermediate,1,,B,722.0,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,,BAO_0000219,D,,3680,,HEK293
3724,,,10209,,Intermediate,1,,B,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,,BAO_0000357,D,,3680,,
3725,,,10209,,Autocuration,1,,B,643.0,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,,BAO_0000219,H,,15316,,COS-7
3726,,,10209,,Autocuration,1,,B,722.0,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,,BAO_0000219,H,,15146,,HEK293
3727,,,10209,,Expert,1,,B,722.0,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,,BAO_0000219,H,,5213,,HEK293
3728,,,10209,,Autocuration,1,,B,722.0,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,,BAO_0000219,H,,5213,,HEK293
3729,,,10209,9606.0,Expert,1,,B,722.0,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,,BAO_0000219,D,,14818,Homo sapiens,HEK293
3730,,,10209,,Autocuration,1,,B,722.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,,BAO_0000219,H,,14818,,HEK293
3731,,,10209,,Autocuration,1,,B,722.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,,BAO_0000219,H,,14818,,HEK293
3732,,,10209,,Autocuration,1,,B,722.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,,BAO_0000219,H,,4829,,HEK293
3733,,,10209,9606.0,Autocuration,1,,B,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,,BAO_0000357,D,,17200,Homo sapiens,
3734,,,10022,10090.0,Expert,1,,B,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,,BAO_0000357,D,,17066,Mus musculus,
3735,,,10209,9986.0,Autocuration,1,,B,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,,BAO_0000019,H,,14025,Oryctolagus cuniculus,
3736,,,11923,,Autocuration,1,,B,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,,BAO_0000219,H,,15250,,CHO
3737,,,11923,,Autocuration,1,,B,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,,BAO_0000219,H,,16372,,CHO
3738,,,11923,,Autocuration,1,,B,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,,BAO_0000219,H,,16372,,CHO
3739,,,11923,,Autocuration,1,,B,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,,BAO_0000219,H,,16372,,CHO
3740,,,11923,,Autocuration,1,,B,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,,BAO_0000219,H,,16372,,CHO
3741,,,11923,,Autocuration,1,,B,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,,BAO_0000219,H,,16372,,CHO
3742,,,11923,,Autocuration,1,,B,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,,BAO_0000219,H,,16372,,CHO
3743,,,11923,,Autocuration,1,,B,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,,BAO_0000219,H,,16372,,CHO
3744,,,11923,,Autocuration,1,,B,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,,BAO_0000219,H,,16372,,CHO
3745,,,11923,,Autocuration,1,,B,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,,BAO_0000219,H,,16372,,CHO
3746,,,11923,,Autocuration,1,,B,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,,BAO_0000219,H,,16372,,CHO
3747,,,11923,,Autocuration,1,,B,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,,BAO_0000219,H,,16372,,CHO
3748,,,11923,,Autocuration,1,,B,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,,BAO_0000219,H,,16372,,CHO
3749,,,11923,,Expert,1,,B,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,,BAO_0000357,H,,17066,,
3750,,,11923,10116.0,Expert,1,,B,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,,BAO_0000357,D,,17066,Rattus norvegicus,
3751,,,11923,,Expert,1,,B,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,,BAO_0000357,H,,17386,,
3752,,,11923,,Autocuration,1,,B,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,,BAO_0000019,H,,14423,,
3753,,,11923,10116.0,Expert,1,,B,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,,BAO_0000357,D,,15874,Rattus norvegicus,
3754,,,11923,10116.0,Expert,1,,B,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,,BAO_0000357,D,,15874,Rattus norvegicus,
3755,,,11923,10116.0,Expert,1,,B,449.0,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,,BAO_0000219,D,,16372,Rattus norvegicus,CHO
3756,,,11923,,Autocuration,1,,B,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,BAO_0000357,H,,4622,,
3757,,,11923,,Autocuration,1,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,,BAO_0000357,H,,15086,,
3758,,,11923,,Autocuration,1,,B,449.0,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,,BAO_0000219,H,,16372,,CHO
3759,,,11923,,Autocuration,1,,B,449.0,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,,BAO_0000219,H,,16372,,CHO
3760,,,11923,,Autocuration,1,,B,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,,BAO_0000219,H,,16372,,CHO
3761,,,11923,,Autocuration,1,,B,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,,BAO_0000219,H,,16372,,CHO
3762,,2116.0,11923,,Autocuration,1,Ileum,F,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,,BAO_0000221,H,,17386,,
3763,,2116.0,11923,,Autocuration,1,Ileum,F,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,BAO_0000221,H,,17386,,
3764,,2116.0,11923,,Autocuration,1,Ileum,F,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,,BAO_0000221,H,,17386,,
3765,,,11923,10116.0,Expert,1,,B,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,Membranes,,BAO_0000249,D,,5831,Rattus norvegicus,
3766,,,11923,,Autocuration,1,,B,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,,BAO_0000357,H,,4342,,
3767,,,11923,,Expert,1,,B,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,,BAO_0000357,H,,17319,,
3768,,1898.0,11923,,Expert,1,Hypothalamus,B,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,,BAO_0000019,H,,17342,,
3769,,,11923,,Autocuration,1,,B,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,,BAO_0000357,H,,17342,,
3770,,1898.0,11923,,Expert,1,Hypothalamus,B,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,,BAO_0000249,H,,3680,,
3771,,,11923,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,BAO_0000357,H,,3680,,
3772,,,11923,10116.0,Expert,1,,F,722.0,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,,BAO_0000219,D,,17319,Rattus norvegicus,HEK293
3773,,,11923,10116.0,Expert,1,,F,722.0,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,,BAO_0000219,D,,17319,Rattus norvegicus,HEK293
3774,,,11923,10116.0,Autocuration,1,,F,722.0,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,,BAO_0000219,D,,17319,Rattus norvegicus,HEK293
3775,,,10209,,Expert,1,,B,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,BAO_0000357,H,,4820,,
3776,,,10209,,Autocuration,1,,B,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,,BAO_0000357,H,,4639,,
3777,,,10209,,Autocuration,1,,B,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,,BAO_0000357,H,,6011,,
3778,,,10209,9606.0,Expert,1,,B,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,,BAO_0000357,D,,17066,Homo sapiens,
3779,,,10209,,Expert,1,,B,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,,BAO_0000357,H,,17066,,
3780,,,10209,,Autocuration,1,,B,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,,BAO_0000357,H,,17515,,
3781,,,10209,,Autocuration,1,,B,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,BAO_0000357,H,,4373,,
3782,,,10209,,Expert,1,,F,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,,BAO_0000019,H,,17066,,
3783,,,10209,,Autocuration,1,,B,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,,BAO_0000357,H,,4373,,
3784,,,10209,,Autocuration,1,,B,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,BAO_0000357,H,,4373,,
3785,,,10209,,Autocuration,1,,B,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,,BAO_0000357,H,,4687,,
3786,,,10209,,Expert,1,,B,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,,BAO_0000357,H,,17342,,
3787,,,10209,,Autocuration,1,,B,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,,BAO_0000357,H,,16946,,
3788,,,10209,,Autocuration,1,,B,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,,BAO_0000357,H,,16946,,
3789,,,10209,,Autocuration,1,,B,,Binding affinities against 5-hydroxytryptamine 7 receptor,,,BAO_0000357,H,,16633,,
3790,,,10209,,Autocuration,1,,B,,Binding affinities towards 5-hydroxytryptamine 7 receptor,,,BAO_0000357,H,,16633,,
3791,,,10209,,Expert,1,,B,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,,BAO_0000357,H,,17066,,
3792,,,10209,,Autocuration,1,,B,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,,BAO_0000357,H,,16700,,
3793,,2116.0,10209,,Autocuration,1,Ileum,B,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,,BAO_0000221,H,,17386,,
3794,,,55,,Autocuration,1,,F,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,,BAO_0000019,H,,14080,,
3795,,,55,9606.0,Expert,1,,F,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,,BAO_0000019,D,,14080,Homo sapiens,
3796,,,55,,Autocuration,1,,B,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,,BAO_0000357,H,,409,,
3797,,,55,,Autocuration,1,,B,,In vitro inhibition of human recombinant lipoxygenase enzyme,,,BAO_0000357,H,,409,,
3798,,,55,,Autocuration,1,,B,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,,BAO_0000357,H,,409,,
3799,,178.0,55,,Expert,1,Blood,B,,Inhibition of 5-lipoxygenase in human whole blood.,,,BAO_0000357,H,,11090,,
3800,,178.0,55,,Expert,1,Blood,B,,Inhibition of 5-lipoxygenase in human whole blood.,,,BAO_0000357,H,,11090,,
3801,,,55,,Autocuration,1,,B,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,,BAO_0000357,H,,948,,
3802,,,55,,Autocuration,1,,B,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,,BAO_0000357,H,,948,,
3803,,,55,,Expert,1,,F,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,,BAO_0000219,H,,13622,,
3804,,178.0,55,,Autocuration,1,Blood,F,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,,BAO_0000019,H,,13622,,
3805,,,55,,Autocuration,1,,B,,In vitro inhibition of 5-lipoxygenase from human polymorphs,,,BAO_0000357,H,,9637,,
3806,,,55,,Autocuration,1,,B,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,,BAO_0000357,H,,11320,,
3807,,,55,,Expert,1,,B,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,,BAO_0000357,H,,11320,,
3808,,,55,,Autocuration,1,,B,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,,BAO_0000357,H,,6838,,
3809,,178.0,55,9606.0,Expert,1,Blood,B,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,,BAO_0000357,D,,17667,Homo sapiens,
3810,,,55,,Autocuration,1,,B,,In vitro potency against human 5-Lipoxygenase,,,BAO_0000357,H,,12703,,
3811,,,55,9606.0,Expert,1,,F,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,,BAO_0000019,D,,14312,Homo sapiens,
3812,,178.0,55,,Autocuration,1,Blood,F,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,,BAO_0000019,H,,14312,,
3813,,,55,,Autocuration,1,,F,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,BAO_0000019,H,,5364,,
3814,,,55,,Autocuration,1,,B,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,,BAO_0000219,H,,951,,
3815,,,55,,Autocuration,1,,B,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,,BAO_0000219,H,,951,,
3816,,,55,,Autocuration,1,,B,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,,BAO_0000219,H,,951,,
3817,,,55,,Autocuration,1,,B,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,,BAO_0000219,H,,951,,
3818,,,55,,Autocuration,1,,B,,Inhibition of human 5-lipoxygenase in human cells,,,BAO_0000219,H,,12365,,
3819,,,55,,Expert,1,,B,,Inhibition of human neutrophil 5-lipoxygenase,,,BAO_0000357,H,,10603,,
3820,,,55,,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,,BAO_0000019,H,,10501,,
3821,,178.0,55,,Expert,1,Blood,B,,Inhibition of 5-lipoxygenase from human whole blood,,,BAO_0000357,H,,12281,,
3822,,,55,,Autocuration,1,,B,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,BAO_0000357,H,,2567,,
3823,,,55,,Autocuration,1,,B,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,,BAO_0000219,H,,2567,,
3824,,,55,,Expert,1,,B,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,,BAO_0000357,H,,10193,,
3825,,,55,,Autocuration,1,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,BAO_0000357,H,,10193,,
3826,,,55,,Expert,1,,B,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,,BAO_0000357,H,,13623,,
3827,,,55,,Autocuration,1,,B,,Tested against 5-lipoxygenase,,,BAO_0000357,H,,12780,,
3828,,,55,,Autocuration,1,,B,,Tested for activity against 5-Lipoxygenase (5-LO),,,BAO_0000357,H,,12780,,
3829,,,55,,Autocuration,1,,B,,Tested for activity against 5-lipoxygenase,,,BAO_0000357,H,,12780,,
3830,,,55,,Autocuration,1,,B,,Tested for inhibition of 5-HPETE production by human 5-LO,,,BAO_0000357,H,,11966,,
3831,,,55,,Autocuration,1,,F,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,BAO_0000019,H,,5364,,
3832,,,55,,Expert,1,,B,,Inhibition of Human 5-lipoxygenase,,,BAO_0000357,H,,13165,,
3833,,,55,,Autocuration,1,,B,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,,BAO_0000019,H,,5364,,
3834,,,55,,Autocuration,1,,B,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,BAO_0000219,H,,11311,,
3835,,,55,,Autocuration,1,,B,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,,BAO_0000219,H,,11311,,
3836,,,55,,Autocuration,1,,B,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,,BAO_0000019,H,,14863,,
3837,,,55,,Autocuration,1,,B,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,,BAO_0000019,H,,14863,,
3838,,178.0,55,,Autocuration,1,Blood,B,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,,BAO_0000357,H,,11087,,
3839,,,55,,Autocuration,1,,B,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,,BAO_0000357,H,,455,,
3840,,,55,,Autocuration,1,,B,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,BAO_0000357,H,,13183,,
3841,,,55,,Expert,1,,B,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,,BAO_0000019,H,,10319,,
3842,,,55,,Autocuration,1,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,BAO_0000357,H,,10193,,
3843,,,55,,Autocuration,1,,B,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,,BAO_0000219,H,,951,,
3844,,,55,,Autocuration,1,,B,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,,BAO_0000219,H,,951,,
3845,,,55,,Autocuration,1,,B,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,,BAO_0000219,H,,951,,
3846,,,55,,Autocuration,1,,B,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,,BAO_0000219,H,,951,,
3847,,,55,,Expert,1,,B,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,,BAO_0000357,H,,9859,,
3848,,,55,,Expert,1,,B,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,,BAO_0000357,H,,9859,,
3849,,,55,,Autocuration,1,,B,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,,BAO_0000357,H,,9859,,
3850,,,55,,Autocuration,1,,B,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,BAO_0000357,H,,2567,,
3851,,,55,,Autocuration,1,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,,BAO_0000357,H,,10193,,
3852,,,55,,Autocuration,1,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,BAO_0000357,H,,10193,,
3853,,,55,,Autocuration,1,,B,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,,BAO_0000019,H,,949,,
3854,,,55,,Autocuration,1,,B,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,,BAO_0000019,H,,949,,
3855,,,55,,Expert,1,,B,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,,BAO_0000357,H,,10603,,
3856,,,55,,Expert,1,,B,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,BAO_0000357,H,,10603,,
3857,,,55,,Autocuration,1,,F,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,BAO_0000019,H,,10603,,
3858,,,55,,Expert,1,,B,,Inhibition of lipoxygenase at the concentration of 0.1 uM,,,BAO_0000357,H,,10603,,
3859,,,55,,Expert,1,,B,,Inhibition of lipoxygenase at the concentration of 1 uM,,,BAO_0000357,H,,10603,,
3860,,,55,,Autocuration,1,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,,BAO_0000357,H,,10193,,
3861,,,55,9606.0,Expert,1,,B,,Inhibition of 5-Lipoxygenase (5-LOX),,,BAO_0000357,D,,14580,Homo sapiens,
3862,,,17087,,Expert,1,,B,,Inhibition of 5-lipoxygenase in mouse macrophages.,,,BAO_0000357,H,,11090,,
3863,,,17087,,Expert,1,,B,,Inhibition of 5-lipoxygenase in mouse macrophages.,,,BAO_0000357,H,,11090,,
3864,,,17087,,Autocuration,1,,B,,Inhibitory activity against lipoxygenase-2 in mice,,,BAO_0000357,H,,6339,,
3865,,,17087,,Expert,1,,B,,Inhibitory activity against murine lipoxygenase-2.,,,BAO_0000357,H,,6339,,
3866,,,17087,10090.0,Expert,1,,B,,Inhibition of 5-lipoxygenase from mouse macrophage,,,BAO_0000357,D,,12281,Mus musculus,
3867,,,17087,,Autocuration,1,,B,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,,BAO_0000357,H,,11311,,
3868,,,55,9823.0,Autocuration,1,,B,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,,BAO_0000019,H,,11089,Sus scrofa,
3869,,,55,9823.0,Autocuration,1,,B,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,,BAO_0000019,H,,10091,Sus scrofa,
3870,,,55,9986.0,Autocuration,1,,B,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,,BAO_0000019,H,,14352,Oryctolagus cuniculus,
3871,,,12166,10116.0,Expert,1,,B,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,,BAO_0000019,D,,13329,Rattus norvegicus,
3872,,,12166,,Autocuration,1,,B,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,,BAO_0000019,H,,13329,,
3873,,,12166,,Autocuration,1,,B,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,BAO_0000019,H,,13329,,
3874,,,12166,,Autocuration,1,,B,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,,BAO_0000019,H,,13329,,
3875,,,12166,,Expert,1,,B,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,,BAO_0000019,H,,13329,,
3876,,,12166,,Expert,1,,B,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,,BAO_0000019,H,,13329,,
3877,,,12166,,Autocuration,1,,B,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,,BAO_0000019,H,,13329,,
3878,,,12166,,Autocuration,1,,B,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,,BAO_0000019,H,,11311,,
3879,,,12166,,Autocuration,1,,B,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,,BAO_0000019,H,,11311,,
3880,,,12166,,Autocuration,1,,B,702.0,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,,BAO_0000219,H,,105,,RBL-1
3881,,,12166,,Autocuration,1,,B,702.0,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,,BAO_0000219,H,,105,,RBL-1
3882,,,12166,,Autocuration,1,,B,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,,BAO_0000357,H,,9138,,
3883,,,12166,,Autocuration,1,,B,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,,BAO_0000357,H,,9138,,
3884,,,12166,,Autocuration,1,,B,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,,BAO_0000357,H,,9138,,
3885,,,12166,,Autocuration,1,,B,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,BAO_0000357,H,,14427,,
3886,,,12166,,Autocuration,1,,B,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,BAO_0000019,H,,13329,,
3887,,,12166,,Autocuration,1,,B,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,,BAO_0000019,H,,13329,,
3888,,,12166,10116.0,Expert,1,,B,663.0,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,,BAO_0000219,D,,14427,Rattus norvegicus,RBL-2H3
3889,,,12166,,Autocuration,1,,B,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,BAO_0000357,H,,14427,,
3890,,,12166,,Autocuration,1,,B,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,,BAO_0000357,H,,14427,,
3891,,,12166,,Expert,1,,B,702.0,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,,BAO_0000219,H,,10293,,RBL-1
3892,,,12166,10116.0,Expert,1,,B,702.0,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,,BAO_0000219,D,,338,Rattus norvegicus,RBL-1
3893,,,12166,,Autocuration,1,,B,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,,BAO_0000357,H,,303,,
3894,,,12166,,Autocuration,1,,B,702.0,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,,BAO_0000219,H,,303,,RBL-1
3895,,,12166,,Expert,1,,B,702.0,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,,BAO_0000219,H,,9247,,RBL-1
3896,,,12166,,Autocuration,1,,B,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,,BAO_0000219,H,,9247,,RBL-1
3897,,,12166,,Autocuration,1,,B,702.0,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,,BAO_0000219,H,,137,,RBL-1
3898,,,12166,,Expert,1,,B,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,,BAO_0000357,H,,11481,,
3899,,,12166,,Expert,1,,B,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,,BAO_0000357,H,,11481,,
3900,,,12166,,Expert,1,,B,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,,BAO_0000357,H,,9029,,
3901,,,12166,,Autocuration,1,,B,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,,BAO_0000019,H,,1701,,
3902,,,12166,,Autocuration,1,,B,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,,BAO_0000019,H,,1701,,
3903,,,12166,,Autocuration,1,,B,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,,BAO_0000019,H,,1701,,
3904,,,12166,,Autocuration,1,,B,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,,BAO_0000019,H,,1701,,
3905,,,12166,,Expert,1,,F,702.0,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,,BAO_0000219,H,,13358,,RBL-1
3906,,,12166,,Expert,1,,B,702.0,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,,BAO_0000219,H,,1175,,RBL-1
3907,,,12166,,Expert,1,,B,702.0,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,,BAO_0000219,H,,8797,,RBL-1
3908,,,12166,,Autocuration,1,,B,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,,BAO_0000019,H,,8797,,
3909,,,12166,10116.0,Expert,1,,B,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,,BAO_0000357,D,,577,Rattus norvegicus,
3910,,,12166,,Expert,1,,B,702.0,In vitro inhibitory activity against RBL-1 5-LO,,,BAO_0000219,H,,9295,,RBL-1
3911,,,12166,,Autocuration,1,,B,702.0,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,,BAO_0000219,H,,9295,,RBL-1
3912,,,12166,,Autocuration,1,,B,702.0,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,,BAO_0000219,H,,9295,,RBL-1
3913,,,12166,,Autocuration,1,,B,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,,BAO_0000218,H,,9295,,
3914,,,12166,,Autocuration,1,,B,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,,BAO_0000357,H,,9295,,
3915,,,12166,,Autocuration,1,,B,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,,BAO_0000218,H,,216,,
3916,,,12166,,Autocuration,1,,B,702.0,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,,BAO_0000219,H,,11090,,RBL-1
3917,,178.0,12166,,Autocuration,1,Blood,B,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,,BAO_0000019,H,,11090,,
3918,,,12166,,Expert,1,,B,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,,BAO_0000357,H,,10091,,
3919,,,12166,,Autocuration,1,,F,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,,BAO_0000019,H,,10274,,
3920,,,12166,,Autocuration,1,,F,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,,BAO_0000219,H,,13622,,
3921,,,12166,,Expert,1,,B,702.0,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,,BAO_0000219,H,,12118,,RBL-1
3922,,,12166,,Expert,1,,B,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,,BAO_0000357,H,,12576,,
3923,,,12166,,Expert,1,,B,702.0,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,,BAO_0000219,H,,9546,,RBL-1
3924,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,,BAO_0000219,H,,9521,,RBL-1
3925,,,12166,,Expert,1,,B,702.0,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,,BAO_0000219,H,,10626,,RBL-1
3926,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase,,,BAO_0000219,H,,9225,,RBL-1
3927,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,,BAO_0000219,H,,9225,,RBL-1
3928,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,,BAO_0000219,H,,9225,,RBL-1
3929,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,,BAO_0000219,H,,9225,,RBL-1
3930,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,,BAO_0000219,H,,9225,,RBL-1
3931,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,,BAO_0000219,H,,9225,,RBL-1
3932,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,,BAO_0000219,H,,9225,,RBL-1
3933,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,,BAO_0000219,H,,9225,,RBL-1
3934,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,,BAO_0000219,H,,9225,,RBL-1
3935,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,,BAO_0000219,H,,9225,,RBL-1
3936,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,,BAO_0000219,H,,9225,,RBL-1
3937,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,,BAO_0000219,H,,9225,,RBL-1
3938,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,,BAO_0000219,H,,9225,,RBL-1
3939,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,,BAO_0000219,H,,9225,,RBL-1
3940,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,,BAO_0000219,H,,9225,,RBL-1
3941,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,,BAO_0000219,H,,9225,,RBL-1
3942,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,,BAO_0000219,H,,9225,,RBL-1
3943,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,,BAO_0000219,H,,9225,,RBL-1
3944,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,,BAO_0000219,H,,9225,,RBL-1
3945,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,,BAO_0000219,H,,9225,,RBL-1
3946,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,,BAO_0000219,H,,9225,,RBL-1
3947,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,,BAO_0000219,H,,9225,,RBL-1
3948,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,,BAO_0000219,H,,9225,,RBL-1
3949,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,,BAO_0000219,H,,9225,,RBL-1
3950,,,12166,,Expert,1,,B,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,,BAO_0000019,H,,9401,,
3951,,,12166,,Autocuration,1,,B,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,,BAO_0000019,H,,10325,,
3952,,,12166,,Expert,1,,F,663.0,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,,BAO_0000219,H,,1556,,RBL-2H3
3953,,,12166,,Expert,1,,F,663.0,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,,BAO_0000219,H,,1556,,RBL-2H3
3954,,,12166,10116.0,Expert,1,,B,702.0,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,,BAO_0000219,D,,961,Rattus norvegicus,RBL-1
3955,,,12166,,Autocuration,1,,B,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,,BAO_0000019,H,,6838,,
3956,,,12166,,Expert,1,,B,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,,BAO_0000019,H,,10325,,
3957,,,12166,10116.0,Expert,1,,B,702.0,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,,BAO_0000219,D,,9209,Rattus norvegicus,RBL-1
3958,,,12166,,Expert,1,,B,702.0,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,,BAO_0000219,H,,11520,,RBL-1
3959,,,12166,,Autocuration,1,,B,,In vitro inhibitory activity against 5-lipoxygenase was determined,,,BAO_0000357,H,,137,,
3960,,,12166,,Autocuration,1,,B,702.0,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,,BAO_0000219,H,,4717,,RBL-1
3961,,,12166,,Expert,1,,B,702.0,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,,BAO_0000219,H,,10636,,RBL-1
3962,,,12166,10116.0,Expert,1,,F,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,,BAO_0000019,D,,14312,Rattus norvegicus,
3963,,,12166,,Autocuration,1,,B,702.0,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,,BAO_0000219,H,,1203,,RBL-1
3964,,,12166,,Autocuration,1,,B,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,,BAO_0000019,H,,1203,,
3965,,,12166,,Expert,1,,B,702.0,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,,BAO_0000219,H,,13622,,RBL-1
3966,,,12166,,Autocuration,1,,B,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,,BAO_0000357,H,,9793,,
3967,,,12166,10116.0,Expert,1,,B,702.0,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,,BAO_0000219,D,,1143,Rattus norvegicus,RBL-1
3968,,,12166,10116.0,Expert,1,,B,702.0,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,,BAO_0000219,D,,11854,Rattus norvegicus,RBL-1
3969,,,12166,,Autocuration,1,,B,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,BAO_0000219,H,,3595,,RBL-1
3970,,,12166,,Autocuration,1,,B,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,,BAO_0000219,H,,3595,,RBL-1
3971,,,12166,10116.0,Expert,1,,B,702.0,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,,BAO_0000219,D,,10501,Rattus norvegicus,RBL-1
3972,,,12166,,Expert,1,,B,702.0,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,BAO_0000219,H,,12526,,RBL-1
3973,,349.0,10825,,Autocuration,1,Limbic system,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,,BAO_0000019,H,,10034,,
3974,,349.0,10825,,Autocuration,1,Limbic system,F,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,BAO_0000019,H,,10034,,
3975,,,10825,,Autocuration,1,,F,,Approximate dose levels for a half maximal reduction of 5-HTP levels,,,BAO_0000019,H,,10034,,
3976,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,BAO_0000221,H,,10046,,
3977,,10000000.0,10576,,Autocuration,1,Hippocampus,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,BAO_0000221,H,,10046,,
3978,,,10577,,Autocuration,1,,B,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,BAO_0000019,H,,10046,,
3979,,178.0,55,9615.0,Autocuration,1,Blood,F,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,,BAO_0000019,H,,12079,Canis lupus familiaris,
3980,,178.0,55,,Autocuration,1,Blood,F,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,,BAO_0000019,H,,12079,,
3981,,,12166,,Autocuration,1,,B,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,BAO_0000219,H,,11311,,
3982,,,17140,,Expert,1,,B,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,,BAO_0000219,H,,12338,,
3983,,,17140,,Expert,1,,B,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,,BAO_0000219,H,,12143,,
3984,,,17140,,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,,BAO_0000219,H,,12143,,
3985,,,17140,,Expert,1,,B,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,BAO_0000219,H,,12143,,
3986,,,17140,,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,BAO_0000219,H,,12143,,
3987,,,17140,,Expert,1,,B,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,,BAO_0000357,H,,12365,,
3988,,,17140,,Expert,1,,B,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,,BAO_0000357,H,,13500,,
3989,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
3990,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
3991,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
3992,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
3993,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
3994,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
3995,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
3996,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
3997,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
3998,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
3999,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4000,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4001,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4002,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4003,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4004,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4005,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4006,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4007,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4008,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4009,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4010,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4011,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4012,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4013,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4014,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4015,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4016,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4017,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4018,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4019,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4020,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4021,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4022,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4023,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4024,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4025,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4026,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4027,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4028,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4029,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4030,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4031,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4032,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4033,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4034,In vivo,178.0,55,9615.0,Autocuration,1,Blood,F,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Canis lupus familiaris,
4035,,,55,9615.0,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,,BAO_0000218,H,,3595,Canis lupus familiaris,
4036,,,55,9615.0,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,,BAO_0000218,H,,3595,Canis lupus familiaris,
4037,,,55,9615.0,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,,BAO_0000218,H,,3595,Canis lupus familiaris,
4038,,,55,9615.0,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,,BAO_0000218,H,,3595,Canis lupus familiaris,
4039,,,55,9615.0,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,,BAO_0000218,H,,3595,Canis lupus familiaris,
4040,,,55,9615.0,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,,BAO_0000218,H,,3595,Canis lupus familiaris,
4041,,,55,9615.0,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,,BAO_0000218,H,,3595,Canis lupus familiaris,
4042,,,55,9615.0,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,,BAO_0000218,H,,3595,Canis lupus familiaris,
4043,,,55,10141.0,Autocuration,1,,B,,Ability to inhibit 5-lipoxygenase in guinea pig,,,BAO_0000357,H,,9203,Cavia porcellus,
4044,,,55,10141.0,Expert,1,,B,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,,BAO_0000357,H,,82,Cavia porcellus,
4045,,,55,10141.0,Autocuration,1,,B,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,,BAO_0000357,H,,11090,Cavia porcellus,
4046,,178.0,55,10141.0,Autocuration,1,Blood,B,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,,BAO_0000218,H,,12832,Cavia porcellus,
4047,,,55,10141.0,Autocuration,1,,B,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,,BAO_0000357,H,,1065,Cavia porcellus,
4048,,,55,10141.0,Autocuration,1,,B,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,,BAO_0000357,H,,1065,Cavia porcellus,
4049,,,55,10141.0,Expert,1,,B,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,,BAO_0000019,H,,12832,Cavia porcellus,
4050,,,55,10141.0,Expert,1,,B,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,,BAO_0000019,H,,12832,Cavia porcellus,
4051,,,55,10141.0,Autocuration,1,,B,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,,BAO_0000019,H,,12832,Cavia porcellus,
4052,,,55,10141.0,Autocuration,1,,B,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,,BAO_0000019,H,,10504,Cavia porcellus,
4053,,,55,10141.0,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase,,,BAO_0000357,H,,7788,Cavia porcellus,
4054,,,55,10141.0,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,,BAO_0000357,H,,10001,Cavia porcellus,
4055,,,55,10141.0,Autocuration,1,,B,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,,BAO_0000357,H,,10193,Cavia porcellus,
4056,,,55,10141.0,Autocuration,1,,B,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,,BAO_0000357,H,,13243,Cavia porcellus,
4057,,,55,10141.0,Autocuration,1,,B,,Inhibitory activity uM,,,BAO_0000357,H,,13243,Cavia porcellus,
4058,,,55,10141.0,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,,BAO_0000219,H,,969,Cavia porcellus,
4059,,,55,10141.0,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase at 10 uM,,,BAO_0000357,H,,10001,Cavia porcellus,
4060,,,55,10141.0,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,,BAO_0000357,H,,7788,Cavia porcellus,
4061,,,55,10141.0,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,,BAO_0000357,H,,10001,Cavia porcellus,
4062,,,55,10141.0,Autocuration,1,,B,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,,BAO_0000357,H,,10193,Cavia porcellus,
4063,,,55,10141.0,Autocuration,1,,B,,Inhibitory activity uM,,,BAO_0000357,H,,13243,Cavia porcellus,
4064,,,55,10141.0,Autocuration,1,,B,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,,BAO_0000357,H,,13243,Cavia porcellus,
4065,,,55,10141.0,Expert,1,,B,,Inhibitory activity uM,,,BAO_0000357,H,,13243,Cavia porcellus,
4066,,,55,10141.0,Autocuration,1,,F,,Inhibitory activity uM,,,BAO_0000019,H,,13243,Cavia porcellus,
4067,,,55,10141.0,Autocuration,1,,B,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,,BAO_0000019,H,,10504,Cavia porcellus,
4068,,,55,10141.0,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,,BAO_0000357,H,,7788,Cavia porcellus,
4069,,2116.0,55,10141.0,Expert,1,Ileum,F,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,,BAO_0000221,H,,10546,Cavia porcellus,
4070,,,55,,Autocuration,1,,B,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,BAO_0000357,H,,13183,,
4071,,,55,,Autocuration,1,,B,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,BAO_0000357,H,,13183,,
4072,,,55,,Autocuration,1,,B,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,,BAO_0000357,H,,2578,,
4073,,,55,,Expert,1,,B,,In vitro inhibition of human 5-Lipoxygenase.,,,BAO_0000357,H,,12780,,
4074,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4075,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4076,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4077,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4078,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4079,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4080,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4081,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4082,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4083,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4084,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4085,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4086,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4087,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4088,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4089,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4090,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4091,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4092,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4093,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4094,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4095,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4096,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4097,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4098,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4099,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4100,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4101,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4102,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4103,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4104,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4105,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4106,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4107,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4108,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4109,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4110,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4111,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4112,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4113,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4114,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4115,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4116,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4117,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4118,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4119,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4120,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4121,,,22226,10116.0,Autocuration,1,,B,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4122,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4123,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4124,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4125,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4126,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4127,,,80433,9606.0,Intermediate,1,,F,741.0,In vitro inhibition of 7226/S myeloma cancer cell line,,,BAO_0000219,N,,10797,Homo sapiens,RPMI-8226
4128,,,80698,9606.0,Intermediate,1,,F,993.0,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,,BAO_0000219,N,,6881,Homo sapiens,BEL-7404 tumor cell line
4129,,,80640,9606.0,Intermediate,1,,F,391.0,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,,BAO_0000219,N,,3838,Homo sapiens,786-0
4130,,,80640,9606.0,Intermediate,1,,F,391.0,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,,BAO_0000219,N,,3838,Homo sapiens,786-0
4131,,,81264,10029.0,Expert,1,,F,505.0,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,,BAO_0000219,N,,12981,Cricetulus griseus,V79
4132,,,81264,10029.0,Expert,1,,F,505.0,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,,BAO_0000219,N,,12981,Cricetulus griseus,V79
4133,,,80635,10116.0,Intermediate,1,,F,1119.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,,BAO_0000219,N,,7653,Rattus norvegicus,7800C1 cell line
4134,,,80635,10116.0,Intermediate,1,,F,1119.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,,BAO_0000219,N,,7653,Rattus norvegicus,7800C1 cell line
4135,,,80635,10116.0,Intermediate,1,,F,1119.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,,BAO_0000219,N,,7653,Rattus norvegicus,7800C1 cell line
4136,,,80635,10116.0,Intermediate,1,,F,1119.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,,BAO_0000219,N,,7653,Rattus norvegicus,7800C1 cell line
4137,,,80635,10116.0,Intermediate,1,,F,1119.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,,BAO_0000219,N,,7653,Rattus norvegicus,7800C1 cell line
4138,,,80635,10116.0,Intermediate,1,,F,1119.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,,BAO_0000219,N,,7653,Rattus norvegicus,7800C1 cell line
4139,,,80640,9606.0,Intermediate,1,,F,391.0,In vitro antitumor activity against renal 786-0 tumor cell lines,,,BAO_0000219,N,,17229,Homo sapiens,786-0
4140,,,80640,9606.0,Intermediate,1,,F,391.0,Cytotoxic activity against 786-0 Renal cancer cell line,,,BAO_0000219,N,,12858,Homo sapiens,786-0
4141,,,80640,9606.0,Intermediate,1,,F,391.0,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,,BAO_0000219,N,,16325,Homo sapiens,786-0
4142,,,80640,9606.0,Intermediate,1,,F,391.0,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,,BAO_0000219,N,,16325,Homo sapiens,786-0
4143,,,80640,9606.0,Intermediate,1,,F,391.0,In vitro antitumor activity against human renal 786-0 cell line,,,BAO_0000219,N,,5858,Homo sapiens,786-0
4144,,,80640,9606.0,Intermediate,1,,F,391.0,Inhibition of Renal cancer in 786-0 cancer cell lines,,,BAO_0000219,N,,16325,Homo sapiens,786-0
4145,,,80640,9606.0,Intermediate,1,,F,391.0,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,,BAO_0000219,N,,14696,Homo sapiens,786-0
4146,,,80640,9606.0,Intermediate,1,,F,391.0,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,,BAO_0000219,N,,3786,Homo sapiens,786-0
4147,,,80640,9606.0,Intermediate,1,,F,391.0,inhibition of the growth of renal cancer(786-0) cell line,,,BAO_0000219,N,,14696,Homo sapiens,786-0
4148,,,80640,9606.0,Intermediate,1,,F,391.0,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,,BAO_0000219,N,,14769,Homo sapiens,786-0
4149,,,80640,9606.0,Intermediate,1,,F,391.0,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,,BAO_0000219,N,,15354,Homo sapiens,786-0
4150,,,80640,9606.0,Intermediate,1,,F,391.0,The IC50 value was measured on 786-0 cell line in ovarian tumor,,,BAO_0000219,N,,14255,Homo sapiens,786-0
4151,,,80640,9606.0,Intermediate,1,,F,391.0,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,,BAO_0000219,N,,14255,Homo sapiens,786-0
4152,,,80640,9606.0,Intermediate,1,,F,391.0,The IC50 value was measured on 786-0 cell line in renal tumor type.,,,BAO_0000219,N,,14255,Homo sapiens,786-0
4153,,,80640,9606.0,Intermediate,1,,F,391.0,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,,BAO_0000219,N,,14696,Homo sapiens,786-0
4154,,,80640,9606.0,Intermediate,1,,F,391.0,Tested for cytotoxic activity against renal cancer 786-0 cell line,,,BAO_0000219,N,,12016,Homo sapiens,786-0
4155,,,80640,9606.0,Intermediate,1,,F,391.0,Compound was tested for growth inhibitory activity against 786-0 cell line,,,BAO_0000219,N,,2597,Homo sapiens,786-0
4156,,,12166,,Autocuration,1,,B,702.0,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,,BAO_0000219,H,,12526,,RBL-1
4157,,,12166,,Autocuration,1,,B,702.0,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,,BAO_0000219,H,,12526,,RBL-1
4158,,,12166,,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,,BAO_0000019,H,,14799,,
4159,,,12166,,Expert,1,,B,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,BAO_0000219,H,,3595,,RBL-1
4160,,,12166,,Expert,1,,B,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,,BAO_0000219,H,,3595,,RBL-1
4161,,,12166,,Autocuration,1,,B,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,,BAO_0000357,H,,12767,,
4162,,,12166,,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,,BAO_0000219,H,,10997,,
4163,,,12166,,Autocuration,1,,B,702.0,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,,BAO_0000219,H,,11388,,RBL-1
4164,,,12166,,Autocuration,1,,B,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,,BAO_0000357,H,,167,,
4165,,,12166,,Autocuration,1,,B,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,,BAO_0000357,H,,167,,
4166,,,12166,,Expert,1,,B,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,,BAO_0000357,H,,13744,,
4167,,,12166,,Autocuration,1,,B,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,,BAO_0000357,H,,1630,,
4168,,,12166,,Autocuration,1,,B,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,,BAO_0000357,H,,1630,,
4169,,,12166,10116.0,Expert,1,,B,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,,BAO_0000019,D,,969,Rattus norvegicus,
4170,,,12166,,Autocuration,1,,B,702.0,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,,BAO_0000219,H,,13621,,RBL-1
4171,,,12166,,Autocuration,1,,B,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,,BAO_0000357,H,,10089,,
4172,,,12166,,Expert,1,,B,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,,BAO_0000357,H,,10193,,
4173,,,12166,,Autocuration,1,,B,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,,BAO_0000357,H,,11966,,
4174,,,12166,,Autocuration,1,,B,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,BAO_0000019,H,,12251,,
4175,,,12166,,Autocuration,1,,B,702.0,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,,BAO_0000219,H,,211,,RBL-1
4176,,,12166,,Expert,1,,F,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,BAO_0000019,H,,12251,,
4177,,,12166,,Autocuration,1,,B,702.0,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,,BAO_0000219,H,,12495,,RBL-1
4178,,,12166,,Autocuration,1,,B,,Tested for its inhibitory activity against 5-lipoxygenase,,,BAO_0000357,H,,414,,
4179,,,12166,,Autocuration,1,,B,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,,BAO_0000357,H,,414,,
4180,,,12166,,Expert,1,,B,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,,BAO_0000019,H,,10325,,
4181,,,12166,,Expert,1,,B,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,BAO_0000019,H,,11966,,
4182,,,12166,,Expert,1,,B,702.0,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,,BAO_0000219,H,,165,,RBL-1
4183,,,12166,,Autocuration,1,,B,702.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,,BAO_0000219,H,,165,,RBL-1
4184,,,12166,,Autocuration,1,,B,702.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,,BAO_0000219,H,,165,,RBL-1
4185,,,12166,,Expert,1,,B,702.0,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,,BAO_0000219,H,,165,,RBL-1
4186,,,12166,,Autocuration,1,,B,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,,BAO_0000218,H,,11311,,
4187,,,12166,,Autocuration,1,,B,702.0,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,,BAO_0000219,H,,11311,,RBL-1
4188,,,12166,,Autocuration,1,,B,702.0,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,,BAO_0000219,H,,11311,,RBL-1
4189,,,12166,,Autocuration,1,,B,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,BAO_0000219,H,,11311,,
4190,,,12166,,Autocuration,1,,B,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,,BAO_0000219,H,,11311,,
4191,In vivo,,12166,,Autocuration,1,,B,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,,BAO_0000218,H,,11311,,
4192,,,12166,,Autocuration,1,,F,663.0,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,,BAO_0000219,H,,11311,,RBL-2H3
4193,,,12166,,Autocuration,1,,F,663.0,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,,BAO_0000219,H,,11311,,RBL-2H3
4194,,,12166,,Autocuration,1,,B,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,,BAO_0000019,H,,11311,,
4195,,,12166,,Autocuration,1,,B,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,,BAO_0000019,H,,11732,,
4196,,,12166,,Expert,1,,B,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,,BAO_0000019,H,,11732,,
4197,,,12166,,Expert,1,,B,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,,BAO_0000019,H,,11087,,
4198,,,12166,,Autocuration,1,,B,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,,BAO_0000019,H,,11087,,
4199,,,12166,,Autocuration,1,,B,702.0,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,,BAO_0000219,H,,11087,,RBL-1
4200,,,12166,10116.0,Expert,1,,B,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,,BAO_0000357,D,,11087,Rattus norvegicus,
4201,,,12166,,Autocuration,1,,B,702.0,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,,BAO_0000219,H,,496,,RBL-1
4202,,,12166,,Expert,1,,F,702.0,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,,BAO_0000219,H,,13986,,RBL-1
4203,,,12166,,Autocuration,1,,B,,Compound was evaluated for the inhibition of 5-lipoxygenase,,,BAO_0000357,H,,11520,,
4204,,,12166,,Autocuration,1,,B,702.0,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,,BAO_0000219,H,,10293,,RBL-1
4205,,,12166,,Autocuration,1,,B,702.0,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,,BAO_0000219,H,,303,,RBL-1
4206,,,12166,,Autocuration,1,,B,702.0,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,,BAO_0000219,H,,303,,RBL-1
4207,,,12166,,Autocuration,1,,B,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,,BAO_0000219,H,,9247,,RBL-1
4208,,,12166,10116.0,Expert,1,,B,702.0,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,,BAO_0000219,D,,9247,Rattus norvegicus,RBL-1
4209,,,12166,,Autocuration,1,,B,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,,BAO_0000219,H,,9247,,RBL-1
4210,,,12166,,Autocuration,1,,B,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,,BAO_0000219,H,,9247,,RBL-1
4211,,,12166,,Autocuration,1,,B,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,,BAO_0000219,H,,9247,,RBL-1
4212,,,12166,,Autocuration,1,,B,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,,BAO_0000219,H,,9247,,RBL-1
4213,,,12166,,Autocuration,1,,B,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,,BAO_0000219,H,,9247,,RBL-1
4214,,,12166,,Autocuration,1,,B,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,,BAO_0000219,H,,9247,,RBL-1
4215,,,12166,10116.0,Expert,1,,B,,Inhibitory activity against 5-lipoxygenase at 10 uM,,,BAO_0000357,D,,11481,Rattus norvegicus,
4216,,,12166,,Autocuration,1,,B,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,,BAO_0000357,H,,105,,
4217,,,12166,,Expert,1,,B,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,,BAO_0000357,H,,9029,,
4218,,,12166,,Expert,1,,B,702.0,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,,BAO_0000219,H,,1175,,RBL-1
4219,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,,BAO_0000219,H,,12118,,RBL-1
4220,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,,BAO_0000219,H,,12118,,RBL-1
4221,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,,BAO_0000219,H,,12118,,RBL-1
4222,,,12166,,Autocuration,1,,B,702.0,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,,BAO_0000219,H,,9225,,RBL-1
4223,,,12166,,Autocuration,1,,B,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,,BAO_0000019,H,,9401,,
4224,,,12166,,Autocuration,1,,B,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,BAO_0000357,H,,137,,
4225,,,12166,,Autocuration,1,,B,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,BAO_0000357,H,,137,,
4226,,,12166,,Autocuration,1,,B,702.0,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,,BAO_0000219,H,,4717,,RBL-1
4227,,,12166,,Autocuration,1,,B,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,,BAO_0000219,H,,3595,,RBL-1
4228,,,12166,,Autocuration,1,,B,702.0,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,,BAO_0000219,H,,10501,,RBL-1
4229,,,12166,,Autocuration,1,,B,702.0,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,,BAO_0000219,H,,10501,,RBL-1
4230,,,12166,,Autocuration,1,,B,702.0,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,,BAO_0000219,H,,10501,,RBL-1
4231,,,12166,,Autocuration,1,,B,702.0,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,BAO_0000219,H,,12526,,RBL-1
4232,,,12166,10116.0,Expert,1,,B,702.0,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,,BAO_0000219,D,,14799,Rattus norvegicus,RBL-1
4233,,,12166,,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,,BAO_0000019,H,,14799,,
4234,,,12166,,Autocuration,1,,B,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,,BAO_0000219,H,,3595,,RBL-1
4235,,,12166,,Expert,1,,B,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,,BAO_0000219,H,,3595,,RBL-1
4236,,,12166,,Autocuration,1,,B,702.0,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,BAO_0000219,H,,12526,,RBL-1
4237,,,12166,,Autocuration,1,,B,702.0,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,BAO_0000219,H,,12526,,RBL-1
4238,,,12166,,Autocuration,1,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,BAO_0000019,H,,10193,,
4239,,,12166,,Autocuration,1,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,BAO_0000019,H,,10193,,
4240,,,12166,,Autocuration,1,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,BAO_0000019,H,,10193,,
4241,,,12166,,Autocuration,1,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,,BAO_0000019,H,,10193,,
4242,,,12166,,Expert,1,,B,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,,BAO_0000357,H,,9138,,
4243,,,12166,,Autocuration,1,,B,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,,BAO_0000357,H,,9138,,
4244,,,12166,,Autocuration,1,,B,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,BAO_0000019,H,,11966,,
4245,,,12166,,Autocuration,1,,B,702.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,,BAO_0000219,H,,165,,RBL-1
4246,,,12166,,Autocuration,1,,B,702.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,,BAO_0000219,H,,165,,RBL-1
4247,,,12166,,Autocuration,1,,B,663.0,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,,BAO_0000219,H,,11311,,RBL-2H3
4248,,,12166,,Autocuration,1,,B,663.0,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,,BAO_0000219,H,,11311,,RBL-2H3
4249,,,12166,,Autocuration,1,,F,663.0,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,,BAO_0000219,H,,11311,,RBL-2H3
4250,,,12166,,Autocuration,1,,F,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,,BAO_0000019,H,,11311,,
4251,,,12166,,Autocuration,1,,B,,The compound was tested for inhibition of isolated 5-lipoxygenase,,,BAO_0000357,H,,11311,,
4252,,,12166,,Autocuration,1,,F,663.0,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,,BAO_0000219,H,,11311,,RBL-2H3
4253,,,12166,,Autocuration,1,,B,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,,BAO_0000019,H,,11087,,
4254,,,12166,,Autocuration,1,,B,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,,BAO_0000019,H,,11087,,
4255,,,12166,,Autocuration,1,,B,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,,BAO_0000019,H,,11087,,
4256,,,12166,,Autocuration,1,,B,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,BAO_0000019,H,,11087,,
4257,,,12166,,Autocuration,1,,B,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,BAO_0000019,H,,11087,,
4258,,,12166,,Autocuration,1,,B,702.0,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,,BAO_0000219,H,,496,,RBL-1
4259,,,12166,,Autocuration,1,,B,702.0,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,,BAO_0000219,H,,496,,RBL-1
4260,,,12166,,Autocuration,1,,F,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,,BAO_0000219,H,,13986,,RBL-1
4261,,,12166,,Autocuration,1,,F,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,,BAO_0000219,H,,13986,,RBL-1
4262,,,12166,,Autocuration,1,,F,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,,BAO_0000219,H,,13986,,RBL-1
4263,,,12166,,Autocuration,1,,F,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,,BAO_0000219,H,,13986,,RBL-1
4264,,,12166,,Autocuration,1,,F,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,,BAO_0000219,H,,13986,,RBL-1
4265,,,12166,,Autocuration,1,,F,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,,BAO_0000219,H,,13986,,RBL-1
4266,,,12166,,Autocuration,1,,F,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,,BAO_0000219,H,,13986,,RBL-1
4267,,,12166,,Autocuration,1,,F,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,,BAO_0000219,H,,13986,,RBL-1
4268,,,12166,,Autocuration,1,,F,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,,BAO_0000219,H,,13986,,RBL-1
4269,,,12166,10116.0,Expert,1,,F,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,,BAO_0000019,D,,13986,Rattus norvegicus,
4270,,,12166,,Autocuration,1,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,,BAO_0000357,H,,10193,,
4271,,,12166,,Autocuration,1,,B,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,,BAO_0000357,H,,9295,,
4272,,,12166,,Autocuration,1,,B,702.0,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,,BAO_0000219,H,,4717,,RBL-1
4273,,,12166,,Autocuration,1,,B,702.0,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,,BAO_0000219,H,,4717,,RBL-1
4274,,,12166,,Autocuration,1,,B,702.0,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,,BAO_0000219,H,,11854,,RBL-1
4275,,,12166,,Autocuration,1,,B,702.0,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,,BAO_0000219,H,,11854,,RBL-1
4276,,,12166,,Autocuration,1,,B,702.0,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,,BAO_0000219,H,,11854,,RBL-1
4277,,,12166,,Autocuration,1,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,BAO_0000019,H,,10193,,
4278,,,12166,,Autocuration,1,,B,702.0,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,,BAO_0000219,H,,9295,,RBL-1
4279,,,12166,,Autocuration,1,,B,702.0,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,,BAO_0000219,H,,9295,,RBL-1
4280,,,12166,,Autocuration,1,,B,702.0,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,,BAO_0000219,H,,9295,,RBL-1
4281,,,12166,,Autocuration,1,,B,702.0,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,,BAO_0000219,H,,9295,,RBL-1
4282,,,12166,,Autocuration,1,,B,702.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,,BAO_0000219,H,,165,,RBL-1
4283,,,12166,,Autocuration,1,,B,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,,BAO_0000219,H,,11311,,
4284,,,12166,9606.0,Expert,1,,B,702.0,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,,BAO_0000219,H,,10489,Homo sapiens,RBL-1
4285,,,12166,10116.0,Expert,1,,B,702.0,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,,BAO_0000219,D,,10489,Rattus norvegicus,RBL-1
4286,,,12166,10116.0,Expert,1,,B,702.0,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,,BAO_0000219,D,,10489,Rattus norvegicus,RBL-1
4287,,,12166,10116.0,Autocuration,1,,B,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,,BAO_0000019,D,,14799,Rattus norvegicus,
4288,,,12054,3847.0,Autocuration,1,,B,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,,BAO_0000357,H,,9295,Glycine max,
4289,,,22226,,Autocuration,1,,B,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,,BAO_0000019,U,,16811,,
4290,,,55,,Expert,1,,B,,In vitro inhibition of 5-Lipoxygenase; Inactive.,,,BAO_0000357,H,,168,,
4291,,,55,,Autocuration,1,,B,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,,BAO_0000357,H,,6309,,
4292,,,55,,Autocuration,1,,B,,Inhibitory concentration against 5-lipoxygenase; No inhibition,,,BAO_0000357,H,,6309,,
4293,,,55,,Autocuration,1,,B,702.0,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,,BAO_0000219,H,,3092,,RBL-1
4294,,,55,,Expert,1,,B,,Inhibitory activity against 5-lipoxygenase.,,,BAO_0000357,H,,168,,
4295,,,55,,Autocuration,1,,B,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,,BAO_0000357,H,,168,,
4296,,,55,,Autocuration,1,,B,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,,BAO_0000357,H,,168,,
4297,,,55,,Autocuration,1,,B,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,,BAO_0000357,H,,168,,
4298,,,55,,Expert,1,,F,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,,BAO_0000019,H,,12338,,
4299,,,55,,Autocuration,1,,B,,Tested for the inhibitory activity against 5-lipoxygenase,,,BAO_0000357,H,,4501,,
4300,,,55,,Autocuration,1,,B,,Compound was tested for its inhibitory activity against 5-lipoxygenase,,,BAO_0000357,H,,1132,,
4301,,,55,,Autocuration,1,,B,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,,BAO_0000357,H,,2117,,
4302,,,55,,Autocuration,1,,B,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,,BAO_0000357,H,,168,,
4303,,,55,,Autocuration,1,,B,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,,BAO_0000357,H,,168,,
4304,,,12166,,Autocuration,1,,B,702.0,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,,BAO_0000219,H,,13575,,RBL-1
4305,,,12166,,Autocuration,1,,B,,,,,BAO_0000357,H,,11089,,
4306,,,10102,,Autocuration,1,,B,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,,BAO_0000357,H,,216,,
4307,,,10102,,Autocuration,1,,B,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,,BAO_0000019,H,,13165,,
4308,,,10102,,Autocuration,1,,B,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,,BAO_0000357,H,,3278,,
4309,,,10102,,Expert,1,,B,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,,BAO_0000357,H,,3278,,
4310,,,10102,,Autocuration,1,,B,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,,BAO_0000357,H,,11966,,
4311,,,10102,,Autocuration,1,,B,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,,BAO_0000357,H,,175,,
4312,,,10102,,Autocuration,1,,B,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,,BAO_0000357,H,,175,,
4313,,,10102,,Autocuration,1,,B,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,,BAO_0000357,H,,13449,,
4314,,,11238,,Autocuration,1,,B,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,,BAO_0000019,H,,12014,,
4315,,,11238,,Autocuration,1,,B,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,,BAO_0000019,H,,12014,,
4316,,,11238,,Autocuration,1,,B,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,,BAO_0000019,H,,12014,,
4317,,,100284,,Intermediate,1,,B,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,,BAO_0000220,S,,99,,
4318,,,22226,9606.0,Autocuration,1,,F,,The dark toxicity against 543 human galactophore carcinoma cells,,,BAO_0000019,U,,4349,Homo sapiens,
4319,,,80623,9606.0,Expert,1,,F,390.0,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,,BAO_0000219,N,,4071,Homo sapiens,Panel (56 tumour cell lines)
4320,,,80008,9606.0,Expert,1,,F,345.0,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,,BAO_0000219,N,,17589,Homo sapiens,5637
4321,,,80008,9606.0,Intermediate,1,,F,345.0,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,,BAO_0000219,N,,15002,Homo sapiens,5637
4322,,,80008,9606.0,Intermediate,1,,F,345.0,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,,BAO_0000219,N,,13958,Homo sapiens,5637
4323,,,80008,9606.0,Expert,1,,F,345.0,Growth inhibition against human 5637 cell lines,,,BAO_0000219,N,,17589,Homo sapiens,5637
4324,,,80008,9606.0,Expert,1,,F,345.0,Antitumor activity against human bladder carcinoma 5637 cells.,,,BAO_0000219,N,,16748,Homo sapiens,5637
4325,,,80008,9606.0,Intermediate,1,,F,345.0,Antitumor activity against human bladder carcinoma 5637 cells,,,BAO_0000219,N,,16747,Homo sapiens,5637
4326,,,80008,9606.0,Intermediate,1,,F,345.0,Antitumor activity against human bladder carcinoma 5637 cells,,,BAO_0000219,N,,16747,Homo sapiens,5637
4327,,,10443,9913.0,Expert,1,,B,,In vitro inhibition of bovine trypsin(Trp).,,,BAO_0000357,D,,15285,Bos taurus,
4328,,,240,9527.0,Expert,1,,B,407.0,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,,BAO_0000219,H,,3726,Cercopithecidae,CV-1
4329,,,10577,,Autocuration,1,,B,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,,BAO_0000357,H,,5033,,
4330,,,104698,,Autocuration,1,,F,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,,BAO_0000019,H,,11756,,
4331,In vivo,,22226,,Autocuration,1,,F,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,,BAO_0000218,U,,11953,,
4332,,,20033,10141.0,Intermediate,1,,B,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,,BAO_0000357,D,,5033,Cavia porcellus,
4333,,,17045,10116.0,Expert,1,,A,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Microsomes,,BAO_0000251,H,,11347,Rattus norvegicus,
4334,,,17045,10116.0,Expert,1,,A,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Microsomes,,BAO_0000251,H,,11347,Rattus norvegicus,
4335,,,22226,,Intermediate,1,,F,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,BAO_0000019,U,,1229,,
4336,,,22226,,Intermediate,1,,F,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,BAO_0000019,U,,1229,,
4337,,,11938,5691.0,Expert,1,,B,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,,BAO_0000019,H,,17588,Trypanosoma brucei,
4338,,,11938,5691.0,Autocuration,1,,B,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,,BAO_0000019,H,,17588,Trypanosoma brucei,
4339,,,11938,9940.0,Expert,1,,B,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,,BAO_0000019,H,,17588,Ovis aries,
4340,,,11938,9940.0,Autocuration,1,,B,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,,BAO_0000019,H,,17588,Ovis aries,
4341,,,11938,,Autocuration,1,,B,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,,BAO_0000357,H,,16485,,
4342,,,22226,9606.0,Intermediate,1,,F,,Average inhibitory concentration against 60 human cell lines was reported,,,BAO_0000019,U,,4337,Homo sapiens,
4343,,,22226,9606.0,Expert,1,,F,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,,BAO_0000019,U,,4112,Homo sapiens,
4344,,,80315,9606.0,Intermediate,1,,F,542.0,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,,BAO_0000219,N,,16160,Homo sapiens,Panel NCI-60 (60 carcinoma cell lines)
4345,,,80315,9606.0,Intermediate,1,,F,542.0,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,,BAO_0000219,N,,16160,Homo sapiens,Panel NCI-60 (60 carcinoma cell lines)
4346,,,80315,,Expert,1,,F,542.0,In vitro mean growth inhibitory activity against 60-cell panel,,,BAO_0000219,N,,17376,,Panel NCI-60 (60 carcinoma cell lines)
4347,,,80315,,Expert,1,,F,542.0,In vitro mean growth lethal concentration against 60-cell panel,,,BAO_0000219,N,,17376,,Panel NCI-60 (60 carcinoma cell lines)
4348,,,80315,,Expert,1,,F,542.0,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,,BAO_0000219,N,,17376,,Panel NCI-60 (60 carcinoma cell lines)
4349,,,80315,,Expert,1,,F,542.0,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,,BAO_0000219,N,,17376,,Panel NCI-60 (60 carcinoma cell lines)
4350,,,104775,,Autocuration,1,,F,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,BAO_0000019,H,,3241,,
4351,,,104775,,Autocuration,1,,F,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,BAO_0000019,H,,3241,,
4352,,,275,,Expert,1,,B,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,,BAO_0000357,H,,3725,,
4353,,,50425,5833.0,Expert,1,,F,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,,BAO_0000218,N,,10805,Plasmodium falciparum,
4354,,,50425,5833.0,Expert,1,,F,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,,BAO_0000218,N,,10805,Plasmodium falciparum,
4355,,,50425,5833.0,Expert,1,,F,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,,BAO_0000218,N,,10805,Plasmodium falciparum,
4356,,,50425,5833.0,Expert,1,,F,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,,BAO_0000218,N,,10805,Plasmodium falciparum,
4357,,,50425,5833.0,Intermediate,1,,F,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,,BAO_0000218,N,,10805,Plasmodium falciparum,
4358,,,80628,10090.0,Intermediate,1,,F,850.0,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,,BAO_0000218,N,,10144,Mus musculus,6C3HED
4359,,,80628,10090.0,Intermediate,1,,F,850.0,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,,BAO_0000218,N,,10144,Mus musculus,6C3HED
4360,,,80628,10090.0,Intermediate,1,,F,850.0,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,,BAO_0000218,N,,10144,Mus musculus,6C3HED
4361,,,80628,10090.0,Intermediate,1,,F,850.0,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,,BAO_0000218,N,,10144,Mus musculus,6C3HED
4362,,,80628,10090.0,Intermediate,1,,F,850.0,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,,BAO_0000218,N,,10144,Mus musculus,6C3HED
4363,,,80628,10090.0,Intermediate,1,,F,850.0,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,,BAO_0000218,N,,10144,Mus musculus,6C3HED
4364,In vivo,,22224,10090.0,Autocuration,1,,F,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,,BAO_0000218,U,,10685,Mus musculus,
4365,In vivo,,22224,10090.0,Autocuration,1,,F,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,,BAO_0000218,U,,10685,Mus musculus,
4366,In vivo,,22224,10090.0,Autocuration,1,,F,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,,BAO_0000218,U,,10685,Mus musculus,
4367,In vivo,,22224,10090.0,Autocuration,1,,F,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,,BAO_0000218,U,,10685,Mus musculus,
4368,In vivo,,22224,10090.0,Autocuration,1,,F,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,,BAO_0000218,U,,10685,Mus musculus,
4369,In vivo,,22224,10090.0,Autocuration,1,,F,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,,BAO_0000218,U,,10685,Mus musculus,
4370,In vivo,,22224,10090.0,Autocuration,1,,F,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,,BAO_0000218,U,,10685,Mus musculus,
4371,In vivo,,22224,10090.0,Autocuration,1,,F,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,,BAO_0000218,U,,10685,Mus musculus,
4372,In vivo,,22224,10090.0,Autocuration,1,,F,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,,BAO_0000218,U,,10685,Mus musculus,
4373,In vivo,,22224,10090.0,Autocuration,1,,F,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,,BAO_0000218,U,,10685,Mus musculus,
4374,In vivo,,22224,10090.0,Autocuration,1,,F,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,,BAO_0000218,U,,10685,Mus musculus,
4375,,,22224,10090.0,Autocuration,1,,F,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,,BAO_0000218,U,,10144,Mus musculus,
4376,,,22224,10090.0,Autocuration,1,,F,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,,BAO_0000218,U,,10144,Mus musculus,
4377,,,22224,10090.0,Autocuration,1,,F,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,,BAO_0000218,U,,10144,Mus musculus,
4378,,,22224,10090.0,Autocuration,1,,F,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,,BAO_0000218,U,,10144,Mus musculus,
4379,,,22224,10090.0,Autocuration,1,,F,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,,BAO_0000218,U,,10685,Mus musculus,
4380,,,22224,10090.0,Autocuration,1,,F,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,,BAO_0000218,U,,10685,Mus musculus,
4381,,,22224,10090.0,Autocuration,1,,F,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,,BAO_0000218,U,,10685,Mus musculus,
4382,,,22224,10090.0,Autocuration,1,,F,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,,BAO_0000218,U,,10685,Mus musculus,
4383,,,22224,10090.0,Autocuration,1,,A,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,,BAO_0000218,U,,10685,Mus musculus,
4384,,,22224,10090.0,Autocuration,1,,A,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,,BAO_0000218,U,,10685,Mus musculus,
4385,,,22224,10090.0,Autocuration,1,,A,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,,BAO_0000218,U,,10685,Mus musculus,
4386,,,22224,10090.0,Autocuration,1,,A,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,,BAO_0000218,U,,10685,Mus musculus,
4387,,,80628,10090.0,Intermediate,1,,F,850.0,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,,BAO_0000218,N,,8831,Mus musculus,6C3HED
4388,In vivo,,22224,,Autocuration,1,,F,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,,BAO_0000218,U,,11704,,
4389,,,50594,10090.0,Intermediate,1,,A,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,,BAO_0000218,N,,11704,Mus musculus,
4390,In vivo,,80628,10090.0,Intermediate,1,,F,850.0,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,,,BAO_0000218,N,,10685,Mus musculus,6C3HED
4391,In vivo,,80628,10090.0,Intermediate,1,,F,850.0,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,,,BAO_0000218,N,,10685,Mus musculus,6C3HED
4392,,,80628,10090.0,Expert,1,,F,850.0,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,,BAO_0000218,N,,11368,Mus musculus,6C3HED
4393,,,80628,10090.0,Intermediate,1,,F,850.0,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,,BAO_0000218,N,,11368,Mus musculus,6C3HED
4394,,,80628,10090.0,Expert,1,,F,850.0,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,,BAO_0000218,N,,11368,Mus musculus,6C3HED
4395,,,22226,1280.0,Autocuration,1,,B,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,,BAO_0000019,U,,17763,Staphylococcus aureus,
4396,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4397,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4398,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4399,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4400,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4401,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4402,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4403,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4404,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4405,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4406,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4407,,2107.0,22226,10116.0,Autocuration,1,Liver,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Microsomes,,BAO_0000251,U,,7411,Rattus norvegicus,
4408,In vivo,1969.0,22224,9527.0,Autocuration,1,Plasma,A,,The apparent total plasma clearance in monkey,,,BAO_0000218,U,,347,Cercopithecidae,
4409,In vivo,,22224,9527.0,Autocuration,1,,A,,Compound was evaluated for Hepatic clearance in monkey,,,BAO_0000218,U,,3341,Cercopithecidae,
4410,In vivo,,22224,9527.0,Autocuration,1,,A,,Lower clearance in monkey (i.v.) at 0.5 mpk,,,BAO_0000218,U,,17853,Cercopithecidae,
4411,In vivo,,22224,9527.0,Autocuration,1,,A,,Plasma clearance in rhesus monkey,,,BAO_0000218,U,,4514,Cercopithecidae,
4412,In vivo,,22224,9527.0,Autocuration,1,,A,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,,BAO_0000218,U,,6062,Cercopithecidae,
4413,In vivo,,22224,9527.0,Autocuration,1,,A,,Plasma clearance of compound was determined in monkey,,,BAO_0000218,U,,6821,Cercopithecidae,
4414,In vivo,,22224,9527.0,Autocuration,1,,A,,Plasma clearance was calculated in rhesus monkey,,,BAO_0000218,U,,6057,Cercopithecidae,
4415,In vivo,,22224,9527.0,Autocuration,1,,A,,Plasma clearance in rhesus monkey,,,BAO_0000218,U,,5145,Cercopithecidae,
4416,In vivo,,22224,9527.0,Autocuration,1,,A,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,BAO_0000218,U,,6641,Cercopithecidae,
4417,In vivo,,22224,9527.0,Autocuration,1,,A,,Plasma clearance was evaluated in rhesus,,,BAO_0000218,U,,5472,Cercopithecidae,
4418,In vivo,,22224,9527.0,Autocuration,1,,A,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,,BAO_0000218,U,,4257,Cercopithecidae,
4419,In vivo,,22224,9527.0,Autocuration,1,,A,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,,BAO_0000218,U,,5546,Cercopithecidae,
4420,In vivo,,22224,9527.0,Autocuration,1,,A,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,BAO_0000218,U,,5334,Cercopithecidae,
4421,In vivo,,22224,9527.0,Autocuration,1,,A,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,BAO_0000218,U,,5334,Cercopithecidae,
4422,In vivo,,22224,9527.0,Autocuration,1,,A,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,,BAO_0000218,U,,17509,Cercopithecidae,
4423,In vivo,,22224,9527.0,Autocuration,1,,A,,Cmax in monkey after administration of 1 mg/kg iv,,,BAO_0000218,U,,6535,Cercopithecidae,
4424,In vivo,,22224,9527.0,Autocuration,1,,A,,Cmax was determine after peroral administration at 10 mpk in Rhesus,,,BAO_0000218,U,,5668,Cercopithecidae,
4425,In vivo,,22224,9527.0,Autocuration,1,,A,,Cmax in cynomolgus monkey by iv administration,,,BAO_0000218,U,,5922,Cercopithecidae,
4426,In vivo,,22224,9527.0,Autocuration,1,,A,,Cmax in cynomolgus monkey by po administration,,,BAO_0000218,U,,5922,Cercopithecidae,
4427,In vivo,,22224,9527.0,Autocuration,1,,A,,Cmax value evaluated in monkey,,,BAO_0000218,U,,6078,Cercopithecidae,
4428,In vivo,,22224,9527.0,Autocuration,1,,A,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,BAO_0000218,U,,2661,Cercopithecidae,
4429,In vivo,1969.0,22224,9527.0,Autocuration,1,Plasma,A,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,,,BAO_0000218,U,,3249,Cercopithecidae,
4430,In vivo,1969.0,22224,9527.0,Autocuration,1,Plasma,A,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,,,BAO_0000218,U,,3249,Cercopithecidae,
4431,In vivo,1969.0,22224,9527.0,Autocuration,1,Plasma,A,,Maximal plasma concentration in squirrel monkeys,,,BAO_0000218,U,,5553,Cercopithecidae,
4432,In vivo,,22224,9527.0,Autocuration,1,,A,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,BAO_0000218,U,,1916,Cercopithecidae,
4433,In vivo,1969.0,22224,9527.0,Autocuration,1,Plasma,A,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,,,BAO_0000218,U,,6227,Cercopithecidae,
4434,In vivo,,22224,9527.0,Autocuration,1,,A,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,BAO_0000218,U,,4809,Cercopithecidae,
4435,In vivo,,22224,9527.0,Autocuration,1,,A,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,,BAO_0000218,U,,5355,Cercopithecidae,
4436,In vivo,,22224,9527.0,Autocuration,1,,A,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,,BAO_0000218,U,,5355,Cercopithecidae,
4437,In vivo,,22224,9527.0,Autocuration,1,,A,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,,BAO_0000218,U,,5355,Cercopithecidae,
4438,In vivo,,22224,9527.0,Autocuration,1,,A,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,,BAO_0000218,U,,5355,Cercopithecidae,
4439,In vivo,1969.0,22224,9527.0,Autocuration,1,Plasma,A,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,,,BAO_0000218,U,,6221,Cercopithecidae,
4440,,,22224,9527.0,Autocuration,1,,A,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,,BAO_0000218,U,,167,Cercopithecidae,
4441,,,22224,9527.0,Autocuration,1,,A,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,,BAO_0000218,U,,167,Cercopithecidae,
4442,In vivo,,22224,9443.0,Autocuration,1,,A,,Absolute bioavailability was evaluated in monkey,,,BAO_0000218,U,,4257,monkey,
4443,In vivo,,22224,9443.0,Autocuration,1,,A,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,,BAO_0000218,U,,6221,monkey,
4444,In vivo,,22224,9443.0,Autocuration,1,,A,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,,BAO_0000218,U,,17667,monkey,
4445,In vivo,,22224,9544.0,Autocuration,1,,A,,Bioavailability of compound was determined in rhesus monkey,,,BAO_0000218,U,,17267,Macaca mulatta,
4446,In vivo,,22224,38020.0,Autocuration,1,,A,,Bioavailability determined after oral administration in marmoset,,,BAO_0000218,U,,4256,marmosets,
4447,In vivo,,22224,9541.0,Autocuration,1,,A,,Oral bioavailability in cynomolgus monkey,,,BAO_0000218,U,,4256,Macaca fascicularis,
4448,In vivo,,22224,9443.0,Autocuration,1,,A,,Bioavailability in monkey (p.o.) at 2.0 mpk,,,BAO_0000218,U,,17853,monkey,
4449,In vivo,,22224,9443.0,Autocuration,1,,A,,Bioavailability was evaluated after oral administration in monkey,,,BAO_0000218,U,,16365,monkey,
4450,In vivo,,22224,9541.0,Autocuration,1,,A,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,BAO_0000218,U,,1916,Macaca fascicularis,
4451,In vivo,,22224,9544.0,Autocuration,1,,A,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,BAO_0000218,U,,5334,Macaca mulatta,
4452,In vivo,,22224,9544.0,Autocuration,1,,A,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,BAO_0000218,U,,5334,Macaca mulatta,
4453,In vivo,,22224,9443.0,Autocuration,1,,A,,Bioavailability of the compound was determined in monkey,,,BAO_0000218,U,,17592,monkey,
4454,In vivo,,22224,9521.0,Autocuration,1,,A,,Bioavailability in squirrel monkey (dose 5 mg/kg),,,BAO_0000218,U,,1399,Saimiri sciureus,
4455,In vivo,,22224,9443.0,Autocuration,1,,A,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,BAO_0000218,U,,4809,monkey,
4456,In vivo,,22224,9443.0,Autocuration,1,,A,,Oral bioavailability in monkey,,,BAO_0000218,U,,3341,monkey,
4457,In vivo,,22224,9521.0,Autocuration,1,,A,,Compound was tested for bioavailability in squirrel monkey,,,BAO_0000218,U,,64,Saimiri sciureus,
4458,In vivo,,22224,9544.0,Autocuration,1,,A,,Oral bioavailability in Rhesus monkey,,,BAO_0000218,U,,5005,Macaca mulatta,
4459,In vivo,,22224,9544.0,Autocuration,1,,A,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,,BAO_0000218,U,,5005,Macaca mulatta,
4460,In vivo,,22224,9541.0,Autocuration,1,,A,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,,BAO_0000218,U,,5237,Macaca fascicularis,
4461,In vivo,,22224,9541.0,Autocuration,1,,A,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,,BAO_0000218,U,,5237,Macaca fascicularis,
4462,In vivo,,22224,9443.0,Autocuration,1,,A,,Oral bioavailability in monkey (dose 5 mg/kg),,,BAO_0000218,U,,5302,monkey,
4463,In vivo,,22224,9443.0,Autocuration,1,,A,,Oral bioavailability of compound at 5 mg/kg in monkey,,,BAO_0000218,U,,17667,monkey,
4464,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,,BAO_0000218,N,,6161,Canis lupus familiaris,
4465,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,,BAO_0000218,N,,6161,Canis lupus familiaris,
4466,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Plasma half life determined,,,BAO_0000218,N,,3854,Canis lupus familiaris,
4467,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Plasma half life in dog,,,BAO_0000218,N,,993,Canis lupus familiaris,
4468,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Plasma half-life in Beagle dogs,,,BAO_0000218,N,,4514,Canis lupus familiaris,
4469,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,,BAO_0000218,N,,5334,Canis lupus familiaris,
4470,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),,,BAO_0000218,N,,5334,Canis lupus familiaris,
4471,In vivo,,50588,9615.0,Intermediate,1,,A,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,,BAO_0000218,N,,1466,Canis lupus familiaris,
4472,In vivo,,50588,9615.0,Intermediate,1,,A,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,,BAO_0000218,N,,1466,Canis lupus familiaris,
4473,,,50588,9615.0,Intermediate,1,,A,,Tested for the half life period in dog,,,BAO_0000218,N,,5313,Canis lupus familiaris,
4474,In vivo,,50588,9615.0,Intermediate,1,,A,,Tested for the half life period in dog at dosage of 10 mpk,,,BAO_0000218,N,,5313,Canis lupus familiaris,
4475,,,50588,9615.0,Intermediate,1,,A,,The compound was tested for half life in dog,,,BAO_0000218,N,,3880,Canis lupus familiaris,
4476,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,,BAO_0000218,N,,3639,Canis lupus familiaris,
4477,,,50588,9615.0,Intermediate,1,,A,,The half life was determined,,,BAO_0000218,N,,3880,Canis lupus familiaris,
4478,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,The plasma half-life in dogs,,,BAO_0000218,N,,3918,Canis lupus familiaris,
4479,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,,BAO_0000218,N,,16452,Canis lupus familiaris,
4480,,,50588,9615.0,Intermediate,1,,A,,Half life in dog,,,BAO_0000218,N,,17796,Canis lupus familiaris,
4481,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,,BAO_0000218,N,,5983,Canis lupus familiaris,
4482,In vivo,,50588,9615.0,Intermediate,1,,A,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,,BAO_0000218,N,,1466,Canis lupus familiaris,
4483,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,BAO_0000218,N,,16456,Canis lupus familiaris,
4484,In vivo,,50506,9669.0,Expert,1,,A,,Cmax in ferrets after 30 mg/kg oral dose,,,BAO_0000218,N,,6113,Mustela putorius furo,
4485,In vivo,,50506,9669.0,Expert,1,,F,,Emesis in ferrets at 30 mg/kg oral dose,,,BAO_0000218,N,,6113,Mustela putorius furo,
4486,In vivo,,22224,9541.0,Autocuration,1,,A,,Bioavailability in cynomolgus monkey,,,BAO_0000218,U,,17796,Macaca fascicularis,
4487,In vivo,,100710,9541.0,Intermediate,1,,A,,Volume of distribution in cynomolgus,,,BAO_0000218,N,,17796,Macaca fascicularis,
4488,,1969.0,22224,10141.0,Autocuration,1,Plasma,A,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,,BAO_0000218,U,,5308,Cavia porcellus,
4489,,,22224,10141.0,Autocuration,1,,A,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,,BAO_0000218,U,,4877,Cavia porcellus,
4490,,,22224,10141.0,Autocuration,1,,A,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,,BAO_0000218,U,,4876,Cavia porcellus,
4491,In vivo,1969.0,22224,10141.0,Autocuration,1,Plasma,A,,AUC in guinea pig after 3mg/kg oral dose,,,BAO_0000218,U,,4878,Cavia porcellus,
4492,In vivo,,22224,10141.0,Autocuration,1,,A,,Bioavailability in guinea pig was tested,,,BAO_0000218,U,,5308,Cavia porcellus,
4493,In vivo,,22224,10141.0,Autocuration,1,,A,,Tested for oral bioavailability in guinea pig at 5 mg/kg,,,BAO_0000218,U,,4877,Cavia porcellus,
4494,In vivo,,22224,10141.0,Autocuration,1,,A,,Tested for the oral bioavailability of the compound,,,BAO_0000218,U,,4876,Cavia porcellus,
4495,In vivo,,22224,10141.0,Autocuration,1,,A,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,,BAO_0000218,U,,4876,Cavia porcellus,
4496,In vivo,,22224,10141.0,Autocuration,1,,A,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,,BAO_0000218,U,,5308,Cavia porcellus,
4497,In vivo,2048.0,22224,10141.0,Autocuration,1,Lung,A,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,,BAO_0000218,U,,4877,Cavia porcellus,
4498,In vivo,,22224,10141.0,Autocuration,1,,A,,Cmax in guinea pig after 3mg/kg oral dose,,,BAO_0000218,U,,4878,Cavia porcellus,
4499,,178.0,22224,10141.0,Autocuration,1,Blood,A,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,,BAO_0000019,U,,5689,Cavia porcellus,
4500,,955.0,22224,10141.0,Autocuration,1,Brain,A,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,,BAO_0000019,U,,5689,Cavia porcellus,
4501,,,22224,10141.0,Autocuration,1,,A,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,,BAO_0000019,U,,5689,Cavia porcellus,
4502,,160.0,22224,10141.0,Autocuration,1,Intestine,A,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,,BAO_0000019,U,,5689,Cavia porcellus,
4503,,2113.0,22224,10141.0,Autocuration,1,Kidney,A,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,,BAO_0000019,U,,5689,Cavia porcellus,
4504,,2107.0,22224,10141.0,Autocuration,1,Liver,A,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,,BAO_0000019,U,,5689,Cavia porcellus,
4505,,,22224,10141.0,Autocuration,1,,A,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,,BAO_0000019,U,,5689,Cavia porcellus,
4506,,2106.0,22224,10141.0,Autocuration,1,Spleen,A,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,,BAO_0000019,U,,5689,Cavia porcellus,
4507,In vivo,,22224,10141.0,Autocuration,1,,A,,Elimination T1/2 in Guinea pig (PO dose),,,BAO_0000218,U,,14465,Cavia porcellus,
4508,,,22224,10141.0,Autocuration,1,,A,,Partition coefficient was measured as -log (counts per min ),,,BAO_0000019,U,,5689,Cavia porcellus,
4509,In vivo,,22224,10141.0,Autocuration,1,,A,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,,BAO_0000218,U,,611,Cavia porcellus,
4510,In vivo,,22224,10141.0,Autocuration,1,,A,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,,BAO_0000218,U,,611,Cavia porcellus,
4511,In vivo,,22224,10141.0,Autocuration,1,,A,,Elimination T1/2 in Guinea pig (PO dose),,,BAO_0000218,U,,14465,Cavia porcellus,
4512,In vivo,,22224,10141.0,Autocuration,1,,A,,"Tested for the half life period of the compound, intravenously",,,BAO_0000218,U,,4876,Cavia porcellus,
4513,,,22224,10141.0,Autocuration,1,,A,,Half-life was measured,,,BAO_0000019,U,,5689,Cavia porcellus,
4514,,,22224,10141.0,Autocuration,1,,A,,The time required for onset of inotropy after addition of a single dose of delta F75,,,BAO_0000019,U,,7515,Cavia porcellus,
4515,In vivo,,22224,10141.0,Autocuration,1,,A,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,,BAO_0000218,U,,17667,Cavia porcellus,
4516,In vivo,,22224,10141.0,Autocuration,1,,A,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,,BAO_0000218,U,,17667,Cavia porcellus,
4517,In vivo,,22224,10029.0,Autocuration,1,,A,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,,BAO_0000218,U,,4727,Cricetulus griseus,
4518,In vivo,,50594,10090.0,Intermediate,1,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,BAO_0000218,N,,10107,Mus musculus,
4519,In vivo,,50594,10090.0,Intermediate,1,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,BAO_0000218,N,,10107,Mus musculus,
4520,In vivo,,50594,10090.0,Intermediate,1,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,BAO_0000218,N,,10107,Mus musculus,
4521,In vivo,,50594,10090.0,Intermediate,1,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,BAO_0000218,N,,10107,Mus musculus,
4522,In vivo,,50594,10090.0,Intermediate,1,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,,BAO_0000218,N,,10107,Mus musculus,
4523,In vivo,,50594,10090.0,Intermediate,1,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,BAO_0000218,N,,10107,Mus musculus,
4524,In vivo,,50594,10090.0,Intermediate,1,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,BAO_0000218,N,,10107,Mus musculus,
4525,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4526,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4527,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4528,In vivo,10000001.0,50594,10090.0,Intermediate,1,Bone,A,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4529,In vivo,10000001.0,50594,10090.0,Intermediate,1,Bone,A,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4530,In vivo,10000001.0,50594,10090.0,Intermediate,1,Bone,A,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4531,In vivo,955.0,50594,10090.0,Intermediate,1,Brain,A,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4532,In vivo,955.0,50594,10090.0,Intermediate,1,Brain,A,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4533,In vivo,955.0,50594,10090.0,Intermediate,1,Brain,A,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4534,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4535,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4536,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4537,In vivo,160.0,50594,10090.0,Intermediate,1,Intestine,A,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4538,In vivo,160.0,50594,10090.0,Intermediate,1,Intestine,A,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4539,In vivo,160.0,50594,10090.0,Intermediate,1,Intestine,A,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4540,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4541,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4542,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4543,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4544,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4545,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4546,In vivo,2048.0,50594,10090.0,Intermediate,1,Lung,A,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4547,In vivo,2048.0,50594,10090.0,Intermediate,1,Lung,A,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4548,In vivo,2048.0,50594,10090.0,Intermediate,1,Lung,A,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4549,In vivo,2385.0,50594,10090.0,Intermediate,1,Muscle tissue,A,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4550,In vivo,2385.0,50594,10090.0,Intermediate,1,Muscle tissue,A,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4551,In vivo,2385.0,50594,10090.0,Intermediate,1,Muscle tissue,A,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4552,In vivo,2106.0,50594,10090.0,Intermediate,1,Spleen,A,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4553,In vivo,2106.0,50594,10090.0,Intermediate,1,Spleen,A,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4554,In vivo,2106.0,50594,10090.0,Intermediate,1,Spleen,A,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4555,In vivo,945.0,50594,10090.0,Intermediate,1,Stomach,A,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4556,In vivo,945.0,50594,10090.0,Intermediate,1,Stomach,A,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4557,In vivo,945.0,50594,10090.0,Intermediate,1,Stomach,A,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,,,BAO_0000218,N,,3655,Mus musculus,
4558,In vivo,,50594,10090.0,Intermediate,1,,A,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,,BAO_0000218,N,,16597,Mus musculus,
4559,In vivo,,50594,10090.0,Intermediate,1,,F,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,,BAO_0000218,N,,16597,Mus musculus,
4560,In vivo,,50594,10090.0,Intermediate,1,,A,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,,BAO_0000218,N,,16597,Mus musculus,
4561,In vivo,,50594,10090.0,Intermediate,1,,A,,MRT value at a dose of 10 mg/kg peroral administration in mice.,,,BAO_0000218,N,,16597,Mus musculus,
4562,In vivo,,50594,10090.0,Intermediate,1,,A,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
4563,In vivo,,50594,10090.0,Intermediate,1,,F,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
4564,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,,BAO_0000219,N,,3830,Homo sapiens,A2780
4565,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,,BAO_0000219,N,,3829,Homo sapiens,A2780
4566,,,81034,9606.0,Intermediate,1,,F,478.0,Compound was evaluated for cytotoxicity against A2780 cell lines.,,,BAO_0000219,N,,2040,Homo sapiens,A2780
4567,,,81034,9606.0,Intermediate,1,,F,478.0,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,,BAO_0000219,N,,15684,Homo sapiens,A2780
4568,,,81034,9606.0,Intermediate,1,,F,478.0,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,,BAO_0000219,N,,15684,Homo sapiens,A2780
4569,,,81034,9606.0,Intermediate,1,,F,478.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,,BAO_0000219,N,,15684,Homo sapiens,A2780
4570,,,81034,9606.0,Intermediate,1,,F,478.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,,BAO_0000219,N,,15684,Homo sapiens,A2780
4571,,,81034,9606.0,Intermediate,1,,F,478.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,,BAO_0000219,N,,15684,Homo sapiens,A2780
4572,,,81034,9606.0,Intermediate,1,,F,478.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,,BAO_0000219,N,,15684,Homo sapiens,A2780
4573,,,81034,9606.0,Intermediate,1,,F,478.0,Compound was evaluated for cytotoxicity against A2780 cell line,,,BAO_0000219,N,,2859,Homo sapiens,A2780
4574,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro inhibitory activity against human tumor cell line A2780,,,BAO_0000219,N,,5618,Homo sapiens,A2780
4575,,,81034,9606.0,Intermediate,1,,F,478.0,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,,BAO_0000219,N,,15684,Homo sapiens,A2780
4576,,,81034,9606.0,Intermediate,1,,F,478.0,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,,BAO_0000219,N,,15684,Homo sapiens,A2780
4577,,,81034,9606.0,Intermediate,1,,F,478.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,,BAO_0000219,N,,15684,Homo sapiens,A2780
4578,,,81034,9606.0,Intermediate,1,,F,478.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,,BAO_0000219,N,,15684,Homo sapiens,A2780
4579,,,81034,9606.0,Intermediate,1,,F,478.0,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,,BAO_0000219,N,,2113,Homo sapiens,A2780
4580,,,81034,9606.0,Intermediate,1,,F,478.0,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,,BAO_0000219,N,,2113,Homo sapiens,A2780
4581,,,81034,9606.0,Intermediate,1,,F,478.0,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,,BAO_0000219,N,,16745,Homo sapiens,A2780
4582,,,81034,9606.0,Expert,1,,F,478.0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,,BAO_0000218,N,,16597,Homo sapiens,A2780
4583,,,81034,9606.0,Intermediate,1,,F,478.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,,BAO_0000219,N,,15684,Homo sapiens,A2780
4584,,,81034,9606.0,Intermediate,1,,F,478.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,,BAO_0000219,N,,15684,Homo sapiens,A2780
4585,,,81034,9606.0,Intermediate,1,,F,478.0,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,,BAO_0000219,N,,2040,Homo sapiens,A2780
4586,,,81034,9606.0,Intermediate,1,,F,478.0,Relative resistance factor in A2780 cisplatin-resistant line,,,BAO_0000219,N,,2040,Homo sapiens,A2780
4587,,,81034,9606.0,Intermediate,1,,F,478.0,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,,BAO_0000219,N,,16165,Homo sapiens,A2780
4588,,,81034,9606.0,Intermediate,1,,F,478.0,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,,BAO_0000219,N,,16165,Homo sapiens,A2780
4589,,,81034,9606.0,Expert,1,,F,478.0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,,BAO_0000218,N,,16597,Homo sapiens,A2780
4590,,,81034,9606.0,Expert,1,,F,478.0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,,BAO_0000218,N,,16597,Homo sapiens,A2780
4591,,,81034,9606.0,Intermediate,1,,F,478.0,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,,BAO_0000219,N,,3992,Homo sapiens,A2780
4592,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,,BAO_0000219,N,,10553,Homo sapiens,A2780
4593,,,81034,9606.0,Intermediate,1,,F,478.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,,BAO_0000219,N,,15608,Homo sapiens,A2780
4594,,,81034,9606.0,Intermediate,1,,F,478.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,,BAO_0000219,N,,15608,Homo sapiens,A2780
4595,,,81034,9606.0,Intermediate,1,,F,478.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,,BAO_0000219,N,,15608,Homo sapiens,A2780
4596,,,81034,9606.0,Intermediate,1,,F,478.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,,BAO_0000219,N,,15608,Homo sapiens,A2780
4597,,,81034,9606.0,Intermediate,1,,F,478.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,,BAO_0000219,N,,15608,Homo sapiens,A2780
4598,,,81034,9606.0,Intermediate,1,,F,478.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,,BAO_0000219,N,,15608,Homo sapiens,A2780
4599,,,81034,9606.0,Intermediate,1,,F,478.0,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,,BAO_0000219,N,,15569,Homo sapiens,A2780
4600,,,81034,9606.0,Intermediate,1,,F,478.0,Antiproliferative effect of compound on A2780/DX cell line,,,BAO_0000219,N,,17420,Homo sapiens,A2780
4601,,,81034,9606.0,Intermediate,1,,F,478.0,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,,BAO_0000219,N,,17420,Homo sapiens,A2780
4602,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,,BAO_0000219,N,,15099,Homo sapiens,A2780
4603,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,,BAO_0000219,N,,15099,Homo sapiens,A2780
4604,,,81034,9606.0,Intermediate,1,,F,478.0,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,,BAO_0000219,N,,17672,Homo sapiens,A2780
4605,,,81034,9606.0,Intermediate,1,,F,478.0,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,,BAO_0000219,N,,17672,Homo sapiens,A2780
4606,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro cytotoxicity against A2780ADR cell line,,,BAO_0000219,N,,17270,Homo sapiens,A2780
4607,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro cytotoxicity against A2780CIS cell line,,,BAO_0000219,N,,17270,Homo sapiens,A2780
4608,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,,BAO_0000219,N,,5574,Homo sapiens,A2780
4609,,,81034,9606.0,Intermediate,1,,F,478.0,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,,BAO_0000219,N,,2113,Homo sapiens,A2780
4610,,,81034,9606.0,Intermediate,1,,F,478.0,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,,BAO_0000219,N,,16913,Homo sapiens,A2780
4611,,,81034,9606.0,Intermediate,1,,F,478.0,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,,BAO_0000219,N,,16913,Homo sapiens,A2780
4612,In vivo,,22224,9544.0,Autocuration,1,,A,,Oral bioavailability of compound in rhesus macaques,,,BAO_0000218,U,,17839,Macaca mulatta,
4613,In vivo,,22224,9443.0,Autocuration,1,,A,,Oral bioavailability in monkey,,,BAO_0000218,U,,6821,monkey,
4614,In vivo,,22224,9443.0,Autocuration,1,,A,,Oral bioavailability evaluated in monkey,,,BAO_0000218,U,,6078,monkey,
4615,In vivo,,22224,9443.0,Autocuration,1,,A,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,,BAO_0000218,U,,6535,monkey,
4616,In vivo,,22224,9544.0,Autocuration,1,,A,,Oral bioavailability in Rhesus monkey,,,BAO_0000218,U,,4449,Macaca mulatta,
4617,In vivo,,22224,9544.0,Autocuration,1,,A,,Oral bioavailability was calculated in rhesus monkey,,,BAO_0000218,U,,6057,Macaca mulatta,
4618,In vivo,,22224,9541.0,Autocuration,1,,A,,Oral bioavailability in cynomolgus monkey,,,BAO_0000218,U,,5922,Macaca fascicularis,
4619,In vivo,,22224,9443.0,Autocuration,1,,A,,Oral bioavailability in monkey,,,BAO_0000218,U,,5940,monkey,
4620,In vivo,,22224,9443.0,Autocuration,1,,A,,Oral bioavailability in monkey,,,BAO_0000218,U,,6265,monkey,
4621,In vivo,,22224,9443.0,Autocuration,1,,A,,Oral bioavailability in monkey (dose 1 mg/kg),,,BAO_0000218,U,,6265,monkey,
4622,In vivo,,22224,9443.0,Autocuration,1,,A,,Oral bioavailability in monkey (dose 5 mg/kg),,,BAO_0000218,U,,6265,monkey,
4623,In vivo,,22224,9443.0,Autocuration,1,,A,,Oral bioavailability in monkey,,,BAO_0000218,U,,5940,monkey,
4624,In vivo,,22224,9443.0,Autocuration,1,,A,,Oral bioavailability in monkey,,,BAO_0000218,U,,5940,monkey,
4625,In vivo,,22224,9544.0,Autocuration,1,,A,,Oral bioavailability in rhesus monkey,,,BAO_0000218,U,,4514,Macaca mulatta,
4626,In vivo,,22224,9544.0,Autocuration,1,,A,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,,BAO_0000218,U,,5546,Macaca mulatta,
4627,In vivo,,22224,9521.0,Autocuration,1,,A,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,,BAO_0000218,U,,5553,Saimiri sciureus,
4628,In vivo,,22224,9443.0,Autocuration,1,,A,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,BAO_0000218,U,,6641,monkey,
4629,In vivo,,22224,9544.0,Autocuration,1,,A,,Oral bioavailability in Rhesus monkey,,,BAO_0000218,U,,5472,Macaca mulatta,
4630,In vivo,,22224,9544.0,Autocuration,1,,A,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,,BAO_0000218,U,,5668,Macaca mulatta,
4631,In vivo,,22224,9443.0,Autocuration,1,,A,,Oral bioavailability in monkey at 10 mg/kg of the compound,,,BAO_0000218,U,,5711,monkey,
4632,In vivo,,22224,9544.0,Autocuration,1,,A,,Bioavailability in Rhesus monkey,,,BAO_0000218,U,,5145,Macaca mulatta,
4633,,,22224,9527.0,Autocuration,1,,A,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,BAO_0000218,U,,3443,Cercopithecidae,
4634,,,22224,9527.0,Autocuration,1,,A,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,BAO_0000218,U,,3443,Cercopithecidae,
4635,In vivo,,22224,9527.0,Autocuration,1,,A,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,,BAO_0000218,U,,3249,Cercopithecidae,
4636,In vivo,,22224,9527.0,Autocuration,1,,A,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,,BAO_0000218,U,,3249,Cercopithecidae,
4637,In vivo,,22224,9527.0,Autocuration,1,,A,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,,BAO_0000218,U,,5355,Cercopithecidae,
4638,In vivo,,22224,9527.0,Autocuration,1,,A,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,,BAO_0000218,U,,5355,Cercopithecidae,
4639,In vivo,,22224,9527.0,Autocuration,1,,A,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,,BAO_0000218,U,,5355,Cercopithecidae,
4640,In vivo,,22224,9527.0,Autocuration,1,,A,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,BAO_0000218,U,,4809,Cercopithecidae,
4641,In vivo,,22224,9527.0,Autocuration,1,,A,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,BAO_0000218,U,,4809,Cercopithecidae,
4642,,,22224,9527.0,Autocuration,1,,A,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),Microsomes,,BAO_0000251,U,,14294,Cercopithecidae,
4643,,,22224,9527.0,Autocuration,1,,A,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),Microsomes,,BAO_0000251,U,,14294,Cercopithecidae,
4644,,,22224,9527.0,Autocuration,1,,A,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),Microsomes,,BAO_0000251,U,,14294,Cercopithecidae,
4645,,,22224,9527.0,Autocuration,1,,A,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),Microsomes,,BAO_0000251,U,,14294,Cercopithecidae,
4646,In vivo,,22224,9527.0,Autocuration,1,,A,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,BAO_0000218,U,,3443,Cercopithecidae,
4647,In vivo,,22224,9527.0,Autocuration,1,,A,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,BAO_0000218,U,,3443,Cercopithecidae,
4648,,,22224,9527.0,Autocuration,1,,A,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,,BAO_0000019,U,,11271,Cercopithecidae,
4649,,,22224,9527.0,Autocuration,1,,A,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,BAO_0000218,U,,3443,Cercopithecidae,
4650,,,22224,9527.0,Autocuration,1,,A,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,BAO_0000218,U,,3443,Cercopithecidae,
4651,,,22224,9527.0,Autocuration,1,,A,,Elimination Half-life of compound was determined in monkey,,,BAO_0000019,U,,6821,Cercopithecidae,
4652,,,22224,9527.0,Autocuration,1,,A,,Half life of compound was determined in rhesus monkey,,,BAO_0000019,U,,17267,Cercopithecidae,
4653,,1969.0,22224,9527.0,Autocuration,1,Plasma,A,,Half life in monkey plasma,,,BAO_0000366,U,,5819,Cercopithecidae,
4654,,1969.0,22224,9527.0,Autocuration,1,Plasma,A,,Half life in monkey plasma; Not detected,,,BAO_0000366,U,,5819,Cercopithecidae,
4655,In vivo,,22224,9527.0,Autocuration,1,,A,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,BAO_0000218,U,,1916,Cercopithecidae,
4656,In vivo,,22224,9527.0,Autocuration,1,,A,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,,BAO_0000218,U,,17509,Cercopithecidae,
4657,,,22224,9527.0,Autocuration,1,,A,,Terminal half life of the compound.,,,BAO_0000019,U,,1399,Cercopithecidae,
4658,In vivo,,22224,9527.0,Autocuration,1,,A,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,BAO_0000218,U,,1916,Cercopithecidae,
4659,In vivo,,22224,9527.0,Autocuration,1,,A,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,BAO_0000218,U,,4809,Cercopithecidae,
4660,,,22224,9527.0,Autocuration,1,,A,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,,BAO_0000218,U,,5546,Cercopithecidae,
4661,,1088.0,22224,9527.0,Autocuration,1,Urine,A,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,BAO_0000218,U,,3443,Cercopithecidae,
4662,,1088.0,22224,9527.0,Autocuration,1,Urine,A,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,BAO_0000218,U,,3443,Cercopithecidae,
4663,In vivo,,22224,9527.0,Autocuration,1,,A,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,,BAO_0000218,U,,4257,Cercopithecidae,
4664,In vivo,,22224,9527.0,Autocuration,1,,A,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,,BAO_0000218,U,,6221,Cercopithecidae,
4665,In vivo,,22224,9527.0,Autocuration,1,,A,,Volume of distribution was evaluated in rhesus,,,BAO_0000218,U,,5472,Cercopithecidae,
4666,In vivo,,22224,10029.0,Autocuration,1,,A,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,,BAO_0000218,U,,4727,Cricetulus griseus,
4667,In vivo,,22224,10029.0,Autocuration,1,,A,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,,BAO_0000218,U,,4727,Cricetulus griseus,
4668,In vivo,,22224,10029.0,Autocuration,1,,A,,Bioavailability in hamster was determined,,,BAO_0000218,U,,4727,Cricetulus griseus,
4669,In vivo,,22224,10029.0,Autocuration,1,,A,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,,BAO_0000218,U,,4727,Cricetulus griseus,
4670,In vivo,,22224,10029.0,Autocuration,1,,A,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,,BAO_0000218,U,,4727,Cricetulus griseus,
4671,,178.0,22224,10029.0,Autocuration,1,Blood,A,,Half life of compound was determined in hamster blood,,,BAO_0000221,U,,4727,Cricetulus griseus,
4672,,,22224,9823.0,Autocuration,1,,A,,Michaelis-Menten constant of the compound.,,,BAO_0000019,U,,1452,Sus scrofa,
4673,,,22224,9823.0,Autocuration,1,,A,,Vmax value was measured at 0 uM concentration of silyl ether.,,,BAO_0000019,U,,1452,Sus scrofa,
4674,,,22224,9823.0,Autocuration,1,,A,,Vmax value was measured at 10 uM concentration of silyl ether.,,,BAO_0000019,U,,1452,Sus scrofa,
4675,,,22224,9823.0,Autocuration,1,,A,,Vmax value was measured at 5 uM concentration of silyl ether.,,,BAO_0000019,U,,1452,Sus scrofa,
4676,,,235,9606.0,Expert,1,,B,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,,BAO_0000357,D,,11706,Homo sapiens,
4677,,,22224,9606.0,Autocuration,1,,A,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,,BAO_0000218,U,,1916,Homo sapiens,
4678,,,22224,9606.0,Autocuration,1,,A,,Compound was evaluated for area under the curve expressed as (h*ug/ml),,,BAO_0000019,U,,17791,Homo sapiens,
4679,,,22224,9606.0,Autocuration,1,,A,,Active metabolite of ifosfamide determined in humans; A-Active,,,BAO_0000019,U,,7766,Homo sapiens,
4680,,,22224,9606.0,Autocuration,1,,A,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,,BAO_0000019,U,,6567,Homo sapiens,
4681,,,22224,9606.0,Autocuration,1,,A,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,,BAO_0000019,U,,6567,Homo sapiens,
4682,,,22224,9606.0,Autocuration,1,,A,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,,BAO_0000019,U,,6567,Homo sapiens,
4683,,,22224,9606.0,Autocuration,1,,A,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,,BAO_0000019,U,,6567,Homo sapiens,
4684,,,22224,9606.0,Autocuration,1,,A,,Compound was evaluated for oral bioavailability in human,,,BAO_0000218,U,,17791,Homo sapiens,
4685,,1088.0,22224,9606.0,Autocuration,1,Urine,A,,Metabolite of ifosfamide determined in urine; NF-Not found,,,BAO_0000019,U,,7766,Homo sapiens,
4686,,,22224,9606.0,Autocuration,1,,A,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,,BAO_0000019,U,,6852,Homo sapiens,
4687,,,22224,9606.0,Autocuration,1,,A,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,,BAO_0000019,U,,6852,Homo sapiens,
4688,,,22224,9606.0,Autocuration,1,,A,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,,BAO_0000019,U,,6852,Homo sapiens,
4689,,,22224,9606.0,Autocuration,1,,A,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,,BAO_0000019,U,,6852,Homo sapiens,
4690,,,22224,9606.0,Autocuration,1,,A,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,,BAO_0000019,U,,6852,Homo sapiens,
4691,,,22224,9606.0,Autocuration,1,,A,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,,BAO_0000019,U,,6852,Homo sapiens,
4692,,,22224,9606.0,Autocuration,1,,A,,Percent of compound in healthy individuals (Group D),,,BAO_0000019,U,,6852,Homo sapiens,
4693,,2107.0,22224,9606.0,Autocuration,1,Liver,A,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Microsomes,,BAO_0000251,U,,4397,Homo sapiens,
4694,,,22224,9606.0,Autocuration,1,,A,,Binding towards human plasma protein at 10 uM,,,BAO_0000019,U,,17409,Homo sapiens,
4695,,,22224,9606.0,Autocuration,1,,A,,Binding towards human plasma protein at 100 uM,,,BAO_0000019,U,,17409,Homo sapiens,
4696,,,22224,9606.0,Autocuration,1,,A,,Human plasma protein binding activity was determined,,,BAO_0000019,U,,17176,Homo sapiens,
4697,,,22224,9606.0,Autocuration,1,,A,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,,BAO_0000019,U,,15444,Homo sapiens,
4698,,,22224,9606.0,Autocuration,1,,A,,Percent binding of compound towards human plasma protein was determined,,,BAO_0000019,U,,17267,Homo sapiens,
4699,In vitro,2107.0,22224,9606.0,Autocuration,1,Liver,A,,Plasma clearance in human liver microsomes,Microsomes,,BAO_0000251,U,,5944,Homo sapiens,
4700,In vitro,2107.0,22224,9606.0,Autocuration,1,Liver,A,,In vitro intrinsic clearance in human liver microsome,Microsomes,,BAO_0000251,U,,5668,Homo sapiens,
4701,In vitro,2107.0,22224,9606.0,Autocuration,1,Liver,A,,In vitro intrinsic clearance in human liver microsome,Microsomes,,BAO_0000251,U,,5669,Homo sapiens,
4702,In vitro,,22224,9606.0,Autocuration,1,,A,,In vitro microsome metabolism clearance in human was determined,Microsomes,,BAO_0000251,U,,5041,Homo sapiens,
4703,In vitro,,22224,9606.0,Autocuration,1,,A,,In vitro microsome metabolism clearance in human was determined; High,Microsomes,,BAO_0000251,U,,5041,Homo sapiens,
4704,In vitro,,22224,9606.0,Autocuration,1,,A,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,Microsomes,,BAO_0000251,U,,5041,Homo sapiens,
4705,In vitro,2107.0,22224,9606.0,Autocuration,1,Liver,A,,Pharmacokinetic property (clearance) in human liver microsome,Microsomes,,BAO_0000251,U,,5676,Homo sapiens,
4706,In vitro,2107.0,22224,9606.0,Autocuration,1,Liver,A,,Plasma clearance in human liver microsomes,Microsomes,,BAO_0000251,U,,5944,Homo sapiens,
4707,In vitro,2107.0,22224,9606.0,Autocuration,1,Liver,A,,In vitro clearance in human liver microsomes,Microsomes,,BAO_0000251,U,,17538,Homo sapiens,
4708,In vitro,2107.0,22224,9606.0,Autocuration,1,Liver,A,,Intrinsic clearance in human liver microsomes was determined,Microsomes,,BAO_0000251,U,,6331,Homo sapiens,
4709,In vitro,2107.0,22224,9606.0,Autocuration,1,Liver,A,,Intrinsic clearance in human liver microsomes was determined,Microsomes,,BAO_0000251,U,,5948,Homo sapiens,
4710,In vivo,,22224,9606.0,Autocuration,1,,A,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,,BAO_0000218,U,,5965,Homo sapiens,
4711,In vivo,,22224,9606.0,Autocuration,1,,A,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,,BAO_0000218,U,,1916,Homo sapiens,
4712,,,22224,9606.0,Autocuration,1,,A,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,,BAO_0000218,U,,5965,Homo sapiens,
4713,,,22224,9606.0,Autocuration,1,,A,,Stability in human plasma 2 hr after incubation expressed as percent concentration,,,BAO_0000019,U,,1299,Homo sapiens,
4714,,,22224,9606.0,Autocuration,1,,A,,Stability in human plasma 4 hr after incubation expressed as percent concentration,,,BAO_0000019,U,,1299,Homo sapiens,
4715,,1088.0,22224,9606.0,Autocuration,1,Urine,A,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,BAO_0000019,U,,7766,Homo sapiens,
4716,,1088.0,22224,9606.0,Autocuration,1,Urine,A,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,BAO_0000019,U,,7766,Homo sapiens,
4717,,1088.0,22224,9606.0,Autocuration,1,Urine,A,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,BAO_0000019,U,,7766,Homo sapiens,
4718,,1088.0,22224,9606.0,Autocuration,1,Urine,A,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,BAO_0000019,U,,7766,Homo sapiens,
4719,In vivo,,50594,10090.0,Intermediate,1,,F,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
4720,In vivo,,50594,10090.0,Intermediate,1,,F,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
4721,In vivo,,50594,10090.0,Intermediate,1,,F,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
4722,In vivo,,50594,10090.0,Intermediate,1,,F,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
4723,,,50594,10090.0,Intermediate,1,,A,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,,BAO_0000218,N,,14294,Mus musculus,
4724,,,50594,10090.0,Intermediate,1,,A,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,,BAO_0000218,N,,14294,Mus musculus,
4725,,,50594,10090.0,Intermediate,1,,A,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,,BAO_0000218,N,,14294,Mus musculus,
4726,,2107.0,50594,10090.0,Intermediate,1,Liver,A,,In vitro metabolic potential in mouse liver microsomes,,,BAO_0000218,N,,6251,Mus musculus,
4727,,,50594,10090.0,Intermediate,1,,A,,Ability of compound to bind to plasma protein was evaluated in HSA cells,,,BAO_0000218,N,,17582,Mus musculus,
4728,,2369.0,50594,10090.0,Intermediate,1,Adrenal gland,A,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,,BAO_0000218,N,,17811,Mus musculus,
4729,,955.0,50594,10090.0,Intermediate,1,Brain,A,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,,BAO_0000218,N,,17811,Mus musculus,
4730,,955.0,50594,10090.0,Intermediate,1,Brain,A,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,,BAO_0000218,N,,17811,Mus musculus,
4731,,,50594,10090.0,Intermediate,1,,A,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,,BAO_0000218,N,,17811,Mus musculus,
4732,,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,,BAO_0000218,N,,17811,Mus musculus,
4733,,,50594,10090.0,Intermediate,1,,A,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,,BAO_0000218,N,,17811,Mus musculus,
4734,,,50594,10090.0,Intermediate,1,,A,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,,BAO_0000218,N,,5288,Mus musculus,
4735,,1977.0,50594,10090.0,Intermediate,1,Serum,A,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,,BAO_0000218,N,,2717,Mus musculus,
4736,,1977.0,50594,10090.0,Intermediate,1,Serum,A,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,,BAO_0000218,N,,2717,Mus musculus,
4737,,1977.0,50594,10090.0,Intermediate,1,Serum,A,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,,BAO_0000218,N,,2717,Mus musculus,
4738,In vivo,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,Half life of compound was determined in plasma of mice at 24 mg/Kg,,,BAO_0000218,N,,17753,Mus musculus,
4739,In vivo,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,Half life of compound was determined in plasma of mice at 40 mg/Kg,,,BAO_0000218,N,,17753,Mus musculus,
4740,In vivo,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,Half life of compound was determined in plasma of mice at 5 mg/Kg,,,BAO_0000218,N,,17753,Mus musculus,
4741,In vivo,,50594,10090.0,Intermediate,1,,F,,Half life after intraperitoneal administration in mice at 18 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
4742,In vivo,,50594,10090.0,Intermediate,1,,F,,Half life after intraperitoneal administration in mice at 23 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
4743,In vivo,,50594,10090.0,Intermediate,1,,F,,Half life after intraperitoneal administration in mice at 25 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
4744,In vivo,,50594,10090.0,Intermediate,1,,F,,Half life after intraperitoneal administration in mice at 26 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
4745,In vivo,,50594,10090.0,Intermediate,1,,F,,Half life after intravenous administration in mice at 23 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
4746,In vivo,,50594,10090.0,Intermediate,1,,A,,Half life after intravenous administration in mice at 24 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
4747,In vivo,,50594,10090.0,Intermediate,1,,A,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,,BAO_0000218,N,,16597,Mus musculus,
4748,In vivo,,50594,10090.0,Intermediate,1,,A,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,,BAO_0000218,N,,2675,Mus musculus,
4749,In vivo,,50594,10090.0,Intermediate,1,,A,,Maximum time required to reach Cp max was evaluated in mice after oral administration,,,BAO_0000218,N,,2675,Mus musculus,
4750,In vivo,,50594,10090.0,Intermediate,1,,A,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,,BAO_0000218,N,,16597,Mus musculus,
4751,In vivo,,50594,10090.0,Intermediate,1,,A,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,,BAO_0000218,N,,4890,Mus musculus,
4752,In vivo,,50594,10090.0,Intermediate,1,,A,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,,BAO_0000218,N,,429,Mus musculus,
4753,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,,,BAO_0000218,N,,17837,Mus musculus,
4754,In vivo,,50594,10090.0,Intermediate,1,,A,,Half life at a dose of 10 mg/kg intravenous administration in mice.,,,BAO_0000218,N,,16597,Mus musculus,
4755,In vivo,,50594,10090.0,Intermediate,1,,A,,Half life at a dose of 10 mg/kg peroral administration in mice.,,,BAO_0000218,N,,16597,Mus musculus,
4756,,,50594,10090.0,Intermediate,1,,A,,Half life in ob/ob mice,,,BAO_0000218,N,,6619,Mus musculus,
4757,In vivo,,50594,10090.0,Intermediate,1,,A,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,,BAO_0000218,N,,4066,Mus musculus,
4758,,,50594,10090.0,Intermediate,1,,A,,Half-life was measured in mouse,,,BAO_0000218,N,,4239,Mus musculus,
4759,In vivo,,50594,10090.0,Intermediate,1,,A,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,,BAO_0000218,N,,5969,Mus musculus,
4760,,,50594,10090.0,Intermediate,1,,A,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,,BAO_0000218,N,,8999,Mus musculus,
4761,,,50594,10090.0,Intermediate,1,,A,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,,BAO_0000218,N,,8999,Mus musculus,
4762,,955.0,50594,10090.0,Intermediate,1,Brain,A,,T2 in brain of mice at the oral dose of 50 mg/kg,,,BAO_0000218,N,,17641,Mus musculus,
4763,,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,T2 in kidney of mice at the oral dose of 50 mg/kg,,,BAO_0000218,N,,17641,Mus musculus,
4764,,2107.0,50594,10090.0,Intermediate,1,Liver,A,,T2 in liver of mice at the oral dose of 50 mg/kg,,,BAO_0000218,N,,17641,Mus musculus,
4765,,2048.0,50594,10090.0,Intermediate,1,Lung,A,,T2 in lungs of mice at the oral dose of 50 mg/kg,,,BAO_0000218,N,,17641,Mus musculus,
4766,,2106.0,50594,10090.0,Intermediate,1,Spleen,A,,T2 in spleen of mice at the oral dose of 50 mg/kg,,,BAO_0000218,N,,17641,Mus musculus,
4767,In vivo,,50594,10090.0,Intermediate,1,,A,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,,BAO_0000218,N,,16597,Mus musculus,
4768,In vivo,,50594,10090.0,Intermediate,1,,A,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,,BAO_0000218,N,,4890,Mus musculus,
4769,In vivo,,50594,10090.0,Intermediate,1,,A,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,,BAO_0000218,N,,429,Mus musculus,
4770,In vivo,,50594,10090.0,Intermediate,1,,A,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,,BAO_0000218,N,,429,Mus musculus,
4771,In vivo,,50594,10090.0,Intermediate,1,,A,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,,BAO_0000218,N,,5969,Mus musculus,
4772,,,81034,9606.0,Intermediate,1,,F,478.0,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,,BAO_0000219,N,,16913,Homo sapiens,A2780
4773,,,81034,9606.0,Intermediate,1,,F,478.0,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,,BAO_0000219,N,,16913,Homo sapiens,A2780
4774,,,81034,9606.0,Intermediate,1,,F,478.0,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,,BAO_0000219,N,,16913,Homo sapiens,A2780
4775,,,81034,9606.0,Intermediate,1,,F,478.0,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,,BAO_0000219,N,,16913,Homo sapiens,A2780
4776,,,81034,9606.0,Intermediate,1,,F,478.0,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,,BAO_0000219,N,,16913,Homo sapiens,A2780
4777,,,81034,9606.0,Intermediate,1,,F,478.0,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,,BAO_0000219,N,,16913,Homo sapiens,A2780
4778,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro cytotoxicity against A2780TAX cell line,,,BAO_0000219,N,,17270,Homo sapiens,A2780
4779,,,80017,9606.0,Intermediate,1,,F,481.0,In vitro inhibitory activity against human tumor cell line A2780cis,,,BAO_0000219,N,,5618,Homo sapiens,A2780cisR
4780,,,81034,9606.0,Expert,1,,F,478.0,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,,BAO_0000219,N,,17777,Homo sapiens,A2780
4781,,,80017,9606.0,Intermediate,1,,F,481.0,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,,BAO_0000219,N,,16112,Homo sapiens,A2780cisR
4782,,,80017,9606.0,Intermediate,1,,F,481.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,,BAO_0000219,N,,15748,Homo sapiens,A2780cisR
4783,,,81034,9606.0,Intermediate,1,,F,478.0,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,,BAO_0000219,N,,6633,Homo sapiens,A2780
4784,,,81034,9606.0,Intermediate,1,,F,478.0,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,,BAO_0000219,N,,16930,Homo sapiens,A2780
4785,,,81034,9606.0,Intermediate,1,,F,478.0,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,,BAO_0000219,N,,17496,Homo sapiens,A2780
4786,,,81034,9606.0,Expert,1,,F,478.0,In vitro antitumor activity against A2780cisR cell line.,,,BAO_0000219,N,,12989,Homo sapiens,A2780
4787,,,81034,9606.0,Intermediate,1,,F,478.0,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,,BAO_0000219,N,,4840,Homo sapiens,A2780
4788,,,81034,9606.0,Expert,1,,F,478.0,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,,BAO_0000219,N,,12989,Homo sapiens,A2780
4789,,,80017,9606.0,Intermediate,1,,F,481.0,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,,BAO_0000219,N,,16745,Homo sapiens,A2780cisR
4790,,,81034,9606.0,Expert,1,,F,478.0,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,,BAO_0000219,N,,16597,Homo sapiens,A2780
4791,,,11736,10116.0,Expert,1,,B,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,,BAO_0000019,D,,16547,Rattus norvegicus,
4792,,,11736,,Expert,1,,F,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,,BAO_0000019,H,,16547,,
4793,,,11736,10116.0,Expert,1,,F,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,,BAO_0000019,D,,16547,Rattus norvegicus,
4794,,,278,9606.0,Expert,1,,F,722.0,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,,BAO_0000219,D,,15856,Homo sapiens,HEK293
4795,,,278,9606.0,Expert,1,,F,722.0,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,,BAO_0000219,D,,15856,Homo sapiens,HEK293
4796,,,11831,10090.0,Expert,1,,B,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,,BAO_0000019,D,,16547,Mus musculus,
4797,,,11831,,Expert,1,,F,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,,BAO_0000019,H,,16547,,
4798,,,11831,10090.0,Expert,1,,F,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,,BAO_0000019,D,,16547,Mus musculus,
4799,,,280,,Expert,1,,B,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,,BAO_0000357,H,,17402,,
4800,,,22226,9606.0,Autocuration,1,,F,574.0,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,,BAO_0000219,U,,11746,Homo sapiens,T-cells
4801,,,22226,9606.0,Autocuration,1,,F,574.0,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,,BAO_0000219,U,,11746,Homo sapiens,T-cells
4802,,,80018,9606.0,Intermediate,1,,F,455.0,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,,BAO_0000219,N,,5455,Homo sapiens,A-375
4803,,,80018,9606.0,Intermediate,1,,F,455.0,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,,BAO_0000219,N,,2068,Homo sapiens,A-375
4804,,,80018,9606.0,Intermediate,1,,F,455.0,In vitro antitumor activity against A375cell line extracted form melanoma,,,BAO_0000219,N,,2683,Homo sapiens,A-375
4805,,,80018,9606.0,Expert,1,,F,455.0,Inhibition of cell growth in (A375) melan cell line,,,BAO_0000219,N,,15313,Homo sapiens,A-375
4806,,,80018,9606.0,Intermediate,1,,F,455.0,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,,BAO_0000219,N,,13739,Homo sapiens,A-375
4807,,,80018,9606.0,Intermediate,1,,F,455.0,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,,BAO_0000219,N,,13739,Homo sapiens,A-375
4808,,,80018,9606.0,Intermediate,1,,F,455.0,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,,BAO_0000219,N,,14750,Homo sapiens,A-375
4809,,,80019,9606.0,Intermediate,1,,F,797.0,Antiproliferative activity measured against A427 human lung carcinoma,,,BAO_0000219,N,,14777,Homo sapiens,A-427
4810,,,80019,9606.0,Intermediate,1,,F,797.0,Antiproliferative activity measured against A427 human lung carcinoma,,,BAO_0000219,N,,14777,Homo sapiens,A-427
4811,,,80019,9606.0,Intermediate,1,,F,797.0,Cytotoxicity against lung carcinoma A427 tumor cell lines,,,BAO_0000219,N,,17672,Homo sapiens,A-427
4812,,,80019,9606.0,Intermediate,1,,F,797.0,Inhibition of large cell lung carcinoma (A427),,,BAO_0000219,N,,14368,Homo sapiens,A-427
4813,,,80019,9606.0,Intermediate,1,,F,797.0,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,,BAO_0000219,N,,14368,Homo sapiens,A-427
4814,,,80019,9606.0,Intermediate,1,,F,797.0,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,,BAO_0000219,N,,13866,Homo sapiens,A-427
4815,,,80019,9606.0,Intermediate,1,,F,797.0,Inhibitory concentration in human lung carcinoma A427 cell line,,,BAO_0000219,N,,2545,Homo sapiens,A-427
4816,,,80019,9606.0,Intermediate,1,,F,797.0,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,,BAO_0000219,N,,2545,Homo sapiens,A-427
4817,In vivo,,22224,9527.0,Autocuration,1,,A,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,,BAO_0000218,U,,6062,Cercopithecidae,
4818,In vivo,,22224,9527.0,Autocuration,1,,A,,Tested for volume of distribution upon iv administration to african green monkey,,,BAO_0000218,U,,4578,Cercopithecidae,
4819,In vivo,,22224,9527.0,Autocuration,1,,A,,Volume of distribution in monkey,,,BAO_0000218,U,,17592,Cercopithecidae,
4820,In vivo,,22224,9544.0,Autocuration,1,,A,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,BAO_0000218,U,,5005,Macaca mulatta,
4821,In vivo,,22224,9544.0,Autocuration,1,,A,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,,BAO_0000218,U,,5005,Macaca mulatta,
4822,In vivo,,22224,9527.0,Autocuration,1,,A,,Pharmacokinetic property(Vdss) in cynomolgus monkey,,,BAO_0000218,U,,5922,Cercopithecidae,
4823,In vivo,,22224,9527.0,Autocuration,1,,A,,The distribution volume after intravenous administration in cynomolgus monkeys,,,BAO_0000218,U,,5355,Cercopithecidae,
4824,In vivo,,22224,9527.0,Autocuration,1,,A,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,,BAO_0000218,U,,5355,Cercopithecidae,
4825,In vivo,,22224,9527.0,Autocuration,1,,A,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,,BAO_0000218,U,,5355,Cercopithecidae,
4826,In vivo,,22224,9527.0,Autocuration,1,,A,,Volume displacement was calculated in rhesus monkey,,,BAO_0000218,U,,6057,Cercopithecidae,
4827,In vivo,,22224,9527.0,Autocuration,1,,A,,Volume of distribution in steady state was determined in rhesus monkey,,,BAO_0000218,U,,5145,Cercopithecidae,
4828,In vivo,,22224,9527.0,Autocuration,1,,A,,Volume of distribution of compound was determined in monkey,,,BAO_0000218,U,,6821,Cercopithecidae,
4829,In vivo,,22224,9527.0,Autocuration,1,,A,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,BAO_0000218,U,,5334,Cercopithecidae,
4830,In vivo,,22224,9527.0,Autocuration,1,,A,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,BAO_0000218,U,,5334,Cercopithecidae,
4831,In vivo,,22224,9527.0,Autocuration,1,,A,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,BAO_0000218,U,,6641,Cercopithecidae,
4832,In vivo,,22224,9527.0,Autocuration,1,,A,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,BAO_0000218,U,,2661,Cercopithecidae,
4833,In vivo,,22224,9527.0,Autocuration,1,,A,,Volume distribution in monkey after administration of 1 mg/kg iv,,,BAO_0000218,U,,6535,Cercopithecidae,
4834,In vivo,,22224,9527.0,Autocuration,1,,A,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,BAO_0000218,U,,4809,Cercopithecidae,
4835,In vivo,,22224,9527.0,Autocuration,1,,A,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,,BAO_0000218,U,,6062,Cercopithecidae,
4836,In vivo,,22224,9527.0,Autocuration,1,,A,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,BAO_0000218,U,,3443,Cercopithecidae,
4837,In vivo,,22224,9527.0,Autocuration,1,,A,,Oral systemic bioavailability upon iv administration to african green monkey,,,BAO_0000218,U,,4578,Cercopithecidae,
4838,In vivo,,22224,9527.0,Autocuration,1,,A,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,BAO_0000218,U,,4809,Cercopithecidae,
4839,,,22224,9527.0,Autocuration,1,,A,,Baboon plasma free fraction. ,,,BAO_0000019,U,,11271,Cercopithecidae,
4840,,,22224,9527.0,Autocuration,1,,A,,Area under the curve was calculated in rhesus monkey after iv administration,,,BAO_0000218,U,,6057,Cercopithecidae,
4841,,,22224,9527.0,Autocuration,1,,A,,Area under the curve was calculated in rhesus monkey after peroral administration,,,BAO_0000019,U,,6057,Cercopithecidae,
4842,,,22224,9527.0,Autocuration,1,,A,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,,BAO_0000019,U,,17853,Cercopithecidae,
4843,In vivo,,22224,9527.0,Autocuration,1,,A,,Half life period in monkey after 5 mg/kg dose,,,BAO_0000218,U,,5302,Cercopithecidae,
4844,In vivo,,22224,9527.0,Autocuration,1,,A,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,,BAO_0000218,U,,4257,Cercopithecidae,
4845,In vivo,,22224,9527.0,Autocuration,1,,A,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,,BAO_0000218,U,,4257,Cercopithecidae,
4846,In vivo,1969.0,22224,9527.0,Autocuration,1,Plasma,A,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,,BAO_0000218,U,,13501,Cercopithecidae,
4847,In vivo,,22224,9527.0,Autocuration,1,,A,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,,BAO_0000218,U,,5394,Cercopithecidae,
4848,In vivo,,22224,9527.0,Autocuration,1,,A,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,BAO_0000218,U,,2661,Cercopithecidae,
4849,,,22224,9527.0,Autocuration,1,,A,,Compound was evaluated for terminal half life in monkey,,,BAO_0000019,U,,3341,Cercopithecidae,
4850,In vivo,,22224,9527.0,Autocuration,1,,A,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,,BAO_0000218,U,,3045,Cercopithecidae,
4851,In vivo,1969.0,22224,9544.0,Autocuration,1,Plasma,A,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,BAO_0000218,U,,5005,Macaca mulatta,
4852,,,22224,9527.0,Autocuration,1,,A,,Half life of compound was determined in squirrel monkey,,,BAO_0000019,U,,4847,Cercopithecidae,
4853,In vivo,,22224,9541.0,Autocuration,1,,A,,Half life after iv administration in cynomolgus monkey,,,BAO_0000218,U,,4256,Macaca fascicularis,
4854,In vivo,1969.0,22224,9527.0,Autocuration,1,Plasma,A,,Half life in monkey plasma after administration of 1 mg/kg iv,,,BAO_0000218,U,,6535,Cercopithecidae,
4855,,,22224,9527.0,Autocuration,1,,A,,Half life was calculated in rhesus monkey,,,BAO_0000019,U,,6057,Cercopithecidae,
4856,,,22224,9527.0,Autocuration,1,,A,,Half life in monkey,,,BAO_0000019,U,,17592,Cercopithecidae,
4857,In vivo,,22224,9527.0,Autocuration,1,,A,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,BAO_0000218,U,,6641,Cercopithecidae,
4858,,,22224,9527.0,Autocuration,1,,A,,Half life was evaluated in rhesus,,,BAO_0000019,U,,5472,Cercopithecidae,
4859,In vivo,,22224,9527.0,Autocuration,1,,A,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,,BAO_0000218,U,,6221,Cercopithecidae,
4860,In vivo,,22224,9527.0,Autocuration,1,,A,,Half life period was determine after peroral administration at 10 mpk in Rhesus,,,BAO_0000218,U,,5668,Cercopithecidae,
4861,In vivo,,22224,9527.0,Autocuration,1,,A,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,BAO_0000218,U,,4809,Cercopithecidae,
4862,In vivo,,22224,9527.0,Autocuration,1,,A,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,,BAO_0000218,U,,5546,Cercopithecidae,
4863,In vivo,,22224,9527.0,Autocuration,1,,A,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,,BAO_0000218,U,,5553,Cercopithecidae,
4864,,,22224,9527.0,Autocuration,1,,A,,Half-life was calculated in monkey,,,BAO_0000019,U,,6078,Cercopithecidae,
4865,,,22224,9527.0,Autocuration,1,,A,,Half-life in Squirrel monkey,,,BAO_0000019,U,,5147,Cercopithecidae,
4866,,,22224,9527.0,Autocuration,1,,A,,Half-life in rhesus monkey,,,BAO_0000019,U,,5145,Cercopithecidae,
4867,In vivo,,22224,9527.0,Autocuration,1,,A,,Half-life was measured in monkey after an iv dose of 1 mg/kg,,,BAO_0000218,U,,6062,Cercopithecidae,
4868,In vivo,,22224,9527.0,Autocuration,1,,A,,Half-life period after intravenous administration in cynomolgus monkeys,,,BAO_0000218,U,,5355,Cercopithecidae,
4869,In vivo,,22224,9527.0,Autocuration,1,,A,,Half-life period after oral administration in cynomolgus monkeys,,,BAO_0000218,U,,5355,Cercopithecidae,
4870,In vivo,,22224,9527.0,Autocuration,1,,A,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,,BAO_0000218,U,,5355,Cercopithecidae,
4871,,1088.0,22224,9606.0,Autocuration,1,Urine,A,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,BAO_0000019,U,,7766,Homo sapiens,
4872,,1088.0,22224,9606.0,Autocuration,1,Urine,A,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,BAO_0000019,U,,7766,Homo sapiens,
4873,,1088.0,22224,9606.0,Autocuration,1,Urine,A,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,BAO_0000019,U,,7766,Homo sapiens,
4874,,1088.0,22224,9606.0,Autocuration,1,Urine,A,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,BAO_0000019,U,,7766,Homo sapiens,
4875,,1088.0,22224,9606.0,Autocuration,1,Urine,A,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,,BAO_0000019,U,,7766,Homo sapiens,
4876,,1088.0,22224,9606.0,Autocuration,1,Urine,A,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,,BAO_0000019,U,,7766,Homo sapiens,
4877,,1088.0,22224,9606.0,Autocuration,1,Urine,A,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,,BAO_0000019,U,,7766,Homo sapiens,
4878,,1088.0,22224,9606.0,Autocuration,1,Urine,A,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,,BAO_0000019,U,,7766,Homo sapiens,
4879,In vivo,,22224,9606.0,Autocuration,1,,A,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,,BAO_0000218,U,,1916,Homo sapiens,
4880,In vivo,,22224,9606.0,Autocuration,1,,A,,Oral bioavailability in human,,,BAO_0000218,U,,16643,Homo sapiens,
4881,,,22224,9606.0,Autocuration,1,,A,,Compound was tested for human plasma protein binding,,,BAO_0000019,U,,17248,Homo sapiens,
4882,,,22224,9606.0,Autocuration,1,,A,,Compound was tested for human plasma protein binding; Not determined,,,BAO_0000019,U,,17248,Homo sapiens,
4883,,,22224,9606.0,Autocuration,1,,A,,Protein binding activity of compound in human plasma; % Free,,,BAO_0000019,U,,6241,Homo sapiens,
4884,,,22224,9606.0,Autocuration,1,,A,,Unbound fraction (plasma),,,BAO_0000019,U,,17716,Homo sapiens,
4885,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Half life for the hydrolysis of compound in human blood serum,,,BAO_0000366,U,,17605,Homo sapiens,
4886,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Half life period in human plasma using phosphate buffer (0.08 M),,,BAO_0000366,U,,17625,Homo sapiens,
4887,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Half life period in human plasma using phosphate buffer (0.1 M),,,BAO_0000366,U,,17625,Homo sapiens,
4888,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Half-life in human plasma was determined,,,BAO_0000366,U,,17747,Homo sapiens,
4889,,,22224,9606.0,Autocuration,1,,A,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,,BAO_0000019,U,,15613,Homo sapiens,
4890,,,22224,9606.0,Autocuration,1,,A,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,,BAO_0000019,U,,354,Homo sapiens,
4891,,,22224,9606.0,Autocuration,1,,A,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,,BAO_0000019,U,,3741,Homo sapiens,
4892,,,22224,9606.0,Autocuration,1,,A,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,,BAO_0000019,U,,3741,Homo sapiens,
4893,,,22224,9606.0,Autocuration,1,,A,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,,BAO_0000019,U,,3741,Homo sapiens,
4894,,,22224,9606.0,Autocuration,1,,A,,Partition coefficient (logP),,,BAO_0000019,U,,17599,Homo sapiens,
4895,,,22224,9606.0,Autocuration,1,,A,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,,BAO_0000019,U,,5486,Homo sapiens,
4896,,,22224,9606.0,Autocuration,1,,A,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,Microsomes,,BAO_0000251,U,,5600,Homo sapiens,
4897,,,22224,9606.0,Autocuration,1,,A,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,,BAO_0000019,U,,14294,Homo sapiens,
4898,,,22224,9606.0,Autocuration,1,,A,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,,BAO_0000019,U,,14294,Homo sapiens,
4899,,,22224,9606.0,Autocuration,1,,A,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,,BAO_0000019,U,,14294,Homo sapiens,
4900,,,22224,9606.0,Autocuration,1,,A,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),Microsomes,,BAO_0000251,U,,14294,Homo sapiens,
4901,,,22224,9606.0,Autocuration,1,,A,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),Microsomes,,BAO_0000251,U,,14294,Homo sapiens,
4902,,,22224,9606.0,Autocuration,1,,A,,Metabolism of compound in human microsomes; Trace,Microsomes,,BAO_0000251,U,,14294,Homo sapiens,
4903,,2107.0,22224,9606.0,Autocuration,1,Liver,A,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,Microsomes,,BAO_0000251,U,,6260,Homo sapiens,
4904,,,22224,9606.0,Autocuration,1,,A,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,Microsomes,,BAO_0000251,U,,6187,Homo sapiens,
4905,,2107.0,22224,9606.0,Autocuration,1,Liver,A,,In vitro metabolic potential in human liver microsomes,Microsomes,,BAO_0000251,U,,6251,Homo sapiens,
4906,,,22224,9606.0,Autocuration,1,,A,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,,BAO_0000019,U,,3246,Homo sapiens,
4907,,,22224,9606.0,Autocuration,1,,A,,Tested for human plasma protein binding of the compound; Not tested,,,BAO_0000019,U,,17313,Homo sapiens,
4908,,,22224,9606.0,Autocuration,1,,A,,Compound was tested for percent protein binding (PB) in human,,,BAO_0000019,U,,6227,Homo sapiens,
4909,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Protein binding in human plasma,,,BAO_0000019,U,,5530,Homo sapiens,
4910,,,22224,9606.0,Autocuration,1,,A,,Permeability coefficient (B to A) in Caco-2 cell,,,BAO_0000019,U,,6108,Homo sapiens,
4911,,,22224,9606.0,Autocuration,1,,A,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,,BAO_0000019,U,,6108,Homo sapiens,
4912,,,22224,9606.0,Autocuration,1,,A,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,,BAO_0000019,U,,2774,Homo sapiens,
4913,,,22224,9606.0,Autocuration,1,,A,,In vitro rate of absorption observed as Caco-2 permeability in humans,,,BAO_0000019,U,,16643,Homo sapiens,
4914,,,22224,9606.0,Autocuration,1,,A,495.0,Cellular permeability of compound was determined in Caco-2 cells; High,,,BAO_0000219,U,,17582,Homo sapiens,Caco-2
4915,,,22224,9606.0,Autocuration,1,,A,495.0,Permeability in Caco-2 cells of compound,,,BAO_0000219,U,,6838,Homo sapiens,Caco-2
4916,,,22224,9606.0,Autocuration,1,,A,,Permeability coefficient (A to B) in Caco-2 cell,,,BAO_0000019,U,,6108,Homo sapiens,
4917,,,22224,9606.0,Autocuration,1,,A,,Permeability coefficient (B to A) in Caco-2 cell,,,BAO_0000019,U,,6108,Homo sapiens,
4918,,,22224,9606.0,Autocuration,1,,A,,Permeability coefficient (Papp) (Caco-2 cell monolayer),,,BAO_0000019,U,,6108,Homo sapiens,
4919,,,22224,9606.0,Autocuration,1,,A,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,,BAO_0000019,U,,2146,Homo sapiens,
4920,,,22224,9606.0,Autocuration,1,,A,,Compound was tested for protein binding in human plasma,,,BAO_0000019,U,,4514,Homo sapiens,
4921,,,22224,9606.0,Autocuration,1,,A,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,,BAO_0000019,U,,6108,Homo sapiens,
4922,,1088.0,22224,9606.0,Autocuration,1,Urine,A,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,,BAO_0000019,U,,7766,Homo sapiens,
4923,In vivo,,50594,10090.0,Intermediate,1,,A,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,,BAO_0000218,N,,5969,Mus musculus,
4924,In vivo,,50594,10090.0,Intermediate,1,,A,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,BAO_0000218,N,,3277,Mus musculus,
4925,In vivo,,50594,10090.0,Intermediate,1,,A,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,,BAO_0000218,N,,3802,Mus musculus,
4926,In vivo,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,,,BAO_0000218,N,,2862,Mus musculus,
4927,In vivo,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,BAO_0000218,N,,6348,Mus musculus,
4928,In vivo,,50594,10090.0,Intermediate,1,,F,,Tmax after intraperitoneal administration in mice at 23 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
4929,In vivo,,50594,10090.0,Intermediate,1,,A,,Tmax after oral administration at 30 mg/kg in ICR mouse,,,BAO_0000218,N,,5781,Mus musculus,
4930,In vivo,,50594,10090.0,Intermediate,1,,A,,Tmax after peroral administration in mice at 2.4 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
4931,In vivo,,50594,10090.0,Intermediate,1,,A,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,,BAO_0000218,N,,4066,Mus musculus,
4932,In vivo,955.0,50594,10090.0,Intermediate,1,Brain,A,,Tmax in brain of mice at the oral dose of 50 mg/kg,,,BAO_0000218,N,,17641,Mus musculus,
4933,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Tmax in kidney of mice at the oral dose of 50 mg/kg,,,BAO_0000218,N,,17641,Mus musculus,
4934,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Tmax in liver of mice at the oral dose of 50 mg/kg,,,BAO_0000218,N,,17641,Mus musculus,
4935,In vivo,2048.0,50594,10090.0,Intermediate,1,Lung,A,,Tmax in lungs of mice at the oral dose of 50 mg/kg,,,BAO_0000218,N,,17641,Mus musculus,
4936,In vivo,,50594,10090.0,Intermediate,1,,F,,Tmax in mice at 18 uM/kg i.p. administration,,,BAO_0000218,N,,17764,Mus musculus,
4937,In vivo,,50594,10090.0,Intermediate,1,,F,,Tmax in mice at 23 uM/kg i.v. administration,,,BAO_0000218,N,,17764,Mus musculus,
4938,In vivo,,50594,10090.0,Intermediate,1,,F,,Tmax in mice at 25 uM/kg i.p. administration,,,BAO_0000218,N,,17764,Mus musculus,
4939,In vivo,,50594,10090.0,Intermediate,1,,F,,Tmax in mice at 26 uM/kg i.p. administration,,,BAO_0000218,N,,17764,Mus musculus,
4940,In vivo,2106.0,50594,10090.0,Intermediate,1,Spleen,A,,Tmax in spleen of mice at the oral dose of 50 mg/kg,,,BAO_0000218,N,,17641,Mus musculus,
4941,In vivo,,50594,10090.0,Intermediate,1,,A,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,,BAO_0000218,N,,16597,Mus musculus,
4942,In vivo,,50594,10090.0,Intermediate,1,,A,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,,BAO_0000218,N,,16597,Mus musculus,
4943,,,50594,10090.0,Intermediate,1,,A,,Tmax value in IRC mice,,,BAO_0000218,N,,5951,Mus musculus,
4944,In vivo,,50594,10090.0,Intermediate,1,,A,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,,BAO_0000218,N,,5506,Mus musculus,
4945,In vivo,,50594,10090.0,Intermediate,1,,A,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,,BAO_0000218,N,,5506,Mus musculus,
4946,,1088.0,50594,10090.0,Intermediate,1,Urine,A,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,,BAO_0000218,N,,429,Mus musculus,
4947,,1088.0,50594,10090.0,Intermediate,1,Urine,A,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,,BAO_0000218,N,,429,Mus musculus,
4948,,1088.0,50594,10090.0,Intermediate,1,Urine,A,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,,BAO_0000218,N,,4066,Mus musculus,
4949,,,50594,10090.0,Intermediate,1,,A,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,BAO_0000218,N,,17734,Mus musculus,
4950,,,50594,10090.0,Intermediate,1,,A,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,BAO_0000218,N,,17734,Mus musculus,
4951,In vivo,,50594,10090.0,Intermediate,1,,A,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,,BAO_0000218,N,,6062,Mus musculus,
4952,In vivo,,50594,10090.0,Intermediate,1,,A,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,,BAO_0000218,N,,5969,Mus musculus,
4953,In vivo,,50594,10090.0,Intermediate,1,,A,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,,BAO_0000218,N,,5969,Mus musculus,
4954,In vivo,,50594,10090.0,Intermediate,1,,A,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,,BAO_0000218,N,,5969,Mus musculus,
4955,In vivo,,50594,10090.0,Intermediate,1,,A,,Vd in mice,,,BAO_0000218,N,,5980,Mus musculus,
4956,In vivo,,50594,10090.0,Intermediate,1,,A,,Volume of distribution in mouse,,,BAO_0000218,N,,17592,Mus musculus,
4957,In vivo,,50594,10090.0,Intermediate,1,,A,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,BAO_0000218,N,,6348,Mus musculus,
4958,In vivo,,50594,10090.0,Intermediate,1,,A,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,,BAO_0000218,N,,17753,Mus musculus,
4959,In vivo,,50594,10090.0,Intermediate,1,,A,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,,BAO_0000218,N,,17753,Mus musculus,
4960,In vivo,,50594,10090.0,Intermediate,1,,A,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,,BAO_0000218,N,,17753,Mus musculus,
4961,In vivo,,50594,10090.0,Intermediate,1,,A,,Pharmacokinetic property (vdss) was measured in mouse,,,BAO_0000218,N,,4239,Mus musculus,
4962,In vivo,,50594,10090.0,Intermediate,1,,A,,Value distribution upon iv administration in mouse,,,BAO_0000218,N,,2862,Mus musculus,
4963,In vivo,,50594,10090.0,Intermediate,1,,A,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,BAO_0000218,N,,17734,Mus musculus,
4964,In vivo,,50594,10090.0,Intermediate,1,,A,,Volume of distribution was evaluated in mice after intravenous administration,,,BAO_0000218,N,,2675,Mus musculus,
4965,In vivo,,50594,10090.0,Intermediate,1,,A,,Volume of distribution was evaluated in mice after oral administration,,,BAO_0000218,N,,2675,Mus musculus,
4966,In vivo,,50594,10090.0,Intermediate,1,,A,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,,BAO_0000218,N,,17837,Mus musculus,
4967,In vivo,,50594,10090.0,Intermediate,1,,A,,Steady state volume of distribution was determined in mice,,,BAO_0000218,N,,5727,Mus musculus,
4968,In vivo,,50594,10090.0,Intermediate,1,,A,,Volume distribution (steady state) of compound was determined in mouse,,,BAO_0000218,N,,17852,Mus musculus,
4969,In vivo,,50594,10090.0,Intermediate,1,,A,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
4970,In vivo,,50594,10090.0,Intermediate,1,,A,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,,BAO_0000218,N,,16597,Mus musculus,
4971,In vivo,,50594,10090.0,Intermediate,1,,A,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,,BAO_0000218,N,,6062,Mus musculus,
4972,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Biodistribution of compound (oxidized form) in in kidney tissue,,,BAO_0000218,N,,16438,Mus musculus,
4973,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,,,BAO_0000218,N,,16438,Mus musculus,
4974,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,,BAO_0000218,N,,16438,Mus musculus,
4975,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,BAO_0000218,N,,16438,Mus musculus,
4976,,,80019,9606.0,Intermediate,1,,F,797.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,,BAO_0000219,N,,10708,Homo sapiens,A-427
4977,,,80852,9606.0,Expert,1,,F,500.0,Inhibition of A431 human squamous cell carcinoma cell proliferation,,,BAO_0000219,N,,16597,Homo sapiens,A-431
4978,,,80852,9606.0,Expert,1,,F,500.0,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,,BAO_0000219,N,,16062,Homo sapiens,A-431
4979,,,80852,9606.0,Expert,1,,F,500.0,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,,BAO_0000219,N,,16062,Homo sapiens,A-431
4980,,,80852,9606.0,Expert,1,,F,500.0,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,,BAO_0000219,N,,16958,Homo sapiens,A-431
4981,,,80852,9606.0,Expert,1,,F,500.0,Inhibition of A431 human carcinoma cell proliferation,,,BAO_0000219,N,,6700,Homo sapiens,A-431
4982,,,80852,9606.0,Expert,1,,F,500.0,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,,BAO_0000219,N,,17226,Homo sapiens,A-431
4983,,,80852,9606.0,Intermediate,1,,F,500.0,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,,BAO_0000219,N,,6828,Homo sapiens,A-431
4984,,,80852,9606.0,Intermediate,1,,F,500.0,In vitro cytotoxicity against epidermoid carcinoma cell line,,,BAO_0000219,N,,12314,Homo sapiens,A-431
4985,,,9,9606.0,Expert,1,,F,500.0,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,,BAO_0000218,D,,13412,Homo sapiens,A-431
4986,,,80852,9606.0,Intermediate,1,,F,500.0,Antiproliferative activity of compound was measured on human tumor cell line A431.,,,BAO_0000219,N,,13299,Homo sapiens,A-431
4987,,,80852,9606.0,Intermediate,1,,F,500.0,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,,BAO_0000219,N,,17420,Homo sapiens,A-431
4988,,,80852,9606.0,Intermediate,1,,F,500.0,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,,BAO_0000219,N,,13678,Homo sapiens,A-431
4989,,,9,,Expert,1,,F,500.0,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,,BAO_0000219,H,,14171,,A-431
4990,,,80852,9606.0,Expert,1,,F,500.0,Tested for antiproliferative activity against human A431 cells,,,BAO_0000219,N,,6333,Homo sapiens,A-431
4991,,,9,9606.0,Expert,1,,F,500.0,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,,BAO_0000219,D,,2356,Homo sapiens,A-431
4992,,,80852,9606.0,Expert,1,,F,500.0,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,,BAO_0000219,N,,15578,Homo sapiens,A-431
4993,,,80852,9606.0,Expert,1,,F,500.0,Inhibition of A431 cell proliferation,,,BAO_0000219,N,,5126,Homo sapiens,A-431
4994,,,80852,9606.0,Expert,1,,F,500.0,Cytotoxic effect on A431 human epidermoid carcinoma cells,,,BAO_0000219,N,,6844,Homo sapiens,A-431
4995,,,80852,9606.0,Expert,1,,F,500.0,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,,BAO_0000219,N,,6844,Homo sapiens,A-431
4996,,,80852,9606.0,Intermediate,1,,F,500.0,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,,BAO_0000219,N,,4925,Homo sapiens,A-431
4997,,,80852,9606.0,Intermediate,1,,F,500.0,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,,BAO_0000219,N,,4925,Homo sapiens,A-431
4998,,,80852,9606.0,Intermediate,1,,F,500.0,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,,BAO_0000219,N,,13978,Homo sapiens,A-431
4999,,,80852,9606.0,Intermediate,1,,F,500.0,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,,BAO_0000219,N,,16786,Homo sapiens,A-431
5000,,,9,,Expert,1,,F,500.0,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,,BAO_0000219,H,,13412,,A-431
5001,,,80852,9606.0,Intermediate,1,,F,500.0,In vivo antiproliferative activity against A431 cell line,,,BAO_0000218,N,,17824,Homo sapiens,A-431
5002,,,9,9606.0,Expert,1,,F,500.0,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,,BAO_0000219,D,,12751,Homo sapiens,A-431
5003,,,80852,9606.0,Expert,1,,F,500.0,Inhibition of A431 human epidermoid carcinoma cell proliferation,,,BAO_0000219,N,,12380,Homo sapiens,A-431
5004,,,9,9606.0,Expert,1,,F,500.0,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,,BAO_0000219,D,,4959,Homo sapiens,A-431
5005,,,80852,9606.0,Intermediate,1,,F,500.0,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,,BAO_0000219,N,,6333,Homo sapiens,A-431
5006,,,80852,9606.0,Intermediate,1,,F,500.0,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,,BAO_0000219,N,,6333,Homo sapiens,A-431
5007,,,80852,9606.0,Intermediate,1,,F,500.0,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,,BAO_0000219,N,,6333,Homo sapiens,A-431
5008,,,9,9606.0,Expert,1,,F,,Inhibition of EGFR overexpressing A431 cell proliferation,,,BAO_0000019,D,,5296,Homo sapiens,
5009,,,80852,9606.0,Expert,1,,F,500.0,Inhibition of A431 cell proliferation,,,BAO_0000219,N,,12624,Homo sapiens,A-431
5010,,,9,9606.0,Expert,1,,F,500.0,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,,BAO_0000219,D,,14926,Homo sapiens,A-431
5011,,,9,9606.0,Expert,1,,F,500.0,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,,BAO_0000219,D,,14926,Homo sapiens,A-431
5012,,,9,,Expert,1,,F,500.0,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,,BAO_0000219,H,,14926,,A-431
5013,,,80852,9606.0,Intermediate,1,,F,500.0,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,,BAO_0000219,N,,15144,Homo sapiens,A-431
5014,,,80852,9606.0,Intermediate,1,,F,500.0,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,,BAO_0000219,N,,15144,Homo sapiens,A-431
5015,,,80852,9606.0,Intermediate,1,,F,500.0,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,,BAO_0000219,N,,5245,Homo sapiens,A-431
5016,,,80852,9606.0,Intermediate,1,,F,500.0,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,,BAO_0000219,N,,5245,Homo sapiens,A-431
5017,,,80852,9606.0,Intermediate,1,,F,500.0,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,,BAO_0000219,N,,5245,Homo sapiens,A-431
5018,,,80852,9606.0,Intermediate,1,,F,500.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,,BAO_0000219,N,,5245,Homo sapiens,A-431
5019,,,80852,9606.0,Intermediate,1,,F,500.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,,BAO_0000219,N,,5245,Homo sapiens,A-431
5020,,,22224,9527.0,Autocuration,1,,A,,Half-life period in cynomolgus monkey,,,BAO_0000019,U,,5922,Cercopithecidae,
5021,In vitro,1969.0,22224,9527.0,Autocuration,1,Plasma,A,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",,,BAO_0000366,U,,1116,Cercopithecidae,
5022,In vivo,,22224,9527.0,Autocuration,1,,A,,Longer half-life in monkey (i.v.) at 0.5 mpk,,,BAO_0000218,U,,17853,Cercopithecidae,
5023,,1969.0,22224,9527.0,Autocuration,1,Plasma,A,,Plasma half life in monkey,,,BAO_0000366,U,,993,Cercopithecidae,
5024,,1969.0,22224,9527.0,Autocuration,1,Plasma,A,,Plasma half-life in rhesus monkey,,,BAO_0000366,U,,4514,Cercopithecidae,
5025,In vivo,1969.0,22224,9527.0,Autocuration,1,Plasma,A,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,BAO_0000218,U,,5334,Cercopithecidae,
5026,In vivo,1969.0,22224,9527.0,Autocuration,1,Plasma,A,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,BAO_0000218,U,,5334,Cercopithecidae,
5027,In vivo,,22224,9527.0,Autocuration,1,,A,,Tested for half life upon iv administration to african green monkey,,,BAO_0000218,U,,4578,Cercopithecidae,
5028,In vivo,,22224,9527.0,Autocuration,1,,A,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,BAO_0000218,U,,2661,Cercopithecidae,
5029,In vivo,,22224,9527.0,Autocuration,1,,A,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,,BAO_0000218,U,,5355,Cercopithecidae,
5030,In vivo,,22224,9527.0,Autocuration,1,,A,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,,BAO_0000218,U,,5355,Cercopithecidae,
5031,In vivo,,22224,9527.0,Autocuration,1,,A,,The time for peak concentration value after oral administration in cynomolgus monkeys,,,BAO_0000218,U,,5355,Cercopithecidae,
5032,,,22224,9527.0,Autocuration,1,,A,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,,BAO_0000019,U,,11271,Cercopithecidae,
5033,,,22224,9527.0,Autocuration,1,,A,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,,BAO_0000019,U,,11271,Cercopithecidae,
5034,,,22224,9527.0,Autocuration,1,,A,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,,BAO_0000019,U,,11271,Cercopithecidae,
5035,,,22224,9527.0,Autocuration,1,,A,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,,BAO_0000019,U,,11271,Cercopithecidae,
5036,,,22224,9527.0,Autocuration,1,,A,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,,BAO_0000019,U,,11271,Cercopithecidae,
5037,,,22224,9527.0,Autocuration,1,,A,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,,BAO_0000019,U,,11271,Cercopithecidae,
5038,,,22224,9527.0,Autocuration,1,,A,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,,BAO_0000019,U,,11271,Cercopithecidae,
5039,,,22224,9527.0,Autocuration,1,,A,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,,BAO_0000019,U,,11271,Cercopithecidae,
5040,,,22224,9527.0,Autocuration,1,,A,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,,BAO_0000019,U,,11271,Cercopithecidae,
5041,,,22224,9527.0,Autocuration,1,,A,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,,BAO_0000019,U,,11271,Cercopithecidae,
5042,,,22224,9527.0,Autocuration,1,,A,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,,BAO_0000019,U,,11271,Cercopithecidae,
5043,,,22224,9527.0,Autocuration,1,,A,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,,BAO_0000019,U,,11271,Cercopithecidae,
5044,,,22224,9527.0,Autocuration,1,,A,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,,BAO_0000019,U,,11271,Cercopithecidae,
5045,,,22224,9527.0,Autocuration,1,,A,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,,BAO_0000019,U,,11271,Cercopithecidae,
5046,,,22224,9527.0,Autocuration,1,,A,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,,BAO_0000019,U,,11271,Cercopithecidae,
5047,,,22224,9527.0,Autocuration,1,,A,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,,BAO_0000019,U,,11271,Cercopithecidae,
5048,In vivo,,50597,10116.0,Intermediate,1,,A,,Bioavailability in rat (cannulated) (dose 2 mg/kg),,,BAO_0000218,N,,5809,Rattus norvegicus,
5049,In vivo,1969.0,50597,10116.0,Intermediate,1,Plasma,A,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,,BAO_0000218,N,,17720,Rattus norvegicus,
5050,,1969.0,50597,10116.0,Intermediate,1,Plasma,A,,AUC value in rat after IV administration at a dose of 10 mg/kg,,,BAO_0000218,N,,3546,Rattus norvegicus,
5051,,1969.0,50597,10116.0,Intermediate,1,Plasma,A,,AUC value in rat after oral administration at a dose of 10 mg/kg,,,BAO_0000218,N,,3546,Rattus norvegicus,
5052,In vivo,,50597,10116.0,Intermediate,1,,A,,Cmax value in rat after oral administration at a dose of 10 mg/kg,,,BAO_0000218,N,,3546,Rattus norvegicus,
5053,In vivo,,50597,10116.0,Intermediate,1,,A,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,,BAO_0000218,N,,3546,Rattus norvegicus,
5054,In vivo,,50597,10116.0,Intermediate,1,,A,,Tmax value in rat after oral administration at a dose of 10 mg/kg,,,BAO_0000218,N,,3546,Rattus norvegicus,
5055,,,50597,10116.0,Intermediate,1,,A,,Vc value in rat after IV administration at a dose of 10 mg/kg,,,BAO_0000218,N,,3546,Rattus norvegicus,
5056,In vivo,,50597,10116.0,Intermediate,1,,A,,Half life period in rat after IV administration at a dose of 10 mg/kg,,,BAO_0000218,N,,3546,Rattus norvegicus,
5057,,,22224,9557.0,Autocuration,1,,A,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,,BAO_0000019,U,,10625,Papio hamadryas,
5058,,,22224,9557.0,Autocuration,1,,A,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,,BAO_0000019,U,,10625,Papio hamadryas,
5059,,,22224,9557.0,Autocuration,1,,A,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,,BAO_0000019,U,,10625,Papio hamadryas,
5060,,,22224,9557.0,Autocuration,1,,A,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,,BAO_0000019,U,,10625,Papio hamadryas,
5061,,,22224,9557.0,Autocuration,1,,A,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,,BAO_0000019,U,,10625,Papio hamadryas,
5062,,,22224,9557.0,Autocuration,1,,A,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,,BAO_0000019,U,,10625,Papio hamadryas,
5063,,,22224,9557.0,Autocuration,1,,A,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,,BAO_0000019,U,,10625,Papio hamadryas,
5064,,,22224,9557.0,Autocuration,1,,A,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,,BAO_0000019,U,,10625,Papio hamadryas,
5065,,,22224,9615.0,Autocuration,1,,A,,Area under curve after 1 mpk peroral administration to beagles,,,BAO_0000019,U,,3510,beagle,
5066,,,22224,9615.0,Autocuration,1,,A,,Area under curve after 2 mpk peroral administration to beagles,,,BAO_0000019,U,,3510,beagle,
5067,In vivo,,22224,9615.0,Autocuration,1,,A,,Cmax value after 1 mpk peroral administration to beagles,,,BAO_0000218,U,,3510,beagle,
5068,,1088.0,22224,9606.0,Autocuration,1,Urine,A,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,,BAO_0000019,U,,7766,Homo sapiens,
5069,,1088.0,22224,9606.0,Autocuration,1,Urine,A,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,,BAO_0000019,U,,7766,Homo sapiens,
5070,,1088.0,22224,9606.0,Autocuration,1,Urine,A,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,,BAO_0000019,U,,7766,Homo sapiens,
5071,,1088.0,22224,9606.0,Autocuration,1,Urine,A,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,,BAO_0000019,U,,7766,Homo sapiens,
5072,,1088.0,22224,9606.0,Autocuration,1,Urine,A,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,,BAO_0000019,U,,7766,Homo sapiens,
5073,,1088.0,22224,9606.0,Autocuration,1,Urine,A,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,,BAO_0000019,U,,7766,Homo sapiens,
5074,,1088.0,22224,9606.0,Autocuration,1,Urine,A,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,,BAO_0000019,U,,7766,Homo sapiens,
5075,,2107.0,22224,9606.0,Autocuration,1,Liver,A,,Metabolic stability observed at 30 min after administration in human liver microsomes,Microsomes,,BAO_0000251,U,,16643,Homo sapiens,
5076,,,22224,9606.0,Autocuration,1,,A,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,,BAO_0000019,U,,6852,Homo sapiens,
5077,,,22224,9606.0,Autocuration,1,,A,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,,BAO_0000019,U,,6852,Homo sapiens,
5078,,,22224,9606.0,Autocuration,1,,A,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,,BAO_0000019,U,,6852,Homo sapiens,
5079,,2107.0,22224,9606.0,Autocuration,1,Liver,A,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",Microsomes,,BAO_0000251,U,,6567,Homo sapiens,
5080,,,22224,9606.0,Autocuration,1,,A,,Metabolic stability (% remaining at 30 mins) in human S9.,,,BAO_0000019,U,,6570,Homo sapiens,
5081,,,22224,9606.0,Autocuration,1,,A,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,,BAO_0000019,U,,6570,Homo sapiens,
5082,,2107.0,22224,9606.0,Autocuration,1,Liver,A,,Percent parent compound remaining after 20 min incubation with human liver microsomes,Microsomes,,BAO_0000251,U,,5237,Homo sapiens,
5083,,2107.0,22224,9606.0,Autocuration,1,Liver,A,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,Microsomes,,BAO_0000251,U,,5237,Homo sapiens,
5084,,2107.0,22224,9606.0,Autocuration,1,Liver,A,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,Microsomes,,BAO_0000251,U,,5237,Homo sapiens,
5085,,,22224,9606.0,Autocuration,1,,A,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,,BAO_0000218,U,,5202,Homo sapiens,
5086,,,22224,9606.0,Autocuration,1,,A,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,,BAO_0000019,U,,5481,Homo sapiens,
5087,,,22224,9606.0,Autocuration,1,,A,,Percent remaining in human plasma after incubation for 60 min at 37 C.,,,BAO_0000019,U,,5481,Homo sapiens,
5088,,,22224,9606.0,Autocuration,1,,A,,The percent remaining in human plasma after 30 min was determined,,,BAO_0000019,U,,3956,Homo sapiens,
5089,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Conversion rate of the prodrug in human plasma,,,BAO_0000366,U,,5074,Homo sapiens,
5090,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Conversion rate of the prodrug in human plasma; ND means no data,,,BAO_0000366,U,,5074,Homo sapiens,
5091,,178.0,22224,9606.0,Autocuration,1,Blood,A,,Half life of compound was determined in human blood,,,BAO_0000221,U,,4727,Homo sapiens,
5092,,,22224,9606.0,Autocuration,1,,A,,Half life of compound was determined in man with once daily dosing,,,BAO_0000019,U,,5965,Homo sapiens,
5093,In vitro,,22224,9606.0,Autocuration,1,,A,,Half life in human microsomes,Microsomes,,BAO_0000251,U,,5732,Homo sapiens,
5094,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Half life in human plasma,,,BAO_0000366,U,,5819,Homo sapiens,
5095,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Half life in human plasma; Not detected,,,BAO_0000366,U,,5819,Homo sapiens,
5096,In vivo,,22224,9606.0,Autocuration,1,,A,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,,BAO_0000218,U,,1916,Homo sapiens,
5097,In vitro,2107.0,22224,9606.0,Autocuration,1,Liver,A,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,Microsomes,,BAO_0000251,U,,6597,Homo sapiens,
5098,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Half-life in human plasma,,,BAO_0000366,U,,5229,Homo sapiens,
5099,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Half-life of the parent prodrug in plasma,,,BAO_0000366,U,,5229,Homo sapiens,
5100,In vitro,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,In vitro half life in human plasma was determined,,,BAO_0000366,U,,2192,Homo sapiens,
5101,In vitro,2107.0,22224,9606.0,Autocuration,1,Liver,A,,The compound was tested In Vitro for half life in human liver microsomes.,Microsomes,,BAO_0000251,U,,3032,Homo sapiens,
5102,In vivo,,22224,9606.0,Autocuration,1,,A,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,,BAO_0000218,U,,1916,Homo sapiens,
5103,In vivo,,22224,9606.0,Autocuration,1,,A,,Observed volume of distribution,,,BAO_0000218,U,,17716,Homo sapiens,
5104,In vivo,,22224,9606.0,Autocuration,1,,A,,Oral bioavailability in human,,,BAO_0000218,U,,15778,Homo sapiens,
5105,,,22224,9606.0,Autocuration,1,,A,,Tested for human plasma protein binding of the compound,,,BAO_0000019,U,,17313,Homo sapiens,
5106,,,22224,9606.0,Autocuration,1,,A,,"First order rate constant, k was determined in human plasma",,,BAO_0000019,U,,4231,Homo sapiens,
5107,,,22224,9606.0,Autocuration,1,,A,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,,BAO_0000019,U,,4755,Homo sapiens,
5108,,,22224,9606.0,Autocuration,1,,A,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,,BAO_0000019,U,,4755,Homo sapiens,
5109,,2107.0,22224,9606.0,Autocuration,1,Liver,A,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Microsomes,,BAO_0000251,U,,16907,Homo sapiens,
5110,,,22224,9606.0,Autocuration,1,,A,,The compound was tested for the plasma binding in human,,,BAO_0000019,U,,10839,Homo sapiens,
5111,,,22224,9606.0,Autocuration,1,,A,,Plasma protein binding (human),,,BAO_0000019,U,,10839,Homo sapiens,
5112,In vitro,2107.0,22224,9606.0,Autocuration,1,Liver,A,,Compound was evaluated for half-life in human liver microsomes,Microsomes,,BAO_0000251,U,,3199,Homo sapiens,
5113,In vitro,178.0,22224,9606.0,Autocuration,1,Blood,A,,Half life measured in vitro for its stability in human blood,,,BAO_0000221,U,,1345,Homo sapiens,
5114,,1977.0,22224,9606.0,Autocuration,1,Serum,A,,Half life in human serum,,,BAO_0000019,U,,4297,Homo sapiens,
5115,,1977.0,22224,9606.0,Autocuration,1,Serum,A,,Half life in human serum; ND=not determined,,,BAO_0000019,U,,4297,Homo sapiens,
5116,,,22224,9606.0,Autocuration,1,,A,,Half life were determined in CEM-SS cell extract in decomposition step 1,,,BAO_0000019,U,,4297,Homo sapiens,
5117,,,22224,9606.0,Autocuration,1,,A,,Half life were determined in CEM-SS cell extract in decomposition step 2,,,BAO_0000019,U,,4297,Homo sapiens,
5118,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Half life of the in human plasma,,,BAO_0000366,U,,4231,Homo sapiens,
5119,In vitro,,22224,9606.0,Autocuration,1,,A,,Half life period in human hepatic S9 fraction was determined,S9,,BAO_0000220,U,,5633,Homo sapiens,
5120,In vitro,2107.0,22224,9606.0,Autocuration,1,Liver,A,,Half life period in human liver microsome was determined,Microsomes,,BAO_0000251,U,,5633,Homo sapiens,
5121,,,22224,9606.0,Autocuration,1,,A,,Half life period was determined; 6-7,,,BAO_0000019,U,,17791,Homo sapiens,
5122,,,22224,9606.0,Autocuration,1,,A,,Half life period was evaluated in human,,,BAO_0000019,U,,17791,Homo sapiens,
5123,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Half life time in human plasma,,,BAO_0000366,U,,3160,Homo sapiens,
5124,In vivo,955.0,50594,10090.0,Intermediate,1,Brain,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,BAO_0000218,N,,16438,Mus musculus,
5125,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,BAO_0000218,N,,16438,Mus musculus,
5126,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,BAO_0000218,N,,16438,Mus musculus,
5127,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,BAO_0000218,N,,16438,Mus musculus,
5128,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,,BAO_0000218,N,,16438,Mus musculus,
5129,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,BAO_0000218,N,,16438,Mus musculus,
5130,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,BAO_0000218,N,,16438,Mus musculus,
5131,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,,,BAO_0000218,N,,16438,Mus musculus,
5132,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,BAO_0000218,N,,16438,Mus musculus,
5133,In vivo,2106.0,50594,10090.0,Intermediate,1,Spleen,A,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,,,BAO_0000218,N,,16438,Mus musculus,
5134,In vivo,2106.0,50594,10090.0,Intermediate,1,Spleen,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,,BAO_0000218,N,,16438,Mus musculus,
5135,In vivo,2106.0,50594,10090.0,Intermediate,1,Spleen,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,BAO_0000218,N,,16438,Mus musculus,
5136,In vivo,955.0,50594,10090.0,Intermediate,1,Brain,A,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,BAO_0000218,N,,16438,Mus musculus,
5137,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,Biodistribution of compound (oxidized form) in blood tissue,,,BAO_0000218,N,,16438,Mus musculus,
5138,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,BAO_0000218,N,,16438,Mus musculus,
5139,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,,BAO_0000218,N,,16438,Mus musculus,
5140,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,BAO_0000218,N,,16438,Mus musculus,
5141,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,BAO_0000218,N,,16438,Mus musculus,
5142,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,BAO_0000218,N,,16438,Mus musculus,
5143,In vivo,955.0,50594,10090.0,Intermediate,1,Brain,A,,Biodistribution of compound (oxidized form) in brain tissue of mice,,,BAO_0000218,N,,16438,Mus musculus,
5144,In vivo,955.0,50594,10090.0,Intermediate,1,Brain,A,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,BAO_0000218,N,,16438,Mus musculus,
5145,In vivo,955.0,50594,10090.0,Intermediate,1,Brain,A,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,,BAO_0000218,N,,16438,Mus musculus,
5146,In vivo,955.0,50594,10090.0,Intermediate,1,Brain,A,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,BAO_0000218,N,,16438,Mus musculus,
5147,In vivo,955.0,50594,10090.0,Intermediate,1,Brain,A,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,BAO_0000218,N,,16438,Mus musculus,
5148,In vivo,955.0,50594,10090.0,Intermediate,1,Brain,A,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",,,BAO_0000218,N,,16438,Mus musculus,
5149,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,Biodistribution of compound (oxidized form) in heart tissue of mice,,,BAO_0000218,N,,16438,Mus musculus,
5150,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,BAO_0000218,N,,16438,Mus musculus,
5151,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,BAO_0000218,N,,16438,Mus musculus,
5152,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,,BAO_0000218,N,,16438,Mus musculus,
5153,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,BAO_0000218,N,,16438,Mus musculus,
5154,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,BAO_0000218,N,,16438,Mus musculus,
5155,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,BAO_0000218,N,,16438,Mus musculus,
5156,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,,BAO_0000218,N,,16438,Mus musculus,
5157,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,,BAO_0000218,N,,16438,Mus musculus,
5158,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,BAO_0000218,N,,16438,Mus musculus,
5159,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,BAO_0000218,N,,16438,Mus musculus,
5160,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Biodistribution of compound (oxidized form) in liver tissue,,,BAO_0000218,N,,16438,Mus musculus,
5161,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,BAO_0000218,N,,16438,Mus musculus,
5162,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,BAO_0000218,N,,16438,Mus musculus,
5163,,,80852,9606.0,Intermediate,1,,F,500.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,,BAO_0000219,N,,5245,Homo sapiens,A-431
5164,,,80852,9606.0,Intermediate,1,,F,500.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,,BAO_0000219,N,,5245,Homo sapiens,A-431
5165,,,80852,,Expert,1,,F,500.0,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,,BAO_0000218,N,,16289,,A-431
5166,,,80852,,Expert,1,,F,500.0,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,,BAO_0000218,N,,16289,,A-431
5167,,,9,9606.0,Expert,1,,F,500.0,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,,BAO_0000219,D,,16093,Homo sapiens,A-431
5168,,,80852,9606.0,Intermediate,1,,F,500.0,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,,BAO_0000219,N,,16825,Homo sapiens,A-431
5169,,,80852,9606.0,Intermediate,1,,F,500.0,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,,BAO_0000219,N,,4848,Homo sapiens,A-431
5170,,,9,9606.0,Expert,1,,F,500.0,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,,BAO_0000219,D,,14827,Homo sapiens,A-431
5171,,,9,9606.0,Expert,1,,F,500.0,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,,BAO_0000219,D,,14827,Homo sapiens,A-431
5172,,,80852,,Expert,1,,F,500.0,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,,BAO_0000218,N,,16289,,A-431
5173,,,80852,,Expert,1,,F,500.0,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,,BAO_0000218,N,,16289,,A-431
5174,,,80852,,Expert,1,,F,500.0,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,,BAO_0000218,N,,16289,,A-431
5175,,,80852,,Expert,1,,F,500.0,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,,BAO_0000218,N,,16289,,A-431
5176,,,80852,,Expert,1,,F,500.0,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,,BAO_0000218,N,,16289,,A-431
5177,,,9,9606.0,Expert,1,,F,500.0,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,,BAO_0000219,D,,16289,Homo sapiens,A-431
5178,,,9,,Expert,1,,F,500.0,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,,BAO_0000219,H,,16289,,A-431
5179,,,80852,,Expert,1,,F,500.0,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,,BAO_0000218,N,,16289,,A-431
5180,,,80852,,Expert,1,,F,500.0,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,,BAO_0000218,N,,16289,,A-431
5181,,,80852,,Expert,1,,F,500.0,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,,BAO_0000218,N,,16289,,A-431
5182,,,80852,10090.0,Expert,1,,F,500.0,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,,BAO_0000218,N,,14555,Mus musculus,A-431
5183,,,80852,10090.0,Expert,1,,F,500.0,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,,BAO_0000218,N,,14555,Mus musculus,A-431
5184,,,80852,10090.0,Expert,1,,F,500.0,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,,BAO_0000218,N,,14555,Mus musculus,A-431
5185,,,80852,10090.0,Expert,1,,F,500.0,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,,BAO_0000218,N,,14555,Mus musculus,A-431
5186,,,80852,9606.0,Expert,1,,F,500.0,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,,BAO_0000219,N,,1937,Homo sapiens,A-431
5187,,,80852,9606.0,Intermediate,1,,F,500.0,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,,BAO_0000219,N,,13739,Homo sapiens,A-431
5188,,,80852,9606.0,Intermediate,1,,F,500.0,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,,BAO_0000219,N,,3558,Homo sapiens,A-431
5189,,,80852,9606.0,Intermediate,1,,F,500.0,Dose giving a 50% decrease in the living cell number (A437 cells),,,BAO_0000219,N,,3558,Homo sapiens,A-431
5190,,,80682,9606.0,Expert,1,,F,646.0,In vitro inhibitory concentration against proliferation of A459 cell line.,,,BAO_0000219,N,,17686,Homo sapiens,A549
5191,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,,BAO_0000219,N,,5305,Homo sapiens,A549
5192,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,,BAO_0000219,N,,3614,Homo sapiens,A549
5193,,,80021,9606.0,Intermediate,1,,F,624.0,In vitro antitumor activity against renal A498 tumor cell lines,,,BAO_0000219,N,,17229,Homo sapiens,A498
5194,,,80021,9606.0,Intermediate,1,,F,624.0,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,,BAO_0000219,N,,15935,Homo sapiens,A498
5195,,,80021,9606.0,Intermediate,1,,F,624.0,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,,BAO_0000219,N,,15935,Homo sapiens,A498
5196,,,80021,9606.0,Intermediate,1,,F,624.0,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,,BAO_0000219,N,,15560,Homo sapiens,A498
5197,,,80021,9606.0,Intermediate,1,,F,624.0,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,,BAO_0000219,N,,13891,Homo sapiens,A498
5198,,,80021,9606.0,Intermediate,1,,F,624.0,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,,BAO_0000219,N,,13891,Homo sapiens,A498
5199,,,80021,9606.0,Intermediate,1,,F,624.0,Cytotoxicity on kidney carcinoma (A-498) cell line,,,BAO_0000219,N,,13788,Homo sapiens,A498
5200,,,80021,9606.0,Intermediate,1,,F,624.0,Compound was evaluated against Human cell line renal A498,,,BAO_0000219,N,,15403,Homo sapiens,A498
5201,,,80021,9606.0,Intermediate,1,,F,624.0,Compound was tested for inhibition of A498 human renal cancer cell line,,,BAO_0000219,N,,1009,Homo sapiens,A498
5202,,,80021,9606.0,Intermediate,1,,F,624.0,Growth inhibitory activity against A498 human cancer cell line,,,BAO_0000219,N,,1043,Homo sapiens,A498
5203,,,80021,9606.0,Intermediate,1,,F,624.0,In vitro antitumor activity against human renal A498 cell line,,,BAO_0000219,N,,5858,Homo sapiens,A498
5204,,,80021,9606.0,Intermediate,1,,F,624.0,In vitro cytotoxic activity against renal (A498) cell line,,,BAO_0000219,N,,5958,Homo sapiens,A498
5205,,,80021,9606.0,Intermediate,1,,F,624.0,In vitro cytotoxic activity against human renal cancer (A498) cell line,,,BAO_0000219,N,,5506,Homo sapiens,A498
5206,,,80021,9606.0,Intermediate,1,,F,624.0,Tested for cytostatic activity against renal A498 cell line,,,BAO_0000219,N,,12781,Homo sapiens,A498
5207,,,80021,9606.0,Intermediate,1,,F,624.0,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,,BAO_0000219,N,,14399,Homo sapiens,A498
5208,,,80021,9606.0,Expert,1,,F,624.0,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,,BAO_0000219,N,,5958,Homo sapiens,A498
5209,In vivo,,22224,9615.0,Autocuration,1,,A,,Cmax value after 2 mpk peroral administration to beagles,,,BAO_0000218,U,,3510,beagle,
5210,In vivo,,22224,9615.0,Autocuration,1,,A,,Bioavailability,,,BAO_0000218,U,beagle,3510,Canis lupus familiaris,
5211,In vivo,,22224,9615.0,Autocuration,1,,A,,Bioavailability after 1 mpk peroral administration to beagles,,,BAO_0000218,U,beagle,3510,Canis lupus familiaris,
5212,In vivo,,22224,9615.0,Autocuration,1,,A,,Bioavailability after 2 mpk peroral administration to beagles,,,BAO_0000218,U,beagle,3510,Canis lupus familiaris,
5213,,,22224,9913.0,Autocuration,1,,A,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,,BAO_0000019,U,,3085,Bos taurus,
5214,,,22224,9913.0,Autocuration,1,,A,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,,BAO_0000019,U,,3085,Bos taurus,
5215,,,22224,9913.0,Autocuration,1,,A,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,,BAO_0000019,U,,3085,Bos taurus,
5216,,,22224,9913.0,Autocuration,1,,A,,Solubility against bovine alpha-chymotrypsin,,,BAO_0000019,U,,9372,Bos taurus,
5217,,,22224,9913.0,Autocuration,1,,A,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,,BAO_0000019,U,,3085,Bos taurus,
5218,,,22224,9913.0,Autocuration,1,,A,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,,BAO_0000019,U,,3085,Bos taurus,
5219,,2106.0,22224,9913.0,Autocuration,1,Spleen,A,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,,BAO_0000221,U,,1469,Bos taurus,
5220,,,22224,9913.0,Autocuration,1,,A,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,,BAO_0000019,U,,4297,Bos taurus,
5221,,,22224,9913.0,Autocuration,1,,A,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,,BAO_0000019,U,,4297,Bos taurus,
5222,,,22224,9913.0,Autocuration,1,,A,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,,BAO_0000019,U,,17585,Bos taurus,
5223,,2106.0,22224,9913.0,Autocuration,1,Spleen,A,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,,BAO_0000221,U,,1336,Bos taurus,
5224,,,22224,9913.0,Autocuration,1,,A,,Half life in presence of 2 mg/mL BSA at pH 8.8,,,BAO_0000019,U,,3085,Bos taurus,
5225,,,22224,9913.0,Autocuration,1,,A,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,,BAO_0000019,U,,2857,Bos taurus,
5226,,,22224,9913.0,Autocuration,1,,A,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,,BAO_0000019,U,,2857,Bos taurus,
5227,,,22224,9913.0,Autocuration,1,,A,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,,BAO_0000019,U,,2857,Bos taurus,
5228,,,22224,9913.0,Autocuration,1,,A,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,,BAO_0000019,U,,1540,Bos taurus,
5229,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,,BAO_0000218,N,,6316,Canis lupus familiaris,
5230,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,AUC after administration at 100 mg/kg/day in dogs,,,BAO_0000218,N,,17594,Canis lupus familiaris,
5231,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,,BAO_0000218,N,,4953,Canis lupus familiaris,
5232,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,AUC value after 15 mg/kg iv dose in Dogs,,,BAO_0000218,N,,16907,Canis lupus familiaris,
5233,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,AUC value after 30 mg/kg po dose in Dogs,,,BAO_0000218,N,,16907,Canis lupus familiaris,
5234,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,AUC value after administration of 4 mg/Kg oral dose in dog,,,BAO_0000218,N,,2959,Canis lupus familiaris,
5235,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,,BAO_0000218,N,,17594,Canis lupus familiaris,
5236,,,50588,9615.0,Intermediate,1,,A,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,,BAO_0000218,N,,5356,Canis lupus familiaris,
5237,,,50588,9615.0,Intermediate,1,,A,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,,BAO_0000218,N,,16807,Canis lupus familiaris,
5238,,,50588,9615.0,Intermediate,1,,A,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,,BAO_0000218,N,,4527,Canis lupus familiaris,
5239,,,50588,9615.0,Intermediate,1,,A,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,,BAO_0000218,N,,4527,Canis lupus familiaris,
5240,,,50588,9615.0,Intermediate,1,,A,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,,BAO_0000218,N,,15660,Canis lupus familiaris,
5241,,,50588,9615.0,Intermediate,1,,A,,Area under curve determined in dogs after oral administration of 10 mg/kg,,,BAO_0000218,N,,15660,Canis lupus familiaris,
5242,,,50588,9615.0,Intermediate,1,,A,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,BAO_0000218,N,,5802,Canis lupus familiaris,
5243,,,50588,9615.0,Expert,1,,A,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,,BAO_0000218,N,,3598,Canis lupus familiaris,
5244,,,50588,9615.0,Expert,1,,A,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,,BAO_0000218,N,,3598,Canis lupus familiaris,
5245,,,50588,9615.0,Intermediate,1,,A,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,,BAO_0000218,N,,5944,Canis lupus familiaris,
5246,,,50588,9615.0,Intermediate,1,,A,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,,BAO_0000218,N,,5944,Canis lupus familiaris,
5247,,,50588,9615.0,Intermediate,1,,A,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,,BAO_0000218,N,,5944,Canis lupus familiaris,
5248,,,50588,9615.0,Intermediate,1,,A,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,,BAO_0000218,N,,5944,Canis lupus familiaris,
5249,,,50588,9615.0,Intermediate,1,,A,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,,BAO_0000218,N,,4186,Canis lupus familiaris,
5250,,,50588,9615.0,Intermediate,1,,A,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,BAO_0000218,N,,5007,Canis lupus familiaris,
5251,,,50588,9615.0,Intermediate,1,,A,,Area under curve was determine after peroral administration at 10 mpk in dog,,,BAO_0000218,N,,5668,Canis lupus familiaris,
5252,,,50588,9615.0,Intermediate,1,,A,,Area under curve was determine after peroral administration at 5 mpk in dog,,,BAO_0000218,N,,5668,Canis lupus familiaris,
5253,,,50588,9615.0,Intermediate,1,,A,,Area under curve was determined,,,BAO_0000218,N,,5006,Canis lupus familiaris,
5254,,,50588,9615.0,Intermediate,1,,A,,Area under curve in dogs,,,BAO_0000218,N,,5006,Canis lupus familiaris,
5255,,,50588,9615.0,Intermediate,1,,A,,Area under curve in dogs at 10 mg/kg dose fo oral administration,,,BAO_0000218,N,,3771,Canis lupus familiaris,
5256,,,50588,9615.0,Intermediate,1,,A,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,,BAO_0000218,N,,3771,Canis lupus familiaris,
5257,,,50588,9615.0,Intermediate,1,,A,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,,BAO_0000218,N,,3771,Canis lupus familiaris,
5258,,,50588,9615.0,Intermediate,1,,A,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,BAO_0000218,N,,1916,Canis lupus familiaris,
5259,,,50588,9615.0,Intermediate,1,,A,,Area under curve value in dog at a dose of 5 mg/kg,,,BAO_0000218,N,,5302,Canis lupus familiaris,
5260,,,50588,9615.0,Intermediate,1,,A,,Area under curve was determined after 0.1 mg/kg iv administration in dog,,,BAO_0000218,N,,5600,Canis lupus familiaris,
5261,,,50588,9615.0,Intermediate,1,,A,,Area under curve was determined after 0.3 mg/kg po administration in dog,,,BAO_0000218,N,,5600,Canis lupus familiaris,
5262,,,50588,9615.0,Intermediate,1,,A,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,,BAO_0000218,N,,17764,Canis lupus familiaris,
5263,,,50588,9615.0,Intermediate,1,,A,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,,BAO_0000218,N,,4368,Canis lupus familiaris,
5264,,,22224,9606.0,Autocuration,1,,A,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,,BAO_0000019,U,,5318,Homo sapiens,
5265,,,22224,9606.0,Autocuration,1,,A,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,,BAO_0000019,U,,5318,Homo sapiens,
5266,,,22224,9606.0,Autocuration,1,,A,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,,BAO_0000019,U,,5318,Homo sapiens,
5267,,,22224,9606.0,Autocuration,1,,A,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,,BAO_0000019,U,,5318,Homo sapiens,
5268,,178.0,22224,9606.0,Autocuration,1,Blood,A,,Time taken to reduce 50% of the concentration of compound in blood plasma,,,BAO_0000221,U,,14518,Homo sapiens,
5269,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,,BAO_0000366,U,,2209,Homo sapiens,
5270,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Half life in human plasma,,,BAO_0000366,U,,6787,Homo sapiens,
5271,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Half life in human plasma was reported,,,BAO_0000366,U,,4898,Homo sapiens,
5272,,1977.0,22224,9606.0,Autocuration,1,Serum,A,,Half life in human serum,,,BAO_0000019,U,,6072,Homo sapiens,
5273,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Half life upon exposure to human plasma,,,BAO_0000366,U,,16907,Homo sapiens,
5274,In vitro,,22224,9606.0,Autocuration,1,,A,,t1/2 in human microsomes,Microsomes,,BAO_0000251,U,,5656,Homo sapiens,
5275,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Half life period in 80% human plasma at 37 degree Centigrade,,,BAO_0000366,U,,4755,Homo sapiens,
5276,,14.0,22224,9606.0,Autocuration,1,Zone of skin,A,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,,BAO_0000221,U,,17503,Homo sapiens,
5277,In vitro,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Half-life measured in in vitro Cathepsin B assay in human plasma,,,BAO_0000366,U,,12357,Homo sapiens,
5278,,,22224,9606.0,Autocuration,1,,A,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,,BAO_0000019,U,,3076,Homo sapiens,
5279,In vitro,2107.0,22224,9606.0,Autocuration,1,Liver,A,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,Microsomes,,BAO_0000251,U,,6410,Homo sapiens,
5280,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,,BAO_0000366,U,,3741,Homo sapiens,
5281,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,,BAO_0000366,U,,3741,Homo sapiens,
5282,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,,BAO_0000366,U,,3741,Homo sapiens,
5283,,,22224,9606.0,Autocuration,1,,A,,Half-life in the CEM cell extracts,,,BAO_0000019,U,,1540,Homo sapiens,
5284,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,,BAO_0000366,U,,2905,Homo sapiens,
5285,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,,BAO_0000366,U,,2905,Homo sapiens,
5286,,,22224,9606.0,Autocuration,1,,A,,Half-life was determined,,,BAO_0000019,U,,5523,Homo sapiens,
5287,,178.0,22224,9606.0,Autocuration,1,Blood,A,,Half-life (human blood stability),,,BAO_0000221,U,,1499,Homo sapiens,
5288,,178.0,22224,9606.0,Autocuration,1,Blood,A,,Half-life (human blood stability); no data,,,BAO_0000221,U,,1499,Homo sapiens,
5289,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Half-life in human plasma,,,BAO_0000366,U,,17065,Homo sapiens,
5290,,,22224,9606.0,Autocuration,1,,A,,CYP3A4 metabolism half-life (t1/2),,,BAO_0000019,U,,6861,Homo sapiens,
5291,,178.0,22224,9606.0,Autocuration,1,Blood,A,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,,BAO_0000221,U,,1499,Homo sapiens,
5292,In vitro,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,In vitro half life in human plasma,,,BAO_0000366,U,,530,Homo sapiens,
5293,In vitro,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",,,BAO_0000366,U,,1116,Homo sapiens,
5294,In vitro,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,In vitro hydrolysis in human plasma,,,BAO_0000366,U,,6695,Homo sapiens,
5295,In vitro,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,In vitro hydrolysis in human plasma; no data,,,BAO_0000366,U,,6695,Homo sapiens,
5296,In vitro,2107.0,22224,9606.0,Autocuration,1,Liver,A,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,Microsomes,,BAO_0000251,U,,10,Homo sapiens,
5297,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Plasma half life in human,,,BAO_0000366,U,,993,Homo sapiens,
5298,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,Stability after incubation with human plasma (at 37 degree C),,,BAO_0000366,U,,15429,Homo sapiens,
5299,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,T1/2 was evaluated in human plasma,,,BAO_0000366,U,,1675,Homo sapiens,
5300,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,,BAO_0000366,U,,2209,Homo sapiens,
5301,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,,BAO_0000366,U,,2209,Homo sapiens,
5302,,,22224,9606.0,Autocuration,1,,A,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,,BAO_0000019,U,,5318,Homo sapiens,
5303,In vitro,,22224,9606.0,Autocuration,1,,A,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,,BAO_0000019,U,,2412,Homo sapiens,
5304,In vitro,,22224,9606.0,Autocuration,1,,A,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,,BAO_0000019,U,,2412,Homo sapiens,
5305,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,,BAO_0000366,U,,2906,Homo sapiens,
5306,,1969.0,22224,9606.0,Autocuration,1,Plasma,A,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,,BAO_0000366,U,,2906,Homo sapiens,
5307,,,22224,9606.0,Autocuration,1,,A,,Time taken for 50% to be consumed by serum PON1 was determined,,,BAO_0000019,U,,5495,Homo sapiens,
5308,,,22224,9606.0,Autocuration,1,,A,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,,BAO_0000019,U,,5495,Homo sapiens,
5309,,2107.0,22224,9606.0,Autocuration,1,Liver,A,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Microsomes,,BAO_0000251,U,,4397,Homo sapiens,
5310,,,22224,10095.0,Autocuration,1,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,BAO_0000218,U,,2413,Mus sp.,
5311,,,22224,10095.0,Autocuration,1,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,BAO_0000218,U,,2413,Mus sp.,
5312,,,22224,10095.0,Autocuration,1,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,BAO_0000218,U,,2413,Mus sp.,
5313,,,22224,10095.0,Autocuration,1,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,BAO_0000218,U,,2413,Mus sp.,
5314,,,22224,10095.0,Autocuration,1,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,BAO_0000218,U,,2413,Mus sp.,
5315,,,22224,10095.0,Autocuration,1,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,BAO_0000218,U,,2413,Mus sp.,
5316,,,80640,9606.0,Intermediate,1,,F,391.0,Compound tested for growth inhibition of renal cancer cell line 786-0,,,BAO_0000219,N,,6058,Homo sapiens,786-0
5317,,,80640,9606.0,Intermediate,1,,F,391.0,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,,BAO_0000219,N,,17708,Homo sapiens,786-0
5318,,,80640,9606.0,Expert,1,,F,391.0,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,,BAO_0000219,N,,14017,Homo sapiens,786-0
5319,,,80640,9606.0,Intermediate,1,,F,391.0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,,BAO_0000219,N,,16818,Homo sapiens,786-0
5320,,,80640,9606.0,Intermediate,1,,F,391.0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,,BAO_0000219,N,,16818,Homo sapiens,786-0
5321,,,80640,9606.0,Intermediate,1,,F,391.0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,,BAO_0000219,N,,16818,Homo sapiens,786-0
5322,,,80640,9606.0,Intermediate,1,,F,391.0,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,,BAO_0000219,N,,11970,Homo sapiens,786-0
5323,,,80640,9606.0,Intermediate,1,,F,391.0,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,,BAO_0000219,N,,12400,Homo sapiens,786-0
5324,,,80640,9606.0,Expert,1,,F,391.0,Cytotoxic effect on renal cancer line 786-0,,,BAO_0000219,N,,12888,Homo sapiens,786-0
5325,,,80640,9606.0,Intermediate,1,,F,391.0,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,,BAO_0000219,N,,15300,Homo sapiens,786-0
5326,,,80640,9606.0,Intermediate,1,,F,391.0,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,,BAO_0000219,N,,14769,Homo sapiens,786-0
5327,,,80640,9606.0,Intermediate,1,,F,391.0,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,,BAO_0000219,N,,15895,Homo sapiens,786-0
5328,,,80640,9606.0,Intermediate,1,,F,391.0,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,,BAO_0000219,N,,17376,Homo sapiens,786-0
5329,,,80640,9606.0,Intermediate,1,,F,391.0,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,,BAO_0000219,N,,14882,Homo sapiens,786-0
5330,,,80640,9606.0,Intermediate,1,,F,391.0,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,,BAO_0000219,N,,14882,Homo sapiens,786-0
5331,,,80640,9606.0,Intermediate,1,,F,391.0,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,,BAO_0000219,N,,15176,Homo sapiens,786-0
5332,,,80640,9606.0,Intermediate,1,,F,391.0,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,,BAO_0000219,N,,12696,Homo sapiens,786-0
5333,,,80640,9606.0,Intermediate,1,,F,391.0,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,,BAO_0000219,N,,2496,Homo sapiens,786-0
5334,,,80641,9606.0,Intermediate,1,,F,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,,BAO_0000219,N,,11831,Homo sapiens,791T cell line
5335,,,80641,9606.0,Intermediate,1,,F,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,,BAO_0000219,N,,11831,Homo sapiens,791T cell line
5336,,,80641,9606.0,Intermediate,1,,F,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,,BAO_0000219,N,,11831,Homo sapiens,791T cell line
5337,,,80641,9606.0,Intermediate,1,,F,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,,BAO_0000219,N,,11831,Homo sapiens,791T cell line
5338,,,80641,9606.0,Intermediate,1,,F,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,,BAO_0000219,N,,11831,Homo sapiens,791T cell line
5339,,,80641,9606.0,Intermediate,1,,F,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,,BAO_0000219,N,,11831,Homo sapiens,791T cell line
5340,,,80641,9606.0,Intermediate,1,,F,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,,BAO_0000219,N,,11831,Homo sapiens,791T cell line
5341,,,80641,9606.0,Intermediate,1,,F,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,,BAO_0000219,N,,11831,Homo sapiens,791T cell line
5342,,,80641,9606.0,Intermediate,1,,F,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,,BAO_0000219,N,,11831,Homo sapiens,791T cell line
5343,,,80641,9606.0,Intermediate,1,,F,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,,BAO_0000219,N,,11831,Homo sapiens,791T cell line
5344,,,80640,9606.0,Intermediate,1,,F,391.0,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,,BAO_0000219,N,,12782,Homo sapiens,786-0
5345,,,22226,,Intermediate,1,,F,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,,BAO_0000019,U,,1229,,
5346,,,80433,9606.0,Expert,1,,F,741.0,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,,BAO_0000219,N,,15313,Homo sapiens,RPMI-8226
5347,,,80433,9606.0,Expert,1,,F,741.0,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,,BAO_0000219,N,,15313,Homo sapiens,RPMI-8226
5348,,,80433,9606.0,Intermediate,1,,F,741.0,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,,BAO_0000219,N,,11544,Homo sapiens,RPMI-8226
5349,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5350,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5351,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5352,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5353,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5354,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5355,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5356,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5357,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5358,,,80021,9606.0,Intermediate,1,,F,624.0,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,,BAO_0000219,N,,14769,Homo sapiens,A498
5359,,,80021,9606.0,Intermediate,1,,F,624.0,Compound was tested for the growth inhibition of A498 renal tumor cell line,,,BAO_0000219,N,,15354,Homo sapiens,A498
5360,,,80021,9606.0,Intermediate,1,,F,624.0,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,,BAO_0000219,N,,17445,Homo sapiens,A498
5361,,,80021,9606.0,Intermediate,1,,F,624.0,In vitro inhibitory concentration against renal cancer cell line A498,,,BAO_0000219,N,,4337,Homo sapiens,A498
5362,,,80021,9606.0,Intermediate,1,,F,624.0,Cytotoxicity against A 498 tumor cell line,,,BAO_0000219,N,,15277,Homo sapiens,A498
5363,,,80021,9606.0,Intermediate,1,,F,624.0,In vitro antitumor activity against A498 human cancer cell line,,,BAO_0000219,N,,4812,Homo sapiens,A498
5364,,,80021,9606.0,Intermediate,1,,F,624.0,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,,BAO_0000219,N,,4812,Homo sapiens,A498
5365,,,80021,9606.0,Intermediate,1,,F,624.0,Inhibitory dose required against A498 human tumor cell lines,,,BAO_0000219,N,,4995,Homo sapiens,A498
5366,,,80021,9606.0,Intermediate,1,,F,624.0,Anticancer activity against one renal cancer (A498 cell line),,,BAO_0000219,N,,5847,Homo sapiens,A498
5367,,,80021,9606.0,Intermediate,1,,F,624.0,In vitro cytotoxicity against melanoma A498 cell line,,,BAO_0000219,N,,6557,Homo sapiens,A498
5368,,,80021,9606.0,Intermediate,1,,F,624.0,Compound was tested for growth inhibitory activity against A498 cell line,,,BAO_0000219,N,,2597,Homo sapiens,A498
5369,,,80021,9606.0,Intermediate,1,,F,624.0,Compound tested for growth inhibition of renal cancer cell line A498,,,BAO_0000219,N,,6058,Homo sapiens,A498
5370,,,80021,9606.0,Intermediate,1,,F,624.0,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,,BAO_0000219,N,,17708,Homo sapiens,A498
5371,,,80021,9606.0,Intermediate,1,,F,624.0,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,,BAO_0000219,N,,15176,Homo sapiens,A498
5372,,,80021,9606.0,Intermediate,1,,F,624.0,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,,BAO_0000219,N,,15300,Homo sapiens,A498
5373,,,80021,9606.0,Intermediate,1,,F,624.0,Tested for cytotoxicity against A498 cell lines in renal cancer,,,BAO_0000219,N,,11970,Homo sapiens,A498
5374,,,80021,9606.0,Intermediate,1,,F,624.0,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,,BAO_0000219,N,,12400,Homo sapiens,A498
5375,,,80021,9606.0,Expert,1,,F,624.0,Cytotoxic effect on renal cancer lines A498,,,BAO_0000219,N,,12888,Homo sapiens,A498
5376,,,80021,9606.0,Intermediate,1,,F,624.0,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,,BAO_0000219,N,,3030,Homo sapiens,A498
5377,,,80021,9606.0,Intermediate,1,,F,624.0,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,,BAO_0000219,N,,14769,Homo sapiens,A498
5378,,,80021,9606.0,Intermediate,1,,F,624.0,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,,BAO_0000219,N,,17376,Homo sapiens,A498
5379,,,80021,9606.0,Intermediate,1,,F,624.0,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,,BAO_0000219,N,,16558,Homo sapiens,A498
5380,,,80021,9606.0,Intermediate,1,,F,624.0,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,,BAO_0000219,N,,5194,Homo sapiens,A498
5381,,,80021,9606.0,Intermediate,1,,F,624.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,,BAO_0000219,N,,10708,Homo sapiens,A498
5382,,,80682,9606.0,Expert,1,,F,646.0,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,,BAO_0000219,N,,16880,Homo sapiens,A549
5383,,,80682,9606.0,Intermediate,1,,F,646.0,Antitumor activity against A549 human lung carcinoma cell line,,,BAO_0000219,N,,10196,Homo sapiens,A549
5384,,,80682,9606.0,Intermediate,1,,F,646.0,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,,BAO_0000219,N,,10196,Homo sapiens,A549
5385,,,80682,9606.0,Intermediate,1,,F,646.0,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,,BAO_0000219,N,,10196,Homo sapiens,A549
5386,,,80682,9606.0,Intermediate,1,,F,646.0,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,,BAO_0000219,N,,12083,Homo sapiens,A549
5387,,,80682,9606.0,Expert,1,,F,646.0,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,,BAO_0000219,N,,16464,Homo sapiens,A549
5388,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,BAO_0000219,N,,16464,Homo sapiens,A549
5389,,,80682,9606.0,Expert,1,,F,646.0,In vitro cytotoxic activity against human lung A549 cell line,,,BAO_0000219,N,,16470,Homo sapiens,A549
5390,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,,BAO_0000219,N,,16470,Homo sapiens,A549
5391,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxic activity against human lung A549 cell line),,,BAO_0000219,N,,16470,Homo sapiens,A549
5392,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,,BAO_0000219,N,,16470,Homo sapiens,A549
5393,,,80682,9606.0,Expert,1,,F,646.0,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,,BAO_0000219,N,,16582,Homo sapiens,A549
5394,,,80682,9606.0,Intermediate,1,,F,646.0,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,,BAO_0000219,N,,15935,Homo sapiens,A549
5395,,,80682,9606.0,Intermediate,1,,F,646.0,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,,BAO_0000219,N,,15935,Homo sapiens,A549
5396,,,80682,9606.0,Expert,1,,F,646.0,Inhibition of A549 human lung carcinoma cell proliferation,,,BAO_0000219,N,,16597,Homo sapiens,A549
5397,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory activity against A549 lung adenocarcinoma cell line,,,BAO_0000219,N,,17376,Homo sapiens,A549
5398,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,,BAO_0000219,N,,16496,Homo sapiens,A549
5399,,,80682,9606.0,Intermediate,1,,F,646.0,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,,BAO_0000219,N,,16152,Homo sapiens,A549
5400,,,80682,9606.0,Intermediate,1,,F,646.0,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,,BAO_0000219,N,,16152,Homo sapiens,A549
5401,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,BAO_0000219,N,,16464,Homo sapiens,A549
5402,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,,BAO_0000219,N,,2288,Homo sapiens,A549
5403,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,,BAO_0000219,N,,17350,Homo sapiens,A549
5404,,,80682,9606.0,Expert,1,,F,646.0,Inhibition of A549 cancer cell proliferation,,,BAO_0000219,N,,4090,Homo sapiens,A549
5405,,,80682,9606.0,Expert,1,,F,646.0,Inhibition of A549 cancer cell proliferation (Not tested),,,BAO_0000219,N,,4090,Homo sapiens,A549
5406,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,,BAO_0000219,N,,17350,Homo sapiens,A549
5407,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,,BAO_0000219,N,,4197,Homo sapiens,A549
5408,,,80682,9606.0,Intermediate,1,,F,646.0,Antiproliferative potency determined as inhibitory concentration against A549 cells,,,BAO_0000219,N,,17072,Homo sapiens,A549
5409,,,80682,9606.0,Intermediate,1,,F,646.0,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,,BAO_0000219,N,,17072,Homo sapiens,A549
5410,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity against Renal cell lines A549 was determined,,,BAO_0000219,N,,5194,Homo sapiens,A549
5411,,,50588,9615.0,Intermediate,1,,A,,Area under curve was determined in dog after a 3 mg/kg of oral dose,,,BAO_0000218,N,,4257,Canis lupus familiaris,
5412,,,50588,9615.0,Intermediate,1,,A,,Area under curve was determined in dog after oral administration at 1 mg/kg,,,BAO_0000218,N,,6123,Canis lupus familiaris,
5413,,,50588,9615.0,Intermediate,1,,A,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,BAO_0000218,N,,1337,Canis lupus familiaris,
5414,,,50588,9615.0,Intermediate,1,,A,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,BAO_0000218,N,,1337,Canis lupus familiaris,
5415,,,50588,9615.0,Intermediate,1,,A,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,,BAO_0000218,N,,8833,Canis lupus familiaris,
5416,,,50588,9615.0,Intermediate,1,,A,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,,BAO_0000218,N,,8833,Canis lupus familiaris,
5417,,,50588,9615.0,Intermediate,1,,A,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,,BAO_0000218,N,,8833,Canis lupus familiaris,
5418,,,50588,9615.0,Intermediate,1,,A,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,,BAO_0000218,N,,8833,Canis lupus familiaris,
5419,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Area under plasma concentration time curve in dog upon oral administration,,,BAO_0000218,N,,17657,Canis lupus familiaris,
5420,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,,BAO_0000218,N,,17650,Canis lupus familiaris,
5421,,,50588,9615.0,Intermediate,1,,A,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,,BAO_0000218,N,,1977,Canis lupus familiaris,
5422,,,50588,9615.0,Intermediate,1,,A,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,,BAO_0000218,N,,1977,Canis lupus familiaris,
5423,,,50588,9615.0,Intermediate,1,,A,,Area under the curve for the compound was obtained when tested in dog,,,BAO_0000218,N,,3132,Canis lupus familiaris,
5424,,,50588,9615.0,Intermediate,1,,A,,Area under the curve at a dose of 1 mg/kg,,,BAO_0000218,N,,5473,Canis lupus familiaris,
5425,,,50588,9615.0,Intermediate,1,,A,,Area under the curve at a dose of 1 mg/kg (oral),,,BAO_0000218,N,,5474,Canis lupus familiaris,
5426,,,50588,9615.0,Intermediate,1,,A,,Area under the curve at i.v. dose of 0.2 mg/kg,,,BAO_0000218,N,,5474,Canis lupus familiaris,
5427,,,50588,9615.0,Intermediate,1,,A,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,,BAO_0000218,N,,6062,Canis lupus familiaris,
5428,,,50588,9615.0,Intermediate,1,,A,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,,BAO_0000218,N,,4709,Canis lupus familiaris,
5429,,,50588,9615.0,Intermediate,1,,A,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,,BAO_0000218,N,,2652,Canis lupus familiaris,
5430,,,50588,9615.0,Intermediate,1,,A,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,,BAO_0000218,N,,2652,Canis lupus familiaris,
5431,,,50588,9615.0,Intermediate,1,,A,,Compound was evaluated for area under the curve in dog blood.,,,BAO_0000218,N,,2877,Canis lupus familiaris,
5432,,,50588,9615.0,Intermediate,1,,A,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,,BAO_0000218,N,,5444,Canis lupus familiaris,
5433,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,AUC in dog after oral dose (1 mg/kg),,,BAO_0000218,N,,5130,Canis lupus familiaris,
5434,,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,,BAO_0000218,N,,6265,Canis lupus familiaris,
5435,,,50588,9615.0,Intermediate,1,,A,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,,BAO_0000218,N,,4657,Canis lupus familiaris,
5436,,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic parameter AUC after intravenous administration to dogs,,,BAO_0000218,N,,16367,Canis lupus familiaris,
5437,,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic parameter AUC after oral administration to dogs,,,BAO_0000218,N,,16367,Canis lupus familiaris,
5438,,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,,BAO_0000218,N,,9579,Canis lupus familiaris,
5439,,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,,BAO_0000218,N,,9579,Canis lupus familiaris,
5440,,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,,BAO_0000218,N,,5983,Canis lupus familiaris,
5441,,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,,BAO_0000218,N,,6241,Canis lupus familiaris,
5442,,,50588,9615.0,Intermediate,1,,A,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,,BAO_0000218,N,,5313,Canis lupus familiaris,
5443,,,50588,9615.0,Intermediate,1,,A,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,,BAO_0000218,N,,5313,Canis lupus familiaris,
5444,,,50588,9615.0,Intermediate,1,,A,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,BAO_0000218,N,,6642,Canis lupus familiaris,
5445,,,50588,9615.0,Intermediate,1,,A,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,BAO_0000218,N,,6642,Canis lupus familiaris,
5446,,,50588,9615.0,Intermediate,1,,A,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,,BAO_0000218,N,,6641,Canis lupus familiaris,
5447,,,50588,9615.0,Intermediate,1,,A,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,,BAO_0000218,N,,6642,Canis lupus familiaris,
5448,,,50588,9615.0,Intermediate,1,,A,,Compound was evaluated for oral bioavailability in dog; 90-100,,,BAO_0000218,N,,17791,Canis lupus familiaris,
5449,,,50588,9615.0,Intermediate,1,,A,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,,BAO_0000218,N,,17655,Canis lupus familiaris,
5450,,,50588,9615.0,Intermediate,1,,A,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,,BAO_0000218,N,,17655,Canis lupus familiaris,
5451,,,50588,9615.0,Intermediate,1,,A,,PAPP (membrane permeability) in dog kidney cell monolayer assay,,,BAO_0000218,N,,6596,Canis lupus familiaris,
5452,,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,3880,Canis lupus familiaris,
5453,,,50588,9615.0,Intermediate,1,,A,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,,BAO_0000218,N,,16367,Canis lupus familiaris,
5454,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Plasma protein binding towards dog plasma at 10 uM,,,BAO_0000218,N,,17409,Canis lupus familiaris,
5455,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Plasma protein binding towards dog plasma at 100 uM,,,BAO_0000218,N,,17409,Canis lupus familiaris,
5456,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog (dose 4 mg/kg p.o.),,,BAO_0000218,N,,2959,Canis lupus familiaris,
5457,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,,BAO_0000218,N,,13501,Canis lupus familiaris,
5458,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,,BAO_0000218,N,,4527,Canis lupus familiaris,
5459,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dogs,,,BAO_0000218,N,,15145,Canis lupus familiaris,
5460,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability,,,BAO_0000218,N,,4219,Canis lupus familiaris,
5461,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (dose 10 mg/kg),,,BAO_0000218,N,,17538,Canis lupus familiaris,
5462,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,,BAO_0000218,N,,17538,Canis lupus familiaris,
5463,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog (dose 10.0 mg/kg p.o.),,,BAO_0000218,N,,1466,Canis lupus familiaris,
5464,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,,BAO_0000218,N,,17650,Canis lupus familiaris,
5465,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,,BAO_0000218,N,,3132,Canis lupus familiaris,
5466,,,22224,10095.0,Autocuration,1,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,BAO_0000218,U,,2413,Mus sp.,
5467,,2107.0,22224,10095.0,Autocuration,1,Liver,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,BAO_0000218,U,,2413,Mus sp.,
5468,,2107.0,22224,10095.0,Autocuration,1,Liver,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,BAO_0000218,U,,2413,Mus sp.,
5469,,2107.0,22224,10095.0,Autocuration,1,Liver,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,BAO_0000218,U,,2413,Mus sp.,
5470,,,22224,10095.0,Autocuration,1,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,BAO_0000218,U,,2413,Mus sp.,
5471,,,22224,10095.0,Autocuration,1,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,BAO_0000218,U,,2413,Mus sp.,
5472,,2385.0,22224,10095.0,Autocuration,1,Muscle tissue,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,BAO_0000218,U,,2413,Mus sp.,
5473,,2385.0,22224,10095.0,Autocuration,1,Muscle tissue,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,BAO_0000218,U,,2413,Mus sp.,
5474,,2385.0,22224,10095.0,Autocuration,1,Muscle tissue,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,BAO_0000218,U,,2413,Mus sp.,
5475,,2106.0,22224,10095.0,Autocuration,1,Spleen,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,BAO_0000218,U,,2413,Mus sp.,
5476,,2106.0,22224,10095.0,Autocuration,1,Spleen,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,BAO_0000218,U,,2413,Mus sp.,
5477,,,22224,10095.0,Autocuration,1,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,BAO_0000218,U,,2413,Mus sp.,
5478,,,22224,10095.0,Autocuration,1,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,BAO_0000218,U,,2413,Mus sp.,
5479,,,22224,10095.0,Autocuration,1,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,BAO_0000218,U,,2413,Mus sp.,
5480,,,22224,10095.0,Autocuration,1,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,BAO_0000218,U,,2413,Mus sp.,
5481,,,22224,10095.0,Autocuration,1,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,BAO_0000218,U,,2413,Mus sp.,
5482,,,22224,9527.0,Autocuration,1,,A,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,,BAO_0000019,U,,17827,Cercopithecidae,
5483,,2037.0,22224,9527.0,Autocuration,1,Cerebellum,A,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,,BAO_0000019,U,,17827,Cercopithecidae,
5484,,1870.0,22224,9527.0,Autocuration,1,Frontal cortex,A,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,,BAO_0000019,U,,17827,Cercopithecidae,
5485,,,22224,9527.0,Autocuration,1,,A,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,,BAO_0000019,U,,17827,Cercopithecidae,
5486,,2435.0,22224,9527.0,Autocuration,1,Striatum,A,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,,BAO_0000019,U,,17827,Cercopithecidae,
5487,,,22224,9527.0,Autocuration,1,,A,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,,BAO_0000019,U,,17827,Cercopithecidae,
5488,,2037.0,22224,9527.0,Autocuration,1,Cerebellum,A,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,,BAO_0000019,U,,17827,Cercopithecidae,
5489,,1870.0,22224,9527.0,Autocuration,1,Frontal cortex,A,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,,BAO_0000019,U,,17827,Cercopithecidae,
5490,,,22224,9527.0,Autocuration,1,,A,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,,BAO_0000019,U,,17827,Cercopithecidae,
5491,,2435.0,22224,9527.0,Autocuration,1,Striatum,A,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,,BAO_0000019,U,,17827,Cercopithecidae,
5492,,,22224,9527.0,Autocuration,1,,A,,Compound was evaluated for oral bioavailability in rats,,,BAO_0000218,U,,17791,Cercopithecidae,
5493,In vivo,1969.0,22224,9527.0,Autocuration,1,Plasma,A,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,,,BAO_0000218,U,,17667,Cercopithecidae,
5494,,,22224,9527.0,Autocuration,1,,A,,Half life period was evaluated in monkey,,,BAO_0000019,U,,17791,Cercopithecidae,
5495,In vivo,,22224,9527.0,Autocuration,1,,A,,Half-life in rhesus monkeys by intravenous administration of dose,,,BAO_0000218,U,,110,Cercopithecidae,
5496,,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,,BAO_0000218,N,,5781,Mus musculus,
5497,,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,AUC after intraperitoneal administration of 100 mg/kg in mice,,,BAO_0000218,N,,17734,Mus musculus,
5498,,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,AUC value was determined after oral administration,,,BAO_0000218,N,,17718,Mus musculus,
5499,,,50594,10090.0,Intermediate,1,,A,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,,BAO_0000218,N,,4573,Mus musculus,
5500,,,50594,10090.0,Intermediate,1,,A,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,BAO_0000218,N,,3277,Mus musculus,
5501,,,50594,10090.0,Intermediate,1,,A,,Area under curve by ioral administration in mouse,,,BAO_0000218,N,,2862,Mus musculus,
5502,,,50594,10090.0,Intermediate,1,,A,,Area under curve by iv administration in mouse,,,BAO_0000218,N,,2862,Mus musculus,
5503,,,50594,10090.0,Intermediate,1,,A,,Area under curve at 0-8 hr in IRC mice after peroral administration,,,BAO_0000218,N,,5951,Mus musculus,
5504,,,50594,10090.0,Intermediate,1,,A,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,,BAO_0000218,N,,17729,Mus musculus,
5505,,,50594,10090.0,Intermediate,1,,A,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,,BAO_0000218,N,,17728,Mus musculus,
5506,,,50594,10090.0,Intermediate,1,,A,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,,BAO_0000218,N,,17728,Mus musculus,
5507,,,50594,10090.0,Intermediate,1,,A,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,,BAO_0000218,N,,17729,Mus musculus,
5508,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5509,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5510,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5511,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5512,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5513,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5514,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5515,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5516,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5517,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5518,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5519,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5520,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5521,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5522,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5523,,,80433,9606.0,Intermediate,1,,F,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5524,,,80433,9606.0,Expert,1,,F,741.0,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,,BAO_0000219,N,,9424,Homo sapiens,RPMI-8226
5525,,,80433,9606.0,Intermediate,1,,F,741.0,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,,BAO_0000219,N,,11544,Homo sapiens,RPMI-8226
5526,,,80433,9606.0,Intermediate,1,,F,741.0,Cytotoxicity of compound against 8226/DOX1V cells,,,BAO_0000219,N,,17378,Homo sapiens,RPMI-8226
5527,,,80433,9606.0,Intermediate,1,,F,741.0,Cytotoxicity of compound against 8226/S cells,,,BAO_0000219,N,,17378,Homo sapiens,RPMI-8226
5528,,,80433,9606.0,Intermediate,1,,F,741.0,Inhibitory concentration against 8226 myeloma cancer cell line,,,BAO_0000219,N,,17079,Homo sapiens,RPMI-8226
5529,,,80433,9606.0,Intermediate,1,,F,741.0,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,,BAO_0000219,N,,17079,Homo sapiens,RPMI-8226
5530,,,80647,9606.0,Intermediate,1,,F,854.0,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,,BAO_0000219,N,,13466,Homo sapiens,833K
5531,,,80647,9606.0,Intermediate,1,,F,854.0,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,,BAO_0000219,N,,13466,Homo sapiens,833K
5532,,,80647,9606.0,Expert,1,,F,854.0,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,,BAO_0000219,N,,2392,Homo sapiens,833K
5533,,,80647,9606.0,Intermediate,1,,F,854.0,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,,BAO_0000219,N,,2392,Homo sapiens,833K
5534,,,22226,,Autocuration,1,,B,,Inhibitory activity against caspase-1,,,BAO_0000019,U,,6608,,
5535,,,45,1351.0,Autocuration,1,,B,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,,BAO_0000357,H,,10199,Enterococcus faecalis,
5536,,,80648,9606.0,Intermediate,1,,F,705.0,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,,BAO_0000219,N,,17749,Homo sapiens,8701-BC
5537,,,80648,9606.0,Intermediate,1,,F,705.0,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,,BAO_0000219,N,,17749,Homo sapiens,8701-BC
5538,,,22226,,Intermediate,1,,F,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,,BAO_0000019,U,,1229,,
5539,,,22226,,Intermediate,1,,F,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,,BAO_0000019,U,,1229,,
5540,,,22226,,Intermediate,1,,F,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,,BAO_0000019,U,,1229,,
5541,,,22226,,Autocuration,1,,B,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,,BAO_0000019,U,,6390,,
5542,,,22226,1314.0,Autocuration,1,,F,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,,BAO_0000019,U,,16219,Streptococcus pyogenes,
5543,,,22226,1314.0,Autocuration,1,,F,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,,BAO_0000019,U,,16219,Streptococcus pyogenes,
5544,,,11922,,Autocuration,1,,B,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,,BAO_0000357,H,,17043,,
5545,,,81115,9606.0,Intermediate,1,,F,324.0,Tested for in vitro cytotoxic potency of compound in 9KB assay,,,BAO_0000219,N,,6929,Homo sapiens,KB 
5546,,,81115,9606.0,Intermediate,1,,A,324.0,Tested for in vitro cytotoxic potency of compound in 9KB assay,,,BAO_0000219,N,,6929,Homo sapiens,KB 
5547,,,22226,9606.0,Autocuration,1,,F,,In vitro cytotoxicity of compound was tested against 9KB cells.,,,BAO_0000219,U,,7083,Homo sapiens,
5548,,,80653,10116.0,Intermediate,1,,F,392.0,Cytotoxic concentration against 9L cells was determined on day 3,,,BAO_0000219,N,,12446,Rattus norvegicus,9L
5549,,,80653,10116.0,Expert,1,,F,392.0,Tested in vitro for anticancer activity against 9L cells,,,BAO_0000219,N,,15345,Rattus norvegicus,9L
5550,,,80653,10116.0,Expert,1,,F,392.0,Tested in vitro for anticancer activity against 9L cells; Not determined,,,BAO_0000219,N,,15345,Rattus norvegicus,9L
5551,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,,BAO_0000219,N,,6301,Homo sapiens,A549
5552,,,80682,9606.0,Intermediate,1,,F,646.0,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,,BAO_0000219,N,,4833,Homo sapiens,A549
5553,,,80682,9606.0,Intermediate,1,,F,646.0,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,,BAO_0000219,N,,4833,Homo sapiens,A549
5554,,,80682,9606.0,Intermediate,1,,F,646.0,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,,BAO_0000219,N,,4833,Homo sapiens,A549
5555,,,80682,9606.0,Expert,1,,F,646.0,Cytotoxicity against human lung carcinoma A549 cell line,,,BAO_0000219,N,,13330,Homo sapiens,A549
5556,,,25,9606.0,Expert,1,,F,646.0,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,,BAO_0000219,D,,17517,Homo sapiens,A549
5557,,,25,9606.0,Expert,1,,F,646.0,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,,BAO_0000219,D,,17517,Homo sapiens,A549
5558,,,80682,9606.0,Intermediate,1,,F,646.0,"In vitro growth inhibition of A549, lung carcinoma",,,BAO_0000219,N,,14425,Homo sapiens,A549
5559,,,80682,9606.0,Intermediate,1,,F,646.0,"In vitro growth inhibition of A549, lung carcinoma.",,,BAO_0000219,N,,14425,Homo sapiens,A549
5560,,,80682,9606.0,Expert,1,,F,646.0,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,,BAO_0000219,N,,5228,Homo sapiens,A549
5561,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxic activity against human lung cancer A549 cell line was determined,,,BAO_0000219,N,,5351,Homo sapiens,A549
5562,,,80682,9606.0,Expert,1,,F,646.0,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,,BAO_0000219,N,,12198,Homo sapiens,A549
5563,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,,BAO_0000219,N,,13891,Homo sapiens,A549
5564,,,80682,9606.0,Expert,1,,F,646.0,Cytotoxicity in A549 (human carcinoma) cell line.,,,BAO_0000219,N,,5677,Homo sapiens,A549
5565,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity on lung carcinoma (A-549) cell line,,,BAO_0000219,N,,13788,Homo sapiens,A549
5566,,,80682,9606.0,Expert,1,,F,646.0,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,,BAO_0000219,N,,13384,Homo sapiens,A549
5567,,,80682,9606.0,Intermediate,1,,F,646.0,Effective dose of compound against replication of A549 cell line was evaluated,,,BAO_0000219,N,,6726,Homo sapiens,A549
5568,,,80682,9606.0,Expert,1,,F,646.0,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,,BAO_0000219,N,,3455,Homo sapiens,A549
5569,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,,BAO_0000219,N,,5726,Homo sapiens,A549
5570,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,,BAO_0000219,N,,5726,Homo sapiens,A549
5571,,,80682,9606.0,Intermediate,1,,F,646.0,The compound was evaluated for antiproliferative activity against A549 cell line,,,BAO_0000219,N,,3936,Homo sapiens,A549
5572,,,80682,9606.0,Intermediate,1,,F,646.0,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,,BAO_0000219,N,,14991,Homo sapiens,A549
5573,,,80682,9606.0,Intermediate,1,,F,646.0,Concentration required for growth inhibition of human lung carcinoma cell line A549,,,BAO_0000219,N,,5243,Homo sapiens,A549
5574,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,,BAO_0000219,N,,12858,Homo sapiens,A549
5575,,,80682,9606.0,Intermediate,1,,F,646.0,Growth inhibition against A549 cell line was evaluated,,,BAO_0000219,N,,6776,Homo sapiens,A549
5576,,,80682,9606.0,Intermediate,1,,F,646.0,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,,BAO_0000219,N,,16558,Homo sapiens,A549
5577,,,80682,9606.0,Expert,1,,F,646.0,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,,BAO_0000219,N,,4583,Homo sapiens,A549
5578,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,,BAO_0000219,N,,13514,Homo sapiens,A549
5579,,,80682,9606.0,Expert,1,,F,646.0,Chemosensitivity against DT-diaphorase rich A549 cell lines,,,BAO_0000219,N,,15166,Homo sapiens,A549
5580,,,80682,9606.0,Intermediate,1,,F,646.0,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,,BAO_0000219,N,,13873,Homo sapiens,A549
5581,,,80682,9606.0,Expert,1,,F,646.0,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,,BAO_0000219,N,,6447,Homo sapiens,A549
5582,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,,BAO_0000219,N,,2068,Homo sapiens,A549
5583,,,80682,9606.0,Expert,1,,F,646.0,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,,BAO_0000219,N,,1863,Homo sapiens,A549
5584,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,,BAO_0000219,N,,13873,Homo sapiens,A549
5585,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,,BAO_0000219,N,,13873,Homo sapiens,A549
5586,,,80682,9606.0,Expert,1,,F,646.0,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,,BAO_0000219,N,,13873,Homo sapiens,A549
5587,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,,BAO_0000219,N,,579,Homo sapiens,A549
5588,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,,BAO_0000219,N,,579,Homo sapiens,A549
5589,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,,BAO_0000219,N,,4584,Homo sapiens,A549
5590,,,80682,9606.0,Expert,1,,F,646.0,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,,BAO_0000219,N,,5421,Homo sapiens,A549
5591,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,,BAO_0000219,N,,5421,Homo sapiens,A549
5592,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,,BAO_0000219,N,,5421,Homo sapiens,A549
5593,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,,BAO_0000219,N,,5421,Homo sapiens,A549
5594,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,,BAO_0000219,N,,14188,Homo sapiens,A549
5595,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,,BAO_0000219,N,,14188,Homo sapiens,A549
5596,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested for the growth inhibition of A549 lung tumor cell line,,,BAO_0000219,N,,15354,Homo sapiens,A549
5597,,,80682,9606.0,Expert,1,,F,646.0,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,,BAO_0000219,N,,14253,Homo sapiens,A549
5598,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,,BAO_0000219,N,,13873,Homo sapiens,A549
5599,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (conscious),,,BAO_0000218,N,,3043,Canis lupus familiaris,
5600,In vivo,,50588,9615.0,Intermediate,1,,A,,Compound was evaluated for the oral bioavailability after oral administration in dog.,,,BAO_0000218,N,,3045,Canis lupus familiaris,
5601,In vivo,,50588,9615.0,Intermediate,1,,A,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,,BAO_0000218,N,,3022,Canis lupus familiaris,
5602,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,4453,Canis lupus familiaris,
5603,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,1696,Canis lupus familiaris,
5604,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,5045,Canis lupus familiaris,
5605,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (fasted),,,BAO_0000218,N,,5356,Canis lupus familiaris,
5606,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,,BAO_0000218,N,,17764,Canis lupus familiaris,
5607,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,6448,Canis lupus familiaris,
5608,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,1475,Canis lupus familiaris,
5609,In vivo,,50588,9615.0,Intermediate,1,,A,,Percent bioavailability in dog,,,BAO_0000218,N,,3788,Canis lupus familiaris,
5610,In vivo,,50588,9615.0,Intermediate,1,,A,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,,BAO_0000218,N,,3639,Canis lupus familiaris,
5611,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,13397,Canis lupus familiaris,
5612,In vivo,,50588,9615.0,Intermediate,1,,A,,The compound was evaluated for bioavailability in dogs; 34-44,,,BAO_0000218,N,,2137,Canis lupus familiaris,
5613,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog (dose 4 mg/kg p.o.),,,BAO_0000218,N,,2959,Canis lupus familiaris,
5614,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,6448,Canis lupus familiaris,
5615,,,50588,9615.0,Intermediate,1,,A,,8 hour trough Blood level in dog was measured after administration of compound,,,BAO_0000218,N,,6084,Canis lupus familiaris,
5616,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,,,BAO_0000218,N,,3639,Canis lupus familiaris,
5617,,,50588,9615.0,Intermediate,1,,A,,C24 after oral administration at 5 mg/kg,,,BAO_0000218,N,,6316,Canis lupus familiaris,
5618,,,50588,9615.0,Intermediate,1,,A,,Clearance after oral and iv dosing in dogs,,,BAO_0000218,N,,5238,Canis lupus familiaris,
5619,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Clearance of the drug was measured in the plasma of dog,,,BAO_0000218,N,,17796,Canis lupus familiaris,
5620,,,50588,9615.0,Intermediate,1,,A,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,,BAO_0000218,N,,2652,Canis lupus familiaris,
5621,In vivo,,50588,9615.0,Intermediate,1,,A,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,,BAO_0000218,N,,5654,Canis lupus familiaris,
5622,In vivo,,50588,9615.0,Intermediate,1,,A,,Clearance of compound was determined in dogs,,,BAO_0000218,N,,6621,Canis lupus familiaris,
5623,In vivo,,50588,9615.0,Intermediate,1,,A,,Clearance on i.v. administration of 2 mg/kg was measured in dog,,,BAO_0000218,N,,6505,Canis lupus familiaris,
5624,In vivo,,50588,9615.0,Intermediate,1,,A,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,BAO_0000218,N,,5802,Canis lupus familiaris,
5625,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance in dog was determined,,,BAO_0000218,N,,17267,Canis lupus familiaris,
5626,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,BAO_0000218,N,,4521,Canis lupus familiaris,
5627,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance in dog after administration of 0.25 mg/kg iv,,,BAO_0000218,N,,6535,Canis lupus familiaris,
5628,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance in dog after administration of 1 mg/kg iv,,,BAO_0000218,N,,6535,Canis lupus familiaris,
5629,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance in dogs,,,BAO_0000218,N,,6535,Canis lupus familiaris,
5630,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,,BAO_0000218,N,,5542,Canis lupus familiaris,
5631,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,,BAO_0000218,N,,5199,Canis lupus familiaris,
5632,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance after 15 mg/kg iv dose in Dogs,,,BAO_0000218,N,,16907,Canis lupus familiaris,
5633,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance after 30 mg/kg po dose in Dogs,,,BAO_0000218,N,,16907,Canis lupus familiaris,
5634,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma administration to dogs,,,BAO_0000218,N,,16367,Canis lupus familiaris,
5635,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance was determined,,,BAO_0000218,N,,5505,Canis lupus familiaris,
5636,In vivo,,50588,9615.0,Intermediate,1,,A,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,,BAO_0000218,N,,6215,Canis lupus familiaris,
5637,In vivo,,50588,9615.0,Intermediate,1,,A,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,,BAO_0000218,N,,1466,Canis lupus familiaris,
5638,In vitro,2107.0,102164,9606.0,Intermediate,1,Liver,A,,Intrinsic clearance in human liver microsomes,Microsomes,,BAO_0000251,S,,5007,Homo sapiens,
5639,In vitro,2107.0,102164,9606.0,Intermediate,1,Liver,A,,Intrinsic clearance in human liver microsomes,Microsomes,,BAO_0000251,S,,5007,Homo sapiens,
5640,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,,BAO_0000218,N,,16452,Canis lupus familiaris,
5641,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,,BAO_0000218,N,,16452,Canis lupus familiaris,
5642,In vivo,,50588,9615.0,Intermediate,1,,A,,Clearance in dog (dose 1 mg/kg i.v.),,,BAO_0000218,N,,16452,Canis lupus familiaris,
5643,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,,BAO_0000218,N,,6221,Canis lupus familiaris,
5644,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,BAO_0000218,N,,5007,Canis lupus familiaris,
5645,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance after peroral administration at 10 mpk in dog,,,BAO_0000218,N,,5668,Canis lupus familiaris,
5646,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance after peroral administration at 5 mpk in dog,,,BAO_0000218,N,,5668,Canis lupus familiaris,
5647,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance after peroral administration at 5 mg/kg in dog,,,BAO_0000218,N,,5668,Canis lupus familiaris,
5648,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance was measured in dog,,,BAO_0000218,N,,15660,Canis lupus familiaris,
5649,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance was measured in dog,,,BAO_0000218,N,,15660,Canis lupus familiaris,
5650,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,,BAO_0000218,N,,5983,Canis lupus familiaris,
5651,In vivo,,50588,9615.0,Intermediate,1,,A,,Total clearance was determined after 0.1 mg/kg iv administration in dog,,,BAO_0000218,N,,5600,Canis lupus familiaris,
5652,In vivo,,50588,9615.0,Intermediate,1,,A,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,,BAO_0000218,N,,17764,Canis lupus familiaris,
5653,In vivo,,50588,9615.0,Intermediate,1,,A,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,,BAO_0000218,N,,6039,Canis lupus familiaris,
5654,In vivo,,50588,9615.0,Intermediate,1,,A,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,,BAO_0000218,N,,6039,Canis lupus familiaris,
5655,In vivo,,50588,9615.0,Intermediate,1,,A,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,,BAO_0000218,N,,6039,Canis lupus familiaris,
5656,In vivo,,50588,9615.0,Intermediate,1,,A,,Clearance by intravenous administration of 1.2 mg/kg in dog,,,BAO_0000218,N,,4368,Canis lupus familiaris,
5657,In vivo,,50588,9615.0,Intermediate,1,,A,,Clearance by iv administration in dogs at a dose of 1 mg/kg,,,BAO_0000218,N,,4305,Canis lupus familiaris,
5658,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Clearance value was evaluated in dog plasma,,,BAO_0000218,N,,1918,Canis lupus familiaris,
5659,In vivo,,50588,9615.0,Intermediate,1,,A,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,,BAO_0000218,N,,6005,Canis lupus familiaris,
5660,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Compound was tested for plasma clearance in dog,,,BAO_0000218,N,,4839,Canis lupus familiaris,
5661,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic property (Plasma clearance) was measured in dog,,,BAO_0000218,N,,4239,Canis lupus familiaris,
5662,,,50594,10090.0,Intermediate,1,,A,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,,BAO_0000218,N,,17729,Mus musculus,
5663,,,50594,10090.0,Intermediate,1,,A,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,,BAO_0000218,N,,17728,Mus musculus,
5664,,,50594,10090.0,Intermediate,1,,A,,Area under curve value in mouse at a dose of 10 mg/kg,,,BAO_0000218,N,,5302,Mus musculus,
5665,,,50594,10090.0,Intermediate,1,,A,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,,BAO_0000218,N,,5506,Mus musculus,
5666,,,50594,10090.0,Intermediate,1,,A,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,,BAO_0000218,N,,5506,Mus musculus,
5667,,,50594,10090.0,Intermediate,1,,F,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
5668,,,50594,10090.0,Intermediate,1,,F,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
5669,,,50594,10090.0,Intermediate,1,,F,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
5670,,,50594,10090.0,Intermediate,1,,F,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
5671,,,50594,10090.0,Intermediate,1,,A,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
5672,,,50594,10090.0,Intermediate,1,,A,,Area under curve was determined for the compound at 24 mg/Kg,,,BAO_0000218,N,,17753,Mus musculus,
5673,,,50594,10090.0,Intermediate,1,,A,,Area under curve was determined for the compound at 40 mg/Kg,,,BAO_0000218,N,,17753,Mus musculus,
5674,,,50594,10090.0,Intermediate,1,,A,,Area under curve was determined for the compound at 5 mg/Kg,,,BAO_0000218,N,,17753,Mus musculus,
5675,,,50594,10090.0,Intermediate,1,,A,,Area under the curve for the compound is obtained at dose 25 mg/kg,,,BAO_0000218,N,,3132,Mus musculus,
5676,,,50594,10090.0,Intermediate,1,,A,,Area under the curve for the compound was obtained when tested in mouse,,,BAO_0000218,N,,3132,Mus musculus,
5677,,,50594,10090.0,Intermediate,1,,A,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,,BAO_0000218,N,,17837,Mus musculus,
5678,,,50594,10090.0,Intermediate,1,,A,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,,BAO_0000218,N,,17837,Mus musculus,
5679,,,50594,10090.0,Intermediate,1,,A,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,,BAO_0000218,N,,6062,Mus musculus,
5680,,,50594,10090.0,Intermediate,1,,A,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,,BAO_0000218,N,,4066,Mus musculus,
5681,,,50594,10090.0,Intermediate,1,,A,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,,BAO_0000218,N,,16597,Mus musculus,
5682,,,50594,10090.0,Intermediate,1,,A,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,,BAO_0000218,N,,14239,Mus musculus,
5683,,,50594,10090.0,Intermediate,1,,A,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,,BAO_0000218,N,,14239,Mus musculus,
5684,,,50594,10090.0,Intermediate,1,,A,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,,BAO_0000218,N,,4890,Mus musculus,
5685,,,50594,10090.0,Intermediate,1,,A,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,,BAO_0000218,N,,429,Mus musculus,
5686,,,50594,10090.0,Intermediate,1,,A,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,,BAO_0000218,N,,429,Mus musculus,
5687,,,50594,10090.0,Intermediate,1,,A,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,,BAO_0000218,N,,5969,Mus musculus,
5688,,,50594,10090.0,Intermediate,1,,A,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,,BAO_0000218,N,,5969,Mus musculus,
5689,,,50594,10090.0,Intermediate,1,,A,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,,BAO_0000218,N,,5969,Mus musculus,
5690,,,50594,10090.0,Intermediate,1,,A,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,,BAO_0000218,N,,6091,Mus musculus,
5691,,,50594,10090.0,Intermediate,1,,A,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,,BAO_0000218,N,,6091,Mus musculus,
5692,,,50594,10090.0,Intermediate,1,,A,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,,BAO_0000218,N,,6091,Mus musculus,
5693,,,50594,10090.0,Intermediate,1,,A,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,,BAO_0000218,N,,6091,Mus musculus,
5694,,,50594,10090.0,Intermediate,1,,A,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,,BAO_0000218,N,,6178,Mus musculus,
5695,,,50594,10090.0,Intermediate,1,,A,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,,BAO_0000218,N,,6178,Mus musculus,
5696,,,50594,10090.0,Intermediate,1,,A,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,,BAO_0000218,N,,6619,Mus musculus,
5697,,,50594,10090.0,Intermediate,1,,A,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,,BAO_0000218,N,,6619,Mus musculus,
5698,,,50594,10090.0,Intermediate,1,,A,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,,BAO_0000218,N,,3760,Mus musculus,
5699,,,50594,10090.0,Intermediate,1,,A,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,,BAO_0000218,N,,3760,Mus musculus,
5700,,,50594,10090.0,Intermediate,1,,A,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,,BAO_0000218,N,,3760,Mus musculus,
5701,,,50594,10090.0,Intermediate,1,,A,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,,BAO_0000218,N,,3760,Mus musculus,
5702,,,50594,10090.0,Intermediate,1,,A,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,,BAO_0000218,N,,3192,Mus musculus,
5703,,,50594,10090.0,Intermediate,1,,A,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,,BAO_0000218,N,,3192,Mus musculus,
5704,,,50594,10090.0,Intermediate,1,,A,,Area under the curve was evaluated in mice after intravenous administration,,,BAO_0000218,N,,2675,Mus musculus,
5705,,,50594,10090.0,Intermediate,1,,A,,Area under the curve was evaluated in mice after oral administration,,,BAO_0000218,N,,2675,Mus musculus,
5706,,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,,BAO_0000218,N,,16597,Mus musculus,
5707,,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,,BAO_0000218,N,,16597,Mus musculus,
5708,,,50594,10090.0,Intermediate,1,,A,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,,BAO_0000218,N,,16597,Mus musculus,
5709,,,50594,10090.0,Intermediate,1,,A,,AUMC after intraperitoneal administration of 100 mg/kg in mice,,,BAO_0000218,N,,17734,Mus musculus,
5710,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5711,,,80653,,Intermediate,1,,F,392.0,The compound was tested in vitro for anticancer activity against 9L cells,,,BAO_0000219,N,,15345,,9L
5712,,,22226,10116.0,Autocuration,1,,F,,Anti proliferation activity determined; Weak effect,,,BAO_0000019,U,,2181,Rattus norvegicus,
5713,,,22226,10116.0,Autocuration,1,,F,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,,BAO_0000219,U,,2181,Rattus norvegicus,
5714,,,22226,10116.0,Autocuration,1,,F,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,,BAO_0000219,U,,2181,Rattus norvegicus,
5715,,,22226,10116.0,Autocuration,1,,F,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,,BAO_0000219,U,,2181,Rattus norvegicus,
5716,,,22226,10090.0,Autocuration,1,,F,,The cytotoxic activity was in vitro tested by 9PS assay method,,,BAO_0000019,U,,10486,Mus musculus,
5717,,,22226,10090.0,Autocuration,1,,F,,The cytotoxic activity was in vitro tested by 9PS assay method.,,,BAO_0000019,U,,10486,Mus musculus,
5718,,,22224,,Autocuration,1,,A,,Partition coefficient (logD6.5),,,BAO_0000019,U,,15508,,
5719,,,81034,9606.0,Expert,1,,F,478.0,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,,BAO_0000219,N,,5242,Homo sapiens,A2780
5720,,,80018,9606.0,Intermediate,1,,F,455.0,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,,BAO_0000219,N,,16167,Homo sapiens,A-375
5721,,,80852,9606.0,Expert,1,,F,500.0,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,,BAO_0000219,N,,4782,Homo sapiens,A-431
5722,,,9,9606.0,Expert,1,,F,500.0,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,,BAO_0000219,D,,16093,Homo sapiens,A-431
5723,,,80021,9606.0,Intermediate,1,,F,624.0,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,,BAO_0000219,N,,2596,Homo sapiens,A498
5724,,,80021,9606.0,Intermediate,1,,F,624.0,in vitro cytotoxicity against A 498 cancer cell line,,,BAO_0000219,N,,2596,Homo sapiens,A498
5725,,,80021,9606.0,Intermediate,1,,F,624.0,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,,BAO_0000219,N,,3239,Homo sapiens,A498
5726,,,80021,9606.0,Intermediate,1,,F,624.0,Cytotoxic activity against A 498 renal cancer cell lines.,,,BAO_0000219,N,,1847,Homo sapiens,A498
5727,,,80021,9606.0,Intermediate,1,,F,624.0,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,,BAO_0000219,N,,10553,Homo sapiens,A498
5728,,,22226,1280.0,Autocuration,1,,F,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,,BAO_0000019,U,,16219,Staphylococcus aureus,
5729,,,22226,1280.0,Autocuration,1,,F,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,,BAO_0000019,U,,16219,Staphylococcus aureus,
5730,,,22226,1280.0,Autocuration,1,,F,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,,BAO_0000019,U,,16219,Staphylococcus aureus,
5731,,,22226,1280.0,Autocuration,1,,F,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,,BAO_0000019,U,,16219,Staphylococcus aureus,
5732,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory concentration required against A 549 lung cancer cell line,,,BAO_0000219,N,,4782,Homo sapiens,A549
5733,,,80682,9606.0,Intermediate,1,,F,646.0,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,,BAO_0000219,N,,11805,Homo sapiens,A549
5734,,,80682,9606.0,Intermediate,1,,F,646.0,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,,BAO_0000219,N,,11805,Homo sapiens,A549
5735,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity against lung cancer A 549 cell lines,,,BAO_0000219,N,,2007,Homo sapiens,A549
5736,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested for its cytotoxicity against A 549 cell line,,,BAO_0000219,N,,4594,Homo sapiens,A549
5737,,,80682,9606.0,Expert,1,,F,646.0,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,,BAO_0000219,N,,6018,Homo sapiens,A549
5738,,,80682,9606.0,Intermediate,1,,F,646.0,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,,BAO_0000219,N,,6018,Homo sapiens,A549
5739,,,80682,9606.0,Expert,1,,F,646.0,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,,BAO_0000219,N,,3599,Homo sapiens,A549
5740,,,80682,9606.0,Intermediate,1,,F,646.0,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,,BAO_0000219,N,,2551,Homo sapiens,A549
5741,,,80682,9606.0,Expert,1,,F,646.0,In vitro inhibition of A549 (human lung cancer) cell growth.,,,BAO_0000219,N,,16132,Homo sapiens,A549
5742,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,,BAO_0000219,N,,16132,Homo sapiens,A549
5743,,,80682,9606.0,Expert,1,,F,646.0,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,,BAO_0000219,N,,2551,Homo sapiens,A549
5744,,,80682,9606.0,Expert,1,,F,646.0,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,,BAO_0000219,N,,2551,Homo sapiens,A549
5745,,,22226,,Autocuration,1,,F,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,,BAO_0000218,U,,11913,,
5746,In vivo,,104694,,Autocuration,1,,F,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,,BAO_0000218,H,,12621,,
5747,In vivo,,104694,,Autocuration,1,,F,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,,BAO_0000218,H,,12621,,
5748,In vivo,,104694,,Autocuration,1,,F,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,,BAO_0000218,H,,12621,,
5749,In vivo,,104694,,Autocuration,1,,F,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,,BAO_0000218,H,,12621,,
5750,In vivo,,104694,,Autocuration,1,,F,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,,BAO_0000218,H,,12621,,
5751,,,80021,9606.0,Expert,1,,F,624.0,Inhibition of A-498 human Renal cell proliferation,,,BAO_0000219,N,,3600,Homo sapiens,A498
5752,,,22226,10116.0,Autocuration,1,,F,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,,BAO_0000019,U,,1796,Rattus norvegicus,
5753,,,22226,10116.0,Autocuration,1,,F,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,,BAO_0000019,U,,1796,Rattus norvegicus,
5754,,,22226,10116.0,Autocuration,1,,F,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,,BAO_0000019,U,,1796,Rattus norvegicus,
5755,,,80012,9606.0,Expert,1,,F,622.0,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,,BAO_0000219,N,,16464,Homo sapiens,A 172
5756,,,80012,9606.0,Intermediate,1,,F,622.0,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,BAO_0000219,N,,16464,Homo sapiens,A 172
5757,,,80012,9606.0,Intermediate,1,,F,622.0,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,BAO_0000219,N,,16464,Homo sapiens,A 172
5758,,,80682,9606.0,Expert,1,,F,646.0,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,,BAO_0000219,N,,13617,Homo sapiens,A549
5759,,,80682,9606.0,Intermediate,1,,F,646.0,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,,BAO_0000219,N,,4584,Homo sapiens,A549
5760,,,80682,9606.0,Expert,1,,F,646.0,Cytotoxic activity evaluated against A549 tumor cells,,,BAO_0000219,N,,13799,Homo sapiens,A549
5761,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,,BAO_0000219,N,,16726,Homo sapiens,A549
5762,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,,BAO_0000219,N,,16109,Homo sapiens,A549
5763,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,,BAO_0000219,N,,16109,Homo sapiens,A549
5764,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,,BAO_0000219,N,,15474,Homo sapiens,A549
5765,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity of compound against A549 cell line,,,BAO_0000219,N,,6851,Homo sapiens,A549
5766,,,80682,9606.0,Expert,1,,F,646.0,Cytotoxicity against human lung cell carcinoma A549 cell line,,,BAO_0000219,N,,17534,Homo sapiens,A549
5767,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,,BAO_0000219,N,,2621,Homo sapiens,A549
5768,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,,BAO_0000219,N,,830,Homo sapiens,A549
5769,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,,BAO_0000219,N,,14255,Homo sapiens,A549
5770,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,,BAO_0000219,N,,14255,Homo sapiens,A549
5771,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,,BAO_0000219,N,,1590,Homo sapiens,A549
5772,,,80682,9606.0,Expert,1,,F,646.0,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,,BAO_0000219,N,,6146,Homo sapiens,A549
5773,,,80682,9606.0,Expert,1,,F,646.0,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,,BAO_0000219,N,,17427,Homo sapiens,A549
5774,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,,BAO_0000219,N,,5280,Homo sapiens,A549
5775,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,,BAO_0000219,N,,16786,Homo sapiens,A549
5776,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity against A549 (human lung cancer),,,BAO_0000219,N,,5895,Homo sapiens,A549
5777,,,80682,9606.0,Expert,1,,F,646.0,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,,BAO_0000219,N,,14297,Homo sapiens,A549
5778,,,80682,9606.0,Intermediate,1,,F,646.0,In vivo antiproliferative activity against A549 cell line,,,BAO_0000218,N,,17824,Homo sapiens,A549
5779,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibition of non-small-cell lung adenocarcinoma (A549),,,BAO_0000219,N,,14368,Homo sapiens,A549
5780,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,,BAO_0000219,N,,14368,Homo sapiens,A549
5781,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,,BAO_0000219,N,,14254,Homo sapiens,A549
5782,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,,BAO_0000219,N,,15897,Homo sapiens,A549
5783,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,,BAO_0000219,N,,13866,Homo sapiens,A549
5784,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,,BAO_0000219,N,,13370,Homo sapiens,A549
5785,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory activity against A549 lung cancer cell line,,,BAO_0000219,N,,4862,Homo sapiens,A549
5786,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,,BAO_0000219,N,,4862,Homo sapiens,A549
5787,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,,BAO_0000219,N,,4862,Homo sapiens,A549
5788,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory concentration against A549 (lung cancer) cell line,,,BAO_0000219,N,,15970,Homo sapiens,A549
5789,,,80682,9606.0,Expert,1,,F,646.0,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,,BAO_0000219,N,,17713,Homo sapiens,A549
5790,,,80682,9606.0,Intermediate,1,,F,646.0,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,,BAO_0000219,N,,4833,Homo sapiens,A549
5791,,,80682,9606.0,Expert,1,,F,646.0,Activity against A549 cancer cell line.,,,BAO_0000219,N,,13736,Homo sapiens,A549
5792,,,80682,9606.0,Intermediate,1,,F,646.0,The compound was evaluated for cytotoxicity against A549 cell line,,,BAO_0000219,N,,4312,Homo sapiens,A549
5793,,,80682,9606.0,Intermediate,1,,F,646.0,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,,BAO_0000219,N,,5421,Homo sapiens,A549
5794,,,80682,9606.0,Intermediate,1,,F,646.0,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,,BAO_0000219,N,,5421,Homo sapiens,A549
5795,,,80682,9606.0,Intermediate,1,,F,646.0,Growth inhibitory activity was measured for human A549 tumor cell line.,,,BAO_0000219,N,,14717,Homo sapiens,A549
5796,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory activity against A549 lung cancer cell line,,,BAO_0000219,N,,4634,Homo sapiens,A549
5797,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory activity against A549 cell line; inactive,,,BAO_0000219,N,,1149,Homo sapiens,A549
5798,,,80682,9606.0,Expert,1,,F,646.0,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,,BAO_0000219,N,,5421,Homo sapiens,A549
5799,,,80682,9606.0,Expert,1,,F,646.0,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,,BAO_0000219,N,,5421,Homo sapiens,A549
5800,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,,BAO_0000219,N,,5421,Homo sapiens,A549
5801,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,,BAO_0000219,N,,3320,Homo sapiens,A549
5802,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,,BAO_0000219,N,,3320,Homo sapiens,A549
5803,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,,BAO_0000219,N,,3320,Homo sapiens,A549
5804,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,,BAO_0000219,N,,3320,Homo sapiens,A549
5805,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,,BAO_0000219,N,,3320,Homo sapiens,A549
5806,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,,BAO_0000219,N,,5726,Homo sapiens,A549
5807,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance (in vivo) in mongrel dogs was determined,,,BAO_0000218,N,,17800,Canis lupus familiaris,
5808,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance was measured in dog,,,BAO_0000218,N,,5985,Canis lupus familiaris,
5809,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,,BAO_0000218,N,,5530,Canis lupus familiaris,
5810,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,,BAO_0000218,N,,5530,Canis lupus familiaris,
5811,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Tested for plasma clearance in dog,,,BAO_0000218,N,,4839,Canis lupus familiaris,
5812,In vivo,,50588,9615.0,Intermediate,1,,A,,The compound was tested for clearance in dog plasma.,,,BAO_0000218,N,,3639,Canis lupus familiaris,
5813,In vivo,,50588,9615.0,Intermediate,1,,A,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,,BAO_0000218,N,,4838,Canis lupus familiaris,
5814,In vivo,,50588,9615.0,Intermediate,1,,A,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,,BAO_0000218,N,,4137,Canis lupus familiaris,
5815,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,,BAO_0000218,N,,5017,Canis lupus familiaris,
5816,In vitro,2107.0,50588,9615.0,Intermediate,1,Liver,A,,In vitro clearance in dog liver microsomes,Microsomes,,BAO_0000218,N,,17538,Canis lupus familiaris,
5817,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,,BAO_0000218,N,,6161,Canis lupus familiaris,
5818,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,,BAO_0000218,N,,6161,Canis lupus familiaris,
5819,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance in dog,,,BAO_0000218,N,,1696,Canis lupus familiaris,
5820,In vivo,,50588,9615.0,Intermediate,1,,A,,Clearance rate in dog,,,BAO_0000218,N,,6762,Canis lupus familiaris,
5821,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,,BAO_0000218,N,,5932,Canis lupus familiaris,
5822,In vivo,,50588,9615.0,Intermediate,1,,A,,Clearance in dogs,,,BAO_0000218,N,,6305,Canis lupus familiaris,
5823,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance in dogs,,,BAO_0000218,N,,4942,Canis lupus familiaris,
5824,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance was determined,,,BAO_0000218,N,,4219,Canis lupus familiaris,
5825,In vivo,,50588,9615.0,Intermediate,1,,A,,Lower clearance in dog (i.v.) at 0.5 mpk,,,BAO_0000218,N,,17853,Canis lupus familiaris,
5826,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance in Beagle dogs,,,BAO_0000218,N,,4514,Canis lupus familiaris,
5827,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance (Clp) in dog,,,BAO_0000218,N,,6448,Canis lupus familiaris,
5828,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,,BAO_0000218,N,,6227,Canis lupus familiaris,
5829,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance (pharmacokinetic parameter) in dog was determined,,,BAO_0000218,N,,6227,Canis lupus familiaris,
5830,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,,BAO_0000218,N,,6062,Canis lupus familiaris,
5831,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance of compound was determined in dog,,,BAO_0000218,N,,6821,Canis lupus familiaris,
5832,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance after intravenous administration of 1 mg/kg in dog,,,BAO_0000218,N,,4709,Canis lupus familiaris,
5833,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,,BAO_0000218,N,,4521,Canis lupus familiaris,
5834,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance in dog was determined,,,BAO_0000218,N,,5374,Canis lupus familiaris,
5835,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance was calculated in dog,,,BAO_0000218,N,,6057,Canis lupus familiaris,
5836,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance at the dose of 2 mg/kg in dog,,,BAO_0000218,N,,4727,Canis lupus familiaris,
5837,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance in dog,,,BAO_0000218,N,,5145,Canis lupus familiaris,
5838,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance in dog,,,BAO_0000218,N,,17657,Canis lupus familiaris,
5839,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance in dog; Unable to calculate,,,BAO_0000218,N,,17657,Canis lupus familiaris,
5840,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance in rhesus monkey,,,BAO_0000218,N,,5145,Canis lupus familiaris,
5841,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,BAO_0000218,N,,6642,Canis lupus familiaris,
5842,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,BAO_0000218,N,,6641,Canis lupus familiaris,
5843,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,BAO_0000218,N,,6642,Canis lupus familiaris,
5844,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance was evaluated in dog,,,BAO_0000218,N,,5472,Canis lupus familiaris,
5845,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance was evaluated in dog; Not tested,,,BAO_0000218,N,,5472,Canis lupus familiaris,
5846,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance was evaluated in rhesus,,,BAO_0000218,N,,5472,Canis lupus familiaris,
5847,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance was evaluated in rhesus; Not tested,,,BAO_0000218,N,,5472,Canis lupus familiaris,
5848,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,,BAO_0000218,N,,4257,Canis lupus familiaris,
5849,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,BAO_0000218,N,,6679,Canis lupus familiaris,
5850,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,,BAO_0000218,N,,5546,Canis lupus familiaris,
5851,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,BAO_0000218,N,,6348,Canis lupus familiaris,
5852,In vivo,,50588,9615.0,Intermediate,1,,A,,Clearance value at a dose of 0.2 mg/kg i.v.,,,BAO_0000218,N,,5474,Canis lupus familiaris,
5853,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,,,BAO_0000218,N,,6316,Canis lupus familiaris,
5854,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax after oral dose of compound at 3 mg/kg in dogs,,,BAO_0000218,N,,17594,Canis lupus familiaris,
5855,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax after single intravenous bolus of 1 mg/kg in dogs,,,BAO_0000218,N,,17594,Canis lupus familiaris,
5856,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,BAO_0000218,N,,5802,Canis lupus familiaris,
5857,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,,BAO_0000218,N,,6535,Canis lupus familiaris,
5858,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax in dog after administration of 1 mg/kg iv,,,BAO_0000218,N,,6535,Canis lupus familiaris,
5859,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,,,BAO_0000218,N,,1466,Canis lupus familiaris,
5860,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax on p.o. administration of 10 mg/kg was measured in dog,,,BAO_0000218,N,,6505,Canis lupus familiaris,
5861,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax was determine after peroral administration at 10 mpk in dog,,,BAO_0000218,N,,5668,Canis lupus familiaris,
5862,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax was determine after peroral administration at 5 mpk in dog,,,BAO_0000218,N,,5668,Canis lupus familiaris,
5863,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax was determine after peroral administration at 5 mg/kg in dog,,,BAO_0000218,N,,5668,Canis lupus familiaris,
5864,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax after 0.3 mg/kg po administration in dog,,,BAO_0000218,N,,5600,Canis lupus familiaris,
5865,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax after peroral administration in dogs at 2.4 uM/kg,,,BAO_0000218,N,,17764,Canis lupus familiaris,
5866,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax in dog after oral administration at 1 mg/kg,,,BAO_0000218,N,,6123,Canis lupus familiaris,
5867,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,,BAO_0000218,N,,6123,Canis lupus familiaris,
5868,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,,BAO_0000218,N,,6757,Canis lupus familiaris,
5869,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax value after 15 mg/kg iv dose in Dogs,,,BAO_0000218,N,,16907,Canis lupus familiaris,
5870,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5871,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5872,In vivo,10000001.0,50594,10090.0,Intermediate,1,Bone,A,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5873,In vivo,10000001.0,50594,10090.0,Intermediate,1,Bone,A,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5874,In vivo,10000001.0,50594,10090.0,Intermediate,1,Bone,A,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5875,In vivo,,50594,10090.0,Intermediate,1,,A,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5876,In vivo,,50594,10090.0,Intermediate,1,,A,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5877,In vivo,,50594,10090.0,Intermediate,1,,A,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5878,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5879,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5880,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5881,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5882,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5883,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5884,In vivo,160.0,50594,10090.0,Intermediate,1,Intestine,A,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5885,In vivo,160.0,50594,10090.0,Intermediate,1,Intestine,A,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5886,In vivo,160.0,50594,10090.0,Intermediate,1,Intestine,A,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5887,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5888,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5889,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5890,In vivo,2048.0,50594,10090.0,Intermediate,1,Lung,A,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5891,In vivo,2048.0,50594,10090.0,Intermediate,1,Lung,A,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5892,In vivo,2048.0,50594,10090.0,Intermediate,1,Lung,A,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5893,In vivo,2385.0,50594,10090.0,Intermediate,1,Muscle tissue,A,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5894,In vivo,2385.0,50594,10090.0,Intermediate,1,Muscle tissue,A,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5895,In vivo,2385.0,50594,10090.0,Intermediate,1,Muscle tissue,A,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5896,In vivo,,50594,10090.0,Intermediate,1,,A,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5897,In vivo,,50594,10090.0,Intermediate,1,,A,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5898,In vivo,,50594,10090.0,Intermediate,1,,A,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5899,In vivo,160.0,50594,10090.0,Intermediate,1,Intestine,A,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5900,In vivo,160.0,50594,10090.0,Intermediate,1,Intestine,A,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5901,In vivo,160.0,50594,10090.0,Intermediate,1,Intestine,A,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5902,In vivo,2106.0,50594,10090.0,Intermediate,1,Spleen,A,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5903,In vivo,2106.0,50594,10090.0,Intermediate,1,Spleen,A,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5904,In vivo,2106.0,50594,10090.0,Intermediate,1,Spleen,A,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5905,In vivo,945.0,50594,10090.0,Intermediate,1,Stomach,A,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5906,In vivo,945.0,50594,10090.0,Intermediate,1,Stomach,A,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
5907,,,80012,9606.0,Expert,1,,F,622.0,Cytotoxicity against A-172 human tumor cell lines,,,BAO_0000219,N,,2036,Homo sapiens,A 172
5908,,,80012,9606.0,Intermediate,1,,F,622.0,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,,BAO_0000219,N,,2357,Homo sapiens,A 172
5909,,,80014,9606.0,Intermediate,1,,F,623.0,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,,BAO_0000219,N,,1457,Homo sapiens,A204
5910,,,81034,9606.0,Intermediate,1,,F,478.0,Tested for antiproliferative activity against A-2780 tumoral cell line,,,BAO_0000219,N,,4379,Homo sapiens,A2780
5911,,,80018,9606.0,Intermediate,1,,F,455.0,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,,BAO_0000219,N,,1093,Homo sapiens,A-375
5912,,,80018,9606.0,Intermediate,1,,F,455.0,Tested in vitro against A-375 cell line human melanoma,,,BAO_0000219,N,,12152,Homo sapiens,A-375
5913,,,80019,9606.0,Expert,1,,F,797.0,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,,BAO_0000219,N,,16464,Homo sapiens,A-427
5914,,,80019,9606.0,Intermediate,1,,F,797.0,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,BAO_0000219,N,,16464,Homo sapiens,A-427
5915,,,80019,9606.0,Expert,1,,F,797.0,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,,BAO_0000219,N,,16582,Homo sapiens,A-427
5916,,,80019,9606.0,Intermediate,1,,F,797.0,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,BAO_0000219,N,,16464,Homo sapiens,A-427
5917,,,80019,9606.0,Intermediate,1,,F,797.0,Antitumor activity on A-427 lung carcinoma cell lines,,,BAO_0000219,N,,10413,Homo sapiens,A-427
5918,,,80019,9606.0,Intermediate,1,,F,797.0,Cytotoxic activity against human A-427 lung tumor cell line,,,BAO_0000219,N,,6418,Homo sapiens,A-427
5919,,,80019,9606.0,Expert,1,,F,797.0,In vitro antitumor effects against human A-427 cell lines.,,,BAO_0000219,N,,17134,Homo sapiens,A-427
5920,,,80019,9606.0,Expert,1,,F,797.0,In vitro inhibition of A-427 (human lung cancer) cell growth.,,,BAO_0000219,N,,16132,Homo sapiens,A-427
5921,,,80019,9606.0,Intermediate,1,,F,797.0,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,,BAO_0000219,N,,16132,Homo sapiens,A-427
5922,,,80019,9606.0,Intermediate,1,,F,797.0,Cytotoxic activity of compound against A-427 lung human tumor cell line,,,BAO_0000219,N,,16780,Homo sapiens,A-427
5923,,,80852,9606.0,Expert,1,,F,500.0,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,,BAO_0000219,N,,4085,Homo sapiens,A-431
5924,,,80021,9606.0,Intermediate,1,,F,624.0,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,,BAO_0000219,N,,1276,Homo sapiens,A498
5925,,,80021,9606.0,Expert,1,,F,624.0,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,,BAO_0000219,N,,3498,Homo sapiens,A498
5926,,,80021,9606.0,Intermediate,1,,F,624.0,Cytotoxicity against human kidney carcinoma A-498cell lines,,,BAO_0000219,N,,1169,Homo sapiens,A498
5927,,,80021,9606.0,Intermediate,1,,F,624.0,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,,BAO_0000219,N,,4450,Homo sapiens,A498
5928,,,80021,9606.0,Intermediate,1,,F,624.0,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,,BAO_0000219,N,,3311,Homo sapiens,A498
5929,,,80021,9606.0,Intermediate,1,,F,624.0,Antitumor cytotoxic activity against A-498 cell line was determined,,,BAO_0000219,N,,4461,Homo sapiens,A498
5930,,,80021,9606.0,Intermediate,1,,F,624.0,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,,BAO_0000219,N,,3311,Homo sapiens,A498
5931,,,80021,9606.0,Intermediate,1,,F,624.0,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,,BAO_0000219,N,,3311,Homo sapiens,A498
5932,,,80021,9606.0,Intermediate,1,,F,624.0,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,,BAO_0000219,N,,1457,Homo sapiens,A498
5933,,,80021,9606.0,Intermediate,1,,F,624.0,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,,BAO_0000219,N,,3664,Homo sapiens,A498
5934,,,80021,9606.0,Intermediate,1,,F,624.0,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,,BAO_0000219,N,,15895,Homo sapiens,A498
5935,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,,BAO_0000219,N,,11843,Homo sapiens,A549
5936,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,,BAO_0000219,N,,11843,Homo sapiens,A549
5937,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro antiproliferative activity against human A-549 NSCL cell line,,,BAO_0000219,N,,17705,Homo sapiens,A549
5938,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,,BAO_0000219,N,,17705,Homo sapiens,A549
5939,,,80682,9606.0,Intermediate,1,,F,646.0,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,,BAO_0000219,N,,4369,Homo sapiens,A549
5940,,,80682,9606.0,Intermediate,1,,F,646.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,,BAO_0000219,N,,4369,Homo sapiens,A549
5941,,,80682,9606.0,Intermediate,1,,F,646.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,,BAO_0000219,N,,4369,Homo sapiens,A549
5942,,,80682,9606.0,Intermediate,1,,F,646.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,,BAO_0000219,N,,4369,Homo sapiens,A549
5943,,,80682,9606.0,Intermediate,1,,F,646.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,,BAO_0000219,N,,4369,Homo sapiens,A549
5944,,,80682,9606.0,Intermediate,1,,F,646.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,,BAO_0000219,N,,4369,Homo sapiens,A549
5945,,,80682,9606.0,Intermediate,1,,F,646.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,,BAO_0000219,N,,4369,Homo sapiens,A549
5946,,,80682,9606.0,Expert,1,,F,646.0,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,,BAO_0000219,N,,4787,Homo sapiens,A549
5947,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,,BAO_0000219,N,,4787,Homo sapiens,A549
5948,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxic activity against A-549 cell line,,,BAO_0000219,N,,6513,Homo sapiens,A549
5949,,,80682,9606.0,Intermediate,1,,F,646.0,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,,BAO_0000219,N,,6690,Homo sapiens,A549
5950,,,80682,9606.0,Intermediate,1,,F,646.0,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,,BAO_0000219,N,,6690,Homo sapiens,A549
5951,,,80682,9606.0,Expert,1,,F,646.0,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,,BAO_0000219,N,,12263,Homo sapiens,A549
5952,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,,BAO_0000219,N,,1054,Homo sapiens,A549
5953,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,,BAO_0000219,N,,1359,Homo sapiens,A549
5954,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxic activity against human lung carcinoma (A-549) cell line,,,BAO_0000219,N,,3547,Homo sapiens,A549
5955,,,80682,9606.0,Expert,1,,F,646.0,Cytotoxic activity towards A-549 cells,,,BAO_0000219,N,,5771,Homo sapiens,A549
5956,,,80682,9606.0,Intermediate,1,,F,646.0,"In vitro percent inhibition of A549, lung carcinoma.",,,BAO_0000219,N,,14425,Homo sapiens,A549
5957,,,80682,9606.0,Intermediate,1,,F,646.0,"In vitro percent inhibition of A549, lung carcinoma",,,BAO_0000219,N,,14425,Homo sapiens,A549
5958,,,80682,9606.0,Intermediate,1,,F,646.0,"In vitro percent inhibition of A549, lung carcinoma.",,,BAO_0000219,N,,14425,Homo sapiens,A549
5959,,,80682,9606.0,Intermediate,1,,F,646.0,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,,BAO_0000219,N,,14425,Homo sapiens,A549
5960,,,80682,9606.0,Intermediate,1,,F,646.0,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,,BAO_0000219,N,,5280,Homo sapiens,A549
5961,,,80682,9606.0,Intermediate,1,,F,646.0,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,,BAO_0000219,N,,15176,Homo sapiens,A549
5962,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,,BAO_0000219,N,,15300,Homo sapiens,A549
5963,,,80682,9606.0,Intermediate,1,,F,646.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,BAO_0000218,N,,17824,Homo sapiens,A549
5964,,,80682,9606.0,Intermediate,1,,F,646.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,BAO_0000218,N,,17824,Homo sapiens,A549
5965,,,80682,9606.0,Intermediate,1,,F,646.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,BAO_0000218,N,,17824,Homo sapiens,A549
5966,,,80682,9606.0,Intermediate,1,,F,646.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,BAO_0000218,N,,17824,Homo sapiens,A549
5967,,,80682,9606.0,Intermediate,1,,F,646.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,BAO_0000218,N,,17824,Homo sapiens,A549
5968,,,80682,9606.0,Intermediate,1,,F,646.0,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,,BAO_0000219,N,,17824,Homo sapiens,A549
5969,,,80682,9606.0,Intermediate,1,,F,646.0,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,,BAO_0000218,N,,17528,Homo sapiens,A549
5970,,,80682,9606.0,Expert,1,,F,646.0,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,,BAO_0000219,N,,6870,Homo sapiens,A549
5971,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,,BAO_0000219,N,,6870,Homo sapiens,A549
5972,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,,BAO_0000219,N,,6870,Homo sapiens,A549
5973,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,,BAO_0000219,N,,6870,Homo sapiens,A549
5974,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,,BAO_0000219,N,,16726,Homo sapiens,A549
5975,,,80682,9606.0,Intermediate,1,,F,646.0,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,,BAO_0000219,N,,6170,Homo sapiens,A549
5976,,,80682,9606.0,Expert,1,,F,646.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,,BAO_0000219,N,,6583,Homo sapiens,A549
5977,,,80682,9606.0,Expert,1,,F,646.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,,BAO_0000219,N,,6583,Homo sapiens,A549
5978,,,80682,9606.0,Expert,1,,F,646.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,,BAO_0000219,N,,6583,Homo sapiens,A549
5979,,,80682,9606.0,Expert,1,,F,646.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,,BAO_0000219,N,,6583,Homo sapiens,A549
5980,,,80682,9606.0,Expert,1,,F,646.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,,BAO_0000219,N,,6583,Homo sapiens,A549
5981,,,80682,9606.0,Intermediate,1,,F,646.0,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,,BAO_0000219,N,,17321,Homo sapiens,A549
5982,,,80682,9606.0,Expert,1,,F,646.0,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,,BAO_0000219,N,,17528,Homo sapiens,A549
5983,,,80682,9606.0,Expert,1,,F,646.0,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,,BAO_0000219,N,,12888,Homo sapiens,A549
5984,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,,BAO_0000219,N,,4312,Homo sapiens,A549
5985,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,,BAO_0000219,N,,4312,Homo sapiens,A549
5986,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,,BAO_0000219,N,,4312,Homo sapiens,A549
5987,,,80682,10090.0,Intermediate,1,,F,646.0,In vitro antiproliferative activity against A549 cell line,,,BAO_0000219,N,,17737,Mus musculus,A549
5988,,,80682,,Intermediate,1,,F,646.0,Synergism with indomethacin in A549 cells,,,BAO_0000219,N,,6630,,A549
5989,,,80682,,Intermediate,1,,F,646.0,Synergism with tolmetin in A549 cells,,,BAO_0000219,N,,6630,,A549
5990,,,80682,,Intermediate,1,,F,646.0,Synergism with sulindac in A549 cells,,,BAO_0000219,N,,6630,,A549
5991,,,80682,,Intermediate,1,,F,646.0,Antagonism of indomethacin in A549 cells,,,BAO_0000219,N,,6630,,A549
5992,,,80682,,Intermediate,1,,F,646.0,Antagonism of sulindac in A549 cells,,,BAO_0000219,N,,6630,,A549
5993,,,80682,,Intermediate,1,,F,646.0,Antagonism of tolmetin in A549 cells,,,BAO_0000219,N,,6630,,A549
5994,,,80682,,Intermediate,1,,F,646.0,Synergism with indomethacin in A549 cells,,,BAO_0000219,N,,6630,,A549
5995,,,80682,,Intermediate,1,,F,646.0,Synergism with sulindac in A549 cells,,,BAO_0000219,N,,6630,,A549
5996,,,80682,,Intermediate,1,,F,646.0,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,,BAO_0000219,N,,6630,,A549
5997,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax value after 30 mg/kg po dose in Dogs,,,BAO_0000218,N,,16907,Canis lupus familiaris,
5998,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,,BAO_0000218,N,,5944,Canis lupus familiaris,
5999,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,,BAO_0000218,N,,5944,Canis lupus familiaris,
6000,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,,BAO_0000218,N,,5944,Canis lupus familiaris,
6001,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,,BAO_0000218,N,,5944,Canis lupus familiaris,
6002,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax value after administration of 4 mg/Kg oral dose in dog,,,BAO_0000218,N,,2959,Canis lupus familiaris,
6003,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax value in dog,,,BAO_0000218,N,,6241,Canis lupus familiaris,
6004,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax value in dogs after oral administration at 1 mg/kg,,,BAO_0000218,N,,6241,Canis lupus familiaris,
6005,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,,BAO_0000218,N,,2652,Canis lupus familiaris,
6006,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,,,BAO_0000218,N,,1806,Canis lupus familiaris,
6007,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,,,BAO_0000218,N,,1806,Canis lupus familiaris,
6008,In vivo,,50588,9615.0,Intermediate,1,,A,,Concentration maxima after oral dosing in dogs,,,BAO_0000218,N,,1021,Canis lupus familiaris,
6009,In vivo,,50588,9615.0,Intermediate,1,,A,,Concentration maxima after oral dosing in dogs; not available,,,BAO_0000218,N,,1021,Canis lupus familiaris,
6010,In vivo,,50588,9615.0,Intermediate,1,,A,,Concentration maxima after oral dosing in dogs; not available,,,BAO_0000218,N,,1021,Canis lupus familiaris,
6011,In vivo,,50588,9615.0,Intermediate,1,,A,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,,BAO_0000218,N,,5444,Canis lupus familiaris,
6012,In vivo,,50588,9615.0,Intermediate,1,,A,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,,BAO_0000218,N,,5444,Canis lupus familiaris,
6013,In vivo,,50588,9615.0,Intermediate,1,,A,,In vivo maximal concentration was calculated at 1 mg/kg in dog,,,BAO_0000218,N,,5444,Canis lupus familiaris,
6014,In vivo,,50588,9615.0,Intermediate,1,,A,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,,BAO_0000218,N,,5444,Canis lupus familiaris,
6015,In vivo,,50588,9615.0,Intermediate,1,,A,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,,BAO_0000218,N,,5444,Canis lupus familiaris,
6016,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Cmax in dog plasma after oral dose (1 mg/kg),,,BAO_0000218,N,,5130,Canis lupus familiaris,
6017,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,,,BAO_0000218,N,,3249,Canis lupus familiaris,
6018,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximal plasma concentration at a dose of 1 mg/kg,,,BAO_0000218,N,,5473,Canis lupus familiaris,
6019,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximal plasma concentration at a dose of 1 mg/kg (oral),,,BAO_0000218,N,,5474,Canis lupus familiaris,
6020,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,,,BAO_0000218,N,,4657,Canis lupus familiaris,
6021,In vivo,,50588,9615.0,Intermediate,1,,A,,Maximum concentration of compound in dog was evaluated.,,,BAO_0000218,N,,3031,Canis lupus familiaris,
6022,In vivo,,50588,9615.0,Intermediate,1,,A,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,,BAO_0000218,N,,4527,Canis lupus familiaris,
6023,In vivo,,50588,9615.0,Intermediate,1,,A,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,,BAO_0000218,N,,4186,Canis lupus familiaris,
6024,In vivo,,50588,9615.0,Intermediate,1,,A,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,BAO_0000218,N,,5007,Canis lupus familiaris,
6025,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum concentration obtained in dog plasma was determined,,,BAO_0000218,N,,3132,Canis lupus familiaris,
6026,In vivo,,50588,9615.0,Intermediate,1,,A,,Maximum concentration was determined,,,BAO_0000218,N,,5006,Canis lupus familiaris,
6027,In vivo,,50588,9615.0,Intermediate,1,,A,,Maximum concentration at the dose of 2 mg/kg in dog,,,BAO_0000218,N,,4727,Canis lupus familiaris,
6028,In vivo,,50588,9615.0,Intermediate,1,,A,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,BAO_0000218,N,,1916,Canis lupus familiaris,
6029,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum concentration was evaluated in dog plasma,,,BAO_0000218,N,,1918,Canis lupus familiaris,
6030,In vivo,,50588,9615.0,Intermediate,1,,A,,Maximum concentration was evaluated after 75 min after administration in dog,,,BAO_0000218,N,,3045,Canis lupus familiaris,
6031,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum plasma concentration determined in dog after oral administration of 17b,,,BAO_0000218,N,,9579,Canis lupus familiaris,
6032,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum plasma concentration determined in dog after oral administration of 2b,,,BAO_0000218,N,,9579,Canis lupus familiaris,
6033,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum plasma concentration in dog,,,BAO_0000218,N,,933,Canis lupus familiaris,
6034,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,,,BAO_0000218,N,,17839,Canis lupus familiaris,
6035,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,,,BAO_0000218,N,,17839,Canis lupus familiaris,
6036,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,,,BAO_0000218,N,,17839,Canis lupus familiaris,
6037,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,,,BAO_0000218,N,,17839,Canis lupus familiaris,
6038,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,BAO_0000218,N,,6348,Canis lupus familiaris,
6039,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,,,BAO_0000218,N,,16367,Canis lupus familiaris,
6040,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,BAO_0000218,N,,1337,Canis lupus familiaris,
6041,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,BAO_0000218,N,,1337,Canis lupus familiaris,
6042,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,,BAO_0000218,N,,5199,Canis lupus familiaris,
6043,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,,BAO_0000218,N,,17650,Canis lupus familiaris,
6044,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,,BAO_0000218,N,,6679,Canis lupus familiaris,
6045,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,,,BAO_0000218,N,,5356,Canis lupus familiaris,
6046,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,,,BAO_0000218,N,,5356,Canis lupus familiaris,
6047,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,,,BAO_0000218,N,,6227,Canis lupus familiaris,
6048,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,,,BAO_0000218,N,,6227,Canis lupus familiaris,
6049,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,,,BAO_0000218,N,,6227,Canis lupus familiaris,
6050,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,,,BAO_0000218,N,,6227,Canis lupus familiaris,
6051,In vivo,1969.0,50588,9615.0,Expert,1,Plasma,A,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,,,BAO_0000218,N,,3598,Canis lupus familiaris,
6052,In vivo,,50588,9615.0,Intermediate,1,,A,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,,BAO_0000218,N,,4368,Canis lupus familiaris,
6053,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,,BAO_0000218,N,,6265,Canis lupus familiaris,
6054,In vivo,945.0,50594,10090.0,Intermediate,1,Stomach,A,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
6055,In vivo,1088.0,50594,10090.0,Intermediate,1,Urine,A,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,BAO_0000218,N,,7767,Mus musculus,
6056,In vivo,1088.0,50594,10090.0,Intermediate,1,Urine,A,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,,,BAO_0000218,N,,7767,Mus musculus,
6057,In vivo,1088.0,50594,10090.0,Intermediate,1,Urine,A,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,,,BAO_0000218,N,,7767,Mus musculus,
6058,,,50594,10090.0,Intermediate,1,,A,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,,BAO_0000218,N,,17811,Mus musculus,
6059,,,50594,10090.0,Intermediate,1,,A,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,,BAO_0000218,N,,17811,Mus musculus,
6060,,,50594,10090.0,Intermediate,1,,A,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,,BAO_0000218,N,,17827,Mus musculus,
6061,,178.0,50594,10090.0,Intermediate,1,Blood,A,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,,BAO_0000218,N,,17827,Mus musculus,
6062,,,50594,10090.0,Intermediate,1,,A,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,,BAO_0000218,N,,17827,Mus musculus,
6063,,,50594,10090.0,Intermediate,1,,A,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,,BAO_0000218,N,,17827,Mus musculus,
6064,,,50594,10090.0,Intermediate,1,,A,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,,BAO_0000218,N,,17827,Mus musculus,
6065,,178.0,50594,10090.0,Intermediate,1,Blood,A,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,,BAO_0000218,N,,17827,Mus musculus,
6066,,178.0,50594,10090.0,Intermediate,1,Blood,A,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,,BAO_0000218,N,,17827,Mus musculus,
6067,,,50594,10090.0,Intermediate,1,,A,,Compound was evaluated for washout rate in mice (Radiolabeled compound),,,BAO_0000218,N,,17827,Mus musculus,
6068,,,50594,10090.0,Intermediate,1,,A,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,,BAO_0000218,N,,17827,Mus musculus,
6069,,,50594,10090.0,Intermediate,1,,A,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,BAO_0000218,N,,17827,Mus musculus,
6070,,,50594,10090.0,Intermediate,1,,A,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,BAO_0000218,N,,17827,Mus musculus,
6071,,,50594,10090.0,Intermediate,1,,A,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,BAO_0000218,N,,17827,Mus musculus,
6072,,,50594,10090.0,Intermediate,1,,A,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,,BAO_0000218,N,,17257,Mus musculus,
6073,,,50594,10090.0,Intermediate,1,,A,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,,BAO_0000218,N,,17257,Mus musculus,
6074,,,50594,10090.0,Intermediate,1,,A,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,,BAO_0000218,N,,17257,Mus musculus,
6075,,,50594,10090.0,Intermediate,1,,A,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,,BAO_0000218,N,,17257,Mus musculus,
6076,,,50594,10090.0,Intermediate,1,,A,,Time at maximum activity in mice (Radiolabeled compound),,,BAO_0000218,N,,17827,Mus musculus,
6077,,,50594,10090.0,Intermediate,1,,A,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,,BAO_0000218,N,,3760,Mus musculus,
6078,,,50594,10090.0,Intermediate,1,,A,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,,BAO_0000218,N,,3760,Mus musculus,
6079,,,50594,10090.0,Intermediate,1,,A,,Binding towards mouse plasma protein at 10 uM,,,BAO_0000218,N,,17409,Mus musculus,
6080,,,50594,10090.0,Intermediate,1,,A,,Binding towards mouse plasma protein at 100 uM,,,BAO_0000218,N,,17409,Mus musculus,
6081,In vivo,,50594,10090.0,Intermediate,1,,A,,Bioavailability was evaluated in mice after intravenous administration,,,BAO_0000218,N,,2675,Mus musculus,
6082,In vivo,,50594,10090.0,Intermediate,1,,A,,Bioavailability was evaluated in mice after oral administration,,,BAO_0000218,N,,2675,Mus musculus,
6083,In vivo,,50594,10090.0,Intermediate,1,,A,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,,BAO_0000218,N,,3132,Mus musculus,
6084,In vivo,,50594,10090.0,Intermediate,1,,A,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,,BAO_0000218,N,,3132,Mus musculus,
6085,In vivo,,50594,10090.0,Intermediate,1,,A,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,,BAO_0000218,N,,16597,Mus musculus,
6086,In vivo,,50594,10090.0,Intermediate,1,,A,,Oral bioavailability in mouse,,,BAO_0000218,N,,2862,Mus musculus,
6087,In vivo,,50594,10090.0,Intermediate,1,,A,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
6088,In vivo,955.0,50594,10090.0,Intermediate,1,Brain,A,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6089,In vivo,955.0,50594,10090.0,Intermediate,1,Brain,A,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6090,In vivo,955.0,50594,10090.0,Intermediate,1,Brain,A,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6091,In vivo,955.0,50594,10090.0,Intermediate,1,Brain,A,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6092,In vivo,955.0,50594,10090.0,Intermediate,1,Brain,A,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6093,In vivo,955.0,50594,10090.0,Intermediate,1,Brain,A,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6094,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6095,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6096,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6097,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6098,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,,BAO_0000219,N,,1276,Homo sapiens,A549
6099,,,80682,9606.0,Expert,1,,F,646.0,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,,BAO_0000219,N,,3498,Homo sapiens,A549
6100,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity against human lung carcinoma A-549 cell lines,,,BAO_0000219,N,,1169,Homo sapiens,A549
6101,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,,BAO_0000219,N,,4450,Homo sapiens,A549
6102,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity against human lung carcinoma cell line A-549,,,BAO_0000219,N,,358,Homo sapiens,A549
6103,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,,BAO_0000219,N,,358,Homo sapiens,A549
6104,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,,BAO_0000219,N,,358,Homo sapiens,A549
6105,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,,BAO_0000219,N,,358,Homo sapiens,A549
6106,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,,BAO_0000219,N,,358,Homo sapiens,A549
6107,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,,BAO_0000219,N,,358,Homo sapiens,A549
6108,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,,BAO_0000219,N,,358,Homo sapiens,A549
6109,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity against A-549 human lung cancer cells,,,BAO_0000219,N,,15167,Homo sapiens,A549
6110,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,,BAO_0000219,N,,4139,Homo sapiens,A549
6111,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,,BAO_0000219,N,,833,Homo sapiens,A549
6112,,,80682,9606.0,Expert,1,,F,646.0,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,,BAO_0000219,N,,15718,Homo sapiens,A549
6113,,,80682,9606.0,Intermediate,1,,F,646.0,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,,BAO_0000219,N,,12373,Homo sapiens,A549
6114,,,80682,9606.0,Intermediate,1,,F,646.0,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,,BAO_0000219,N,,637,Homo sapiens,A549
6115,,,80682,9606.0,Expert,1,,F,646.0,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,,BAO_0000219,N,,14867,Homo sapiens,A549
6116,,,80682,9606.0,Intermediate,1,,F,646.0,Antitumor cytotoxic activity against A-549 cell line was determined,,,BAO_0000219,N,,4461,Homo sapiens,A549
6117,,,80682,9606.0,Intermediate,1,,F,646.0,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,,BAO_0000219,N,,5406,Homo sapiens,A549
6118,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,,BAO_0000219,N,,4457,Homo sapiens,A549
6119,,,80682,9606.0,Expert,1,,F,646.0,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,,BAO_0000219,N,,1386,Homo sapiens,A549
6120,,,80682,9606.0,Intermediate,1,,F,646.0,Antitumoral activity was assayed against A-549 cell line,,,BAO_0000219,N,,3265,Homo sapiens,A549
6121,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,,BAO_0000219,N,,2359,Homo sapiens,A549
6122,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,,BAO_0000219,N,,4457,Homo sapiens,A549
6123,,,80682,9606.0,Expert,1,,F,646.0,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,,BAO_0000219,N,,12454,Homo sapiens,A549
6124,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested for inhibition of cell growth of A-549 cells,,,BAO_0000219,N,,1481,Homo sapiens,A549
6125,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,,BAO_0000219,N,,1750,Homo sapiens,A549
6126,,,80682,9606.0,Intermediate,1,,F,646.0,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,,BAO_0000219,N,,5065,Homo sapiens,A549
6127,,,80682,9606.0,Expert,1,,F,646.0,In vitro cytotoxicity against A549-human lung carcinoma cells.,,,BAO_0000219,N,,808,Homo sapiens,A549
6128,,,80682,9606.0,Expert,1,,F,646.0,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,,BAO_0000219,N,,16364,Homo sapiens,A549
6129,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxic activity against A-549 cell lines.,,,BAO_0000219,N,,1847,Homo sapiens,A549
6130,,,80682,9606.0,Expert,1,,F,646.0,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,,BAO_0000219,N,,1747,Homo sapiens,A549
6131,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity against human A549 non small cell lung cell lines,,,BAO_0000219,N,,1003,Homo sapiens,A549
6132,,,80682,9606.0,Expert,1,,F,646.0,Inhibition of cell growth in (A-549) lung cell line,,,BAO_0000219,N,,15313,Homo sapiens,A549
6133,,,80682,9606.0,Intermediate,1,,F,646.0,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,,BAO_0000219,N,,3122,Homo sapiens,A549
6134,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro antitumor activity against A-549 tumor cells.,,,BAO_0000219,N,,16049,Homo sapiens,A549
6135,,,80682,9606.0,Expert,1,,F,646.0,In vitro antitumor effects against human A-549 cell lines.,,,BAO_0000219,N,,17134,Homo sapiens,A549
6136,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxic activity of compound against A-549 cell line,,,BAO_0000219,N,,6406,Homo sapiens,A549
6137,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,,BAO_0000219,N,,627,Homo sapiens,A549
6138,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,,BAO_0000219,N,,12307,Homo sapiens,A549
6139,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,,BAO_0000219,N,,17861,Homo sapiens,A549
6140,,,80682,9606.0,Expert,1,,F,646.0,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,,BAO_0000219,N,,6682,Homo sapiens,A549
6141,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory concentration of compound against A-549 cell line,,,BAO_0000219,N,,6663,Homo sapiens,A549
6142,,,80682,9606.0,Intermediate,1,,F,646.0,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,,BAO_0000219,N,,2454,Homo sapiens,A549
6143,,,80682,9606.0,Intermediate,1,,F,646.0,cytotoxic activity against leukemia (A-549) cancer cell line,,,BAO_0000219,N,,14709,Homo sapiens,A549
6144,,,80682,9606.0,Expert,1,,F,646.0,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,,BAO_0000219,N,,15718,Homo sapiens,A549
6145,,,80682,9606.0,Intermediate,1,,F,646.0,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,,BAO_0000219,N,,15718,Homo sapiens,A549
6146,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,,BAO_0000219,N,,17130,Homo sapiens,A549
6147,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,,BAO_0000219,N,,17130,Homo sapiens,A549
6148,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,,BAO_0000219,N,,17130,Homo sapiens,A549
6149,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,,BAO_0000219,N,,17130,Homo sapiens,A549
6150,,,80682,,Intermediate,1,,F,646.0,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,,BAO_0000219,N,,6630,,A549
6151,,,80682,9606.0,Intermediate,1,,F,646.0,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,,BAO_0000219,N,,16726,Homo sapiens,A549
6152,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity against A549 cells; No cytotoxicity,,,BAO_0000219,N,,17846,Homo sapiens,A549
6153,,,80682,9606.0,Expert,1,,F,646.0,Cytotoxicity against human lung carcinoma (A549) cell lines,,,BAO_0000219,N,,3415,Homo sapiens,A549
6154,,,80682,9606.0,Expert,1,,F,646.0,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,,BAO_0000219,N,,3415,Homo sapiens,A549
6155,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro anticancer activity against human lung (A549) cell line,,,BAO_0000219,N,,5609,Homo sapiens,A549
6156,,,80682,9606.0,Intermediate,1,,F,646.0,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,,BAO_0000219,N,,17206,Homo sapiens,A549
6157,,,80682,9606.0,Intermediate,1,,F,646.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,,BAO_0000219,N,,17206,Homo sapiens,A549
6158,,,80682,9606.0,Intermediate,1,,F,646.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,,BAO_0000219,N,,17206,Homo sapiens,A549
6159,,,80682,9606.0,Intermediate,1,,F,646.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,,BAO_0000219,N,,17206,Homo sapiens,A549
6160,,,80682,9606.0,Intermediate,1,,F,646.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,,BAO_0000219,N,,17206,Homo sapiens,A549
6161,,,80682,9606.0,Intermediate,1,,F,646.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,,BAO_0000219,N,,17206,Homo sapiens,A549
6162,,,80682,9606.0,Expert,1,,F,646.0,Inhibition of A549 human lung tumor cell proliferation,,,BAO_0000219,N,,16295,Homo sapiens,A549
6163,,,80682,9606.0,Intermediate,1,,F,646.0,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,,BAO_0000219,N,,16825,Homo sapiens,A549
6164,,,80682,9606.0,Expert,1,,F,646.0,In vitro cytotoxicity against human tumor cell line A549,,,BAO_0000219,N,,3439,Homo sapiens,A549
6165,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,,BAO_0000219,N,,10870,Homo sapiens,A549
6166,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,,BAO_0000219,N,,4845,Homo sapiens,A549
6167,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,,BAO_0000219,N,,5822,Homo sapiens,A549
6168,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,,BAO_0000219,N,,5822,Homo sapiens,A549
6169,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,,BAO_0000219,N,,5822,Homo sapiens,A549
6170,,,80682,9606.0,Intermediate,1,,F,646.0,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,,BAO_0000219,N,,16381,Homo sapiens,A549
6171,,,80682,9606.0,Intermediate,1,,F,646.0,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,,BAO_0000219,N,,16381,Homo sapiens,A549
6172,,,80682,9606.0,Intermediate,1,,F,646.0,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,,BAO_0000219,N,,16381,Homo sapiens,A549
6173,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro anticancer activity against human lung (A549) cell line,,,BAO_0000219,N,,5609,Homo sapiens,A549
6174,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,,BAO_0000219,N,,4644,Homo sapiens,A549
6175,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,,BAO_0000219,N,,4644,Homo sapiens,A549
6176,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,,BAO_0000219,N,,4644,Homo sapiens,A549
6177,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,,BAO_0000219,N,,4644,Homo sapiens,A549
6178,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,,BAO_0000219,N,,5822,Homo sapiens,A549
6179,,,80682,9606.0,Expert,1,,F,646.0,Percentage inhibition of human lung carcinoma (A549) cell lines,,,BAO_0000219,N,,3415,Homo sapiens,A549
6180,,,80682,9606.0,Intermediate,1,,F,646.0,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,,BAO_0000219,N,,16726,Homo sapiens,A549
6181,,,80682,9606.0,Intermediate,1,,F,646.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,,BAO_0000219,N,,17206,Homo sapiens,A549
6182,,,80682,9606.0,Intermediate,1,,F,646.0,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,,BAO_0000219,N,,17206,Homo sapiens,A549
6183,,,80682,9606.0,Intermediate,1,,F,646.0,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,,BAO_0000219,N,,17206,Homo sapiens,A549
6184,,,80682,9606.0,Intermediate,1,,F,646.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,,BAO_0000219,N,,17206,Homo sapiens,A549
6185,,,80682,9606.0,Intermediate,1,,F,646.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,,BAO_0000219,N,,17206,Homo sapiens,A549
6186,,,80682,9606.0,Intermediate,1,,F,646.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,,BAO_0000219,N,,17206,Homo sapiens,A549
6187,,,80682,9606.0,Intermediate,1,,F,646.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,,BAO_0000219,N,,17206,Homo sapiens,A549
6188,,,80682,9606.0,Intermediate,1,,F,646.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,,BAO_0000219,N,,17206,Homo sapiens,A549
6189,,,80682,9606.0,Intermediate,1,,F,646.0,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,,BAO_0000219,N,,17206,Homo sapiens,A549
6190,,,80682,9606.0,Intermediate,1,,F,646.0,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,,BAO_0000219,N,,17206,Homo sapiens,A549
6191,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,,BAO_0000219,N,,16726,Homo sapiens,A549
6192,,,80682,9606.0,Intermediate,1,,F,646.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,,BAO_0000219,N,,17206,Homo sapiens,A549
6193,,,80682,9606.0,Intermediate,1,,F,646.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,,BAO_0000219,N,,17206,Homo sapiens,A549
6194,,,80682,9606.0,Intermediate,1,,F,646.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,,BAO_0000219,N,,17206,Homo sapiens,A549
6195,,,80682,9606.0,Intermediate,1,,F,646.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,,BAO_0000219,N,,17206,Homo sapiens,A549
6196,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,,BAO_0000218,N,,6084,Canis lupus familiaris,
6197,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic activity (Cmax) in dog,,,BAO_0000218,N,,6084,Canis lupus familiaris,
6198,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,,BAO_0000218,N,,4809,Canis lupus familiaris,
6199,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,,BAO_0000218,N,,5983,Canis lupus familiaris,
6200,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,,BAO_0000218,N,,6251,Canis lupus familiaris,
6201,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Cmax in dog plasma after 30mg/kg oral dose,,,BAO_0000218,N,,5932,Canis lupus familiaris,
6202,In vivo,178.0,50588,9615.0,Intermediate,1,Blood,A,,Tested for the peak blood level in dog,,,BAO_0000218,N,,4273,Canis lupus familiaris,
6203,In vivo,,50588,9615.0,Intermediate,1,,A,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,,BAO_0000218,N,,5313,Canis lupus familiaris,
6204,In vivo,,50588,9615.0,Intermediate,1,,A,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,,BAO_0000218,N,,5313,Canis lupus familiaris,
6205,In vivo,178.0,50588,9615.0,Intermediate,1,Blood,A,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,,,BAO_0000218,N,,6221,Canis lupus familiaris,
6206,,,50588,9615.0,Intermediate,1,,A,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,,BAO_0000218,N,,4709,Canis lupus familiaris,
6207,,,50588,9615.0,Intermediate,1,,A,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,,BAO_0000218,N,,167,Canis lupus familiaris,
6208,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Final plasma concentration in dogs after oral administration at 1 mg/kg,,,BAO_0000218,N,,6241,Canis lupus familiaris,
6209,,,50588,9615.0,Intermediate,1,,A,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,,BAO_0000218,N,,344,Canis lupus familiaris,
6210,,,50588,9615.0,Intermediate,1,,A,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,,BAO_0000218,N,,344,Canis lupus familiaris,
6211,,,50588,9615.0,Intermediate,1,,A,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,,BAO_0000218,N,,344,Canis lupus familiaris,
6212,,,50588,9615.0,Intermediate,1,,A,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,,BAO_0000218,N,,2189,Canis lupus familiaris,
6213,,1088.0,50588,9615.0,Intermediate,1,Urine,A,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,,BAO_0000218,N,,2189,Canis lupus familiaris,
6214,,1088.0,50588,9615.0,Intermediate,1,Urine,A,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,,BAO_0000218,N,,2189,Canis lupus familiaris,
6215,,1088.0,50588,9615.0,Intermediate,1,Urine,A,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,,BAO_0000218,N,,2189,Canis lupus familiaris,
6216,In vivo,,50588,9615.0,Intermediate,1,,A,,Absolute bioavailability was evaluated in dog,,,BAO_0000218,N,,4257,Canis lupus familiaris,
6217,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,,BAO_0000218,N,,6221,Canis lupus familiaris,
6218,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,,BAO_0000218,N,,6215,Canis lupus familiaris,
6219,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog,,,BAO_0000218,N,,17267,Canis lupus familiaris,
6220,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog,,,BAO_0000218,N,,6621,Canis lupus familiaris,
6221,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability after intravenous administration in dogs,,,BAO_0000218,N,,3854,Canis lupus familiaris,
6222,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability after peroral administration in dogs,,,BAO_0000218,N,,3854,Canis lupus familiaris,
6223,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,,BAO_0000218,N,,5007,Canis lupus familiaris,
6224,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,,BAO_0000218,N,,4333,Canis lupus familiaris,
6225,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,,,BAO_0000218,N,,4333,Canis lupus familiaris,
6226,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability,,,BAO_0000218,N,,5006,Canis lupus familiaris,
6227,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability,,,BAO_0000218,N,,5199,Canis lupus familiaris,
6228,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,,BAO_0000218,N,,4368,Canis lupus familiaris,
6229,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog,,,BAO_0000218,N,,3771,Canis lupus familiaris,
6230,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog,,,BAO_0000218,N,,4953,Canis lupus familiaris,
6231,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog,,,BAO_0000218,N,,5064,Canis lupus familiaris,
6232,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog,,,BAO_0000218,N,,17657,Canis lupus familiaris,
6233,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog,,,BAO_0000218,N,,17796,Canis lupus familiaris,
6234,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog (p.o.) at 2.0 mpk,,,BAO_0000218,N,,17853,Canis lupus familiaris,
6235,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,,BAO_0000218,N,,4521,Canis lupus familiaris,
6236,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,BAO_0000218,N,,4521,Canis lupus familiaris,
6237,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog,,,BAO_0000218,N,,5006,Canis lupus familiaris,
6238,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability was evaluated after oral administration in dog,,,BAO_0000218,N,,16365,Canis lupus familiaris,
6239,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,BAO_0000218,N,,1916,Canis lupus familiaris,
6240,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability was evaluated in dog,,,BAO_0000218,N,,1918,Canis lupus familiaris,
6241,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog,,,BAO_0000218,N,,4239,Canis lupus familiaris,
6242,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog,,,BAO_0000218,N,,6505,Canis lupus familiaris,
6243,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,,BAO_0000218,N,,5334,Canis lupus familiaris,
6244,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,,BAO_0000218,N,,5334,Canis lupus familiaris,
6245,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,,BAO_0000218,N,,4809,Canis lupus familiaris,
6246,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,BAO_0000218,N,,6348,Canis lupus familiaris,
6247,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,,BAO_0000218,N,,6005,Canis lupus familiaris,
6248,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability of compound in dog was determined after peroral administration,,,BAO_0000218,N,,17804,Canis lupus familiaris,
6249,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,3184,Canis lupus familiaris,
6250,In vivo,,50588,9615.0,Intermediate,1,,A,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,,BAO_0000218,N,,1806,Canis lupus familiaris,
6251,In vivo,,50588,9615.0,Intermediate,1,,A,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,,BAO_0000218,N,,1806,Canis lupus familiaris,
6252,In vivo,,50588,9615.0,Intermediate,1,,A,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,,BAO_0000218,N,,1806,Canis lupus familiaris,
6253,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog,,,BAO_0000218,N,,4839,Canis lupus familiaris,
6254,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,,BAO_0000218,N,,5017,Canis lupus familiaris,
6255,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6256,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6257,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6258,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6259,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6260,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6261,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6262,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6263,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6264,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6265,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6266,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6267,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6268,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6269,In vivo,2048.0,50594,10090.0,Intermediate,1,Lung,A,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6270,In vivo,2048.0,50594,10090.0,Intermediate,1,Lung,A,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6271,In vivo,2048.0,50594,10090.0,Intermediate,1,Lung,A,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6272,In vivo,2048.0,50594,10090.0,Intermediate,1,Lung,A,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6273,In vivo,2048.0,50594,10090.0,Intermediate,1,Lung,A,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6274,In vivo,2048.0,50594,10090.0,Intermediate,1,Lung,A,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,BAO_0000218,N,,846,Mus musculus,
6275,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6276,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6277,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6278,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6279,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6280,,955.0,50594,10090.0,Intermediate,1,Brain,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6281,,955.0,50594,10090.0,Intermediate,1,Brain,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6282,,955.0,50594,10090.0,Intermediate,1,Brain,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6283,,955.0,50594,10090.0,Intermediate,1,Brain,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6284,,955.0,50594,10090.0,Intermediate,1,Brain,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6285,,948.0,50594,10090.0,Intermediate,1,Heart,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6286,,948.0,50594,10090.0,Intermediate,1,Heart,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6287,,948.0,50594,10090.0,Intermediate,1,Heart,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6288,,948.0,50594,10090.0,Intermediate,1,Heart,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6289,,948.0,50594,10090.0,Intermediate,1,Heart,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6290,,2113.0,50594,10090.0,Intermediate,1,Kidney,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6291,,2113.0,50594,10090.0,Intermediate,1,Kidney,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6292,,2113.0,50594,10090.0,Intermediate,1,Kidney,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6293,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,,BAO_0000219,N,,17130,Homo sapiens,A549
6294,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,,BAO_0000219,N,,17130,Homo sapiens,A549
6295,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,,BAO_0000219,N,,17130,Homo sapiens,A549
6296,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,,BAO_0000219,N,,17130,Homo sapiens,A549
6297,,,80682,9606.0,Expert,1,,F,646.0,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,,BAO_0000219,N,,3263,Homo sapiens,A549
6298,,,80682,9606.0,Expert,1,,F,646.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,,BAO_0000219,N,,6663,Homo sapiens,A549
6299,,,80682,9606.0,Expert,1,,F,646.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,,BAO_0000219,N,,6663,Homo sapiens,A549
6300,,,80682,9606.0,Expert,1,,F,646.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,,BAO_0000219,N,,6663,Homo sapiens,A549
6301,,,80682,9606.0,Expert,1,,F,646.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,,BAO_0000219,N,,6663,Homo sapiens,A549
6302,,,80682,9606.0,Expert,1,,F,646.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,,BAO_0000219,N,,6663,Homo sapiens,A549
6303,,,80682,9606.0,Intermediate,1,,F,646.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,,BAO_0000219,N,,6663,Homo sapiens,A549
6304,,,80682,9606.0,Intermediate,1,,F,646.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,,BAO_0000219,N,,6663,Homo sapiens,A549
6305,,,80682,9606.0,Intermediate,1,,F,646.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,,BAO_0000219,N,,6663,Homo sapiens,A549
6306,,,80682,9606.0,Intermediate,1,,F,646.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,,BAO_0000219,N,,6663,Homo sapiens,A549
6307,,,80682,9606.0,Intermediate,1,,F,646.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,,BAO_0000219,N,,6663,Homo sapiens,A549
6308,,,80682,9606.0,Intermediate,1,,F,646.0,The compound was evaluated for its cytotoxic potency against A-549 cell line,,,BAO_0000219,N,,3983,Homo sapiens,A549
6309,,,80682,9606.0,Expert,1,,F,646.0,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,,BAO_0000219,N,,11141,Homo sapiens,A549
6310,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxic activity of compound against A-549 tumor cell line.,,,BAO_0000219,N,,5076,Homo sapiens,A549
6311,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,,BAO_0000219,N,,3311,Homo sapiens,A549
6312,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,,BAO_0000219,N,,3311,Homo sapiens,A549
6313,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,,BAO_0000219,N,,3311,Homo sapiens,A549
6314,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,,BAO_0000219,N,,5076,Homo sapiens,A549
6315,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,,BAO_0000219,N,,4150,Homo sapiens,A549
6316,,,80682,9606.0,Expert,1,,F,646.0,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,,BAO_0000219,N,,2150,Homo sapiens,A549
6317,,,80682,9606.0,Intermediate,1,,F,646.0,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,,BAO_0000219,N,,4644,Homo sapiens,A549
6318,,,80682,9606.0,Intermediate,1,,F,646.0,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,,BAO_0000219,N,,263,Homo sapiens,A549
6319,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxic concentration against A-549 tumor cells.,,,BAO_0000219,N,,11333,Homo sapiens,A549
6320,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,,BAO_0000219,N,,11333,Homo sapiens,A549
6321,,,80682,9606.0,Intermediate,1,,F,646.0,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,,BAO_0000219,N,,15895,Homo sapiens,A549
6322,,,50191,470.0,Expert,1,,F,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,,BAO_0000218,N,,16677,Acinetobacter baumannii,
6323,,,50192,471.0,Intermediate,1,,F,,Activity against Acinetobacter calcoaceticus (AC54),,,BAO_0000218,N,,10624,Acinetobacter calcoaceticus,
6324,,,50274,5059.0,Expert,1,,F,,In vitro antifungal activity against Aspergillus flavus CM74,,,BAO_0000218,N,,16717,Aspergillus flavus,
6325,,,50274,5059.0,Expert,1,,F,,In vitro antifungal activity against Aspergillus flavus CM74,,,BAO_0000218,N,,16717,Aspergillus flavus,
6326,,,50416,746128.0,Intermediate,1,,F,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,,BAO_0000218,N,,5513,Aspergillus fumigatus,
6327,,,50416,746128.0,Intermediate,1,,F,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,,BAO_0000218,N,,15962,Aspergillus fumigatus,
6328,,,50416,746128.0,Intermediate,1,,F,,Antimicrobial activity against Aspergillus fumigatus (MIC),,,BAO_0000218,N,,15962,Aspergillus fumigatus,
6329,,,50416,746128.0,Intermediate,1,,F,,Antimicrobial activity against Aspergillus fumigatus (MIC),,,BAO_0000218,N,,15962,Aspergillus fumigatus,
6330,,,50416,746128.0,Intermediate,1,,F,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,,BAO_0000218,N,,15962,Aspergillus fumigatus,
6331,,,50416,746128.0,Expert,1,,F,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,,BAO_0000218,N,,16717,Aspergillus fumigatus,
6332,,,50416,746128.0,Expert,1,,F,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,,BAO_0000218,N,,16717,Aspergillus fumigatus,
6333,,,50296,1655.0,Intermediate,1,,F,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,,BAO_0000218,N,,8117,Actinomyces naeslundii,
6334,,,50366,1656.0,Intermediate,1,,F,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,,BAO_0000218,N,,8117,Actinomyces viscosus,
6335,,,50535,6277.0,Intermediate,1,,F,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,,BAO_0000218,N,,15472,Acanthocheilonema viteae,
6336,,,50535,6277.0,Intermediate,1,,F,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,,BAO_0000218,N,,15472,Acanthocheilonema viteae,
6337,,,50169,714.0,Intermediate,1,,F,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,,BAO_0000218,N,,16443,Aggregatibacter actinomycetemcomitans,
6338,,,50169,714.0,Intermediate,1,,F,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,,BAO_0000218,N,,16443,Aggregatibacter actinomycetemcomitans,
6339,,,50169,714.0,Intermediate,1,,F,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,,BAO_0000218,N,,16443,Aggregatibacter actinomycetemcomitans,
6340,,,80682,9606.0,Intermediate,1,,F,646.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,,BAO_0000219,N,,17206,Homo sapiens,A549
6341,,,80682,9606.0,Intermediate,1,,F,646.0,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,,BAO_0000219,N,,17206,Homo sapiens,A549
6342,,,80682,9606.0,Intermediate,1,,F,646.0,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,,BAO_0000219,N,,16381,Homo sapiens,A549
6343,,,80682,9606.0,Intermediate,1,,F,646.0,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,,BAO_0000219,N,,16381,Homo sapiens,A549
6344,,,80682,9606.0,Intermediate,1,,F,646.0,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,,BAO_0000219,N,,16381,Homo sapiens,A549
6345,,,80682,9606.0,Intermediate,1,,F,646.0,GI values against A549 cells (lung cancer),,,BAO_0000219,N,,16381,Homo sapiens,A549
6346,,,80682,9606.0,Intermediate,1,,F,646.0,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,,BAO_0000219,N,,17206,Homo sapiens,A549
6347,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory activity against A549 human adenocarcinoma,,,BAO_0000219,N,,16325,Homo sapiens,A549
6348,,,80682,9606.0,Intermediate,1,,F,646.0,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,,BAO_0000218,N,,10708,Homo sapiens,A549
6349,,,80682,9606.0,Intermediate,1,,F,646.0,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,,BAO_0000218,N,,10708,Homo sapiens,A549
6350,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory activity against A549 lung adenocarcinoma cell line,,,BAO_0000219,N,,17376,Homo sapiens,A549
6351,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,,BAO_0000219,N,,17376,Homo sapiens,A549
6352,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity against human A549 lung cells,,,BAO_0000219,N,,17488,Homo sapiens,A549
6353,,,80682,9606.0,Intermediate,1,,F,646.0,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,,BAO_0000218,N,,17404,Homo sapiens,A549
6354,,,80682,9606.0,Expert,1,,F,646.0,Growth inhibition of A549 (human lung carcinoma) cell line.,,,BAO_0000219,N,,10958,Homo sapiens,A549
6355,,,80682,9606.0,Expert,1,,F,646.0,Effective dose required for inhibitory activity against A549 human tumor cell line.,,,BAO_0000219,N,,17099,Homo sapiens,A549
6356,,,80682,9606.0,Intermediate,1,,F,646.0,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,,BAO_0000219,N,,17099,Homo sapiens,A549
6357,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,,BAO_0000219,N,,4096,Homo sapiens,A549
6358,,,80682,9606.0,Expert,1,,F,646.0,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,,BAO_0000219,N,,4096,Homo sapiens,A549
6359,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,,BAO_0000219,N,,4096,Homo sapiens,A549
6360,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro inhibitory activity against A549 tumor cell culture,,,BAO_0000219,N,,2525,Homo sapiens,A549
6361,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,,BAO_0000219,N,,2525,Homo sapiens,A549
6362,,,80682,9606.0,Intermediate,1,,F,646.0,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,,BAO_0000219,N,,5302,Homo sapiens,A549
6363,,,80682,9606.0,Intermediate,1,,F,646.0,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,,BAO_0000219,N,,16325,Homo sapiens,A549
6364,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,,BAO_0000219,N,,16939,Homo sapiens,A549
6365,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,,BAO_0000219,N,,17229,Homo sapiens,A549
6366,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,,BAO_0000219,N,,17380,Homo sapiens,A549
6367,,,80682,9606.0,Intermediate,1,,F,646.0,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,,BAO_0000219,N,,17380,Homo sapiens,A549
6368,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,,BAO_0000219,N,,1903,Homo sapiens,A549
6369,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,,BAO_0000219,N,,3838,Homo sapiens,A549
6370,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,,BAO_0000219,N,,14696,Homo sapiens,A549
6371,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,,BAO_0000219,N,,3838,Homo sapiens,A549
6372,,,80682,9606.0,Intermediate,1,,F,646.0,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,,BAO_0000219,N,,1522,Homo sapiens,A549
6373,,,80682,9606.0,Intermediate,1,,F,646.0,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,,BAO_0000219,N,,12400,Homo sapiens,A549
6374,,,80682,9606.0,Intermediate,1,,F,646.0,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,,BAO_0000219,N,,14696,Homo sapiens,A549
6375,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,,BAO_0000219,N,,14769,Homo sapiens,A549
6376,,,80682,9606.0,Intermediate,1,,F,646.0,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,,BAO_0000219,N,,14696,Homo sapiens,A549
6377,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,,BAO_0000219,N,,1888,Homo sapiens,A549
6378,,,80682,9606.0,Intermediate,1,,F,646.0,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,,BAO_0000219,N,,12016,Homo sapiens,A549
6379,,,80682,9606.0,Intermediate,1,,F,646.0,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,,BAO_0000219,N,,6058,Homo sapiens,A549
6380,,,80682,9606.0,Intermediate,1,,F,646.0,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,,BAO_0000219,N,,17708,Homo sapiens,A549
6381,,,80682,9606.0,Intermediate,1,,F,646.0,Antitumor activity against A549/ATCC cell line,,,BAO_0000219,N,,12301,Homo sapiens,A549
6382,,,80682,9606.0,Intermediate,1,,F,646.0,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,,BAO_0000219,N,,11970,Homo sapiens,A549
6383,,,80682,9606.0,Expert,1,,F,646.0,In vitro cytotoxicity against A549/ATCC cell line.,,,BAO_0000219,N,,11818,Homo sapiens,A549
6384,,,80682,9606.0,Intermediate,1,,F,646.0,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,,BAO_0000219,N,,12400,Homo sapiens,A549
6385,,,80682,9606.0,Intermediate,1,,F,646.0,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,,BAO_0000219,N,,3381,Homo sapiens,A549
6386,,,80682,9606.0,Intermediate,1,,F,646.0,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,,BAO_0000219,N,,17376,Homo sapiens,A549
6387,,,80682,9606.0,Intermediate,1,,F,646.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,,BAO_0000219,N,,10708,Homo sapiens,A549
6388,,,22226,9606.0,Autocuration,1,,F,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,,BAO_0000219,U,,2964,Homo sapiens,
6389,In vivo,,22224,9615.0,Intermediate,1,,A,,Compound was tested for oral bioavailability in dogs,,,BAO_0000218,U,,5005,Canis lupus familiaris,
6390,In vivo,,50588,9615.0,Intermediate,1,,A,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,,BAO_0000218,N,,6229,Canis lupus familiaris,
6391,In vivo,,50588,9615.0,Intermediate,1,,A,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,,BAO_0000218,N,,6229,Canis lupus familiaris,
6392,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,5374,Canis lupus familiaris,
6393,In vivo,,50588,9615.0,Intermediate,1,,A,,Compound was tested for the oral bioavailability in dog; No availability,,,BAO_0000218,N,,5374,Canis lupus familiaris,
6394,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (dose 5 mg/kg),,,BAO_0000218,N,,6265,Canis lupus familiaris,
6395,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,,BAO_0000218,N,,5654,Canis lupus familiaris,
6396,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,,BAO_0000218,N,,5654,Canis lupus familiaris,
6397,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,,BAO_0000218,N,,16456,Canis lupus familiaris,
6398,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (dose 5 mg/kg),,,BAO_0000218,N,,5302,Canis lupus familiaris,
6399,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,,BAO_0000218,N,,3624,Canis lupus familiaris,
6400,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability of active FTIs in dogs,,,BAO_0000218,N,,16452,Canis lupus familiaris,
6401,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,,BAO_0000218,N,,5802,Canis lupus familiaris,
6402,In vivo,,50588,9615.0,Expert,1,,A,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,,BAO_0000218,N,,3598,Canis lupus familiaris,
6403,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,17839,Canis lupus familiaris,
6404,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,6762,Canis lupus familiaris,
6405,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,6821,Canis lupus familiaris,
6406,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability of compound was determined in dog; Not tested,,,BAO_0000218,N,,6821,Canis lupus familiaris,
6407,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,5210,Canis lupus familiaris,
6408,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability (10 mg/kg) was determined in dog,,,BAO_0000218,N,,6227,Canis lupus familiaris,
6409,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability,,,BAO_0000218,N,,761,Canis lupus familiaris,
6410,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,,BAO_0000218,N,,761,Canis lupus familiaris,
6411,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability administered in solution in rats,,,BAO_0000218,N,,761,Canis lupus familiaris,
6412,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability after 30 mg/kg po dose in Dogs,,,BAO_0000218,N,,16907,Canis lupus familiaris,
6413,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability at a dose of 1 mg/kg in dogs,,,BAO_0000218,N,,5474,Canis lupus familiaris,
6414,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (dose 1 mg/kg p.o.),,,BAO_0000218,N,,6535,Canis lupus familiaris,
6415,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in Dog; ND = not determined,,,BAO_0000218,N,,6535,Canis lupus familiaris,
6416,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,3352,Canis lupus familiaris,
6417,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,6168,Canis lupus familiaris,
6418,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,5988,Canis lupus familiaris,
6419,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,4942,Canis lupus familiaris,
6420,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dogs; No data,,,BAO_0000218,N,,4942,Canis lupus familiaris,
6421,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability measured in dogs,,,BAO_0000218,N,,14541,Canis lupus familiaris,
6422,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,4449,Canis lupus familiaris,
6423,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability was calculated in dog,,,BAO_0000218,N,,6057,Canis lupus familiaris,
6424,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability after 0.3 mg/kg po administration in dog,,,BAO_0000218,N,,5600,Canis lupus familiaris,
6425,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (i.v. dosing),,,BAO_0000218,N,,5542,Canis lupus familiaris,
6426,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,5542,Canis lupus familiaris,
6427,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,,BAO_0000218,N,,5546,Canis lupus familiaris,
6428,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in Beagle dogs,,,BAO_0000218,N,,4514,Canis lupus familiaris,
6429,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,3624,Canis lupus familiaris,
6430,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,3854,Canis lupus familiaris,
6431,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,5836,Canis lupus familiaris,
6432,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,5940,Canis lupus familiaris,
6433,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,6168,Canis lupus familiaris,
6434,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,6227,Canis lupus familiaris,
6435,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,6251,Canis lupus familiaris,
6436,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,6448,Canis lupus familiaris,
6437,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,6647,Canis lupus familiaris,
6438,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,5940,Canis lupus familiaris,
6439,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,933,Canis lupus familiaris,
6440,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,5210,Canis lupus familiaris,
6441,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,,BAO_0000218,N,,6642,Canis lupus familiaris,
6442,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,,BAO_0000218,N,,6641,Canis lupus familiaris,
6443,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,,BAO_0000218,N,,6642,Canis lupus familiaris,
6444,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,5472,Canis lupus familiaris,
6445,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,5985,Canis lupus familiaris,
6446,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,15660,Canis lupus familiaris,
6447,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,,BAO_0000218,N,,5530,Canis lupus familiaris,
6448,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (dose 1 mg/kg i.v.),,,BAO_0000218,N,,5530,Canis lupus familiaris,
6449,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability (F) in dogs,,,BAO_0000218,N,,6305,Canis lupus familiaris,
6450,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,5210,Canis lupus familiaris,
6451,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog,,,BAO_0000218,N,,5238,Canis lupus familiaris,
6452,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (dose 10 mg/kg),,,BAO_0000218,N,,5668,Canis lupus familiaris,
6453,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability after peroral administration at 5 mpk in Dog,,,BAO_0000218,N,,5668,Canis lupus familiaris,
6454,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (dose 5 mg/kg),,,BAO_0000218,N,,5668,Canis lupus familiaris,
6455,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (dose 10 mg/kg),,,BAO_0000218,N,,6084,Canis lupus familiaris,
6456,,2113.0,50594,10090.0,Intermediate,1,Kidney,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6457,,2113.0,50594,10090.0,Intermediate,1,Kidney,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6458,,2107.0,50594,10090.0,Intermediate,1,Liver,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6459,,2107.0,50594,10090.0,Intermediate,1,Liver,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6460,,2107.0,50594,10090.0,Intermediate,1,Liver,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6461,,2107.0,50594,10090.0,Intermediate,1,Liver,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6462,,2107.0,50594,10090.0,Intermediate,1,Liver,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6463,,2048.0,50594,10090.0,Intermediate,1,Lung,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6464,,2048.0,50594,10090.0,Intermediate,1,Lung,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6465,,2048.0,50594,10090.0,Intermediate,1,Lung,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6466,,2048.0,50594,10090.0,Intermediate,1,Lung,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6467,,2048.0,50594,10090.0,Intermediate,1,Lung,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6468,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6469,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6470,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6471,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6472,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6473,,2106.0,50594,10090.0,Intermediate,1,Spleen,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6474,,2106.0,50594,10090.0,Intermediate,1,Spleen,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6475,,2106.0,50594,10090.0,Intermediate,1,Spleen,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6476,,2106.0,50594,10090.0,Intermediate,1,Spleen,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6477,,2106.0,50594,10090.0,Intermediate,1,Spleen,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6478,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6479,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6480,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6481,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6482,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6483,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6484,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6485,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6486,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6487,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6488,,948.0,50594,10090.0,Intermediate,1,Heart,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6489,,948.0,50594,10090.0,Intermediate,1,Heart,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6490,,948.0,50594,10090.0,Intermediate,1,Heart,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6491,,948.0,50594,10090.0,Intermediate,1,Heart,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6492,,948.0,50594,10090.0,Intermediate,1,Heart,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6493,,2107.0,50594,10090.0,Intermediate,1,Liver,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6494,,2107.0,50594,10090.0,Intermediate,1,Liver,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6495,,2107.0,50594,10090.0,Intermediate,1,Liver,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6496,,2107.0,50594,10090.0,Intermediate,1,Liver,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6497,,2107.0,50594,10090.0,Intermediate,1,Liver,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6498,,2048.0,50594,10090.0,Intermediate,1,Lung,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6499,,2048.0,50594,10090.0,Intermediate,1,Lung,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6500,,,50067,107673.0,Intermediate,1,,F,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,BAO_0000218,N,,12269,aeinetobacter anitrotap,
6501,,,50067,107673.0,Intermediate,1,,F,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,BAO_0000218,N,,12269,Acinetobacter calcoaceticus subsp. anitratus,
6502,,,50067,107673.0,Intermediate,1,,F,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,BAO_0000218,N,,12269,Acinetobacter calcoaceticus subsp. anitratus,
6503,,,50067,107673.0,Intermediate,1,,F,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,BAO_0000218,N,,12269,aeinetobacter anitrotap,
6504,,,50192,471.0,Intermediate,1,,F,,Activity against Acinetobacter calcoaceticus (AC54),,,BAO_0000218,N,,10624,Acinetobacter calcoaceticus,
6505,,,50714,28377.0,Intermediate,1,,F,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,,BAO_0000218,N,,17216,Anolis carolinensis,
6506,,,50714,28377.0,Intermediate,1,,F,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,,BAO_0000218,N,,17216,Anolis carolinensis,
6507,,,50296,1655.0,Intermediate,1,,F,,Chlorohexidine coefficient for Actinomyces naeslundii 631,,,BAO_0000218,N,,9560,Actinomyces naeslundii,
6508,,,50296,1655.0,Intermediate,1,,F,,Chlorohexidine coefficient for Actinomyces naeslundii B74,,,BAO_0000218,N,,9560,Actinomyces naeslundii,
6509,,,50296,1655.0,Intermediate,1,,F,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,,BAO_0000218,N,,9560,Actinomyces naeslundii,
6510,,,50296,1655.0,Intermediate,1,,F,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,,BAO_0000218,N,,9560,Actinomyces naeslundii,
6511,,,50296,1655.0,Intermediate,1,,F,,Plaque bactericidal index against Actinomyces naeslundii 631,,,BAO_0000218,N,,9560,Actinomyces naeslundii,
6512,,,50296,1655.0,Intermediate,1,,F,,Plaque bactericidal index against Actinomyces naeslundii N/9,,,BAO_0000218,N,,9560,Actinomyces naeslundii,
6513,,,50296,1655.0,Intermediate,1,,F,,Plaque bactericidal index against Actinomyces naeslundii B74,,,BAO_0000218,N,,9560,Actinomyces naeslundii,
6514,,,50296,1655.0,Intermediate,1,,F,,Plaque bactericidal index against Actinomyces naeslundii N/3,,,BAO_0000218,N,,9560,Actinomyces naeslundii,
6515,,,50056,85549.0,Intermediate,1,,F,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,,BAO_0000218,N,,114,Artemia salina,
6516,,,50056,85549.0,Intermediate,1,,F,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,,BAO_0000218,N,,114,Artemia salina,
6517,,,50532,6253.0,Intermediate,1,,F,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,,BAO_0000218,N,,10841,Ascaris suum,
6518,,,50532,6253.0,Intermediate,1,,F,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,,BAO_0000218,N,,10841,Ascaris suum,
6519,,,50532,6253.0,Intermediate,1,,F,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,,BAO_0000218,N,,10841,Ascaris suum,
6520,,,50532,6253.0,Intermediate,1,,F,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,,BAO_0000218,N,,10841,Ascaris suum,
6521,,,50532,6253.0,Intermediate,1,,F,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,,BAO_0000218,N,,10841,Ascaris suum,
6522,,,50532,6253.0,Intermediate,1,,F,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,,BAO_0000218,N,,10841,Ascaris suum,
6523,,,50532,6253.0,Intermediate,1,,F,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,,BAO_0000218,N,,10841,Ascaris suum,
6524,,,50532,6253.0,Intermediate,1,,F,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,,BAO_0000218,N,,10841,Ascaris suum,
6525,,,50532,6253.0,Intermediate,1,,F,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,,BAO_0000218,N,,10841,Ascaris suum,
6526,,,50532,6253.0,Intermediate,1,,F,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,,BAO_0000218,N,,10841,Ascaris suum,
6527,,,50532,6253.0,Intermediate,1,,F,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,,BAO_0000218,N,,10841,Ascaris suum,
6528,,,50532,6253.0,Intermediate,1,,F,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,,BAO_0000218,N,,10841,Ascaris suum,
6529,,,50366,1656.0,Intermediate,1,,F,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,,BAO_0000218,N,,8117,Actinomyces viscosus,
6530,,,50366,1656.0,Intermediate,1,,F,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,,BAO_0000218,N,,8117,Actinomyces viscosus,
6531,,,50366,1656.0,Intermediate,1,,F,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,,BAO_0000218,N,,9560,Actinomyces viscosus,
6532,,,50366,1656.0,Expert,1,,F,,Chlorohexidine coefficient for Actinomyces viscosus M-100,,,BAO_0000218,N,,9560,Actinomyces viscosus,
6533,,,50366,1656.0,Intermediate,1,,F,,Chlorohexidine coefficient for Actinomyces viscosus M-626,,,BAO_0000218,N,,9560,Actinomyces viscosus,
6534,,,50366,1656.0,Intermediate,1,,F,,Chlorohexidine coefficient for Actinomyces viscosus T14V,,,BAO_0000218,N,,9560,Actinomyces viscosus,
6535,,,50366,1656.0,Intermediate,1,,F,,Plaque bactericidal index against Actinomyces viscosus 8A06,,,BAO_0000218,N,,9560,Actinomyces viscosus,
6536,,,50366,1656.0,Intermediate,1,,F,,Plaque bactericidal index against Actinomyces viscosus M-100,,,BAO_0000218,N,,9560,Actinomyces viscosus,
6537,,,50366,1656.0,Expert,1,,F,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,,BAO_0000218,N,,9560,Actinomyces viscosus,
6538,,,50366,1656.0,Intermediate,1,,F,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,,BAO_0000218,N,,9560,Actinomyces viscosus,
6539,,,50366,1656.0,Intermediate,1,,F,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,,BAO_0000218,N,,9560,Actinomyces viscosus,
6540,,,50366,1656.0,Intermediate,1,,F,,Plaque bactericidal index against Actinomyces viscosus 626,,,BAO_0000218,N,,9560,Actinomyces viscosus,
6541,,,50366,1656.0,Intermediate,1,,F,,Plaque bactericidal index against Actinomyces viscosus T14V,,,BAO_0000218,N,,9560,Actinomyces viscosus,
6542,,,50535,6277.0,Intermediate,1,,F,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,,BAO_0000218,N,,10986,Acanthocheilonema viteae,
6543,,,50535,6277.0,Intermediate,1,,F,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,,BAO_0000218,N,,10986,Acanthocheilonema viteae,
6544,,,50535,6277.0,Intermediate,1,,F,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,,BAO_0000218,N,,10986,Acanthocheilonema viteae,
6545,,,50535,6277.0,Intermediate,1,,F,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,,BAO_0000218,N,,10986,Acanthocheilonema viteae,
6546,,,50535,6277.0,Intermediate,1,,F,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,,BAO_0000218,N,,10986,Acanthocheilonema viteae,
6547,,,80023,9606.0,Intermediate,1,,F,165.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,,BAO_0000219,N,,10708,Homo sapiens,A673
6548,,,80661,9606.0,Intermediate,1,,F,645.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,,BAO_0000219,N,,10708,Homo sapiens,A704
6549,,,22226,10116.0,Autocuration,1,,F,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,,BAO_0000219,U,,416,Rattus norvegicus,
6550,,,80024,10090.0,Intermediate,1,,F,625.0,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,,BAO_0000219,N,,14354,Mus musculus,A9
6551,,,80024,10090.0,Intermediate,1,,F,625.0,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,,BAO_0000219,N,,14354,Mus musculus,A9
6552,,,80024,9606.0,Intermediate,1,,F,625.0,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,,BAO_0000219,N,,5116,Homo sapiens,A9
6553,,,80024,9606.0,Intermediate,1,,F,625.0,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,,BAO_0000219,N,,5116,Homo sapiens,A9
6554,,,81037,9606.0,Expert,1,,F,874.0,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,,BAO_0000219,N,,15694,Homo sapiens,Human ovarian carcinoma cell line
6555,,,80024,10090.0,Expert,1,,F,625.0,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,,BAO_0000219,N,,13038,Mus musculus,A9
6556,,,80024,10090.0,Expert,1,,F,625.0,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,,BAO_0000219,N,,13038,Mus musculus,A9
6557,,,80024,10090.0,Expert,1,,F,625.0,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,,BAO_0000219,N,,10923,Mus musculus,A9
6558,,,80024,10090.0,Intermediate,1,,F,625.0,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,,BAO_0000219,N,,10923,Mus musculus,A9
6559,,,80024,10090.0,Intermediate,1,,F,625.0,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,,BAO_0000219,N,,10923,Mus musculus,A9
6560,,,10649,,Expert,1,,F,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,,BAO_0000019,H,,10923,,
6561,,,80024,10090.0,Intermediate,1,,F,625.0,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,,BAO_0000219,N,,10923,Mus musculus,A9
6562,,,80024,10090.0,Intermediate,1,,F,625.0,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,,BAO_0000219,N,,10923,Mus musculus,A9
6563,,,80663,10029.0,Intermediate,1,,F,975.0,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,,BAO_0000219,N,,8158,Cricetulus griseus,AA6
6564,,,22226,9606.0,Autocuration,1,,F,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,,BAO_0000219,U,,15494,Homo sapiens,
6565,,,22226,9606.0,Autocuration,1,,F,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,,BAO_0000219,U,,15494,Homo sapiens,
6566,,,80662,9606.0,Intermediate,1,,F,974.0,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,,BAO_0000219,N,,12348,Homo sapiens,AA5
6567,,,80662,9606.0,Intermediate,1,,F,974.0,Cytotoxicity was measured against AA5/HIV-1(IIIB),,,BAO_0000219,N,,12348,Homo sapiens,AA5
6568,,,80662,9606.0,Intermediate,1,,F,974.0,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,,BAO_0000219,N,,2726,Homo sapiens,AA5
6569,,,80566,9606.0,Intermediate,1,,F,379.0,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,,BAO_0000219,N,,2726,Homo sapiens,U-937
6570,,,80578,10029.0,Intermediate,1,,F,274.0,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,,BAO_0000219,N,,10747,Cricetulus griseus,UV4
6571,,,80089,10029.0,Expert,1,,F,185.0,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,,BAO_0000219,N,,11005,Cricetulus griseus,CHO-AA8
6572,,,80089,10029.0,Intermediate,1,,F,185.0,Average intracellular compound concentration when the hypoxic SER=1.6,,,BAO_0000219,N,,12687,Cricetulus griseus,CHO-AA8
6573,,,80089,10029.0,Intermediate,1,,F,185.0,Average intracellular compound concentration when the hypoxic SER=1.6.,,,BAO_0000219,N,,12687,Cricetulus griseus,CHO-AA8
6574,,,80089,10029.0,Intermediate,1,,F,185.0,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,,BAO_0000219,N,,12687,Cricetulus griseus,CHO-AA8
6575,,,80089,10029.0,Intermediate,1,,F,185.0,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,,BAO_0000219,N,,12687,Cricetulus griseus,CHO-AA8
6576,,,80089,10029.0,Intermediate,1,,F,185.0,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,,BAO_0000219,N,,12687,Cricetulus griseus,CHO-AA8
6577,,,80089,10029.0,Intermediate,1,,F,185.0,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,,BAO_0000219,N,,13436,Cricetulus griseus,CHO-AA8
6578,,,80089,10029.0,Intermediate,1,,F,185.0,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,,BAO_0000219,N,,13435,Cricetulus griseus,CHO-AA8
6579,,,80089,10029.0,Intermediate,1,,F,185.0,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,,BAO_0000219,N,,13302,Cricetulus griseus,CHO-AA8
6580,,,80089,10029.0,Intermediate,1,,F,185.0,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,,BAO_0000219,N,,12687,Cricetulus griseus,CHO-AA8
6581,,,80089,10029.0,Intermediate,1,,A,185.0,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,,BAO_0000219,N,,12687,Cricetulus griseus,CHO-AA8
6582,,,80089,10029.0,Intermediate,1,,A,185.0,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,,BAO_0000219,N,,12687,Cricetulus griseus,CHO-AA8
6583,,,80089,10029.0,Expert,1,,A,185.0,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,,BAO_0000219,N,,12878,Cricetulus griseus,CHO-AA8
6584,,,80089,10029.0,Intermediate,1,,A,185.0,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,,BAO_0000219,N,,12878,Cricetulus griseus,CHO-AA8
6585,,,80089,10029.0,Expert,1,,F,185.0,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,,BAO_0000219,N,,14367,Cricetulus griseus,CHO-AA8
6586,,,80089,10029.0,Intermediate,1,,F,185.0,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,,BAO_0000219,N,,14367,Cricetulus griseus,CHO-AA8
6587,,,80089,36483.0,Expert,1,,F,185.0,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,,BAO_0000219,N,,12398,hampster,CHO-AA8
6588,,,80089,10029.0,Expert,1,,F,185.0,Aerobic growth inhibition in Chinese hamster cell line AA8,,,BAO_0000219,N,,12878,Cricetulus griseus,CHO-AA8
6589,,,80089,10029.0,Expert,1,,F,185.0,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,,BAO_0000219,N,,13820,Cricetulus griseus,CHO-AA8
6590,,,80089,10029.0,Expert,1,,F,185.0,Inhibition of growth under aerobic conditions in AA8 cells,,,BAO_0000219,N,,13436,Cricetulus griseus,CHO-AA8
6591,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (dose 10 mg/kg),,,BAO_0000218,N,,6084,Canis lupus familiaris,
6592,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog at 10 mg/kg of the compound,,,BAO_0000218,N,,5711,Canis lupus familiaris,
6593,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (dose 5 uM/kg),,,BAO_0000218,N,,4353,Canis lupus familiaris,
6594,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (dose 5 uM/kg),,,BAO_0000218,N,,4353,Canis lupus familiaris,
6595,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (mongrel),,,BAO_0000218,N,,17800,Canis lupus familiaris,
6596,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (dose 10 mg/kg),,,BAO_0000218,N,,3994,Canis lupus familiaris,
6597,In vivo,,50588,9615.0,Intermediate,1,,F,,Oral bioavailability in dog (dose 10 mg/kg),,,BAO_0000218,N,,3994,Canis lupus familiaris,
6598,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog,,,BAO_0000218,N,,5145,Canis lupus familiaris,
6599,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog (dose 1 mg/kg i.v.),,,BAO_0000218,N,,16452,Canis lupus familiaris,
6600,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,,BAO_0000218,N,,16452,Canis lupus familiaris,
6601,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,,BAO_0000218,N,,5983,Canis lupus familiaris,
6602,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog,,,BAO_0000218,N,,4273,Canis lupus familiaris,
6603,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog (dose 3-10 mg/kg),,,BAO_0000218,N,,12500,Canis lupus familiaris,
6604,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,The compound was tested for bioavailability of compound in plasma of dog; Complete,,,BAO_0000218,N,,12500,Canis lupus familiaris,
6605,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,3639,Canis lupus familiaris,
6606,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,3880,Canis lupus familiaris,
6607,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog,,,BAO_0000218,N,,4838,Canis lupus familiaris,
6608,In vivo,,50588,9615.0,Intermediate,1,,A,,oral bioavailability was measured in dogs,,,BAO_0000218,N,,15600,Canis lupus familiaris,
6609,,,50588,9615.0,Intermediate,1,,A,,Compound was tested for plasma protein binding in dog; Not determined,,,BAO_0000218,N,,17248,Canis lupus familiaris,
6610,,,50588,9615.0,Intermediate,1,,A,,Compound was tested for plasma protein binding of dog,,,BAO_0000218,N,,17248,Canis lupus familiaris,
6611,,,50588,9615.0,Intermediate,1,,A,,Compound was tested for plasma protein binding of dog; Not determined,,,BAO_0000218,N,,17248,Canis lupus familiaris,
6612,,,50588,9615.0,Intermediate,1,,A,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,,BAO_0000218,N,,17443,Canis lupus familiaris,
6613,In vivo,,50588,9615.0,Intermediate,1,,A,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,,BAO_0000218,N,,4186,Canis lupus familiaris,
6614,,,50588,9615.0,Intermediate,1,,A,,Half life was determined,,,BAO_0000218,N,,3749,Canis lupus familiaris,
6615,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,,BAO_0000218,N,,3249,Canis lupus familiaris,
6616,,,50588,9615.0,Intermediate,1,,A,,Half life was evaluated in dog,,,BAO_0000218,N,,3022,Canis lupus familiaris,
6617,,,50588,9615.0,Intermediate,1,,A,,Half life was determined,,,BAO_0000218,N,,3749,Canis lupus familiaris,
6618,In vivo,,50588,9615.0,Intermediate,1,,A,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,BAO_0000218,N,,2517,Canis lupus familiaris,
6619,In vivo,948.0,50588,9615.0,Intermediate,1,Heart,A,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,BAO_0000218,N,,2517,Canis lupus familiaris,
6620,In vivo,2113.0,50588,9615.0,Intermediate,1,Kidney,A,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,BAO_0000218,N,,2517,Canis lupus familiaris,
6621,In vivo,2107.0,50588,9615.0,Intermediate,1,Liver,A,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,BAO_0000218,N,,2517,Canis lupus familiaris,
6622,In vivo,2048.0,50588,9615.0,Intermediate,1,Lung,A,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,BAO_0000218,N,,2517,Canis lupus familiaris,
6623,In vivo,2106.0,50588,9615.0,Intermediate,1,Spleen,A,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,BAO_0000218,N,,2517,Canis lupus familiaris,
6624,,,50588,9615.0,Intermediate,1,,A,,LogP in dog,,,BAO_0000218,N,,3639,Canis lupus familiaris,
6625,,,50588,9615.0,Intermediate,1,,A,,Partition coefficient (logP),,,BAO_0000218,N,,6227,Canis lupus familiaris,
6626,,,50588,9615.0,Intermediate,1,,A,,Partition coefficient in dog,,,BAO_0000218,N,,6227,Canis lupus familiaris,
6627,In vivo,,50588,9615.0,Intermediate,1,,A,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,,BAO_0000218,N,,17764,Canis lupus familiaris,
6628,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,,BAO_0000218,N,,4809,Canis lupus familiaris,
6629,,,50588,9615.0,Intermediate,1,,A,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,,BAO_0000218,N,,5600,Canis lupus familiaris,
6630,,,50588,9615.0,Intermediate,1,,A,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,,BAO_0000218,N,,14294,Canis lupus familiaris,
6631,,,50588,9615.0,Intermediate,1,,A,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,,BAO_0000218,N,,14294,Canis lupus familiaris,
6632,,,50588,9615.0,Intermediate,1,,A,,Metabolism of compound in dog S9 microsomes; Trace,,,BAO_0000218,N,,14294,Canis lupus familiaris,
6633,,2107.0,50588,9615.0,Intermediate,1,Liver,A,,In vitro metabolic potential in dog liver microsomes,,,BAO_0000218,N,,6251,Canis lupus familiaris,
6634,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,,BAO_0000218,N,,3748,Canis lupus familiaris,
6635,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,2713,Canis lupus familiaris,
6636,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,6512,Canis lupus familiaris,
6637,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,BAO_0000218,N,,6679,Canis lupus familiaris,
6638,In vivo,,50588,9615.0,Intermediate,1,,A,,The compound was tested for bioavailability in dogs,,,BAO_0000218,N,,3749,Canis lupus familiaris,
6639,In vivo,,50588,9615.0,Intermediate,1,,A,,The compound was tested for oral bioavailability in dogs,,,BAO_0000218,N,,3749,Canis lupus familiaris,
6640,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog,,,BAO_0000218,N,,6742,Canis lupus familiaris,
6641,,,50588,9615.0,Intermediate,1,,A,,Compound was tested for percent protein binding (PB) in dog,,,BAO_0000218,N,,6227,Canis lupus familiaris,
6642,,,50588,9615.0,Intermediate,1,,A,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,,BAO_0000218,N,,6874,Canis lupus familiaris,
6643,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Compound was evaluated for plasma clearance.,,,BAO_0000218,N,,2877,Canis lupus familiaris,
6644,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,The compound was tested for plasma clearance in dog,,,BAO_0000218,N,,12500,Canis lupus familiaris,
6645,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,,,BAO_0000218,N,,12500,Canis lupus familiaris,
6646,,,50588,9615.0,Intermediate,1,,A,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,,BAO_0000218,N,,4709,Canis lupus familiaris,
6647,,2107.0,50588,9615.0,Intermediate,1,Liver,A,,In vitro relative rate of metabolism was determined in dog liver microsomes,,,BAO_0000218,N,,5542,Canis lupus familiaris,
6648,In vivo,,50588,9615.0,Intermediate,1,,A,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,,BAO_0000218,N,,17594,Canis lupus familiaris,
6649,In vivo,,50588,9615.0,Intermediate,1,,A,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,,BAO_0000218,N,,2652,Canis lupus familiaris,
6650,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life after intravenous administration in dogs at 1.2 uM/kg,,,BAO_0000218,N,,17764,Canis lupus familiaris,
6651,,2048.0,50594,10090.0,Intermediate,1,Lung,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6652,,2048.0,50594,10090.0,Intermediate,1,Lung,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6653,,2048.0,50594,10090.0,Intermediate,1,Lung,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6654,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6655,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6656,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6657,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6658,,,50594,10090.0,Intermediate,1,,A,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,,BAO_0000218,N,,6599,Mus musculus,CCRF S-180
6659,,955.0,50594,10090.0,Intermediate,1,Brain,A,,C2 in brain of mice at the oral dose of 50 mg/kg,,,BAO_0000218,N,,17641,Mus musculus,
6660,,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,C2 in kidney of mice at the oral dose of 50 mg/kg,,,BAO_0000218,N,,17641,Mus musculus,
6661,,2107.0,50594,10090.0,Intermediate,1,Liver,A,,C2 in liver of mice at the oral dose of 50 mg/kg,,,BAO_0000218,N,,17641,Mus musculus,
6662,,2048.0,50594,10090.0,Intermediate,1,Lung,A,,C2 in lungs of mice at the oral dose of 50 mg/kg,,,BAO_0000218,N,,17641,Mus musculus,
6663,,2106.0,50594,10090.0,Intermediate,1,Spleen,A,,C2 in spleen of mice at the oral dose of 50 mg/kg,,,BAO_0000218,N,,17641,Mus musculus,
6664,In vivo,,50594,10090.0,Intermediate,1,,A,,Plasma clearance in mouse,,,BAO_0000218,N,,17852,Mus musculus,
6665,In vivo,,50594,10090.0,Intermediate,1,,A,,Clearance of compound after intravenous administration in mice at 24 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
6666,In vivo,,50594,10090.0,Intermediate,1,,A,,Clearance from mouse blood following i.v. administration of 10 mg/kg,,,BAO_0000218,N,,17837,Mus musculus,
6667,In vivo,,50594,10090.0,Intermediate,1,,A,,Clearance was evaluated in mice after intravenous administration,,,BAO_0000218,N,,2675,Mus musculus,
6668,In vivo,,50594,10090.0,Intermediate,1,,A,,Clearance was evaluated in mice after oral administration,,,BAO_0000218,N,,2675,Mus musculus,
6669,In vivo,,50594,10090.0,Intermediate,1,,A,,Pharmacokinetic property (Plasma clearance) was measured in mouse,,,BAO_0000218,N,,4239,Mus musculus,
6670,In vivo,,50594,10090.0,Intermediate,1,,A,,Plasma clearance of compound was determined at 40 mg/Kg,,,BAO_0000218,N,,17753,Mus musculus,
6671,In vivo,,50594,10090.0,Intermediate,1,,A,,Plasma clearance of at 24 mg/Kg,,,BAO_0000218,N,,17753,Mus musculus,
6672,In vivo,,50594,10090.0,Intermediate,1,,A,,Plasma clearance at 24 mg/Kg,,,BAO_0000218,N,,17753,Mus musculus,
6673,In vivo,,50594,10090.0,Intermediate,1,,A,,Plasma clearance at 5 mg/Kg,,,BAO_0000218,N,,17753,Mus musculus,
6674,In vivo,,50594,10090.0,Intermediate,1,,A,,Plasma clearance in mice,,,BAO_0000218,N,,5727,Mus musculus,
6675,In vivo,,50594,10090.0,Intermediate,1,,A,,Plasma clearance value upon iv administration in mouse,,,BAO_0000218,N,,2862,Mus musculus,
6676,In vivo,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,Total plasma clearance in mice,,,BAO_0000218,N,,5980,Mus musculus,
6677,In vivo,,50594,10090.0,Intermediate,1,,A,,Clearance in mouse,,,BAO_0000218,N,,17592,Mus musculus,
6678,In vivo,,50594,10090.0,Intermediate,1,,A,,Clearance value was determined,,,BAO_0000218,N,,17718,Mus musculus,
6679,In vivo,,50594,10090.0,Intermediate,1,,A,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,,BAO_0000218,N,,16597,Mus musculus,
6680,,,22229,,Intermediate,1,,P,,Calculated partition coefficient (clogP),,,BAO_0000100,U,,17384,,
6681,In vivo,,50594,10090.0,Intermediate,1,,A,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,,BAO_0000218,N,,6062,Mus musculus,
6682,In vivo,,50594,10090.0,Intermediate,1,,A,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,,BAO_0000218,N,,17734,Mus musculus,
6683,In vivo,,50594,10090.0,Intermediate,1,,A,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,BAO_0000218,N,,6348,Mus musculus,
6684,In vivo,,50594,10090.0,Intermediate,1,,A,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,,BAO_0000218,N,,5969,Mus musculus,
6685,In vivo,,50594,10090.0,Intermediate,1,,A,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,,BAO_0000218,N,,5969,Mus musculus,
6686,In vivo,,50594,10090.0,Intermediate,1,,A,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,,BAO_0000218,N,,5969,Mus musculus,
6687,In vivo,,50594,10090.0,Intermediate,1,,A,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,,BAO_0000218,N,,16597,Mus musculus,
6688,In vivo,,50594,10090.0,Intermediate,1,,A,,Cmax after oral administration at 30 mg/kg in ICR mouse,,,BAO_0000218,N,,5781,Mus musculus,
6689,In vivo,,50594,10090.0,Intermediate,1,,A,,Cmax after peroral administration in mice at 2.4 uM/kg,,,BAO_0000218,N,,17764,Mus musculus,
6690,In vivo,955.0,50594,10090.0,Intermediate,1,Brain,A,,Cmax in brain of mice at the oral dose of 50 mg/kg,,,BAO_0000218,N,,17641,Mus musculus,
6691,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Cmax in kidney of mice at the oral dose of 50 mg/kg,,,BAO_0000218,N,,17641,Mus musculus,
6692,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Cmax in liver of mice at the oral dose of 50 mg/kg,,,BAO_0000218,N,,17641,Mus musculus,
6693,In vivo,2048.0,50594,10090.0,Intermediate,1,Lung,A,,Cmax in lungs of mice at the oral dose of 50 mg/kg,,,BAO_0000218,N,,17641,Mus musculus,
6694,In vivo,,50594,10090.0,Intermediate,1,,F,,Cmax in mice at 18 uM/kg i.p. administration,,,BAO_0000218,N,,17764,Mus musculus,
6695,In vivo,,50594,10090.0,Intermediate,1,,F,,Cmax in mice at 23 uM/kg i.v. administration,,,BAO_0000218,N,,17764,Mus musculus,
6696,In vivo,,50594,10090.0,Intermediate,1,,F,,Cmax in mice at 24 uM/kg i.p. administration,,,BAO_0000218,N,,17764,Mus musculus,
6697,In vivo,,50594,10090.0,Intermediate,1,,F,,Cmax in mice at 25 uM/kg i.p. administration,,,BAO_0000218,N,,17764,Mus musculus,
6698,In vivo,,50594,10090.0,Intermediate,1,,F,,Cmax in mice at 26 uM/kg i.p. administration,,,BAO_0000218,N,,17764,Mus musculus,
6699,In vivo,2106.0,50594,10090.0,Intermediate,1,Spleen,A,,Cmax in spleen of mice at the oral dose of 50 mg/kg,,,BAO_0000218,N,,17641,Mus musculus,
6700,In vivo,,50594,10090.0,Intermediate,1,,A,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,,BAO_0000218,N,,16597,Mus musculus,
6701,In vivo,,50594,10090.0,Intermediate,1,,A,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,,BAO_0000218,N,,16597,Mus musculus,
6702,In vivo,,50594,10090.0,Intermediate,1,,A,,Cmax value was determined,,,BAO_0000218,N,,5727,Mus musculus,
6703,In vivo,,50594,10090.0,Intermediate,1,,A,,Cmax value in IRC mice,,,BAO_0000218,N,,5951,Mus musculus,
6704,In vivo,,50594,10090.0,Intermediate,1,,A,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,,BAO_0000218,N,,5506,Mus musculus,
6705,In vivo,,50594,10090.0,Intermediate,1,,A,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,,BAO_0000218,N,,5506,Mus musculus,
6706,In vivo,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,,BAO_0000218,N,,14239,Mus musculus,
6707,In vivo,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",,,BAO_0000218,N,,4890,Mus musculus,
6708,In vivo,,50594,10090.0,Intermediate,1,,A,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,,BAO_0000218,N,,429,Mus musculus,
6709,,,50535,6277.0,Intermediate,1,,F,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,,BAO_0000218,N,,10986,Acanthocheilonema viteae,
6710,,,50535,6277.0,Intermediate,1,,F,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,,BAO_0000218,N,,10986,Acanthocheilonema viteae,
6711,,,50535,6277.0,Intermediate,1,,F,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,,BAO_0000218,N,,10986,Acanthocheilonema viteae,
6712,,,80018,9606.0,Intermediate,1,,F,455.0,Inhibitory activity against human tumor cell line A0375 melanoma.,,,BAO_0000219,N,,13227,Homo sapiens,A-375
6713,,,12512,10116.0,Expert,1,,B,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,Brain membranes,,BAO_0000249,D,,4481,Rattus norvegicus,
6714,,,114,9606.0,Expert,1,,F,,Forskolin-induced cAMP production at human A1 adenosine receptor,,,BAO_0000019,D,,16931,Homo sapiens,
6715,,,114,,Autocuration,1,,F,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,,BAO_0000219,H,,3850,,CHO
6716,,,114,,Autocuration,1,,F,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,,BAO_0000219,H,,3850,,CHO
6717,,,114,,Expert,1,,F,449.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,,BAO_0000219,H,,3850,,CHO
6718,,,114,,Expert,1,,F,449.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,,BAO_0000219,H,,3850,,CHO
6719,,,114,,Autocuration,1,,F,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,,BAO_0000219,H,,3850,,CHO
6720,,,114,,Autocuration,1,,F,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,,BAO_0000219,H,,3850,,CHO
6721,,,114,,Autocuration,1,,F,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,,BAO_0000219,H,,3850,,CHO
6722,,,114,9606.0,Expert,1,,F,449.0,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,,BAO_0000219,D,,3850,Homo sapiens,CHO
6723,,,114,,Autocuration,1,,F,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,,BAO_0000219,H,,3850,,CHO
6724,,,114,,Autocuration,1,,F,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,,BAO_0000219,H,,3850,,CHO
6725,,,114,,Expert,1,,F,449.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,,BAO_0000219,H,,3850,,CHO
6726,,,114,,Autocuration,1,,F,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,,BAO_0000219,H,,3850,,CHO
6727,,,114,,Expert,1,,F,449.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,,BAO_0000219,H,,3850,,CHO
6728,,,114,,Autocuration,1,,F,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,,BAO_0000219,H,,3850,,CHO
6729,,,114,,Autocuration,1,,F,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,,BAO_0000219,H,,3850,,CHO
6730,,,114,,Autocuration,1,,F,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,,BAO_0000219,H,,3850,,CHO
6731,,,114,,Expert,1,,F,449.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,,BAO_0000219,H,,3850,,CHO
6732,,,114,,Autocuration,1,,F,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,,BAO_0000219,H,,3850,,CHO
6733,,,114,,Autocuration,1,,F,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,,BAO_0000219,H,,3850,,CHO
6734,,,114,,Expert,1,,F,449.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,,BAO_0000219,H,,3850,,CHO
6735,,,80013,9986.0,Intermediate,1,,F,164.0,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,,BAO_0000219,N,,12680,Oryctolagus cuniculus,A10
6736,,,22226,10116.0,Autocuration,1,,F,164.0,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,,BAO_0000219,U,,1313,Rattus norvegicus,A10
6737,,,22226,10116.0,Autocuration,1,,F,164.0,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,,BAO_0000219,U,,1313,Rattus norvegicus,A10
6738,,,80013,10116.0,Intermediate,1,,F,164.0,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,,BAO_0000219,N,,17567,Rattus norvegicus,A10
6739,,,80013,10116.0,Intermediate,1,,F,164.0,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,,BAO_0000219,N,,17567,Rattus norvegicus,A10
6740,,,80013,10116.0,Intermediate,1,,F,164.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,,BAO_0000219,N,,11819,Rattus norvegicus,A10
6741,,,80089,10029.0,Intermediate,1,,F,185.0,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,,BAO_0000219,N,,13436,Cricetulus griseus,CHO-AA8
6742,,,80089,10029.0,Intermediate,1,,F,185.0,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,,BAO_0000219,N,,12687,Cricetulus griseus,CHO-AA8
6743,,,80089,10029.0,Intermediate,1,,F,185.0,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,,BAO_0000219,N,,12651,Cricetulus griseus,CHO-AA8
6744,,,80089,10029.0,Intermediate,1,,F,185.0,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,,BAO_0000219,N,,13300,Cricetulus griseus,CHO-AA8
6745,,,80089,10029.0,Intermediate,1,,F,185.0,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,,BAO_0000219,N,,15296,Cricetulus griseus,CHO-AA8
6746,,,80089,10029.0,Intermediate,1,,F,185.0,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,,BAO_0000219,N,,15328,Cricetulus griseus,CHO-AA8
6747,,,80089,10029.0,Intermediate,1,,F,185.0,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,,BAO_0000219,N,,13302,Cricetulus griseus,CHO-AA8
6748,,,80089,10029.0,Expert,1,,F,185.0,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,,BAO_0000219,N,,14367,Cricetulus griseus,CHO-AA8
6749,,,80089,10029.0,Expert,1,,F,185.0,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,,BAO_0000219,N,,17002,Cricetulus griseus,CHO-AA8
6750,,,80089,10029.0,Intermediate,1,,F,185.0,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,,BAO_0000219,N,,13436,Cricetulus griseus,CHO-AA8
6751,,,80089,10029.0,Intermediate,1,,F,185.0,Inhibitory activity against aerobic growth of AA8 cells.,,,BAO_0000219,N,,13435,Cricetulus griseus,CHO-AA8
6752,,,80089,10029.0,Intermediate,1,,A,185.0,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,,BAO_0000219,N,,10503,Cricetulus griseus,CHO-AA8
6753,,,80089,10029.0,Expert,1,,F,185.0,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,,BAO_0000219,N,,10503,Cricetulus griseus,CHO-AA8
6754,,,80089,10029.0,Intermediate,1,,F,185.0,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,,BAO_0000219,N,,10503,Cricetulus griseus,CHO-AA8
6755,,,80089,10029.0,Expert,1,,F,185.0,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,,BAO_0000219,N,,15090,Cricetulus griseus,CHO-AA8
6756,,,80089,10029.0,Expert,1,,F,185.0,Cytotoxicity against AA8 cell line,,,BAO_0000219,N,,10368,Cricetulus griseus,CHO-AA8
6757,,,80089,10029.0,Intermediate,1,,F,185.0,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,,BAO_0000219,N,,12651,Cricetulus griseus,CHO-AA8
6758,,,80089,10029.0,Intermediate,1,,A,185.0,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,,BAO_0000219,N,,12687,Cricetulus griseus,CHO-AA8
6759,,,80089,10029.0,Intermediate,1,,F,185.0,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,,BAO_0000219,N,,12687,Cricetulus griseus,CHO-AA8
6760,,,80089,10029.0,Intermediate,1,,A,185.0,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,,BAO_0000219,N,,12687,Cricetulus griseus,CHO-AA8
6761,,,80089,10029.0,Intermediate,1,,F,185.0,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,,BAO_0000219,N,,1890,Cricetulus griseus,CHO-AA8
6762,,,80089,10029.0,Intermediate,1,,F,185.0,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,,BAO_0000219,N,,10747,Cricetulus griseus,CHO-AA8
6763,,,80089,10029.0,Intermediate,1,,F,185.0,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,,BAO_0000219,N,,10747,Cricetulus griseus,CHO-AA8
6764,,,22224,10029.0,Autocuration,1,,F,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,,BAO_0000218,U,,11616,Cricetulus griseus,
6765,,,80089,10029.0,Expert,1,,F,185.0,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,,BAO_0000219,N,,11616,Cricetulus griseus,CHO-AA8
6766,,,22224,10029.0,Autocuration,1,,F,185.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,,BAO_0000219,U,,3471,Cricetulus griseus,CHO-AA8
6767,,,22224,10029.0,Autocuration,1,,F,185.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,,BAO_0000219,U,,3471,Cricetulus griseus,CHO-AA8
6768,,,22224,10029.0,Autocuration,1,,F,185.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,,BAO_0000219,U,,3471,Cricetulus griseus,CHO-AA8
6769,,,22224,10029.0,Autocuration,1,,F,185.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,,BAO_0000219,U,,3471,Cricetulus griseus,CHO-AA8
6770,,,22224,10029.0,Autocuration,1,,F,185.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,,BAO_0000219,U,,3471,Cricetulus griseus,CHO-AA8
6771,,,22224,10029.0,Autocuration,1,,F,185.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,,BAO_0000219,U,,3471,Cricetulus griseus,CHO-AA8
6772,,,22224,10029.0,Autocuration,1,,F,185.0,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,,BAO_0000219,U,,3471,Cricetulus griseus,CHO-AA8
6773,,,80089,10029.0,Expert,1,,F,185.0,Concentration required to reduce AA8 cell survival by 10%,,,BAO_0000219,N,,11616,Cricetulus griseus,CHO-AA8
6774,,,22224,10029.0,Autocuration,1,,F,185.0,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,,BAO_0000219,U,,2656,Cricetulus griseus,CHO-AA8
6775,,,22224,10029.0,Autocuration,1,,F,185.0,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,,BAO_0000219,U,,10518,Cricetulus griseus,CHO-AA8
6776,,,22224,10029.0,Autocuration,1,,F,185.0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,,BAO_0000219,U,,10518,Cricetulus griseus,CHO-AA8
6777,,,22224,10029.0,Autocuration,1,,F,185.0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,,BAO_0000219,U,,10518,Cricetulus griseus,CHO-AA8
6778,,,22224,10029.0,Autocuration,1,,F,185.0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,,BAO_0000219,U,,10518,Cricetulus griseus,CHO-AA8
6779,,,22224,10029.0,Autocuration,1,,F,185.0,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,,BAO_0000219,U,,16156,Cricetulus griseus,CHO-AA8
6780,,,22224,10029.0,Autocuration,1,,F,185.0,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,,BAO_0000219,U,,2656,Cricetulus griseus,CHO-AA8
6781,,,22224,10029.0,Autocuration,1,,F,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,,BAO_0000019,U,,11005,Cricetulus griseus,
6782,,,22224,10029.0,Autocuration,1,,F,185.0,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,,BAO_0000219,U,,11942,Cricetulus griseus,CHO-AA8
6783,,,22224,10029.0,Autocuration,1,,F,185.0,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,,BAO_0000219,U,,2128,Cricetulus griseus,CHO-AA8
6784,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life period after 15 mg/kg iv dose in Dogs,,,BAO_0000218,N,,16907,Canis lupus familiaris,
6785,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life period after 30 mg/kg po dose in Dogs,,,BAO_0000218,N,,16907,Canis lupus familiaris,
6786,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life was measured after oral 2b administration (tested in 6 dogs),,,BAO_0000218,N,,9579,Canis lupus familiaris,
6787,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life was measured in dog after oral 17b administration,,,BAO_0000218,N,,9579,Canis lupus familiaris,
6788,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,,BAO_0000218,N,,9579,Canis lupus familiaris,
6789,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,,BAO_0000218,N,,9579,Canis lupus familiaris,
6790,In vivo,,50588,9615.0,Intermediate,1,,A,,Tmax value after 15 mg/kg iv dose in Dogs,,,BAO_0000218,N,,16907,Canis lupus familiaris,
6791,In vivo,,50588,9615.0,Intermediate,1,,A,,Tmax value after 30 mg/kg po dose in Dogs,,,BAO_0000218,N,,16907,Canis lupus familiaris,
6792,In vivo,,50588,9615.0,Intermediate,1,,A,,Compound was evaluated for its half life when administered intravenously in dog,,,BAO_0000218,N,,3184,Canis lupus familiaris,
6793,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,,BAO_0000218,N,,5017,Canis lupus familiaris,
6794,,,50588,9615.0,Intermediate,1,,A,,Elimination Half-life of compound was determined in dog,,,BAO_0000218,N,,6821,Canis lupus familiaris,
6795,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life of compound in dog following oral administration,,,BAO_0000218,N,,17839,Canis lupus familiaris,
6796,,,50588,9615.0,Intermediate,1,,A,,Half life of compound was determined in dog,,,BAO_0000218,N,,17267,Canis lupus familiaris,
6797,,178.0,50588,9615.0,Intermediate,1,Blood,A,,Half life of compound was determined in dog blood,,,BAO_0000218,N,,4727,Canis lupus familiaris,
6798,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life after oral and iv dosing in dogs,,,BAO_0000218,N,,5238,Canis lupus familiaris,
6799,,,50588,9615.0,Intermediate,1,,A,,Half life in dogs in hours,,,BAO_0000218,N,,4942,Canis lupus familiaris,
6800,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life on i.v. administration of 2 mg/kg was measured in dog,,,BAO_0000218,N,,6505,Canis lupus familiaris,
6801,In vivo,,50588,9615.0,Intermediate,1,,A,,t1/2 in dog after oral dose (1 mg/kg),,,BAO_0000218,N,,5130,Canis lupus familiaris,
6802,,,50588,9615.0,Intermediate,1,,A,,Half life was evaluated in dog,,,BAO_0000218,N,,1475,Canis lupus familiaris,
6803,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life period of compound was determined after intravenous administration at 2 mg/kg,,,BAO_0000218,N,,17804,Canis lupus familiaris,
6804,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life period of compound was determined after peroral administration at 2 mg/kg,,,BAO_0000218,N,,17804,Canis lupus familiaris,
6805,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life period (10 mg/kg) was determined in dog,,,BAO_0000218,N,,6084,Canis lupus familiaris,
6806,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life period (10 mg/kg) was determined in dog,,,BAO_0000218,N,,6084,Canis lupus familiaris,
6807,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,,BAO_0000218,N,,5542,Canis lupus familiaris,
6808,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life period by po administration in dog at a dose of 0.3 mg/kg,,,BAO_0000218,N,,5542,Canis lupus familiaris,
6809,,,50588,9615.0,Intermediate,1,,A,,Half life period in dog,,,BAO_0000218,N,,6084,Canis lupus familiaris,
6810,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life period in dogs after oral administration at 1 mg/kg,,,BAO_0000218,N,,6241,Canis lupus familiaris,
6811,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,BAO_0000218,N,,1916,Canis lupus familiaris,
6812,,,50588,9615.0,Intermediate,1,,A,,Half-life of compound was determined in dogs,,,BAO_0000218,N,,6621,Canis lupus familiaris,
6813,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Half-life in dog plasma,,,BAO_0000218,N,,1696,Canis lupus familiaris,
6814,,,50588,9615.0,Intermediate,1,,A,,Half-life in mongrel dogs was determined,,,BAO_0000218,N,,17800,Canis lupus familiaris,
6815,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life in dog upon oral administration,,,BAO_0000218,N,,17657,Canis lupus familiaris,
6816,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life in dog upon oral administration; Unable to calculate,,,BAO_0000218,N,,17657,Canis lupus familiaris,
6817,,,50588,9615.0,Intermediate,1,,A,,Half-life was measured in dog,,,BAO_0000218,N,,4239,Canis lupus familiaris,
6818,,,50588,9615.0,Intermediate,1,,A,,Half-life was measured in dog,,,BAO_0000218,N,,5985,Canis lupus familiaris,
6819,,,50588,9615.0,Intermediate,1,,A,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,,BAO_0000218,N,,9932,Canis lupus familiaris,
6820,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral half life was determined,,,BAO_0000218,N,,5199,Canis lupus familiaris,
6821,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,,,BAO_0000218,N,,5199,Canis lupus familiaris,
6822,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Plasma half life was evaluated,,,BAO_0000218,N,,1475,Canis lupus familiaris,
6823,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Plasma half life was evaluated in Dog,,,BAO_0000218,N,,1475,Canis lupus familiaris,
6824,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Plasma half life was evaluated in dog,,,BAO_0000218,N,,1475,Canis lupus familiaris,
6825,In vivo,,50588,9615.0,Intermediate,1,,A,,T1/2 (Half-life) was after oral administration at 5 mg/kg,,,BAO_0000218,N,,6316,Canis lupus familiaris,
6826,,,50588,9615.0,Intermediate,1,,A,,Tested for the half life value in dog,,,BAO_0000218,N,,4883,Canis lupus familiaris,
6827,In vivo,,50588,9615.0,Intermediate,1,,A,,Maximum time at the dose of 2 mg/kg in dog,,,BAO_0000218,N,,4727,Canis lupus familiaris,
6828,In vivo,,50588,9615.0,Intermediate,1,,A,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,BAO_0000218,N,,1916,Canis lupus familiaris,
6829,In vivo,178.0,50588,9615.0,Intermediate,1,Blood,A,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,BAO_0000218,N,,1337,Canis lupus familiaris,
6830,In vivo,178.0,50588,9615.0,Intermediate,1,Blood,A,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,BAO_0000218,N,,1337,Canis lupus familiaris,
6831,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,,BAO_0000218,N,,6265,Canis lupus familiaris,
6832,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,,BAO_0000218,N,,4809,Canis lupus familiaris,
6833,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,,BAO_0000218,N,,5983,Canis lupus familiaris,
6834,,,50588,9615.0,Intermediate,1,,A,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,,BAO_0000218,N,,5313,Canis lupus familiaris,
6835,In vivo,,50588,9615.0,Intermediate,1,,A,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,,BAO_0000218,N,,5313,Canis lupus familiaris,
6836,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,,BAO_0000218,N,,17650,Canis lupus familiaris,
6837,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,,BAO_0000218,N,,5199,Canis lupus familiaris,
6838,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Time taken for maximum plasma concentration in dog,,,BAO_0000218,N,,933,Canis lupus familiaris,
6839,In vivo,,50588,9615.0,Intermediate,1,,A,,Time to reach Cmax after oral administration to dogs,,,BAO_0000218,N,,16367,Canis lupus familiaris,
6840,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,BAO_0000218,N,,6348,Canis lupus familiaris,
6841,In vivo,,50588,9615.0,Intermediate,1,,A,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,,BAO_0000218,N,,6316,Canis lupus familiaris,
6842,In vivo,,50588,9615.0,Intermediate,1,,A,,Tmax after peroral administration (1 mg/kg) was determined in dog,,,BAO_0000218,N,,6215,Canis lupus familiaris,
6843,In vivo,,50588,9615.0,Expert,1,,A,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,,BAO_0000218,N,,3598,Canis lupus familiaris,
6844,In vivo,,50588,9615.0,Intermediate,1,,A,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,,BAO_0000218,N,,4527,Canis lupus familiaris,
6845,In vivo,,50588,9615.0,Intermediate,1,,A,,Tmax after peroral administration in dogs at 2.4 uM/kg,,,BAO_0000218,N,,17764,Canis lupus familiaris,
6846,In vivo,,50594,10090.0,Intermediate,1,,A,,In vivo Cmax in mice at dose of 100 mg/kg,,,BAO_0000218,N,,5969,Mus musculus,
6847,In vivo,,50594,10090.0,Intermediate,1,,A,,In vivo Cmax in mice at dose of 50 mg/kg,,,BAO_0000218,N,,5969,Mus musculus,
6848,In vivo,,50594,10090.0,Intermediate,1,,A,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,,BAO_0000218,N,,4573,Mus musculus,
6849,In vivo,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,BAO_0000218,N,,3277,Mus musculus,
6850,In vivo,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,,,BAO_0000218,N,,17734,Mus musculus,
6851,In vivo,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,Maximum concentration obtained in mouse plasma was determined,,,BAO_0000218,N,,3132,Mus musculus,
6852,In vivo,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,,,BAO_0000218,N,,3132,Mus musculus,
6853,In vivo,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,BAO_0000218,N,,6348,Mus musculus,
6854,In vivo,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,,,BAO_0000218,N,,17729,Mus musculus,
6855,In vivo,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,,,BAO_0000218,N,,17729,Mus musculus,
6856,In vivo,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,,,BAO_0000218,N,,17729,Mus musculus,
6857,In vivo,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,,,BAO_0000218,N,,17728,Mus musculus,
6858,In vivo,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,,,BAO_0000218,N,,17728,Mus musculus,
6859,In vivo,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,,,BAO_0000218,N,,17728,Mus musculus,
6860,In vivo,,50594,10090.0,Intermediate,1,,A,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,,BAO_0000218,N,,4066,Mus musculus,
6861,In vivo,,50594,10090.0,Intermediate,1,,A,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,,BAO_0000218,N,,6178,Mus musculus,
6862,In vivo,,50594,10090.0,Intermediate,1,,A,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,,BAO_0000218,N,,6178,Mus musculus,
6863,In vivo,,50594,10090.0,Intermediate,1,,A,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,,BAO_0000218,N,,3760,Mus musculus,
6864,In vivo,,50594,10090.0,Intermediate,1,,A,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,,BAO_0000218,N,,3760,Mus musculus,
6865,In vivo,,50594,10090.0,Intermediate,1,,A,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,,BAO_0000218,N,,3760,Mus musculus,
6866,In vivo,,50594,10090.0,Intermediate,1,,A,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,,BAO_0000218,N,,3760,Mus musculus,
6868,In vivo,,50594,10090.0,Intermediate,1,,A,,Cmax in male mice after 2 mg/kg oral dose,,,BAO_0000218,N,,5961,Mus musculus,
6869,In vivo,,50594,10090.0,Intermediate,1,,A,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,,BAO_0000218,N,,6137,Mus musculus,
6870,In vivo,,50594,10090.0,Intermediate,1,,A,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,,BAO_0000218,N,,3802,Mus musculus,
6871,,,50594,10090.0,Intermediate,1,,A,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,,BAO_0000218,N,,3535,Mus musculus,
6872,,,50594,10090.0,Intermediate,1,,A,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,,BAO_0000218,N,,3535,Mus musculus,
6873,,,50594,10090.0,Intermediate,1,,A,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,,BAO_0000218,N,,3535,Mus musculus,
6874,,,50594,10090.0,Intermediate,1,,A,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,,BAO_0000218,N,,3535,Mus musculus,
6875,,,50594,10090.0,Intermediate,1,,A,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,,BAO_0000218,N,,3535,Mus musculus,
6876,,,50594,10090.0,Intermediate,1,,A,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,,BAO_0000218,N,,3535,Mus musculus,
6877,,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,Maximum concentration in plasma upon oral administration in mouse,,,BAO_0000218,N,,2862,Mus musculus,
6878,,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,Maximum plasma concentration was evaluated in mice after oral administration,,,BAO_0000218,N,,2675,Mus musculus,
6879,In vivo,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,,,BAO_0000218,N,,2675,Mus musculus,
6880,,,50594,10090.0,Intermediate,1,,A,,Dose at which the compound induced fecal excretion in mice,,,BAO_0000218,N,,5399,Mus musculus,
6893,,,80013,10116.0,Expert,1,,F,164.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,,BAO_0000219,N,,11819,Rattus norvegicus,A10
6894,,,80013,10116.0,Expert,1,,F,164.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,,BAO_0000219,N,,11819,Rattus norvegicus,A10
6895,,,80013,10116.0,Expert,1,,F,164.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,,BAO_0000219,N,,11819,Rattus norvegicus,A10
6896,,,80013,10116.0,Expert,1,,F,164.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,,BAO_0000219,N,,11819,Rattus norvegicus,A10
6897,,,80013,10116.0,Intermediate,1,,F,164.0,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,,BAO_0000219,N,,16361,Rattus norvegicus,A10
6898,,,80655,9606.0,Intermediate,1,,F,393.0,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,,BAO_0000219,N,,2288,Homo sapiens,A121
6899,,,80655,9606.0,Intermediate,1,,F,393.0,Anticancer activity against human ovarian carcinoma A121 cells,,,BAO_0000219,N,,10404,Homo sapiens,A121
6900,,,80655,9606.0,Intermediate,1,,F,393.0,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,,BAO_0000219,N,,14790,Homo sapiens,A121
6901,,,80655,9606.0,Intermediate,1,,F,393.0,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,,BAO_0000219,N,,14790,Homo sapiens,A121
6902,,,80655,9606.0,Expert,1,,F,393.0,Growth inhibition of human ovarian carcinoma (A121) cell line,,,BAO_0000219,N,,14253,Homo sapiens,A121
6903,,,80655,9606.0,Expert,1,,F,393.0,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,,BAO_0000219,N,,13617,Homo sapiens,A121
6904,,,80655,9606.0,Intermediate,1,,F,393.0,Cytotoxicity against human A121 ovarian cells,,,BAO_0000219,N,,1003,Homo sapiens,A121
6905,,,80655,9606.0,Intermediate,1,,F,393.0,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,,BAO_0000219,N,,830,Homo sapiens,A121
6906,,,80655,9606.0,Intermediate,1,,F,393.0,In vitro cytotoxicity against human ovarian carcinoma A21,,,BAO_0000219,N,,12307,Homo sapiens,A121
6907,,,80655,9606.0,Intermediate,1,,F,393.0,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,,BAO_0000219,N,,14254,Homo sapiens,A121
6908,,,80655,9606.0,Intermediate,1,,F,393.0,Inhibitory activity of compound against human A121 ovarian cell line.,,,BAO_0000219,N,,13370,Homo sapiens,A121
6909,,,80655,9606.0,Intermediate,1,,F,393.0,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,,BAO_0000219,N,,14790,Homo sapiens,A121
6910,,,80655,9606.0,Intermediate,1,,F,393.0,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,,BAO_0000219,N,,3614,Homo sapiens,A121
6911,,,80012,9606.0,Intermediate,1,,F,622.0,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,,BAO_0000219,N,,2664,Homo sapiens,A 172
6912,,,80012,9606.0,Expert,1,,F,622.0,In vitro cytotoxicity against A172 human tumor cell lines.,,,BAO_0000219,N,,2037,Homo sapiens,A 172
6913,,,80012,9606.0,Intermediate,1,,F,622.0,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,,BAO_0000219,N,,14539,Homo sapiens,A 172
6914,,,80012,9606.0,Intermediate,1,,F,622.0,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,,BAO_0000219,N,,2836,Homo sapiens,A 172
6915,,,80012,9606.0,Intermediate,1,,F,622.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,,BAO_0000219,N,,10708,Homo sapiens,A 172
6916,,,104729,9615.0,Autocuration,1,,B,,Association constant against A2 adenosine receptor,,,BAO_0000224,H,,8975,Canis lupus familiaris,
6917,,,80656,,Intermediate,1,,F,1085.0,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,,BAO_0000219,N,,7645,fish,A2
6918,,,104713,10116.0,Autocuration,1,,B,,Ratio of Ki for adenosine A2 and A1 receptor binding,,,BAO_0000224,D,,11377,Rattus norvegicus,
6919,,,80014,9606.0,Expert,1,,F,623.0,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,,BAO_0000219,N,,13528,Homo sapiens,A204
6920,,,80014,9606.0,Expert,1,,F,623.0,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,,BAO_0000219,N,,10160,Homo sapiens,A204
6921,,,80015,9606.0,Intermediate,1,,F,404.0,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,,BAO_0000219,N,,15144,Homo sapiens,A2058
6922,,,80657,9606.0,Intermediate,1,,F,973.0,Growth inhibition against Human squamous cell line(A 253),,,BAO_0000219,N,,13160,Homo sapiens,A253 cell line
6923,,,80657,9606.0,Intermediate,1,,F,973.0,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,,BAO_0000219,N,,12898,Homo sapiens,A253 cell line
6924,,,80657,9606.0,Intermediate,1,,F,973.0,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,,BAO_0000219,N,,13069,Homo sapiens,A253 cell line
6925,,,80657,9606.0,Intermediate,1,,F,973.0,Growth inhibition of A253 cell lines.,,,BAO_0000219,N,,15984,Homo sapiens,A253 cell line
6926,,,80657,9606.0,Intermediate,1,,F,973.0,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,,BAO_0000219,N,,15564,Homo sapiens,A253 cell line
6927,,,80657,9606.0,Intermediate,1,,F,973.0,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,,BAO_0000219,N,,15564,Homo sapiens,A253 cell line
6928,,,80657,9606.0,Intermediate,1,,F,973.0,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,,BAO_0000219,N,,15564,Homo sapiens,A253 cell line
6929,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,,BAO_0000219,N,,4720,Homo sapiens,A2780
6930,,,81034,9606.0,Intermediate,1,,F,478.0,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,,BAO_0000219,N,,16112,Homo sapiens,A2780
6931,,,81034,9606.0,Expert,1,,F,478.0,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,,BAO_0000219,N,,16597,Homo sapiens,A2780
6932,,,81034,9606.0,Intermediate,1,,F,478.0,Cytotoxicity against human cancer cell lines A2780 (ovarian),,,BAO_0000219,N,,16378,Homo sapiens,A2780
6933,,,81034,9606.0,Expert,1,,F,478.0,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,,BAO_0000219,N,,16085,Homo sapiens,A2780
6934,,,81034,9606.0,Intermediate,1,,F,478.0,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,,BAO_0000219,N,,16317,Homo sapiens,A2780
6935,,,81034,9606.0,Intermediate,1,,F,478.0,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,,BAO_0000219,N,,15748,Homo sapiens,A2780
6936,,,81034,9606.0,Expert,1,,F,478.0,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,,BAO_0000219,N,,16597,Homo sapiens,A2780
6937,,,81034,9606.0,Expert,1,,F,478.0,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,,BAO_0000219,N,,16597,Homo sapiens,A2780
6938,,,81034,9606.0,Expert,1,,F,478.0,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,,BAO_0000219,N,,16597,Homo sapiens,A2780
6939,,,81034,9606.0,Intermediate,1,,F,478.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,,BAO_0000219,N,,15608,Homo sapiens,A2780
6940,,,81034,9606.0,Intermediate,1,,F,478.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,,BAO_0000219,N,,15608,Homo sapiens,A2780
6941,,,81034,9606.0,Intermediate,1,,F,478.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,,BAO_0000219,N,,15608,Homo sapiens,A2780
6942,,,22224,10029.0,Autocuration,1,,F,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,,BAO_0000019,U,,15296,Cricetulus griseus,
6943,,,22224,10029.0,Autocuration,1,,A,185.0,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,,BAO_0000219,U,,10251,Cricetulus griseus,CHO-AA8
6944,,,22224,10029.0,Autocuration,1,,F,185.0,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,,BAO_0000219,U,,10251,Cricetulus griseus,CHO-AA8
6945,,,22224,10029.0,Autocuration,1,,F,185.0,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,,BAO_0000219,U,,10251,Cricetulus griseus,CHO-AA8
6946,,,22224,10029.0,Autocuration,1,,F,185.0,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,,BAO_0000219,U,,10251,Cricetulus griseus,CHO-AA8
6947,,,22224,10029.0,Autocuration,1,,F,,Growth inhibition against CHO-derived cell line AA8,,,BAO_0000019,U,,11858,Cricetulus griseus,
6948,,,22224,10029.0,Autocuration,1,,F,185.0,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,,BAO_0000219,U,,11858,Cricetulus griseus,CHO-AA8
6949,,,80089,36483.0,Expert,1,,F,185.0,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,,BAO_0000219,N,,11616,hampster,CHO-AA8
6950,,,80089,10029.0,Expert,1,,F,185.0,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,,BAO_0000219,N,,11616,Cricetulus griseus,CHO-AA8
6951,,,22224,10029.0,Autocuration,1,,F,185.0,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,,BAO_0000219,U,,10518,Cricetulus griseus,CHO-AA8
6952,,,22224,10029.0,Autocuration,1,,F,185.0,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,,BAO_0000219,U,,11396,Cricetulus griseus,CHO-AA8
6953,,,22224,10029.0,Autocuration,1,,F,185.0,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,,BAO_0000219,U,,10518,Cricetulus griseus,CHO-AA8
6954,,,80089,10029.0,Expert,1,,F,185.0,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,,BAO_0000219,N,,11616,Cricetulus griseus,CHO-AA8
6955,,,12675,,Autocuration,1,,F,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,,BAO_0000019,H,,14837,,
6956,,,12675,,Autocuration,1,,F,,Number of binding sites (n) of isolated serum protein AAG,,,BAO_0000019,H,,14837,,
6957,,,22222,,Intermediate,1,,B,,Association constant for binding to AATT duplex,,,BAO_0000225,M,,16037,,
6958,,,100090,9606.0,Expert,1,,F,416.0,Inhibition of ABAE human fibroblast cell proliferation,,,BAO_0000219,N,,16597,Homo sapiens,ABAE
6959,,,80668,10090.0,Intermediate,1,,F,1064.0,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,,BAO_0000218,N,,8831,Mus musculus,AC755
6960,,,102444,9986.0,Expert,1,,F,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,,BAO_0000218,D,,13419,Oryctolagus cuniculus,
6961,In vivo,,102444,9986.0,Expert,1,,F,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,,BAO_0000218,D,,13419,Oryctolagus cuniculus,
6962,,,69,,Autocuration,1,,B,,Inhibitory activity against angiotensin-converting enzyme (ACE).,,,BAO_0000357,H,,15778,,
6963,,,69,,Autocuration,1,,B,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,,BAO_0000357,H,,15778,,
6964,,,80669,9606.0,Intermediate,1,,F,978.0,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,,BAO_0000219,N,,12988,Homo sapiens,ACH-2 cell line
6965,,,80669,9606.0,Intermediate,1,,F,978.0,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,,BAO_0000219,N,,12988,Homo sapiens,ACH-2 cell line
6966,,,22224,11676.0,Autocuration,1,,F,998.0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,,BAO_0000219,U,,12988,Human immunodeficiency virus 1,T cell line
6967,,,22224,11676.0,Autocuration,1,,F,998.0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,,BAO_0000219,U,,12988,Human immunodeficiency virus 1,T cell line
6968,,,22224,11676.0,Autocuration,1,,F,998.0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,,BAO_0000219,U,,12988,Human immunodeficiency virus 1,T cell line
6969,,,80025,9606.0,Intermediate,1,,F,626.0,Inhibition of growth of renal cancer ACHN cell line,,,BAO_0000219,N,,11843,Homo sapiens,ACHN
6970,,,80025,9606.0,Intermediate,1,,F,626.0,Inhibition of growth of ACHN renal cancer cell line,,,BAO_0000219,N,,16939,Homo sapiens,ACHN
6971,,,80025,9606.0,Intermediate,1,,F,626.0,Inhibitory concentration required against ACHN renal cancer cell line,,,BAO_0000219,N,,4782,Homo sapiens,ACHN
6972,,,80025,9606.0,Expert,1,,F,626.0,Concentration required to inhibit growth of human renal (ACHN) cell line,,,BAO_0000219,N,,6310,Homo sapiens,ACHN
6973,,,80025,9606.0,Intermediate,1,,F,626.0,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,,BAO_0000219,N,,6310,Homo sapiens,ACHN
6974,,,80025,9606.0,Intermediate,1,,F,626.0,Cytotoxic activity against ACHN Renal cancer cell line,,,BAO_0000219,N,,12858,Homo sapiens,ACHN
6975,,,80025,9606.0,Intermediate,1,,F,626.0,Cytotoxicity evaluation against ACHN renal cancer cells,,,BAO_0000219,N,,17380,Homo sapiens,ACHN
6976,,,80025,9606.0,Intermediate,1,,F,626.0,In vitro antitumor activity against human renal ACHN cell line,,,BAO_0000219,N,,5858,Homo sapiens,ACHN
6977,,,80025,9606.0,Intermediate,1,,F,626.0,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,,BAO_0000219,N,,3838,Homo sapiens,ACHN
6978,,,80025,9606.0,Intermediate,1,,F,626.0,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,,BAO_0000219,N,,3838,Homo sapiens,ACHN
6979,,,80025,9606.0,Intermediate,1,,F,626.0,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,,BAO_0000219,N,,5406,Homo sapiens,ACHN
6980,,,80025,9606.0,Intermediate,1,,F,626.0,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,,BAO_0000219,N,,4071,Homo sapiens,ACHN
6981,,,80025,9606.0,Expert,1,,F,626.0,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,,BAO_0000219,N,,4071,Homo sapiens,ACHN
6982,,,80025,9606.0,Intermediate,1,,F,626.0,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,,BAO_0000219,N,,4071,Homo sapiens,ACHN
6983,,,80025,9606.0,Intermediate,1,,F,626.0,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,,BAO_0000219,N,,15002,Homo sapiens,ACHN
6984,,,80025,9606.0,Intermediate,1,,F,626.0,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,,BAO_0000219,N,,14769,Homo sapiens,ACHN
6985,,,80025,9606.0,Intermediate,1,,F,626.0,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,,BAO_0000219,N,,13958,Homo sapiens,ACHN
6986,,,80025,9606.0,Intermediate,1,,F,626.0,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,,BAO_0000219,N,,1665,Homo sapiens,ACHN
6987,,,80025,9606.0,Intermediate,1,,F,626.0,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,,BAO_0000219,N,,15354,Homo sapiens,ACHN
6988,,,80025,9606.0,Intermediate,1,,F,626.0,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,,BAO_0000219,N,,15354,Homo sapiens,ACHN
6989,,,80025,9606.0,Intermediate,1,,F,626.0,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,,BAO_0000219,N,,13978,Homo sapiens,ACHN
6990,,,80025,9606.0,Intermediate,1,,F,626.0,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,,BAO_0000219,N,,6798,Homo sapiens,ACHN
6991,In vivo,,50588,9615.0,Intermediate,1,,A,,Tmax value after administration of 4 mg/Kg oral dose in dog,,,BAO_0000218,N,,2959,Canis lupus familiaris,
6992,,,50588,9615.0,Intermediate,1,,A,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,,BAO_0000218,N,,9932,Canis lupus familiaris,
6993,,,50588,9615.0,Intermediate,1,,A,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,,BAO_0000218,N,,5546,Canis lupus familiaris,
6994,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume distribution after 15 mg/kg iv dose in Dogs,,,BAO_0000218,N,,16907,Canis lupus familiaris,
6995,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume distribution after 30 mg/kg po dose in Dogs,,,BAO_0000218,N,,16907,Canis lupus familiaris,
6996,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,,BAO_0000218,N,,4257,Canis lupus familiaris,
6997,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,,BAO_0000218,N,,4305,Canis lupus familiaris,
6998,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume of distribution was evaluated in dog,,,BAO_0000218,N,,5472,Canis lupus familiaris,
6999,In vivo,,50588,9615.0,Intermediate,1,,A,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,,BAO_0000218,N,,6062,Canis lupus familiaris,
7000,,,50588,9615.0,Expert,1,,A,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,,BAO_0000218,N,,3598,Canis lupus familiaris,
7001,In vivo,,50588,9615.0,Intermediate,1,,A,,The compound was tested for volume of distribution in dog,,,BAO_0000218,N,,12500,Canis lupus familiaris,
7002,In vivo,,50588,9615.0,Intermediate,1,,A,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,,BAO_0000218,N,,12500,Canis lupus familiaris,
7003,In vivo,,50588,9615.0,Intermediate,1,,A,,Vd (1 mg/kg) was determined in dog (in vivo),,,BAO_0000218,N,,6227,Canis lupus familiaris,
7004,In vivo,,50588,9615.0,Intermediate,1,,A,,Vd in dog,,,BAO_0000218,N,,6227,Canis lupus familiaris,
7005,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume distribution was determined,,,BAO_0000218,N,,4219,Canis lupus familiaris,
7006,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume of distribution in dog,,,BAO_0000218,N,,1696,Canis lupus familiaris,
7007,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume of distribution by as 4 fold increase by iv administration in dogs,,,BAO_0000218,N,,5542,Canis lupus familiaris,
7008,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,,BAO_0000218,N,,5199,Canis lupus familiaris,
7009,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,BAO_0000218,N,,6348,Canis lupus familiaris,
7010,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume distribution at the dose of 2 mg/kg in dog,,,BAO_0000218,N,,4727,Canis lupus familiaris,
7011,In vivo,,50588,9615.0,Intermediate,1,,A,,Steady state volume of distribution was determined,,,BAO_0000218,N,,16367,Canis lupus familiaris,
7012,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,,BAO_0000218,N,,2652,Canis lupus familiaris,
7013,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,,BAO_0000218,N,,16452,Canis lupus familiaris,
7014,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,,BAO_0000218,N,,16452,Canis lupus familiaris,
7015,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog (dose 1 mg/kg i.v.),,,BAO_0000218,N,,16452,Canis lupus familiaris,
7016,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,,BAO_0000218,N,,5334,Canis lupus familiaris,
7017,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic property (vdss) was measured in dog,,,BAO_0000218,N,,4239,Canis lupus familiaris,
7018,In vivo,,50588,9615.0,Intermediate,1,,A,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,,BAO_0000218,N,,4709,Canis lupus familiaris,
7019,In vivo,,50588,9615.0,Intermediate,1,,A,,Vdss was determined after iv 0.1 mg/kg administration in dog,,,BAO_0000218,N,,5600,Canis lupus familiaris,
7020,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume displacement was calculated in dog,,,BAO_0000218,N,,6057,Canis lupus familiaris,
7021,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,,BAO_0000218,N,,5654,Canis lupus familiaris,
7022,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume distribution constant was determined,,,BAO_0000218,N,,5505,Canis lupus familiaris,
7023,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume distribution at a dose of 1 uM/kg in dog was determined,,,BAO_0000218,N,,4527,Canis lupus familiaris,
7024,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,,BAO_0000218,N,,4521,Canis lupus familiaris,
7025,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,BAO_0000218,N,,4521,Canis lupus familiaris,
7026,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume distribution (Vdss) was measured in dog,,,BAO_0000218,N,,15660,Canis lupus familiaris,
7027,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume distribution (Vdss) was measured in dog,,,BAO_0000218,N,,15660,Canis lupus familiaris,
7028,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,BAO_0000218,N,,6679,Canis lupus familiaris,
7029,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume of distribution in steady state was determined in dog,,,BAO_0000218,N,,5145,Canis lupus familiaris,
7030,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume of distribution of compound was determined in dog,,,BAO_0000218,N,,6821,Canis lupus familiaris,
7031,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,,BAO_0000218,N,,4137,Canis lupus familiaris,
7032,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,,BAO_0000218,N,,5334,Canis lupus familiaris,
7033,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume of distribution (Vdss) was measured in dog,,,BAO_0000218,N,,15660,Canis lupus familiaris,
7034,In vivo,,50588,9615.0,Intermediate,1,,A,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,BAO_0000218,N,,6642,Canis lupus familiaris,
7035,In vivo,,50588,9615.0,Intermediate,1,,A,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,BAO_0000218,N,,6641,Canis lupus familiaris,
7036,In vivo,,50588,9615.0,Intermediate,1,,A,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,BAO_0000218,N,,6642,Canis lupus familiaris,
7037,,,50588,9615.0,Intermediate,1,,A,,Maximum rate of depolarization of the upstroke of the action potential,,,BAO_0000218,N,,11659,Canis lupus familiaris,
7038,In vivo,,50588,9615.0,Intermediate,1,,A,,Steady state volume distribution in dog,,,BAO_0000218,N,,6448,Canis lupus familiaris,
7039,In vivo,,50588,9615.0,Intermediate,1,,A,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,,BAO_0000218,N,,5474,Canis lupus familiaris,
7040,In vivo,,50588,9615.0,Intermediate,1,,A,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,,BAO_0000218,N,,1466,Canis lupus familiaris,
7041,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,,BAO_0000218,N,,6535,Canis lupus familiaris,
7042,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume distribution in dog after administration of 1 mg/kg iv,,,BAO_0000218,N,,6535,Canis lupus familiaris,
7043,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,,BAO_0000218,N,,17764,Canis lupus familiaris,
7044,In vivo,,50588,9615.0,Intermediate,1,,A,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,,BAO_0000218,N,,6215,Canis lupus familiaris,
7045,In vivo,,50588,9615.0,Intermediate,1,,A,,Vss on i.v. administration of 2 mg/kg was measured in dog,,,BAO_0000218,N,,6505,Canis lupus familiaris,
7046,,,50588,9615.0,Intermediate,1,,A,,Vss was determined,,,BAO_0000218,N,,3639,Canis lupus familiaris,
7047,,,50588,9615.0,Intermediate,1,,A,,Vss in dog,,,BAO_0000218,N,,3639,Canis lupus familiaris,
7048,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,,BAO_0000218,N,,6062,Canis lupus familiaris,
7049,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume distribution in dogs,,,BAO_0000218,N,,4942,Canis lupus familiaris,
7050,In vivo,,50588,9615.0,Intermediate,1,,A,,Volume of distribution in dog,,,BAO_0000218,N,,17796,Canis lupus familiaris,
7051,In vivo,,50588,9615.0,Intermediate,1,,A,,Tested for the oral bioavailability in dog,,,BAO_0000218,N,,4883,Canis lupus familiaris,
7060,In vivo,,50594,10090.0,Intermediate,1,,A,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,,BAO_0000218,N,,17837,Mus musculus,
7061,In vivo,,50594,10090.0,Intermediate,1,,A,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,,BAO_0000218,N,,17729,Mus musculus,
7062,In vivo,,50594,10090.0,Intermediate,1,,A,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,,BAO_0000218,N,,17729,Mus musculus,
7063,In vivo,,50594,10090.0,Intermediate,1,,A,,Bioavailability was measured in mouse,,,BAO_0000218,N,,4239,Mus musculus,
7064,In vivo,,50594,10090.0,Intermediate,1,,A,,Bioavailability in mouse,,,BAO_0000218,N,,17592,Mus musculus,
7065,In vivo,,50594,10090.0,Intermediate,1,,A,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,BAO_0000218,N,,6348,Mus musculus,
7066,In vivo,,50594,10090.0,Intermediate,1,,A,,Bioavailability in mouse,,,BAO_0000218,N,,2801,Mus musculus,
7067,In vivo,,50594,10090.0,Intermediate,1,,A,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,,BAO_0000218,N,,2801,Mus musculus,
7068,In vivo,,50594,10090.0,Intermediate,1,,A,,Oral bioavailability in mouse,,,BAO_0000218,N,,17718,Mus musculus,
7069,In vivo,,50594,10090.0,Intermediate,1,,A,,Oral availability at 50 mg/kg po in male mice,,,BAO_0000218,N,,5727,Mus musculus,
7070,In vivo,,50594,10090.0,Intermediate,1,,A,,Oral bioavailability in mouse (dose 10 mg/kg),,,BAO_0000218,N,,5302,Mus musculus,
7071,In vivo,,50594,10090.0,Expert,1,,A,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,,BAO_0000218,N,,3598,Mus musculus,
7072,In vivo,,50594,10090.0,Intermediate,1,,A,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,,BAO_0000218,N,,5961,Mus musculus,
7074,In vivo,,50594,10090.0,Intermediate,1,,A,,Oral bioavailability in mouse,,,BAO_0000218,N,,6091,Mus musculus,
7075,In vivo,,50594,10090.0,Intermediate,1,,A,,Oral bioavailability in vivo in mice;ND=Not determined,,,BAO_0000218,N,,6091,Mus musculus,
7076,In vivo,,50594,10090.0,Intermediate,1,,A,,Oral bioavailability in mouse at 10 mg/kg of the compound,,,BAO_0000218,N,,5711,Mus musculus,
7077,In vivo,,50594,10090.0,Intermediate,1,,A,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,,BAO_0000218,N,,17728,Mus musculus,
7078,In vivo,,50594,10090.0,Intermediate,1,,A,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,,BAO_0000218,N,,17728,Mus musculus,
7079,In vivo,,50594,10090.0,Intermediate,1,,A,,Tested for bioavailability of the compound,,,BAO_0000218,N,,3802,Mus musculus,
7080,In vivo,,50594,10090.0,Intermediate,1,,A,,Tested for half life at the dose of 10 mg/kg when administered intravenously,,,BAO_0000218,N,,3802,Mus musculus,
7081,,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,,BAO_0000218,N,,14029,Mus musculus,
7082,,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,The plasma half life of compound was determined on heparin prepared by human plasma. ,,,BAO_0000218,N,,14029,Mus musculus,
7083,,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,,BAO_0000218,N,,14029,Mus musculus,
7084,,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,,BAO_0000218,N,,14029,Mus musculus,
7085,,1969.0,50594,10090.0,Intermediate,1,Plasma,A,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,,BAO_0000218,N,,14029,Mus musculus,
7086,,,50594,10090.0,Intermediate,1,,F,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,,BAO_0000218,N,,17753,Mus musculus,
7087,,,50594,10090.0,Intermediate,1,,A,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,,BAO_0000218,N,,17753,Mus musculus,
7088,,,50594,10090.0,Intermediate,1,,A,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,,BAO_0000218,N,,17753,Mus musculus,
7089,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,BAO_0000218,N,,10107,Mus musculus,
7090,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,BAO_0000218,N,,10107,Mus musculus,
7091,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,BAO_0000218,N,,10107,Mus musculus,
7092,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,BAO_0000218,N,,10107,Mus musculus,
7093,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,BAO_0000218,N,,10107,Mus musculus,
7094,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,BAO_0000218,N,,10107,Mus musculus,
7095,In vivo,178.0,50594,10090.0,Intermediate,1,Blood,A,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,BAO_0000218,N,,10107,Mus musculus,
7096,In vivo,10000001.0,50594,10090.0,Intermediate,1,Bone,A,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,BAO_0000218,N,,10107,Mus musculus,
7097,In vivo,10000001.0,50594,10090.0,Intermediate,1,Bone,A,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,BAO_0000218,N,,10107,Mus musculus,
7098,,,81034,9606.0,Intermediate,1,,F,478.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,,BAO_0000219,N,,15608,Homo sapiens,A2780
7099,,,81034,9606.0,Expert,1,,F,478.0,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,,BAO_0000219,N,,3290,Homo sapiens,A2780
7100,,,81034,9606.0,Intermediate,1,,F,478.0,Compound was evaluated for cytotoxicity against A2780 cell line,,,BAO_0000219,N,,2859,Homo sapiens,A2780
7101,,,81034,9606.0,Expert,1,,F,478.0,Inhibition of A2780 cell clonogenic assay,,,BAO_0000219,N,,15688,Homo sapiens,A2780
7102,,,81034,9606.0,Expert,1,,F,478.0,Cytotoxic effect on ovarian cancer cell line (A2780),,,BAO_0000219,N,,5642,Homo sapiens,A2780
7103,,,81034,9606.0,Intermediate,1,,F,478.0,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,,BAO_0000219,N,,6633,Homo sapiens,A2780
7104,,,81034,9606.0,Intermediate,1,,F,478.0,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,,BAO_0000219,N,,3906,Homo sapiens,A2780
7105,,,81034,9606.0,Expert,1,,F,478.0,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,,BAO_0000219,N,,6788,Homo sapiens,A2780
7106,,,81034,9606.0,Expert,1,,F,478.0,Antiproliferative activity against human A2780 cells,,,BAO_0000219,N,,17582,Homo sapiens,A2780
7107,,,81034,9606.0,Expert,1,,F,478.0,Inhibition of human A2780 cell proliferation,,,BAO_0000219,N,,17764,Homo sapiens,A2780
7108,,,81034,9606.0,Expert,1,,F,478.0,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,,BAO_0000219,N,,17764,Homo sapiens,A2780
7109,,,81034,9606.0,Expert,1,,F,478.0,Inhibition of human A2780 cell proliferation (No data),,,BAO_0000219,N,,17764,Homo sapiens,A2780
7110,,,81034,9606.0,Intermediate,1,,F,478.0,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,,BAO_0000219,N,,2815,Homo sapiens,A2780
7111,,,81034,9606.0,Intermediate,1,,F,478.0,Compound was evaluated against human Ovarian carcinoma cell line A2780,,,BAO_0000219,N,,16930,Homo sapiens,A2780
7112,,,81034,9606.0,Expert,1,,F,478.0,Growth inhibition against A2780 wild-type ovarian cell lines,,,BAO_0000219,N,,17777,Homo sapiens,A2780
7113,,,81034,9606.0,Intermediate,1,,F,478.0,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,,BAO_0000219,N,,17777,Homo sapiens,A2780
7114,,,104766,9606.0,Autocuration,1,,F,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,,BAO_0000019,D,,16936,Homo sapiens,
7115,,,81034,9606.0,Intermediate,1,,F,478.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,,BAO_0000219,N,,13759,Homo sapiens,A2780
7116,,,81034,9606.0,Intermediate,1,,F,478.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,,BAO_0000219,N,,13759,Homo sapiens,A2780
7117,,,81034,9606.0,Intermediate,1,,F,478.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,,BAO_0000219,N,,13759,Homo sapiens,A2780
7118,,,81034,9606.0,Intermediate,1,,F,478.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,,BAO_0000219,N,,13759,Homo sapiens,A2780
7119,,,81034,9606.0,Intermediate,1,,F,478.0,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,,BAO_0000219,N,,15292,Homo sapiens,A2780
7120,,,81034,9606.0,Intermediate,1,,F,478.0,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,,BAO_0000219,N,,15292,Homo sapiens,A2780
7121,,,81034,9606.0,Expert,1,,F,478.0,In vitro inhibition of human ovarian cell line A2780,,,BAO_0000219,N,,15069,Homo sapiens,A2780
7122,,,81034,9606.0,Expert,1,,F,478.0,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,,BAO_0000219,N,,15069,Homo sapiens,A2780
7123,,,81034,9606.0,Intermediate,1,,F,478.0,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,,BAO_0000219,N,,14073,Homo sapiens,A2780
7124,,,81034,9606.0,Expert,1,,F,478.0,Concentration required to inhibit A2780-cell growth by 50%,,,BAO_0000219,N,,14553,Homo sapiens,A2780
7125,,,81034,9606.0,Expert,1,,F,478.0,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,,BAO_0000219,N,,13040,Homo sapiens,A2780
7126,,,81034,9606.0,Expert,1,,F,478.0,Cytotoxic effect on human ovarian (A2780) cancer cell line,,,BAO_0000219,N,,6891,Homo sapiens,A2780
7127,,,81034,9606.0,Intermediate,1,,F,478.0,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,,BAO_0000219,N,,15569,Homo sapiens,A2780
7128,,,81034,9606.0,Expert,1,,F,478.0,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,,BAO_0000219,N,,14190,Homo sapiens,A2780
7129,,,81034,9606.0,Expert,1,,F,478.0,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,,BAO_0000219,N,,15014,Homo sapiens,A2780
7130,,,81034,9606.0,Intermediate,1,,F,478.0,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,,BAO_0000219,N,,15014,Homo sapiens,A2780
7131,,,81034,9606.0,Intermediate,1,,F,478.0,Cytotoxicity against human ovarian carcinoma A2780 cell line,,,BAO_0000219,N,,17496,Homo sapiens,A2780
7132,,,81034,9606.0,Intermediate,1,,F,478.0,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,,BAO_0000219,N,,13617,Homo sapiens,A2780
7133,,,81034,9606.0,Intermediate,1,,F,478.0,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,,BAO_0000219,N,,13617,Homo sapiens,A2780
7134,,,81034,9606.0,Intermediate,1,,F,478.0,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,,BAO_0000219,N,,13617,Homo sapiens,A2780
7135,,,81034,9606.0,Intermediate,1,,F,478.0,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,,BAO_0000219,N,,13617,Homo sapiens,A2780
7136,,,81034,9606.0,Intermediate,1,,F,478.0,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,,BAO_0000219,N,,17672,Homo sapiens,A2780
7137,,,81034,9606.0,Intermediate,1,,F,478.0,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,,BAO_0000219,N,,4544,Homo sapiens,A2780
7138,,,81034,9606.0,Intermediate,1,,F,478.0,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,,BAO_0000219,N,,4544,Homo sapiens,A2780
7139,,,81034,9606.0,Intermediate,1,,F,478.0,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,,BAO_0000219,N,,16317,Homo sapiens,A2780
7140,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,,BAO_0000219,N,,15099,Homo sapiens,A2780
7141,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,,BAO_0000219,N,,13978,Homo sapiens,A2780
7142,,,81034,9606.0,Expert,1,,F,478.0,In vitro antitumor activity against A2780 cell line.,,,BAO_0000219,N,,12989,Homo sapiens,A2780
7143,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,,BAO_0000219,N,,5574,Homo sapiens,A2780
7144,,,81034,9606.0,Expert,1,,F,478.0,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,,BAO_0000219,N,,13528,Homo sapiens,A2780
7145,,,80025,9606.0,Intermediate,1,,F,626.0,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,,BAO_0000219,N,,12782,Homo sapiens,ACHN
7146,,,80025,9606.0,Intermediate,1,,F,626.0,The IC50 value was measured on ACHN cell line in renal tumor type.,,,BAO_0000219,N,,14255,Homo sapiens,ACHN
7147,,,80025,9606.0,Intermediate,1,,F,626.0,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,,BAO_0000219,N,,16364,Homo sapiens,ACHN
7148,,,80025,9606.0,Expert,1,,F,626.0,In vitro lethal concentration against most sensitive ACHN cell line,,,BAO_0000219,N,,17376,Homo sapiens,ACHN
7149,,,80025,9606.0,Intermediate,1,,F,626.0,Tested for cytotoxic activity against renal cancer ACHN cell line,,,BAO_0000219,N,,12016,Homo sapiens,ACHN
7150,,,80025,9606.0,Intermediate,1,,F,626.0,Compound tested for growth inhibition of renal cancer cell line ACHN,,,BAO_0000219,N,,6058,Homo sapiens,ACHN
7151,,,80025,9606.0,Intermediate,1,,F,626.0,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,,BAO_0000219,N,,17708,Homo sapiens,ACHN
7152,,,80025,9606.0,Intermediate,1,,F,626.0,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,,BAO_0000219,N,,15176,Homo sapiens,ACHN
7153,,,80025,9606.0,Intermediate,1,,F,626.0,In vitro anticancer activity against ACHN renal cancer cell line,,,BAO_0000219,N,,2806,Homo sapiens,ACHN
7154,,,80025,9606.0,Intermediate,1,,F,626.0,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,,BAO_0000219,N,,15300,Homo sapiens,ACHN
7155,,,80025,9606.0,Intermediate,1,,F,626.0,Percent selectivity was evaluated in renal ACHN cell lines,,,BAO_0000219,N,,16364,Homo sapiens,ACHN
7156,,,80025,9606.0,Intermediate,1,,F,626.0,In vitro inhibitory activity against renal ACHN cancer cell line,,,BAO_0000219,N,,13859,Homo sapiens,ACHN
7157,,,80025,9606.0,Intermediate,1,,F,626.0,Tested for cytotoxicity against ACHN cell lines in renal cancer,,,BAO_0000219,N,,11970,Homo sapiens,ACHN
7158,,,80025,9606.0,Intermediate,1,,F,626.0,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,,BAO_0000219,N,,2450,Homo sapiens,ACHN
7159,,,80025,9606.0,Intermediate,1,,F,626.0,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,,BAO_0000219,N,,12696,Homo sapiens,ACHN
7160,,,80025,9606.0,Intermediate,1,,F,626.0,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,,BAO_0000219,N,,12400,Homo sapiens,ACHN
7161,,,80025,9606.0,Expert,1,,F,626.0,Cytotoxic effect on renal cancer line ACHN,,,BAO_0000219,N,,12888,Homo sapiens,ACHN
7162,,,80025,9606.0,Intermediate,1,,F,626.0,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,,BAO_0000219,N,,3156,Homo sapiens,ACHN
7163,,,80025,9606.0,Intermediate,1,,F,626.0,In vitro inhibition of Renal Cancer ACHN cell lines,,,BAO_0000219,N,,3381,Homo sapiens,ACHN
7164,,,80025,9606.0,Intermediate,1,,F,626.0,Antitumor activity against human renal adenocarcinoma ACHN cells,,,BAO_0000219,N,,16747,Homo sapiens,ACHN
7165,,,80025,9606.0,Expert,1,,F,626.0,Antitumor activity against human renal adenocarcinoma ACHN cells.,,,BAO_0000219,N,,16748,Homo sapiens,ACHN
7166,,,80025,9606.0,Intermediate,1,,F,626.0,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,,BAO_0000219,N,,12062,Homo sapiens,ACHN
7167,,,80025,9606.0,Intermediate,1,,F,626.0,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,,BAO_0000219,N,,14769,Homo sapiens,ACHN
7168,,,80025,9606.0,Intermediate,1,,F,626.0,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,,BAO_0000219,N,,15895,Homo sapiens,ACHN
7169,,,80025,9606.0,Intermediate,1,,F,626.0,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,,BAO_0000219,N,,17376,Homo sapiens,ACHN
7170,,,80025,9606.0,Intermediate,1,,F,626.0,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,,BAO_0000219,N,,14882,Homo sapiens,ACHN
7171,,,80025,9606.0,Intermediate,1,,F,626.0,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,,BAO_0000219,N,,14882,Homo sapiens,ACHN
7172,,,80025,9606.0,Intermediate,1,,F,626.0,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,,BAO_0000219,N,,15661,Homo sapiens,ACHN
7173,,,22224,,Autocuration,1,,A,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,,BAO_0000019,U,,9680,,
7174,,,10647,,Autocuration,1,,F,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,,BAO_0000019,H,,14579,,
7175,,,50529,10358.0,Expert,1,,F,468.0,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,,BAO_0000218,N,,17290,Cytomegalovirus,HEL
7176,,,50529,10358.0,Intermediate,1,,F,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,,BAO_0000218,N,,17290,Cytomegalovirus,
7177,,,12159,,Autocuration,1,,B,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,,BAO_0000357,H,,15891,,
7178,,,12159,,Autocuration,1,,B,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,,BAO_0000357,H,,15890,,
7179,,,80670,9913.0,Intermediate,1,,F,979.0,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,,BAO_0000219,N,,3801,Bos taurus,ADDP cell line
7180,,,80671,10090.0,Intermediate,1,,F,980.0,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,,BAO_0000219,N,,9222,Mus musculus,ADJ/PC6
7181,,,80671,10090.0,Intermediate,1,,F,980.0,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,,BAO_0000219,N,,9222,Mus musculus,ADJ/PC6
7182,,,80671,10090.0,Intermediate,1,,F,980.0,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,,BAO_0000219,N,,7257,Mus musculus,ADJ/PC6
7183,,,80671,10090.0,Intermediate,1,,F,980.0,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,,BAO_0000219,N,,7257,Mus musculus,ADJ/PC6
7184,,,80671,10090.0,Intermediate,1,,A,980.0,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,,BAO_0000219,N,,7257,Mus musculus,ADJ/PC6
7185,,,80671,10090.0,Intermediate,1,,F,980.0,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,,BAO_0000219,N,,8084,Mus musculus,ADJ/PC6
7186,,,22224,10090.0,Autocuration,1,,F,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,,BAO_0000019,U,,14943,Mus musculus,
7187,,,22224,10090.0,Autocuration,1,,F,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,,BAO_0000019,U,,14943,Mus musculus,
7188,,,22224,10090.0,Autocuration,1,,F,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,,BAO_0000019,U,,14943,Mus musculus,
7189,In vivo,,22224,1423.0,Autocuration,1,,A,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,,BAO_0000218,U,,10524,Bacillus subtilis,
7190,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,AUC value in dog after IV administration at a dose of 5 mg/kg,,,BAO_0000218,N,,3546,Canis lupus familiaris,
7191,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,AUC value in dog after oral administration at a dose of 5 mg/kg,,,BAO_0000218,N,,3546,Canis lupus familiaris,
7192,In vivo,,50588,9615.0,Intermediate,1,,A,,Cmax value in dog after oral administration at a dose of 5 mg/kg,,,BAO_0000218,N,,3546,Canis lupus familiaris,
7193,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,,BAO_0000218,N,,3546,Canis lupus familiaris,
7194,In vivo,,50588,9615.0,Intermediate,1,,A,,Tmax value in dog after oral administration at a dose of 5 mg/kg,,,BAO_0000218,N,,3546,Canis lupus familiaris,
7195,In vivo,,50588,9615.0,Intermediate,1,,A,,Compound was evaluated for its clearance when administered intravenously in dog,,,BAO_0000218,N,,3184,Canis lupus familiaris,
7196,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,BAO_0000218,N,,16456,Canis lupus familiaris,
7197,In vivo,,50588,9615.0,Intermediate,1,,A,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,,BAO_0000218,N,,4809,Canis lupus familiaris,
7198,,,22229,,Intermediate,1,,P,,Calculated partition coefficient (clogP),,,BAO_0000100,U,,4219,,
7199,,,50588,9615.0,Intermediate,1,,A,,Half life in dog,,,BAO_0000218,N,,3748,Canis lupus familiaris,
7200,,,50588,9615.0,Intermediate,1,,A,,Time taken for EC90 was determined when tested in dog,,,BAO_0000218,N,,3132,Canis lupus familiaris,
7201,,,50588,9615.0,Intermediate,1,,A,,Half life (iv) was determined,,,BAO_0000218,N,,4219,Canis lupus familiaris,
7202,,2107.0,50588,9615.0,Intermediate,1,Liver,A,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,,BAO_0000218,N,,16907,Canis lupus familiaris,
7203,,,50588,9615.0,Intermediate,1,,A,,Area under the curve was calculated in dog after iv administration,,,BAO_0000218,N,,6057,Canis lupus familiaris,
7204,,,50588,9615.0,Intermediate,1,,A,,Area under the curve was calculated in dog after peroral administration,,,BAO_0000218,N,,6057,Canis lupus familiaris,
7205,,,50588,9615.0,Intermediate,1,,A,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,,BAO_0000218,N,,17853,Canis lupus familiaris,
7206,,,50588,9615.0,Intermediate,1,,A,,pKa was evaluated in dog,,,BAO_0000218,N,,3639,Canis lupus familiaris,
7207,,,50588,9615.0,Intermediate,1,,A,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,,BAO_0000218,N,,14541,Canis lupus familiaris,
7208,In vivo,,50588,9615.0,Intermediate,1,,A,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,BAO_0000218,N,,16456,Canis lupus familiaris,
7209,In vivo,,50588,9615.0,Intermediate,1,,A,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,BAO_0000218,N,,16456,Canis lupus familiaris,
7210,In vivo,,50588,9615.0,Intermediate,1,,A,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,,BAO_0000218,N,,2652,Canis lupus familiaris,
7211,,,50588,9615.0,Intermediate,1,,A,,Compound was evaluated for the half-life (t 1/2) in hours,,,BAO_0000218,N,,3624,Canis lupus familiaris,
7212,In vivo,178.0,50588,9615.0,Intermediate,1,Blood,A,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,BAO_0000218,N,,1337,Canis lupus familiaris,
7213,In vivo,178.0,50588,9615.0,Intermediate,1,Blood,A,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,BAO_0000218,N,,1337,Canis lupus familiaris,
7214,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life after intravenous administration of 1 mg/kg in dog,,,BAO_0000218,N,,4709,Canis lupus familiaris,
7215,,,50588,9615.0,Intermediate,1,,A,,Half life was measured in dog,,,BAO_0000218,N,,15660,Canis lupus familiaris,
7216,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life period in dog after 5 mg/kg dose,,,BAO_0000218,N,,5302,Canis lupus familiaris,
7217,,,50588,9615.0,Intermediate,1,,A,,Half life period was evaluated in dog; 4-4.8,,,BAO_0000218,N,,17791,Canis lupus familiaris,
7218,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,BAO_0000218,N,,6348,Canis lupus familiaris,
7219,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life was determined in dog after a3 mg/kg of iv dose,,,BAO_0000218,N,,4257,Canis lupus familiaris,
7220,,,50588,9615.0,Intermediate,1,,A,,Half-life was determined,,,BAO_0000218,N,,3771,Canis lupus familiaris,
7221,,,50588,9615.0,Intermediate,1,,A,,Half life in dogs,,,BAO_0000218,N,,6305,Canis lupus familiaris,
7222,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,,,BAO_0000218,N,,13501,Canis lupus familiaris,
7223,In vivo,,50588,9615.0,Intermediate,1,,A,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,,BAO_0000218,N,,17594,Canis lupus familiaris,
7224,In vivo,,50588,9615.0,Intermediate,1,,A,,Compound was evaluated for the half life period after iv administration in Beagle dog.,,,BAO_0000218,N,,3045,Canis lupus familiaris,
7225,In vivo,,50588,9615.0,Intermediate,1,,A,,Compound was evaluated for the half life period after oral administration in conscious dog.,,,BAO_0000218,N,,3043,Canis lupus familiaris,
7226,,,50588,9615.0,Intermediate,1,,A,,Compound was tested for half life in dog,,,BAO_0000218,N,,4839,Canis lupus familiaris,
7227,,,50588,9615.0,Intermediate,1,,A,,Compound was tested for its half life in dog,,,BAO_0000218,N,,4839,Canis lupus familiaris,
7228,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,BAO_0000218,N,,5802,Canis lupus familiaris,
7229,,,50588,9615.0,Intermediate,1,,A,,Half life of compound in dog was determined,,,BAO_0000218,N,,17839,Canis lupus familiaris,
7230,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life (iv) was determined,,,BAO_0000218,N,,4219,Canis lupus familiaris,
7231,,178.0,50588,9615.0,Intermediate,1,Blood,A,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,,BAO_0000218,N,,13966,Canis lupus familiaris,
7232,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,,BAO_0000218,N,,3994,Canis lupus familiaris,
7233,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,F,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,,BAO_0000218,N,,3994,Canis lupus familiaris,
7234,,,50588,9615.0,Intermediate,1,,A,,Half life in dog,,,BAO_0000218,N,,4453,Canis lupus familiaris,
7235,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Half life in dog plasma,,,BAO_0000218,N,,6535,Canis lupus familiaris,
7236,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Half life in dog plasma after administration of 0.25 mg/kg iv,,,BAO_0000218,N,,6535,Canis lupus familiaris,
7237,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Half life in dog plasma after administration of 1 mg/kg iv,,,BAO_0000218,N,,6535,Canis lupus familiaris,
7238,In vivo,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Half life in dog plasma was determined at dose 10 mg/kg,,,BAO_0000218,N,,3132,Canis lupus familiaris,
7239,,,50588,9615.0,Intermediate,1,,A,,Half life in dog was determined,,,BAO_0000218,N,,5374,Canis lupus familiaris,
7240,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,BAO_0000218,N,,5007,Canis lupus familiaris,
7241,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Half life upon exposure to human plasma,,,BAO_0000218,N,,16907,Canis lupus familiaris,
7242,,,50588,9615.0,Intermediate,1,,A,,Half life was calculated in dog,,,BAO_0000218,N,,6057,Canis lupus familiaris,
7243,,,50588,9615.0,Intermediate,1,,A,,Half life was determined,,,BAO_0000218,N,,5006,Canis lupus familiaris,
7244,,,50588,9615.0,Intermediate,1,,A,,Half life was determined,,,BAO_0000218,N,,5473,Canis lupus familiaris,
7245,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life by intravenous administration of 1.2 mg/kg in dog,,,BAO_0000218,N,,4368,Canis lupus familiaris,
7246,,,50588,9615.0,Intermediate,1,,A,,Half life in dog,,,BAO_0000218,N,,6448,Canis lupus familiaris,
7247,,,50588,9615.0,Intermediate,1,,A,,Half life in dog after intra venous administration of the compound,,,BAO_0000218,N,,4353,Canis lupus familiaris,
7248,,,50588,9615.0,Intermediate,1,,A,,Half life in dog after intra venous administration of the compound; ND means Not determined,,,BAO_0000218,N,,4353,Canis lupus familiaris,
7249,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life in dog after po administration of the compound,,,BAO_0000218,N,,4353,Canis lupus familiaris,
7250,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life in dog after po administration of the compound; ND means Not determined,,,BAO_0000218,N,,4353,Canis lupus familiaris,
7251,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life in dog at the single oral dose of 1 mg/kg,,,BAO_0000218,N,,6265,Canis lupus familiaris,
7252,,,50588,9615.0,Intermediate,1,,A,,Half life in dogs,,,BAO_0000218,N,,5006,Canis lupus familiaris,
7253,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,,BAO_0000218,N,,5356,Canis lupus familiaris,
7254,,,50588,9615.0,Intermediate,1,,A,,Half life in rat,,,BAO_0000218,N,,405,Canis lupus familiaris,
7255,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,BAO_0000218,N,,6642,Canis lupus familiaris,
7256,In vivo,10000001.0,50594,10090.0,Intermediate,1,Bone,A,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,BAO_0000218,N,,10107,Mus musculus,
7257,In vivo,10000001.0,50594,10090.0,Intermediate,1,Bone,A,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,BAO_0000218,N,,10107,Mus musculus,
7258,In vivo,10000001.0,50594,10090.0,Intermediate,1,Bone,A,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,BAO_0000218,N,,10107,Mus musculus,
7259,In vivo,10000001.0,50594,10090.0,Intermediate,1,Bone,A,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,BAO_0000218,N,,10107,Mus musculus,
7260,In vivo,10000001.0,50594,10090.0,Intermediate,1,Bone,A,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,BAO_0000218,N,,10107,Mus musculus,
7261,In vivo,10000004.0,50594,10090.0,Intermediate,1,Gut,A,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,BAO_0000218,N,,10107,Mus musculus,
7262,In vivo,10000004.0,50594,10090.0,Intermediate,1,Gut,A,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,BAO_0000218,N,,10107,Mus musculus,
7263,In vivo,10000004.0,50594,10090.0,Intermediate,1,Gut,A,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,BAO_0000218,N,,10107,Mus musculus,
7264,In vivo,10000004.0,50594,10090.0,Intermediate,1,Gut,A,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,BAO_0000218,N,,10107,Mus musculus,
7265,In vivo,10000004.0,50594,10090.0,Intermediate,1,Gut,A,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,BAO_0000218,N,,10107,Mus musculus,
7266,In vivo,10000004.0,50594,10090.0,Intermediate,1,Gut,A,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,BAO_0000218,N,,10107,Mus musculus,
7267,In vivo,10000004.0,50594,10090.0,Intermediate,1,Gut,A,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,BAO_0000218,N,,10107,Mus musculus,
7268,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,BAO_0000218,N,,10107,Mus musculus,
7269,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,BAO_0000218,N,,10107,Mus musculus,
7270,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,BAO_0000218,N,,10107,Mus musculus,
7271,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,BAO_0000218,N,,10107,Mus musculus,
7272,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,BAO_0000218,N,,10107,Mus musculus,
7273,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,BAO_0000218,N,,10107,Mus musculus,
7274,In vivo,948.0,50594,10090.0,Intermediate,1,Heart,A,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,BAO_0000218,N,,10107,Mus musculus,
7275,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,BAO_0000218,N,,10107,Mus musculus,
7276,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,BAO_0000218,N,,10107,Mus musculus,
7277,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,BAO_0000218,N,,10107,Mus musculus,
7278,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,BAO_0000218,N,,10107,Mus musculus,
7279,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,BAO_0000218,N,,10107,Mus musculus,
7280,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,BAO_0000218,N,,10107,Mus musculus,
7281,In vivo,2113.0,50594,10090.0,Intermediate,1,Kidney,A,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,BAO_0000218,N,,10107,Mus musculus,
7282,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,BAO_0000218,N,,10107,Mus musculus,
7283,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,BAO_0000218,N,,10107,Mus musculus,
7284,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,BAO_0000218,N,,10107,Mus musculus,
7285,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,BAO_0000218,N,,10107,Mus musculus,
7286,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,BAO_0000218,N,,10107,Mus musculus,
7287,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,BAO_0000218,N,,10107,Mus musculus,
7288,In vivo,2107.0,50594,10090.0,Intermediate,1,Liver,A,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,BAO_0000218,N,,10107,Mus musculus,
7289,In vivo,2048.0,50594,10090.0,Intermediate,1,Lung,A,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,BAO_0000218,N,,10107,Mus musculus,
7290,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro cytotoxicity against A2780 (human ovarian cancer),,,BAO_0000219,N,,5895,Homo sapiens,A2780
7291,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,,BAO_0000219,N,,6338,Homo sapiens,A2780
7292,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,,BAO_0000219,N,,15163,Homo sapiens,A2780
7293,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,,BAO_0000219,N,,15163,Homo sapiens,A2780
7294,,,81034,9606.0,Expert,1,,F,478.0,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,,BAO_0000219,N,,15000,Homo sapiens,A2780
7295,,,81034,9606.0,Expert,1,,F,478.0,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,,BAO_0000219,N,,15000,Homo sapiens,A2780
7296,,,81034,9606.0,Expert,1,,F,478.0,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,,BAO_0000219,N,,14729,Homo sapiens,A2780
7297,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro cytotoxicity against A2780 cell line,,,BAO_0000219,N,,17270,Homo sapiens,A2780
7298,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,,BAO_0000219,N,,5685,Homo sapiens,A2780
7299,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,,BAO_0000219,N,,3563,Homo sapiens,A2780
7300,,,81034,9606.0,Intermediate,1,,F,478.0,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,,BAO_0000218,N,,17753,Homo sapiens,A2780
7301,,,81034,9606.0,Intermediate,1,,F,478.0,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,,BAO_0000219,N,,16317,Homo sapiens,A2780
7302,,,81034,9606.0,Intermediate,1,,F,478.0,Inhibition of tubulin polymerization in analogy of ca.,,,BAO_0000219,N,,16936,Homo sapiens,A2780
7303,,,81034,9606.0,Intermediate,1,,F,478.0,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,,BAO_0000219,N,,3801,Homo sapiens,A2780
7304,,,81034,9606.0,Expert,1,,F,478.0,Cytotoxic effect in ovarian cancer cell line (A2780),,,BAO_0000219,N,,6181,Homo sapiens,A2780
7305,,,81034,9606.0,Intermediate,1,,F,478.0,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,,BAO_0000219,N,,5318,Homo sapiens,A2780
7306,,,81034,9606.0,Intermediate,1,,F,478.0,Tested for the cytotoxicity in A2780 ovarian cell line,,,BAO_0000219,N,,4840,Homo sapiens,A2780
7307,,,81034,9606.0,Intermediate,1,,F,478.0,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,,BAO_0000219,N,,15748,Homo sapiens,A2780
7308,,,81034,9606.0,Intermediate,1,,F,478.0,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,,BAO_0000219,N,,15748,Homo sapiens,A2780
7309,,,80017,,Intermediate,1,,F,481.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,,BAO_0000219,N,,15748,,A2780cisR
7310,,,80017,,Intermediate,1,,F,481.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,,BAO_0000219,N,,15748,,A2780cisR
7311,,,80017,,Intermediate,1,,F,481.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,,BAO_0000219,N,,15748,,A2780cisR
7312,,,80017,,Intermediate,1,,F,481.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,,BAO_0000219,N,,15748,,A2780cisR
7313,,,81034,9606.0,Intermediate,1,,F,478.0,In vivo log of cells killed after administration of compound in A2780 cell line,,,BAO_0000218,N,,17753,Homo sapiens,A2780
7314,In vivo,,81034,9606.0,Intermediate,1,,F,478.0,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,,,BAO_0000218,N,,17753,Homo sapiens,A2780
7315,,,81034,9606.0,Intermediate,1,,F,478.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,,BAO_0000219,N,,16936,Homo sapiens,A2780
7316,,,81034,9606.0,Intermediate,1,,F,478.0,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,,BAO_0000219,N,,16936,Homo sapiens,A2780
7317,,,81034,9606.0,Intermediate,1,,F,478.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,,BAO_0000219,N,,16936,Homo sapiens,A2780
7318,,,81034,9606.0,Intermediate,1,,F,478.0,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,,BAO_0000219,N,,16936,Homo sapiens,A2780
7319,,,81034,9606.0,Intermediate,1,,F,478.0,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,,BAO_0000218,N,,17528,Homo sapiens,A2780
7320,,,81034,9606.0,Intermediate,1,,F,478.0,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,,BAO_0000219,N,,6633,Homo sapiens,A2780
7321,,,81034,9606.0,Expert,1,,F,478.0,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,,BAO_0000219,N,,15000,Homo sapiens,A2780
7322,,,81034,9606.0,Expert,1,,F,478.0,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,,BAO_0000219,N,,17528,Homo sapiens,A2780
7323,,,81034,9606.0,Intermediate,1,,F,478.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,,BAO_0000219,N,,16936,Homo sapiens,A2780
7324,,,81034,9606.0,Intermediate,1,,F,478.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,,BAO_0000219,N,,16936,Homo sapiens,A2780
7325,,,81034,9606.0,Intermediate,1,,F,478.0,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,,BAO_0000219,N,,16936,Homo sapiens,A2780
7326,,,81034,9606.0,Intermediate,1,,F,478.0,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,,BAO_0000219,N,,16936,Homo sapiens,A2780
7327,,,81034,9606.0,Intermediate,1,,F,478.0,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,,BAO_0000219,N,,16936,Homo sapiens,A2780
7328,,,81034,9606.0,Expert,1,,F,478.0,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,,BAO_0000219,N,,16936,Homo sapiens,A2780
7329,,,81034,9606.0,Intermediate,1,,F,478.0,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,,BAO_0000219,N,,16936,Homo sapiens,A2780
7330,,,81034,9606.0,Intermediate,1,,F,478.0,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,,BAO_0000219,N,,16936,Homo sapiens,A2780
7331,,,81034,9606.0,Intermediate,1,,F,478.0,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,,BAO_0000219,N,,16936,Homo sapiens,A2780
7332,,,81034,10090.0,Intermediate,1,,F,478.0,In vitro antiproliferative activity against A2780 cell line,,,BAO_0000219,N,,17737,Mus musculus,A2780
7333,,,81034,10090.0,Expert,1,,F,478.0,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,,BAO_0000219,N,,17764,Mus musculus,A2780
7334,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,,BAO_0000219,N,,3830,Homo sapiens,A2780
7335,,,81034,9606.0,Intermediate,1,,F,478.0,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,,BAO_0000219,N,,3829,Homo sapiens,A2780
7336,,,50588,9615.0,Intermediate,1,,A,,Vc value in dog after IV administration at a dose of 5 mg/kg,,,BAO_0000218,N,,3546,Canis lupus familiaris,
7337,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life period in dog after IV administration at a dose of 5 mg/kg,,,BAO_0000218,N,,3546,Canis lupus familiaris,
7338,,,22224,9527.0,Autocuration,1,,A,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,,BAO_0000019,U,,5668,Cercopithecidae,
7339,,1969.0,22224,9527.0,Autocuration,1,Plasma,A,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,BAO_0000218,U,,3443,Cercopithecidae,
7340,,1969.0,22224,9527.0,Autocuration,1,Plasma,A,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,BAO_0000218,U,,3443,Cercopithecidae,
7341,In vivo,,22224,9541.0,Autocuration,1,,A,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,,BAO_0000218,U,,4256,Macaca fascicularis,
7342,In vivo,,22224,9541.0,Autocuration,1,,A,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,,BAO_0000218,U,,4256,Macaca fascicularis,
7343,In vivo,,22224,9541.0,Autocuration,1,,A,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,,BAO_0000218,U,,4256,Macaca fascicularis,
7344,In vivo,,22224,10116.0,Autocuration,1,,A,,Oral Bioavailability in rat,,,BAO_0000218,U,,4256,Rattus norvegicus,
7345,,,22224,9527.0,Autocuration,1,,A,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,BAO_0000218,U,,1916,Cercopithecidae,
7346,,,22224,9527.0,Autocuration,1,,A,,Area under curve value in monkey at a dose of 5 mg/kg,,,BAO_0000218,U,,5302,Cercopithecidae,
7347,,,22224,9527.0,Autocuration,1,,A,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,,BAO_0000218,U,,4257,Cercopithecidae,
7348,,,22224,9527.0,Autocuration,1,,A,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,,BAO_0000019,U,,5355,Cercopithecidae,
7349,,,22224,9527.0,Autocuration,1,,A,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,,BAO_0000019,U,,5355,Cercopithecidae,
7350,,,22224,9527.0,Autocuration,1,,A,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,,BAO_0000019,U,,5355,Cercopithecidae,
7351,,,22224,9527.0,Autocuration,1,,A,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,,BAO_0000218,U,,6078,Cercopithecidae,
7352,,,22224,9527.0,Autocuration,1,,A,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,,BAO_0000218,U,,6078,Cercopithecidae,
7353,,,22224,9527.0,Autocuration,1,,A,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,,BAO_0000218,U,,6062,Cercopithecidae,
7354,,,22224,9527.0,Autocuration,1,,A,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,BAO_0000218,U,,2661,Cercopithecidae,
7355,,,22224,9527.0,Autocuration,1,,A,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,BAO_0000019,U,,2661,Cercopithecidae,
7356,,,22224,9527.0,Autocuration,1,,A,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,,BAO_0000218,U,,5394,Cercopithecidae,
7357,,,22224,9527.0,Autocuration,1,,A,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,,BAO_0000218,U,,4397,Cercopithecidae,
7358,,,22224,9527.0,Autocuration,1,,A,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,,BAO_0000218,U,,17509,Cercopithecidae,
7359,,,22224,9527.0,Autocuration,1,,A,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,,BAO_0000218,U,,17509,Cercopithecidae,
7360,In vivo,,22224,9527.0,Autocuration,1,,A,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,,BAO_0000218,U,,6641,Cercopithecidae,
7361,,,22224,9527.0,Autocuration,1,,A,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,,BAO_0000218,U,,5355,Cercopithecidae,
7362,In vivo,,22224,9527.0,Autocuration,1,,A,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,BAO_0000218,U,,3443,Cercopithecidae,
7363,In vivo,,22224,9527.0,Autocuration,1,,A,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,BAO_0000218,U,,3443,Cercopithecidae,
7364,,,22224,9527.0,Autocuration,1,,A,,Binding towards monkey plasma protein at 10 uM,,,BAO_0000019,U,,17409,Cercopithecidae,
7365,,,22224,9527.0,Autocuration,1,,A,,Binding towards monkey plasma protein at 100 uM,,,BAO_0000019,U,,17409,Cercopithecidae,
7366,In vivo,,22224,9527.0,Autocuration,1,,A,,Apparent bioavailability in squirrel monkey was determined,,,BAO_0000218,U,,1052,Cercopithecidae,
7367,In vivo,,22224,9527.0,Autocuration,1,,A,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,,BAO_0000218,U,,13501,Cercopithecidae,
7368,In vivo,,22224,9443.0,Autocuration,1,,A,,Bioavailability in monkey (dose 2 mg/kg),,,BAO_0000218,U,,17509,monkey,
7369,In vivo,,22224,9527.0,Autocuration,1,,A,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,,BAO_0000218,U,,5394,Cercopithecidae,
7370,In vivo,,22224,9527.0,Autocuration,1,,A,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,BAO_0000218,U,,2661,Cercopithecidae,
7371,In vivo,,22224,9443.0,Autocuration,1,,A,,Bioavailability in monkey (i.d. dosing),,,BAO_0000218,U,,11219,monkey,
7372,In vivo,,22224,9527.0,Autocuration,1,,A,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,,BAO_0000218,U,,3045,Cercopithecidae,
7373,,,22224,9527.0,Autocuration,1,,A,,Clearance of the drug was measured in cynomolgus,,,BAO_0000019,U,,17796,Cercopithecidae,
7374,In vivo,,22224,9527.0,Autocuration,1,,A,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,,BAO_0000218,U,,1399,Cercopithecidae,
7375,In vivo,,22224,9527.0,Autocuration,1,,A,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,BAO_0000218,U,,2661,Cercopithecidae,
7376,In vivo,1969.0,22224,9544.0,Autocuration,1,Plasma,A,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,BAO_0000218,U,,5005,Macaca mulatta,
7377,In vivo,,22224,9527.0,Autocuration,1,,A,,Plasma clearance in rhesus monkey was determined,,,BAO_0000218,U,,17267,Cercopithecidae,
7378,In vivo,,22224,9527.0,Autocuration,1,,A,,Plasma clearance in monkey after administration of 1 mg/kg iv,,,BAO_0000218,U,,6535,Cercopithecidae,
7379,In vivo,,22224,9527.0,Autocuration,1,,A,,Plasma clearance in cynomolgus monkey,,,BAO_0000218,U,,5922,Cercopithecidae,
7380,In vivo,,22224,9527.0,Autocuration,1,,A,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,,BAO_0000218,U,,6221,Cercopithecidae,
7381,In vivo,,22224,9527.0,Autocuration,1,,A,,Plasma clearance after peroral administration at 10 mpk in Rhesus,,,BAO_0000218,U,,5668,Cercopithecidae,
7382,In vivo,,22224,9527.0,Autocuration,1,,A,,The total clearance was determined after intravenous administration in cynomolgus monkeys,,,BAO_0000218,U,,5355,Cercopithecidae,
7383,In vivo,,22224,9527.0,Autocuration,1,,A,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,,BAO_0000218,U,,5355,Cercopithecidae,
7384,In vivo,,22224,9527.0,Autocuration,1,,A,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,,BAO_0000218,U,,5355,Cercopithecidae,
7385,In vivo,,22224,9527.0,Autocuration,1,,A,,Tested for Clearance upon iv administration to african green monkey,,,BAO_0000218,U,,4578,Cercopithecidae,
7386,In vivo,,22224,9527.0,Autocuration,1,,A,,Clearance in monkey,,,BAO_0000218,U,,17592,Cercopithecidae,
7387,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,BAO_0000218,N,,6641,Canis lupus familiaris,
7388,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,BAO_0000218,N,,6642,Canis lupus familiaris,
7389,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life was evaluated after intravenous administration to dogs,,,BAO_0000218,N,,16367,Canis lupus familiaris,
7390,,,50588,9615.0,Intermediate,1,,A,,Half life was evaluated in dog,,,BAO_0000218,N,,5472,Canis lupus familiaris,
7391,,,50588,9615.0,Intermediate,1,,A,,Half life was evaluated in dog,,,BAO_0000218,N,,5474,Canis lupus familiaris,
7392,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,,BAO_0000218,N,,5654,Canis lupus familiaris,
7393,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,,BAO_0000218,N,,6227,Canis lupus familiaris,
7394,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life period after intravenous administration in dog,,,BAO_0000218,N,,6227,Canis lupus familiaris,
7395,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life period after oral administration (2.5 mg/kg) in dog was determined,,,BAO_0000218,N,,6221,Canis lupus familiaris,
7396,,,50588,9615.0,Intermediate,1,,A,,Half life period at a dose of 1 uM/kg in dog was determined,,,BAO_0000218,N,,4527,Canis lupus familiaris,
7397,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life period was determine after peroral administration at 10 mpk in dog,,,BAO_0000218,N,,5668,Canis lupus familiaris,
7398,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life period was determine after peroral administration at 5 mpk in dog,,,BAO_0000218,N,,5668,Canis lupus familiaris,
7399,,,50588,9615.0,Intermediate,1,,A,,Half life period was determined,,,BAO_0000218,N,,3854,Canis lupus familiaris,
7400,,,50588,9615.0,Intermediate,1,,A,,Half life period was determined,,,BAO_0000218,N,,5505,Canis lupus familiaris,
7401,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life period by iv administration in dog at a dose of 6 mg/kg,,,BAO_0000218,N,,6251,Canis lupus familiaris,
7402,,,50588,9615.0,Intermediate,1,,A,,Half life period was evaluated in dog,,,BAO_0000218,N,,1918,Canis lupus familiaris,
7403,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,,BAO_0000218,N,,5546,Canis lupus familiaris,
7404,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,,BAO_0000218,N,,4809,Canis lupus familiaris,
7405,In vivo,,50588,9615.0,Intermediate,1,,A,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,,BAO_0000218,N,,6215,Canis lupus familiaris,
7406,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,,BAO_0000218,N,,4527,Canis lupus familiaris,
7407,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life after oral dose of compound at 3 mg/kg in dogs,,,BAO_0000218,N,,17594,Canis lupus familiaris,
7408,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,,BAO_0000218,N,,17839,Canis lupus familiaris,
7409,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,,BAO_0000218,N,,17839,Canis lupus familiaris,
7410,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,,BAO_0000218,N,,17839,Canis lupus familiaris,
7411,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life of compound in dog following p.o. administration of 1 mg/kg,,,BAO_0000218,N,,17839,Canis lupus familiaris,
7412,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Half-life of compound in plasma of dog was determined,,,BAO_0000218,N,,5210,Canis lupus familiaris,
7413,,,50588,9615.0,Intermediate,1,,A,,Half-life of compound was determined in dogs,,,BAO_0000218,N,,5210,Canis lupus familiaris,
7414,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life after administration of 4 mg/Kg oral dose in dog,,,BAO_0000218,N,,2959,Canis lupus familiaris,
7415,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life after intravenous administration of 1 mg/kg/h in dog,,,BAO_0000218,N,,4137,Canis lupus familiaris,
7416,,,50588,9615.0,Intermediate,1,,A,,Half-life in Dog,,,BAO_0000218,N,,5064,Canis lupus familiaris,
7417,,,50588,9615.0,Intermediate,1,,A,,Half-life in Dog,,,BAO_0000218,N,,5147,Canis lupus familiaris,
7418,,,50588,9615.0,Intermediate,1,,A,,Half-life in dog,,,BAO_0000218,N,,5145,Canis lupus familiaris,
7419,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life in dog after oral administration at 1 mg/kg,,,BAO_0000218,N,,6123,Canis lupus familiaris,
7420,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,,BAO_0000218,N,,6123,Canis lupus familiaris,
7421,,,50588,9615.0,Intermediate,1,,A,,Half-life in dogs,,,BAO_0000218,N,,4333,Canis lupus familiaris,
7422,,,50588,9615.0,Intermediate,1,,A,,Half-life in dogs; ND indicates not determined,,,BAO_0000218,N,,4333,Canis lupus familiaris,
7423,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Half-life in plasma of dog,,,BAO_0000218,N,,12500,Canis lupus familiaris,
7424,,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,Half-life in plasma of dog at dose of 3-10 mgkg,,,BAO_0000218,N,,12500,Canis lupus familiaris,
7425,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,,BAO_0000218,N,,6005,Canis lupus familiaris,
7426,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life was measured in dog after an iv dose of 1 mg/kg,,,BAO_0000218,N,,6062,Canis lupus familiaris,
7427,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life was measured in dogs after an oral dose of 10 uM/kg,,,BAO_0000218,N,,17650,Canis lupus familiaris,
7428,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,,BAO_0000218,N,,5530,Canis lupus familiaris,
7429,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,,BAO_0000218,N,,5530,Canis lupus familiaris,
7430,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life of the compound after 0.3 mg/kg po administration in dog,,,BAO_0000218,N,,5600,Canis lupus familiaris,
7431,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,,BAO_0000218,N,,6039,Canis lupus familiaris,
7432,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,,BAO_0000218,N,,6039,Canis lupus familiaris,
7433,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,,BAO_0000218,N,,6039,Canis lupus familiaris,
7434,,,50588,9615.0,Intermediate,1,,A,,t1/2 in dog,,,BAO_0000218,N,,6227,Canis lupus familiaris,
7435,,,50588,9615.0,Intermediate,1,,A,,Half-life period measured in dogs,,,BAO_0000218,N,,14541,Canis lupus familiaris,
7436,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,,BAO_0000218,N,,4521,Canis lupus familiaris,
7437,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,BAO_0000218,N,,4521,Canis lupus familiaris,
7438,In vivo,,50588,9615.0,Intermediate,1,,A,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,BAO_0000218,N,,6679,Canis lupus familiaris,
7439,In vitro,1969.0,50588,9615.0,Intermediate,1,Plasma,A,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",,,BAO_0000218,N,,1116,Canis lupus familiaris,
7440,In vivo,,50588,9615.0,Intermediate,1,,A,,In vivo half life period was calculated at 1 mg/kg in dog,,,BAO_0000218,N,,5444,Canis lupus familiaris,
7441,In vivo,,50588,9615.0,Intermediate,1,,A,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,,BAO_0000218,N,,5444,Canis lupus familiaris,
7442,In vivo,,50588,9615.0,Intermediate,1,,A,,Longer half-life in dog (i.v.) at 0.5 mpk,,,BAO_0000218,N,,17853,Canis lupus familiaris,
7443,In vivo,,50588,9615.0,Intermediate,1,,A,,Oral bioavailability in dog (dose 5 uM/kg),,,BAO_0000218,N,,4353,Canis lupus familiaris,
7444,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,,BAO_0000218,N,,16452,Canis lupus familiaris,
7445,In vivo,,50588,9615.0,Intermediate,1,,A,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,,BAO_0000218,N,,16452,Canis lupus familiaris,
7446,In vivo,,50588,9615.0,Intermediate,1,,A,,Bioavailability in dog (dose 1 mg/kg i.v.),,,BAO_0000218,N,,16452,Canis lupus familiaris,
7447,In vivo,2048.0,50594,10090.0,Intermediate,1,Lung,A,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,BAO_0000218,N,,10107,Mus musculus,
7448,In vivo,2048.0,50594,10090.0,Intermediate,1,Lung,A,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,BAO_0000218,N,,10107,Mus musculus,
7449,In vivo,2048.0,50594,10090.0,Intermediate,1,Lung,A,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,BAO_0000218,N,,10107,Mus musculus,
7450,In vivo,2048.0,50594,10090.0,Intermediate,1,Lung,A,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,BAO_0000218,N,,10107,Mus musculus,
7451,In vivo,2048.0,50594,10090.0,Intermediate,1,Lung,A,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,BAO_0000218,N,,10107,Mus musculus,
7452,In vivo,2048.0,50594,10090.0,Intermediate,1,Lung,A,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,BAO_0000218,N,,10107,Mus musculus,
7453,In vivo,2385.0,50594,10090.0,Intermediate,1,Muscle tissue,A,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,BAO_0000218,N,,10107,Mus musculus,
7454,In vivo,2385.0,50594,10090.0,Intermediate,1,Muscle tissue,A,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,BAO_0000218,N,,10107,Mus musculus,
7455,In vivo,2385.0,50594,10090.0,Intermediate,1,Muscle tissue,A,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,BAO_0000218,N,,10107,Mus musculus,
7456,In vivo,2385.0,50594,10090.0,Intermediate,1,Muscle tissue,A,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,BAO_0000218,N,,10107,Mus musculus,
7457,In vivo,2385.0,50594,10090.0,Intermediate,1,Muscle tissue,A,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,BAO_0000218,N,,10107,Mus musculus,
7458,In vivo,2385.0,50594,10090.0,Intermediate,1,Muscle tissue,A,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,BAO_0000218,N,,10107,Mus musculus,
7459,In vivo,2385.0,50594,10090.0,Intermediate,1,Muscle tissue,A,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,BAO_0000218,N,,10107,Mus musculus,
7460,In vivo,14.0,50594,10090.0,Intermediate,1,Zone of skin,A,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,BAO_0000218,N,,10107,Mus musculus,
7461,In vivo,14.0,50594,10090.0,Intermediate,1,Zone of skin,A,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,BAO_0000218,N,,10107,Mus musculus,
7462,In vivo,14.0,50594,10090.0,Intermediate,1,Zone of skin,A,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,BAO_0000218,N,,10107,Mus musculus,
7463,In vivo,14.0,50594,10090.0,Intermediate,1,Zone of skin,A,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,BAO_0000218,N,,10107,Mus musculus,
7464,In vivo,14.0,50594,10090.0,Intermediate,1,Zone of skin,A,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,BAO_0000218,N,,10107,Mus musculus,
7465,In vivo,14.0,50594,10090.0,Intermediate,1,Zone of skin,A,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,BAO_0000218,N,,10107,Mus musculus,
7466,In vivo,14.0,50594,10090.0,Intermediate,1,Zone of skin,A,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,BAO_0000218,N,,10107,Mus musculus,
7467,In vivo,2106.0,50594,10090.0,Intermediate,1,Spleen,A,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,BAO_0000218,N,,10107,Mus musculus,
7468,In vivo,2106.0,50594,10090.0,Intermediate,1,Spleen,A,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,BAO_0000218,N,,10107,Mus musculus,
7469,In vivo,2106.0,50594,10090.0,Intermediate,1,Spleen,A,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,BAO_0000218,N,,10107,Mus musculus,
7470,In vivo,2106.0,50594,10090.0,Intermediate,1,Spleen,A,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,BAO_0000218,N,,10107,Mus musculus,
7471,In vivo,2106.0,50594,10090.0,Intermediate,1,Spleen,A,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,BAO_0000218,N,,10107,Mus musculus,
7472,In vivo,2106.0,50594,10090.0,Intermediate,1,Spleen,A,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,BAO_0000218,N,,10107,Mus musculus,
7473,In vivo,2106.0,50594,10090.0,Intermediate,1,Spleen,A,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,BAO_0000218,N,,10107,Mus musculus,
7474,In vivo,945.0,50594,10090.0,Intermediate,1,Stomach,A,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,BAO_0000218,N,,10107,Mus musculus,
7475,In vivo,945.0,50594,10090.0,Intermediate,1,Stomach,A,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,BAO_0000218,N,,10107,Mus musculus,
7476,In vivo,945.0,50594,10090.0,Intermediate,1,Stomach,A,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,BAO_0000218,N,,10107,Mus musculus,
7477,In vivo,945.0,50594,10090.0,Intermediate,1,Stomach,A,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,BAO_0000218,N,,10107,Mus musculus,
7478,In vivo,945.0,50594,10090.0,Intermediate,1,Stomach,A,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,BAO_0000218,N,,10107,Mus musculus,
7479,In vivo,945.0,50594,10090.0,Intermediate,1,Stomach,A,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,BAO_0000218,N,,10107,Mus musculus,
7480,In vivo,945.0,50594,10090.0,Intermediate,1,Stomach,A,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,BAO_0000218,N,,10107,Mus musculus,
7481,In vivo,,50597,10116.0,Intermediate,1,,A,,Oral bioavailability in rat,,,BAO_0000218,N,,4689,Rattus norvegicus,
7482,In vivo,,50597,10116.0,Intermediate,1,,A,,Tested for the bioavailability in rat,,,BAO_0000218,N,,4950,Rattus norvegicus,
7483,In vivo,,50597,10116.0,Intermediate,1,,A,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,,BAO_0000218,N,,5328,Rattus norvegicus,
7484,In vivo,,50597,10116.0,Intermediate,1,,A,,Bioavailability in rat,,,BAO_0000218,N,,406,Rattus norvegicus,
7485,In vivo,,50597,10116.0,Intermediate,1,,A,,Bioavailability in rat,,,BAO_0000218,N,,12500,Rattus norvegicus,
7486,In vivo,,50597,10116.0,Intermediate,1,,A,,Bioavailability in rat (dose 3-10 mg/kg),,,BAO_0000218,N,,12500,Rattus norvegicus,
7487,In vivo,,50597,10116.0,Intermediate,1,,A,,Bioavailability in rat,,,BAO_0000218,N,,5247,Rattus norvegicus,
7488,In vivo,1969.0,50597,10116.0,Intermediate,1,Plasma,A,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,,BAO_0000218,N,,4186,Rattus norvegicus,
7489,In vivo,1969.0,50597,10116.0,Intermediate,1,Plasma,A,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,,BAO_0000218,N,,4186,Rattus norvegicus,
7490,In vivo,,50597,10116.0,Intermediate,1,,A,,Half life after oral administration was determined in rats at 6 mg/kg,,,BAO_0000218,N,,6647,Rattus norvegicus,
7491,,,50597,10116.0,Intermediate,1,,A,,Half life was determined,,,BAO_0000218,N,,6484,Rattus norvegicus,
7492,In vivo,,50597,10116.0,Intermediate,1,,A,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,,BAO_0000218,N,,3249,Rattus norvegicus,
7493,In vivo,1969.0,50597,10116.0,Intermediate,1,Plasma,A,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,,,BAO_0000218,N,,6281,Rattus norvegicus,
7494,,,50597,10116.0,Intermediate,1,,A,,Half life in rats,,,BAO_0000218,N,,3307,Rattus norvegicus,
7495,In vivo,178.0,50597,10116.0,Intermediate,1,Blood,A,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,,,BAO_0000218,N,,12058,Rattus norvegicus,
7496,,,50597,10116.0,Intermediate,1,,A,,Hill coefficient of the compound,,,BAO_0000218,N,,8833,Rattus norvegicus,
7497,,178.0,50597,10116.0,Intermediate,1,Blood,A,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,,BAO_0000218,N,,3193,Rattus norvegicus,
7498,,178.0,50597,10116.0,Intermediate,1,Blood,A,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,,BAO_0000218,N,,3193,Rattus norvegicus,
7499,,178.0,50597,10116.0,Intermediate,1,Blood,A,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,,BAO_0000218,N,,3193,Rattus norvegicus,
7500,,178.0,50597,10116.0,Intermediate,1,Blood,A,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,,BAO_0000218,N,,3193,Rattus norvegicus,
7501,,178.0,50597,10116.0,Intermediate,1,Blood,A,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,,BAO_0000218,N,,3193,Rattus norvegicus,
7502,,178.0,50597,10116.0,Intermediate,1,Blood,A,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,,BAO_0000218,N,,3193,Rattus norvegicus,
7503,,178.0,50597,10116.0,Intermediate,1,Blood,A,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,,BAO_0000218,N,,3193,Rattus norvegicus,
7504,,,50597,10116.0,Intermediate,1,,A,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,,BAO_0000218,N,,5960,Rattus norvegicus,
7505,In vivo,955.0,50597,10116.0,Intermediate,1,Brain,A,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,,,BAO_0000218,N,,13950,Rattus norvegicus,
7506,In vivo,955.0,50597,10116.0,Intermediate,1,Brain,A,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,,,BAO_0000218,N,,13950,Rattus norvegicus,
7507,In vivo,955.0,50597,10116.0,Intermediate,1,Brain,A,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,,,BAO_0000218,N,,13950,Rattus norvegicus,
7508,In vivo,955.0,50597,10116.0,Intermediate,1,Brain,A,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,,,BAO_0000218,N,,13950,Rattus norvegicus,
7509,In vivo,955.0,50597,10116.0,Intermediate,1,Brain,A,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,,,BAO_0000218,N,,13950,Rattus norvegicus,
7510,In vivo,2046.0,50597,10116.0,Intermediate,1,Thyroid gland,A,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,,,BAO_0000218,N,,13950,Rattus norvegicus,
7511,In vivo,2046.0,50597,10116.0,Intermediate,1,Thyroid gland,A,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,,,BAO_0000218,N,,13950,Rattus norvegicus,
7512,In vivo,2046.0,50597,10116.0,Intermediate,1,Thyroid gland,A,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,,,BAO_0000218,N,,13950,Rattus norvegicus,
7513,In vivo,2046.0,50597,10116.0,Intermediate,1,Thyroid gland,A,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,,,BAO_0000218,N,,13950,Rattus norvegicus,
7514,In vivo,2046.0,50597,10116.0,Intermediate,1,Thyroid gland,A,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,,,BAO_0000218,N,,13950,Rattus norvegicus,
7515,In vivo,178.0,50597,10116.0,Intermediate,1,Blood,A,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,BAO_0000218,N,,9866,Rattus norvegicus,
7516,In vivo,178.0,50597,10116.0,Intermediate,1,Blood,A,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,,,BAO_0000218,N,,9866,Rattus norvegicus,
7517,In vivo,178.0,50597,10116.0,Intermediate,1,Blood,A,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,,,BAO_0000218,N,,9866,Rattus norvegicus,
7518,In vivo,10000001.0,50597,10116.0,Intermediate,1,Bone,A,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,BAO_0000218,N,,9866,Rattus norvegicus,
7519,In vivo,10000001.0,50597,10116.0,Intermediate,1,Bone,A,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,,,BAO_0000218,N,,9866,Rattus norvegicus,
7520,In vivo,10000001.0,50597,10116.0,Intermediate,1,Bone,A,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,,,BAO_0000218,N,,9866,Rattus norvegicus,
7521,In vivo,948.0,50597,10116.0,Intermediate,1,Heart,A,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,BAO_0000218,N,,9866,Rattus norvegicus,
7522,In vivo,948.0,50597,10116.0,Intermediate,1,Heart,A,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,,,BAO_0000218,N,,9866,Rattus norvegicus,
7523,In vivo,948.0,50597,10116.0,Intermediate,1,Heart,A,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,,,BAO_0000218,N,,9866,Rattus norvegicus,
